"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Q4 2015 Boston Scientific Earnings Call. [Operator Instructions] And as a reminder, this conference is being recorded. I'd now like to turn the conference over to our host, Ms. Susie Lisa. Pl",45,"Ladies and gentlemen, thank you for standing by. Welcome to the Q4 2015 Boston Scientific Earnings Call. [Operator Instructions] And as a reminder, this conference is being recorded. I'd now like to turn the conference over to our host, Ms. Susie Lisa. Please go ahead."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, David. Good morning, everyone. Thanks for joining us. With me on today's call are Mike Mahoney, President and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.We issued a press release earlier thi",378,"Thank you, David. Good morning, everyone. Thanks for joining us. With me on today's call are Mike Mahoney, President and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.
We issued a press release earlier this morning announcing our fourth quarter and full year 2015 results, which included reconciliations of the non-GAAP measures used in the release.
We have posted a copy of that release as well as reconciliations of the non-GAAP measures used in today's call to the Investor Relations section of our website under the heading, Financial Information.
The duration of this morning's call will be approximately 1 hour. Mike will provide strategic and revenue highlights of the fourth quarter. Dan will review the financials for the quarter and then provide first quarter '16 and full year 2016 guidance, and then we'll take your questions. During today's Q&A session, Mike and Dan will be joined by our Chief Medical Officers, Dr. Keith Dawkins and Dr. Ken Stein. 
Before we begin, I'd like to remind everyone that on the call organic revenue growth is defined as excluding the impact of sales from divested businesses, changes in foreign currency exchange rates and sales from the acquisition of the American Medical Systems or AMS male urology portfolio over the prior year period. Also note this call contains forward-looking statements within the meaning of federal securities laws, which may be identified by words like anticipate, expect, believe, estimate and other similar words
They include, among other things, statements about our growth and market share; new product approvals and launches; clinical trials; cost savings and growth opportunities; our cash flow and expected use; our financial performance, including sales, margins, earnings and other Q4 and full year 2015 results and Q1 and full year 2016 guidance; as well as our tax rates, R&D spend and other expenses.
Actual results may differ materially from those discussed in the forward-looking statements.
Factors that may cause such differences include those described in the Risk Factors section of our most recent 10-K and subsequent 10-Qs and 8-Ks filed with the SEC.
These statements speak only as of today's date, and we disclaim any intention or obligation to update them.
At this point, I'll turn it over to Mike for his comments. Mike?"
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Susie, and good morning, everyone. in, fourth quarter, Boston Scientific posted another quarter of strong results and closed out an excellent 2015 as we continued to execute against our strategic planned goals. At our May 2015 Investor Day meet",2211,"Thank you, Susie, and good morning, everyone. in, fourth quarter, Boston Scientific posted another quarter of strong results and closed out an excellent 2015 as we continued to execute against our strategic planned goals. At our May 2015 Investor Day meeting, we outlined plans to drive mid-single-digit organic revenue growth and consistent adjusted operating margin expansion, which, in turn, will drive double-digit adjusted EPS growth excluding the impact of FX. 
We are delivering against these objectives. In Q4, we grew worldwide sales 5% organically and 10% operationally, which includes the benefit of the AMS Urology business. We also grew adjusted operating income by 10% in the fourth quarter, which represents 100 basis point year-over-year improvement to 21.7%. 
The solid revenue growth and margin expansion drove very strong 18% adjusted EPS growth to $0.26, and our fourth quarter results reflect our focus on delivering meaningful innovation while also providing clinical and economic value to our hospital customers. 
Importantly, our Q4 results built upon the consistent momentum generated over the past few years and contributed to the following full year '15 results. For the full year, we delivered 5% organic revenue growth and 8% operational revenue growth, which includes the acquired sales from Bayer Peripheral and EMS. In parallel with the consistent revenue growth, we are driving a strong improvements through our operating margin. 
In 2014, we delivered 130 basis point improvement in adjusted operating margin. In 2015, we delivered an additional 210 basis point improvement to a full year 22.3%. In prior previous calls, we continue to expect to deliver 25% plus adjusted operating margin in 2017 with plans to deliver an additional 200 to 300 basis points of improvement by year-end 2020. 
We delivered full year of '15 adjusted EPS growth -- I'm sorry, EPS of $0.93, representing 11% growth for the full year. It's important to note that the 11% adjusted EPS growth includes a significant negative foreign exchange impact of $0.10 versus our original expectation of a $0.04 hit when we originally gave '15 guidance. We are very pleased that we are able to overcome this FX headwind while investing in the long-term growth of the company yet still delivering on our commitment for diluted adjusted EPS growth. 
We continue to believe that Boston Scientific is uniquely positioned to deliver differentiated shareholder value to durable mid-single-digit revenue growth and double-digit adjusted EPS growth via our ongoing opportunity improvement initiatives. We're excited by our 2016 and our plans to build upon our global momentum. 
In 2016, we're targeting full year organic revenue growth of 4% to 7% and operational revenue growth of 7% to 10%. We're guiding adjusted EPS to $1.03 to $1.07, which represents 11% to 15% earnings growth. Importantly, this EPS once again includes an expected $0.06 negative impact from foreign exchange. 
I'll now provide some highlights on fourth quarter and '15 results along with thoughts on our '16 outlook. In my remarks, all reference to growth in an organic year-over-year constant currency basis and unless otherwise specified. 
Our fourth quarter organic revenue growth of 5% was broad based across businesses and regions. It's led by exciting new product launches, which continued; global expansion; and execution of our category leadership strategy. With the exception of the anticipated 1% decline in CRM sales, all of our other businesses grew organic revenue by at least 6%, led by 10% growth in PI. IC had a strong quarter growing 6% against a very tough 10% comp in Q4 2014. And importantly, all 3 medical/surgical businesses grew revenue at 7% while also improving segmented adjusted operating margin by 90 basis points year-over-year to 34.1%. 
We delivered another quarter of balanced global growth led by 6% revenue growth in Asia, 5% growth in the U.S. and Europe. Another highlight was strong 15% revenue growth in emerging markets led by 20% growth in China and Brazil. 
The MedSurg businesses continued to deliver. In Endoscopy, we delivered 7% growth in Q4, fueled by the strength portfolio, our expanding global commercial reach and ongoing launches of our SpyGlass DS and axial stent. SpyGlass DS is launched in July 2015, and is in advance single-use visualization system for the diagnosis and treatment of complex disorders of the pancreas and bile ducts. It's truly a cornerstone product that is highly differentiated and complementary to our core endo portfolio. Our axial stent used for transluminal drainage pancreatic fluid collections is also off to a strong start. We'll continue to innovate in endoscopic ultrasound and other exciting therapeutic categories, including pulmonary and ecology, to further enhance our global leadership in Endoscopy. 
Urology and Pelvic Health also continued a strong performance trend, growing 7% organically in Q4 led by laser fibers, capital equipment and strong international growth. Importantly, this quarter, we launched LithoVue, a disposable uterus scope, which provides customers with visualization and navigation capabilities to diagnose and treat stones and other conditions of the kidney, uterus and bladder. And after closing the AMS Urology acquisition in August, we remain on track to realize our adjusted EPS accretion goals of at least $0.03 in 2016 and $0.07 in 2017. 
Neuromodulation revenue grew 7% in the fourth quarter led by strong growth in both the U.S. and international. Sales were driven by the market-leading Specter platform and the launch of precision Novi, our first product in the primary self nonrechargeable market. 
In addition, we're seeing really promising uptake of our precise Deep Brain Stimulation system due to its Cartesian directional lead system and our partnership with Brainlab. Our USDBS trial is making progress, and we expect to complete enrollment in 2016 and enter the market in late 2017 or early '18. 
Our Cardiovascular group grew 7% in Q4 led by impressive 10% growth in Peripheral Interventions. The core PI business continues to execute, and we are very pleased with integration of the legacy Bayer business. The legacy Bayer business grew over 20% for the second quarter in a row as we continue to grow share in the market, and we're encouraged by early results by global launch of our Zelante DVT catheter and the U.S. launch of our stent for the SFA. 
We also recently began to enroll our U.S. IDE trial for Eluvia, our drug-eluting stent and remain on track for a European launch of Eluvia this quarter. In addition, we recently closed the CeloNova transaction, which is a synergistic tuck-in acquisition focused on the treatment of liver cancer via localized delivery of chemotherapeutic agents. 
And finally in PI, we continue to benefit from our commercial relationship with CR Bard and drug coated balloon technology. 
Interventional Cardiology continues to deliver with 6% growth in the quarter, which represents the sixth consecutive quarter of plus 6% growth in IC. Growth was led by worldwide imaging, U.S. and European drug-eluting stents, our complex PCI portfolio and Structural Heart. 
PCI guidance grew low teens globally, and we're encouraged by the market enthusiasm of our integrated fractional flow platform. In DES, the U.S. synergy launch is going well. We anticipate that synergy will represent approximately 50% of our DES revenue mix in the U.S. by the end of 2016. 
In addition, we're launching SYNERGY in Japan, and we'll continue to expand SYNERGY in other international markets. We also continue to divest and build upon our strong clinical evidence for SYNERGY as we have initiated the evolve short DAPT study. 
Finally, the IC performance was fueled by our strengthening Structural Heart business, which includes our Lotus aortic valve and WATCHMAN Left Atrial Appendage Closure Device. We're truly in an exciting position to drive growth and share gains over the long run in these fast-growing markets. 
Lotus delivered a strong quarter for the -- in the European market as the platform continues to build momentum despite our near-term size major limitations. Lotus offers physicians excellent control during implantation and best-in-class leakage rates. 
In our RESPOND Post-Market Study, 95.1% of patients had 0 to trace PDL. Importantly, we completed enrollment in our REPRISE III IDE study in December, which we anticipate will position us for late 2017 U.S. market entrance. We're also pleased to announce completion of the 1,000-patient respond Lotus plus market study, and those results will be presented at Euro PCR in May. 
We're expanding the Lotus platform and expect to launch our NexGen 14 French delivery system along with additional sizes in Europe this year. Also in Structural Heart, the U.S. WATCHMAN launch continues to progress ahead of plan. We're pleased with the implant success rates and the high quality of patient outcomes thus far, which reflect our controlled rollout and proven training program. 
In addition, Dr. Visik Reddy of Mount Sinai recently published in JECC a study highlighting WATCHMAN's cost-effectiveness versus warfarin and novel oral anticoagulants. In the U.S., we opened more than 100 WATCHMAN accounts in 2015 and expect to open an additional 100 accounts in 2016. 
In Europe, we're looking forward to a full launch of our second-gen WATCHMAN flex, which also -- which already CE marked. As our U.S. reimbursement, we will await final NCD decision from CMS by February 8, and we remain confident that WATCHMAN will represent at least a $500 million worldwide market opportunity. 
So overall, we're very pleased with our progress in Structural Heart and excited about our capabilities and the long-term prospects for this business. We exceeded our full year of '15 Structural Heart revenue goal of $75 million to $100 million, and in 2016, we anticipate Structural Heart sales between $175 million and $200 million. 
Now turning to CRM. On our first quarter '15 earnings call, we projected a slowdown in our worldwide CRM sales for the balance of '15 and through first quarter '16, primarily due to replacement cycle headwinds and competitive launches in the U.S. Our forecast is accurate as global CRM sales declined 1% in Q4. However, we're very encouraged by about our forward-looking CRM position given the strong cadence of new launches expected in the U.S. and Japan in '16, our leading position and growing awareness of S-ICD and our replacement cycle headwind becoming more favorable as we exit 2016. 
In the U.S., we plan to launch our full X4 quad system with our ACCOLADE EMI same system in the first half and EMBLEM MRI in the second half of '16, and we anticipate these releases will strengthen 2016 CRM performance, particularly in the second half. 
Pacemaker sales again grew 2%, and we recently launched X4 CRTD quad device. And while our ICD sales declined 2%, we continue to be pleased with our de novo ICD performance in the Emblem SICD in particular. Emblem continues to drive strong growth in de novo share gains in both the Europe and the U.S. Emblem is building momentum globally, and we look forward to launching Emblem in Japan this quarter with the reimbursement premium and expanding SICD to additional international markets in 2016. 
In Europe, we continue to gain share and grow our CRM business in the mid-single-digit range with our complete portfolio. These consistent European CRM results are encouraging as we look forward to our anticipated U.S. approvals in '16. Lastly in CRM, we're continuously mounting third-party evidence of the economic benefits associated with our EnduraLife extended battery technology. And recently another third-party data set from the Europace was published, demonstrating the 6-year survival of BSC CRTDs over our competitors. 
Also recent U.S. study modeled a 14% reduction in Medicare cost from a 2-year increase in ICD battery longevity, and an Italian study showed Extended Longevity drove a 29% to 34% reduction in long-term health care costs over 15-year period. 
Turning to our EP business. We delivered 8% growth in the quarter. Arrhythmia platform continues to rollout nicely driven by new installations and high case volumes. We have a strong arrhythmia customer pipeline in 2016 as well as new platform enhancement scheduled for release. 
We did see some softness in EP in fourth quarter, primarily driven by the delay in our European launch of our IntellaMap ablation catheter, which we anticipate launching later in the first quarter. We continue to strengthen our EP business, and we look forward to continued progress in 2016. 
Our strategy of category leadership is working. It's helping us to become a stronger partner with our global customers. As the health care environment continues to evolve, we're building new capabilities to support our customers be on our part of portfolio with our ADVANTICS solutions offerings. These offerings are focused on driving operational excellence within Cardiovascular and GI lives and improving standardizing care for chronic Cardiovascular diseases. 
And just last week, we announced an alliance with Accenture to develop a data-driven digital health solutions improve patient outcomes and reduce costs to treat patients with chronic Cardiovascular disease. 
So to wrap up my section, our company has great momentum, and our 2015 results reflect the strength of our portfolio and our ongoing investment investor growth markets, our globalization efforts and execution of our global teams. 
More importantly, we believe that we are well positioned to continue and strengthen our performance track record in 2016 and beyond. I really want to thank our employees for their winning spirit and a great commitment to Boston Scientific. 
And now let me turn the call over to Dan for more detailed review of our financials."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Mike. I'll start with some overall perspective on the quarter before getting into the detail. We generated adjusted earnings per share of $0.26, exceeding the high end of our guidance range of $0.23 to $0.25 and representing 18% year-over-year g",2753,"Thanks, Mike. I'll start with some overall perspective on the quarter before getting into the detail. 
We generated adjusted earnings per share of $0.26, exceeding the high end of our guidance range of $0.23 to $0.25 and representing 18% year-over-year growth in the quarter. Excluding a $0.03 unfavorable foreign exchange impact, Q4 adjusted earnings per share grew 31% year-over-year. The strong performance in Q4 was driven primarily by operational revenue growth in gross margin expansion. 
Our Q4 2015 adjusted operating margin of 21.7% represents an improvement of 100 basis points over the fourth quarter of 2014. For the full year 2015, total company adjusted operating margin expanded by 210 basis points over the full year of '14, and we effectively offset a $0.10 FX headwind through operational savings and initiatives. 
Our full year 2015 adjusted earnings per share of $0.93 represents 11% growth and 23% growth excluding FX versus 2014. 
Now for the P&L highlights. For the fourth quarter of 2015, consolidated revenue of $1,978,000,000 represented operational growth of 10%, which excludes the impact of foreign exchange. Excluding an approximate 500 basis point contribution from the AMS male urology portfolio, organic revenue growth was 5% in the quarter. 
On an as-reported basis, revenue grew 5% year-over-year. The foreign exchange impact on sale was a $110 million headwind compared to the prior year period, which was about $25 million worse than we assumed in our Q4 guidance range. 
Adjusted gross margin for the fourth quarter was 72.8%, increasing 140 basis points year-over-year. The increase resulted primarily from cost improvements, driven by our value improvement programs as the impact of foreign exchange was negligible in the quarter. 
For the full year 2015, adjusted gross margin was 72% compared to 70.7% for the full year 2014. The 130 basis point full year adjusted gross margin improvement was driven by benefits of 180 and 50 basis points from cost improvements and FX, respectively. This was partially offset by 100 basis points of headwind attributed primarily to price. 
Adjusted SG&A expenses were $757 million or 38.3% of sales in the fourth quarter, down 10 basis points year-over-year. The Q4 rate includes 80 basis points a higher spend related to fixed asset write-offs, full year related benefits and litigation fees. 
Our full year 2015 adjusted SG&A rate of 37.4% is down 50 basis points versus the full year 2014. As a reminder, the medical device tax has been suspended for 2016 and 2017, which would benefit our adjusted SG&A rate by roughly 100 basis points annually. We're pleased to see that this tax has been temporarily suspended and intent to reinvest virtually all of the benefits into jobs, innovation, R&D, collaborations with universities and other initiatives that will help treat patients and sustain top line growth over the long term. 
We expect the reinvestment of approximately 100 basis points to be split roughly equally between R&D and SG&A. Our guidance for full year 2016 assumes our adjusted SG&A rate will come down by a total of 140 basis points at the midpoint, which breaks down into 50 basis points on the medical device tax suspension and 90 basis points from operational improvements. 
Adjusted research and development expenses were $238 million in the fourth quarter or 12% of sales. For the full year 2015, adjusted R&D expenses were $850 million or 11.4% of sales. We expect our full year 2016 adjusted R&D rate to be roughly 11.5%. Again, this includes a 50 basis point increase due to the reinvestment of the medical device tax, offset by increased efficiencies and improved utilization of our global footprint. 
Royalty expense was 0.9% of sales in both the fourth quarter and the full year 2015. This represents a 60 basis point reduction compared to the full year 2014 rate, and we expect our royalty rate to remain at approximately 1% of sales in 2016. 
On an adjusted basis, operating income was  $429 million in the quarter or 21.7% of sales, up 100 basis points year-over-year. We are very pleased with our consistent and adjusted operating margin improvement throughout 2015 as we saw year-over-year improvement of at least 100 basis points in each of the 4 quarters. 
Rhythm Management's adjusted operating margin in Q4 was 13.9%, down substantially from Q3 2015, which resulted in a second half 2015 Rhythm Management adjusted operating margin of 15.9% falling short of our respect to of 17% due to the timing of manufacturing variances and reserve charges as we transition our portfolio and prepare for new product launches in 2016. 
Full year 2015 Rhythm Management adjusted operating margin of 15% represents an improvement of 160 basis points over the full year 2014. 
And turning to 2016, we expect Rhythm Management adjusted operating margin to increase sequentially in Q1 versus Q4 of '15 with more noticeable improvement in Q2 as we begin to realize the full benefit of 2016 product costs and leverage the improved top line performance expected from the global CRM and EP franchises. In the second half 2016, Rhythm Management adjusted operating margin is also expected to benefit from our Plant Network Optimization program completed at the end of 2015, which transferred a portion of our EP effective tax rate to lower-cost locations. 
The net of all these factors drive our expectation for full year Rhythm Management adjusted operating margin to approach 18% for the full year 2016, and we remain confident in 20% plus in 2017. 
GAAP operating income, which includes GAAP to adjusted items of $700 million, was a loss of $271 million in Q4 2015. The primary GAAP to adjusted items for the quarter included restructuring-related charges of $26 million, acquisition-related SG&A expenses of $15 million, contingent consideration expense of $37 million, amortization expense of $135 million and litigation-related charges of $456 million. 
The $456 million in litigation-related net charges were primarily related to increases in our litigation reserve for a recent appellate court ruling in Maryland in the case, with the remainder related to a combination of increases in our transvaginal surgical product liability reserves and other adjustments. The Murawski case traces back to the mid-2000 and relates to licensing agreement on patents that have expired. We continue to believe the facts and the law do not support the court's findings or the amount of the damages, and we plan to seek review of the judgment by the Maryland Supreme Court. 
We increased our reserve this quarter as we became aware of additional claims during the quarter as we continue to work through the settlement evaluation process. Currently, our known claim count is approximately 35,000, and we've agreed in principle to settle over 10,000 of those 35,000 claims. 
We intend to continue to contest cases against those vigorously while also looking to settle when reasonable terms are presented. Our total legal reserve was $1,936,000,000 as of December 31, 2015. 
Separately, a case was recently filed against Boston Scientific in West Virginia regarding the resin use in our transvaginal mesh products. We are confident that the revenues in the manufacturing of these devices is neither counterfeit nor adulterated and meets required material biocompatibility and design specifications. We provided information and materials to a European notified body, the FDA and the Department of Justice regarding the resin, our quality processes and our commitment to producing medical devices of the highest quality. 
Now I'll move on to other income and expense. Interest expense for the quarter was $59 million compared to $54 million in Q4 of 2014. The increase was primarily due to the incremental debt raised in Q2 of 2015 to finance the AMS male urology portfolio acquisition. 
Our average interest rate was 3.9% [ph] in Q4 2015 compared to 4.8% in Q4 2014. The lower interest expense rate in Q4 2015 was primarily due to lower average cost of debt resulting from the senior notes refinancing completed in Q2 of 2015. 
Other expense was $10 million, and this consisted primarily of foreign exchange losses and investment losses incurred during the quarter. Our tax rate for the fourth quarter was 58% on a reported basis and 0.2% on an adjusted basis. 
Our Q4 adjusted tax rate includes $3.9 million [ph] of favorable discrete tax items and other onetime benefits primarily related to foreign exchange. Excluding these items, our Q4 operational tax rate would have been 13%. 
Now I'll provide a bit more detail on our full year 2015 adjusted tax rate where our guidance as of the third quarter had been 13%. As you may know, the U.S. R&D tax credit was permanently reinstated in December, which benefited the full year 2015 adjusted tax rate by slightly more than 100 basis points. We've decided to reinvest this benefit in our tax structure to improve long-term flexibility in our capital structure, the net result of this being a 13% adjusted tax rate for the full year excluding discrete and onetime tax items and a 9.2% rate including them. 
After this onetime investment, we continue to expect an approximately 100 basis point increase in our adjusted tax rate annually and therefore, continue to expect our full year 2016 adjusted tax rate to be approximately 14%. 
Finally, as mentioned, Q4 2015 adjusted EPS of $0.26 includes approximately $0.03 of unfavorable foreign exchange and represents 18% year-over-year growth or 31% growth, excluding the impact of foreign exchange. On a reported GAAP basis, Q4 2015 EPS was a loss of $0.11 and includes net charges and amortization expenses totaling $504 million after tax. 
The GAAP loss of $0.11 compares to a GAAP loss of $0.23 in the fourth quarter of 2014. For the full year 2015, we reported adjusted EPS of $0.93, exceeding our guidance range while absorbing $0.10 of unfavorable FX. 
Recall this is $0.02 more than we expected as of our Q3 2015 earnings call and $0.06 more than we expected at the beginning of 2015. Full year 2015 adjusted EPS grew 11% over prior year and 23% excluding the impact of foreign exchange. On a reported GAAP basis, 2015 EPS was a loss of $0.18 compared to a full year 2014 GAAP loss per share of $0.09. 
Moving onto the balance sheet. Days sales outstanding of 59 days increased 1 day compared to December of 2014. Days inventory on hand of 163 days was up 7 days compared to December of last year due primarily to the acquisition of the AMS male urology portfolio. 
Capital expenditures were $86 million in Q4 2015 compared to $79 million in Q4 2014. For the full year 2015, capital expenditures were $248 million. 
For the full year 2016, we expect capital expenditures to be roughly $100 million higher, primarily due to the construction of our new manufacturing facility and distribution center in Malaysia. Beyond 2016, we expect capital expenditures to return to our historical run rate of approximately $250 million annually. 
Adjusted free cash flow for the quarter was $448 million compared to $508 million in Q4 2014. Our full year 2015 adjusted free cash flow of $1,366,000,000 represents growth of 8% over the full year 2014. 
For 2016, we expect full year adjusted free cash flow to exceed $1.5 billion, representing growth of 10% and have a stretch goal to exceed $1.6 billion for the year with initiatives aimed at improving the working capital contribution to cash flow. 
In Q4, we repaid $150 million of our term loan and expect to repay an additional $250 million by the end of 2016, at which time, we expect our debt leverage will be consistent with our goal of returning to pre-AMS debt leverage by year-end. There were no share repurchases in the quarter, consistent with our decision to suspend the share repurchase program temporarily following the announcement of the AMS male urology portfolio acquisition. And near term, our capital allocation priorities are to repay debt, manage contingencies and pursue tuck-in M&A. 
We ended 2015 with 1,363,000,000 fully diluted weighted average shares outstanding, consistent with our prior guidance. We expect our share count to increase by roughly 5 million per quarter through the end of 2016 as we plan to keep the buyback suspended for the balance of 2016. We expect this to result in a fully diluted weighted average share count of approximately 1,380,000,000 for the full year 2016. 
I'd like to conclude with guidance for Q1 and full year 2016. For the full year, we expect consolidated revenue to be in a range of $7,900,000,000 to $8,100,000,000, which represents year-over-year growth of 4% to 7% on an organic basis, 7% to 10% on an operational basis and 6% to 8% on a reported basis. 
As a result of a stronger dollar and current rates, we expect foreign exchange to be a roughly $150 million headwind for the full year 2016 on revenue. We expect our adjusted gross margin for the year as a percentage of sales to be in a range of 72% to 73%. We expect foreign exchange to have an unfavorable impact of approximately 50 basis points on adjusted gross margin in 2016 as hedging contracts from our 3-year program are layered in. We expect this headwind be offset by favorable mix, market segmentation, the ramp of accretive new products and our standard cost-reduction programs. 
As mentioned, we expect our full year 2016 adjusted SG&A rate to be between 35.5% and 36.5% of sales and our full year R&D rate to be between 11% and 12% of sales. This implies a full year 2016 adjusted operating margin in the range of 23.5% to 24.5%, the midpoint of which represents 170 basis points of improvement over full year 2015. 
And importantly, we remain on track to achieve an adjusted operating margin of 25% plus in 2017. Full year 2016 interest expense is expected to be $245 million, about $10 million higher than the full year 2015 due to incremental debt raised in Q2 of 2015. 
As mentioned, we expect our tax rate for the full year 2016 to be approximately 14%. As a result, we expect adjusted earnings per share for the full year 2016 to be in a range of $1.03 to $1.07, representing 11% to 15% adjusted earnings per share growth. 
We expect 2016 adjusted earnings per share to be impacted negatively by approximately $0.06 of FX or roughly $80 million of adjusted income. In terms of timing, this $0.06 should be roughly $0.02 per quarter in Q1 and Q2 and $0.01 per quarter in Q3 and Q4. 
Excluding the $0.06 of unfavorable foreign exchange, our full year adjusted EPS guidance range represents growth of 17% to 21%. Despite this approximate $0.06 hit, we remain confident in our ability to deliver double-digit adjusted EPS growth. 
Let me walk you through the 2016 adjusted EPS guidance. We've delivered adjusted EPS of $0.93 in 2015, representing 11% growth or 23% growth excluding the $0.10 of negative FX impact. 
As you know, our stated goal is to grow EPS double digits, which would imply $1.02 in 2016. Adding $0.03 of AMS accretion gets us to $1.05, which is the midpoint of our guidance. We expect unfavorable FX of approximately $0.06, as I mentioned, but our goal is to offset this through operational initiatives and savings as we did in 2015, and as mentioned, the medical device tax is worth roughly 100 basis points on the OM line, but we intend to reinvest substantially all of that back into innovation and have developed the detailed plans to do so. 
On a GAAP basis, we expect EPS to be in a range of $0.62 to $0.67. Lastly, for 2016 our guidance assumes pretax amortization of approximately $534 million. 
Now turning to the first quarter of 2016. We expect consolidated revenues to be in a range of $1,890,000,000 to $1,940,000,000. If current foreign exchange rates hold constants, the headwind from foreign exchange should be approximately $45 million or 250 basis points relative to Q1 2015. 
We expect consolidated Q1 sales to grow year-over-year in a range of 4% to 6% organically and 9% to 11% operationally. 
For the first quarter, adjusted earnings per share is expected to be in a range of $0.23 to $0.25 per share, and GAAP earnings per share is expected to be in a range of $0.11 to $0.13 per share. 
I encourage you to check our Investor Relations website for Q4 2015 financial and operational highlights, which outlines Q4 results as well as Q1 and full year 2016 guidance, including P&L line item guidance. 
So with that, I will turn it back to Susie, who will moderate the Q&A."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Dan. David, let's open it up to questions for the next 25 minutes or so. [Operator Instructions] David, please go ahead.",22,"Thanks, Dan. David, let's open it up to questions for the next 25 minutes or so. [Operator Instructions] David, please go ahead."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","[Operator Instructions] The first question is coming from the line of David Lewis of Morgan Stanley.",16,"[Operator Instructions] The first question is coming from the line of David Lewis of Morgan Stanley."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","First, your guidance on the top end of the range. It's 7% obviously higher than we expected. I guess, we expected 4% to 6%. What factors get us to the top end of the range? And specifically what's assumed for WATCHMAN? And then I had a quick follow-up.",48,"First, your guidance on the top end of the range. It's 7% obviously higher than we expected. I guess, we expected 4% to 6%. What factors get us to the top end of the range? And specifically what's assumed for WATCHMAN? And then I had a quick follow-up."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks. Yes, the guidance 4% to 7% is higher than we showed at recent investor meeting. In terms of get into the higher the range, we still have to have some good results on our product launches with SYNERGY, WATCHMAN, ongoing advancements of Lotus. We ha",163,"Thanks. Yes, the guidance 4% to 7% is higher than we showed at recent investor meeting. In terms of get into the higher the range, we still have to have some good results on our product launches with SYNERGY, WATCHMAN, ongoing advancements of Lotus. We have key product approvals that we're expecting first half. Those need to come through. We also launched a number of key products and then with SYNERGY and also SICD. So we need some strong execution there and continued emerging market growth. So it's -- we've got a lot of product launches, a number of approvals needed. So delivered the top end of that, we have to have excellent commercial execution and great execution on the regulatory side. And potentially you have some of the downside we continue to manage, as I mentioned, some of the CRM headwinds, which we anticipate will after Q1, improve in second quarter and then improve dramatically in the second half of the year."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","That's very helpful, Mike. And then specifically in MS and CRM just to follow up there, in the fourth quarter was there anything particular with third quarter, fourth quarter slight decline, was there any particular or unique to the fourth quarter you can",72,"That's very helpful, Mike. And then specifically in MS and CRM just to follow up there, in the fourth quarter was there anything particular with third quarter, fourth quarter slight decline, was there any particular or unique to the fourth quarter you can cite? And then once again your confidence what specifically implied in '16 numbers? Is that the '16 guidance implies improvement in the CRM business in '16 over '15?"
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. So we're really pleased with, quite frankly, our overall Urology business and the AMS deal. The business grew 7% in fourth quarter, and I'm sorry. Was your first question on Urology? Or was it all CRM related?",38,"Yes. So we're really pleased with, quite frankly, our overall Urology business and the AMS deal. The business grew 7% in fourth quarter, and I'm sorry. Was your first question on Urology? Or was it all CRM related?"
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","I'm happy to hear about Urology, but it was focused on CRM.",13,"I'm happy to hear about Urology, but it was focused on CRM."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Sorry, jet lagged from Asia.",5,"Sorry, jet lagged from Asia."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Will hold the comments for later I guess. So on the CRM we do anticipate improvement clearly in 2016, as I mentioned, particularly in the second half. We anticipate the launch of the approval of the pace MRI and the quad in the second quarter, and we'll a",68,"Will hold the comments for later I guess. So on the CRM we do anticipate improvement clearly in 2016, as I mentioned, particularly in the second half. We anticipate the launch of the approval of the pace MRI and the quad in the second quarter, and we'll also have favorable comps in second quarter, third quarter and fourth quarter. So we do see strengthening CRM business in 2016."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Rick Wise with Stifel.",12,"The next question comes from the line of Rick Wise with Stifel."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Just a couple of things. Maybe start with the CRM operating margin. Dan, great, clear job of laying out the of 15.9% instead of your 17% goal. Is the whole of that these variances? And do you come into '16 thinking that -- do we start off with that sort o",64,"Just a couple of things. Maybe start with the CRM operating margin. Dan, great, clear job of laying out the of 15.9% instead of your 17% goal. Is the whole of that these variances? And do you come into '16 thinking that -- do we start off with that sort of 17% level or better as we head into the first quarter first half?"
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Rick. Yes, I think the way I would say -- characterized it on the Q3 call, we had talked about kind of being in that 17% range for the back half of '15. The variances were a piece of it. We also had a little bit higher R&D, about 60 basis points i",215,"Thanks, Rick. Yes, I think the way I would say -- characterized it on the Q3 call, we had talked about kind of being in that 17% range for the back half of '15. The variances were a piece of it. We also had a little bit higher R&D, about 60 basis points in the quarter. That's timing. That's just going to come 1 quarter to another, so that doesn't concern me. The manufacturing and the inventory reserve charges are really in anticipation of the launches that might just mentioned around the MRI safe brady and the quad launch in the U.S. So those are kind of out of the way now at this point as opposed to having had to take those in different quarters. So I think the way I would think of it is the 13 9 in Q4, I'd expect a little bit of a sequential improvement in Q1, not a tremendous amount just a little bit. Q2 gets a little bit better than that, and really the back half is where it accelerates to get to that overall 18% for the year. So I wouldn't look for Q1 to be in that 18% range or Q2, but I think the net of the year, we're very comfortable with that 18%."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","And just one product specific question. WATCHMAN, a possible entities up here real soon. And if I understood you correctly, you're basically saying still a $500 million market if that early language holds. But what is the language is basically equivalent",90,"And just one product specific question. WATCHMAN, a possible entities up here real soon. And if I understood you correctly, you're basically saying still a $500 million market if that early language holds. But what is the language is basically equivalent to the FDA approval label? Docs are telling us that they're doing 4 patients a month, and that would double if that were the case. Is that the way you see it? And so that is that back to $1 billion market? How do we think about all that?"
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","We're obviously very proud of our success in 2015 with WATCHMAN. Structural Heart overall, we've delivered the high end of the range there. We opened up 100 accounts. We're going to hear the NCD decision here shortly here. But overall, we continue to expe",108,"We're obviously very proud of our success in 2015 with WATCHMAN. Structural Heart overall, we've delivered the high end of the range there. We opened up 100 accounts. We're going to hear the NCD decision here shortly here. But overall, we continue to expect guidance in '16 of $175 million to $200 million, and our job will be to continue to focus on the penetration rate. With 15 million or so eligible patients, we'll continue to drive new programs excellent outcomes, but for now, we'll continue with our $175 million to $200 million range, and we'll see what happens over the next few days on the reimbursement."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Ken, you want to add anything?",6,"Ken, you want to add anything?"
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, we have some concerns about that first draft proposed. Overall, it was consistent with our expectations, which are that the NCD we expect to be more limited than the full FDA label. Likewise, expect to have the registry, et cetera, and as Mike said,",75,"Yes, we have some concerns about that first draft proposed. Overall, it was consistent with our expectations, which are that the NCD we expect to be more limited than the full FDA label. Likewise, expect to have the registry, et cetera, and as Mike said, we've always assumed modest penetration into the indicated population and really where we go is much more dependent on our ability to train new physicians use device safely and effectively."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question is coming from the line of Mike Weinstein with JPMorgan.",13,"The next question is coming from the line of Mike Weinstein with JPMorgan."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","So just one quick follow-up on that. Susie, did you say where you ended up in 2015 on that Structural Heart number?",23,"So just one quick follow-up on that. Susie, did you say where you ended up in 2015 on that Structural Heart number?"
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, we didn't give a -- we guided 75 to 100, and we did meet the high end of the range and give specific number.",25,"Yes, we didn't give a -- we guided 75 to 100, and we did meet the high end of the range and give specific number."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay, great.",2,"Okay, great."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Over 100.",2,"Over 100."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Over 100. Let me ask about SYNERGY and the launch so far the feedback we're getting is has been very positive, particularly deliverability of products. It does feel like you are trying to set a premium pricing for the product in the marketplace. Can you t",54,"Over 100. Let me ask about SYNERGY and the launch so far the feedback we're getting is has been very positive, particularly deliverability of products. It does feel like you are trying to set a premium pricing for the product in the marketplace. Can you talk about your success in doing so thus far?"
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, we're very pleased with the results. It's really tracking to our plan. In the fourth quarter, we did see U.S. DES growth in the mid-single-digit range, and now it's against about a 10% comparison from fourth quarter 2015, and so we delivered a nice n",164,"Yes, we're very pleased with the results. It's really tracking to our plan. In the fourth quarter, we did see U.S. DES growth in the mid-single-digit range, and now it's against about a 10% comparison from fourth quarter 2015, and so we delivered a nice number in the first quarter. And just as you said, we are asking, and we believe we deserve a pricing premium for the product. It's only bioabsorbable product in the marketplace with excellent stent thrombosis rates, and we also have a tiered offering that has excellent market share as well. So we think we're uniquely positioned with it and the great news is we're launching in Japan as we speak, which is obviously did market. We also received reimbursement in France. So we're really position well. We're being very careful with the launch of it, and some of it are meeting we anticipate about 50% of our mix in the U.S. and Japan by the end of the year."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","One product follow-up. Mike, it sounds like Lotus edge the timing of introducing that in Europe may be sliding. Just can you provide some clarity on that?",28,"One product follow-up. Mike, it sounds like Lotus edge the timing of introducing that in Europe may be sliding. Just can you provide some clarity on that?"
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. In terms of the slide, we do anticipate 2016 we will launch Lotus edge, and so I guess, maybe with a push that a bit, but we are confident in a 2016 launch of Lotus edge, and it really the SYNERGY. We continue to exceed our commitments with Lotus. We",94,"Yes. In terms of the slide, we do anticipate 2016 we will launch Lotus edge, and so I guess, maybe with a push that a bit, but we are confident in a 2016 launch of Lotus edge, and it really the SYNERGY. We continue to exceed our commitments with Lotus. We exceeded a high enough the range. We're on track deliver our 21-millimeter valve. We'll be launching our Lotus edge platform, and we continue to drive great outcomes on our clinical data. Maybe, Keith, you can comment some of the news you anticipated Europe."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. I mean, I think, Mike, the important thing is when we commercialize Lotus in the U.S. late in '17, we'll have edge. We'll have 5 trial sizes 21 through 29. We'll have the 14 French compatibility and increased flexibility. The 21 valve is already in c",103,"Yes. I mean, I think, Mike, the important thing is when we commercialize Lotus in the U.S. late in '17, we'll have edge. We'll have 5 trial sizes 21 through 29. We'll have the 14 French compatibility and increased flexibility. The 21 valve is already in clinical trials so that will give us 4 valves. That will be followed by the 29. And we'll anticipate edge around about Euro PCR or just after. Edge is already in clinical trials. So we're very confident about moving to the 14 French compatibility, which of course, makes us comparable with the other competitors in the market."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question is coming from the line of Bob Hopkins with Bank of America.",15,"The next question is coming from the line of Bob Hopkins with Bank of America."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","So just wanted to follow up and make sure I heard you correctly on the U.S. ICD and pacemaker pipeline and the time lines for the pipeline. So specifically could you just tell us when you expect quad pulse lead approval in the U.S. and then MRI-safe pacem",85,"So just wanted to follow up and make sure I heard you correctly on the U.S. ICD and pacemaker pipeline and the time lines for the pipeline. So specifically could you just tell us when you expect quad pulse lead approval in the U.S. and then MRI-safe pacemakers approval in the U.S. and then also give us an updated thoughts on MRI safety additional ICD and CRTD time lines for the U.S. since it feels like that's where Medtronic is having the most success."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. Really proud of our CRM business. We clearly want to grow faster, but we're in a position now, where we can see as we go forward in 2016 and '17 and beyond really the strength of the portfolio, and I'll give answers to your specific MRI questions in",294,"Sure. Really proud of our CRM business. We clearly want to grow faster, but we're in a position now, where we can see as we go forward in 2016 and '17 and beyond really the strength of the portfolio, and I'll give answers to your specific MRI questions in a second here, but we've got these product launches coming second half of '16. The SICD is really getting excellent momentum globally. We're expanding that, and we're going to be moving beyond the replacement cycle headwind. In terms of the product launches, we feel comfortable with a second quarter launch of both the quad system and the MRI pacer. The likely slipped a little bit out of first quarter into second quarter. We'll also have emblem MRI approval likely in the third quarter of 2016. So big, big approvals in second quarter and third quarter, and then as we go forward with the ICD, MRI capability we'll start that trial very quickly here, and we anticipate approval of that product likely in second quarter or third quarter of 2017. So we've got a really strong cadence of product approvals coming MRI capabilities, but I think what's most unique about our offering is this as IDD momentum that we are seeing around the world we just received approval in Japan. We have a 5% premium, reimbursement premium in Japan, continued strong acceptance of the product and training and a multiyear head start. So as you look at our business going forward, these product cadence will come through, SICD's continuing to grow and our replacement cycle headwind will reverse itself. So as you look forward to CRM, I believe that you're going to see this business strengthen in the second half of '16 and '17 and '18."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","That's very helpful, and then one for Dan. Just want to make sure I understand the margin story just specifically in the fourth quarter. Is the right way to think about operating margins in the fourth quarter and all the moving parts that you had very str",89,"That's very helpful, and then one for Dan. Just want to make sure I understand the margin story just specifically in the fourth quarter. Is the right way to think about operating margins in the fourth quarter and all the moving parts that you had very strong gross margin performance and that you took advantage of a very low tax rates invest a little bit more in SG&A than you originally anticipate it is that from a big picture perspective the right way to thing about Q4 margins?"
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, I think overall, and then I mentioned in our prepared remarks, we did have 80 basis points of the fixed asset write-offs and the litigation fees. So I wouldn't call that kind of investing for the future. So if you take that off, I'd say again as we m",103,"Yes, I think overall, and then I mentioned in our prepared remarks, we did have 80 basis points of the fixed asset write-offs and the litigation fees. So I wouldn't call that kind of investing for the future. So if you take that off, I'd say again as we mentioned very proud of where we ended for the year and the overall improvement we've had over the past 2 years. If you take 2016 and '15 together, if you're looking at almost 400 basis points of operating margin expansion. So any given quarter, you'll see fluctuations, but the overall trend is extremely positive."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of David Roman with Goldman Sachs.",13,"The next question comes from the line of David Roman with Goldman Sachs."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Maybe I will switch gears to the Urology business, and maybe, Mike, you could talk about how the integration is going with AMS and very specifically focused on some of the issues that you may be undertaking to help accelerate top line growth from where AM",57,"Maybe I will switch gears to the Urology business, and maybe, Mike, you could talk about how the integration is going with AMS and very specifically focused on some of the issues that you may be undertaking to help accelerate top line growth from where AMS was performing that's sort of the exit rate of the acquisition."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","I won't give a CRM answer on this one. So I guess, I just wanted to talk about Urology. I like what we're doing so much. So again we had nice results from fourth quarter, business growing 7% overall. Really nice job taking international markets as continu",238,"I won't give a CRM answer on this one. So I guess, I just wanted to talk about Urology. I like what we're doing so much. So again we had nice results from fourth quarter, business growing 7% overall. Really nice job taking international markets as continue to invest in our stone business and training programs. That's growing very well double digits outside the U.S. consistently. And the AMS integration's on track. Thankfully, the team did really nice to job due diligence. We did project softness the first 6 months postacquisition as we went through down distributor inventory levels to appropriate levels. That's exactly what we're seeing. So that's happening, and we'll likely we'll see continued softness in Q1, but improving in terms of the legacy AMS business and that's been offset by the BSC legacy business. As we go forward in the second quarter, we expect that legacy AMS business to grow much closer to the BSC overall growth rate, and then we will see additional benefit on top of that as we see synergies between the BPH portfolio, the stone portfolio, the ED portfolio and the incontinence portfolio overall. So really we are right on track. We're going to deliver our EPS accretion commitment of $0.03 in '16, and I think it's $0.07 in 2017. So the integrations has gone well. We've had exceptionally low turnover, and it's being met very well by the customers."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","That's helpful. And then maybe just a follow-up on the price/mix environment we serve you look at your growth rate another acceleration potentially on track for 2016 at the midpoint of your guidance organic basis and you may be sort of talk about how the",85,"That's helpful. And then maybe just a follow-up on the price/mix environment we serve you look at your growth rate another acceleration potentially on track for 2016 at the midpoint of your guidance organic basis and you may be sort of talk about how the pricing and mix environment is shaping up because at least from your and your peers reported earnings results thus far, it sounds like the environment is a tad better and maybe any thoughts from your perspective would be appreciated."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, David this is Dan. In terms of prices, as you heard, it's about 100 basis points drag on gross margin. So you can have back into what that is. Obviously, we don't make assumptions about significant improvement to the pricing environment or significa",121,"Sure, David this is Dan. In terms of prices, as you heard, it's about 100 basis points drag on gross margin. So you can have back into what that is. Obviously, we don't make assumptions about significant improvement to the pricing environment or significant deteriorations in that. It's contemplated within the range, but as we look at it, it feels stable. So their product lines that have historically declined are continuing to decline at that historical rate. They haven't moved significantly and likewise, the ones where prices stay flat and, in some cases, increase have stayed pretty constant and stable. Over the past 12 to 18 months, it felt relatively stable and the guidance for '16 assumes that for the year."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","And mix?",2,"And mix?"
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Mix in general for us, mix is a good guy. So as we sell more of the newer technologies, a lot of which Mike went through that list, the majority of those are accretive to overall Boston Scientific margins, gross margins.",41,"Mix in general for us, mix is a good guy. So as we sell more of the newer technologies, a lot of which Mike went through that list, the majority of those are accretive to overall Boston Scientific margins, gross margins."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question is coming from the line of Brooks West with Piper Jaffray.",14,"The next question is coming from the line of Brooks West with Piper Jaffray."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Let me start with Peripheral actually, a very strong performance there. You've got a lot going on. I wonder if you could give us just a little more detail on kind of product cadence, market dynamics. And if we can see the business kind of continuing to pe",53,"Let me start with Peripheral actually, a very strong performance there. You've got a lot going on. I wonder if you could give us just a little more detail on kind of product cadence, market dynamics. And if we can see the business kind of continuing to perform at this level going forward."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. The team's done a really nice job. Jeff and the Peripheral group delivered 20% growth in legacy Bayer business and 10% organically overall. So obviously very strong growth in a few quarters in a row here. And we're projected to set up really nicely",264,"Sure. The team's done a really nice job. Jeff and the Peripheral group delivered 20% growth in legacy Bayer business and 10% organically overall. So obviously very strong growth in a few quarters in a row here. And we're projected to set up really nicely in 2016. So I think just the backdrop the markets they are very healthy. We're seeing nice market growth in. Our core business, we just launched new DBT product and also clearly the growing acceptance of the drug coated technologies. So the markets overall our strong, and we really have a unique position in terms of our portfolio you've heard a lot about our drug eluting stent, Eluvia. We've been the only company with both a drug eluting stent in a drug eluting balloon in Europe, and we're also kicking off our Eluvia Imperial trial in the first half of 2016. So we are uniquely positioned in our DES. We're also launching our core SFA metal stent in Japan and Asia in China, which will help us grow that business, and we also continued to really spend globally. We're lightweight in terms of the emerging markets in Peripheral 5 years ago, and we put a lot of investment in there, and we're starting to see that become a more meaningful in places like China and Brazil, and lastly, we commented on the call about our deal. our Interventional Oncology maybe of the different than some competitors Peripheral business, but that I/O business is a strong grower for us, and we like that CeloNova transaction, particularly for the emerging markets."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","And if I could just follow up with one on, Dan, you mentioned earlier the leverage on the balance sheet was good to get back to preAMS acquisition levels by the end of the year. Can you just update us on your thoughts on acquisitions? And are you seeing v",56,"And if I could just follow up with one on, Dan, you mentioned earlier the leverage on the balance sheet was good to get back to preAMS acquisition levels by the end of the year. Can you just update us on your thoughts on acquisitions? And are you seeing valuation expectations come down in the market?"
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, Brooks. So yes, just in terms of the leverage levels that get back to about 2.5x debt to EBITDA. We remain on track do that as we had announced in conjunction with the AMS acquisition by the end of this year. We do the debt pay down that we needed t",174,"Sure, Brooks. So yes, just in terms of the leverage levels that get back to about 2.5x debt to EBITDA. We remain on track do that as we had announced in conjunction with the AMS acquisition by the end of this year. We do the debt pay down that we needed to do at the end of '15 and have in our cash flow projections in '16 to do the remainder to get to that levels will feel very comfortable there. Relative to valuations and M&A, so we're series still very active in the market relative to tuck in M&A. Obviously, screen a lot of different opportunities. I wouldn't say I've seen significant changes in valuations expectations across the landscape. It would depend on what division and what states you're talking about, but in general, the valuations have stayed fairly constant, and we are actively in the market obviously, looking for tuck-in deals, and that is part of our cash flow projection for '16 as well to be able to do some tuck-in deals."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question is coming from the line of Larry Eagleson with Wells Fargo.",14,"The next question is coming from the line of Larry Eagleson with Wells Fargo."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","So Mike, you're one of the few companies that actually showed an acceleration in emerging growth this quarter I think about 15% organic versus 13% last quarter. A lot of companies have shown the opposite trend. So my question what's the outlook in 2016? H",68,"So Mike, you're one of the few companies that actually showed an acceleration in emerging growth this quarter I think about 15% organic versus 13% last quarter. A lot of companies have shown the opposite trend. So my question what's the outlook in 2016? How comfortable -- how much visibility you have on growth in those markets? And any color would be helpful, and I had a follow-up."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","I'm sorry. The emerging markets.",6,"I'm sorry. The emerging markets."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","I'm sorry. Emerging market growth. I think you had 15% organic in Q4, I think 13% in Q3.",19,"I'm sorry. Emerging market growth. I think you had 15% organic in Q4, I think 13% in Q3."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, we were a little bit slower in second quarter, and we had nice pickup really did pick up second half of 2015 was good, but it was also more consistent with what we expected and did in 2014 quite frankly, and so it's really a continuation of ex may be",172,"Yes, we were a little bit slower in second quarter, and we had nice pickup really did pick up second half of 2015 was good, but it was also more consistent with what we expected and did in 2014 quite frankly, and so it's really a continuation of ex may be the soft quarter, 1 soft quarter, second quarter kind of a continuation of what we've been doing 2014 and what we expect to continue to do in 2016. So we had some softness in Russia in second quarter. We see that stabilize a bit. We had excellent growth in China, excellent growth in Brazil and a number of other countries it would continue to register new products, and commercial capable of these we're building articulable of his new education training centers just got back from last night so a lot of time and effort in it. We just did a joint venture deal Frankenman there in the endo business. Feel comfortable about our prospects in the mid-teens rate in emerging markets."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","And then Neuromodulation, I think has come up on this call, but you had a nice year Neuromodulation this year but obviously, the competitive dynamics are changing. So just color on 2016 and how we should think about growth and trends there and the sustain",53,"And then Neuromodulation, I think has come up on this call, but you had a nice year Neuromodulation this year but obviously, the competitive dynamics are changing. So just color on 2016 and how we should think about growth and trends there and the sustainability of the nice growth you showed in 2015."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Larry, we'll hit that in a sec, but we're going back emerging markets question.",14,"Larry, we'll hit that in a sec, but we're going back emerging markets question."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Just one other thing Larry on that. So one of the other items with respect to emerging markets is just a foreign currency exchange rates. So if you look back at Q4 and think of our 19 78 that we reported, again that included $25 million negative headwind",95,"Just one other thing Larry on that. So one of the other items with respect to emerging markets is just a foreign currency exchange rates. So if you look back at Q4 and think of our 19 78 that we reported, again that included $25 million negative headwind from FX compared to what we had talked about when we give guidance. So kind of adjusted for that we would have been over $2 billion and kind of closer to the higher and of the range and emerging markets obviously is a big piece of that."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Neuroma continues to perform well. We grew 7% in the quarter. We grew 8% full year, and we had consistently strong growth throughout the year, and we really don't see that we anticipate that trend to continue. Spectra continues to perform very well. The l",146,"Neuroma continues to perform well. We grew 7% in the quarter. We grew 8% full year, and we had consistently strong growth throughout the year, and we really don't see that we anticipate that trend to continue. Spectra continues to perform very well. The launch of Novi outside the U.S. is picking up, and we are getting a lot of we are building momentum international markets and Deep Brain Stimulation, and we'll hopefully get some good luck and get that clinical trial enrolled in '16 to position that launch. So it's a very healthy market right now, and there's a lot of patient demand, and so we like to see that markets clearly growing in the mid-single-digit range if not a bit more so with the growing market. We have some unique innovation and it's a bit more competitive, but it hasn't slowed down our performance."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you. With that, we'd like to go conclude the call. Thank you very much for joining us today, and we sincerely appreciate your interest in Boston Scientific. Before you disconnect, David will give you all the details for the replay.",41,"Thank you. With that, we'd like to go conclude the call. Thank you very much for joining us today, and we sincerely appreciate your interest in Boston Scientific. Before you disconnect, David will give you all the details for the replay."
317627,321212230,926312,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, this conference will be made available for replay after 10:30 Eastern Standard Time today until February 18 at midnight. You may access is the AT&T playback service any time by dialing 1 (800) 475-6701 and entering access code, 38146",70,"Ladies and gentlemen, this conference will be made available for replay after 10:30 Eastern Standard Time today until February 18 at midnight. You may access is the AT&T playback service any time by dialing 1 (800) 475-6701 and entering access code, 381463. International participants may dial 1 (320) 365-3844. That does conclude our conference for today. Thank you for your participation and for using AT&T Teleconference. You may now disconnect."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Q4 2015 Boston Scientific Earnings Call. [Operator Instructions] And as a reminder, this conference is being recorded. I'd now like to turn the conference over to our host, Ms. Susie Lisa.",45,"Ladies and gentlemen, thank you for standing by. Welcome to the Q4 2015 Boston Scientific Earnings Call. [Operator Instructions] And as a reminder, this conference is being recorded. 
I'd now like to turn the conference over to our host, Ms. Susie Lisa. Please go ahead."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, David. Good morning, everyone. Thanks for joining us. With me on today's call are Mike Mahoney, President and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.We issued a press release earlier thi",378,"Thank you, David. Good morning, everyone. Thanks for joining us. With me on today's call are Mike Mahoney, President and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.
We issued a press release earlier this morning announcing our fourth quarter and full year 2015 results, which included reconciliations of the non-GAAP measures used in the release. We have posted a copy of that release as well as reconciliations of the non-GAAP measures used in today's call to the Investor Relations section of our website under the heading Financial Information.
The duration of this morning's call will be approximately 1 hour. Mike will provide strategic and revenue highlights of the fourth quarter. Dan will review the financials for the quarter and then provide first quarter '16 and full year 2016 guidance, and then we'll take your questions. During today's Q&A session, Mike and Dan will be joined by our Chief Medical Officers, Dr. Keith Dawkins and Dr. Ken Stein. 
Before we begin, I'd like to remind everyone that on the call, organic revenue growth is defined as excluding the impact of sales from divested businesses, changes in foreign currency exchange rates and sales from the acquisition of the American Medical Systems, or AMS, male urology portfolio over the prior year period.
Also note, this call contains forward-looking statements within the meaning of federal securities laws, which may be identified by words like anticipate, expect, believe, estimate and other similar words. They include, among other things, statements about our growth and market share; new product approvals and launches; clinical trials; cost savings and growth opportunities; our cash flow and expected use; our financial performance, including sales, margins, earnings and other Q4 and full year 2015 results and Q1 and full year 2016 guidance; as well as our tax rates, R&D spend and other expenses.
Actual results may differ materially from those discussed in the forward-looking statements. Factors that may cause such differences include those described in the Risk Factors section of our most recent 10-K and subsequent 10-Qs and 8-Ks filed with the SEC.
These statements speak only as of today's date, and we disclaim any intention or obligation to update them.
At this point, I'll turn it over to Mike for his comments. Mike?"
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Susie, and good morning, everyone. In fourth quarter, Boston Scientific posted another quarter of strong results and closed out an excellent 2015 as we continued to execute against our strategic plan goals. At our May 2015 Investor Day meetin",2223,"Thank you, Susie, and good morning, everyone. 
In fourth quarter, Boston Scientific posted another quarter of strong results and closed out an excellent 2015 as we continued to execute against our strategic plan goals. At our May 2015 Investor Day meeting, we outlined plans to drive mid-single-digit organic revenue growth and consistent adjusted operating margin expansion, which, in turn, will drive double-digit adjusted EPS growth excluding the impact of FX. 
We are delivering against these objectives. In Q4, we grew worldwide sales 5% organically and 10% operationally, which includes the benefit of the AMS urology business. We also grew adjusted operating income by 10% in the fourth quarter, which represents 100 basis point year-over-year improvement to 21.7%. 
The solid revenue growth and margin expansion drove very strong 18% adjusted EPS growth to $0.26, and our fourth quarter results reflect our focus on delivering meaningful innovation, while also providing clinical and economic value to our hospital to customers. 
Importantly, our Q4 results built upon the consistent momentum generated over the past few years and contributed to the following full year '15 results. For the full year, we delivered 5% organic revenue growth and 8% operational revenue growth, which includes the acquired sales from Bayer Peripheral and AMS.
In parallel with the consistent revenue growth, we are driving a strong improvements through our operating margin. In 2014, we delivered 130-basis-point improvement in adjusted operating margin. In 2015, we delivered an additional 210-basis-point improvement to a full year 22.3%. In prior previous goals, we continue to expect to deliver 25% plus adjusted operating margin in 2017 with plans to deliver an additional 200 to 300 basis points of improvement by year-end 2020. 
We delivered full year of '15 adjusted EPS growth -- I'm sorry, EPS of $0.93, representing 11% growth for the full year. It's important to note that the 11% adjusted EPS growth includes a significant negative foreign exchange impact of $0.10 versus our original expectation of a $0.04 hit when we originally gave '15 guidance. We're very pleased that we're able to overcome this FX headwind while investing in the long-term growth of the company, yet still delivering on our commitment for double-digit adjusted EPS growth. 
We continue to believe that Boston Scientific is uniquely positioned to deliver differentiated shareholder value through durable mid-single-digit revenue growth and double-digit adjusted EPS growth via our ongoing operating margin improvement initiatives. We're excited by our 2016 and our plans to build upon our global momentum. 
In 2016, we're targeting full year organic revenue growth of 4% to 7% and operational revenue growth of 7% to 10%. We're guiding adjusted EPS to $1.03 to $1.07, which represents 11% to 15% earnings growth. Importantly, this EPS once again includes an expected $0.06 negative impact from foreign exchange. 
I'll now provide some highlights on fourth quarter and '15 results along with thoughts on our '16 outlook. In my remarks, I'll reference to growth in an organic year-over-year constant currency basis, unless otherwise specified. 
Our fourth quarter organic revenue growth of 5% was broad-based across businesses and regions. It's led by exciting new product launches, which continued; global expansion; and execution of our category leadership strategy. With the exception of the anticipated 1% decline in CRM sales, all of our other businesses grew organic revenue by at least 6%, led by 10% growth in PI. IC had a strong quarter, growing 6% against a very tough 10% comp in Q4 2014. And importantly, all 3 medical/surgical businesses grew revenue at 7%, while also improving segmented adjusted operating margin by 90 basis points year-over-year to 34.1%. 
We delivered another quarter of balanced global growth, led by 6% revenue growth in Asia, 5% growth in the U.S. and Europe. Another highlight was strong 15% revenue growth in emerging markets, led by 20% growth in China and Brazil. 
The MedSurg businesses continued to deliver. In Endoscopy, we delivered 7% growth in Q4, fueled by the strength of our portfolio, our expanding global commercial reach and ongoing launches of our SpyGlass DS and AXIOS Stents. SpyGlass DS was launched in July 2015, and is an advance single-use visualization system for the diagnosis and treatment of complex disorders of the pancreas and bile ducts. It's truly a cornerstone product that is highly differentiated and complementary to our core Endo portfolio. Our AXIOS Stent is used for transluminal drainage of pancreatic fluid collections and is also off to a strong start. We'll continue to innovate in endoscopic ultrasound and other exciting therapeutic categories, including pulmonary and oncology, to further enhance our global leadership in Endoscopy. 
Urology and Pelvic Health also continued a strong performance trend, growing 7% organically in Q4, led by laser fibers, capital equipment and strong international growth. Importantly, this quarter, we launched LithoVue, a disposable uterus scope, which provides customers with visualization and navigation capabilities to diagnose and treat stones and other conditions of the kidney, uterus and bladder. And after closing the AMS Urology acquisition in August, we remain on track to realize our adjusted EPS accretion goals of at least $0.03 in 2016 and $0.07 in 2017. 
Neuromodulation revenue grew 7% in the fourth quarter, led by strong growth in both the U.S. and international. Sales were driven by the market-leading Spectra platform and the launch of Precision Novi, our first product of the primary cell non-rechargeable market. 
In addition, we're seeing really promising uptake of our precise Deep Brain Stimulation system due to its Cartesian directional lead system and our partnership with Brainlab. Our U.S. DBS trial's making progress, and we expect to complete enrollment in 2016 and enter the market in late 2017 or early '18. 
Our Cardiovascular group grew 7% in Q4, led by impressive 10% growth in Peripheral Interventions. The core PI business continues to execute, and we're very pleased with integration of the legacy Bayer business. The legacy Bayer business grew over 20% for the second quarter in a row as we continue to grow share in the atherectomy market, and we're encouraged by our early results from the global launch of our ZelanteDVT catheter and the U.S. launch of our Innova Stent for the SFA. We also recently began to enroll our IMPERIAL U.S. IDE trial for Eluvia, our drug-eluting stent, and remain on track for a European launch of Eluvia this quarter. 
In addition, we recently closed the CeloNova transaction, which is a synergistic tuck-in acquisition focused on the treatment of liver cancer via localized delivery of chemotherapeutic agents. 
And finally in PI, we continue to benefit from our commercial relationship with C.R. Bard and the Lutonix Drug Coated Balloon technology. 
Interventional Cardiology continues to deliver, with 6% growth in the quarter, which represents the sixth consecutive quarter of plus 6% growth in IC. Growth was led by worldwide imaging, U.S. and European drug-eluting stents, our complex PCI portfolio and structural heart. 
PCI guidance grew low-teens globally, and we're encouraged by the market enthusiasm of our fractional flow reserve platform. In DES, the U.S. synergy launch is going well. We anticipate that synergy will represent approximately 50% of our DES revenue mix in the U.S. by the end of 2016. 
In addition, we're launching SYNERGY in Japan, and we'll continue to expand SYNERGY in other international markets. We also continue to divest and build upon a strong clinical evidence for SYNERGY as we have initiated the EVOLVE Short DAPT Study. 
Finally, the IC performance was fueled by our strengthening structural heart business, which includes our Lotus Aortic Valve and WATCHMAN Left Atrial Appendage Closure Device. We're truly in an exciting position to drive growth and share gains over the long run in these fast-growing markets. 
Lotus delivered a strong quarter for the -- in the European market as the platform continues to build momentum despite our near-term size major [ph] limitations. Lotus offers physicians excellent control during implantation and best-in-class paravalvular leakage rates. In our RESPOND Post-Market Study, 95.1% of patients had 0 to trace PVL.
Importantly, we completed enrollment in our REPRISE III IDE study in December, which we anticipate will position us for a late 2017 U.S. market entrance. We're also pleased to announce completion of the 1,000-patient RESPOND Lotus Post-Market Study and those results will be presented at EuroPCR in May. We're expanding the Lotus platform and expect to launch our next-gen 14 French delivery system along with additional sizes in Europe this year. 
Also in structural heart, the U.S. WATCHMAN launch continues to progress ahead of plan. We're pleased with the implant success rates and the high quality of patient outcomes thus far, which reflect our controlled rollout and proven training program. 
In addition, Dr. Vivek Reddy of Mount Sinai recently published in JACC a study highlighting WATCHMAN's cost-effectiveness versus both warfarin and novel oral anticoagulants. In the U.S., we opened more than 100 WATCHMAN accounts in 2015 and expect to open an additional 100 accounts in 2016. 
In Europe, we're looking forward to a full launch of our second-gen WATCHMAN FLX, which also -- which already has CE Mark. As our U.S. reimbursement, we will await final NCD decision from CMS by February 8, and we remain confident that WATCHMAN will represent at least a $500 million worldwide market opportunity. 
So overall, we're very pleased with our progress in structural heart and excited about our capabilities and the long-term prospects for this business. We exceeded our full year of '15 structural heart revenue goal of $75 million to $100 million, and in 2016, we anticipate structural heart sales between $175 million and $200 million. 
Now turning to CRM. On our first quarter '15 earnings call, we projected a slowdown in our worldwide CRM sales for the balance of '15 and through first quarter '16, primarily due to replacement cycle headwinds and competitive launches in the U.S. Our forecast is accurate as global CRM sales declined 1% in Q4. However, we're very encouraged about our forward-looking CRM position given the strong cadence of new launches expected in the U.S. and Japan in '16, our leading position and growing awareness of S-ICD and our replacement cycle headwind becoming more favorable as we exit 2016. 
In the U.S., we plan to launch our full X4 quad system with our ACCOLADE brady MRI-safe system in the first half and the EMBLEM MRI-safe in the second half of '16. And we anticipate these releases will strengthen 2016 CRM performance, particularly in the second half. 
Pacemaker sales again grew 2%, and we recently launched X4 CRT-P quad device. And while our ICD sales declined 2%, we continue to be pleased with our de novo ICD performance, in the EMBLEM S-ICD in particular. EMBLEM continues to drive strong growth in de novo shared gains in both the Europe and the U.S. EMBLEM is building momentum globally, and we look forward to launching EMBLEM in Japan this quarter with a reimbursement premium and expanding S-ICD to additional international markets in 2016. 
In Europe, we continue to gain share and grow our CRM business in the mid-single-digit range with our complete portfolio. These consistent European CRM results are encouraging as we look forward to our anticipated U.S. approvals in '16. 
Lastly in CRM, we're continuously mounting third-party evidence of the economic benefits associated with our EnduraLife extended battery technology. And recently, another third-party data set from the Europace was published, demonstrating the 6-year survival of BSC CRT-Ds over our competitors. 
Also, recent U.S. study modeled a 14% reduction in Medicare cost from a 2-year increase in ICD battery longevity. And an Italian study showed Extended Longevity drove a 29% to 34% reduction in long-term health care costs over a 15-year period. 
Turning to our EP business. We delivered 8% growth in the quarter. Arrhythmia platform continues to rollout nicely, driven by new installations and higher case volumes. We have a strong arrhythmia customer pipeline in 2016 as well as new platform enhancements scheduled for release. 
We did see some softness in EP in fourth quarter, primarily driven by the delay in our European launch of our IntellaMap ablation catheter, which we anticipate launching later in the first quarter. We continue to strengthen our EP business, and we look forward to continued progress in 2016. 
Our strategy of category leadership is working, and it's helping us to become a stronger partner with our global customers. As the health care environment continues to evolve, we're building new capabilities to support our customers be on our part of portfolio with our ADVANTICS solutions offerings. These offerings are focused on driving operational excellence within Cardiovascular and GI labs and improving a standardizing care for chronic cardiovascular diseases. And just last week, we announced an alliance with Accenture to develop a data-driven digital health solution to improve patient outcomes and reduce costs to treat patients with chronic cardiovascular diseases. 
So to wrap up my section, our company has great momentum, and our 2015 results reflect the strength of our portfolio and our ongoing investment into faster growth markets, our globalization efforts and the execution of our global teams. More importantly, we believe that we are well positioned to continue and strengthen our performance track record in 2016 and beyond. I would like to thank our employees for their winning spirit and a great commitment to Boston Scientific. 
Now let me turn the call over to Dan for a more detailed review of our financials."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Mike. I'll start with some overall perspective on the quarter before getting into the details. We generated adjusted earnings per share of $0.26, exceeding the high end of our guidance range of $0.23 to $0.25 and representing 18% year-over-year",2750,"Thanks, Mike. I'll start with some overall perspective on the quarter before getting into the details. 
We generated adjusted earnings per share of $0.26, exceeding the high end of our guidance range of $0.23 to $0.25 and representing 18% year-over-year growth in the quarter. Excluding a $0.03 unfavorable foreign exchange impact, Q4 adjusted earnings per share grew 31% year-over-year. The strong performance in Q4 was driven primarily by operational revenue growth and gross margin expansion. 
Our Q4 2015 adjusted operating margin of 21.7% represents an improvement of 100 basis points over the fourth quarter of 2014. For the full year 2015, total company adjusted operating margin expanded by 210 basis points over the full year of '14, and we effectively offset a $0.10 FX headwind through operational savings and initiatives. 
Our full year 2015 adjusted earnings per share of $0.93 represents 11% growth and 23% growth excluding FX versus 2014. 
Now for the P&L highlights. For the fourth quarter of 2015, consolidated revenue of $1,978,000,000 represented operational growth of 10%, which excludes the impact of foreign exchange. Excluding an approximate 500 basis point contribution from the AMS male urology portfolio, organic revenue growth was 5% in the quarter. 
On an as-reported basis, revenue grew 5% year-over-year. The foreign exchange impact on sales was a $110 million headwind compared to the prior year period, which was about $25 million worse than we assumed in our Q4 guidance range. 
Adjusted gross margin for the fourth quarter was 72.8%, increasing 140 basis points year-over-year. The increase resulted primarily from cost improvements, driven by our value improvement programs, as the impact of foreign exchange was negligible in the quarter. 
For the full year 2015, adjusted gross margin was 72% compared to 70.7% for the full year 2014. The 130 basis point full year adjusted gross margin improvement was driven by benefits of 180 and 50 basis points from cost improvements and FX, respectively. This was partially offset by 100 basis points of headwind attributed primarily to price. 
Adjusted SG&A expenses were $757 million or 38.3% of sales in the fourth quarter, down 10 basis points year-over-year. The Q4 rate includes 80 basis points of higher spend related to fixed asset write-offs, full year related benefits and litigation fees. 
Our full year 2015 adjusted SG&A rate of 37.4% is down 50 basis points versus the full year 2014. As a reminder, the medical device tax has been suspended for 2016 and 2017, which would benefit our adjusted SG&A rate by roughly 100 basis points annually. We're pleased to see that this tax has been temporarily suspended and intend to reinvest virtually all of the benefit into jobs, innovation, R&D, collaborations with universities and other initiatives that will help treat patients and sustain top line growth over the long term. 
We expect the reinvestment of approximately 100 basis points to be split roughly equally between R&D and SG&A. Our guidance for full year 2016 assumes our adjusted SG&A rate will come down by a total of 140 basis points at the midpoint, which breaks down into 50 basis points from the medical device tax suspension and 90 basis points from operational improvements. 
Adjusted research and development expenses were $238 million in the fourth quarter or 12% of sales. For the full year 2015, adjusted R&D expenses were $850 million or 11.4% of sales. We expect our full year 2016 adjusted R&D rate to be roughly 11.5%. Again, this includes a 50-basis-point increase due to the reinvestment of the medical device tax, offset by increased efficiencies and improved utilization of our global footprint. 
Royalty expense was 0.9% of sales in both the fourth quarter and the full year 2015. This represents a 60-basis-point reduction compared to the full year 2014 rate, and we expect our royalty rate to remain at approximately 1% of sales in 2016. 
On an adjusted basis, operating income was $429 million in the quarter or 21.7% of sales, up 100 basis points year-over-year. We are very pleased with our consistent adjusted operating margin improvement throughout 2015 as we saw year-over-year improvement of at least 100 basis points in each of the 4 quarters. 
Rhythm Management's adjusted operating margin in Q4 was 13.9%, down substantially from Q3 2015, which resulted in a second half 2015 Rhythm Management adjusted operating margin of 15.9%, falling short of our expectation of 17% due to the timing of manufacturing variances and reserve charges as we transition our portfolio and prepare for new product launches in 2016. Full year 2015 Rhythm Management adjusted operating margin of 15% represents an improvement of 160 basis points over the full year 2014. 
And turning to 2016, we expect Rhythm Management adjusted operating margin to increase sequentially in Q1 versus Q4 of '15, with more noticeable improvement in Q2 as we begin to realize the full benefit of 2016 product costs and leverage the improved top line performance expected from the global CRM and EP franchises. And the second half 2016 Rhythm Management adjusted operating margin is also expected to benefit from our Plant Network Optimization program completed at the end of 2015, which transferred a portion of our EP manufacturing to lower-cost locations. 
The net of all these factors drive our expectation for full year Rhythm Management adjusted operating margin to approach 18% for the full year 2016, and we remain confident in 20% plus in 2017. 
GAAP operating income, which includes GAAP to adjusted items of $700 million, was a loss of $271 million in Q4 2015. The primary GAAP to adjusted items for the quarter included restructuring-related charges of $26 million, acquisition-related SG&A expenses of $15 million, contingent consideration expense of $37 million, amortization expense of $135 million and litigation-related charges of $456 million. 
The $456 million in litigation-related net charges were primarily related to increases in our litigation reserve for a recent appellate court ruling in Maryland in the Mirowski case, with the remainder related to a combination of increases in our transvaginal surgical mesh product liability reserves and other adjustments. The Mirowski case traces back to the mid-2000 and relates to licensing agreement on patents that have expired. We continue to believe that the facts and the law do not support the court's findings or the amount of the damages, and we plan to seek review of the judgment by the Maryland Supreme Court. 
We increased our mesh reserve this quarter as we became aware of additional claims during the quarter as we continue to work through the settlement evaluation process. Currently, our known claim count is approximately 35,000, and we've agreed in principle to settle over 10,000 of those 35,000 claims. We intend to continue to contest cases against us vigorously, while also looking to settle when reasonable terms are presented. Our total legal reserve was $1,936,000,000 as of December 31, 2015. 
Separately, a case was recently filed against Boston Scientific in West Virginia regarding the resin use in our transvaginal mesh products. We are confident that the resin used in the manufacturing of these devices is neither counterfeit nor adulterated and meets required material biocompatibility and design specifications. We've provided information and materials to DEKRA, a European notified body, the FDA and the Department of Justice regarding the resin, our quality processes and our commitment to producing medical devices of the highest quality. 
Now I'll move on to other income and expense. Interest expense for the quarter was $59 million compared to $54 million in Q4 of 2014. The increase was primarily due to the incremental debt raised in Q2 of 2015 to finance the AMS male urology portfolio acquisition. 
Our average interest rate was 3.9% in Q4 2015 compared to 4.8% in Q4 2014. The lower interest expense rate in Q4 2015 was primarily due to lower average cost of debt resulting from the senior notes refinancing completed in Q2 of 2015. 
Other expense was $10 million, and this consisted primarily of foreign exchange losses and investment losses incurred during the quarter. Our tax rate for the fourth quarter was 58% on a reported basis and 0.2% on an adjusted basis. 
Our Q4 adjusted tax rate includes $3.9 million of favorable discrete tax items and other onetime benefits primarily related to foreign exchange. Excluding these items, our Q4 operational tax rate would have been 13%. 
Now I'll provide a bit more detail on our full year 2015 adjusted tax rate, where our guidance as of the third quarter had been 13%. As you may know, the U.S. R&D tax credit was permanently reinstated in December, which benefited the full year 2015 adjusted tax rate by slightly more than 100 basis points. We've decided to reinvest this benefit in our tax structure to improve long-term flexibility in our capital structure. The net result of this being a 13% adjusted tax rate for the full year excluding discrete and onetime tax items and a 9.2% rate including them. After this onetime investment, we continue to expect an approximately 100-basis-point increase in our adjusted tax rate annually, and therefore continue to expect our full year 2016 adjusted tax rate to be approximately 14%. 
Finally, as mentioned, Q4 2015 adjusted EPS of $0.26 includes approximately $0.03 of unfavorable foreign exchange and represents 18% year-over-year growth or 31% growth, excluding the impact of foreign exchange. On a reported GAAP basis, Q4 2015 EPS was a loss of $0.11 and includes net charges and amortization expenses totaling $504 million after tax. The GAAP loss of $0.11 compares to a GAAP loss of $0.23 in the fourth quarter of 2014. For the full year 2015, we reported adjusted EPS of $0.93, exceeding our guidance range while absorbing $0.10 of unfavorable FX. Recall this is $0.02 more than we expected as of our Q3 2015 earnings call and $0.06 more than we had expected at the beginning of 2015. 
Full year 2015 adjusted EPS grew 11% over prior year and 23% excluding the impact of foreign exchange. On a reported GAAP basis, 2015 EPS was a loss of $0.18 compared to a full year 2014 GAAP loss per share of $0.09. 
Moving on to the balance sheet. Days sales outstanding of 59 days, increased 1 day compared to December of 2014. Days inventory on hand of 163 days, was up 7 days compared to December of last year due primarily to the acquisition of the AMS male urology portfolio. 
Capital expenditures were $86 million in Q4 2015 compared to $79 million in Q4 2014. For the full year 2015, capital expenditures were $248 million. For the full year 2016, we expect capital expenditures to be roughly $100 million higher, primarily due to the construction of our new manufacturing facility and distribution center in Malaysia. Beyond 2016, we expect capital expenditures to return to our historical run rate of approximately $250 million annually. 
Adjusted free cash flow for the quarter was $448 million compared to $508 million in Q4 2014. Our full year 2015 adjusted free cash flow of $1,366,000,000 represents growth of 8% over the full year 2014. For 2016, we expect full year adjusted free cash flow to exceed $1.5 billion, representing growth of 10%, and have a stretch goal to exceed $1.6 billion for the year with initiatives aimed at improving the working capital contribution to cash flow. 
In Q4, we repaid $150 million of our term loan and expect to repay an additional $250 million by the end of 2016. At which time, we expect our debt leverage will be consistent with our goal of returning to pre-AMS debt leverage by year-end. There were no share repurchases in the quarter, consistent with our decision to suspend the share repurchase program temporarily following the announcement of the AMS male urology portfolio acquisition. At near term, our capital allocation priorities are to repay debt, manage contingencies and pursue tuck-in M&A. 
We ended 2015 with 1,363,000,000 fully diluted weighted average shares outstanding, consistent with our prior guidance. We expect our share count to increase by roughly 5 million per quarter through the end of 2016 as we plan to keep the buyback suspended for the balance of 2016. We expect this to result in a fully diluted weighted average share count of approximately 1,380,000,000 for the full year 2016. 
I'd like to conclude with guidance for Q1 and full year 2016. For the full year, we expect consolidated revenue to be in the range of $7,900,000,000 to $8,100,000,000, which represents year-over-year growth of 4% to 7% on an organic basis, 7% to 10% on an operational basis and 6% to 8% on a reported basis. 
As a result of a stronger dollar at current rates, we expect foreign exchange to be a roughly $150 million headwind for the full year 2016 on revenue. We expect our adjusted gross margin for the year, as a percentage of sales, to be in a range of 72% to 73%. We expect foreign exchange to have an unfavorable impact of approximately 50 basis points on adjusted gross margin in 2016 as hedging contracts from our 3-year program are layered in. We expect this headwind be offset by a favorable mix, market segmentation, the ramp of accretive new products and our standard cost-reduction programs. 
As mentioned, we expect our full year 2016 adjusted SG&A rate to be between 35.5% and 36.5% of sales and our full year R&D rate to be between 11% and 12% of sales. This implies a full year 2016 adjusted operating margin in the range of 23.5% to 24.5%, the midpoint of which represents 170 basis points of improvement over full year 2015. 
And importantly, we remain on track to achieve an adjusted operating margin of 25% plus in 2017. Full year 2016 interest expense is expected to be $245 million, about $10 million higher than the full year 2015 due to incremental debt raised in Q2 of 2015. 
As mentioned, we expect our tax rate for the full year 2016 to be approximately 14%. As a result, we expect adjusted earnings per share for the full year 2016 to be in a range of $1.03 to $1.07, representing 11% to 15% adjusted earnings per share growth. We expect 2016 adjusted earnings per share to be impacted negatively by approximately $0.06 of FX or roughly $80 million of adjusted income. In terms of timing, this $0.06 should be roughly $0.02 per quarter in Q1 and Q2 and $0.01 per quarter in Q3 and Q4. 
Excluding the $0.06 of unfavorable foreign exchange, our full year adjusted EPS guidance range represents growth of 17% to 21%. Despite this approximate $0.06 hit, we remain confident in our ability to deliver double-digit adjusted EPS growth. 
Let me walk you through the 2016 adjusted EPS guidance. We delivered adjusted EPS of $0.93 in 2015, representing 11% growth or 23% growth excluding the $0.10 of negative FX impact. As you know, our stated goal is to grow EPS double digits, which would imply $1.02 in 2016. Adding $0.03 of AMS accretion gets us to $1.05, which is the midpoint of our guidance. 
We expect unfavorable FX of approximately $0.06, as I mentioned, but our goal is to offset this through operational initiatives and savings as we did in 2015. And as mentioned, the medical device tax is worth roughly 100 basis points on the OM line, but we intend to reinvest substantially all of that back into innovation and have developed the detailed plans to do so. On a GAAP basis, we expect EPS to be in a range of $0.62 to $0.67. Lastly, for 2016 our guidance assumes pretax amortization of approximately $534 million. 
Now turning to the first quarter of 2016. We expect consolidated revenues to be in a range of $1,890,000,000 to $1,940,000,000. If current foreign exchange rates hold constant, the headwind from foreign exchange should be approximately $45 million or 250 basis points relative to Q1 2015. 
We expect consolidated Q1 sales to grow year-over-year in a range of 4% to 6% organically and 9% to 11% operationally. 
For the first quarter, adjusted earnings per share is expected to be in a range of $0.23 to $0.25 per share, and GAAP earnings per share is expected to be in a range of $0.11 to $0.13 per share. 
I encourage you to check our Investor Relations website for Q4 2015 financial and operational highlights, which outlines Q4 results as well as Q1 and full year 2016 guidance, including P&L line item guidance. 
So with that, I will turn it back to Susie, who will moderate the Q&A."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Dan. David, let's open it up to questions for the next 25 minutes or so. [Operator Instructions] David, please go ahead.",22,"Thanks, Dan. David, let's open it up to questions for the next 25 minutes or so. [Operator Instructions] David, please go ahead."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","[Operator Instructions] The first question comes from the line of David Lewis with Morgan Stanley.",15,"[Operator Instructions] The first question comes from the line of David Lewis with Morgan Stanley."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Just a couple of quick questions on '16 guidance. So the first is your guidance at the top end of the range, it's 7% [indiscernible] higher than we expected. I guess, we expected 4% to 6%. So what factors get us to the top end of the range? And specifical",61,"Just a couple of quick questions on '16 guidance. So the first is your guidance at the top end of the range, it's 7% [indiscernible] higher than we expected. I guess, we expected 4% to 6%. So what factors get us to the top end of the range? And specifically, what's assumed for WATCHMAN? And then I had a quick follow-up."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, David. Yes, the guidance 4% to 7% is higher than we showed at recent Investor Day meeting. In terms of get into the higher end of the range, we still have to have some good results on our product launches with SYNERGY, WATCHMAN, ongoing advancemen",169,"Thanks, David. Yes, the guidance 4% to 7% is higher than we showed at recent Investor Day meeting. In terms of get into the higher end of the range, we still have to have some good results on our product launches with SYNERGY, WATCHMAN, ongoing advancements of Lotus. We have key product approvals that we're expecting in the first half. Those need to come through. We also launched a number of key products in Japan with SYNERGY and also S-ICD, so we need some strong execution there and continued emerging market growth. So it's -- we've got a lot of product launches, a number of approvals needed. So to delivered the top end of that, we have to have excellent commercial execution and great execution on the regulatory side. Potentially, you have some of the downside. We continue to manage, as I mentioned, some of the CRM headwinds, which we anticipate will, after Q1, improve in second quarter and then improve dramatically in the second half of the year."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","That's very helpful, Mike. And then specifically in AMS and CRM, just to follow-up there. In the fourth quarter was there anything particular with that third quarter, fourth quarter slight decline? Was there anything particular or unique to the fourth qua",74,"That's very helpful, Mike. And then specifically in AMS and CRM, just to follow-up there. In the fourth quarter was there anything particular with that third quarter, fourth quarter slight decline? Was there anything particular or unique to the fourth quarter that you can cite? And then once again, your confidence, what specifically implied in '16 numbers? Does that the '16 guidance imply an improvement in the CRM business in '16 over '15?"
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. So we're really pleased with, quite frankly, our overall Urology business and the AMS deal. The business grew 7% in fourth quarter. And -- I'm sorry, was your first question on Urology? Or is it all CRM-related?",38,"Yes. So we're really pleased with, quite frankly, our overall Urology business and the AMS deal. The business grew 7% in fourth quarter. And -- I'm sorry, was your first question on Urology? Or is it all CRM-related?"
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","I'm happy to hear about Urology, but I was focused on CRM.",13,"I'm happy to hear about Urology, but I was focused on CRM."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Sorry, jet-lagged from Asia.",4,"Sorry, jet-lagged from Asia."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","We'll hold the Uro comments for later, I guess. So on the CRM, we do anticipate improvement clearly in 2016, as I mentioned, particularly in the second half. We anticipate the launch of the approval of the pace MRI and the quad in the second quarter, and",73,"We'll hold the Uro comments for later, I guess. So on the CRM, we do anticipate improvement clearly in 2016, as I mentioned, particularly in the second half. We anticipate the launch of the approval of the pace MRI and the quad in the second quarter, and we'll also have favorable comps in second quarter, third quarter and fourth quarter. So we do see a strength in the CRM business in 2016."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Rick Wise with Stifel.",12,"The next question comes from the line of Rick Wise with Stifel."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Just a couple of things. Maybe start with the CRM operating margin. Dan, you did a very clear job of laying out the factors, the timing, that 15.9% instead of your 17% goal. Is the whole of that these variances? And do you come into '16 thinking that -- d",71,"Just a couple of things. Maybe start with the CRM operating margin. Dan, you did a very clear job of laying out the factors, the timing, that 15.9% instead of your 17% goal. Is the whole of that these variances? And do you come into '16 thinking that -- do we start off with that sort of 17% level or better as we head into the first quarter or first half?"
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Rick. Yes, I think the way I would say -- characterized that is on the Q3 call, we had talked about kind of being in that 17% range for the back half of '15. The variances were a piece of it. We also had a little bit higher R&D, about 60 basis poi",214,"Thanks, Rick. Yes, I think the way I would say -- characterized that is on the Q3 call, we had talked about kind of being in that 17% range for the back half of '15. The variances were a piece of it. We also had a little bit higher R&D, about 60 basis points in the quarter. That's timing. That's just going to come 1 quarter to another, so that doesn't concern me. The manufacturing and the inventory reserve charges are really in anticipation of the launches that Mike just mentioned around the MRI-safe brady and the quad launch in the U.S. So those are kind of out of the way now at this point as opposed to having had to take those in different quarters. So I think the way I would think of it is the 13.9% in Q4, I'd expect a little bit of a sequential improvement in Q1. Not a tremendous amount, just a little bit. Q2 gets a little bit better than that. And really, the back half is where it accelerates to get to that overall 18% for the year. So I wouldn't look for Q1 to be in that 18% range or Q2. But I think the net of the year, we're very comfortable with that 18%."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","And just one product-specific question. WATCHMAN, a possible entry up here real soon. And if I understood you correctly, you're basically saying that it's still a $500 million market if that early language holds. But what is the language is basically equi",93,"And just one product-specific question. WATCHMAN, a possible entry up here real soon. And if I understood you correctly, you're basically saying that it's still a $500 million market if that early language holds. But what is the language is basically equivalent to the FDA approval label? Docs are telling us that they're doing 4 patients a month, and that would double if that were the case. Is that the way you see it? And so then is it back to a $1 billion market? How do we think about all that?"
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Well, it's -- overall, we're obviously very proud of our success in 2015 with WATCHMAN. In structural heart overall, we've delivered the high end of the range there. We opened up 100 accounts. We're going to hear the NCD decision very shortly here. But ov",112,"Well, it's -- overall, we're obviously very proud of our success in 2015 with WATCHMAN. In structural heart overall, we've delivered the high end of the range there. We opened up 100 accounts. We're going to hear the NCD decision very shortly here. But overall, we continue to expect guidances in '16 of $175 million to $200 million, and our job will be to continue to focus on the penetration rate. With 15 million or so eligible patients, we'll continue to drive training programs, excellent outcomes. But for now, we'll continue with our $175 million to $200 million range, and we'll see what happens over the next few days on the reimbursement."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Ken, you want to add anything?",6,"Ken, you want to add anything?"
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, Rick, I'd say we -- well, we have some concerns about that first draft of the proposed NCD. Overall, it was consistent with our expectations, which are that the NCD we expect to be more limited than the full FDA label. Likewise, I always expected to",88,"Yes, Rick, I'd say we -- well, we have some concerns about that first draft of the proposed NCD. Overall, it was consistent with our expectations, which are that the NCD we expect to be more limited than the full FDA label. Likewise, I always expected to have the registry, et cetera. And as Mike said, we've always assumed modest penetration into the indicated population. And really, where we go is much more dependent on our ability to train new physicians to use the device safely and effectively."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Mike Weinstein with JPMorgan.",12,"The next question comes from the line of Mike Weinstein with JPMorgan."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","So just one quick follow-up on that. So did you say where you ended up for 2015 on that structural heart number?",23,"So just one quick follow-up on that. So did you say where you ended up for 2015 on that structural heart number?"
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","We didn't give a -- we guided $75 million to $100 million, and we beat the high end of the range. We didn't give a specific number.",28,"We didn't give a -- we guided $75 million to $100 million, and we beat the high end of the range. We didn't give a specific number."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","But you didn't give the exact number. Okay, great.",10,"But you didn't give the exact number. Okay, great."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Over $100 million.",3,"Over $100 million."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Over $100 million, understood. So let me ask about SYNERGY and the launch. So far, the feedback we're getting has been very positive, particularly on the deliverability of the product. It does feel like you are trying to set a premium pricing for the prod",59,"Over $100 million, understood. So let me ask about SYNERGY and the launch. So far, the feedback we're getting has been very positive, particularly on the deliverability of the product. It does feel like you are trying to set a premium pricing for the product in the marketplace. Can you talk about your success in doing so thus far?"
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, we're very pleased with the results. It's really tracking to our plan. In the fourth quarter, we did see U.S. DES growth in the mid-single-digit range, and now it's against about a 10% comparison from fourth quarter 2015. And so we delivered a nice n",170,"Yes, we're very pleased with the results. It's really tracking to our plan. In the fourth quarter, we did see U.S. DES growth in the mid-single-digit range, and now it's against about a 10% comparison from fourth quarter 2015. And so we delivered a nice number in the first quarter. And just as you said, we are asking, and we believe we deserve a pricing premium for the product. It's the only bioabsorbable product in the marketplace with excellent stent thrombosis rates, and we also have a tiered offering that has excellent market share as well. So we think we're uniquely positioned with it. And the great news is, is we're launching in Japan as we speak, which is obviously a big market, and we also received reimbursements in France. So we're really positioned well. We're being very careful with the launch of it. And similar to our comments at your meeting, we anticipate about 50% of our mix in the U.S. and Japan by the end of the year."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Great. I've got one product follow-up. Mike, it sounds like, Lotus EDGE, the timing of introducing that in Europe may be sliding. Just -- can you provide some clarity on that?",31,"Great. I've got one product follow-up. Mike, it sounds like, Lotus EDGE, the timing of introducing that in Europe may be sliding. Just -- can you provide some clarity on that?"
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, the -- in terms of sliding, we do anticipate 2016, we will launch Lotus EDGE. And so we do -- I guess, maybe, we did push that a bit. But we are confident in the 2016 launch of Lotus EDGE. And it -- similar to some of the comments in SYNERGY, we cont",107,"Yes, the -- in terms of sliding, we do anticipate 2016, we will launch Lotus EDGE. And so we do -- I guess, maybe, we did push that a bit. But we are confident in the 2016 launch of Lotus EDGE. And it -- similar to some of the comments in SYNERGY, we continue to exceed our commitments with Lotus. We exceeded the high end of our range. We're on track deliver our 21-millimeter valve. We'll be launching our Lotus EDGE platform, and we continue to drive great outcomes on our clinical data. Maybe, Keith, you could comment on some of the news you anticipated at Europe."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. I mean, I think, Mike, the important thing is when we commercialize Lotus in the U.S. late in '17, we'll have EDGE. We'll have 5 trial sizes, 21 through 29. We'll have the [indiscernible] 14 French compatibility and increased flexibility. The 21-valv",100,"Yes. I mean, I think, Mike, the important thing is when we commercialize Lotus in the U.S. late in '17, we'll have EDGE. We'll have 5 trial sizes, 21 through 29. We'll have the [indiscernible] 14 French compatibility and increased flexibility. The 21-valve is already in clinical trials, so that'll give us 4 valves. That'll be followed by the 29. And we'll anticipate EDGE around about EuroPCR or just after. EDGE is already in clinical trials. So we're very confident about moving to the 14 french compatibility, which of course, makes us comparable with the other competitors in the market."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question is coming from the line of Bob Hopkins with Bank of America.",15,"The next question is coming from the line of Bob Hopkins with Bank of America."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","So just wanted to follow-up and make sure I heard you correctly on the U.S. ICD and pacemaker pipeline and the time lines for the pipeline. So specifically, could you just tell us when you expect quad pulse CRT-D lead approval in the U.S. and then MRI-saf",84,"So just wanted to follow-up and make sure I heard you correctly on the U.S. ICD and pacemaker pipeline and the time lines for the pipeline. So specifically, could you just tell us when you expect quad pulse CRT-D lead approval in the U.S. and then MRI-safe pacemaker approval in the U.S.? And then also give us an updated thoughts on MRI-safe traditional ICD and CRT-D time lines for the U.S. since it feels like that's where Medtronic is having the most success."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. I'm really proud of our CRM business. We clearly want to grow faster. But we're in a position now where we can see, as we go forward in 2016 and '17 and beyond, really the strength of the portfolio. And I'll give answers to your specific MRI questio",300,"Sure. I'm really proud of our CRM business. We clearly want to grow faster. But we're in a position now where we can see, as we go forward in 2016 and '17 and beyond, really the strength of the portfolio. And I'll give answers to your specific MRI questions in a second here. But we've got these product launches coming in the second half of '16. The S-ICD is really getting excellent momentum globally. We're expanding that, and we're going to be moving beyond the replacement cycle headwind. In terms of the product launches, we feel comfortable with a second quarter launch of both the quad system and MRI pacer. The MRI pacer likely slipped a little bit out of first quarter into second quarter. We'll also have EMBLEM MRI approval likely in the third quarter of 2016. So big, big approvals in the second quarter and third quarter. And then as we go forward with the ICD MRI capability, we'll start that trial very quickly here, and we anticipate approval of that product likely in second quarter or third quarter of 2017. So we've got a really strong cadence of product approvals coming, MRI capabilities. But I think what's most unique about our offering is this S-ICD momentum that we're seeing around the world. We just received approval in Japan. We have a 5% premium -- reimbursement premium in Japan, continued strong acceptance of the product and training in a multiyear head start. So as you looked at our business going forward, these product cadence will come through. SICD is continuing to grow, and our replacement cycle headwind will reverse itself. So as you look forward to CRM, I really believe that you're going to see this business strengthen in the second half of '16 and '17 and '18."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Great. That's very helpful. And then one for Dan. I just want to make sure I understand the margin story, just specifically in the fourth quarter. Is the right way to think about operating margins in the fourth quarter and all the moving parts that you ha",91,"Great. That's very helpful. And then one for Dan. I just want to make sure I understand the margin story, just specifically in the fourth quarter. Is the right way to think about operating margins in the fourth quarter and all the moving parts that you had very strong gross margin performance, and that you took advantage of a very low tax rate to invest a little bit more in SG&A than you originally anticipate? It is that, from a big picture perspective, the right way to thing about Q4 margins?"
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. I think, overall, and then as I mentioned in our prepared remarks, the -- we did have 80 basis points of the fixed asset write-offs and the litigation fees. So I wouldn't call that kind of investing for the future. So if you take that off, I'd say we",108,"Yes. I think, overall, and then as I mentioned in our prepared remarks, the -- we did have 80 basis points of the fixed asset write-offs and the litigation fees. So I wouldn't call that kind of investing for the future. So if you take that off, I'd say we, again, as we mentioned, very proud of where we ended for the year and the overall improvement we've had over the past 2 years. If you take 2016 and '15 together, you'd be looking at almost 400 basis points of operating margin expansion. So in a given quarter, you'll see fluctuations, but the overall trend is extremely positive."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of David Roman with Goldman Sachs.",13,"The next question comes from the line of David Roman with Goldman Sachs."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Maybe I will switch gears to the Urology business. And maybe, Mike, you could talk about how the integration is going with AMS and very specifically focused on some of the issues that you may be undertaking to help accelerate top line growth from where AM",57,"Maybe I will switch gears to the Urology business. And maybe, Mike, you could talk about how the integration is going with AMS and very specifically focused on some of the issues that you may be undertaking to help accelerate top line growth from where AMS was performing at sort of the exit rate of the acquisition."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","I won't give a CRM answer on this one. So I guess, I just wanted to talk about Urology because I like what we're doing here so much. So we -- again, we had nice results from fourth quarter, business growing 7% overall. Really nice job taking international",243,"I won't give a CRM answer on this one. So I guess, I just wanted to talk about Urology because I like what we're doing here so much. So we -- again, we had nice results from fourth quarter, business growing 7% overall. Really nice job taking international markets as we continue to invest in our stone business and training programs. That's growing very well, double-digits outside the U.S. consistently. And the AMS integration's on track. Thankfully, the team did a really nice to job due diligence. We did project some softness the first 6 months post-acquisition as we wanted to bleed down distributor inventory levels to appropriate levels, and that's exactly what we're seeing. So that's happening. And we likely we'll see continued softness in Q1, but improving in terms of the legacy AMS business, and that's been offset by the BSC legacy business. As we go forward in the second quarter, we expect that legacy AMS business to grow much closer to the BSC overall growth rate. And then we'll see additional benefit on top of that as we see synergies between the BPH portfolio, the stone portfolio, the ED portfolio and the incontinence portfolio overall. So really, we're right on track. We're going to deliver our EPS accretion commitment of $0.03 in '16, and I think it's $0.07 in 2017. So the integration's going well. We've had exceptionally low turnover, and it's being met very well by the customers."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","That's helpful. And then maybe just a follow-up on the price/mix environment. As we sort of look at your growth rate, another acceleration potentially untapped for 2016 at the midpoint of your guidance on an organic basis. Can you just sort of talk about",86,"That's helpful. And then maybe just a follow-up on the price/mix environment. As we sort of look at your growth rate, another acceleration potentially untapped for 2016 at the midpoint of your guidance on an organic basis. Can you just sort of talk about how the pricing and mix environment is shaping up? Because at least from your peers who have reported earnings results thus far, it sounds like the environment is a tad better, but maybe any thoughts from your perspective would be appreciated."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, David. This is Dan. In terms of price, as you heard, we mentioned it's about 100-basis-point drag on gross margins, so you can kind of back into what that is. Obviously, we don't make assumptions about significant improvements in the pricing environ",123,"Sure, David. This is Dan. In terms of price, as you heard, we mentioned it's about 100-basis-point drag on gross margins, so you can kind of back into what that is. Obviously, we don't make assumptions about significant improvements in the pricing environment or significant deteriorations in that. It's contemplated within the range. But as we look at it, it feels stable. So the product lines that have historically declined are continuing to decline at that historical rate. They haven't moved significantly. And likewise, the ones where prices stay flat, and in some cases, increase, have stayed pretty constant and stable. So over the past 12 to 18 months, it felt relatively stable, and the guidance for '16 assumes that through the year."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","And mix?",2,"And mix?"
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Mix -- in general for us, mix is a good guy. So as we sell more of the newer technologies, a lot of which Mike went through that list, the majority of those are accretive to overall Boston Scientific margins -- gross margins.",43,"Mix -- in general for us, mix is a good guy. So as we sell more of the newer technologies, a lot of which Mike went through that list, the majority of those are accretive to overall Boston Scientific margins -- gross margins."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question is coming from the line of Brooks West with Piper Jaffray.",14,"The next question is coming from the line of Brooks West with Piper Jaffray."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Let me start with Peripheral, actually. Very strong performance there. You've got a lot going on. I wonder if you could give us just a little more detail on kind of product cadence, market dynamics. And if we can see the business kind of continuing to per",52,"Let me start with Peripheral, actually. Very strong performance there. You've got a lot going on. I wonder if you could give us just a little more detail on kind of product cadence, market dynamics. And if we can see the business kind of continuing to perform at this level going forward."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. The team's done a really nice job. Jeff Mirviss and the Peripheral group delivered 20% growth in legacy Bayer business and 10% organically overall. So obviously, very strong growth in a few quarters in a row here. And we're projected to set up reall",272,"Sure. The team's done a really nice job. Jeff Mirviss and the Peripheral group delivered 20% growth in legacy Bayer business and 10% organically overall. So obviously, very strong growth in a few quarters in a row here. And we're projected to set up really nicely in 2016. So I think just the backdrop, the markets there are very healthy. We're seeing nice market growth in atherectomy; our core business, we just launched a new DBT product; and also, clearly, the growing acceptance of the drug coated technologies. So the markets, overall, are strong. And we really have a unique position in terms of our portfolio. You've heard a lot about our drug-eluting stent, Eluvia. We'll be the only company with both a drug-eluting stent in a drug-eluting balloon in Europe. And we're also kicking off our Eluvia IMPERIAL trial in the first half of 2016. So we are uniquely positioned in our DES. We're also launching a number of our core SFA metal stents in Japan and Asia, in China, which will help us grow that business. And we also continue to really spend globally. We've been -- we were lightweight in terms of the emerging markets in Peripheral 5 years ago, and we've put a lot of investment in there. We're starting to see that become more meaningful in places like China and Brazil. And lastly, we commented on the call about our CeloNova deal. our Interventional Oncology may be a little bit different than some competitors' Peripheral business. But that IO business is a strong grower for us, and we like that CeloNova transaction, particularly for the emerging markets."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","And if I could just follow-up with one on -- Dan, you mentioned earlier the leverage on the balance sheet was going to get back to pre-AMS acquisition levels by the end of the year. Can you just update us on your thoughts on acquisitions? And are you seei",57,"And if I could just follow-up with one on -- Dan, you mentioned earlier the leverage on the balance sheet was going to get back to pre-AMS acquisition levels by the end of the year. Can you just update us on your thoughts on acquisitions? And are you seeing valuation expectations come down in the market?"
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, Brooks. So yes, just in terms of the leverage levels, that's to get back to about a 2.5x debt to EBITDA. We remain on track to do that as we had announced in conjunction with the AMS acquisition by the end of this year. We did the debt pay down that",179,"Sure, Brooks. So yes, just in terms of the leverage levels, that's to get back to about a 2.5x debt to EBITDA. We remain on track to do that as we had announced in conjunction with the AMS acquisition by the end of this year. We did the debt pay down that we needed to do at the end of '15 and have in our cash flow projections in '16 to do the remainder to get to that level, so we feel very comfortable there. Relative to valuations and M&A, so we're very -- still very active in the market relative to tuck-in M&A. Obviously, screened a lot of different opportunities. I wouldn't say I've seen significant changes in valuation expectations across the landscape. It would depend on what division and what state you're talking about. But in general, the valuations have stayed fairly constant, and we are actively in the market, obviously, looking for a tuck-in deal. And that is part of our cash flow projection for '16 as well, to be able to do some tuck-in deals."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question is coming from the line of Larry Biegelsen with Wells Fargo.",14,"The next question is coming from the line of Larry Biegelsen with Wells Fargo."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","So Mike, you're one of the few companies that actually showed an acceleration and emerging growth this quarter, I think about 15% organic versus 13% last quarter. A lot of companies have shown the opposite trend. So my question is what's the outlook in 20",70,"So Mike, you're one of the few companies that actually showed an acceleration and emerging growth this quarter, I think about 15% organic versus 13% last quarter. A lot of companies have shown the opposite trend. So my question is what's the outlook in 2016? How comfortable -- how much visibility do you have on growth in those markets? And any color would be helpful, and I had a follow-up."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","I'm sorry. Reflected the emerging markets?",7,"I'm sorry. Reflected the emerging markets?"
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","I'm sorry. Yes, emerging market growth. I think you had 15% organic in Q4. I think 13% in Q3.",20,"I'm sorry. Yes, emerging market growth. I think you had 15% organic in Q4. I think 13% in Q3."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. We were a little bit slower in second quarter, and we had nice pick-up. Really, the pick-up in the second half of 2015 was good, but it was also more consistent with what we expected and did in 2014, quite frankly. And so it's really a continuation o",179,"Yes. We were a little bit slower in second quarter, and we had nice pick-up. Really, the pick-up in the second half of 2015 was good, but it was also more consistent with what we expected and did in 2014, quite frankly. And so it's really a continuation of ex maybe a soft quarter, 1 soft quarter, the second quarter, kind of a continuation of what we've been doing in 2014 and what we expect to continue to do in 2016. So we had some softness in Russia in the second quarter. We've seen that stabilize a bit. We had excellent growth in China, excellent growth in Brazil and a number of other countries. So we continue to register new products, add commercial capabilities, we're building R&D capabilities, new education training centers. I just got back from there last night. So we put a lot of time and effort in it. We just did a joint venture deal with Frankenman there in the endo business. So we feel comfortable about our prospects in that mid-teens rate in emerging markets."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","And then Neuromodulation, I don't think has come up on this call, but you had a nice year in Neuromodulation this year. But obviously, there's -- the competitive dynamics are changing. So just color on 2016 and how we should think about growth and trends",57,"And then Neuromodulation, I don't think has come up on this call, but you had a nice year in Neuromodulation this year. But obviously, there's -- the competitive dynamics are changing. So just color on 2016 and how we should think about growth and trends there and the sustainability of the nice growth you showed in 2015."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Larry, we'll hit that in a sec, but we're going back to the emerging markets revenue question versus indiscernible].",19,"Larry, we'll hit that in a sec, but we're going back to the emerging markets revenue question versus indiscernible]."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Just one other thing, Larry, on that. So one of the other items with respect to emerging markets is just the foreign currency exchange rates. So if you look back at Q4 and think of our $1,978 million that we reported, again that included $25 million negat",95,"Just one other thing, Larry, on that. So one of the other items with respect to emerging markets is just the foreign currency exchange rates. So if you look back at Q4 and think of our $1,978 million that we reported, again that included $25 million negative headwind from FX compared to what we had talked about when we give guidance. So kind of adjusted for that, we would have been over $2 billion and kind of closer to the higher end of the range. And emerging markets, obviously, is a big piece of that."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","And Neuromod continues to perform well. We grew 7% in the quarter. We grew 8% the full year, and we had consistently strong growth throughout the year. And we really don't see that -- we anticipate that trend to continue. Spectra continues to perform very",152,"And Neuromod continues to perform well. We grew 7% in the quarter. We grew 8% the full year, and we had consistently strong growth throughout the year. And we really don't see that -- we anticipate that trend to continue. Spectra continues to perform very well. The launch of Novi outside the U.S. is picking up, and we are getting a lot of -- we are building momentum in international markets in Deep Brain Stimulation, and we'll hopefully get some good luck and get that clinical trial enrolled in '16 to position that launch. So it's a very healthy market right now, and there's a lot of patient demand. And so we like to see that, that market's clearly growing in the mid-single-digit range, if not, a bit more. So it's a growing market. We have some unique innovation. And it's a bit more competitive, but it hasn't slowed down our performance."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you. With that, we'd like to go conclude the call. Thank you very much for joining us today, and we sincerely appreciate your interest in Boston Scientific. Before you disconnect, David will give you all the details for the replay.",41,"Thank you. With that, we'd like to go conclude the call. Thank you very much for joining us today, and we sincerely appreciate your interest in Boston Scientific. Before you disconnect, David will give you all the details for the replay."
317627,321212230,926653,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, this conference will be made available for replay after 10:30 Eastern Standard Time today until February 18 at midnight. You may access the AT&T playback service at any time by dialing 1 (800) 475-6701 and entering access code 381463",70,"Ladies and gentlemen, this conference will be made available for replay after 10:30 Eastern Standard Time today until February 18 at midnight. You may access the AT&T playback service at any time by dialing 1 (800) 475-6701 and entering access code 381463. International participants may dial 1 (320) 365-3844. That does conclude our conference for today. Thank you for your participation and for using AT&T Teleconference. You may now disconnect."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Q4 2015 Boston Scientific Earnings Call. [Operator Instructions] And as a reminder, this conference is being recorded. I'd now like to turn the conference over to our host, Ms. Susie Lisa.",45,"Ladies and gentlemen, thank you for standing by. Welcome to the Q4 2015 Boston Scientific Earnings Call. [Operator Instructions] And as a reminder, this conference is being recorded. 
I'd now like to turn the conference over to our host, Ms. Susie Lisa. Please go ahead."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, David. Good morning, everyone. Thanks for joining us. With me on today's call are Mike Mahoney, President and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.We issued a press release earlier thi",378,"Thank you, David. Good morning, everyone. Thanks for joining us. With me on today's call are Mike Mahoney, President and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.
We issued a press release earlier this morning announcing our fourth quarter and full year 2015 results, which included reconciliations of the non-GAAP measures used in the release. We have posted a copy of that release as well as reconciliations of the non-GAAP measures used in today's call to the Investor Relations section of our website under the heading Financial Information.
The duration of this morning's call will be approximately 1 hour. Mike will provide strategic and revenue highlights of the fourth quarter. Dan will review the financials for the quarter and then provide first quarter '16 and full year 2016 guidance, and then we'll take your questions. During today's Q&A session, Mike and Dan will be joined by our Chief Medical Officers, Dr. Keith Dawkins and Dr. Ken Stein. 
Before we begin, I'd like to remind everyone that on the call, organic revenue growth is defined as excluding the impact of sales from divested businesses, changes in foreign currency exchange rates and sales from the acquisition of the American Medical Systems, or AMS, male urology portfolio over the prior year period.
Also note, this call contains forward-looking statements within the meaning of federal securities laws, which may be identified by words like anticipate, expect, believe, estimate and other similar words. They include, among other things, statements about our growth and market share; new product approvals and launches; clinical trials; cost savings and growth opportunities; our cash flow and expected use; our financial performance, including sales, margins, earnings and other Q4 and full year 2015 results and Q1 and full year 2016 guidance; as well as our tax rates, R&D spend and other expenses.
Actual results may differ materially from those discussed in the forward-looking statements. Factors that may cause such differences include those described in the Risk Factors section of our most recent 10-K and subsequent 10-Qs and 8-Ks filed with the SEC.
These statements speak only as of today's date, and we disclaim any intention or obligation to update them.
At this point, I'll turn it over to Mike for his comments. Mike?"
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Susie, and good morning, everyone. In fourth quarter, Boston Scientific posted another quarter of strong results and closed out an excellent 2015 as we continued to execute against our strategic plan goals. At our May 2015 Investor Day meetin",2224,"Thank you, Susie, and good morning, everyone. 
In fourth quarter, Boston Scientific posted another quarter of strong results and closed out an excellent 2015 as we continued to execute against our strategic plan goals. At our May 2015 Investor Day meeting, we outlined plans to drive mid-single-digit organic revenue growth and consistent adjusted operating margin expansion, which, in turn, will drive double-digit adjusted EPS growth excluding the impact of FX. 
We are delivering against these objectives. In Q4, we grew worldwide sales 5% organically and 10% operationally, which includes the benefit of the AMS urology business. We also grew adjusted operating income by 10% in the fourth quarter, which represents 100 basis point year-over-year improvement to 21.7%. 
The solid revenue growth and margin expansion drove very strong 18% adjusted EPS growth to $0.26, and our fourth quarter results reflect our focus on delivering meaningful innovation, while also providing clinical and economic value to our hospital to customers. 
Importantly, our Q4 results built upon the consistent momentum generated over the past few years and contributed to the following full year '15 results. For the full year, we delivered 5% organic revenue growth and 8% operational revenue growth, which includes the acquired sales from Bayer Peripheral and AMS.
In parallel with the consistent revenue growth, we are driving a strong improvements through our operating margin. In 2014, we delivered 130-basis-point improvement in adjusted operating margin. In 2015, we delivered an additional 210-basis-point improvement to a full year 22.3%. In per our previous goals, we continue to expect to deliver 25% plus adjusted operating margin in 2017 with plans to deliver an additional 200 to 300 basis points of improvement by year-end 2020. 
We delivered full year of '15 adjusted EPS growth -- I'm sorry, EPS of $0.93, representing 11% growth for the full year. It's important to note that the 11% adjusted EPS growth includes a significant negative foreign exchange impact of $0.10 versus our original expectation of a $0.04 hit when we originally gave '15 guidance. We're very pleased that we're able to overcome this FX headwind while investing in the long-term growth of the company, yet still delivering on our commitment for double-digit adjusted EPS growth. 
We continue to believe that Boston Scientific is uniquely positioned to deliver differentiated shareholder value through durable mid-single-digit revenue growth and double-digit adjusted EPS growth to beat our ongoing operating margin improvement initiatives. We're excited by our 2016 and our plans to build upon our global momentum. 
In 2016, we're targeting full year organic revenue growth of 4% to 7% and operational revenue growth of 7% to 10%. We're guiding adjusted EPS to $1.03 to $1.07, which represents 11% to 15% earnings growth. Importantly, this EPS once again includes an expected $0.06 negative impact from foreign exchange. 
I'll now provide some highlights on fourth quarter and '15 results along with thoughts on our '16 outlook. In my remarks, I'll reference to growth in an organic year-over-year constant currency basis, unless otherwise specified. 
Our fourth quarter organic revenue growth of 5% was broad-based across businesses and regions. It's led by exciting new product launches, which continued; global expansion; and execution of our category leadership strategy. With the exception of the anticipated 1% decline in CRM sales, all of our other businesses grew organic revenue by at least 6%, led by 10% growth in PI. IC had a strong quarter, growing 6% against a very tough 10% comp in Q4 2014. And importantly, all 3 medical/surgical businesses grew revenue at 7%, while also improving segmented adjusted operating margin by 90 basis points year-over-year to 34.1%. 
We delivered another quarter of balanced global growth, led by 6% revenue growth in Asia, 5% growth in the U.S. and Europe. Another highlight was strong 15% revenue growth in emerging markets, led by 20% growth in China and Brazil. 
The MedSurg businesses continued to deliver. In Endoscopy, we delivered 7% growth in Q4, fueled by the strength of our portfolio, our expanding global commercial reach and ongoing launches of our SpyGlass DS and AXIOS Stents. SpyGlass DS was launched in July 2015, and is an advanced single-use visualization system for the diagnosis and treatment of complex disorders of the pancreas and bile ducts. It's truly a cornerstone product that is highly differentiated and complementary to our core Endo portfolio. Our AXIOS Stent is used for transluminal drainage of pancreatic fluid collections and is also off to a strong start. We'll continue to innovate in endoscopic ultrasound and other exciting therapeutic categories, including pulmonary and oncology, to further enhance our global leadership in Endoscopy. 
Urology and Pelvic Health also continued a strong performance trend, growing 7% organically in Q4, led by laser fibers, capital equipment and strong international growth. Importantly, this quarter, we launched LithoVue, a disposable uterus scope, which provides customers with visualization and navigation capabilities to diagnose and treat stones and other conditions of the kidney, uterus and bladder. And after closing the AMS Urology acquisition in August, we remain on track to realize our adjusted EPS accretion goals of at least $0.03 in 2016 and $0.07 in 2017. 
Neuromodulation revenue grew 7% in the fourth quarter, led by strong growth in both the U.S. and international. Sales were driven by the market-leading Spectra platform and the launch of Precision Novi, our first product of the primary cell non-rechargeable market. 
In addition, we're seeing really promising uptake of our precise Deep Brain Stimulation system due to its Cartesian directional lead system and our partnership with Brainlab. Our U.S. DBS trial is making progress, and we expect to complete enrollment in 2016 and enter the market in late 2017 or early '18. 
Our Cardiovascular group grew 7% in Q4, led by impressive 10% growth in Peripheral Interventions. The core PI business continues to execute, and we're very pleased with integration of the legacy Bayer business. The legacy Bayer business grew over 20% for the second quarter in a row as we continue to grow share in the atherectomy market, and we're encouraged by our early results from the global launch of our ZelanteDVT catheter and the U.S. launch of our Innova Stent for the SFA. We also recently began to enroll our IMPERIAL U.S. IDE trial for Eluvia, our drug-eluting stent, and remain on track for a European launch of Eluvia this quarter. 
In addition, we recently closed the CeloNova transaction, which is a synergistic tuck-in acquisition focused on the treatment of liver cancer via localized delivery of chemotherapeutic agents. 
And finally in PI, we continue to benefit from our commercial relationship with C.R. Bard and the Lutonix Drug Coated Balloon technology. 
Interventional Cardiology continues to deliver, with 6% growth in the quarter, which represents the sixth consecutive quarter of plus 6% growth in IC. Growth was led by worldwide imaging, U.S. and European drug-eluting stents, our complex PCI portfolio and structural heart. 
PCI guidance grew low-teens globally, and we're encouraged by the market enthusiasm of our integrated fractional flow reserve platform. In DES, the U.S. SYNERGY launch is going extremely well. We anticipate that SYNERGY will represent approximately 50% of our DES revenue mix in the U.S. by the end of 2016. 
In addition, we're launching SYNERGY in Japan, and we'll continue to expand SYNERGY in other international markets. We also continue to invest in building upon a strong clinical evidence for SYNERGY as we have initiated the EVOLVE Short DAPT Study. 
Finally, the IC performance was fueled by our strengthening structural heart business, which includes our Lotus Aortic Valve and WATCHMAN Left Atrial Appendage Closure Device. We're truly in an exciting position to drive growth and share gains over the long run in these fast-growing markets. 
Lotus delivered a strong quarter for the -- in the European market as the platform continues to build momentum despite our near-term size matrix limitations. Lotus offers physicians excellent control during implantation and best-in-class paravalvular leakage rates. In our RESPOND Post-Market Study, 95.1% of patients had 0 to trace PVL.
Importantly, we completed enrollment in our REPRISE III IDE study in December, which we anticipate will position us for a late 2017 U.S. market entrance. We're also pleased to announce completion of the 1,000-patient RESPOND Lotus Post-Market Study and those results will be presented at EuroPCR in May. We're expanding the Lotus platform and expect to launch our next-gen 14 French delivery system along with additional sizes in Europe this year. 
Also in structural heart, the U.S. WATCHMAN launch continues to progress ahead of plan. We're pleased with the implant success rates and the high quality of patient outcomes thus far, which reflect our controlled rollout and proven training program. 
In addition, Dr. Vivek Reddy of Mount Sinai recently published in JACC a study highlighting WATCHMAN's cost-effectiveness versus both warfarin and novel oral anticoagulants. In the U.S., we opened more than 100 WATCHMAN accounts in 2015 and expect to open an additional 100 accounts in 2016. 
In Europe, we're looking forward to a full launch of our second-gen WATCHMAN FLX, which also -- which already has CE Mark. After U.S. reimbursement, we will await final NCD decision from CMS by February 8, and we remain confident that WATCHMAN will represent at least a $500 million worldwide market opportunity. 
So overall, we're very pleased with our progress in structural heart and excited about our capabilities and the long-term prospects for this business. We exceeded our full year of '15 structural heart revenue goal of $75 million to $100 million, and in 2016, we anticipate structural heart sales between $175 million and $200 million. 
Now turning to CRM. On our first quarter '15 earnings call, we projected a slowdown in our worldwide CRM sales for the balance of '15 and through first quarter '16, primarily due to replacement cycle headwinds and competitive launches in the U.S. Our forecast is accurate as global CRM sales declined 1% in Q4. However, we're very encouraged about our forward-looking CRM position given the strong cadence of new launches expected in the U.S. and Japan in '16, our leading position and growing awareness of S-ICD and our replacement cycle headwind becoming more favorable as we exit 2016. 
In the U.S., we plan to launch our full X4 quad system with our ACCOLADE brady MRI-safe system in the first half and the EMBLEM MRI-safe in the second half of '16. And we anticipate these releases will strengthen 2016 CRM performance, particularly in the second half. 
Pacemaker sales again grew 2%, and we recently launched X4 CRT-P quad device. And while our ICD sales declined 2%, we continue to be pleased with our de novo ICD performance in the EMBLEM S-ICD in particular. EMBLEM continues to drive strong growth in de novo shared gains in both the Europe and the U.S. EMBLEM is building momentum globally, and we look forward to launching EMBLEM in Japan this quarter with a reimbursement premium and expanding S-ICD to additional international markets in 2016. 
In Europe, we continue to gain share and grow our CRM business in the mid-single-digit range with our complete portfolio. These consistent European CRM results are encouraging as we look forward to our anticipated U.S. approvals in '16. 
Lastly in CRM, we're continuously mounting third-party evidence of the economic benefits associated with our EnduraLife extended battery technology. And recently, another third-party data set from the Europace was published, demonstrating the 6-year survival of BSC CRT-Ds over our competitors. 
Also, recent U.S. study modeled a 14% reduction in Medicare cost from a 2-year increase in ICD battery longevity. And an Italian study showed Extended Longevity drove a 29% to 34% reduction in long-term health care costs over a 15-year period. 
Turning to our EP business. We delivered 8% growth in the quarter. Arrhythmia platform continues to rollout nicely, driven by new installations and higher case volumes. We have a strong arrhythmia customer pipeline in 2016 as well as new platform enhancements scheduled for release. 
We did see some softness in EP in fourth quarter, primarily driven by the delay in our European launch of our IntellaMap ablation catheter, which we anticipate launching later in the first quarter. We continue to strengthen our EP business, and we look forward to continued progress in 2016. 
Our strategy of category leadership is working, and it's helping us to become a stronger partner with our global customers. As the health care environment continues to evolve, we're building new capabilities to support our customers beyond our product portfolio with our ADVANTICS solutions offerings. These offerings are focused on driving operational excellence within Cardiovascular and GI labs and improving a standardizing care for chronic cardiovascular diseases. And just last week, we announced an alliance with Accenture to develop a data-driven digital health solution to improve patient outcomes and reduce costs to treat patients with chronic cardiovascular diseases. 
So to wrap up my section, our company has great momentum, and our 2015 results reflect the strength of our portfolio and our ongoing investment into faster growth markets, our globalization efforts and the execution of our global teams. More importantly, we believe that we are well positioned to continue and strengthen our performance track record in 2016 and beyond. I would like to thank our employees for their winning spirit and a great commitment to Boston Scientific. 
Now let me turn the call over to Dan for a more detailed review of our financials."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Mike. I'll start with some overall perspective on the quarter before getting into the details. We generated adjusted earnings per share of $0.26, exceeding the high end of our guidance range of $0.23 to $0.25 and representing 18% year-over-year",2753,"Thanks, Mike. I'll start with some overall perspective on the quarter before getting into the details. 
We generated adjusted earnings per share of $0.26, exceeding the high end of our guidance range of $0.23 to $0.25 and representing 18% year-over-year growth in the quarter. Excluding a $0.03 unfavorable foreign exchange impact, Q4 adjusted earnings per share grew 31% year-over-year. The strong performance in Q4 was driven primarily by operational revenue growth and gross margin expansion. 
Our Q4 2015 adjusted operating margin of 21.7% represents an improvement of 100 basis points over the fourth quarter of 2014. For the full year 2015, total company adjusted operating margin expanded by 210 basis points over the full year of '14, and we effectively offset a $0.10 FX headwind through operational savings and initiatives. 
Our full year 2015 adjusted earnings per share of $0.93 represents 11% growth and 23% growth excluding FX versus 2014. 
Now for the P&L highlights. For the fourth quarter of 2015, consolidated revenue of $1,978,000,000 represented operational growth of 10%, which excludes the impact of foreign exchange. Excluding an approximate 500 basis point contribution from the AMS male urology portfolio, organic revenue growth was 5% in the quarter. 
On an as-reported basis, revenue grew 5% year-over-year. The foreign exchange impact on sales was a $110 million headwind compared to the prior year period, which was about $25 million worse than we assumed in our Q4 guidance range. 
Adjusted gross margin for the fourth quarter was 72.8%, increasing 140 basis points year-over-year. The increase resulted primarily from cost improvements, driven by our value improvement programs, as the impact of foreign exchange was negligible in the quarter. 
For the full year 2015, adjusted gross margin was 72% compared to 70.7% for the full year 2014. The 130 basis point full year adjusted gross margin improvement was driven by benefits of 180 and 50 basis points from cost improvements and FX, respectively. This was partially offset by 100 basis points of headwinds attributed primarily to price. 
Adjusted SG&A expenses were $757 million or 38.3% of sales in the fourth quarter, down 10 basis points year-over-year. The Q4 rate includes 80 basis points of higher spend related to fixed asset write-offs, full year related benefits and litigation fees. 
Our full year 2015 adjusted SG&A rate of 37.4% is down 50 basis points versus the full year 2014. As a reminder, the medical device tax has been suspended for 2016 and 2017, which would benefit our adjusted SG&A rate by roughly 100 basis points annually. We're pleased to see that this tax has been temporarily suspended and intend to reinvest virtually all of the benefit into jobs, innovation, R&D, collaborations with universities and other initiatives that will help treat patients and sustain top line growth over the long term. 
We expect the reinvestment of approximately 100 basis points to be split roughly equally between R&D and SG&A. Our guidance for full year 2016 assumes our adjusted SG&A rate will come down by a total of 140 basis points at the midpoint, which breaks down into 50 basis points from the medical device tax suspension and 90 basis points from operational improvements. 
Adjusted research and development expenses were $238 million in the fourth quarter or 12% of sales. For the full year 2015, adjusted R&D expenses were $850 million or 11.4% of sales. We expect our full year 2016 adjusted R&D rate to be roughly 11.5%. Again, this includes a 50 basis point increase due to the reinvestment of the medical device tax, offset by increased efficiencies and improved utilization of our global footprint. 
Royalty expense was 0.9% of sales in both the fourth quarter and the full year 2015. This represents a 60-basis-point reduction compared to the full year 2014 rate, and we expect our royalty rate to remain at approximately 1% of sales in 2016. 
On an adjusted basis, operating income was $429 million in the quarter or 21.7% of sales, up 100 basis points year-over-year. We are very pleased with our consistent adjusted operating margin improvement throughout 2015 as we saw year-over-year improvement of at least 100 basis points in each of the 4 quarters. 
Rhythm Management's adjusted operating margin in Q4 was 13.9%, down substantially from Q3 2015, which resulted in a second half 2015 Rhythm Management adjusted operating margin of 15.9%, falling short of our expectation of 17% due to the timing of manufacturing variances and reserve charges as we transition our portfolio and prepare for new product launches in 2016. Full year 2015 Rhythm Management adjusted operating margin of 15% represents an improvement of 160 basis points over the full year 2014. 
And turning to 2016, we expect Rhythm Management adjusted operating margins to increase sequentially in Q1 versus Q4 of '15, with more noticeable improvement in Q2 as we begin to realize the full benefit of 2016 product costs and leverage the improved top line performance expected from the global CRM and EP franchises. And the second half 2016 Rhythm Management adjusted operating margin is also expected to benefit from our Plant Network Optimization program completed at the end of 2015, which transferred a portion of our EP manufacturing to lower-cost locations. 
The net of all these factors drive our expectation for full year Rhythm Management adjusted operating margin to approach 18% for the full year 2016, and we remain confident in 20% plus in 2017. 
GAAP operating income, which includes GAAP to adjusted items of $700 million, was a loss of $271 million in Q4 2015. The primary GAAP to adjusted items for the quarter included restructuring-related charges of $26 million, acquisition-related SG&A expenses of $15 million, contingent consideration expense of $37 million, amortization expense of $135 million and litigation-related charges of $456 million. 
The $456 million in litigation-related net charges were primarily related to increases in our litigation reserve for a recent appellate court ruling in Maryland in the Mirowski case, with the remainder related to a combination of increases in our transvaginal surgical mesh product liability reserves and other adjustments. The Mirowski case traces back to the mid-2000 and relates to licensing agreements on patents that have expired. We continue to believe that the facts and the law do not support the court's findings or the amount of the damages, and we plan to seek review of the judgment by the Maryland Supreme Court. 
We increased our mesh reserve this quarter as we became aware of additional claims during the quarter as we continue to work through the settlement evaluation process. Currently, our known claim count is approximately 35,000, and we've agreed in principle to settle over 10,000 of those 35,000 claims. We intend to continue to contest cases against us vigorously, while also looking to settle when reasonable terms are presented. Our total legal reserve was $1,936,000,000 as of December 31, 2015. 
Separately, a case was recently filed against Boston Scientific in West Virginia regarding the resin used in our transvaginal mesh products. We are confident that the resin used in the manufacturing of these devices is neither counterfeit nor adulterated and meets required material biocompatibility and design specifications. We've provided information and materials to DEKRA, a European notified body, the FDA and the Department of Justice regarding the resin, our quality processes and our commitment to producing medical devices of the highest quality. 
Now I'll move on to other income and expense. Interest expense for the quarter was $59 million compared to $54 million in Q4 of 2014. The increase was primarily due to the incremental debt raised in Q2 of 2015 to finance the AMS male urology portfolio acquisition. 
Our average interest rate was 3.9% in Q4 2015 compared to 4.8% in Q4 2014. The lower interest expense rate in Q4 2015 was primarily due to lower average cost of debt resulting from the senior notes refinancing completed in Q2 of 2015. 
Other expense was $10 million, and this consisted primarily of foreign exchange losses and investment losses incurred during the quarter. Our tax rate for the fourth quarter was 58% on a reported basis and 0.2% on an adjusted basis. 
Our Q4 adjusted tax rate includes $3.9 million of favorable discrete tax items and other onetime benefits primarily related to foreign exchange. Excluding these items, our Q4 operational tax rate would have been 13%. 
Now I'll provide a bit more detail on our full year 2015 adjusted tax rate, where our guidance as of the third quarter had been 13%. As you may know, the U.S. R&D tax credit was permanently reinstated in December, which benefited the full year 2015 adjusted tax rate by slightly more than 100 basis points. We've decided to reinvest this benefit in our tax structure to improve long-term flexibility in our capital structure. The net result of this being a 13% adjusted tax rate for the full year excluding discrete and onetime tax items and a 9.2% rate including them. After this onetime investment, we continue to expect an approximately 100-basis-point increase in our adjusted tax rate annually, and therefore continue to expect our full year 2016 adjusted tax rate to be approximately 14%. 
Finally, as mentioned, Q4 2015 adjusted EPS of $0.26 includes approximately $0.03 of unfavorable foreign exchange and represents 18% year-over-year growth or 31% growth, excluding the impact of foreign exchange. On a reported GAAP basis, Q4 2015 EPS was a loss of $0.11 and includes net charges and amortization expenses totaling $504 million after tax. The GAAP loss of $0.11 compares to a GAAP loss of $0.23 in the fourth quarter of 2014. For the full year 2015, we reported adjusted EPS of $0.93, exceeding our guidance range while absorbing $0.10 of unfavorable FX. Recall this is $0.02 more than we expected as of our Q3 2015 earnings call and $0.06 more than we had expected at the beginning of 2015. 
Full year 2015 adjusted EPS grew 11% over prior year and 23% excluding the impact of foreign exchange. On a reported GAAP basis, 2015 EPS was a loss of $0.18 compared to a full year 2014 GAAP loss per share of $0.09. 
Moving on to the balance sheet. Days sales outstanding of 59 days, increased 1 day compared to December of 2014. Days inventory on hand of 163 days, was up 7 days compared to December of last year due primarily to the acquisition of the AMS male urology portfolio. 
Capital expenditures were $86 million in Q4 2015 compared to $79 million in Q4 2014. For the full year 2015, capital expenditures were $248 million. For the full year 2016, we expect capital expenditures to be roughly $100 million higher, primarily due to the construction of our new manufacturing facility and distribution center in Malaysia. Beyond 2016, we expect capital expenditures to return to our historical run rate of approximately $250 million annually. 
Adjusted free cash flow for the quarter was $448 million compared to $508 million in Q4 2014. Our full year 2015 adjusted free cash flow of $1,366,000,000 represents growth of 8% over the full year 2014. For 2016, we expect full year adjusted free cash flow to exceed $1.5 billion, representing growth of 10%, and have a stretch goal to exceed $1.6 billion for the year with initiatives aimed at improving the working capital contribution to cash flow. 
In Q4, we repaid $150 million of our term loan and expect to repay an additional $250 million by the end of 2016. At which time, we expect our debt leverage will be consistent with our goal of returning to pre-AMS debt leverage by year-end. There were no share repurchases in the quarter, consistent with our decision to suspend the share repurchase program temporarily following the announcement of the AMS male urology portfolio acquisition. And near term, our capital allocation priorities are to repay debt, manage contingencies and pursue tuck-in M&A. 
We ended 2015 with 1,363,000,000 fully diluted weighted average shares outstanding. Consistent with our prior guidance, we expect our share count to increase by roughly 5 million per quarter through the end of 2016 as we plan to keep the buyback suspended for the balance of 2016. We expect this to result in a fully diluted weighted average share count of approximately 1,380,000,000 for the full year 2016. 
I'd like to conclude with guidance for Q1 and full year 2016. For the full year, we expect consolidated revenue to be in the range of $7,900,000,000 to $8,100,000,000, which represents year-over-year growth of 4% to 7% on an organic basis, 7% to 10% on an operational basis and 6% to 8% on a reported basis. 
As a result of a stronger dollar, at current rates, we expect foreign exchange to be a roughly $150 million headwind for the full year 016 on revenue. We expect our adjusted gross margin for the year, as a percentage of sales, to be in a range of 72% to 73%. We expect foreign exchange to have an unfavorable impact of approximately 50 basis points on adjusted gross margin in 2016 as hedging contracts from our 3-year program are layered in. We expect this headwind be offset by a favorable mix, market segmentation, the ramp of accretive new products and our standard cost-reduction programs. 
As mentioned, we expect our full year 2016 adjusted SG&A rate to be between 35.5% and 36.5% of sales and our full year adjusted R&D rate to be between 11% and 12% of sales. This implies a full year 2016 adjusted operating margin in the range of 23.5% to 24.5%, the midpoint of which represents 170 basis points of improvement over full year 2015. 
And importantly, we remain on track to achieve an adjusted operating margin of 25% plus in 2017. Full year 2016 interest expense is expected to be $245 million, about $10 million higher than the full year 2015 due to incremental debt raised in Q2 of 2015. 
As mentioned, we expect our tax rate for the full year 2016 to be approximately 14%. As a result, we expect adjusted earnings per share for the full year 2016 to be in a range of $1.03 to $1.07, representing 11% to 15% adjusted earnings per share growth. We expect 2016 adjusted earnings per share to be impacted negatively by approximately $0.06 of FX or roughly $80 million of adjusted income. In terms of timing, this $0.06 should be roughly $0.02 per quarter in Q1 and Q2 and $0.01 per quarter in Q3 and Q4. 
Excluding the $0.06 of unfavorable foreign exchange, our full year adjusted EPS guidance range represents growth of 17% to 21%. Despite this approximate $0.06 hit, we remain confident in our ability to deliver double-digit adjusted EPS growth. 
Let me walk you through the 2016 adjusted EPS guidance. We delivered adjusted EPS of $0.93 in 2015, representing 11% growth or 23% growth excluding the $0.10 of negative FX impact. As you know, our stated goal is to grow EPS double digits, which would imply $1.02 in 2016. Adding $0.03 of AMS accretion gets us to $1.05, which is the midpoint of our guidance. 
We expect unfavorable FX of approximately $0.06, as I mentioned, but our goal is to offset this through operational initiatives and savings as we did in 2015. And as mentioned, the medical device tax is worth roughly 100 basis points on the OM line, but we intend to reinvest substantially all of that back into innovation and have developed the detailed plans to do so. On a GAAP basis, we expect EPS to be in a range of $0.62 to $0.67. Lastly, for 2016 our guidance assumes pretax amortization of approximately $534 million. 
Now turning to the first quarter of 2016. We expect consolidated revenues to be in a range of $1,890,000,000 to $1,940,000,000. If current foreign exchange rates hold constant, the headwind from foreign exchange should be approximately $45 million or 250 basis points relative to Q1 2015. 
We expect consolidated Q1 sales to grow year-over-year in a range of 4% to 6% organically and 9% to 11% operationally. 
For the first quarter, adjusted earnings per share is expected to be in a range of $0.23 to $0.25 per share, and GAAP earnings per share is expected to be in a range of $0.11 to $0.13 per share. 
I encourage you to check our Investor Relations website for Q4 2015 financial and operational highlights, which outlines Q4 results as well as Q1 and full year 2016 guidance, including P&L line item guidance. 
So with that, I will turn it back to Susie, who will moderate the Q&A."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Dan. David, let's open it up to questions for the next 25 minutes or so. [Operator Instructions] David, please go ahead.",22,"Thanks, Dan. David, let's open it up to questions for the next 25 minutes or so. [Operator Instructions] David, please go ahead."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","[Operator Instructions] The first question comes from the line of David Lewis with Morgan Stanley.",15,"[Operator Instructions] The first question comes from the line of David Lewis with Morgan Stanley."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Just a couple of quick questions on '16 guidance. So the first is your guidance at the top end of the range at 7%. That's obviously higher than we expected. I guess, we expected 4% to 6%. So what factors get us to the top end of the range? And specificall",62,"Just a couple of quick questions on '16 guidance. So the first is your guidance at the top end of the range at 7%. That's obviously higher than we expected. I guess, we expected 4% to 6%. So what factors get us to the top end of the range? And specifically, what's assumed for WATCHMAN? And then I had a quick follow-up."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, David. Yes, the guidance 4% to 7% is higher than we showed at recent Investor Day meeting. In terms of getting into the higher end of the range, we still have to have some good results on our product launches with SYNERGY, WATCHMAN, ongoing advanc",169,"Thanks, David. Yes, the guidance 4% to 7% is higher than we showed at recent Investor Day meeting. In terms of getting into the higher end of the range, we still have to have some good results on our product launches with SYNERGY, WATCHMAN, ongoing advancements of Lotus. We have key product approvals that we're expecting in the first half. Those need to come through. We also launched a number of key products in Japan with SYNERGY and also S-ICD, so we need some strong execution there and continued emerging market growth. So it's -- we've got a lot of product launches, a number of approvals needed. So to delivered the top end of that, we have to have excellent commercial execution and great execution on the regulatory side. Potentially, you have some of the downside. We continue to manage, as I mentioned, some of the CRM headwinds, which we anticipate will, after Q1, improve in second quarter and then improve dramatically in the second half of the year."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","That's very helpful, Mike. And then specifically in AMS and CRM, just to follow-up there. In the fourth quarter was there anything particular with that third quarter, fourth quarter slight decline? Was there anything in particular or unique to the fourth",75,"That's very helpful, Mike. And then specifically in AMS and CRM, just to follow-up there. In the fourth quarter was there anything particular with that third quarter, fourth quarter slight decline? Was there anything in particular or unique to the fourth quarter that you can cite? And then once again, your confidence, what's specifically implied in '16 numbers? Does that the '16 guidance imply an improvement in the CRM business in '16 over '15?"
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. So we're really pleased with, quite frankly, our overall Urology business and the AMS deal. The business grew 7% in fourth quarter. And -- I'm sorry, was your first question on Urology? Or is it all CRM-related?",38,"Yes. So we're really pleased with, quite frankly, our overall Urology business and the AMS deal. The business grew 7% in fourth quarter. And -- I'm sorry, was your first question on Urology? Or is it all CRM-related?"
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","I'm happy to hear about Urology, but I was focused on CRM.",13,"I'm happy to hear about Urology, but I was focused on CRM."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Sorry, jet-lag from Asia.",4,"Sorry, jet-lag from Asia."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","We'll hold the Uro comments for later, I guess. So on the CRM, we do anticipate improvement clearly in 2016, as I mentioned, particularly in the second half. We anticipate the launch of the approval of our pace MRI and the quad in the second quarter, and",73,"We'll hold the Uro comments for later, I guess. So on the CRM, we do anticipate improvement clearly in 2016, as I mentioned, particularly in the second half. We anticipate the launch of the approval of our pace MRI and the quad in the second quarter, and we'll also have favorable comps in second quarter, third quarter and fourth quarter. So we do see a strength in the CRM business in 2016."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Rick Wise with Stifel.",12,"The next question comes from the line of Rick Wise with Stifel."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Just a couple of things. Maybe start with the CRM operating margin. Dan, you did a very clear job of laying out the factors, the timing, that 15.9% instead of your 17% goal. Is the whole of that these variances? And do you come into '16 thinking that -- d",71,"Just a couple of things. Maybe start with the CRM operating margin. Dan, you did a very clear job of laying out the factors, the timing, that 15.9% instead of your 17% goal. Is the whole of that these variances? And do you come into '16 thinking that -- do we start off with that sort of 17% level or better as we head into the first quarter or first half?"
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Rick. Yes, I think the way I would say -- characterized that is on the Q3 call, we had talked about kind of being in that 17% range for the back half of '15. The variances were a piece of it. We also had a little bit higher R&D, about 60 basis poi",214,"Thanks, Rick. Yes, I think the way I would say -- characterized that is on the Q3 call, we had talked about kind of being in that 17% range for the back half of '15. The variances were a piece of it. We also had a little bit higher R&D, about 60 basis points in the quarter. That's timing. That's just going to come 1 quarter to another, so that doesn't concern me. The manufacturing and the inventory reserve charges are really in anticipation of the launches that Mike just mentioned around the MRI-safe brady and the quad launch in the U.S. So those are kind of out of the way now at this point as opposed to having had to take those in different quarters. So I think the way I would think of it is the 13.9% in Q4, I'd expect a little bit of a sequential improvement in Q1. Not a tremendous amount, just a little bit. Q2 gets a little bit better than that. And really, the back half is where it accelerates to get to that overall 18% for the year. So I wouldn't look for Q1 to be in that 18% range or Q2. But I think the net of the year, we're very comfortable with that 18%."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","And just one product-specific question. WATCHMAN, a possible NCD is up here real soon. And if I understood you correctly, you're basically saying that it's still a $500 million market if that early language holds. But what if the language is basically equ",94,"And just one product-specific question. WATCHMAN, a possible NCD is up here real soon. And if I understood you correctly, you're basically saying that it's still a $500 million market if that early language holds. But what if the language is basically equivalent to the FDA approval label? Docs are telling us that they're doing 4 patients a month, and that would double if that were the case. Is that the way you see it? And so then is it back to a $1 billion market? How do we think about all that?"
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Well, it's -- overall, we're obviously very proud of our success in 2015 with WATCHMAN. In structural heart overall, we've delivered the high end of the range there. We opened up 100 accounts. We're going to hear the NCD decision very shortly here. But ov",113,"Well, it's -- overall, we're obviously very proud of our success in 2015 with WATCHMAN. In structural heart overall, we've delivered the high end of the range there. We opened up 100 accounts. We're going to hear the NCD decision very shortly here. But overall, we continue to expect guidance is in '16 of $175 million to $200 million, and our job will be to continue to focus on the penetration rate. With 15 million or so eligible patients, we'll continue to drive training programs, excellent outcomes. But for now, we'll continue with our $175 million to $200 million range, and we'll see what happens over the next few days on the reimbursement."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Ken, you want to add anything?",6,"Ken, you want to add anything?"
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, Rick, I'd say we -- well, we have some concerns about that first draft of the proposed NCD. Overall, it was consistent with our expectations, which are that the NCD we expect to be more limited than the full FDA label. Likewise, I always expect it to",89,"Yes, Rick, I'd say we -- well, we have some concerns about that first draft of the proposed NCD. Overall, it was consistent with our expectations, which are that the NCD we expect to be more limited than the full FDA label. Likewise, I always expect it to have the registry, et cetera. And as Mike said, we've always assumed modest penetration into the indicated population. And really, where we go is much more dependent on our ability to train new physicians to use the device safely and effectively."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Mike Weinstein with JPMorgan.",12,"The next question comes from the line of Mike Weinstein with JPMorgan."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","So just one quick follow-up on that. So did you say where you ended up for 2015 on that structural heart number?",23,"So just one quick follow-up on that. So did you say where you ended up for 2015 on that structural heart number?"
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","We didn't give a -- we guided $75 million to $100 million, and we beat the high end of the range. We didn't give a specific number.",28,"We didn't give a -- we guided $75 million to $100 million, and we beat the high end of the range. We didn't give a specific number."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","But you didn't give the exact number. Okay, great.",10,"But you didn't give the exact number. Okay, great."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Over $100 million.",3,"Over $100 million."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Over $100 million, understood. So let me ask about SYNERGY and the launch. So far, the feedback we're getting has been very positive, particularly on the deliverability of the product. It does feel like you are trying to set a premium pricing for the prod",59,"Over $100 million, understood. So let me ask about SYNERGY and the launch. So far, the feedback we're getting has been very positive, particularly on the deliverability of the product. It does feel like you are trying to set a premium pricing for the product in the marketplace. Can you talk about your success in doing so thus far?"
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, we're very pleased with the results. It's really tracking to our plan. In the fourth quarter, we did see U.S. DES growth in the mid-single-digit range, and now it's against about a 10% comparison from fourth quarter 2015. And so we delivered a nice n",170,"Yes, we're very pleased with the results. It's really tracking to our plan. In the fourth quarter, we did see U.S. DES growth in the mid-single-digit range, and now it's against about a 10% comparison from fourth quarter 2015. And so we delivered a nice number in the first quarter. And just as you said, we are asking, and we believe we deserve a pricing premium for the product. It's the only bioabsorbable product in the marketplace with excellent stent thrombosis rates, and we also have a tiered offering that has excellent market share as well. So we think we're uniquely positioned with it. And the great news is, is we're launching in Japan as we speak, which is obviously a big market, and we also received reimbursements in France. So we're really positioned well. We're being very careful with the launch of it. And similar to our comments at your meeting, we anticipate about 50% of our mix in the U.S. and Japan by the end of the year."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Great. I've got one product follow-up. Mike, it sounds like, Lotus EDGE, the timing of introducing that in Europe may be sliding. Just -- can you provide some clarity on that?",31,"Great. I've got one product follow-up. Mike, it sounds like, Lotus EDGE, the timing of introducing that in Europe may be sliding. Just -- can you provide some clarity on that?"
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, the -- in terms of sliding, we do anticipate 2016, we will launch Lotus EDGE. And so we do -- I guess, maybe, we did push that a bit. But we are confident in the 2016 launch of Lotus EDGE. And it -- similar to some of the comments in SYNERGY, we cont",107,"Yes, the -- in terms of sliding, we do anticipate 2016, we will launch Lotus EDGE. And so we do -- I guess, maybe, we did push that a bit. But we are confident in the 2016 launch of Lotus EDGE. And it -- similar to some of the comments in SYNERGY, we continue to exceed our commitments with Lotus. We exceeded the high end of our range. We're on track deliver our 21-millimeter valve. We'll be launching our Lotus EDGE platform, and we continue to drive great outcomes on our clinical data. Maybe, Keith, you could comment on some of the news you anticipate at Europe."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. I mean, I think, Mike, the important thing is when we commercialize Lotus in the U.S. late in '17, we'll have EDGE. We'll have 5 trial sizes, 21 through 29. We'll have the [indiscernible] 14 French compatibility and increased flexibility. The 21-valv",100,"Yes. I mean, I think, Mike, the important thing is when we commercialize Lotus in the U.S. late in '17, we'll have EDGE. We'll have 5 trial sizes, 21 through 29. We'll have the [indiscernible] 14 French compatibility and increased flexibility. The 21-valve is already in clinical trials, so that'll give us 4 valves. That'll be followed by the 29. And we'll anticipate EDGE around about EuroPCR or just after. EDGE is already in clinical trials. So we're very confident about moving to the 14 French compatibility, which of course, makes us comparable with the other competitors in the market."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question is coming from the line of Bob Hopkins with Bank of America.",15,"The next question is coming from the line of Bob Hopkins with Bank of America."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","So just wanted to follow-up and make sure I heard you correctly on the U.S. ICD and pacemaker pipeline and the time lines for the pipeline. So specifically, could you just tell us when you expect quad pulse CRT-D lead approval in the U.S. and then MRI-saf",83,"So just wanted to follow-up and make sure I heard you correctly on the U.S. ICD and pacemaker pipeline and the time lines for the pipeline. So specifically, could you just tell us when you expect quad pulse CRT-D lead approval in the U.S. and then MRI-safe pacemaker approval in the U.S.? And then also give us an updated thoughts on MRI-safe traditional ICD and CRT-D timelines for the U.S. since it feels like that's where Medtronic is having the most success."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. I'm really proud of our CRM business. We clearly want to grow faster. But we're in a position now where we can see, as we go forward in 2016 and '17 and beyond, really the strength of the portfolio. And I'll give answers to your specific MRI questio",300,"Sure. I'm really proud of our CRM business. We clearly want to grow faster. But we're in a position now where we can see, as we go forward in 2016 and '17 and beyond, really the strength of the portfolio. And I'll give answers to your specific MRI questions in a second here. But we've got these product launches coming in the second half of '16. The S-ICD is really gaining excellent momentum globally. We're expanding that, and we're going to be moving beyond the replacement cycle headwind. In terms of the product launches, we feel comfortable with a second quarter launch of both the quad system and MRI pacer. The MRI pacer likely slipped a little bit out of first quarter into second quarter. We'll also have EMBLEM MRI approval likely in the third quarter of 2016. So big, big approvals in the second quarter and third quarter. And then as we go forward with the ICD MRI capability, we'll start that trial very quickly here, and we anticipate approval of that product likely in second quarter or third quarter of 2017. So we've got a really strong cadence of product approvals coming, MRI capabilities. But I think what's most unique about our offering is this S-ICD momentum that we're seeing around the world. We just received approval in Japan. We have a 5% premium -- reimbursement premium in Japan, continued strong acceptance of the product and training and a multiyear head start. So as you looked at our business going forward, these product cadence will come through. SICD is continuing to grow, and our replacement cycle headwind will reverse itself. So as you look forward to CRM, I really believe that you're going to see this business strengthen in the second half of '16 and '17 and '18."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Great. That's very helpful. And then one for Dan. I just want to make sure I understand the margin story, just specifically in the fourth quarter. Is the right way to think about operating margins in the fourth quarter and all the moving parts that you ha",91,"Great. That's very helpful. And then one for Dan. I just want to make sure I understand the margin story, just specifically in the fourth quarter. Is the right way to think about operating margins in the fourth quarter and all the moving parts that you had very strong gross margin performance, and that you took advantage of a very low tax rate to invest a little bit more in SG&A than you originally anticipated? It is that, from a big picture perspective, the right way to thing about Q4 margins?"
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. I think, overall, and then as I mentioned in our prepared remarks, the -- we did have 80 basis points of the fixed asset write-offs and the litigation fees. So I wouldn't call that kind of investing for the future. So if you take that off, I'd say we",108,"Yes. I think, overall, and then as I mentioned in our prepared remarks, the -- we did have 80 basis points of the fixed asset write-offs and the litigation fees. So I wouldn't call that kind of investing for the future. So if you take that off, I'd say we, again, as we mentioned, very proud of where we ended for the year and the overall improvement we've had over the past 2 years. If you take 2016 and '15 together, you'd be looking at almost 400 basis points of operating margin expansion. So in a given quarter, you'll see fluctuations, but the overall trend is extremely positive."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of David Roman with Goldman Sachs.",13,"The next question comes from the line of David Roman with Goldman Sachs."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Maybe I will switch gears to the Urology business. And maybe, Mike, you could talk about how the integration is going with AMS and very specifically focused on some of the issues that you may be undertaking to help accelerate top line growth from where AM",57,"Maybe I will switch gears to the Urology business. And maybe, Mike, you could talk about how the integration is going with AMS and very specifically focused on some of the issues that you may be undertaking to help accelerate top line growth from where AMS was performing at sort of the exit rate of the acquisition."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","I won't give a CRM answer on this one. So I guess, I just wanted to talk about Urology because I like what we're doing here so much. So we -- again, we had nice results in fourth quarter, business growing 7% overall. Really nice job taking international m",243,"I won't give a CRM answer on this one. So I guess, I just wanted to talk about Urology because I like what we're doing here so much. So we -- again, we had nice results in fourth quarter, business growing 7% overall. Really nice job taking international markets as we continue to invest in our stone business and training programs. That's growing very well, double-digits outside the U.S. consistently. And the AMS integration's on track. Thankfully, the team did a really nice to job due diligence. We did project some softness the first 6 months post-acquisition as we wanted to bleed down distributor inventory levels to appropriate levels, and that's exactly what we're seeing. So that's happening. And we likely we'll see continued softness in Q1, but improving in terms of the legacy AMS business, and that's being offset by the BSC legacy business. As we go forward in the second quarter, we expect that legacy AMS business to grow much closer to the BSC overall growth rate. And then we'll see additional benefit on top of that as we see synergies between the BPH portfolio, the stone portfolio, the ED portfolio and the incontinence portfolio overall. So really, we're right on track. We're going to deliver our EPS accretion commitment of $0.03 in '16, and I think it's $0.07 in 2017. So the integration's gone well. We've had exceptionally low turnover, and it's being met very well by the customers."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","That's helpful. And then maybe just a follow-up on the price/mix environment. As we sort of look at your growth rate, another acceleration potentially untapped for 2016 at the midpoint of your guidance on an organic basis. Can you just sort of talk about",86,"That's helpful. And then maybe just a follow-up on the price/mix environment. As we sort of look at your growth rate, another acceleration potentially untapped for 2016 at the midpoint of your guidance on an organic basis. Can you just sort of talk about how the pricing and mix environment is shaping up? Because at least from your peers who have reported earnings results thus far, it sounds like the environment is a tad better, but maybe any thoughts from your perspective would be appreciated."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, David. This is Dan. In terms of price, as you heard, we mentioned it's about 100-basis-point drag on gross margins, so you can kind of back into what that is. Obviously, we don't make assumptions about significant improvements in the pricing environ",123,"Sure, David. This is Dan. In terms of price, as you heard, we mentioned it's about 100-basis-point drag on gross margins, so you can kind of back into what that is. Obviously, we don't make assumptions about significant improvements in the pricing environment or significant deteriorations in that. It's contemplated within the range. But as we look at it, it feels stable. So the product lines that have historically declined are continuing to decline at that historical rate. They haven't moved significantly. And likewise, the ones where prices stay flat, and in some cases, increase, have stayed pretty constant and stable. So over the past 12 to 18 months, it felt relatively stable, and the guidance for '16 assumes that through the year."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","And mix?",2,"And mix?"
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Mix -- in general for us, mix is a good guy. So as we sell more of the newer technologies, a lot of which Mike went through that list, the majority of those are accretive to overall Boston Scientific margins -- gross margins.",43,"Mix -- in general for us, mix is a good guy. So as we sell more of the newer technologies, a lot of which Mike went through that list, the majority of those are accretive to overall Boston Scientific margins -- gross margins."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question is coming from the line of Brooks West with Piper Jaffray.",14,"The next question is coming from the line of Brooks West with Piper Jaffray."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Let me start with Peripheral, actually. Very strong performance there. You've got a lot going on. I wonder if you could give us just a little bit more detail on kind of product cadence, market dynamics. And if we can see the business kind of continuing to",53,"Let me start with Peripheral, actually. Very strong performance there. You've got a lot going on. I wonder if you could give us just a little bit more detail on kind of product cadence, market dynamics. And if we can see the business kind of continuing to perform at this level going forward."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. The team's done a really nice job. Jeff Mirviss and the Peripheral group delivered 20% growth in legacy Bayer business and 10% organically overall. So obviously, very strong growth in a few quarters in a row here. And we're projected to set up reall",272,"Sure. The team's done a really nice job. Jeff Mirviss and the Peripheral group delivered 20% growth in legacy Bayer business and 10% organically overall. So obviously, very strong growth in a few quarters in a row here. And we're projected to set up really nicely in 2016. So I think just the backdrop, the markets there are very healthy. We're seeing nice market growth in atherectomy; our core business. We just launched a new DBT product; and also, clearly, the growing acceptance of the drug coated technologies. So the markets, overall, are strong. And we really have a unique position in terms of our portfolio. You've heard a lot about our drug-eluting stent, Eluvia. We'll be the only company with both a drug-eluting stent in a drug-eluting balloon in Europe. And we're also kicking off our Eluvia IMPERIAL trial in the first half of 2016. So we are uniquely positioned in our DES. We're also launching a number of our core SFA metal stents in Japan and Asia, in China, which will help us grow that business. And we also continue to really expand globally. We've been -- we were lightweight in terms of the emerging markets in Peripheral 5 years ago, and we've put a lot of investment in there. We're starting to see that become more meaningful in places like China and Brazil. And lastly, we commented on the call about our CeloNova deal. Our Interventional Oncology may be a little bit different than some competitors' Peripheral business, but that IO business is a strong grower for us, and we like that CeloNova transaction, particularly for the emerging markets."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","And if I could just follow-up with one on -- Dan, you mentioned earlier the leverage on the balance sheet was going to get back to pre-AMS acquisition levels by the end of the year. Can you just update us on your thoughts on acquisitions? And are you seei",57,"And if I could just follow-up with one on -- Dan, you mentioned earlier the leverage on the balance sheet was going to get back to pre-AMS acquisition levels by the end of the year. Can you just update us on your thoughts on acquisitions? And are you seeing valuation expectations come down in the market?"
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, Brooks. So yes, just in terms of the leverage levels, that's to get back to about a 2.5x debt to EBITDA. We remain on track to do that as we had announced in conjunction with the AMS acquisition by the end of this year. We did the debt pay down that",179,"Sure, Brooks. So yes, just in terms of the leverage levels, that's to get back to about a 2.5x debt to EBITDA. We remain on track to do that as we had announced in conjunction with the AMS acquisition by the end of this year. We did the debt pay down that we needed to do at the end of '15 and have in our cash flow projections in '16 to do the remainder to get to that level, so we feel very comfortable there. Relative to valuations and M&A, so we're very -- still very active in the market relative to tuck-in M&A. Obviously, screened a lot of different opportunities. I wouldn't say I've seen significant changes in valuation expectations across the landscape. It would depend on what division and what stage you're talking about. But in general, the valuations have stayed fairly constant, and we are actively in the market, obviously, looking for a tuck-in deal. And that is part of our cash flow projection for '16 as well, to be able to do some tuck-in deals."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question is coming from the line of Larry Biegelsen with Wells Fargo.",14,"The next question is coming from the line of Larry Biegelsen with Wells Fargo."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","So Mike, you're one of the few companies that actually showed an acceleration and emerging growth this quarter, I think about 15% organic versus 13% last quarter. A lot of companies have shown the opposite trend. So my question is what's the outlook in 20",70,"So Mike, you're one of the few companies that actually showed an acceleration and emerging growth this quarter, I think about 15% organic versus 13% last quarter. A lot of companies have shown the opposite trend. So my question is what's the outlook in 2016? How comfortable -- how much visibility do you have on growth in those markets? And any color would be helpful, and I had a follow-up."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","I'm sorry. Reflected the emerging markets?",7,"I'm sorry. Reflected the emerging markets?"
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","I'm sorry. Yes, emerging market growth. I think you had 15% organic in Q4. I think 13% in Q3.",20,"I'm sorry. Yes, emerging market growth. I think you had 15% organic in Q4. I think 13% in Q3."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. We were a little bit slower in second quarter, and we had nice pick-up. Really, the pick-up in the second half of 2015 was good, but it was also more consistent with what we expected and did in 2014, quite frankly. And so it's really a continuation o",179,"Yes. We were a little bit slower in second quarter, and we had nice pick-up. Really, the pick-up in the second half of 2015 was good, but it was also more consistent with what we expected and did in 2014, quite frankly. And so it's really a continuation of ex maybe a soft quarter, 1 soft quarter, the second quarter, kind of a continuation of what we've been doing in 2014 and what we expect to continue to do in 2016. So we had some softness in Russia in the second quarter. We've seen that stabilize a bit. We had excellent growth in China, excellent growth in Brazil and a number of other countries. So we continue to register new products, add commercial capabilities, we're building R&D capabilities, new education training centers. I just got back from there last night. So we put a lot of time and effort in it. We just did a joint venture deal with Frankenman there in our endo business. So we feel comfortable about our prospects in that mid-teens rate in emerging markets."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","And then Neuromodulation, I don't think has come up on this call, but you had a nice year in Neuromodulation this year. But obviously, there's -- the competitive dynamics are changing. So just color on 2016 and how we should think about growth and trends",57,"And then Neuromodulation, I don't think has come up on this call, but you had a nice year in Neuromodulation this year. But obviously, there's -- the competitive dynamics are changing. So just color on 2016 and how we should think about growth and trends there and the sustainability of the nice growth you showed in 2015."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Larry, we'll hit that in a sec, but we're going back to the emerging markets revenue question versus indiscernible].",19,"Larry, we'll hit that in a sec, but we're going back to the emerging markets revenue question versus indiscernible]."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Just one other thing, Larry, on that. So one of the other items with respect to emerging markets is just the foreign currency exchange rates. So if you look back at Q4 and think of our $1,978 million that we reported, again that included $25 million negat",95,"Just one other thing, Larry, on that. So one of the other items with respect to emerging markets is just the foreign currency exchange rates. So if you look back at Q4 and think of our $1,978 million that we reported, again that included $25 million negative headwinds from FX compared to what we had talked about when we give guidance. So kind of adjusted for that, we would have been over $2 billion and kind of closer to the higher end of the range. And emerging markets, obviously, is a big piece of that."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","And Neuromod continues to perform well. We grew 7% in the quarter. We grew 8% full year, and we had consistently strong growth throughout the year. And we really don't see that -- we anticipate that trend to continue. Spectra continues to perform very wel",151,"And Neuromod continues to perform well. We grew 7% in the quarter. We grew 8% full year, and we had consistently strong growth throughout the year. And we really don't see that -- we anticipate that trend to continue. Spectra continues to perform very well. The launch of Novi outside the U.S. is picking up, and we are getting a lot of -- we are building momentum in international markets in deep brain stimulation, and we'll hopefully get some good luck and get that clinical trial enrolled in '16 to position that launch. So it's a very healthy market right now, and there's a lot of patient demand. And so we like to see that, that market's clearly growing in the mid-single-digit range, if not, a bit more. So it's a growing market. We have some unique innovation. And it's a bit more competitive, but it hasn't slowed down our performance."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you. With that, we'd like to go conclude the call. Thank you very much for joining us today, and we sincerely appreciate your interest in Boston Scientific. Before you disconnect, David will give you all the details for the replay.",41,"Thank you. With that, we'd like to go conclude the call. Thank you very much for joining us today, and we sincerely appreciate your interest in Boston Scientific. Before you disconnect, David will give you all the details for the replay."
317627,321212230,926870,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, this conference will be made available for replay after 10:30 Eastern Standard Time today until February 18 at midnight. You may access the AT&T playback service at any time by dialing 1 (800) 475-6701 and entering access code 381463",70,"Ladies and gentlemen, this conference will be made available for replay after 10:30 Eastern Standard Time today until February 18 at midnight. You may access the AT&T playback service at any time by dialing 1 (800) 475-6701 and entering access code 381463. International participants may dial 1 (320) 365-3844. That does conclude our conference for today. Thank you for your participation and for using AT&T Teleconference. You may now disconnect."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Q4 2015 Boston Scientific Earnings Call. [Operator Instructions] And as a reminder, this conference is being recorded. I'd now like to turn the conference over to our host, Ms. Susie Lisa.",45,"Ladies and gentlemen, thank you for standing by. Welcome to the Q4 2015 Boston Scientific Earnings Call. [Operator Instructions] And as a reminder, this conference is being recorded. 
I'd now like to turn the conference over to our host, Ms. Susie Lisa. Please go ahead."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, David. Good morning, everyone. Thanks for joining us. With me on today's call are Mike Mahoney, President and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.We issued a press release earlier thi",378,"Thank you, David. Good morning, everyone. Thanks for joining us. With me on today's call are Mike Mahoney, President and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.
We issued a press release earlier this morning announcing our fourth quarter and full year 2015 results, which included reconciliations of the non-GAAP measures used in the release. We have posted a copy of that release as well as reconciliations of the non-GAAP measures used in today's call to the Investor Relations section of our website under the heading Financial Information.
The duration of this morning's call will be approximately 1 hour. Mike will provide strategic and revenue highlights of the fourth quarter. Dan will review the financials for the quarter and then provide first quarter '16 and full year 2016 guidance, and then we'll take your questions. During today's Q&A session, Mike and Dan will be joined by our Chief Medical Officers, Dr. Keith Dawkins and Dr. Ken Stein. 
Before we begin, I'd like to remind everyone that on the call, organic revenue growth is defined as excluding the impact of sales from divested businesses, changes in foreign currency exchange rates and sales from the acquisition of the American Medical Systems, or AMS, male urology portfolio over the prior year period.
Also note, this call contains forward-looking statements within the meaning of federal securities laws, which may be identified by words like anticipate, expect, believe, estimate and other similar words. They include, among other things, statements about our growth and market share; new product approvals and launches; clinical trials; cost savings and growth opportunities; our cash flow and expected use; our financial performance, including sales, margins, earnings and other Q4 and full year 2015 results and Q1 and full year 2016 guidance; as well as our tax rates, R&D spend and other expenses.
Actual results may differ materially from those discussed in the forward-looking statements. Factors that may cause such differences include those described in the Risk Factors section of our most recent 10-K and subsequent 10-Qs and 8-Ks filed with the SEC.
These statements speak only as of today's date, and we disclaim any intention or obligation to update them.
At this point, I'll turn it over to Mike for his comments. Mike?"
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Susie, and good morning, everyone. In fourth quarter, Boston Scientific posted another quarter of strong results and closed out an excellent 2015 as we continued to execute against our strategic plan goals. At our May 2015 Investor Day meetin",2224,"Thank you, Susie, and good morning, everyone. 
In fourth quarter, Boston Scientific posted another quarter of strong results and closed out an excellent 2015 as we continued to execute against our strategic plan goals. At our May 2015 Investor Day meeting, we outlined plans to drive mid-single-digit organic revenue growth and consistent adjusted operating margin expansion, which, in turn, will drive double-digit adjusted EPS growth excluding the impact of FX. 
We are delivering against these objectives. In Q4, we grew worldwide sales 5% organically and 10% operationally, which includes the benefit of the AMS urology business. We also grew adjusted operating income by 10% in the fourth quarter, which represents 100 basis point year-over-year improvement to 21.7%. 
The solid revenue growth and margin expansion drove very strong 18% adjusted EPS growth to $0.26, and our fourth quarter results reflect our focus on delivering meaningful innovation, while also providing clinical and economic value to our hospital to customers. 
Importantly, our Q4 results built upon the consistent momentum generated over the past few years and contributed to the following full year '15 results. For the full year, we delivered 5% organic revenue growth and 8% operational revenue growth, which includes the acquired sales from Bayer Peripheral and AMS.
In parallel with the consistent revenue growth, we are driving a strong improvements through our operating margin. In 2014, we delivered 130-basis-point improvement in adjusted operating margin. In 2015, we delivered an additional 210-basis-point improvement to a full year 22.3%. In per our previous goals, we continue to expect to deliver 25% plus adjusted operating margin in 2017 with plans to deliver an additional 200 to 300 basis points of improvement by year-end 2020. 
We delivered full year of '15 adjusted EPS growth -- I'm sorry, EPS of $0.93, representing 11% growth for the full year. It's important to note that the 11% adjusted EPS growth includes a significant negative foreign exchange impact of $0.10 versus our original expectation of a $0.04 hit when we originally gave '15 guidance. We're very pleased that we're able to overcome this FX headwind while investing in the long-term growth of the company, yet still delivering on our commitment for double-digit adjusted EPS growth. 
We continue to believe that Boston Scientific is uniquely positioned to deliver differentiated shareholder value through durable mid-single-digit revenue growth and double-digit adjusted EPS growth to beat our ongoing operating margin improvement initiatives. We're excited by our 2016 and our plans to build upon our global momentum. 
In 2016, we're targeting full year organic revenue growth of 4% to 7% and operational revenue growth of 7% to 10%. We're guiding adjusted EPS to $1.03 to $1.07, which represents 11% to 15% earnings growth. Importantly, this EPS once again includes an expected $0.06 negative impact from foreign exchange. 
I'll now provide some highlights on fourth quarter and '15 results along with thoughts on our '16 outlook. In my remarks, I'll reference to growth in an organic year-over-year constant currency basis, unless otherwise specified. 
Our fourth quarter organic revenue growth of 5% was broad-based across businesses and regions. It's led by exciting new product launches, which continued; global expansion; and execution of our category leadership strategy. With the exception of the anticipated 1% decline in CRM sales, all of our other businesses grew organic revenue by at least 6%, led by 10% growth in PI. IC had a strong quarter, growing 6% against a very tough 10% comp in Q4 2014. And importantly, all 3 medical/surgical businesses grew revenue at 7%, while also improving segmented adjusted operating margin by 90 basis points year-over-year to 34.1%. 
We delivered another quarter of balanced global growth, led by 6% revenue growth in Asia, 5% growth in the U.S. and Europe. Another highlight was strong 15% revenue growth in emerging markets, led by 20% growth in China and Brazil. 
The MedSurg businesses continued to deliver. In Endoscopy, we delivered 7% growth in Q4, fueled by the strength of our portfolio, our expanding global commercial reach and ongoing launches of our SpyGlass DS and AXIOS Stents. SpyGlass DS was launched in July 2015, and is an advanced single-use visualization system for the diagnosis and treatment of complex disorders of the pancreas and bile ducts. It's truly a cornerstone product that is highly differentiated and complementary to our core Endo portfolio. Our AXIOS Stent is used for transluminal drainage of pancreatic fluid collections and is also off to a strong start. We'll continue to innovate in endoscopic ultrasound and other exciting therapeutic categories, including pulmonary and oncology, to further enhance our global leadership in Endoscopy. 
Urology and Pelvic Health also continued a strong performance trend, growing 7% organically in Q4, led by laser fibers, capital equipment and strong international growth. Importantly, this quarter, we launched LithoVue, a disposable uterus scope, which provides customers with visualization and navigation capabilities to diagnose and treat stones and other conditions of the kidney, uterus and bladder. And after closing the AMS Urology acquisition in August, we remain on track to realize our adjusted EPS accretion goals of at least $0.03 in 2016 and $0.07 in 2017. 
Neuromodulation revenue grew 7% in the fourth quarter, led by strong growth in both the U.S. and international. Sales were driven by the market-leading Spectra platform and the launch of Precision Novi, our first product of the primary cell non-rechargeable market. 
In addition, we're seeing really promising uptake of our precise Deep Brain Stimulation system due to its Cartesian directional lead system and our partnership with Brainlab. Our U.S. DBS trial is making progress, and we expect to complete enrollment in 2016 and enter the market in late 2017 or early '18. 
Our Cardiovascular group grew 7% in Q4, led by impressive 10% growth in Peripheral Interventions. The core PI business continues to execute, and we're very pleased with integration of the legacy Bayer business. The legacy Bayer business grew over 20% for the second quarter in a row as we continue to grow share in the atherectomy market, and we're encouraged by our early results from the global launch of our ZelanteDVT catheter and the U.S. launch of our Innova Stent for the SFA. We also recently began to enroll our IMPERIAL U.S. IDE trial for Eluvia, our drug-eluting stent, and remain on track for a European launch of Eluvia this quarter. 
In addition, we recently closed the CeloNova transaction, which is a synergistic tuck-in acquisition focused on the treatment of liver cancer via localized delivery of chemotherapeutic agents. 
And finally in PI, we continue to benefit from our commercial relationship with C.R. Bard and the Lutonix Drug Coated Balloon technology. 
Interventional Cardiology continues to deliver, with 6% growth in the quarter, which represents the sixth consecutive quarter of plus 6% growth in IC. Growth was led by worldwide imaging, U.S. and European drug-eluting stents, our complex PCI portfolio and structural heart. 
PCI guidance grew low-teens globally, and we're encouraged by the market enthusiasm of our integrated fractional flow reserve platform. In DES, the U.S. SYNERGY launch is going extremely well. We anticipate that SYNERGY will represent approximately 50% of our DES revenue mix in the U.S. by the end of 2016. 
In addition, we're launching SYNERGY in Japan, and we'll continue to expand SYNERGY in other international markets. We also continue to invest in building upon a strong clinical evidence for SYNERGY as we have initiated the EVOLVE Short DAPT Study. 
Finally, the IC performance was fueled by our strengthening structural heart business, which includes our Lotus Aortic Valve and WATCHMAN Left Atrial Appendage Closure Device. We're truly in an exciting position to drive growth and share gains over the long run in these fast-growing markets. 
Lotus delivered a strong quarter for the -- in the European market as the platform continues to build momentum despite our near-term size matrix limitations. Lotus offers physicians excellent control during implantation and best-in-class paravalvular leakage rates. In our RESPOND Post-Market Study, 95.1% of patients had 0 to trace PVL.
Importantly, we completed enrollment in our REPRISE III IDE study in December, which we anticipate will position us for a late 2017 U.S. market entrance. We're also pleased to announce completion of the 1,000-patient RESPOND Lotus Post-Market Study and those results will be presented at EuroPCR in May. We're expanding the Lotus platform and expect to launch our next-gen 14 French delivery system along with additional sizes in Europe this year. 
Also in structural heart, the U.S. WATCHMAN launch continues to progress ahead of plan. We're pleased with the implant success rates and the high quality of patient outcomes thus far, which reflect our controlled rollout and proven training program. 
In addition, Dr. Vivek Reddy of Mount Sinai recently published in JACC a study highlighting WATCHMAN's cost-effectiveness versus both warfarin and novel oral anticoagulants. In the U.S., we opened more than 100 WATCHMAN accounts in 2015 and expect to open an additional 100 accounts in 2016. 
In Europe, we're looking forward to a full launch of our second-gen WATCHMAN FLX, which also -- which already has CE Mark. After U.S. reimbursement, we will await final NCD decision from CMS by February 8, and we remain confident that WATCHMAN will represent at least a $500 million worldwide market opportunity. 
So overall, we're very pleased with our progress in structural heart and excited about our capabilities and the long-term prospects for this business. We exceeded our full year of '15 structural heart revenue goal of $75 million to $100 million, and in 2016, we anticipate structural heart sales between $175 million and $200 million. 
Now turning to CRM. On our first quarter '15 earnings call, we projected a slowdown in our worldwide CRM sales for the balance of '15 and through first quarter '16, primarily due to replacement cycle headwinds and competitive launches in the U.S. Our forecast is accurate as global CRM sales declined 1% in Q4. However, we're very encouraged about our forward-looking CRM position given the strong cadence of new launches expected in the U.S. and Japan in '16, our leading position and growing awareness of S-ICD and our replacement cycle headwind becoming more favorable as we exit 2016. 
In the U.S., we plan to launch our full X4 quad system with our ACCOLADE brady MRI-safe system in the first half and the EMBLEM MRI-safe in the second half of '16. And we anticipate these releases will strengthen 2016 CRM performance, particularly in the second half. 
Pacemaker sales again grew 2%, and we recently launched X4 CRT-P quad device. And while our ICD sales declined 2%, we continue to be pleased with our de novo ICD performance in the EMBLEM S-ICD in particular. EMBLEM continues to drive strong growth in de novo shared gains in both the Europe and the U.S. EMBLEM is building momentum globally, and we look forward to launching EMBLEM in Japan this quarter with a reimbursement premium and expanding S-ICD to additional international markets in 2016. 
In Europe, we continue to gain share and grow our CRM business in the mid-single-digit range with our complete portfolio. These consistent European CRM results are encouraging as we look forward to our anticipated U.S. approvals in '16. 
Lastly in CRM, we're continuously mounting third-party evidence of the economic benefits associated with our EnduraLife extended battery technology. And recently, another third-party data set from the Europace was published, demonstrating the 6-year survival of BSC CRT-Ds over our competitors. 
Also, recent U.S. study modeled a 14% reduction in Medicare cost from a 2-year increase in ICD battery longevity. And an Italian study showed Extended Longevity drove a 29% to 34% reduction in long-term health care costs over a 15-year period. 
Turning to our EP business. We delivered 8% growth in the quarter. Arrhythmia platform continues to rollout nicely, driven by new installations and higher case volumes. We have a strong arrhythmia customer pipeline in 2016 as well as new platform enhancements scheduled for release. 
We did see some softness in EP in fourth quarter, primarily driven by the delay in our European launch of our IntellaMap ablation catheter, which we anticipate launching later in the first quarter. We continue to strengthen our EP business, and we look forward to continued progress in 2016. 
Our strategy of category leadership is working, and it's helping us to become a stronger partner with our global customers. As the health care environment continues to evolve, we're building new capabilities to support our customers beyond our product portfolio with our ADVANTICS solutions offerings. These offerings are focused on driving operational excellence within Cardiovascular and GI labs and improving a standardizing care for chronic cardiovascular diseases. And just last week, we announced an alliance with Accenture to develop a data-driven digital health solution to improve patient outcomes and reduce costs to treat patients with chronic cardiovascular diseases. 
So to wrap up my section, our company has great momentum, and our 2015 results reflect the strength of our portfolio and our ongoing investment into faster growth markets, our globalization efforts and the execution of our global teams. More importantly, we believe that we are well positioned to continue and strengthen our performance track record in 2016 and beyond. I would like to thank our employees for their winning spirit and a great commitment to Boston Scientific. 
Now let me turn the call over to Dan for a more detailed review of our financials."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Mike. I'll start with some overall perspective on the quarter before getting into the details. We generated adjusted earnings per share of $0.26, exceeding the high end of our guidance range of $0.23 to $0.25 and representing 18% year-over-year",2753,"Thanks, Mike. I'll start with some overall perspective on the quarter before getting into the details. 
We generated adjusted earnings per share of $0.26, exceeding the high end of our guidance range of $0.23 to $0.25 and representing 18% year-over-year growth in the quarter. Excluding a $0.03 unfavorable foreign exchange impact, Q4 adjusted earnings per share grew 31% year-over-year. The strong performance in Q4 was driven primarily by operational revenue growth and gross margin expansion. 
Our Q4 2015 adjusted operating margin of 21.7% represents an improvement of 100 basis points over the fourth quarter of 2014. For the full year 2015, total company adjusted operating margin expanded by 210 basis points over the full year of '14, and we effectively offset a $0.10 FX headwind through operational savings and initiatives. 
Our full year 2015 adjusted earnings per share of $0.93 represents 11% growth and 23% growth excluding FX versus 2014. 
Now for the P&L highlights. For the fourth quarter of 2015, consolidated revenue of $1,978,000,000 represented operational growth of 10%, which excludes the impact of foreign exchange. Excluding an approximate 500 basis point contribution from the AMS male urology portfolio, organic revenue growth was 5% in the quarter. 
On an as-reported basis, revenue grew 5% year-over-year. The foreign exchange impact on sales was a $110 million headwind compared to the prior year period, which was about $25 million worse than we assumed in our Q4 guidance range. 
Adjusted gross margin for the fourth quarter was 72.8%, increasing 140 basis points year-over-year. The increase resulted primarily from cost improvements, driven by our value improvement programs, as the impact of foreign exchange was negligible in the quarter. 
For the full year 2015, adjusted gross margin was 72% compared to 70.7% for the full year 2014. The 130 basis point full year adjusted gross margin improvement was driven by benefits of 180 and 50 basis points from cost improvements and FX, respectively. This was partially offset by 100 basis points of headwinds attributed primarily to price. 
Adjusted SG&A expenses were $757 million or 38.3% of sales in the fourth quarter, down 10 basis points year-over-year. The Q4 rate includes 80 basis points of higher spend related to fixed asset write-offs, full year related benefits and litigation fees. 
Our full year 2015 adjusted SG&A rate of 37.4% is down 50 basis points versus the full year 2014. As a reminder, the medical device tax has been suspended for 2016 and 2017, which would benefit our adjusted SG&A rate by roughly 100 basis points annually. We're pleased to see that this tax has been temporarily suspended and intend to reinvest virtually all of the benefit into jobs, innovation, R&D, collaborations with universities and other initiatives that will help treat patients and sustain top line growth over the long term. 
We expect the reinvestment of approximately 100 basis points to be split roughly equally between R&D and SG&A. Our guidance for full year 2016 assumes our adjusted SG&A rate will come down by a total of 140 basis points at the midpoint, which breaks down into 50 basis points from the medical device tax suspension and 90 basis points from operational improvements. 
Adjusted research and development expenses were $238 million in the fourth quarter or 12% of sales. For the full year 2015, adjusted R&D expenses were $850 million or 11.4% of sales. We expect our full year 2016 adjusted R&D rate to be roughly 11.5%. Again, this includes a 50 basis point increase due to the reinvestment of the medical device tax, offset by increased efficiencies and improved utilization of our global footprint. 
Royalty expense was 0.9% of sales in both the fourth quarter and the full year 2015. This represents a 60-basis-point reduction compared to the full year 2014 rate, and we expect our royalty rate to remain at approximately 1% of sales in 2016. 
On an adjusted basis, operating income was $429 million in the quarter or 21.7% of sales, up 100 basis points year-over-year. We are very pleased with our consistent adjusted operating margin improvement throughout 2015 as we saw year-over-year improvement of at least 100 basis points in each of the 4 quarters. 
Rhythm Management's adjusted operating margin in Q4 was 13.9%, down substantially from Q3 2015, which resulted in a second half 2015 Rhythm Management adjusted operating margin of 15.9%, falling short of our expectation of 17% due to the timing of manufacturing variances and reserve charges as we transition our portfolio and prepare for new product launches in 2016. Full year 2015 Rhythm Management adjusted operating margin of 15% represents an improvement of 160 basis points over the full year 2014. 
And turning to 2016, we expect Rhythm Management adjusted operating margins to increase sequentially in Q1 versus Q4 of '15, with more noticeable improvement in Q2 as we begin to realize the full benefit of 2016 product costs and leverage the improved top line performance expected from the global CRM and EP franchises. And the second half 2016 Rhythm Management adjusted operating margin is also expected to benefit from our Plant Network Optimization program completed at the end of 2015, which transferred a portion of our EP manufacturing to lower-cost locations. 
The net of all these factors drive our expectation for full year Rhythm Management adjusted operating margin to approach 18% for the full year 2016, and we remain confident in 20% plus in 2017. 
GAAP operating income, which includes GAAP to adjusted items of $700 million, was a loss of $271 million in Q4 2015. The primary GAAP to adjusted items for the quarter included restructuring-related charges of $26 million, acquisition-related SG&A expenses of $15 million, contingent consideration expense of $37 million, amortization expense of $135 million and litigation-related charges of $456 million. 
The $456 million in litigation-related net charges were primarily related to increases in our litigation reserve for a recent appellate court ruling in Maryland in the Mirowski case, with the remainder related to a combination of increases in our transvaginal surgical mesh product liability reserves and other adjustments. The Mirowski case traces back to the mid-2000 and relates to licensing agreements on patents that have expired. We continue to believe that the facts and the law do not support the court's findings or the amount of the damages, and we plan to seek review of the judgment by the Maryland Supreme Court. 
We increased our mesh reserve this quarter as we became aware of additional claims during the quarter as we continue to work through the settlement evaluation process. Currently, our known claim count is approximately 35,000, and we've agreed in principle to settle over 10,000 of those 35,000 claims. We intend to continue to contest cases against us vigorously, while also looking to settle when reasonable terms are presented. Our total legal reserve was $1,936,000,000 as of December 31, 2015. 
Separately, a case was recently filed against Boston Scientific in West Virginia regarding the resin used in our transvaginal mesh products. We are confident that the resin used in the manufacturing of these devices is neither counterfeit nor adulterated and meets required material biocompatibility and design specifications. We've provided information and materials to DEKRA, a European notified body, the FDA and the Department of Justice regarding the resin, our quality processes and our commitment to producing medical devices of the highest quality. 
Now I'll move on to other income and expense. Interest expense for the quarter was $59 million compared to $54 million in Q4 of 2014. The increase was primarily due to the incremental debt raised in Q2 of 2015 to finance the AMS male urology portfolio acquisition. 
Our average interest rate was 3.9% in Q4 2015 compared to 4.8% in Q4 2014. The lower interest expense rate in Q4 2015 was primarily due to lower average cost of debt resulting from the senior notes refinancing completed in Q2 of 2015. 
Other expense was $10 million, and this consisted primarily of foreign exchange losses and investment losses incurred during the quarter. Our tax rate for the fourth quarter was 58% on a reported basis and 0.2% on an adjusted basis. 
Our Q4 adjusted tax rate includes $3.9 million of favorable discrete tax items and other onetime benefits primarily related to foreign exchange. Excluding these items, our Q4 operational tax rate would have been 13%. 
Now I'll provide a bit more detail on our full year 2015 adjusted tax rate, where our guidance as of the third quarter had been 13%. As you may know, the U.S. R&D tax credit was permanently reinstated in December, which benefited the full year 2015 adjusted tax rate by slightly more than 100 basis points. We've decided to reinvest this benefit in our tax structure to improve long-term flexibility in our capital structure. The net result of this being a 13% adjusted tax rate for the full year excluding discrete and onetime tax items and a 9.2% rate including them. After this onetime investment, we continue to expect an approximately 100-basis-point increase in our adjusted tax rate annually, and therefore continue to expect our full year 2016 adjusted tax rate to be approximately 14%. 
Finally, as mentioned, Q4 2015 adjusted EPS of $0.26 includes approximately $0.03 of unfavorable foreign exchange and represents 18% year-over-year growth or 31% growth, excluding the impact of foreign exchange. On a reported GAAP basis, Q4 2015 EPS was a loss of $0.11 and includes net charges and amortization expenses totaling $504 million after tax. The GAAP loss of $0.11 compares to a GAAP loss of $0.23 in the fourth quarter of 2014. For the full year 2015, we reported adjusted EPS of $0.93, exceeding our guidance range while absorbing $0.10 of unfavorable FX. Recall this is $0.02 more than we expected as of our Q3 2015 earnings call and $0.06 more than we had expected at the beginning of 2015. 
Full year 2015 adjusted EPS grew 11% over prior year and 23% excluding the impact of foreign exchange. On a reported GAAP basis, 2015 EPS was a loss of $0.18 compared to a full year 2014 GAAP loss per share of $0.09. 
Moving on to the balance sheet. Days sales outstanding of 59 days, increased 1 day compared to December of 2014. Days inventory on hand of 163 days, was up 7 days compared to December of last year due primarily to the acquisition of the AMS male urology portfolio. 
Capital expenditures were $86 million in Q4 2015 compared to $79 million in Q4 2014. For the full year 2015, capital expenditures were $248 million. For the full year 2016, we expect capital expenditures to be roughly $100 million higher, primarily due to the construction of our new manufacturing facility and distribution center in Malaysia. Beyond 2016, we expect capital expenditures to return to our historical run rate of approximately $250 million annually. 
Adjusted free cash flow for the quarter was $448 million compared to $508 million in Q4 2014. Our full year 2015 adjusted free cash flow of $1,366,000,000 represents growth of 8% over the full year 2014. For 2016, we expect full year adjusted free cash flow to exceed $1.5 billion, representing growth of 10%, and have a stretch goal to exceed $1.6 billion for the year with initiatives aimed at improving the working capital contribution to cash flow. 
In Q4, we repaid $150 million of our term loan and expect to repay an additional $250 million by the end of 2016. At which time, we expect our debt leverage will be consistent with our goal of returning to pre-AMS debt leverage by year-end. There were no share repurchases in the quarter, consistent with our decision to suspend the share repurchase program temporarily following the announcement of the AMS male urology portfolio acquisition. And near term, our capital allocation priorities are to repay debt, manage contingencies and pursue tuck-in M&A. 
We ended 2015 with 1,363,000,000 fully diluted weighted average shares outstanding. Consistent with our prior guidance, we expect our share count to increase by roughly 5 million per quarter through the end of 2016 as we plan to keep the buyback suspended for the balance of 2016. We expect this to result in a fully diluted weighted average share count of approximately 1,380,000,000 for the full year 2016. 
I'd like to conclude with guidance for Q1 and full year 2016. For the full year, we expect consolidated revenue to be in the range of $7,900,000,000 to $8,100,000,000, which represents year-over-year growth of 4% to 7% on an organic basis, 7% to 10% on an operational basis and 6% to 8% on a reported basis. 
As a result of a stronger dollar, at current rates, we expect foreign exchange to be a roughly $150 million headwind for the full year '16 on revenue. We expect our adjusted gross margin for the year, as a percentage of sales, to be in a range of 72% to 73%. We expect foreign exchange to have an unfavorable impact of approximately 50 basis points on adjusted gross margin in 2016 as hedging contracts from our 3-year program are layered in. We expect this headwind be offset by a favorable mix, market segmentation, the ramp of accretive new products and our standard cost-reduction programs. 
As mentioned, we expect our full year 2016 adjusted SG&A rate to be between 35.5% and 36.5% of sales and our full year adjusted R&D rate to be between 11% and 12% of sales. This implies a full year 2016 adjusted operating margin in the range of 23.5% to 24.5%, the midpoint of which represents 170 basis points of improvement over full year 2015. 
And importantly, we remain on track to achieve an adjusted operating margin of 25% plus in 2017. Full year 2016 interest expense is expected to be $245 million, about $10 million higher than the full year 2015 due to incremental debt raised in Q2 of 2015. 
As mentioned, we expect our tax rate for the full year 2016 to be approximately 14%. As a result, we expect adjusted earnings per share for the full year 2016 to be in a range of $1.03 to $1.07, representing 11% to 15% adjusted earnings per share growth. We expect 2016 adjusted earnings per share to be impacted negatively by approximately $0.06 of FX or roughly $80 million of adjusted income. In terms of timing, this $0.06 should be roughly $0.02 per quarter in Q1 and Q2 and $0.01 per quarter in Q3 and Q4. 
Excluding the $0.06 of unfavorable foreign exchange, our full year adjusted EPS guidance range represents growth of 17% to 21%. Despite this approximate $0.06 hit, we remain confident in our ability to deliver double-digit adjusted EPS growth. 
Let me walk you through the 2016 adjusted EPS guidance. We delivered adjusted EPS of $0.93 in 2015, representing 11% growth or 23% growth excluding the $0.10 of negative FX impact. As you know, our stated goal is to grow EPS double digits, which would imply $1.02 in 2016. Adding $0.03 of AMS accretion gets us to $1.05, which is the midpoint of our guidance. 
We expect unfavorable FX of approximately $0.06, as I mentioned, but our goal is to offset this through operational initiatives and savings as we did in 2015. And as mentioned, the medical device tax is worth roughly 100 basis points on the OM line, but we intend to reinvest substantially all of that back into innovation and have developed the detailed plans to do so. On a GAAP basis, we expect EPS to be in a range of $0.62 to $0.67. Lastly, for 2016 our guidance assumes pretax amortization of approximately $534 million. 
Now turning to the first quarter of 2016. We expect consolidated revenues to be in a range of $1,890,000,000 to $1,940,000,000. If current foreign exchange rates hold constant, the headwind from foreign exchange should be approximately $45 million or 250 basis points relative to Q1 2015. 
We expect consolidated Q1 sales to grow year-over-year in a range of 4% to 6% organically and 9% to 11% operationally. 
For the first quarter, adjusted earnings per share is expected to be in a range of $0.23 to $0.25 per share, and GAAP earnings per share is expected to be in a range of $0.11 to $0.13 per share. 
I encourage you to check our Investor Relations website for Q4 2015 financial and operational highlights, which outlines Q4 results as well as Q1 and full year 2016 guidance, including P&L line item guidance. 
So with that, I will turn it back to Susie, who will moderate the Q&A."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Dan. David, let's open it up to questions for the next 25 minutes or so. [Operator Instructions] David, please go ahead.",22,"Thanks, Dan. David, let's open it up to questions for the next 25 minutes or so. [Operator Instructions] David, please go ahead."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","[Operator Instructions] The first question comes from the line of David Lewis with Morgan Stanley.",15,"[Operator Instructions] The first question comes from the line of David Lewis with Morgan Stanley."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Just a couple of quick questions on '16 guidance. So the first is your guidance at the top end of the range at 7%. That's obviously higher than we expected. I guess, we expected 4% to 6%. So what factors get us to the top end of the range? And specificall",62,"Just a couple of quick questions on '16 guidance. So the first is your guidance at the top end of the range at 7%. That's obviously higher than we expected. I guess, we expected 4% to 6%. So what factors get us to the top end of the range? And specifically, what's assumed for WATCHMAN? And then I had a quick follow-up."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, David. Yes, the guidance 4% to 7% is higher than we showed at recent Investor Day meeting. In terms of getting into the higher end of the range, we still have to have some good results on our product launches with SYNERGY, WATCHMAN, ongoing advanc",169,"Thanks, David. Yes, the guidance 4% to 7% is higher than we showed at recent Investor Day meeting. In terms of getting into the higher end of the range, we still have to have some good results on our product launches with SYNERGY, WATCHMAN, ongoing advancements of Lotus. We have key product approvals that we're expecting in the first half. Those need to come through. We also launched a number of key products in Japan with SYNERGY and also S-ICD, so we need some strong execution there and continued emerging market growth. So it's -- we've got a lot of product launches, a number of approvals needed. So to delivered the top end of that, we have to have excellent commercial execution and great execution on the regulatory side. Potentially, you have some of the downside. We continue to manage, as I mentioned, some of the CRM headwinds, which we anticipate will, after Q1, improve in second quarter and then improve dramatically in the second half of the year."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","That's very helpful, Mike. And then specifically in AMS and CRM, just to follow-up there. In the fourth quarter was there anything particular with that third quarter, fourth quarter slight decline? Was there anything in particular or unique to the fourth",75,"That's very helpful, Mike. And then specifically in AMS and CRM, just to follow-up there. In the fourth quarter was there anything particular with that third quarter, fourth quarter slight decline? Was there anything in particular or unique to the fourth quarter that you can cite? And then once again, your confidence, what's specifically implied in '16 numbers? Does that the '16 guidance imply an improvement in the CRM business in '16 over '15?"
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. So we're really pleased with, quite frankly, our overall Urology business and the AMS deal. The business grew 7% in fourth quarter. And -- I'm sorry, was your first question on Urology? Or is it all CRM-related?",38,"Yes. So we're really pleased with, quite frankly, our overall Urology business and the AMS deal. The business grew 7% in fourth quarter. And -- I'm sorry, was your first question on Urology? Or is it all CRM-related?"
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","I'm happy to hear about Urology, but I was focused on CRM.",13,"I'm happy to hear about Urology, but I was focused on CRM."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Sorry, jet-lag from Asia.",4,"Sorry, jet-lag from Asia."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","We'll hold the Uro comments for later, I guess. So on the CRM, we do anticipate improvement clearly in 2016, as I mentioned, particularly in the second half. We anticipate the launch of the approval of our pace MRI and the quad in the second quarter, and",73,"We'll hold the Uro comments for later, I guess. So on the CRM, we do anticipate improvement clearly in 2016, as I mentioned, particularly in the second half. We anticipate the launch of the approval of our pace MRI and the quad in the second quarter, and we'll also have favorable comps in second quarter, third quarter and fourth quarter. So we do see a strength in the CRM business in 2016."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Rick Wise with Stifel.",12,"The next question comes from the line of Rick Wise with Stifel."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Just a couple of things. Maybe start with the CRM operating margin. Dan, you did a very clear job of laying out the factors, the timing, that 15.9% instead of your 17% goal. Is the whole of that these variances? And do you come into '16 thinking that -- d",71,"Just a couple of things. Maybe start with the CRM operating margin. Dan, you did a very clear job of laying out the factors, the timing, that 15.9% instead of your 17% goal. Is the whole of that these variances? And do you come into '16 thinking that -- do we start off with that sort of 17% level or better as we head into the first quarter or first half?"
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Rick. Yes, I think the way I would say -- characterized that is on the Q3 call, we had talked about kind of being in that 17% range for the back half of '15. The variances were a piece of it. We also had a little bit higher R&D, about 60 basis poi",214,"Thanks, Rick. Yes, I think the way I would say -- characterized that is on the Q3 call, we had talked about kind of being in that 17% range for the back half of '15. The variances were a piece of it. We also had a little bit higher R&D, about 60 basis points in the quarter. That's timing. That's just going to come 1 quarter to another, so that doesn't concern me. The manufacturing and the inventory reserve charges are really in anticipation of the launches that Mike just mentioned around the MRI-safe brady and the quad launch in the U.S. So those are kind of out of the way now at this point as opposed to having had to take those in different quarters. So I think the way I would think of it is the 13.9% in Q4, I'd expect a little bit of a sequential improvement in Q1. Not a tremendous amount, just a little bit. Q2 gets a little bit better than that. And really, the back half is where it accelerates to get to that overall 18% for the year. So I wouldn't look for Q1 to be in that 18% range or Q2. But I think the net of the year, we're very comfortable with that 18%."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","And just one product-specific question. WATCHMAN, a possible NCD is up here real soon. And if I understood you correctly, you're basically saying that it's still a $500 million market if that early language holds. But what if the language is basically equ",94,"And just one product-specific question. WATCHMAN, a possible NCD is up here real soon. And if I understood you correctly, you're basically saying that it's still a $500 million market if that early language holds. But what if the language is basically equivalent to the FDA approval label? Docs are telling us that they're doing 4 patients a month, and that would double if that were the case. Is that the way you see it? And so then is it back to a $1 billion market? How do we think about all that?"
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Well, it's -- overall, we're obviously very proud of our success in 2015 with WATCHMAN. In structural heart overall, we've delivered the high end of the range there. We opened up 100 accounts. We're going to hear the NCD decision very shortly here. But ov",113,"Well, it's -- overall, we're obviously very proud of our success in 2015 with WATCHMAN. In structural heart overall, we've delivered the high end of the range there. We opened up 100 accounts. We're going to hear the NCD decision very shortly here. But overall, we continue to expect guidance is in '16 of $175 million to $200 million, and our job will be to continue to focus on the penetration rate. With 15 million or so eligible patients, we'll continue to drive training programs, excellent outcomes. But for now, we'll continue with our $175 million to $200 million range, and we'll see what happens over the next few days on the reimbursement."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Ken, you want to add anything?",6,"Ken, you want to add anything?"
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, Rick, I'd say we -- well, we have some concerns about that first draft of the proposed NCD. Overall, it was consistent with our expectations, which are that the NCD we expect to be more limited than the full FDA label. Likewise, I always expect it to",89,"Yes, Rick, I'd say we -- well, we have some concerns about that first draft of the proposed NCD. Overall, it was consistent with our expectations, which are that the NCD we expect to be more limited than the full FDA label. Likewise, I always expect it to have the registry, et cetera. And as Mike said, we've always assumed modest penetration into the indicated population. And really, where we go is much more dependent on our ability to train new physicians to use the device safely and effectively."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Mike Weinstein with JPMorgan.",12,"The next question comes from the line of Mike Weinstein with JPMorgan."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","So just one quick follow-up on that. So did you say where you ended up for 2015 on that structural heart number?",23,"So just one quick follow-up on that. So did you say where you ended up for 2015 on that structural heart number?"
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","We didn't give a -- we guided $75 million to $100 million, and we beat the high end of the range. We didn't give a specific number.",28,"We didn't give a -- we guided $75 million to $100 million, and we beat the high end of the range. We didn't give a specific number."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","But you didn't give the exact number. Okay, great.",10,"But you didn't give the exact number. Okay, great."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Over $100 million.",3,"Over $100 million."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Over $100 million, understood. So let me ask about SYNERGY and the launch. So far, the feedback we're getting has been very positive, particularly on the deliverability of the product. It does feel like you are trying to set a premium pricing for the prod",59,"Over $100 million, understood. So let me ask about SYNERGY and the launch. So far, the feedback we're getting has been very positive, particularly on the deliverability of the product. It does feel like you are trying to set a premium pricing for the product in the marketplace. Can you talk about your success in doing so thus far?"
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, we're very pleased with the results. It's really tracking to our plan. In the fourth quarter, we did see U.S. DES growth in the mid-single-digit range, and now it's against about a 10% comparison from fourth quarter 2015. And so we delivered a nice n",170,"Yes, we're very pleased with the results. It's really tracking to our plan. In the fourth quarter, we did see U.S. DES growth in the mid-single-digit range, and now it's against about a 10% comparison from fourth quarter 2015. And so we delivered a nice number in the first quarter. And just as you said, we are asking, and we believe we deserve a pricing premium for the product. It's the only bioabsorbable product in the marketplace with excellent stent thrombosis rates, and we also have a tiered offering that has excellent market share as well. So we think we're uniquely positioned with it. And the great news is, is we're launching in Japan as we speak, which is obviously a big market, and we also received reimbursements in France. So we're really positioned well. We're being very careful with the launch of it. And similar to our comments at your meeting, we anticipate about 50% of our mix in the U.S. and Japan by the end of the year."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Great. I've got one product follow-up. Mike, it sounds like, Lotus EDGE, the timing of introducing that in Europe may be sliding. Just -- can you provide some clarity on that?",31,"Great. I've got one product follow-up. Mike, it sounds like, Lotus EDGE, the timing of introducing that in Europe may be sliding. Just -- can you provide some clarity on that?"
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, the -- in terms of sliding, we do anticipate 2016, we will launch Lotus EDGE. And so we do -- I guess, maybe, we did push that a bit. But we are confident in the 2016 launch of Lotus EDGE. And it -- similar to some of the comments in SYNERGY, we cont",107,"Yes, the -- in terms of sliding, we do anticipate 2016, we will launch Lotus EDGE. And so we do -- I guess, maybe, we did push that a bit. But we are confident in the 2016 launch of Lotus EDGE. And it -- similar to some of the comments in SYNERGY, we continue to exceed our commitments with Lotus. We exceeded the high end of our range. We're on track deliver our 21-millimeter valve. We'll be launching our Lotus EDGE platform, and we continue to drive great outcomes on our clinical data. Maybe, Keith, you could comment on some of the news you anticipate at Europe."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. I mean, I think, Mike, the important thing is when we commercialize Lotus in the U.S. late in '17, we'll have EDGE. We'll have 5 trial sizes, 21 through 29. We'll have the [indiscernible] 14 French compatibility and increased flexibility. The 21-valv",100,"Yes. I mean, I think, Mike, the important thing is when we commercialize Lotus in the U.S. late in '17, we'll have EDGE. We'll have 5 trial sizes, 21 through 29. We'll have the [indiscernible] 14 French compatibility and increased flexibility. The 21-valve is already in clinical trials, so that'll give us 4 valves. That'll be followed by the 29. And we'll anticipate EDGE around about EuroPCR or just after. EDGE is already in clinical trials. So we're very confident about moving to the 14 French compatibility, which of course, makes us comparable with the other competitors in the market."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question is coming from the line of Bob Hopkins with Bank of America.",15,"The next question is coming from the line of Bob Hopkins with Bank of America."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","So just wanted to follow-up and make sure I heard you correctly on the U.S. ICD and pacemaker pipeline and the time lines for the pipeline. So specifically, could you just tell us when you expect quad pulse CRT-D lead approval in the U.S. and then MRI-saf",83,"So just wanted to follow-up and make sure I heard you correctly on the U.S. ICD and pacemaker pipeline and the time lines for the pipeline. So specifically, could you just tell us when you expect quad pulse CRT-D lead approval in the U.S. and then MRI-safe pacemaker approval in the U.S.? And then also give us an updated thoughts on MRI-safe traditional ICD and CRT-D timelines for the U.S. since it feels like that's where Medtronic is having the most success."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. I'm really proud of our CRM business. We clearly want to grow faster. But we're in a position now where we can see, as we go forward in 2016 and '17 and beyond, really the strength of the portfolio. And I'll give answers to your specific MRI questio",300,"Sure. I'm really proud of our CRM business. We clearly want to grow faster. But we're in a position now where we can see, as we go forward in 2016 and '17 and beyond, really the strength of the portfolio. And I'll give answers to your specific MRI questions in a second here. But we've got these product launches coming in the second half of '16. The S-ICD is really gaining excellent momentum globally. We're expanding that, and we're going to be moving beyond the replacement cycle headwind. In terms of the product launches, we feel comfortable with a second quarter launch of both the quad system and MRI pacer. The MRI pacer likely slipped a little bit out of first quarter into second quarter. We'll also have EMBLEM MRI approval likely in the third quarter of 2016. So big, big approvals in the second quarter and third quarter. And then as we go forward with the ICD MRI capability, we'll start that trial very quickly here, and we anticipate approval of that product likely in second quarter or third quarter of 2017. So we've got a really strong cadence of product approvals coming, MRI capabilities. But I think what's most unique about our offering is this S-ICD momentum that we're seeing around the world. We just received approval in Japan. We have a 5% premium -- reimbursement premium in Japan, continued strong acceptance of the product and training and a multiyear head start. So as you looked at our business going forward, these product cadence will come through. SICD is continuing to grow, and our replacement cycle headwind will reverse itself. So as you look forward to CRM, I really believe that you're going to see this business strengthen in the second half of '16 and '17 and '18."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Great. That's very helpful. And then one for Dan. I just want to make sure I understand the margin story, just specifically in the fourth quarter. Is the right way to think about operating margins in the fourth quarter and all the moving parts that you ha",91,"Great. That's very helpful. And then one for Dan. I just want to make sure I understand the margin story, just specifically in the fourth quarter. Is the right way to think about operating margins in the fourth quarter and all the moving parts that you had very strong gross margin performance, and that you took advantage of a very low tax rate to invest a little bit more in SG&A than you originally anticipated? It is that, from a big picture perspective, the right way to thing about Q4 margins?"
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. I think, overall, and then as I mentioned in our prepared remarks, the -- we did have 80 basis points of the fixed asset write-offs and the litigation fees. So I wouldn't call that kind of investing for the future. So if you take that off, I'd say we",108,"Yes. I think, overall, and then as I mentioned in our prepared remarks, the -- we did have 80 basis points of the fixed asset write-offs and the litigation fees. So I wouldn't call that kind of investing for the future. So if you take that off, I'd say we, again, as we mentioned, very proud of where we ended for the year and the overall improvement we've had over the past 2 years. If you take 2016 and '15 together, you'd be looking at almost 400 basis points of operating margin expansion. So in a given quarter, you'll see fluctuations, but the overall trend is extremely positive."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of David Roman with Goldman Sachs.",13,"The next question comes from the line of David Roman with Goldman Sachs."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Maybe I will switch gears to the Urology business. And maybe, Mike, you could talk about how the integration is going with AMS and very specifically focused on some of the issues that you may be undertaking to help accelerate top line growth from where AM",57,"Maybe I will switch gears to the Urology business. And maybe, Mike, you could talk about how the integration is going with AMS and very specifically focused on some of the issues that you may be undertaking to help accelerate top line growth from where AMS was performing at sort of the exit rate of the acquisition."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","I won't give a CRM answer on this one. So I guess, I just wanted to talk about Urology because I like what we're doing here so much. So we -- again, we had nice results in fourth quarter, business growing 7% overall. Really nice job taking international m",243,"I won't give a CRM answer on this one. So I guess, I just wanted to talk about Urology because I like what we're doing here so much. So we -- again, we had nice results in fourth quarter, business growing 7% overall. Really nice job taking international markets as we continue to invest in our stone business and training programs. That's growing very well, double-digits outside the U.S. consistently. And the AMS integration's on track. Thankfully, the team did a really nice to job due diligence. We did project some softness the first 6 months post-acquisition as we wanted to bleed down distributor inventory levels to appropriate levels, and that's exactly what we're seeing. So that's happening. And we likely we'll see continued softness in Q1, but improving in terms of the legacy AMS business, and that's being offset by the BSC legacy business. As we go forward in the second quarter, we expect that legacy AMS business to grow much closer to the BSC overall growth rate. And then we'll see additional benefit on top of that as we see synergies between the BPH portfolio, the stone portfolio, the ED portfolio and the incontinence portfolio overall. So really, we're right on track. We're going to deliver our EPS accretion commitment of $0.03 in '16, and I think it's $0.07 in 2017. So the integration's gone well. We've had exceptionally low turnover, and it's being met very well by the customers."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","That's helpful. And then maybe just a follow-up on the price/mix environment. As we sort of look at your growth rate, another acceleration potentially untapped for 2016 at the midpoint of your guidance on an organic basis. Can you just sort of talk about",86,"That's helpful. And then maybe just a follow-up on the price/mix environment. As we sort of look at your growth rate, another acceleration potentially untapped for 2016 at the midpoint of your guidance on an organic basis. Can you just sort of talk about how the pricing and mix environment is shaping up? Because at least from your peers who have reported earnings results thus far, it sounds like the environment is a tad better, but maybe any thoughts from your perspective would be appreciated."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, David. This is Dan. In terms of price, as you heard, we mentioned it's about 100-basis-point drag on gross margins, so you can kind of back into what that is. Obviously, we don't make assumptions about significant improvements in the pricing environ",123,"Sure, David. This is Dan. In terms of price, as you heard, we mentioned it's about 100-basis-point drag on gross margins, so you can kind of back into what that is. Obviously, we don't make assumptions about significant improvements in the pricing environment or significant deteriorations in that. It's contemplated within the range. But as we look at it, it feels stable. So the product lines that have historically declined are continuing to decline at that historical rate. They haven't moved significantly. And likewise, the ones where prices stay flat, and in some cases, increase, have stayed pretty constant and stable. So over the past 12 to 18 months, it felt relatively stable, and the guidance for '16 assumes that through the year."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","And mix?",2,"And mix?"
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Mix -- in general for us, mix is a good guy. So as we sell more of the newer technologies, a lot of which Mike went through that list, the majority of those are accretive to overall Boston Scientific margins -- gross margins.",43,"Mix -- in general for us, mix is a good guy. So as we sell more of the newer technologies, a lot of which Mike went through that list, the majority of those are accretive to overall Boston Scientific margins -- gross margins."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question is coming from the line of Brooks West with Piper Jaffray.",14,"The next question is coming from the line of Brooks West with Piper Jaffray."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","Let me start with Peripheral, actually. Very strong performance there. You've got a lot going on. I wonder if you could give us just a little bit more detail on kind of product cadence, market dynamics. And if we can see the business kind of continuing to",53,"Let me start with Peripheral, actually. Very strong performance there. You've got a lot going on. I wonder if you could give us just a little bit more detail on kind of product cadence, market dynamics. And if we can see the business kind of continuing to perform at this level going forward."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. The team's done a really nice job. Jeff Mirviss and the Peripheral group delivered 20% growth in legacy Bayer business and 10% organically overall. So obviously, very strong growth in a few quarters in a row here. And we're projected to set up reall",272,"Sure. The team's done a really nice job. Jeff Mirviss and the Peripheral group delivered 20% growth in legacy Bayer business and 10% organically overall. So obviously, very strong growth in a few quarters in a row here. And we're projected to set up really nicely in 2016. So I think just the backdrop, the markets there are very healthy. We're seeing nice market growth in atherectomy; our core business. We just launched a new DBT product; and also, clearly, the growing acceptance of the drug coated technologies. So the markets, overall, are strong. And we really have a unique position in terms of our portfolio. You've heard a lot about our drug-eluting stent, Eluvia. We'll be the only company with both a drug-eluting stent in a drug-eluting balloon in Europe. And we're also kicking off our Eluvia IMPERIAL trial in the first half of 2016. So we are uniquely positioned in our DES. We're also launching a number of our core SFA metal stents in Japan and Asia, in China, which will help us grow that business. And we also continue to really expand globally. We've been -- we were lightweight in terms of the emerging markets in Peripheral 5 years ago, and we've put a lot of investment in there. We're starting to see that become more meaningful in places like China and Brazil. And lastly, we commented on the call about our CeloNova deal. Our Interventional Oncology may be a little bit different than some competitors' Peripheral business, but that IO business is a strong grower for us, and we like that CeloNova transaction, particularly for the emerging markets."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","And if I could just follow-up with one on -- Dan, you mentioned earlier the leverage on the balance sheet was going to get back to pre-AMS acquisition levels by the end of the year. Can you just update us on your thoughts on acquisitions? And are you seei",57,"And if I could just follow-up with one on -- Dan, you mentioned earlier the leverage on the balance sheet was going to get back to pre-AMS acquisition levels by the end of the year. Can you just update us on your thoughts on acquisitions? And are you seeing valuation expectations come down in the market?"
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, Brooks. So yes, just in terms of the leverage levels, that's to get back to about a 2.5x debt to EBITDA. We remain on track to do that as we had announced in conjunction with the AMS acquisition by the end of this year. We did the debt pay down that",179,"Sure, Brooks. So yes, just in terms of the leverage levels, that's to get back to about a 2.5x debt to EBITDA. We remain on track to do that as we had announced in conjunction with the AMS acquisition by the end of this year. We did the debt pay down that we needed to do at the end of '15 and have in our cash flow projections in '16 to do the remainder to get to that level, so we feel very comfortable there. Relative to valuations and M&A, so we're very -- still very active in the market relative to tuck-in M&A. Obviously, screened a lot of different opportunities. I wouldn't say I've seen significant changes in valuation expectations across the landscape. It would depend on what division and what stage you're talking about. But in general, the valuations have stayed fairly constant, and we are actively in the market, obviously, looking for a tuck-in deal. And that is part of our cash flow projection for '16 as well, to be able to do some tuck-in deals."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","The next question is coming from the line of Larry Biegelsen with Wells Fargo.",14,"The next question is coming from the line of Larry Biegelsen with Wells Fargo."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","So Mike, you're one of the few companies that actually showed an acceleration and emerging growth this quarter, I think about 15% organic versus 13% last quarter. A lot of companies have shown the opposite trend. So my question is what's the outlook in 20",70,"So Mike, you're one of the few companies that actually showed an acceleration and emerging growth this quarter, I think about 15% organic versus 13% last quarter. A lot of companies have shown the opposite trend. So my question is what's the outlook in 2016? How comfortable -- how much visibility do you have on growth in those markets? And any color would be helpful, and I had a follow-up."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","I'm sorry. Reflected the emerging markets?",7,"I'm sorry. Reflected the emerging markets?"
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","I'm sorry. Yes, emerging market growth. I think you had 15% organic in Q4. I think 13% in Q3.",20,"I'm sorry. Yes, emerging market growth. I think you had 15% organic in Q4. I think 13% in Q3."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. We were a little bit slower in second quarter, and we had nice pick-up. Really, the pick-up in the second half of 2015 was good, but it was also more consistent with what we expected and did in 2014, quite frankly. And so it's really a continuation o",179,"Yes. We were a little bit slower in second quarter, and we had nice pick-up. Really, the pick-up in the second half of 2015 was good, but it was also more consistent with what we expected and did in 2014, quite frankly. And so it's really a continuation of ex maybe a soft quarter, 1 soft quarter, the second quarter, kind of a continuation of what we've been doing in 2014 and what we expect to continue to do in 2016. So we had some softness in Russia in the second quarter. We've seen that stabilize a bit. We had excellent growth in China, excellent growth in Brazil and a number of other countries. So we continue to register new products, add commercial capabilities, we're building R&D capabilities, new education training centers. I just got back from there last night. So we put a lot of time and effort in it. We just did a joint venture deal with Frankenman there in our endo business. So we feel comfortable about our prospects in that mid-teens rate in emerging markets."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Analysts","And then Neuromodulation, I don't think has come up on this call, but you had a nice year in Neuromodulation this year. But obviously, there's -- the competitive dynamics are changing. So just color on 2016 and how we should think about growth and trends",57,"And then Neuromodulation, I don't think has come up on this call, but you had a nice year in Neuromodulation this year. But obviously, there's -- the competitive dynamics are changing. So just color on 2016 and how we should think about growth and trends there and the sustainability of the nice growth you showed in 2015."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Larry, we'll hit that in a sec, but we're going back to the emerging markets revenue question versus indiscernible].",19,"Larry, we'll hit that in a sec, but we're going back to the emerging markets revenue question versus indiscernible]."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Just one other thing, Larry, on that. So one of the other items with respect to emerging markets is just the foreign currency exchange rates. So if you look back at Q4 and think of our $1,978 million that we reported, again that included $25 million negat",95,"Just one other thing, Larry, on that. So one of the other items with respect to emerging markets is just the foreign currency exchange rates. So if you look back at Q4 and think of our $1,978 million that we reported, again that included $25 million negative headwinds from FX compared to what we had talked about when we give guidance. So kind of adjusted for that, we would have been over $2 billion and kind of closer to the higher end of the range. And emerging markets, obviously, is a big piece of that."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","And Neuromod continues to perform well. We grew 7% in the quarter. We grew 8% full year, and we had consistently strong growth throughout the year. And we really don't see that -- we anticipate that trend to continue. Spectra continues to perform very wel",151,"And Neuromod continues to perform well. We grew 7% in the quarter. We grew 8% full year, and we had consistently strong growth throughout the year. And we really don't see that -- we anticipate that trend to continue. Spectra continues to perform very well. The launch of Novi outside the U.S. is picking up, and we are getting a lot of -- we are building momentum in international markets in deep brain stimulation, and we'll hopefully get some good luck and get that clinical trial enrolled in '16 to position that launch. So it's a very healthy market right now, and there's a lot of patient demand. And so we like to see that, that market's clearly growing in the mid-single-digit range, if not, a bit more. So it's a growing market. We have some unique innovation. And it's a bit more competitive, but it hasn't slowed down our performance."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you. With that, we'd like to go conclude the call. Thank you very much for joining us today, and we sincerely appreciate your interest in Boston Scientific. Before you disconnect, David will give you all the details for the replay.",41,"Thank you. With that, we'd like to go conclude the call. Thank you very much for joining us today, and we sincerely appreciate your interest in Boston Scientific. Before you disconnect, David will give you all the details for the replay."
317627,321212230,927695,"Boston Scientific Corporation, Q4 2015 Earnings Call, Feb 04, 2016",2016-02-04,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, this conference will be made available for replay after 10:30 Eastern Standard Time today until February 18 at midnight. You may access the AT&T playback service at any time by dialing 1 (800) 475-6701 and entering access code 381463",70,"Ladies and gentlemen, this conference will be made available for replay after 10:30 Eastern Standard Time today until February 18 at midnight. You may access the AT&T playback service at any time by dialing 1 (800) 475-6701 and entering access code 381463. International participants may dial 1 (320) 365-3844. That does conclude our conference for today. Thank you for your participation and for using AT&T Teleconference. You may now disconnect."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2016 Boston Scientific Earnings Call. [Operator Instructions] And as a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Susie Lisa",46,"Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2016 Boston Scientific Earnings Call. [Operator Instructions] And as a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Susie Lisa. Please go ahead."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Roxanne. Good morning, everyone, and thanks for joining us. With me on today's call are Mike Mahoney, President and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.We issued a press release earli",365,"Thank you, Roxanne. Good morning, everyone, and thanks for joining us. With me on today's call are Mike Mahoney, President and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.
We issued a press release earlier this morning announcing our Q1 2016 results, which included reconciliations of the non-GAAP measures used in the release.
We have posted a copy of that release as well as reconciliations of the non-GAAP measures used in today's call to the Investor Relations section of our website under the heading, Financial Information.
The duration of this morning's call will be approximately 1 hour. Mike will provide strategic and revenue highlights for Q1 '16. Dan will review the financials for the quarter and then Q2 '16 and full year 2016 guidance, and then we'll take your questions. During today's Q&A session, Mike and Dan will be joined by our Chief Medical Officers, Dr. Keith Dawkins and Dr. Ken Stein. 
Before we begin, I'd like to remind everyone that on the call, organic revenue growth is defined as excluding the impact of sales from divested businesses, changes in foreign currency exchange rates and sales from the acquisition of the American Medical Systems male urology portfolio over the prior year period. Also note, this call contains forward-looking statements within the meaning of federal securities laws, which may be identified by words like anticipate, expect, believe, estimate and other similar words.
They include, among other things, statements about our growth and market share; new product approvals and launches; clinical trials; cost savings and growth opportunities; our cash flow and expected use; our financial performance, including sales, margins, earnings and other Q1 2016 results and Q2 and full year 2016 guidance; as well as our tax rates, R&D spend and other expenses.
Actual results may differ materially from those discussed in the forward-looking statements.
Factors that may cause such differences include those described in the Risk Factors section of our most recent 10-K and subsequent 10-Qs filed with the SEC.
These statements speak only as of today's date, and we disclaim any intention or obligation to update them.
At this point, I'll turn it over to Mike for his comments. Mike?"
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Susie. Good morning, everyone. We continue to perform against our strategic plan goals, and we're encouraged by the consistent strong execution of our global team. The success of our new product launches across many of our businesses is helping",1617,"Thank you, Susie. Good morning, everyone. We continue to perform against our strategic plan goals, and we're encouraged by the consistent strong execution of our global team. The success of our new product launches across many of our businesses is helping us accelerate expansion into faster-growth markets and deliver solutions that address unmet clinical needs. 
We continue to believe that Boston Scientific is uniquely positioned to deliver differentiated shareholder value through durable mid-single-digit organic revenue growth and double-digit adjusted EPS growth through our ongoing operating margin improvement initiatives. We're very excited about the excellent start to 2016 and our plans to build upon our global momentum in 2017 and beyond. 
We posted excellent results this quarter with total operational revenue growth of 13% and organic revenue growth of 8%, excluding the impact of AMS acquisition benefit. 4 of our 7 businesses grew revenue double digits organically, and we, in turn, leveraged that revenue growth to drive 24% adjusted operating income growth, resulting in adjusted operating margin of 25.1% and a 260 basis point improvement year-over-year. 
We delivered adjusted EPS of $0.28, exceeding the high end of guidance and representing 31% growth, including the negative impact from foreign currency. Importantly, we're increasing our 2016 guidance for revenue, adjusted operating margin and adjusted EPS. We're increasing our full year organic revenue growth guidance from 4% to 7% previously to 6% to 8% full year operational revenue, which includes the benefit of AMS has been increased from 7% to 10% to 9% to 11%. We're increasing our adjusted operating margin guidance to 24% to 24.5%, and we're also increasing our adjusted EPS guidance up $0.03 over our prior range to $1.06 to $1.10, which now represents 14% to 18% growth, and importantly, this EPS guidance includes an expected $0.05 to $0.06 negative impact from foreign exchange. 
I'll now try to highlight on Q1 results and the 2016 outlook. And in my remarks, all references to growth are in constant currency organic year-over-year basis, excluding the benefit of AMS unless otherwise specified. 
Our Q1 revenue growth of 8% was broad based across our businesses and regions, led again by exciting new product launches, continued global expansion and execution of our category leadership strategy. With the exception of a 3% decline in our Cardiac Rhythm Management sales, all of our other businesses delivered strong organic growth, led by Endo at plus 11%, Urology and Pelvic Health of plus 12%, Interventional Cardiology up [ph] 13%, and Peripheral intervention up [ph] 14%. 
We also saw strong growth globally with Asia delivering 14%; U.S., 7%; and Europe, up 6%. Our emerging market sales grew 21%, including China, sales at 19%. The businesses all accelerated in Q4 of last year and delivered adjusted operating margin of 32.6%, up 360 basis points year-over-year. 
Endoscopy revenue grew 11% driven by a single SpyGlass digital DES visualization system, the stent for drainage of pancreatic fluid and the limited launch of our next-generation hemostasis clip, the Resolution 360. We're also extending our category leadership in Endoscopy by developing commercial capabilities in the emerging markets, adding a focus in pulmonary, which helped drive 15% growth in bronchial thermoplasty as recently launched in both Japan and China. Urology and Pelvic Health organic growth accelerated 12% and was broadly based with double-digit growth in kidney stone, pelvic floor and our legacy business grew 15% internationally, led by 36% growth in the emerging markets. The AMS remediation and integration are on track, and we are delivering against our synergy commitments and a global teams are now fully integrated. 
As expected, stand-alone AMS sales declined slightly in the quarter, and we expect inventory to be appropriate levels in the second quarter. At LithoVue, an innovative single digital scope that provides customers with visualization and navigation capabilities, will be featured in multiple presentations next weekend at the American Urology Association meeting in San Diego. 
Neuromodulation revenue growth accelerated 8% in the first quarter, and sales were driven by the market-leading Spectra platform, the most flexible spinal cord stimulation system in the market; the launch of precision Novi for the primary cell nonrechargeable market; and the solid contribution from our emerging Deep Brain Stimulation platform. 
Our U.S. DBS trial is making great progress, and we expect the launch of the U.S. in late 2017 or early 2018. In Cardiovascular, our segment sales grew 14% in the quarter and a delivered adjusted operating margin of 34.1%, up over 350 basis points, both sequentially and year-over-year. 
Peripheral sales grew 14% in the strong results in atherectomy, thrombectomy and our Innova bare metal and Eluvia drug-eluting stent platforms. The legacy Peripheral business continued impressive trend as we grow share atherectomy market and see very strong demand for our new deep vein thrombosis platform. 
The Eluvia IDE trial called IMPERIAL is on track to complete enrollment by late 2016 or early 2017, and we look forward to presenting 24-month data from our initial trial, MAJESTIC, which had a 12-month patency rate of 96.1% later this year. We're also seeing continued progress for our Lutonix distribution agreement and encouraging EU sales of our ranger drug-coated balloon. We're excited to be the only company developing leading drug-eluting technologies globally on multiple platforms, providing physicians with a variety of tools for treating complex peripheral vascular disease. 
Interventional Cardiology turned another double-digit quarter, a 13% growth, led by complex core drug-eluting stents, PCI guidance and Structural Heart. SYNERGY had a very strong quarter, and we estimate that we added to our market-leading share position in the U.S. and regain market-leading position in Japan. 
DES sales grew 14% in the quarter, and we believe SYNERGY is on track to represent approximately 50% of our U.S. DES revenue mix by the end of the year '16. 
PCI guidance again grew double digits on continued share gains on intravascular ultrasound, and we're encouraged by strong feedback on the ease-of-use of our common fractional flow reserve platform. Our leading portal of solutions for complex high-risk PCI patients continues to drive global growth as well. 
The 13% IC revenue growth is also fueled by our strengthening Structural Heart business, which includes our Lotus transcatheter aortic valve and WATCHMAN Left Atrial Appendage Closure Device. We believe we are uniquely positioned to drive long-term growth in these 2 fast-growing markets via our differentiated platforms. 
Our Lotus valve continues to gain share in Europe, and we are investing significantly to further develop our capabilities. Most recently, a best-in-class paravalvular leakage rates reported for Lotus at ACC last month with predischarge rates of 0.4% for moderate regurgitation in the first 750 patients in the RESPOND Post-Market Study. 
We also continue to plan for the U.S. launch with a Lotus EDGE delivery system at the end of 2017, and we also completed enrollment in our REPRISE Japan trial, where we targeted a 2018 launch. 
Importantly the Lotus EDGE features 14 French compatible, more flexibility, simplified deployment and our new depth guard technology, which controls depth of the valve left particular outflow tract. Studies that demonstrate an improved permanent pacemaker rate with this optimize technique will begin enrollment in mid-2016. 
Also at Structural Heart, WATCHMAN sales were strong and procedure growth annual account openings, both helped by the finalized national coverage determination. We're developing additional WATCHMAN capabilities, primarily by adding resources in field clinical support, market development and training courses. Implant success rates and patient outcomes remain very high quality due to our controlled rollout and proven training programs. 
In the ACC earlier this month, Dr. David Holmes of the Mayo Clinic presented data from the first 1,600 patients implanted with a WATCHMAN commercially and reveals 96% procedural success at an average procedure time of 15 [ph] minutes. So overall, we are very pleased with our progress and our 2016 revenue guidance of $175 million to $200 million in Structural Heart revenue. 
Rhythm Management segment sales declined 2% in the quarter yet delivered adjusted operating margin of 16.8, which is up 290 basis points sequentially as improving profitability remains a core focus. In CRM, as anticipated, sales declined 3% as we faced competitive launches in the U.S. and replacement cycle headwinds. We're optimistic for a second quarter and second half 2016 improvement in our CRM performance. 
Also, as projected, we received 2 key FDA approvals in March for our ACUITY X4 quad CRT lead and earlier this week for our ACCOLADE brady MRI platforms, including the INGEVITY MRI patient lead. Pacemaker sales grew 3% globally, aided by a recently launched X4 CRTD quad device while worldwide ICD sales declined 4%. 
We continue to be very pleased with the performance of the EMBLEM S-ICD, which is enjoying strong growth in both Europe and the U.S. and is currently launching in Japan. And we're encouraged by the growth in Europe, led by our arrhythmia installations and recent launches of the IntellaMap OI and IntellaMap MiFi OI ablation catheters. In the U.S., we're now launching our Blazer open-irrigated therapeutic catheter for the treatment of Type 1 atrial flutter as we continue to invest in the franchise, launch a portfolio of navigation-enabled therapeutic catheters and build capabilities in capital equipment sales and service. 
We have a stronger arrhythmia customer pipeline as many of our new platform enhancements scheduled for release in 2016. So to wrap up, our company had an excellent quarter. First quarter results reflect the strength of our portfolio, our ongoing investment into faster-growth markets and our globalization efforts. More importantly, we are well positioned to continue our strong performance in 2016 and beyond. I want to thank our employees for their continued winning spirit and their commitment to the company. 
Now let me turn the call over to Dan for a more detailed review of our financials."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Mike. In Q1, we generated organic revenue growth of 8% versus our 4% to 6% guidance range and adjusted EPS of $0.28, exceeding our guidance range of $0.23 to $0.25 and representing 31% year-over-year growth. Adjusted EPS of $0.28 includes a slig",1942,"Thanks, Mike. In Q1, we generated organic revenue growth of 8% versus our 4% to 6% guidance range and adjusted EPS of $0.28, exceeding our guidance range of $0.23 to $0.25 and representing 31% year-over-year growth. 
Adjusted EPS of $0.28 includes a slightly lower-than-expected tax rate for the quarter due to some discrete tax items. Strong performance in Q1 was driven primarily by revenue growth upside, gross margin expansion and a lower SG&A rate versus the prior year. 
And as Mike mentioned, given the outperformance in Q1, we are raising full year guidance for revenue growth, adjusted operating margins and adjusted EPS. Consolidated revenue of $1,964,000,000 represented operational revenue growth of 13%, which excludes the impact of a $58 million headwind from foreign exchange. Excluding an approximate 500 basis point contribution from the AMS male urology portfolio acquisition, organic revenue growth was 8% in the quarter. 
On an as-reported basis, revenue grew 11% year-over-year. Adjusted gross margin for the first quarter was 72.3%, increasing 100 basis points year-over-year. The increase resulted primarily from cost improvements driven by our value improvement programs and favorable mix, partially offset by price. And similar to Q4 2015, the impact of foreign exchange on gross margin was negligible in the quarter. 
We continue to expect full year 2016 adjusted gross margin to be in the range of 72% to 73%, which we forecast to include approximately 50 basis points of unfavorable FX. Our Q1 2016 adjusted operating margin of 25.1% represents a 260 basis point improvement over Q1 2015, which marks the 7th consecutive quarter in which we've expanded adjusted operating margin by 100 basis points or more. 
There was very modest reinvestment of the medical device tax benefit in Q1, which represents some timing favorability in the quarter, but we are committed to reinvesting substantially all of the full year benefit during the year. Thus, adjusted SG&A expenses were $698 million or 35.5% of sales in the quarter, down 150 basis points year-over-year with some of the benefit due to our targeted initiatives focused on reducing SG&A and a portion due to the more modest medical device tax benefit reinvestments I just mentioned. 
Our Q1 adjusted SG&A rate was the lowest in the last 12 quarters, and we continue to believe our full year rate will be between 35.5% and 36.5%, which, at the midpoint, would be a 140 basis point reduction compared to 2015. 
Adjusted research and development expenses were $209 million in the first quarter or 10.7% of sales, which is roughly flat year-over-year. This is another key area for us to reinvest the benefit of the medical device tax expansion. As a result, we expect our full year 2016 adjusted R&D rate to be between 11% and 12% of sales. 
Royalty expense was 1% of sales in both Q1 of this year and last year and consistent with our guidance. On an adjusted basis, operating income was $494 million in the quarter or 25.1% of sales, up 260 basis points year-over-year. 
Q1 adjusted operating income grew 24% year-over-year, with all 3 reportable segments expanding adjusted operating margin by at least 250 basis points over Q1 of last year. Of particular focus is Rhythm Management, which delivered an adjusted operating margin of 16.8%, which is up from Q4 2015's 13.9% and the full year 2015 rate of 15%. 
For the first half of 2016, we expect Rhythm Management adjusted operating margin to be slightly above 16%. In the second half of 2016, we expect Rhythm Management adjusted operating margin to increase roughly 200 basis points over the first half rate. This second half improvement is expected to result from realizing the full benefit of 2016 product costs, leveraging the improved top line performance expected of the global CRM and EP businesses and realizing the full benefits of our Plant Network Optimization program, which is transferring a portion of our EP manufacturing to lower-cost locations. We continue to believe Rhythm Management is on track to deliver an adjusted operating margin of 20% in 2017. 
GAAP operating income, which includes GAAP to adjusted items of $201 million, was $293 million in Q1 2016. The primary GAAP to adjusted items for the quarter included amortization expense of $136 million, restructuring and related charges of $13 million, acquisition-related SG&A expenses of $14 million and litigation-related charges of $10 million. Our total legal reserve was $1,895,000,000 as of March 31, 2016. 
Now I'll move on to other income and expense. Interest expense for the quarter was $59 million compared to $56 million in Q1 last year, and the increase was primarily due to the incremental debt raised in Q2 of last year to finance the AMS male urology portfolio acquisition. 
Our average interest rate was 4% in Q1 2016 compared to 5.1% in Q1 last year, and the lower interest expense rate in Q1 this year was primarily due to a lower average cost of debt resulting from the senior notes refinancing, which we completed in Q2 last year. 
Other expense was $10 million, and this consisted primarily of foreign exchange losses and investment losses incurred during the quarter. 
Our tax rate for the quarter was 11.4% on a reported basis and 11.8% on an adjusted basis. Excluding discrete tax items in the quarter, our adjusted tax rate would have been 13.5%, and we continue to expect our full year 2016 adjusted tax rate to be approximately 14%. 
On a reported GAAP basis, Q1 2016 EPS was $0.15 and includes net charges and amortization expense totaling $176 million after tax. GAAP EPS of $0.15 compares to break even in Q1 of last year. 
Moving on to the balance sheet. DSO of 60 days increased 1 day compared to March of last year. Days inventory on hand of 162 days was down 4 days compared to March of last year and 1 day from year-end 2015. 
Capital expenditures were $59 million in the quarter compared to $46 million in Q1 2015. And as a reminder, we expect full year 2016 capital expenditures to be roughly $350 million. This is $100 million higher than the full year 2015, primarily due to the construction of our new manufacturing facility and distribution center in Malaysia. And beyond 2016, we expect capital expenditures to return to our more historical run rate of approximately $250 million annually. 
Adjusted free cash flow for the quarter was $250 million compared to $118 million in Q1 2015, and this strong start gives us confidence in our adjusted free cash flow target of $1.5 billion, which represents 10% growth and better visibility to our stretch goal of $1.6 billion, which would represent 17% growth, even in a year with an incremental $100 million in CapEx spend as I mentioned. 
We are also continuing to pursue inventory management initiatives designed to improve the working capital contribution to cash flow. In Q1, we used cash primarily to fund previously agreed legal settlements as well as business development activities. 
Consistent with our goal of returning to pre-AMS debt leverage by year-end 2016, we still expect to repay $250 million of bank term loans by the end of this year. As of March 31 this year, we had cash on hand of $338 million. 
Near term, our capital allocation priorities are to prepay debt, manage contingencies and pursue tuck-in M&A. We ended the quarter with 1,370,000,000 fully diluted weighted average shares outstanding. Consistent with our prior guidance, we expect our share count to increase by roughly 5 million per quarter through the end of the year as we plan to keep the buybacks suspended for the balance of 2016. We would expect this to result in a fully diluted weighted average share count of approximately 1,380,000,000 for the full year 2016. 
I'd like to conclude with revenue and earnings per share guidance for Q2 and full year 2016. For the full year, we now expect consolidated revenue to be in the range of $8,075,000,000 to $8,225,000,000, which represents year-over-year growth of 6% to 8% on an organic basis; 9% to 11% on an operational basis, which includes the AMS revenue; and 8% to 10% on a reported basis. 
As a result of a stronger dollar at current rates, we expect foreign exchange to be a headwind of approximately $100 million for the full year 2016. As we move through 2016, we are reinvesting the benefit of the medical device tax suspension and innovation to help treat patients and sustain top line growth over the long term. Focus areas will include R&D efforts, including clinical trial spend as well as market development, and in Q2, we've already begun to ramp this reinvestment, primarily in the areas of Structural Heart with both Lotus and WATCHMAN and other durable long-term revenue growth platforms such as the EMBLEM S-ICD, our Electrophysiology portfolio, Deep Brain Stimulation and other fast-growing adjacent markets. 
In addition, Q2 is our seasonally high SG&A spend quarter partially due to the highest trade show activity of the year. Thus, for Q2 2016, and consistent with prior years, we would expect a sequential decline in adjusted operating margin to a range of 23% to 24%, which, at the midpoint, represents 140 basis points of improvement year-over-year and puts first half 2016 adjusted operating margin at 200 basis points up versus the first half of last year. 
And for the full year 2016, we are raising our adjusted operating margin guidance from 23.5% to 24.5% to a range of 24% to 24.5% now, which also represents a 200 basis point year-over-year gain. This gain is from operational efficiencies and not the med device tax as we are reinvesting the benefits. 
Turning to adjusted EPS. We now expect full year adjusted EPS for 2016 to be in a range of $1.06 to $1.10, representing 14% to 18% adjusted earnings growth and an increase of $0.03 to each end of the range compared to our prior guidance. 
Now let me walk you through our updated assumptions for the FX impact on adjusted EPS. Our initial 2016 guidance assumed $0.02 of unfavorable FX on adjusted EPS in Q1 and $0.06 for the full year. 
In Q1, the combination of exchange rate movements and timing of hedging contracts resulted in an unfavorable impact of $0.01, and we now believe the full year 2016 unfavorable impact will be $0.05 to $0.06. 
In addition to the $0.01 in Q1, we would expect the remaining $0.04 to $0.05 of unfavorable FX for the full year to break down into $0.02 in Q2 and $0.02 to $0.03 in the second half of 2016. Excluding the unfavorable foreign exchange, our full year adjusted EPS guidance range represents growth of 19% to 24%. 
On a GAAP basis, we expect EPS to be in a range of $0.64 to $0.69. 
Now turning to specifically to Q2 2016. We expect consolidated revenues to be in a range of $2,010,000,000 to $2,060,000,000. If current foreign exchange rates hold constant, the headwind from FX should be approximately $25 million or 135 basis points relative to Q2 of last year. 
We expect consolidated Q2 sales to grow year-over-year in a range of 6% to 8% organically and 11% to 13% operationally. For the second quarter, adjusted EPS is expected to be in a range of $0.25 to $0.27 per share, and GAAP EPS is expected to be in a range of $0.14 to $0.17 per share. 
Please check our Investor Relations website for Q1 2016 financial and operational highlights, which outlines Q1 results as well as Q2 and full year 2016 guidance, including P&L line item guidance. 
So with that, I'll turn it back to Susie, who will moderate the Q&A."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Dan. Roxanne, let's open it up to questions for the next 30 minutes or so. [Operator Instructions] Roxanne, please go ahead.",22,"Thanks, Dan. Roxanne, let's open it up to questions for the next 30 minutes or so. [Operator Instructions] Roxanne, please go ahead."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","[Operator Instructions] Our first question comes from the line of Bob Hopkins, Bank of America.",15,"[Operator Instructions] Our first question comes from the line of Bob Hopkins, Bank of America."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Obviously, this was one of the best growth quarters you've had. Congratulations on the great start to the year. Was wondering if you could talk to us a little bit about just the broader macroenvironment and the health of the markets you're in and maybe ju",87,"Obviously, this was one of the best growth quarters you've had. Congratulations on the great start to the year. Was wondering if you could talk to us a little bit about just the broader macroenvironment and the health of the markets you're in and maybe just talk about the factors driving growth. I would really appreciate if you could talk a little bit about Uro and Endo in some of the products that are driving growth in that division because obviously, that's where some really nice outperformance."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks for the question. Overall, market growth be consistent with what we mentioned in the past kind of playing in 3% to 4% growth markets overall for Boston Scientific and similar to Investor Day presentation, we're investing into faster growth markets",344,"Thanks for the question. Overall, market growth be consistent with what we mentioned in the past kind of playing in 3% to 4% growth markets overall for Boston Scientific and similar to Investor Day presentation, we're investing into faster growth markets that would basically accelerate the growth profile another 100, 200 basis points of the markets that we serve. So kind of similar growth rates in IC and cardiology and CRM kind of in the low single-digit range and more in the 4% to 5% market growth rates for our MedSurg, but I guess, what we're most proud of is really across-the-board with the exception of CRM, we're going and EP, we're going significant faster than our competition and based on -- it's really driven by our product launches and really excellent global execution. We're really pleased with the growth in Asia product, almost 15%, very strong growth in Japan, a very strong growth in Europe. So across our businesses, our regions, our teams are really delivering. In terms of your question on Endo and Urology, we are very thoughtful about the AMS acquisition, and we're seeing the benefits of the commercial synergies between those organizations, given the additional commercial footprint that we have as well as the broadness of the bag, and you're seeing that with a really acceleration of our legacy Urology division, in part due to the synergies of our AMS business. We continue to invest in physician training for our Stone Institute, and we continue to benefit from the category leadership based on the premise of the AMS acquisition. In Endoscopy, it's a very innovative division, and we continue to lead in innovation with our digital SpyGlass system, which is really a terrific platform for us that we can continue to build from, and that also helps drive pull-through of our core portfolio. So the R&D teams are executing as well as the commercial teams, and we continue to be committed to our durable mid-single-digit revenue growth, our operating margin expansion and our double-digit EPS growth over the long term."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Great. Dan, can you help us was there any, in your view, selling day mismatch this quarter versus a year ago? And then on the operating margin performance in the quarter, it sounds like over the course of the rest of the year, there's going to be some inc",94,"Great. Dan, can you help us was there any, in your view, selling day mismatch this quarter versus a year ago? And then on the operating margin performance in the quarter, it sounds like over the course of the rest of the year, there's going to be some incremental spending because obviously, you're guiding to a lower operating margin than you started out in Q1. So maybe just comment on the selling day year-over-year, and then also maybe quantify and describe some of the extra spending undertaking here in the remainder of the year."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, Bob. First quickly on the calendar. No, we don't believe there is an extra impact on Q1. There was obviously a leap year day but then when you factor in the timing of the Easter holiday, I believe it's a true 8% growth for the quarter organically. R",252,"Sure, Bob. First quickly on the calendar. No, we don't believe there is an extra impact on Q1. There was obviously a leap year day but then when you factor in the timing of the Easter holiday, I believe it's a true 8% growth for the quarter organically. Relative to operating margin, so I think the -- when you look at Q1 at the 25% and then you look at the 24.25%, which is the midpoint for the full year, one of the key changes there is that as I mentioned in my prepared remarks, the reinvestment of the medical device tax benefit over the rest of the year. So a little delayed in Q1 getting off to that start but committed to reinvesting the entire amount for the rest of the year. So that's one, and I think the -- this R&D timing as well in Q1 so our Q1 R&D was 10.7%. If you look at the guidance range, you'd see 11.5% at the midpoint. Part of that's the med device tax reinvestment, and part of it's just the timing of overall R&D. So that's another 80 basis points there going from the 10.7% in Q1 to the overall average of the 11.5% for the full year. So still as you look at the 24.25%, still significant growth versus last year, 190 basis points and feel good that we're striking a good balance between delivering differentiated adjusted operating margin and investing for a continually growing top line for the future."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","And our next question comes from the line of David Lewis with Morgan Stanley.",14,"And our next question comes from the line of David Lewis with Morgan Stanley."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Just a few quick questions. Mike, I guess, the issue for us this quarter is that we expected an inflection quarter sometime this year obviously, it's coming earlier, but I guess as we think about the balance of the businesses, we actually thought there co",122,"Just a few quick questions. Mike, I guess, the issue for us this quarter is that we expected an inflection quarter sometime this year obviously, it's coming earlier, but I guess as we think about the balance of the businesses, we actually thought there could be acceleration for whatever the growth rate was in the first quarter, and I wonder can you point us to tailwinds, headwinds of business throughout about of the year based on sort of this thought of acceleration throughout the year? And then specific attention perhaps within Cardiovascular. You talked about this business in terms of stent, WATCHMAN, Lotus, what's really driving that strength in cardio? So acceleration and in particular Cardiovascular then one quick one for Dan."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Multipoint question. Thanks, David. Just overall, we are pleased with our performance for the quarter. We took the guidance up from 4 to 7 to 6 to 8 organically not impacting AMS. And as I mentioned, the businesses and regions are performing at a nice lev",409,"Multipoint question. Thanks, David. Just overall, we are pleased with our performance for the quarter. We took the guidance up from 4 to 7 to 6 to 8 organically not impacting AMS. And as I mentioned, the businesses and regions are performing at a nice level. As we look, we obviously anticipate a solid second quarter, given our 6% to 8% guidance in second quarter. We do face a couple of headwinds through the year. We do anniversary some key product launches in our Peripheral vascular as well as our Endoscopy business. We do anticipate some Japan reimbursement that we'll be working through, and we're very bullish on our WATCHMAN program, but we're also anniversary-ing the initial launch. So there are a few headwinds. But overall, we have an excellent product cadence. The business is performing well, and we feel comfortable with raising our guidance to 6% to 8%. On the cardiology side, we're seeing excellent -- our strategy plan play out. We continue to diversify our Interventional Cardiology as we talked in the future, we really see in the future about 1/3 of our business coming from Structural Heart, about 1/3 from imaging and complex coronary, about 1/3 from drug-eluting stent. And across those kind of 3 slices of the pie, we're doing nice job delivering in the short term and investing for the long term. Our SYNERGY programs really going as planned. We're on track for SYNERGY to represent about 50% of our mix at a appropriate premium price, and physicians continue to see the benefit of the deliverability and the excellent 0 stent thrombosis beyond the first 24 hours. So excellent clinical data there. Our complex coronary business continues to do well as does our Imaging business, and in Structural Heart, as Dan mentioned, actually over in Korea as we speak here, we just had a piece is from Australia today, and just the physician reaction to the deliverability and the low PVL rates of our Lotus valve continues to be very high, and so we are really increasing our investment in that category, given the size of the market potential in the future and also given the differentiation that we believe that Lotus delivers and our commercial capability. So hopefully that gives you a bit of flavor. We are pleased with our raise in the guidance, and we will manage our headwinds continue to hopefully deliver revenue growth at the top tier of our sector."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Dan, I hate to bore you with here, it was such a good quarter but we're getting constant currency growth rate this quarter even higher than you reported. We have a $58 million FX headwind for a 3.3% headwind versus 2%. Are we missing something here in the",58,"Dan, I hate to bore you with here, it was such a good quarter but we're getting constant currency growth rate this quarter even higher than you reported. We have a $58 million FX headwind for a 3.3% headwind versus 2%. Are we missing something here in the quarter or and we can take it off-line if it's..."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","No, David, I think it's just a rounding of 3%. The way we see it is 3%. So it's just a little bit in the rounding at the numbers.",29,"No, David, I think it's just a rounding of 3%. The way we see it is 3%. So it's just a little bit in the rounding at the numbers."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","Our next question is from the line of Mike Weinstein, JPMorgan.",11,"Our next question is from the line of Mike Weinstein, JPMorgan."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","When's the last time Boston Scientific grew 8% organic, you guys know the answer?",15,"When's the last time Boston Scientific grew 8% organic, you guys know the answer?"
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Dan.",1,"Dan."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","I'd say 10 years, Mike.",6,"I'd say 10 years, Mike."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","2Q 2005.",2,"2Q 2005."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","That's right. Let's do it again.",7,"That's right. Let's do it again."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","What strikes me in particular if I you look at the U.S. performance and I back out CRM and I back out AMS, I'm getting to about 15% growth for the U.S. business, in aggregate, which is obviously very, very strong. So I want to circle back first to Bob's q",158,"What strikes me in particular if I you look at the U.S. performance and I back out CRM and I back out AMS, I'm getting to about 15% growth for the U.S. business, in aggregate, which is obviously very, very strong. So I want to circle back first to Bob's question just to make sure you don't think that there's anything kind of unusual going on in selling days, and I heard your answer there, but we are seeing this particular strength and not just Boston Scientific we've seen this in some other end markets over the course of the past week that have come in stronger. Anything that you think is going on that showed up this quarter particular that is driving this really increase in volumes, and I'm speaking not just of your own performance, but do you have any theories on the broader market looking stronger this quarter than we've seen in a while?"
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, we don't see a big change in the market from our peers that have reported, we were kind of seeing kind of 1% to 4% growth rate with the exception of one, which was higher than ours. So we do feel like we're growing faster than most of our peers. And",251,"Yes, we don't see a big change in the market from our peers that have reported, we were kind of seeing kind of 1% to 4% growth rate with the exception of one, which was higher than ours. So we do feel like we're growing faster than most of our peers. And I also think we're going through maybe a bit of a cycle of some good innovation and some mix benefit that we clearly see a lot of enthusiasm, for example, for S-ICD despite our headwinds in the near term on MRI, which we're pleased with the pacer approval. We're getting nice mix benefit from S-ICD as well as global uptake of the S-ICD, particularly in Japan, and I think our strategy of category leadership, which we've really stressed for a number of years now, is starting to pay off. What made large systems in the U.S. willing and wanting to partner with Boston Scientific given our current platform as well as the pipeline that we've committed to. I think the markets are steady. We have a nice pipeline that's helping some of our mix benefit, and I think importantly, we really build our capabilities outside the U.S.. Our Asian business grew very well. And just this year, we've done a grand opening for our Malaysia plant. We have a new R&D center in India. We have new training centers. So our capabilities in Asia are significantly stronger than they used to be. So that's also helping strengthen our business."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","If I look at the cardiology business in the U.S., if you look at the Peripheral vascular business in the U.S., those had exceptional quarters. Cardiology up 21%, Peripheral vascular up 13%. Can you -- would you mind just peeling the onion a little bit and",65,"If I look at the cardiology business in the U.S., if you look at the Peripheral vascular business in the U.S., those had exceptional quarters. Cardiology up 21%, Peripheral vascular up 13%. Can you -- would you mind just peeling the onion a little bit and help us understand how those businesses are doing as well as they are because that's well above expectations."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, I think it really speaks to a category leadership. So we're 2 words that get used a lot in the industry, but I think we're delivering it. We have an excellent portfolio. Interventional Cardiology as I mentioned Korea here large conference, and we bel",157,"Yes, I think it really speaks to a category leadership. So we're 2 words that get used a lot in the industry, but I think we're delivering it. We have an excellent portfolio. Interventional Cardiology as I mentioned Korea here large conference, and we believe we have the best drug-eluting stent in the marketplace. We have an excellent imaging platform with IVUS, and we are launching FFR. We're the leaders in chronic total occlusion. We have the WATCHMAN product for interventional cardiologists want to implant it and a very promising a differentiated TAVR valves. So I think our category leadership strategy is working in cardiology and similarly in Peripheral vascular with our -- I won't go through all of them, but the Bayer acquisition really has exceeded the investment knowledge that we had in terms of synergies and growth in -- excuse me, our drug-eluting stent platforms with a stents and the balloon are doing quite well."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","And our next question is from Rick Wise, Stifel.",9,"And our next question is from Rick Wise, Stifel."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Let me turn to one area of weakness. Obviously, CRM high power down 4%, Mike. Can you talk a little bit more about that, and specifically you called out the replacement headwinds. You've been talking about replacement headwinds in CRM for a while. My sens",106,"Let me turn to one area of weakness. Obviously, CRM high power down 4%, Mike. Can you talk a little bit more about that, and specifically you called out the replacement headwinds. You've been talking about replacement headwinds in CRM for a while. My sense is your comments in the past is that, that it's been a shift more to neutral or even a tailwind at some point in the not-too-distant future. Can you give us any more concrete thoughts about what -- when that happens and the kind of drag it is now and how that can change as we look to '17 and beyond?"
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. Thanks for the question, Rick. Just regarding our CRM performance broadly, and I'll comment on replacement headwind. It's really as we projected almost a year ago when we were going to have some challenges in the U.S. Our Asian business, our Japanese",267,"Yes. Thanks for the question, Rick. Just regarding our CRM performance broadly, and I'll comment on replacement headwind. It's really as we projected almost a year ago when we were going to have some challenges in the U.S. Our Asian business, our Japanese business and our European business CRM are doing quite well and growing either at or above market, and the 2 launches will help us improve growth we anticipate in the second quarter and for the second half. So and also the team continues to improve operating margins despite a negative growth of the quarter, which is good to see. On the replacement headwinds, we don't have any additional breakdown of data that we're going to provide on this call, but I will say, and I think in the future, we'll consider providing some additional detail so we can quantify that, but similar to our last call, I do think we have brighter days ahead of us at CRM, whether they be patient MRI approval, with the quad approval. We've also initiate our MRI approval for our defib platform, which we see getting approval in mid-'17. So the portfolio is very strong. the EMBLEM MRI likely approved in U.S. in third quarter, and so we do see the headwind of the replacement cycle improving at the end of 2016, which will help us in 2017. So with the product cadence and improved replacement cycle headwind, we see some brighter days for our CRM business, and in the future, we look at quantifying more precisely some of the benefit of that tailwind on the replacement cycle."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","And as a follow-up, maybe turning to WATCHMAN. Can you -- are you inclined to give us any kind of numbers for the quarter you're at you're on track for the next 100 accounts? Was there any stocking? And maybe more granular detail about the progress you're",55,"And as a follow-up, maybe turning to WATCHMAN. Can you -- are you inclined to give us any kind of numbers for the quarter you're at you're on track for the next 100 accounts? Was there any stocking? And maybe more granular detail about the progress you're making and the impact of the NCD."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, WATCHMAN continue to do a nice job. Most importantly, we continue to believe in our $175 million to $200 million in Structural Heart revenue guidance. We're on track as planned to open up another 100 centers, and we continually have very thoughtful t",118,"Yes, WATCHMAN continue to do a nice job. Most importantly, we continue to believe in our $175 million to $200 million in Structural Heart revenue guidance. We're on track as planned to open up another 100 centers, and we continually have very thoughtful training program. The NCD is a very good outcome for us, and it really reassures at that and strengthens our view as to the potential size of the market, and we invest, as you mentioned, in clinical specialists. We're investing in physician training and really to build of the market the appropriate way. So we really kind of delivering as planned, and we're very pleased with the outcomes and in using as of WATCHMAN globally."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Rick, I would just probably add one a little bit of color replacement headwinds as well as kind of a tale of 2 pieces within the franchise there. So as Mike said, as we head into the end of '16 and more likely '17, you'll see the more of a tailwind on the",87,"Rick, I would just probably add one a little bit of color replacement headwinds as well as kind of a tale of 2 pieces within the franchise there. So as Mike said, as we head into the end of '16 and more likely '17, you'll see the more of a tailwind on the CRTD side and then it's more of an ending '17 into '18 on the traditional on transvenous ICD side. So it it's a little bit of a bifurcation on that one, so extra color."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","And our next question comes from the line of Bruce Nudell, SunTrust.",12,"And our next question comes from the line of Bruce Nudell, SunTrust."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","This is Imron Zafar in for Bruce. I wanted to ask a couple of questions about the TAVR business. Can you just talk about where you think you are in Europe vis--vis market share, and where you think you can go with that in the next call it couple of year",75,"This is Imron Zafar in for Bruce. I wanted to ask a couple of questions about the TAVR business. Can you just talk about where you think you are in Europe vis--vis market share, and where you think you can go with that in the next call it couple of years in that geography? And then also if you could just give any commentary around this litigation with Edwards on transcatheter valves in the U.S."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. So on the Lotus program, as Dan outlined, we continue to invest significant portion of our med device benefit on Structural Heart franchise. In terms of share, we don't break out our shares specifically in Europe. We are more limited versus some of o",158,"Yes. So on the Lotus program, as Dan outlined, we continue to invest significant portion of our med device benefit on Structural Heart franchise. In terms of share, we don't break out our shares specifically in Europe. We are more limited versus some of our peers in terms of number of countries we're selling into. So we're waiting to get reimbursements still for France. So that's a large market that will open up for us in this future, but we continue to grow above market in the markets that we're serving, particularly in Germany and the physician feedback continues to be very strong on the low PVL rates, which we believe our best-in-class and really is the control full achievable in repositioning capabilities of the platform. So we continue to invest, and we are excited about the enhancements of our technology that I mentioned in the prepared comments. Keith, any additional comments you want to mention on Lotus?"
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. So we've got a pretty rich number of presentations. So your PCR next month on Lotus late-breaking trial on 1,000 patients from the RESPOND study bicuspid valve subgroup from the RESPOND study subclavian approach from the RESPOND study, Lotus symposiu",150,"Yes. So we've got a pretty rich number of presentations. So your PCR next month on Lotus late-breaking trial on 1,000 patients from the RESPOND study bicuspid valve subgroup from the RESPOND study subclavian approach from the RESPOND study, Lotus symposium and on the stent side, the EVOLVE symposium used 5 years data for the first time. And then obviously, as we said at ACC, constant with london valves this year, we're anticipating of launching Lotus EDGE, which has a number of features including 14 French compatibility, more simple implantation procedure, more flexible device and the depth technology, which reduces the amount of the valve dips into the left ventricular atrial track during deployment. So we have a lot going on with Lotus and then the additional slices of 21 and 29 millimeter, and we've completed as Mike said in his statement earlier a REPRISE Japan study, which is important."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. And can you give just any color on the litigation with Edwards?",13,"Okay. And can you give just any color on the litigation with Edwards?"
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, yes, we're not going to comment on our pending legal matters.",12,"Yes, yes, we're not going to comment on our pending legal matters."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","Our next question is from the line of Vijay Kumar, Evercore.",11,"Our next question is from the line of Vijay Kumar, Evercore."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","So maybe the first question I had was maybe a housekeeping question on you mentioned sort of ICD declines and double-digit growth in stents. Was that in both geographies when you say stents up in double digits, was it double digits in both geographies U.S",67,"So maybe the first question I had was maybe a housekeeping question on you mentioned sort of ICD declines and double-digit growth in stents. Was that in both geographies when you say stents up in double digits, was it double digits in both geographies U.S., OUS and similarly on ICDs, I'm just wondering whether declines was only in the U.S. or did you see the OUS."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Dan, you want to comment on that one?",8,"Dan, you want to comment on that one?"
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, P.J. thanks for the question. We're not going to get too specific in terms of the growth rates by geography. Obviously, we think of Japan, we had approval for SYNERGY early in the quarter. So we are off and running there. We're on offense there. We h",164,"Yes, P.J. thanks for the question. We're not going to get too specific in terms of the growth rates by geography. Obviously, we think of Japan, we had approval for SYNERGY early in the quarter. So we are off and running there. We're on offense there. We had synergy in kind of the middle of the fourth quarter in the U.S. So strong growth here in stents. So and Europe has, which is had SYNERGY for a long time is still doing very well. So no -- I don't want to put specific numbers for each of the regions there, and I think overall, I think Mike's commentary around CRM was pretty detailed that if you think of we're doing very well in Japan, we're doing well in Europe and the CRM softness has been more of the U.S. product gap issue, and we hopefully solve a couple of those product gaps with the recent quad approval and with the MRI safe brady group."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Understood, and I had one follow-up. When you think about the longer-term operating model rate, I know you guys have laid out the 25% margin targets for '17. Can you just talk about the leverage in your confidence in bending the SG&A sort of line because",73,"Understood, and I had one follow-up. When you think about the longer-term operating model rate, I know you guys have laid out the 25% margin targets for '17. Can you just talk about the leverage in your confidence in bending the SG&A sort of line because it feels like just looking at the trends, the 25% might be -- there's upside to the 25% number for '17 and any comments on beyond 2017?"
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. We've stated publicly before that by 2020, we believe we'd be at 27% to 28% operating margin just operating margin as a company and the 25.1% is a great start of the year, but as I mentioned, the average for the year should be between 24% and 24.5%,",150,"Sure. We've stated publicly before that by 2020, we believe we'd be at 27% to 28% operating margin just operating margin as a company and the 25.1% is a great start of the year, but as I mentioned, the average for the year should be between 24% and 24.5%, and as always, we seek to strike that balance between delivering the adjusted operating margin and ensuring that durable consistent revenue growth for the long term. And if you look at our numbers this year, as you look at 6% to 8% organic revenue growth, 190 basis points of adjusted operating margin expansion at the midpoint of the range and adjusted EPS growth of 14% in the low and 18% at the high end, I think we're effectively achieving that objective, and as you look at '17 and beyond, we look to continue to deliver high performance, and that's the goal."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","Our next question is from the line of Josh Jennings, Cowen and Company.",13,"Our next question is from the line of Josh Jennings, Cowen and Company."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Wanted to hopefully start of with a question for Dan and just a follow-up on the operating margin discussion and some of the strength you saw in Q1 and the uptick in the guidance. Can you talk about AMS integration? And is AMS contributing already to oper",81,"Wanted to hopefully start of with a question for Dan and just a follow-up on the operating margin discussion and some of the strength you saw in Q1 and the uptick in the guidance. Can you talk about AMS integration? And is AMS contributing already to operating margin? And how do you see the AMS contribution going through the year? And also does it flows down into the bottom right accretion levels you guided to historically still on track there."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, I think the short answer to that, Josh, we are right on track. So we talked about $0.03 accretion in the year from AMS. We're on track to achieve that and then next year, we had talked about $0.07, and we should be on track, and the difference is rea",107,"Yes, I think the short answer to that, Josh, we are right on track. So we talked about $0.03 accretion in the year from AMS. We're on track to achieve that and then next year, we had talked about $0.07, and we should be on track, and the difference is really some of the integration cost that we have this year we expect the quality remediation and some of the things like IT and such that are pushing that down a bit this year, and next year, you should see kind of the full power of what AMS can bring to the margin story for the company."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","That's helpful. I was hoping to just follow up on the CRM business. Clearly, you have some nice approvals over the last month and particularly this week with the MRI-safe product gap low voltage side, and you initiated your MRI-safe trial for high voltage",102,"That's helpful. I was hoping to just follow up on the CRM business. Clearly, you have some nice approvals over the last month and particularly this week with the MRI-safe product gap low voltage side, and you initiated your MRI-safe trial for high voltage. Just wanted to get your level of confidence, your team's level of confidence in the timelines there and maybe just help us think about the steps going forward in terms of the times of enrollments and enrollment period and follow-up period just to help us think about the safety of that mid-'17 timeline on the high-voltage side."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. We feel comfortable with it. I think we've been reasonably accurate on the forecast for some of these big product approvals with the quad and the MRI Pacer. So we're looking at, call it, mid-'17, maybe to hedge that a bit, third quarter 2017 for app",52,"Sure. We feel comfortable with it. I think we've been reasonably accurate on the forecast for some of these big product approvals with the quad and the MRI Pacer. So we're looking at, call it, mid-'17, maybe to hedge that a bit, third quarter 2017 for approval of our tech MRI product."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","Our next question comes down the line of Matt Miksic, UBS.",11,"Our next question comes down the line of Matt Miksic, UBS."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","A couple if I could. One on WATCHMAN, follow up on some of the questions that have already been asked, but what we're hearing is for centers obviously, NCD in place and differentiated device, and I think everyone's excited to see how this rolls out, but t",129,"A couple if I could. One on WATCHMAN, follow up on some of the questions that have already been asked, but what we're hearing is for centers obviously, NCD in place and differentiated device, and I think everyone's excited to see how this rolls out, but there is some question, I guess, about how profitable this is for some of these centers. For some, it does seem a little bit on the tech side, pricing net of reimbursement but, at the same time, it doesn't seem to be, from what we could tell, a significant impediment to interest or early adoption. So any thoughts on how you see that playing out over time or regionally playing out as it begins to and then I have one follow-up for Dan."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. So on the NCD, it was a nice win for us, and we believe we really have the right sweet spot in terms of the WATCHMAN pricing. It is financially viable at most of the heart centers that we have contracted with. So we stay very close to that, and it's",120,"Sure. So on the NCD, it was a nice win for us, and we believe we really have the right sweet spot in terms of the WATCHMAN pricing. It is financially viable at most of the heart centers that we have contracted with. So we stay very close to that, and it's really part of our category leadership strategy. So we want to price it at the appropriate level of getting the investment that we've made in the platform as well as future clinical trials that we're supporting as we advance this new therapy, but we do believe it's financially viable in a healthy product with appropriate margins for the vast majority of our hospitals that are using the stent."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay, that's helpful color, and Dan -- for Dan on some of the work that you're doing to drive manufacturing efficiencies and working capital efficiencies, net operating asset turnover here, obviously, a key driver for ROIC, and you do have an opportunity",121,"Okay, that's helpful color, and Dan -- for Dan on some of the work that you're doing to drive manufacturing efficiencies and working capital efficiencies, net operating asset turnover here, obviously, a key driver for ROIC, and you do have an opportunity there from what we can tell obviously, focus. Wondering if you could sketch out how we should see that begin to play out because understanding your manufacturing rationalization and the efforts you have underway, it may not be apparent from the numbers sort of on a turnover basis the improvements that you've been making, but we love to get a sense when that will start to become apparent and maybe start having the additional impact on returns on capital."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. I think I'd like to believe you'll see some of that impact this year. So we have a significant emphasis on reducing inventory, and I mentioned that in some of my prepared remarks and trying to prove that from our perspective, we can grow sales at th",171,"Sure. I think I'd like to believe you'll see some of that impact this year. So we have a significant emphasis on reducing inventory, and I mentioned that in some of my prepared remarks and trying to prove that from our perspective, we can grow sales at the rate that we're doing but also optimizing inventory, and we have a lot of work ongoing to try and do some things to rationalize that. And from a cash flow as well as the other metrics that you mentioned, reduce inventory overall by the end of the year at the company. So Michael would be that as we go through the year, you'd see that it was pretty reasonable compared to Q4 of last year, inventory this year, and so we've kind of stemmed the tide of it now, and I'd look to -- for the last 3 quarters to see that reduce, which will help all the turnover and asset metrics as well as the contribution of working capital to cash flow."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","All right. With that, we'd like to conclude the call. Thank you for joining us today. We appreciate your interest and before you disconnect, Roxanne will give you all the pertinent details for the replay. Thank you.",37,"All right. With that, we'd like to conclude the call. Thank you for joining us today. We appreciate your interest and before you disconnect, Roxanne will give you all the pertinent details for the replay. Thank you."
317627,329821425,963878,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","And ladies and gentlemen, this conference will be made for available for replay after 10:30 am today running through May 11, 2016, at midnight. You may access AT&T executive playback service at anytime by dialing (800) 475-6701 and entering the access cod",73,"And ladies and gentlemen, this conference will be made for available for replay after 10:30 am today running through May 11, 2016, at midnight. You may access AT&T executive playback service at anytime by dialing (800) 475-6701 and entering the access code of 390210. International participants may dial 1 (320) 365-3844. That concludes our conference for today. Thank you for your participation and for using AT&T Executive TeleConference service. You may now disconnect."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2016 Boston Scientific Earnings Call. [Operator Instructions] And as a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Susie Lisa",46,"Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2016 Boston Scientific Earnings Call. [Operator Instructions] And as a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Susie Lisa. Please go ahead."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Roxanne. Good morning, everyone, and thanks for joining us. With me on today's call are Mike Mahoney, President and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.We issued a press release earli",366,"Thank you, Roxanne. Good morning, everyone, and thanks for joining us. With me on today's call are Mike Mahoney, President and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.
We issued a press release earlier this morning announcing our Q1 2016 results, which included reconciliations of the non-GAAP measures used in the release.
We have posted a copy of that release as well as reconciliations of the non-GAAP measures used in today's call to the Investor Relations section of our website under the heading, Financial Information.
The duration of this morning's call will be approximately 1 hour. Mike will provide strategic and revenue highlights of Q1 '16. Dan will review the financials for the quarter and then Q2 '16 and full year 2016 guidance, and then we'll take your questions. During today's Q&A session, Mike and Dan will be joined by our Chief Medical Officers, Dr. Keith Dawkins and Dr. Ken Stein. 
Before we begin, I'd like to remind everyone that on the call, organic revenue growth is defined as excluding the impact of sales from divested businesses, changes in foreign currency exchange rates and sales from the acquisition of the American Medical Systems male urology portfolio over the prior year period. Also of note, this call contains forward-looking statements within the meaning of federal securities laws, which may be identified by words like anticipate, expect, believe, estimate and other similar words.
They include, among other things, statements about our growth and market share; new product approvals and launches; clinical trials; cost savings and growth opportunities; our cash flow and expected use; our financial performance, including sales, margins, earnings and other Q1 2016 results and Q2 and full year 2016 guidance; as well as our tax rates, R&D spend and other expenses.
Actual results may differ materially from those discussed in the forward-looking statements.
Factors that may cause such differences include those described in the Risk Factors section of our most recent 10-K and subsequent 10-Qs filed with the SEC.
These statements speak only as of today's date, and we disclaim any intention or obligation to update them.
At this point, I'll turn it over to Mike for his comments. Mike?"
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Susie, and good morning, everyone. We continue to perform against our strategic plan goals, and we're encouraged by the consistent strong execution of our global team. The success of our new product launches across many of our businesses is hel",1633,"Thank you, Susie, and good morning, everyone. We continue to perform against our strategic plan goals, and we're encouraged by the consistent strong execution of our global team. The success of our new product launches across many of our businesses is helping us accelerate expansion into faster-growth markets and deliver solutions that address unmet clinical needs. 
We continue to believe that Boston Scientific is uniquely positioned to deliver differentiated shareholder value through durable mid-single-digit organic revenue growth and double-digit adjusted EPS growth through our ongoing operating margin improvement initiatives. We're very excited about the excellent start to 2016 and our plans to build upon our global momentum in 2017 and beyond. 
We posted excellent results this quarter with total operational revenue growth of 13% and organic revenue growth of 8%, excluding the impact of AMS acquisition benefit. 4 of our 7 businesses grew revenue double digits organically, and we, in turn, leveraged that revenue growth to drive 24% adjusted operating income growth, resulting in adjusted operating margin of 25.1% and a 260 basis point improvement year-over-year. 
We delivered adjusted EPS of $0.28, exceeding the high end of guidance and representing 31% growth, including the negative impact from foreign currency. Importantly, we're increasing our 2016 guidance for revenue, adjusted operating margin and adjusted EPS. We're increasing our full year organic revenue growth guidance from 4% to 7% previously to 6% to 8%. Full year operational revenue, which includes the benefit of AMS, has been increased from 7% to 10% to 9% to 11%. We're increasing our adjusted operating margin guidance to 24% to 24.5%, and we're also increasing our adjusted EPS guidance up $0.03 over our prior range to $1.06 to $1.10, which now represents 14% to 18% growth. And importantly, this EPS guidance includes an expected $0.05 to $0.06 negative impact from foreign exchange. 
I'll now provide some highlight on Q1 results and the 2016 outlook. And in my remarks, all references to growth are in a constant currency organic year-over-year basis, excluding the benefit of AMS, unless otherwise specified. 
Our Q1 revenue growth of 8% was broad based across our businesses and regions, led again by exciting new product launches, continued global expansion and execution of our category leadership strategy. With the exception of a 3% decline in our Cardiac Rhythm Management sales, all of our other businesses delivered strong organic growth, led by Endo at plus 11%, Urology and Pelvic Health of plus 12%, Interventional Cardiology at 13% and Peripheral Intervention at 14%. 
We also saw strong growth globally with Asia delivering 14%; U.S., 7%; and Europe, up 6%. Emerging market sales grew 21%, including China, sales at 19%. The MedSurg businesses all accelerated from Q4 of last year and delivered adjusted operating margin of 32.6%, up 360 basis points year-over-year. 
Endoscopy revenue grew 11%, driven by our single-use SpyGlass digital DES visualization system, the AXIOS Stent for drainage of pancreatic fluid and the limited launch of our next-generation hemostasis clip, the Resolution 360. We're also extending our category leadership in Endoscopy by developing commercial capabilities in the emerging markets, adding a focus in pulmonary, which helped drive 15% growth in bronchial thermoplasty as they recently launched in both Japan and China. Urology and Pelvic Health organic growth accelerated 12% and was broadly based with double-digit growth in kidney stone, pelvic floor and surg/gyn. Our legacy business grew 15% internationally, led by 36% growth in the emerging markets. The AMS remediation and integration are on track, and we're delivering against our synergy commitments and the global teams are now fully integrated. 
As expected, stand-alone AMS sales declined slightly in the quarter, and we expect inventory to be appropriate levels in the second quarter. At LithoVue, an innovative single digital ureteroscope that provides customers with visualization and navigation capabilities, will be featured in multiple presentations next weekend at the American Urology Association meeting in San Diego. 
Neuromodulation revenue growth accelerated 8% in the first quarter, and sales were driven by the market-leading Spectra platform, the most flexible spinal cord stimulation system in the market; the launch of Precision Novi for the primary cell non-rechargeable market; and the solid contribution from our Vercise, our emerging Deep Brain Stimulation platform. 
Our U.S. DBS trial is making great progress, and we expect to launch in the U.S. in late 2017 or early 2018. In Cardiovascular, our segment sales grew 14% in the quarter and delivered adjusted operating margin of 34.1%, up over 350 basis points, both sequentially and year-over-year. 
Peripheral sales grew 14% in the strong results in atherectomy, thrombectomy and our Innova bare metal and Eluvia drug-eluting stent platforms. The legacy Peripheral business continued its recent impressive trend as we grow share in the atherectomy market and see very strong demand for our new Zelante deep vein thrombosis platform. 
The Eluvia IDE trial called IMPERIAL is on track to complete enrollment by late 2016 or early '17, and we look forward to presenting 24-month data from our initial trial, MAJESTIC, which had a 12-month patency rate of 96.1% later this year. We're also seeing continued progress for our Lutonix distribution agreement and encouraging EU sales of our Ranger Drug-Coated Balloon. We're excited to be the only company developing leading drug-eluting technologies globally on multiple platforms, providing physicians with a variety of tools for treating complex peripheral vascular disease. 
Interventional Cardiology turned another double-digit quarter, a 13% growth, led by complex coronary drug-eluting stents, PCI guidance and structural heart. SYNERGY had a very strong quarter, and we estimate that we add it to our market-leading share position in the U.S. and regain market leadership position in Japan. 
DES sales grew 14% in the quarter, and we believe SYNERGY is on track to represent approximately 50% of our U.S. DES revenue mix by the end of the year '16. 
PCI guidance again grew double digits on continued share gains on intravascular ultrasound, and we're encouraged by strong feedback on the ease-of-use of our common fractional flow reserve platform. Our leading portfolio of solutions for complex high-risk PCI patients continues to drive global growth as well. 
The 13% IC revenue growth was also fueled by our strengthening structural heart business, which includes our Lotus transcatheter aortic valve and WATCHMAN Left Atrial Appendage Closure device. We believe we are uniquely positioned to drive long-term growth in these 2 fast-growing markets via our differentiated platforms. 
Our Lotus valve continues to gain share in Europe, and we are investing significantly to further develop our capabilities. Most recently, best-in-class paravalvular leakage rates were reported for Lotus at ACC last month with predischarge rates of 0.4% for moderate paravalvular regurgitation in the first 750 patients of the RESPOND Post-Market Study. 
We also continue to plan for the U.S. launch with the Lotus EDGE delivery system at the end of 2017, and we also completed enrollment in our REPRISE Japan trial, where we targeted a 2018 launch. 
Importantly the Lotus EDGE features 14 French compatible, more flexibility, simplified deployment and our new depth guard technology, which controls depth of the valve in the left ventricular outflow tract. Studies that demonstrate an improved permanent pacemaker rate with this optimized technique will begin enrollment in mid-2016. 
Also at structural heart, WATCHMAN sales were strong on procedure growth and new account openings, both helped by the finalized national coverage determination. We're developing additional WATCHMAN capabilities, primarily by adding resources in field clinical support, market development and training courses. Implant success rates and patient outcomes remain very high quality due to our controlled rollout and proven training programs. 
In the ACC earlier this month, Dr. David Holmes of the Mayo Clinic presented data from the first 1,600 patients implanted with a WATCHMAN commercially and revealed 96% procedural success at an average procedure time of 15 minutes. So overall, we are very pleased with our progress and our 2016 revenue guidance of $175 million to $200 million in Structural Heart revenue. 
Rhythm Management segment sales declined 2% in the quarter yet delivered adjusted operating margin of 16.8%, which is up 290 basis points sequentially as improving profitability remains a core focus. In CRM, as anticipated, sales declined 3% as we faced competitive launches in the U.S. and replacement cycle headwinds. We're optimistic for a second quarter and second half 2016 improvement in our CRM performance. 
Also, as projected, we received 2 key FDA approvals in March for our ACUITY X4 quad CRT lead, and earlier this week for our ACCOLADE brady MRI platforms, including the INGEVITY MRI patient lead. Pacemaker sales grew 3% globally, aided by a recently launched X4 CRT-P quad device while worldwide ICD sales declined 4%. 
We continue to be very pleased with the performance of the EMBLEM S-ICD, which is enjoying a strong growth in both Europe and the U.S. and is currently launching in Japan. In Electrophysiology, we're encouraged by double-digit growth in Europe, led by our arrhythmia installations and the recent launches of the IntellaMap OI and IntellaTip MiFi OI ablation catheters. In the U.S., we're now launching our Blazer Open-Irrigated Therapeutic Catheter for the treatment of Type 1 atrial flutter as we continue to invest in the franchise, launch a portfolio of navigation-enabled therapeutic catheters and build capabilities in capital equipment sales and service. 
We have a stronger arrhythmia customer pipeline as many of our new platform enhancements scheduled for release in 2016. So to wrap up, our company had an excellent quarter. First quarter results reflect the strength of our portfolio, our ongoing investment in faster-growth markets and our globalization efforts. More importantly, we are well positioned to continue our strong performance in 2016 and beyond. I wanted to thank our employees for their continued winning spirit and their commitment to the company. 
Now let me turn the call over to Dan for a more detailed review of our financials."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Mike. In Q1, we generated organic revenue growth of 8% versus our 4% to 6% guidance range and adjusted EPS of $0.28, exceeding our guidance range of $0.23 to $0.25 and representing 31% year-over-year growth. Adjusted EPS of $0.28 includes a slig",1943,"Thanks, Mike. In Q1, we generated organic revenue growth of 8% versus our 4% to 6% guidance range and adjusted EPS of $0.28, exceeding our guidance range of $0.23 to $0.25 and representing 31% year-over-year growth. 
Adjusted EPS of $0.28 includes a slightly lower-than-expected tax rate for the quarter due to some discrete tax items. The strong performance in Q1 was driven primarily by revenue growth upside, gross margin expansion and a lower SG&A rate versus the prior year. 
And as Mike mentioned, given the outperformance in Q1, we are raising full year guidance for revenue growth, adjusted operating margin and adjusted EPS. Consolidated revenue of $1,964,000,000 represented operational revenue growth of 13%, which excludes the impact of a $58 million headwind from foreign exchange. Excluding an approximate 500 basis point contribution from the AMS male urology portfolio acquisition, organic revenue growth was 8% in the quarter. 
On an as-reported basis, revenue grew 11% year-over-year. Adjusted gross margin for the first quarter was 72.3%, increasing 100 basis points year-over-year. The increase resulted primarily from cost improvements driven by our value improvement programs and favorable mix, partially offset by price. And similar to Q4 of 2015, the impact of foreign exchange on gross margin was negligible in the quarter. 
We continue to expect full year 2016 adjusted gross margin to be in the range of 72% to 73%, which we forecast to include approximately 50 basis points of unfavorable FX. Our Q1 2016 adjusted operating margin of 25.1% represents a 260 basis point improvement over Q1 2015, which marks the 7th consecutive quarter in which we've expanded adjusted operating margin by 100 basis points or more. 
There was very modest reinvestment of the medical device tax benefit in Q1, which represents some timing favorability in the quarter, but we are committed to reinvesting substantially all of the full year benefit during the year. Thus, adjusted SG&A expenses were $698 million or 35.5% of sales in the quarter, down 150 basis points year-over-year with some of the benefit due to our targeted initiatives focused on reducing SG&A and a portion due to the more modest medical device tax benefit reinvestment I just mentioned. 
Our Q1 adjusted SG&A rate was the lowest in the last 12 quarters, and we continue to believe our full year rate will be between 35.5% and 36.5%, which, at the midpoint, would be a 140 basis point reduction compared to 2015. 
Adjusted research and development expenses were $209 million in the first quarter or 10.7% of sales, which is roughly flat year-over-year. This is another key area for us to reinvest the benefit of the medical device tax suspension. As a result, we expect our full year 2016 adjusted R&D rate to be between 11% and 12% of sales. 
Royalty expense was 1% of sales in both Q1 of this year and last year and consistent with our guidance. On an adjusted basis, operating income was $494 million in the quarter or 25.1% of sales, up 260 basis points year-over-year. 
Q1 adjusted operating income grew 24% year-over-year, with all 3 reportable segments expanding adjusted operating margin by at least 250 basis points over Q1 of last year. Of particular focus is Rhythm Management, which delivered an adjusted operating margin of 16.8%, which is up from Q4 2015's 13.9% and the full year 2015 rate of 15%. 
For the first half of 2016, we expect Rhythm Management adjusted operating margin to be slightly above 16%. In the second half of 2016, we expect Rhythm Management adjusted operating margin to increase roughly 200 basis points over the first half rate. This second half improvement is expected to result from realizing the full benefit of 2016 product costs, leveraging the improved top line performance expected of the global CRM and EP businesses and realizing the full benefits of our Plant Network Optimization program, which is transferring a portion of our EP manufacturing to lower-cost locations. We continue to believe Rhythm Management is on track to deliver an adjusted operating margin of 20% in 2017. 
GAAP operating income, which includes GAAP to adjusted items of $201 million, was $293 million in Q1 2016. The primary GAAP to adjusted items for the quarter included amortization expense of $136 million, restructuring and related charges of $13 million, acquisition-related SG&A expenses of $14 million and litigation-related charges of $10 million. Our total legal reserve was $1,895,000,000 as of March 31, 2016. 
Now I'll move on to other income and expense. Interest expense for the quarter was $59 million compared to $56 million in Q1 last year, and the increase was primarily due to the incremental debt raised in Q2 of last year to finance the AMS male urology portfolio acquisition. 
Our average interest rate was 4% in Q1 2016 compared to 5.1% in Q1 last year, and the lower interest expense rate in Q1 this year was primarily due to lower average cost of debt resulting from the senior notes refinancing, which we completed in Q2 last year. 
Other expense was $10 million, and this consisted primarily of foreign exchange losses and investment losses incurred during the quarter. 
Our tax rate for the quarter was 11.4% on a reported basis and 11.8% on an adjusted basis. Excluding discrete tax items in the quarter, our adjusted tax rate would have been 13.5%, and we continue to expect our full year 2016 adjusted tax rate to be approximately 14%. 
On a reported GAAP basis, Q1 2016 EPS was $0.15 and includes net charges and amortization expense totaling $176 million after tax. GAAP EPS of $0.15 compares to breakeven in Q1 of last year. 
Moving on to the balance sheet. DSO of 60 days increased 1 day compared to March of last year. Days inventory on hand of 162 days was down 4 days compared to March of last year and 1 day from year-end 2015. 
Capital expenditures were $59 million in the quarter compared to $46 million in Q1 2015. And as a reminder, we expect full year 2016 capital expenditures to be roughly $350 million. This is $100 million higher than the full year 2015, primarily due to the construction of our new manufacturing facility and distribution center in Malaysia. And beyond 2016, we expect capital expenditures to return to our more historical run rate of approximately $250 million annually. 
Adjusted free cash flow for the quarter was $250 million compared to $118 million in Q1 2015, and this strong start gives us confidence in our adjusted free cash flow target of $1.5 billion, which represents 10% growth and better visibility to our stretch goal of $1.6 billion, which would represent 17% growth, even in a year with an incremental $100 million in CapEx spend as I mentioned. 
We're also continuing to pursue inventory management initiatives designed to improve the working capital contribution to cash flow. In Q1, we used cash primarily to fund previously agreed legal settlements as well as business development activities. 
Consistent with our goal of returning to pre-AMS debt leverage by year-end 2016, we still expect to repay $250 million of bank term loans by the end of this year. As of March 31 this year, we had cash on hand of $338 million. 
Near term, our capital allocation priorities are to prepay debt, manage our contingencies and pursue tuck-in M&A. We ended the quarter with 1,370,000,000 fully diluted weighted average shares outstanding. Consistent with our prior guidance, we expect our share count to increase by roughly 5 million per quarter through the end of the year as we plan to keep the buybacks suspended for the balance of 2016. We would expect this to result in a fully diluted weighted average share count of approximately 1,380,000,000 for the full year 2016. 
I'd like to conclude with revenue and earnings per share guidance for Q2 and full year 2016. For the full year, we now expect consolidated revenue to be in the range of $8,075,000,000 to $8,225,000,000, which represents year-over-year growth of 6% to 8% on an organic basis; 9% to 11% on an operational basis, which includes the AMS revenue; and 8% to 10% on a reported basis. 
As a result of a stronger dollar, at current rates, we expect foreign exchange to be a headwind of approximately $100 million for the full year 2016. As we move through 2016, we are reinvesting the benefit of the medical device tax suspension and to innovation to help treat patients and sustain top line growth over the long term. Focus areas will include R&D efforts, including clinical trial spend as well as market development, and in Q2, we've already begun to ramp this reinvestment, primarily in the areas of structural heart with both Lotus and WATCHMAN, and other durable long-term revenue growth platforms such as the EMBLEM S-ICD, our Electrophysiology portfolio, Deep Brain Stimulation and other fast-growing adjacent market. 
In addition, Q2 is our seasonally high SG&A spend quarter partially due to the highest trade show activity of the year. Thus, for Q2 2016, and consistent with prior years, we would expect a sequential decline in adjusted operating margin to a range of 23% to 24%, which, at the midpoint, represents 140 basis points of improvement year-over-year and puts first half 2016 adjusted operating margin at 200 basis points up versus the first half of last year. 
And for the full year 2016, we are raising our adjusted operating margin guidance from 23.5% to 24.5% to a range of 24% to 24.5% now, which also represents a 200 basis point year-over-year gain. This gain is from operational efficiencies and not the med device tax as we are reinvesting the benefits. 
Turning to adjusted EPS. We now expect full year adjusted EPS for 2016 to be in a range of $1.06 to $1.10, representing 14% to 18% adjusted earnings growth and an increase of $0.03 to each end of the range compared to our prior guidance. 
Now let me walk you through our updated assumptions for the FX impact on adjusted EPS. Our initial 2016 guidance assumed $0.02 of unfavorable FX on adjusted EPS in Q1 and $0.06 for the full year. 
In Q1, the combination of exchange rate movements and timing of hedging contracts resulted in an unfavorable impact of $0.01, and we now believe the full year 2016 unfavorable impact will be $0.05 to $0.06. 
In addition to the $0.01 in Q1, we would expect the remaining $0.04 to $0.05 of unfavorable FX for the full year to break down into $0.02 in Q2 and $0.02 to $0.03 in the second half of 2016. Excluding the unfavorable foreign exchange, our full year adjusted EPS guidance range represents growth of 19% to 24%. 
On a GAAP basis, we expect EPS to be in a range of $0.64 to $0.69. 
Now turning to specifically to Q2 2016. We expect consolidated revenues to be in a range of $2,010,000,000 to $2,060,000,000. If current foreign exchange rates hold constant, the headwind from FX should be approximately $25 million or 135 basis points relative to Q2 of last year. 
We expect consolidated Q2 sales to grow year-over-year in a range of 6% to 8% organically and 11% to 13% operationally. For the second quarter, adjusted EPS is expected to be in a range of $0.25 to $0.27 per share, and GAAP EPS is expected to be in a range of $0.14 to $0.17 per share. 
Please check our Investor Relations website for Q1 2016 financial and operational highlights, which outlines Q1 results as well as Q2 and full year 2016 guidance, including P&L line item guidance. 
So with that, I'll turn it back to Susie, who will moderate the Q&A."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Dan. Roxanne, let's open it up to questions for the next 30 minutes or so. [Operator Instructions] Roxanne, please go ahead.",22,"Thanks, Dan. Roxanne, let's open it up to questions for the next 30 minutes or so. [Operator Instructions] Roxanne, please go ahead."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","[Operator Instructions] Our first question comes from the line of Bob Hopkins, Bank of America.",15,"[Operator Instructions] Our first question comes from the line of Bob Hopkins, Bank of America."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","So to start off, Mike, obviously, this was one of the best growth quarter you guys have had in a while and congratulations on the great start to the year. I was wondering if you could talk to us a little bit about just the broader macro environment and th",103,"So to start off, Mike, obviously, this was one of the best growth quarter you guys have had in a while and congratulations on the great start to the year. I was wondering if you could talk to us a little bit about just the broader macro environment and the health of the markets you're in and maybe just talk about the factors driving growth. And I would really appreciate if you could talk a little bit about Uro and Endo as well and some of the products that are driving growth in that division because, obviously, that's where some really nice outperformance."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. Thanks for the question. Overall, the market growth we see is consistent with what we mentioned in the past, kind of playing in 3% to 4% growth markets overall for Boston Scientific and similar to Investor Day presentation. We're investing into fast",349,"Sure. Thanks for the question. Overall, the market growth we see is consistent with what we mentioned in the past, kind of playing in 3% to 4% growth markets overall for Boston Scientific and similar to Investor Day presentation. We're investing into faster-growth markets that would basically accelerate the growth profile another 100, 200 basis points of the markets that we serve. So kind of similar growth rates in IC and cardiology and CRM kind of in the low single-digit range and more in the 4% to 5% market growth rates for our MedSurg. But I guess, what we're most proud of is really across the board with the exception of CRM. We're going -- and EP. We're growing significantly faster than our competition. And based on -- that's really driven by our product launches and really excellent global execution. Really pleased with the growth in Asia product, almost 15%, very strong growth in Japan, a very strong growth in Europe. So across our businesses, our regions, our teams are really delivering. In terms of your question on Endo and Urology, we are very thoughtful about the AMS acquisition, and we're seeing the benefits of the commercial synergies between those organizations, given the additional commercial footprint that we have as well as the broadness of the bag, and you're seeing that with a really acceleration of our legacy Urology division, in part due to the synergies of our AMS business. We continue to invest in physician training for our Stone Institute, and we continue to benefit from the category leadership based on the premise of the AMS acquisition. In Endoscopy, it's a very innovative division, and we continue to lead in innovation with our digital SpyGlass system, which is really a terrific platform for us that we can continue to build from, and that also helps drive pull-through of our core portfolio. So the R&D teams are executing as well as the commercial teams, and we continue to be committed to our durable mid-single-digit revenue growth, our operating margin expansion and our double-digit EPS growth over the long term."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Great. And then a follow-up maybe for Dan. Dan, can you just help us? Was there any, in your view, selling day mismatch this quarter versus a year ago? And then on the operating margin performance in the quarter, it sounds like over the course of the rest",107,"Great. And then a follow-up maybe for Dan. Dan, can you just help us? Was there any, in your view, selling day mismatch this quarter versus a year ago? And then on the operating margin performance in the quarter, it sounds like over the course of the rest of the year, there's going to be some incremental spending because, obviously, you're guiding to a lower operating margin than you started out in Q1. So maybe just comment on the selling day year-over-year, and then also maybe quantify and describe some of the extra spending that you're going to be undertaking here in the remainder of the year."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, Bob. First quickly on the calendar. No, we don't believe there's an extra impact in Q1. There was obviously a leap year day, but then when you factor in the timing of the Easter holiday, I believe it's a true 8% growth for the quarter organically. R",253,"Sure, Bob. First quickly on the calendar. No, we don't believe there's an extra impact in Q1. There was obviously a leap year day, but then when you factor in the timing of the Easter holiday, I believe it's a true 8% growth for the quarter organically. Relative to operating margin, so I think the -- when you look at Q1 at the 25% and then you look at the 24.25%, which is the midpoint for the full year, one of the key changes there is that, as I mentioned in my prepared remarks, the reinvestment of the medical device tax benefit over the rest of the year. So a little delayed in Q1 getting off to that start but committed to reinvesting the entire amount for the rest of the year. So that's one. And I think the -- this R&D timing as well in Q1 so our Q1 R&D was 10.7%. If you look at the guidance range, you'd see 11.5% at the midpoint. Part of that's the med device tax reinvestment and part of it's just the timing of overall R&D. So that's another 80 basis points there going from the 10.7% in Q1 to the overall average of 11.5% for the full year. So still -- I mean, as you look at the 24.25%, still significant growth versus last year, 190 basis points and feel good that we're striking a good balance between delivering differentiated adjusted operating margin and investing for a continually growing top line for the future."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","And our next question comes from the line of David Lewis with Morgan Stanley.",14,"And our next question comes from the line of David Lewis with Morgan Stanley."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Just a few quick questions. Mike, I guess, the issue, I think, for us this quarter is that we expected an inflection quarter sometime this year. Obviously, it's coming earlier. But I guess, as we think about the balance of the businesses, we actually thou",127,"Just a few quick questions. Mike, I guess, the issue, I think, for us this quarter is that we expected an inflection quarter sometime this year. Obviously, it's coming earlier. But I guess, as we think about the balance of the businesses, we actually thought there could be acceleration for whatever the growth rate was in the first quarter. And I wonder, can you point us to tailwinds, headwinds of the business throughout about of the year based on sort of this thought of acceleration throughout the year? And then specific attention perhaps within Cardiovascular. You talked about those businesses in terms of stents, WATCHMAN, Lotus. What's really driving that strength in Cardio? So acceleration and in particular Cardiovascular, then I had one quick one for Dan."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","That's a multi-point question. Thanks, Dave. Just overall, we are pleased with our performance for the quarter. We took the guidance up from 4% to 7% to 6% to 8% organically, not impacting AMS. And as I mentioned, the businesses and regions are performing",417,"That's a multi-point question. Thanks, Dave. Just overall, we are pleased with our performance for the quarter. We took the guidance up from 4% to 7% to 6% to 8% organically, not impacting AMS. And as I mentioned, the businesses and regions are performing at a nice level. As we look, we obviously anticipate a solid second quarter, given our 6% to 8% guidance in second quarter. We do face a couple of headwinds throughout the year. We do anniversary some key product launches in our peripheral vascular as well as our Endoscopy business. We do anticipate some Japan reimbursement cuts that we'll be working through. And we're very bullish on our WATCHMAN program, but we're also anniversary-ing the initial launch. So there are a few headwinds. But overall, we have an excellent product cadence. The business is performing well, and we feel comfortable with raising our guidance to 6% to 8%. On the cardiology side, we're seeing excellent -- our strategy play out. We continue to diversify our Interventional Cardiology portfolio. As we talked in the future, we really see in the future about 1/3 of our business coming from structural heart, about 1/3 from imaging and complex coronary and about 1/3 from drug-eluting stents. And across those kind of 3 slices of the pie, we're doing a nice job of delivering in the short term and investing for the long term. Our SYNERGY program is really going as planned. We're on track for SYNERGY to represent about 50% of our mix at an appropriate premium price, and physicians continue to see the benefit of the deliverability and the excellent 0 stent thrombosis beyond the first 24 hours. So excellent clinical data there. Our complex coronary business continues to do well as does our Imaging business. And in structural heart, as Dan mentioned, I'm actually over in Korea as we speak here, we just had a live case from Australia today and just the physician reaction to the deliverability and the low PVL rates of our Lotus Valve continues to be very high. And so we are really increasing our investment in that category, given the size of the market potential in the future and also given the differentiation that we believe that Lotus delivers and our commercial capability. So hopefully that gives you a bit of flavor. We're pleased with our raise on the guidance, and we'll manage our headwinds and continue to hopefully deliver revenue growth at the top tier of our sector."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Mike, that's great color. And Dan, I hate to bore you with a nit [ph] here, it was such a good quarter, but we're actually getting your constant currency growth rate this quarter even higher than you reported. We have a $58 million FX headwind for a 3.3%",72,"Mike, that's great color. And Dan, I hate to bore you with a nit [ph] here, it was such a good quarter, but we're actually getting your constant currency growth rate this quarter even higher than you reported. We have a $58 million FX headwind for a 3.3% headwind versus 2%. Are we missing something here in the quarter or -- and we can take it off-line if it's -- if we're..."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","No, David, I think it's just a rounding of 3%. The way we see it is 3%. So it's just a little bit in the rounding of the numbers.",29,"No, David, I think it's just a rounding of 3%. The way we see it is 3%. So it's just a little bit in the rounding of the numbers."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","Our next question is from the line of Mike Weinstein, JPMorgan.",11,"Our next question is from the line of Mike Weinstein, JPMorgan."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","So when's the last time Boston Scientific grew 8% organic? Do you guys know the answer?",17,"So when's the last time Boston Scientific grew 8% organic? Do you guys know the answer?"
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","I bet you Dan knows.",5,"I bet you Dan knows."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","I'd say 10 years, Mike.",6,"I'd say 10 years, Mike."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","2Q 2005?",2,"2Q 2005?"
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","That's right.",3,"That's right."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","There you go. Let's do it again.",7,"There you go. Let's do it again."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","So what strikes me in particular is if I look at the U.S. performance and I back out CRM and I back out AMS, I'm getting to about 15% growth for the U.S. business in aggregate, which is obviously very, very strong. So I want to circle back first to Bob's",160,"So what strikes me in particular is if I look at the U.S. performance and I back out CRM and I back out AMS, I'm getting to about 15% growth for the U.S. business in aggregate, which is obviously very, very strong. So I want to circle back first to Bob's question just to make sure you don't think that there's anything kind of unusual going on in selling days, and I heard your answer there, but we are seeing this particular strength. And not just Boston Scientific, we've seen this in some other end markets over the course of the past week that have come in stronger. Anything that you think is going on that showed up this quarter in particular that is driving this real increase in volumes? And I'm speaking not just of your own performance, but do you have any theories on the broader market looking stronger this quarter than we've seen in a while?"
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, we don't see a big change in the market. From our peers that have reported, we were kind of seeing the kind of 1% to 4% growth rate with the exception of one, which was higher than ours. So we do feel like we're growing faster than most of our peers.",255,"Yes, we don't see a big change in the market. From our peers that have reported, we were kind of seeing the kind of 1% to 4% growth rate with the exception of one, which was higher than ours. So we do feel like we're growing faster than most of our peers. And I also think we're going through maybe a bit of a cycle of some good innovation and some mix benefit that we clearly see a lot of enthusiasm, for example, for S-ICD despite our headwinds in the near term on MRI, which we're pleased with the pacer approval. We're getting nice mix benefit from S-ICD as well as global uptake of the S-ICD, particularly in Japan. And I think our strategy of category leadership, which we've really stressed for a number of years now, is starting to pay off, what made the large systems in the U.S. willing and wanting to partner with Boston Scientific, given our current platform as well as the pipeline that we've committed to. So I think the markets are steady. We have a nice pipeline that's helping some of our mix benefit. And I think, importantly, we're really building up our capabilities outside the U.S. Our Asia business grew very well, and just this year, we've done a grand opening for our Malaysia plant. We have a new R&D center in India. We have new training centers. So our capabilities in Asia are significantly stronger than they used to be. So that's also helping strengthen our business."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Mike, if I look at the Interventional Cardiology business in the U.S., if I look at the peripheral vascular business in the U.S., I mean, both just had exceptional quarters. Interventional Cardiology up 21%. Peripheral vascular up 13%. Can you -- would yo",71,"Mike, if I look at the Interventional Cardiology business in the U.S., if I look at the peripheral vascular business in the U.S., I mean, both just had exceptional quarters. Interventional Cardiology up 21%. Peripheral vascular up 13%. Can you -- would you mind just peeling the onion a little bit and help us understand how those businesses are doing as well as they are? Because, obviously, that's well above expectations."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, I think it really speaks to category leadership. So we're 2 words that get used a lot in the industry, but I think we're delivering it. We have an excellent portfolio. Interventional Cardiology, as I mentioned I'm in Korea here at this large conferen",157,"Yes, I think it really speaks to category leadership. So we're 2 words that get used a lot in the industry, but I think we're delivering it. We have an excellent portfolio. Interventional Cardiology, as I mentioned I'm in Korea here at this large conference, and we believe we have the best drug-eluting stent in the marketplace. We have an excellent imaging platform with IVUS, and we're launching FFR. We're the leaders in chronic total occlusion. We have the WATCHMAN product for interventional cardiologists who want to implant it and a very promising and differentiated TAVR valve. So I think our category leadership strategy is working in cardiology and similarly in peripheral vascular with our -- I won't go through all of them, but the Bayer acquisition really has exceeded the investment models that we've had in terms of synergies and growth. And our drug-eluting stent platforms with the stents and the balloon are doing quite well."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","And our next question is from Rick Wise, Stifel.",9,"And our next question is from Rick Wise, Stifel."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Let me turn to one area of weakness. Obviously, CRM, high power down 4%, Mike. Can you talk a little bit more about that? And specifically, you called out the replacement headwinds. You've been talking about replacement headwinds in CRM and high power for",109,"Let me turn to one area of weakness. Obviously, CRM, high power down 4%, Mike. Can you talk a little bit more about that? And specifically, you called out the replacement headwinds. You've been talking about replacement headwinds in CRM and high power for a while. My sense is your comments in the past is that, that is going to shift more to neutral or even a tailwind at some point in the not-too-distant future. Can you give us any more concrete thoughts about what -- when that happens and the kind of drag it is now and how that could change as we look to '17 and beyond?"
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. Thanks for the question, Rick. Just regarding our CRM performance broadly, and I'll comment on the replacement headwind, it's really as we projected almost a year ago when you were going to have some challenges in the U.S. Our Asia business, our Japa",270,"Yes. Thanks for the question, Rick. Just regarding our CRM performance broadly, and I'll comment on the replacement headwind, it's really as we projected almost a year ago when you were going to have some challenges in the U.S. Our Asia business, our Japanese business and our European business CRM are doing quite well and growing either at or above market. And the 2 launches will help us improve growth we anticipate in the second quarter and for the second half. So -- and also, the team continues to improve operating income margins despite a negative growth in the quarter, which is good to see. On the replacement headwinds, we don't have any additional breakdown of data that we're going to provide on this call, but I will say, and I think in the future, we'll consider providing some additional detail so we can quantify that. But similar to our last call, I do think we have brighter days ahead of us in CRM with the pacer MRI approval, with the quad approval. We've also initiated our MRI approval for our defib platform, which we see getting approval in mid-'17. So the portfolio is very strong. We'll have EMBLEM MRI likely approved in U.S. in third quarter. And so we do see the headwind of the replacement cycle improving at the end of 2016, which will help us in 2017. So with the product cadence and improved replacement cycle headwind, we see some brighter days for our CRM business. And in the future, we'll look at quantifying more precisely some of the benefit of that tailwind on the replacement cycle."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","And as a follow-up, maybe turning to WATCHMAN. Can you -- are you inclined to give us any kind of numbers for the quarter you're at -- you're on track for the next 100 accounts? Was there any stocking? Maybe any more granular detail about the progress you",56,"And as a follow-up, maybe turning to WATCHMAN. Can you -- are you inclined to give us any kind of numbers for the quarter you're at -- you're on track for the next 100 accounts? Was there any stocking? Maybe any more granular detail about the progress you're making and the impact of the NCD."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, WATCHMAN continues to do a nice job. Most importantly, we continue to believe in our $175 million to $200 million in structural heart revenue guidance. We're on track as planned to open up another 100 centers, and we continually have very thoughtful",114,"Yes, WATCHMAN continues to do a nice job. Most importantly, we continue to believe in our $175 million to $200 million in structural heart revenue guidance. We're on track as planned to open up another 100 centers, and we continually have very thoughtful training program. The NCD is a very good outcome for us, and it really reassures and strengthens our view as to the potential size of the market. And we invest, as you mentioned, in clinical specialists. We're investing in physician training and really to build up the market the appropriate way. So we're really kind of delivering as planned, and we're very pleased with the outcomes and enthusiasm of WATCHMAN globally."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","And Rick, I would probably just add one little bit of color on the replacement headwinds as well. It's kind of a tale of 2 pieces within the franchise there. So as Mike said, as we head into the end of '16 and more likely '17, you'll see more of a tailwin",89,"And Rick, I would probably just add one little bit of color on the replacement headwinds as well. It's kind of a tale of 2 pieces within the franchise there. So as Mike said, as we head into the end of '16 and more likely '17, you'll see more of a tailwind on the CRTD side and then it's more of an ending '17 into '18 on the traditional transvenous ICD side. So it's a little bit of a bifurcation on that one, so a little bit extra color."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","And our next question comes from the line of Bruce Nudell, SunTrust.",12,"And our next question comes from the line of Bruce Nudell, SunTrust."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","This is actually Imron Zafar in for Bruce. I wanted to ask a couple of questions about the TAVR business. Can you just talk about where you think you are in Europe vis--vis market share and where you think you can go with the next, call it, couple of ye",74,"This is actually Imron Zafar in for Bruce. I wanted to ask a couple of questions about the TAVR business. Can you just talk about where you think you are in Europe vis--vis market share and where you think you can go with the next, call it, couple of years in that geography? And then also if you could just give any commentary around this litigation with Edwards on transcatheter valves in the U.S."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. So on the Lotus program, as Dan outlined, we continue to invest a significant portion of our med device benefit on structural heart franchise. In terms of share, we don't break out our shares specifically in Europe. We are more limited than -- versus",163,"Yes. So on the Lotus program, as Dan outlined, we continue to invest a significant portion of our med device benefit on structural heart franchise. In terms of share, we don't break out our shares specifically in Europe. We are more limited than -- versus some of our peers in terms of the number of countries we're selling into. So we're waiting to get reimbursements still for France. So that's a large market that will open up for us in the future. But we continue to grow above market in the markets that we're serving, particularly in Germany, and the physician feedback continues to be very strong on the low PVL rates, which we believe are best-in-class and really the control are fully achievable and repositionable capabilities of the platform. So we continue to invest, and we're excited about the enhancements of our depth guard technology that I mentioned in the prepared comments. Keith, any additional comments you want to mention on Lotus?"
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. So we've got a pretty rich number of presentations. The EuroPCR next month on Lotus, late-breaking trial on 1,000 patients from the RESPOND study, bicuspid valve subgroup from the RESPOND study, subclavian approach from the RESPOND study, Lotus sympo",150,"Yes. So we've got a pretty rich number of presentations. The EuroPCR next month on Lotus, late-breaking trial on 1,000 patients from the RESPOND study, bicuspid valve subgroup from the RESPOND study, subclavian approach from the RESPOND study, Lotus symposium. And on the stent side, the EVOLVE symposium used 5 years data for the first time. And then obviously, as we said, at ACC, coincident with london valves later this year. We're anticipating launching Lotus EDGE, which has a number of features including 14 French compatibility, more simple implantation procedure, more flexible device and the depth guard technology, which reduces the amount of the valve dips into the left ventricular outflow tract during deployment. So we have a lot going on with Lotus and then the additional sizes of 21 and 29 millimeter. And we've completed, as Mike said in his statement earlier, a REPRISE Japan study, which is important."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. And can you give just any color on the litigation with Edwards?",13,"Okay. And can you give just any color on the litigation with Edwards?"
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, yes, we're not going to comment on our pending legal matters.",12,"Yes, yes, we're not going to comment on our pending legal matters."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","Our next question is from the line of Vijay Kumar, Evercore.",11,"Our next question is from the line of Vijay Kumar, Evercore."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","So maybe the first question I had was maybe a housekeeping question on you mentioned sort of ICD declines and double-digit growth in stents. Was that in both geographies? When you say stents up double digits, was that double digits in both geographies, U.",67,"So maybe the first question I had was maybe a housekeeping question on you mentioned sort of ICD declines and double-digit growth in stents. Was that in both geographies? When you say stents up double digits, was that double digits in both geographies, U.S., OUS? And similarly, on ICDs, I'm just wondering whether declines was only in the U.S. or did you see declines in OUS?"
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Dan, do you want to comment on that one?",9,"Dan, do you want to comment on that one?"
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, Vijay, thanks for the question. We're not going to get too specific in terms of the growth rates by geography. Obviously, we think of Japan, we had approval for SYNERGY early in the quarter. So we're off and running there. We're on offense there. We",165,"Yes, Vijay, thanks for the question. We're not going to get too specific in terms of the growth rates by geography. Obviously, we think of Japan, we had approval for SYNERGY early in the quarter. So we're off and running there. We're on offense there. We had SYNERGY in kind of the middle of the fourth quarter in the U.S. So strong growth there in stents. So -- and Europe has -- which has had SYNERGY for a long time is still doing very well. So no, I don't want to quote specific numbers for each of the regions there, and I think overall -- I think Mike's commentary around CRM was pretty detailed, that if you think of -- we're doing very well in Japan. We're doing well in Europe. And the CRM softness has been more of a U.S. product gap issue and we hopefully solved a couple of those product gaps with the recent quad approval and with the MRI-safe brady approval."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Understood. And I just had one follow-up, Dan. When you think about the longer-term operating model rate, I know you guys have laid out the 25% margin targets for '17. Can you just talk about the leverage and your confidence in bending that SG&A sort of l",77,"Understood. And I just had one follow-up, Dan. When you think about the longer-term operating model rate, I know you guys have laid out the 25% margin targets for '17. Can you just talk about the leverage and your confidence in bending that SG&A sort of line? Because it feels like, just looking at the trends, the 25% might be a -- there's upside to that 25% number for '17 and then any comments on beyond 2017?"
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. We've stated publicly before that by 2020, we believe we'd be at 27% to 28% operating margin just operating margin as a company and the 25.1% is a great start to the year. But as I mentioned, the average for the year should be between 24% and 24.5%,",150,"Sure. We've stated publicly before that by 2020, we believe we'd be at 27% to 28% operating margin just operating margin as a company and the 25.1% is a great start to the year. But as I mentioned, the average for the year should be between 24% and 24.5%, and as always, we seek to strike that balance between delivering the adjusted operating margin and ensuring that durable consistent revenue growth for the long term. And if you look at our numbers this year, if you look at 6% to 8% organic revenue growth, 190 basis points of adjusted operating margin expansion at the midpoint of the range and adjusted EPS growth of 14% at the low and 18% at the high end, I think we're effectively achieving that objective. And as you look at '17 and beyond, we look to continue to deliver high performance, and that's the goal."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","Our next question is from the line of Josh Jennings, Cowen and Company.",13,"Our next question is from the line of Josh Jennings, Cowen and Company."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Wanted to hopefully start off with a question for Dan and just a follow-up on the operating margin discussion and some of the strength you saw in Q1 and the uptick in the guidance. Can you talk about AMS integration? And is AMS contributing already to ope",87,"Wanted to hopefully start off with a question for Dan and just a follow-up on the operating margin discussion and some of the strength you saw in Q1 and the uptick in the guidance. Can you talk about AMS integration? And is AMS contributing already to operating margin? And how do you see the AMS contribution going through the year? And also as it flows down into the bottom line and the accretion levels you guys had guided to historically, are you still on track there?"
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, I think the short answer to that, Josh, is that we are right on track. So we had talked about $0.03 accretion in the year from AMS. We're on track to achieve that. And then next year, we had talked about $0.07 and we should be on track for that. And",112,"Yes, I think the short answer to that, Josh, is that we are right on track. So we had talked about $0.03 accretion in the year from AMS. We're on track to achieve that. And then next year, we had talked about $0.07 and we should be on track for that. And the difference is really some of the integration costs that we have this year. We expect the quality remediation and some of the things like IT and such that are pushing that down a bit this year. And next year, you should see kind of the full power of what AMS can bring to the margin story for the company."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. Great. That's helpful. And then, Mike, I was hoping to just follow up on the CRM business. Clearly, you have some nice approvals over the last month and particularly this week with the MRI-safe product gap on the low-voltage side, and you initiated",111,"Okay. Great. That's helpful. And then, Mike, I was hoping to just follow up on the CRM business. Clearly, you have some nice approvals over the last month and particularly this week with the MRI-safe product gap on the low-voltage side, and you initiated your MRI-safe trial for high voltage. I just wanted to get your level of confidence, your team's level of confidence in the time lines there and maybe just help us think about the steps going forward in terms of the times of enrollment and the enrollment period and follow-up period just to help us think about the safety of that mid-'17 time line on the high-voltage side."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. We feel comfortable with it. I think we've been reasonably accurate on the forecast for some of these big product approvals with the quad and the MRI pacer. So we're looking at, call it, mid-'17, maybe to hedge that a bit, third quarter 2017 for app",52,"Sure. We feel comfortable with it. I think we've been reasonably accurate on the forecast for some of these big product approvals with the quad and the MRI pacer. So we're looking at, call it, mid-'17, maybe to hedge that a bit, third quarter 2017 for approval of our tachy MRI product."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","Our next question comes down the line of Matt Miksic, UBS.",11,"Our next question comes down the line of Matt Miksic, UBS."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","So a couple, if I could. One on WATCHMAN, just a follow-up on some of the questions that have already been asked, but what we're hearing is for centers, obviously, the NCD in place and differentiated device, and I think everyone's excited to see how this",138,"So a couple, if I could. One on WATCHMAN, just a follow-up on some of the questions that have already been asked, but what we're hearing is for centers, obviously, the NCD in place and differentiated device, and I think everyone's excited to see how this rolls out. But there is some question, I guess, about how profitable this is for some of these centers. For some, it does seem to be a little bit on the tech side, pricing net of reimbursement but, at the same time, it doesn't seem to be, from what we could tell, a significant impediment to interest or early adoption. So any thoughts on how you see that playing out over time or regionally playing out as it begins to pick up steam here? And then I have one follow-up for Dan."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. So on the NCD, it was a nice win for us, and we believe we really have the right sweet spot in terms of the WATCHMAN pricing. It is financially viable at most of the heart centers that we have contracted with. So we stay very close to that, and it's",119,"Sure. So on the NCD, it was a nice win for us, and we believe we really have the right sweet spot in terms of the WATCHMAN pricing. It is financially viable at most of the heart centers that we have contracted with. So we stay very close to that, and it's really part of our category leadership strategy. So we want to price it at the appropriate level, given the investment that we've made in the platform as well as future clinical trials that we're supporting as we advance this new therapy. But we do believe it's financially viable and a healthy product with appropriate margins for the vast majority of our hospitals that are using this today."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay, that's helpful color. And on Dan -- for Dan on some of the work that you're doing to drive manufacturing efficiencies and working capital efficiencies, net operating asset turnover here, obviously, a key driver for ROIC, and you do have an opportuni",125,"Okay, that's helpful color. And on Dan -- for Dan on some of the work that you're doing to drive manufacturing efficiencies and working capital efficiencies, net operating asset turnover here, obviously, a key driver for ROIC, and you do have an opportunity there. From what we can tell, it's obviously a focus. Wondering if you could sketch out how we should see that begin to play out because understanding your manufacturing rationalization and the efforts you have underway, it may not be apparent from the numbers, sort of on a turnover basis, the improvements that you're been making, but would love to get a sense of when that will start to become apparent and maybe start having the additional impact on returns on capital."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. I think I'd like to believe you'll see some of that impact this year. So we have a significant emphasis on reducing inventory, and I mentioned that in some of my prepared remarks and trying to prove that from our perspective, we can grow sales at th",171,"Sure. I think I'd like to believe you'll see some of that impact this year. So we have a significant emphasis on reducing inventory, and I mentioned that in some of my prepared remarks and trying to prove that from our perspective, we can grow sales at the rate that we're doing but also optimize inventory, and we have a lot of work ongoing to try and do some things to rationalize that. And from a cash flow as well as the other metrics that you mentioned, reduce inventory overall by the end of the year as a company. So my goal would be that as we go through the year, you'd see that. It was pretty reasonable compared to Q4 of last year, inventory this year, and so we've kind of stemmed the tide of it now and I'd look to, for the last 3 quarters, to see that reduce, which will help all the turnover and asset metrics as well as the contribution of working capital to cash flow."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","All right. With that, we'd like to conclude the call. Thank you for joining us today. We appreciate your interest. And before you disconnect, Roxanne will give all the pertinent details for the replay. Thank you.",36,"All right. With that, we'd like to conclude the call. Thank you for joining us today. We appreciate your interest. And before you disconnect, Roxanne will give all the pertinent details for the replay. Thank you."
317627,329821425,964245,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","And ladies and gentlemen, this conference will be made available for replay after 10:30 a.m. today running through May 11, 2016, at midnight. You may access the AT&T executive playback service at any time by dialing (800) 475-6701 and entering the access",74,"And ladies and gentlemen, this conference will be made available for replay after 10:30 a.m. today running through May 11, 2016, at midnight. You may access the AT&T executive playback service at any time by dialing (800) 475-6701 and entering the access code of 390210. International participants may dial 1 (320) 365-3844. That concludes our conference for today. Thank you for your participation and for using AT&T Executive TeleConference service. You may now disconnect."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2016 Boston Scientific Earnings Call. [Operator Instructions] And as a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Susie Lisa",46,"Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2016 Boston Scientific Earnings Call. [Operator Instructions] And as a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Susie Lisa. Please go ahead."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Roxanne. Good morning, everyone, and thanks for joining us. With me on today's call are Mike Mahoney, President and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.We issued a press release earli",366,"Thank you, Roxanne. Good morning, everyone, and thanks for joining us. With me on today's call are Mike Mahoney, President and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.
We issued a press release earlier this morning announcing our Q1 2016 results, which included reconciliations of the non-GAAP measures used in the release.
We have posted a copy of that release as well as reconciliations of the non-GAAP measures used in today's call to the Investor Relations section of our website under the heading, Financial Information.
The duration of this morning's call will be approximately 1 hour. Mike will provide strategic and revenue highlights of Q1 '16. Dan will review the financials for the quarter and then Q2 '16 and full year 2016 guidance, and then we'll take your questions. During today's Q&A session, Mike and Dan will be joined by our Chief Medical Officers, Dr. Keith Dawkins and Dr. Ken Stein. 
Before we begin, I'd like to remind everyone that on the call, organic revenue growth is defined as excluding the impact of sales from divested businesses, changes in foreign currency exchange rates and sales from the acquisition of the American Medical Systems male urology portfolio over the prior year period. Also of note, this call contains forward-looking statements within the meaning of Federal securities laws, which may be identified by words like anticipate, expect, believe, estimate and other similar words.
They include, among other things, statements about our growth and market share; new product approvals and launches; clinical trials; cost savings and growth opportunities; our cash flow and expected use; our financial performance, including sales, margins, earnings and other Q1 2016 results and Q2 and full year 2016 guidance; as well as our tax rates, R&D spend and other expenses.
Actual results may differ materially from those discussed in the forward-looking statements.
Factors that may cause such differences include those described in the Risk Factors section of our most recent 10-K and subsequent 10-Qs filed with the SEC.
These statements speak only as of today's date, and we disclaim any intention or obligation to update them.
At this point, I'll turn it over to Mike for his comments. Mike?"
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Susie, and good morning, everyone. We continue to perform against our strategic plan goals, and we're encouraged by the consistent strong execution of our global team. The success of our new product launches across many of our businesses is hel",1637,"Thank you, Susie, and good morning, everyone. We continue to perform against our strategic plan goals, and we're encouraged by the consistent strong execution of our global team. The success of our new product launches across many of our businesses is helping us accelerate expansion into faster-growth markets and deliver solutions that address unmet clinical needs. 
We continue to believe that Boston Scientific is uniquely positioned to deliver differentiated shareholder value through durable mid-single-digit organic revenue growth and double-digit adjusted EPS growth through our ongoing operating margin improvement initiatives. We're very excited about the excellent start to 2016 and our plans to build upon our global momentum in 2017 and beyond. 
We posted excellent results this quarter with total operational revenue growth of 13% and organic revenue growth of 8%, excluding the impact of AMS acquisition benefit. Four of our 7 businesses grew revenue double-digits organically, and we, in turn, leveraged that revenue growth to drive 24% adjusted operating income growth, resulting in an adjusted operating margin of 25.1% and a 260 basis point improvement year-over-year. 
We delivered adjusted EPS of $0.28, exceeding the high end of guidance and representing 31% growth, including the negative impact from foreign currency. Importantly, we're increasing our 2016 guidance for revenue, adjusted operating margin and adjusted EPS. We're increasing our full year organic revenue growth guidance from 4% to 7% previously to 6% to 8%. Full year operational revenue, which includes the benefit of AMS, has been increased from 7% to 10%, to 9% to 11%. We're increasing our adjusted operating margin guidance to 24% to 24.5%, and we're also increasing our adjusted EPS guidance up $0.03 over our prior range to $1.06 to $1.10, which now represents 14% to 18% growth. And importantly, this EPS guidance includes an expected $0.05 to $0.06 negative impact from foreign exchange. 
I'll now provide some highlight on Q1 results and the 2016 outlook. And in my remarks, all references to growth are on a constant currency organic year-over-year basis, excluding the benefit of AMS, unless otherwise specified. 
Our Q1 revenue growth of 8% was broad based across our businesses and regions, led again by exciting new product launches, continued global expansion and execution of our category leadership strategy. With the exception of a 3% decline in our Cardiac Rhythm Management sales, all of our other businesses delivered strong organic growth, led by Endo at plus 11%, Urology and Pelvic Health of plus 12%, Interventional Cardiology at 13% and Peripheral Intervention at 14%. 
We also saw strong growth globally with Asia delivering 14%; U.S., 7%; and Europe, up 6%. Emerging market sales grew 21%, including China, sales at 19%. The MedSurg businesses all accelerated from Q4 of last year and delivered adjusted operating margin of 32.6%, up 360 basis points year-over-year. 
Endoscopy revenue grew 11%, driven by our single-use SpyGlass digital DS visualization system, the AXIOS Stent for drainage of pancreatic fluid and the limited launch of our next-generation hemostasis clip, the Resolution 360. We're also extending our category leadership in Endoscopy by developing commercial capabilities in the emerging markets, adding a focus in pulmonary, which helped drive 15% growth in bronchial thermoplasty as they recently launched in both Japan and China. Urology and pelvic health organic growth accelerated 12% and was broadly based with double-digit growth in kidney stone, and pelvic floor and surg/gyn. Our legacy business grew 15% internationally, led by 36% growth in the emerging markets. The AMS remediation and integration are on track, and we're delivering against our synergy commitments and the global teams are now fully integrated. 
As expected, stand-alone AMS sales declined slightly in the quarter, and we expect inventory to be appropriate levels in the second quarter. At LithoVue, an innovative single digital ureteroscope that provides customers with visualization and navigation capabilities, will be featured in multiple presentations next weekend at the American Urology Association meeting in San Diego. 
Neuromodulation revenue growth accelerated 8% in the first quarter, and sales were driven by the market-leading Spectra platform, the most flexible spinal cord stimulation system in the market; the launch of Precision Novi for the primary cell non-rechargeable market; and the solid contribution from our Vercise, our emerging Deep Brain Stimulation platform. 
Our U.S. DBS trial is making great progress, and we expect to launch in the U.S. in late 2017 or early 2018. In Cardiovascular, our segment sales grew 14% in the quarter and delivered adjusted operating margin of 34.1%, up over 350 basis points, both sequentially and year-over-year. 
Peripheral sales grew 14% in strong results in atherectomy, thrombectomy and our Innova bare metal and Eluvia drug-eluting stent platforms. The legacy Peripheral business continued its recent impressive trend as we grow share in the atherectomy market and see very strong demand for our new Zelante Deep Vein Thrombosis platform. 
The Eluvia IDE trial called IMPERIAL is on track to complete enrollment by late 2016 or early '17, and we look forward to presenting 24-month data from our initial trial of MAJESTIC -- which had a 12-month patency rate of 96.1% -- later this year. We're also seeing continued progress for our Lutonix distribution agreement and encouraging EU sales of our Ranger Drug-Coated Balloon. We're excited to be the only company developing leading drug-eluting technologies globally on multiple platforms, providing physicians with a variety of tools for treating complex peripheral vascular disease. 
Interventional Cardiology turned another double-digit quarter, a 13% growth, led by complex coronary drug-eluting stents, PCI guidance and structural heart. SYNERGY had a very strong quarter, and we estimate that we add it to our market-leading share position in the U.S. and regain market leadership position in Japan. 
DES sales grew 14% in the quarter, and we believe SYNERGY is on track to represent approximately 50% of our U.S. DES revenue mix by the end of the year '16. 
PCI guidance again grew double digits on continued share gains on intravascular ultrasound, and we're encouraged by strong feedback on the ease-of-use of our Comet Fractional Flow Reserve platform. Our leading portfolio of solutions for complex high-risk PCI patients continues to drive global growth as well. 
The 13% IC revenue growth was also fueled by our strengthening structural heart business, which includes our Lotus transcatheter aortic valve and WATCHMAN Left Atrial Appendage Closure device. We believe we are uniquely positioned to drive long-term growth in these 2 fast-growing markets via our differentiated platforms. 
Our Lotus valve continues to gain share in Europe, and we are investing significantly to further develop our capabilities. Most recently, best-in-class paravalvular leakage rates were reported for Lotus at ACC last month with predischarge rates of 0.4% for moderate paravalvular regurgitation in the first 750 patients of the RESPOND Post-Market Study. 
We also continue to plan for the U.S. launch with the Lotus EDGE delivery system at the end of 2017, and we also completed enrollment in our REPRISE Japan trial, where we target a 2018 launch. 
Importantly the Lotus EDGE features a 14 French compatible sheath, more flexibility, simplified deployment and our new depth guard technology, which controls depth of the valve in the left ventricular outflow tract. Studies to demonstrate an improved permanent pacemaker rate with this optimized technique will begin enrollment in mid-2016. 
Also at structural heart, WATCHMAN sales were strong on procedure growth and new account openings, both helped by the finalized national coverage determination. We're developing additional WATCHMAN capabilities, primarily by adding resources in field clinical support, market development and training courses. Implant success rates and patient outcomes remain very high quality due to our controlled rollout and proven training programs. 
In the ACC earlier this month, Dr. David Holmes of the Mayo Clinic presented data from the first 1,600 patients implanted with a WATCHMAN commercially and revealed 96% procedural success at an average procedure time of 15 minutes. So overall, we are very pleased with our progress in our 2016 revenue guidance of $175 million to $200 million in Structural Heart revenue. 
Rhythm Management segment sales declined 2% in the quarter yet delivered adjusted operating margin of 16.8%, which is up 290 basis points sequentially as improving profitability remains a core focus. In CRM, as anticipated, sales declined 3% as we faced competitive launches in the U.S. and replacement cycle headwinds. We're optimistic for a second quarter and second half 2016 improvement in our CRM performance. 
Also, as projected, we received 2 key FDA approvals in March for our ACUITY X4 quad CRT lead, and earlier this week for our ACCOLADE Brady MRI platforms, including the INGEVITY MRI patient lead. Pacemaker sales grew 3% globally, aided by a recently launched X4 CRT-P quad device while worldwide ICD sales declined 4%. 
We continue to be very pleased with the performance of the EMBLEM S-ICD, which is enjoying strong growth in both Europe and the U.S. and is currently launching in Japan. In Electrophysiology, we're encouraged by double-digit growth in Europe, led by our arrhythmia installations and the recent launches of the IntellaMap OI and IntellaTip MiFi OI ablation catheters. In the U.S., we're now launching our Blazer Open-Irrigated Therapeutic Catheter for the treatment of Type 1 atrial flutter as we continue to invest in the franchise, launch a portfolio of navigation-enabled therapeutic catheters and build capabilities in capital equipment sales and service. 
We have a strong arrhythmia customer pipeline as many of our new platform enhancements scheduled for release in 2016. So to wrap up, our company had an excellent quarter. First quarter results reflect the strength of our portfolio, our ongoing investment in faster-growth markets and our globalization efforts. More importantly, we are well positioned to continue our strong performance in 2016 and beyond. I want to thank our employees for their continued winning spirit and their commitment to the company. 
Now let me turn the call over to Dan for a more detailed review of our financials."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Mike. In Q1, we generated organic revenue growth of 8% versus our 4% to 6% guidance range and adjusted EPS of $0.28, exceeding our guidance range of $0.23 to $0.25 and representing 31% year-over-year growth. Adjusted EPS of $0.28 includes a slig",1941,"Thanks, Mike. In Q1, we generated organic revenue growth of 8% versus our 4% to 6% guidance range and adjusted EPS of $0.28, exceeding our guidance range of $0.23 to $0.25 and representing 31% year-over-year growth. 
Adjusted EPS of $0.28 includes a slightly lower-than-expected tax rate for the quarter due to some discrete tax items. The strong performance in Q1 was driven primarily by revenue growth upside, gross margin expansion and a lower SG&A rate versus the prior year. 
And as Mike mentioned, given the outperformance in Q1, we are raising full year guidance for revenue growth, adjusted operating margin and adjusted EPS. Consolidated revenue of $1,964,000,000 represented operational revenue growth of 13%, which excludes the impact of a $58 million headwind from foreign exchange. Excluding an approximate 500 basis point contribution from the AMS male urology portfolio acquisition, organic revenue growth was 8% in the quarter. 
On an as-reported basis, revenue grew 11% year-over-year. Adjusted gross margin for the first quarter was 72.3%, increasing 100 basis points year-over-year. The increase resulted primarily from cost improvements driven by our value improvement programs and favorable mix, partially offset by price. And similar to Q4 of 2015, the impact of foreign exchange on gross margin was negligible in the quarter. 
We continue to expect full year 2016 adjusted gross margin to be in the range of 72% to 73%, which we forecast to include approximately 50 basis points of unfavorable FX. Our Q1 2016 adjusted operating margin of 25.1% represents a 260 basis point improvement over Q1 2015, which marks the 7th consecutive quarter in which we've expanded adjusted operating margin by 100 basis points or more. 
There was very modest reinvestment of the medical device tax benefit in Q1, which represents some timing favorability in the quarter, but we are committed to reinvesting substantially all of the full year benefit during the year. Thus, adjusted SG&A expenses were $698 million or 35.5% of sales in the quarter, down 150 basis points year-over-year with some of the benefit due to our targeted initiatives focused on reducing SG&A and a portion due to the more modest medical device tax benefit reinvestment I just mentioned. 
Our Q1 adjusted SG&A rate was the lowest in the last 12 quarters, and we continue to believe our full year rate will be between 35.5% and 36.5%, which, at the midpoint, would be a 140 basis point reduction compared to 2015. 
Adjusted research and development expenses were $209 million in the first quarter or 10.7% of sales, which is roughly flat year-over-year. This is another key area for us to reinvest the benefit of the medical device tax suspension. As a result, we expect our full year 2016 adjusted R&D rate to be between 11% and 12% of sales. 
Royalty expense was 1% of sales in both Q1 of this year and last year and consistent with our guidance. On an adjusted basis, operating income was $494 million in the quarter or 25.1% of sales, up 260 basis points year-over-year. 
Q1 adjusted operating income grew 24% year-over-year, with all 3 reportable segments expanding adjusted operating margin by at least 250 basis points over Q1 of last year. Of particular focus is Rhythm Management, which delivered an adjusted operating margin of 16.8%, which is up from Q4 2015's 13.9% and the full year 2015 rate of 15%. 
For the first half of 2016, we expect Rhythm Management adjusted operating margin to be slightly above 16%. In the second half of 2016, we expect Rhythm Management adjusted operating margin to increase roughly 200 basis points over the first half rate. This second half improvement is expected to result from realizing the full benefit of 2016 product costs, leveraging the improved top line performance expected of the global CRM and EP businesses and realizing the full benefits of our Plant Network Optimization program, which is transferring a portion of our EP manufacturing to lower-cost locations. We continue to believe Rhythm Management is on track to deliver an adjusted operating margin of 20% in 2017. 
GAAP operating income, which includes GAAP to adjusted items of $201 million, was $293 million in Q1 2016. The primary GAAP to adjusted items for the quarter included amortization expense of $136 million, restructuring and related charges of $13 million, acquisition-related SG&A expenses of $14 million and litigation-related charges of $10 million. Our total legal reserve was $1,895,000,000 as of March 31, 2016. 
Now I'll move on to other income and expense. Interest expense for the quarter was $59 million compared to $56 million in Q1 last year, and the increase was primarily due to the incremental debt raised in Q2 of last year to finance the AMS male urology portfolio acquisition. 
Our average interest rate was 4% in Q1 2016 compared to 5.1% in Q1 last year, and the lower interest expense rate in Q1 this year was primarily due to lower average cost of debt resulting from the senior notes refinancing, which we completed in Q2 last year. 
Other expense was $10 million, and this consisted primarily of foreign exchange losses and investment losses incurred during the quarter. 
Our tax rate for the quarter was 11.4% on a reported basis and 11.8% on an adjusted basis. Excluding discrete tax items in the quarter, our adjusted tax rate would have been 13.5%, and we continue to expect our full year 2016 adjusted tax rate to be approximately 14%. 
On a reported GAAP basis, Q1 2016 EPS was $0.15 and includes net charges and amortization expense totaling $176 million after tax. GAAP EPS of $0.15 compares to breakeven in Q1 of last year. 
Moving on to the balance sheet. DSO of 60 days increased 1 day compared to March of last year. Days inventory on hand of 162 days was down 4 days compared to March of last year and 1 day from year-end 2015. 
Capital expenditures were $59 million in the quarter compared to $46 million in Q1 2015. And as a reminder, we expect full year 2016 capital expenditures to be roughly $350 million. This is $100 million higher than the full year 2015, primarily due to the construction of our new manufacturing facility and distribution center in Malaysia. And beyond 2016, we expect capital expenditures to return to our more historical run rate of approximately $250 million annually. 
Adjusted free cash flow for the quarter was $250 million compared to $118 million in Q1 2015, and this strong start gives us confidence in our adjusted free cash flow target of $1.5 billion, which represents 10% growth and better visibility to our stretch goal of $1.6 billion, which would represent 17% growth, even in a year with an incremental $100 million in CapEx spend as I mentioned. 
We're also continuing to pursue inventory management initiatives designed to improve the working capital contribution to cash flow. In Q1, we used cash primarily to fund previously agreed legal settlements as well as business development activities. 
Consistent with our goal of returning to pre-AMS debt leverage by year-end 2016, we still expect to repay $250 million of bank term loans by the end of this year. As of March 31 this year, we had cash on hand of $338 million. 
Near term, our capital allocation priorities are to prepay debt, manage our contingencies and pursue tuck-in M&A. We ended the quarter with 1,370,000,000 fully diluted weighted average shares outstanding. Consistent with our prior guidance, we expect our share count to increase by roughly 5 million per quarter through the end of the year as we plan to keep the buybacks suspended for the balance of 2016. We would expect this to result in a fully diluted weighted average share count of approximately 1,380,000,000 for the full year 2016. 
I'd like to conclude with revenue and earnings per share guidance for Q2 and full year 2016. For the full year, we now expect consolidated revenue to be in the range of $8,075,000,000 to $8,225,000,000, which represents year-over-year growth of 6% to 8% on an organic basis; 9% to 11% on an operational basis, which includes the AMS revenue; and 8% to 10% on a reported basis. 
As a result of a stronger dollar, at current rates, we expect foreign exchange to be a headwind of approximately $100 million for the full year 2016. As we move through 2016, we are reinvesting the benefit of the medical device tax suspension into innovation to help treat patients and sustain top line growth over the long term. Focus areas will include R&D efforts, including clinical trial spend as well as market development, and in Q2, we've already begun to ramp this reinvestment, primarily in the areas of structural heart with both Lotus and WATCHMAN, and other durable long-term revenue growth platforms such as the EMBLEM S-ICD, our electrophysiology portfolio, deep brain stimulation and other fast-growing adjacent market. 
In addition, Q2 is our seasonally high SG&A spend quarter partially due to the highest trade show activity of the year. Thus, for Q2 2016, and consistent with prior years, we would expect a sequential decline in adjusted operating margin to a range of 23% to 24%, which, at the midpoint, represents 140 basis points of improvement year-over-year and puts first half 2016 adjusted operating margin at 200 basis points up versus the first half of last year. 
And for the full year 2016, we are raising our adjusted operating margin guidance from 23.5% to 24.5% to a range of 24% to 24.5% now, which also represents a 200 basis point year-over-year gain. This gain is from operational efficiencies and not the med device act, as we are reinvesting the benefits. 
Turning to adjusted EPS. We now expect full year adjusted EPS for 2016 to be in a range of $1.06 to $1.10, representing 14% to 18% adjusted earnings growth and an increase of $0.03 to each end of the range compared to our prior guidance. 
Now let me walk you through our updated assumptions for the FX impact on adjusted EPS. Our initial 2016 guidance assumed $0.02 of unfavorable FX on adjusted EPS in Q1 and $0.06 for the full year. 
In Q1, the combination of exchange rate movements and timing of hedging contracts resulted in an unfavorable impact of $0.01, and we now believe the full year 2016 unfavorable impact will be $0.05 to $0.06. 
In addition to the $0.01 in Q1, we would expect the remaining $0.04 to $0.05 of unfavorable FX for the full year to break down into $0.02 in Q2 and $0.02 to $0.03 in the second half of 2016. Excluding the unfavorable foreign exchange, our full year adjusted EPS guidance range represents growth of 19% to 24%. 
On a GAAP basis, we expect EPS to be in a range of $0.64 to $0.69. 
Now turning specifically to Q2 2016. We expect consolidated revenues to be in a range of $2,010,000,000 to $2,060,000,000. If current foreign exchange rates hold constant, the headwind from FX should be approximately $25 million or 135 basis points relative to Q2 of last year. 
We expect consolidated Q2 sales to grow year-over-year in a range of 6% to 8% organically and 11% to 13% operationally. For the second quarter, adjusted EPS is expected to be in a range of $0.25 to $0.27 per share, and GAAP EPS is expected to be in a range of $0.14 to $0.17 per share. 
Please check our Investor Relations website for Q1 2016 financial and operational highlights, which outlines Q1 results as well as Q2 and full year 2016 guidance, including P&L line item guidance. 
So with that, I'll turn it back to Susie, who will moderate the Q&A."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Dan. Roxanne, let's open it up to questions for the next 30 minutes or so. [Operator Instructions] Roxanne, please go ahead.",22,"Thanks, Dan. Roxanne, let's open it up to questions for the next 30 minutes or so. [Operator Instructions] Roxanne, please go ahead."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","[Operator Instructions] Our first question comes from the line of Bob Hopkins, Bank of America.",15,"[Operator Instructions] Our first question comes from the line of Bob Hopkins, Bank of America."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","So to start off, Mike, obviously, this was one of the best growth quarter you guys have had in a while and congratulations on the great start to the year. I was wondering if you could talk to us a little bit about just the broader macro environment and th",105,"So to start off, Mike, obviously, this was one of the best growth quarter you guys have had in a while and congratulations on the great start to the year. I was wondering if you could talk to us a little bit about just the broader macro environment and the health of the markets you're in and maybe just talk about the factors driving growth. And I would really appreciate if you could talk a little bit about uro and endo as well and some of the products that are driving growth in that division because, obviously, that's where you had some really nice outperformance."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. Thanks for the question. Overall, the market growth we see is consistent with what we mentioned in the past, kind of playing in 3% to 4% growth markets overall for Boston Scientific and similar to Investor Day presentation. We're investing into fast",347,"Sure. Thanks for the question. Overall, the market growth we see is consistent with what we mentioned in the past, kind of playing in 3% to 4% growth markets overall for Boston Scientific and similar to Investor Day presentation. We're investing into faster-growth markets that would basically accelerate the growth profile another 100, 200 basis points of the markets that we serve. So kind of similar growth rates in IC and cardiology and CRM, kind of in the low single-digit range and more in the 4% to 5% market growth rates for our MedSurg. But I guess, what we're most proud of is really across the board with the exception of CRM, we're growing -- and EP, we're growing significantly faster than our competition. And based on -- that's really driven by our product launches and really excellent global execution. Really pleased with the growth in Asia product; almost 15%, very strong growth in Japan, a very strong growth in Europe. So across our businesses, our regions, our teams are really delivering. In terms of your question on endo and urology, we are very thoughtful about the AMS acquisition, and we're seeing the benefits of the commercial synergies between those organizations, given the additional commercial footprint that we have as well as the broadness of the bag, and you're seeing that with really acceleration of our legacy Urology division, in part due to the synergies of our AMS business. We continue to invest in physician training for our Stone Institute, and we continue to benefit from the category leadership based on the premise of the AMS acquisition. In Endoscopy, it's a very innovative division, and we continue to lead innovation with our digital SpyGlass system, which is really a terrific platform for us that we can continue to build from, and that also helps drive pull-through of our core portfolio. So the R&D teams are executing, as well as the commercial teams, and we continue to be committed to our durable mid-single-digit revenue growth, our operating margin expansion and our double-digit EPS growth over the long term."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Great. And then a follow-up maybe for Dan. Dan, can you just help us? Was there any, in your view, selling day mismatch this quarter versus a year ago? And then on the operating margin performance in the quarter, it sounds like over the course of the rest",107,"Great. And then a follow-up maybe for Dan. Dan, can you just help us? Was there any, in your view, selling day mismatch this quarter versus a year ago? And then on the operating margin performance in the quarter, it sounds like over the course of the rest of the year, there's going to be some incremental spending because, obviously, you're guiding to a lower operating margin than you started out in Q1. So maybe just comment on the selling day year-over-year, and then also maybe quantify and describe some of the extra spending that you're going to be undertaking here in the remainder of the year."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, Bob. First quickly on the calendar. No, we don't believe there's an extra impact in Q1. There was obviously a Leap year day, but then when you factor in the timing of the Easter holiday, I believe it's a true 8% growth for the quarter organically. R",253,"Sure, Bob. First quickly on the calendar. No, we don't believe there's an extra impact in Q1. There was obviously a Leap year day, but then when you factor in the timing of the Easter holiday, I believe it's a true 8% growth for the quarter organically. Relative to operating margin, so I think the -- when you look at Q1 at the 25% and then you look at the 24.25%, which is the midpoint for the full year, one of the key changes there is that, as I mentioned in my prepared remarks, the reinvestment of the medical device tax benefit over the rest of the year. So a little delayed in Q1 getting off to that start but committed to reinvesting the entire amount for the rest of the year. So that's one. And I think the -- there's R&D timing as well in Q1 so our Q1 R&D was 10.7%. If you look at the guidance range, you'd see 11.5% at the midpoint. Part of that's the med device tax reinvestment and part of it's just the timing of overall R&D. So that's another 80 basis points there going from the 10.7% in Q1 to the overall average of 11.5% for the full year. So still -- I mean, as you look at the 24.25%, still significant growth versus last year, 190 basis points and feel good that we're striking a good balance between delivering differentiated adjusted operating margin and investing for a continually growing top line for the future."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","And our next question comes from the line of David Lewis with Morgan Stanley.",14,"And our next question comes from the line of David Lewis with Morgan Stanley."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Just a few quick questions. Mike, I guess, the issue, I think, for us this quarter is that we expected an inflection quarter sometime this year. Obviously, it's coming earlier. But I guess, as we think about the balance of the businesses, we actually thou",124,"Just a few quick questions. Mike, I guess, the issue, I think, for us this quarter is that we expected an inflection quarter sometime this year. Obviously, it's coming earlier. But I guess, as we think about the balance of the businesses, we actually thought there could be acceleration from whatever the growth rate was in the first quarter. And I wonder, can you point us to tailwinds/headwinds of the business throughout about of the year based on sort of this thought of acceleration throughout the year? And then specific attention perhaps within Cardiovascular. You talked about those businesses in terms of stents, WATCHMAN, Lotus. What's really driving that strength in Cardio? So acceleration and in particular Cardiovascular, then one quick one for Dan."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","That's a multi-point question. Thanks, Dave. Just overall, we are pleased with our performance for the quarter. We took the guidance up from 4% to 7% to 6% to 8% organically, not impacting AMS. And as I mentioned, the businesses and regions are performing",420,"That's a multi-point question. Thanks, Dave. Just overall, we are pleased with our performance for the quarter. We took the guidance up from 4% to 7% to 6% to 8% organically, not impacting AMS. And as I mentioned, the businesses and regions are performing at a nice level. As we look -- we obviously anticipate a solid second quarter, given our 6% to 8% guidance in second quarter -- we do face a couple of headwinds throughout the year. We do anniversary some key product launches in our Peripheral Vascular as well as our Endoscopy business. We do anticipate some Japan reimbursement cuts that we'll be working through. And we're very bullish on our WATCHMAN program, but we're also anniversary-ing the initial launch. So there are a few headwinds. But overall, we have an excellent product cadence. The business is performing well, and we feel comfortable with raising our guidance to 6% to 8%. On the cardiology side, we're seeing excellent -- our strategy play out. We continue to diversify our interventional cardiology portfolio. As we talked in the future, we really see in the future about 1/3 of our business coming from structural heart, about 1/3 from imaging and complex coronary and about 1/3 from drug-eluting stents. And across those kind of 3 slices of the pie, we're doing a nice job of delivering in the short term and investing for the long term. Our SYNERGY program is really going as planned. We're on track for SYNERGY to represent about 50% of our mix at an appropriate premium price, and physicians continue to see the benefit of the deliverability and the excellent 0 stent thrombosis at beyond the first 24 hours. So excellent clinical data there. Our complex coronary business continues to do well as does our imaging business. And in structural heart, as Dan mentioned, I'm actually over in Korea as we speak here, we just had a live case from Australia today and just the physician reaction to the deliverability and the low PVL rates of our Lotus Valve continues to be very high. And so we are really increasing our investment in that category, given the size of the market potential in the future and also given the differentiation that we believe that Lotus delivers and our commercial capability. So hopefully that gives you a bit of flavor. We're pleased with our raise on the guidance, and we'll manage our headwinds and continue to hopefully deliver revenue growth at the top tier of our sector."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Mike, that's great color. And Dan, I hate to bore you with a nit here, it was such a good quarter, but we're actually getting your constant currency growth rate this quarter as even higher than you reported. We have a $58 million FX headwind for a 3.3% he",72,"Mike, that's great color. And Dan, I hate to bore you with a nit here, it was such a good quarter, but we're actually getting your constant currency growth rate this quarter as even higher than you reported. We have a $58 million FX headwind for a 3.3% headwind versus 2%. Are we missing something here in the quarter or -- and we can take it off-line if it's -- if we're..."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","No, David, I think it's just a rounding of 3%. The way we see it is 3%. So it's just a little bit in the rounding of the numbers.",29,"No, David, I think it's just a rounding of 3%. The way we see it is 3%. So it's just a little bit in the rounding of the numbers."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","Our next question is from the line of Mike Weinstein, JPMorgan.",11,"Our next question is from the line of Mike Weinstein, JPMorgan."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","So when's the last time Boston Scientific grew 8% organic? Do you guys know the answer?",17,"So when's the last time Boston Scientific grew 8% organic? Do you guys know the answer?"
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","I bet you Dan knows.",5,"I bet you Dan knows."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","I'd say 10 years, Mike.",6,"I'd say 10 years, Mike."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","2Q 2005?",2,"2Q 2005?"
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","That's right.",3,"That's right."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","There you go. Do it again.",6,"There you go. Do it again."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","So what strikes me in particular is if I look at the U.S. performance and I back out CRM and I back out AMS, I'm getting to about 15% growth for the U.S. business in aggregate, which is obviously very, very strong. So I want to circle back first to Bob's",160,"So what strikes me in particular is if I look at the U.S. performance and I back out CRM and I back out AMS, I'm getting to about 15% growth for the U.S. business in aggregate, which is obviously very, very strong. So I want to circle back first to Bob's question just to make sure you don't think that there's anything kind of unusual going on in selling days, and I heard your answer there, but we are seeing this particular strength. And not just Boston Scientific, we've seen this in some other end markets over the course of the past week that have come in stronger. Anything that you think is going on that showed up this quarter in particular that is driving this real increase in volumes? And I'm speaking not just of your own performance, but do you have any theories on the broader market looking stronger this quarter than we've seen in a while?"
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, we don't see a big change in the market. From our peers that have reported, we were kind of seeing the kind of 1% to 4% growth rate with the exception of one, which was higher than ours. So we do feel like we're growing faster than most of our peers.",256,"Yes, we don't see a big change in the market. From our peers that have reported, we were kind of seeing the kind of 1% to 4% growth rate with the exception of one, which was higher than ours. So we do feel like we're growing faster than most of our peers. And I also think we're going through maybe a bit of a cycle of some good innovation and some mix benefit. That we clearly see a lot of enthusiasm, for example, for S-ICD despite our headwinds in the near term on MRI -- which we're pleased with the pacer approval -- we're getting nice mix benefit from S-ICD as well as global uptake of the S-ICD, particularly in Japan. And I think our strategy of category leadership, which we've really stressed for a number of years now, is starting to pay off; what made large systems in the U.S. willing and wanting to partner with Boston Scientific, given our current platform as well as the pipeline that we've committed to. So I think the markets are steady. We have a nice pipeline that's helping some of our mix benefit. And I think, importantly, we're really building up our capabilities outside the U.S. Our Asia business grew very well, and just this year, we've done a grand opening for our Malaysia plant. We have a new R&D center in India. We have new training centers. So our capabilities in Asia are significantly stronger than they used to be. So that's also helping strengthen our business."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Mike, if I look at the Interventional Cardiology business in the U.S., if I look at the peripheral vascular business in the U.S., I mean, both just had exceptional quarters. Interventional cardiology up 21%. Peripheral vascular up 13%. Can you -- would yo",71,"Mike, if I look at the Interventional Cardiology business in the U.S., if I look at the peripheral vascular business in the U.S., I mean, both just had exceptional quarters. Interventional cardiology up 21%. Peripheral vascular up 13%. Can you -- would you mind just peeling the onion a little bit and help us understand how those businesses are doing as well as they are? Because, obviously, that's well above expectations."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, I think it really speaks to category leadership. So we're -- 2 words that get used a lot in the industry, but I think we're delivering it. We have an excellent portfolio. Interventional cardiology, as I mentioned I'm in Korea here at this large confe",158,"Yes, I think it really speaks to category leadership. So we're -- 2 words that get used a lot in the industry, but I think we're delivering it. We have an excellent portfolio. Interventional cardiology, as I mentioned I'm in Korea here at this large conference, and we believe we have the best drug-eluting stent in the marketplace. We have an excellent imaging platform with IVUS, and we're launching FFR. We're the leaders in chronic total occlusion. We have the WATCHMAN product for interventional cardiologists who want to implant it and a very promising and differentiated TAVR valve. So I think our category leadership strategy is working in cardiology and similarly in peripheral vascular with our -- I won't go through all of them, but the Bayer acquisition really has exceeded the investment models that we've had in terms of synergies and growth. And our drug-eluting stent platforms with the stents and the balloon are doing quite well."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","And our next question is from Rick Wise, Stifel.",9,"And our next question is from Rick Wise, Stifel."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Let me turn to one area of weakness. Obviously, CRM, high power down 4%, Mike. Can you talk a little bit more about that? And specifically, you called out the replacement headwinds. You've been talking about replacement headwinds in CRM and high power for",110,"Let me turn to one area of weakness. Obviously, CRM, high power down 4%, Mike. Can you talk a little bit more about that? And specifically, you called out the replacement headwinds. You've been talking about replacement headwinds in CRM and high power for a while. My sense is from your comments in the past is that, that is going to shift more to neutral or even a tailwind at some point in the not-too-distant future. Can you give us any more concrete thoughts about what -- when that happens and the kind of drag it is now and how that could change as we look to '17 and beyond?"
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. Thanks for the question, Rick. Just regarding our CRM performance broadly, and I'll comment on the replacement headwind, it's really as we projected almost a year ago. We knew we were going to have some challenges in the U.S; our Asia business, our J",272,"Yes. Thanks for the question, Rick. Just regarding our CRM performance broadly, and I'll comment on the replacement headwind, it's really as we projected almost a year ago. We knew we were going to have some challenges in the U.S; our Asia business, our Japanese business and our European business in CRM are doing quite well and growing either at or above market. And the 2 launches will help us improve growth, we anticipate, in the second quarter and for the second half. So -- and also, the team continues to improve operating income margins despite a negative growth in the quarter, which is good to see. On the replacement headwinds, we don't have any additional breakdown of data that we're going to provide on this call, but I will say, and I think in the future, we'll consider providing some additional detail so we can quantify that. But similar to our last call, I do think we have brighter days ahead of us in CRM with a pacer MRI approval, with a quad approval. We've also initiated our MRI approval for our defib platform, which we see getting approval in mid-'17. So the portfolio is very strong. We'll have EMBLEM MRI likely approved in U.S. in third quarter. And so we do see the headwind of the replacement cycle improving at the end of 2016, which will help us in 2017. So with the product cadence and improved replacement cycle headwind, we see some brighter days for our CRM business. And in the future, we'll look at quantifying more precisely some of the benefit of that tailwind on the replacement cycle."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","And as a follow-up, maybe turning to WATCHMAN. Can you -- are you inclined to give us any kind of numbers for the quarter you're at -- you're on track for the next 100 accounts? Was there any stocking? Maybe any more granular detail about the progress you",56,"And as a follow-up, maybe turning to WATCHMAN. Can you -- are you inclined to give us any kind of numbers for the quarter you're at -- you're on track for the next 100 accounts? Was there any stocking? Maybe any more granular detail about the progress you're making and the impact of the NCD."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, WATCHMAN continues doing a nice job. Most importantly, we continue to believe in our $175 million to $200 million in structural heart revenue guidance. We're on track as planned to open up another 100 centers, and we again continually add very though",113,"Yes, WATCHMAN continues doing a nice job. Most importantly, we continue to believe in our $175 million to $200 million in structural heart revenue guidance. We're on track as planned to open up another 100 centers, and we again continually add very thoughtful training programs. The NCD is a very good outcome for us, and it really reassures and strengthens our view as to the potential size of the market. And we invest, as you mentioned, in clinical specialists. We're investing in physician training and really to build up the market the appropriate way. So we're kind of delivering as planned, and we're very pleased with the outcomes and enthusiasm of WATCHMAN globally."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","And Rick, I would probably just add one little bit of color on the replacement headwinds as well. It's kind of a Tale of Two Pieces within the franchise there. So as Mike said, as we head into the end of '16 and more likely '17, you'll see more of a tailw",89,"And Rick, I would probably just add one little bit of color on the replacement headwinds as well. It's kind of a Tale of Two Pieces within the franchise there. So as Mike said, as we head into the end of '16 and more likely '17, you'll see more of a tailwind on the CRTD side and then it's more of an ending '17 into '18 on the traditional transvenous ICD side. So it's a little bit of a bifurcation on that one, so a little bit extra color."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","And our next question comes from the line of Bruce Nudell, SunTrust.",12,"And our next question comes from the line of Bruce Nudell, SunTrust."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","This is actually Imron Zafar in for Bruce. I wanted to ask a couple of questions about the TAVR business. Can you just talk about where you think you are in Europe vis--vis market share and where you think you can go in the next, call it, couple of year",74,"This is actually Imron Zafar in for Bruce. I wanted to ask a couple of questions about the TAVR business. Can you just talk about where you think you are in Europe vis--vis market share and where you think you can go in the next, call it, couple of years in that geography? And then also if you could just give any commentary around this litigation with Edwards on transcatheter valves in the U.S."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. So on the Lotus program, as Dan outlined, we continue to invest a significant portion of our med device benefit; in our structural heart franchise. In terms of share, we don't break out our shares specifically in Europe. We are more limited than -- v",164,"Yes. So on the Lotus program, as Dan outlined, we continue to invest a significant portion of our med device benefit; in our structural heart franchise. In terms of share, we don't break out our shares specifically in Europe. We are more limited than -- versus some of our peers in terms of the number of countries we're selling into. So we're waiting to get reimbursements still for France. So that's a large market that will open up for us in the future. But we continue to grow above market in the markets that we're serving, particularly in Germany. And the physician feedback continues to be very strong on the low PVL rates, which we believe are best-in-class and really the control, and fully retrievable and reposition-able capabilities of the platform. So we continue to invest, and we're excited about the enhancements of our depth guard technology that I mentioned in the prepared comments. Keith, any additional comments you want to mention on Lotus?"
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. So we've got a pretty rich number of presentations: The EuroPCR next month on Lotus, late-breaking trial on 1,000 patients from the RESPOND study, bicuspid valve subgroup from the RESPOND study, subclavian approach from the RESPOND study, Lotus sympo",150,"Yes. So we've got a pretty rich number of presentations: The EuroPCR next month on Lotus, late-breaking trial on 1,000 patients from the RESPOND study, bicuspid valve subgroup from the RESPOND study, subclavian approach from the RESPOND study, Lotus symposium. And on the stent side, the EVOLVE [indiscernible] used 5 years data for the first time. And then obviously, as we said, at ACC, coincident with London Valves later this year. We're anticipating launching Lotus EDGE, which has a number of features including 14 French compatibility, more simple implantation procedure, more flexible device and the depth guard technology, which reduces the amount that the valve dips into the left ventricular outflow tract during deployment. So we have a lot going on with Lotus and then the additional sizes of 21 and 29 millimeter. And we've completed, as Mike said in his statement earlier, a REPRISE Japan study, which is important."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. And can you give just any color on the litigation with Edwards?",13,"Okay. And can you give just any color on the litigation with Edwards?"
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, yes, we're not going to comment on our pending legal matters.",12,"Yes, yes, we're not going to comment on our pending legal matters."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","Our next question is from the line of Vijay Kumar, Evercore.",11,"Our next question is from the line of Vijay Kumar, Evercore."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Congrats on a great quarter. So maybe the first question I had was maybe a housekeeping question on you mentioned sort of ICD declines and double-digit growth in stents. Was that in both geographies? When you say stents up double digits, was that double d",71,"Congrats on a great quarter. So maybe the first question I had was maybe a housekeeping question on you mentioned sort of ICD declines and double-digit growth in stents. Was that in both geographies? When you say stents up double digits, was that double digits in both geographies, U.S., OUS? And similarly, on ICDs, I'm just wondering whether declines was only in the U.S. or did you see declines in OUS?"
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Dan, do you want to comment on that one?",9,"Dan, do you want to comment on that one?"
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, Vijay, thanks for the question. We're not going to get too specific in terms of the growth rates by geography. Obviously, if you think of Japan, we had approval for SYNERGY early in the quarter. So we're off and running there. We're on offense there.",166,"Yes, Vijay, thanks for the question. We're not going to get too specific in terms of the growth rates by geography. Obviously, if you think of Japan, we had approval for SYNERGY early in the quarter. So we're off and running there. We're on offense there. We had SYNERGY in kind of the middle of the fourth quarter in the U.S. So strong growth there in stents. So -- and Europe has -- which has had SYNERGY for a long time is still doing very well. So no, I don't want to quote specific numbers for each of the regions there, and I think overall -- I think Mike's commentary around CRM was pretty detailed, that if you think of -- we're doing very well in Japan. We're doing well in Europe. And the CRM softness has been more of a U.S. product gap issue and we've hopefully solved a couple of those product gaps with the recent quad approval and with the MRI-safe Brady approval."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Understood. And I just had one follow-up, Dan. When you think about the longer-term operating model rate, I know you guys have laid out the 25% margin targets for '17. Can you just talk about the leverage and your confidence in bending that SG&A sort of l",77,"Understood. And I just had one follow-up, Dan. When you think about the longer-term operating model rate, I know you guys have laid out the 25% margin targets for '17. Can you just talk about the leverage and your confidence in bending that SG&A sort of line? Because it feels like, just looking at the trends, the 25% might be a -- there's upside to that 25% number for '17 and then any comments on beyond 2017?"
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. We've stated publicly before that by 2020, we believe we'd be at 27% to 28% operating margin -- just operating margin as a company and the 25.1% is a great start to the year. But as I mentioned, the average for the year should be between 24% and 24.",151,"Sure. We've stated publicly before that by 2020, we believe we'd be at 27% to 28% operating margin -- just operating margin as a company and the 25.1% is a great start to the year. But as I mentioned, the average for the year should be between 24% and 24.5%, and as always, we seek to strike that balance between delivering the adjusted operating margin and ensuring that durable consistent revenue growth for the long term. And if you look at our numbers this year, if you look at 6% to 8% organic revenue growth, 190 basis points of adjusted operating margin expansion at the midpoint of the range and adjusted EPS growth of 14% at the low and 18% at the high end, I think we're effectively achieving that objective. And as you look at '17 and beyond, we look to continue to deliver high performance, and that's the goal."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","Our next question is from the line of Josh Jennings, Cowen and Company.",13,"Our next question is from the line of Josh Jennings, Cowen and Company."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Wanted to hopefully start off with a question for Dan and just a follow-up on the operating margin discussion and some of the strength you saw in Q1 and the uptick in the guidance. Can you talk about AMS integration? And is AMS contributing already to ope",87,"Wanted to hopefully start off with a question for Dan and just a follow-up on the operating margin discussion and some of the strength you saw in Q1 and the uptick in the guidance. Can you talk about AMS integration? And is AMS contributing already to operating margin? And how do you see the AMS contribution going through the year? And also as it flows down into the bottom line and the accretion levels you guys had guided to historically, are you still on track there?"
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, I think the short answer to that, Josh, is that we are right on track. So we had talked about $0.03 accretion in the year from AMS. We're on track to achieve that. And then next year, we had talked about $0.07 and we should be on track for that. And",113,"Yes, I think the short answer to that, Josh, is that we are right on track. So we had talked about $0.03 accretion in the year from AMS. We're on track to achieve that. And then next year, we had talked about $0.07 and we should be on track for that. And the difference is really some of the integration costs that we have this year, with respect to the quality remediation and some of the things like IT and such that are pushing that down a bit this year. And next year, you should see kind of the full power of what AMS can bring to the margin story for the company."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. Great. That's helpful. And then, Mike, I was hoping to just follow up on the CRM business. Clearly, you have some nice approvals over the last month and particularly this week with the MRI-safe product gap on the low-voltage side, and you initiated",111,"Okay. Great. That's helpful. And then, Mike, I was hoping to just follow up on the CRM business. Clearly, you have some nice approvals over the last month and particularly this week with the MRI-safe product gap on the low-voltage side, and you initiated your MRI-safe trial for high voltage. I just wanted to get your level of confidence, your team's level of confidence in the time lines there. And maybe just help us think about the steps going forward in terms of the times of enrollment and the enrollment period and follow-up period just to help us think about the safety of that mid-'17 time line on the high-voltage side."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. We feel comfortable with it. I think we've been reasonably accurate on the forecast for some of these big product approvals with the quad and the MRI pacer. So we're looking at, call it, mid-'17, maybe to hedge that a bit, third quarter 2017 for app",52,"Sure. We feel comfortable with it. I think we've been reasonably accurate on the forecast for some of these big product approvals with the quad and the MRI pacer. So we're looking at, call it, mid-'17, maybe to hedge that a bit, third quarter 2017 for approval of our tachy MRI product."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","Our next question comes down the line of Matt Miksic, UBS.",11,"Our next question comes down the line of Matt Miksic, UBS."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","So a couple, if I could. One on WATCHMAN, just a follow-up on some of the questions that have already been asked, but what we hear, I guess for centers, obviously, the NCD in place and differentiated device, and I think everyone's excited to see how this",139,"So a couple, if I could. One on WATCHMAN, just a follow-up on some of the questions that have already been asked, but what we hear, I guess for centers, obviously, the NCD in place and differentiated device, and I think everyone's excited to see how this rolls out. But there is some question, I guess, about how profitable this is to some of these centers. For some, it does seem to be a little bit on the tight side, pricing net of reimbursement but, at the same time, it doesn't seem to be, from what we could tell, a significant impediment to interest or early adoption. So any thoughts on how you see that playing out over time or regionally playing out as it begins to pick up steam here? And then I have one follow-up for Dan."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. So on the NCD, it was a nice win for us, and we believe we really have the right sweet spot in terms of the WATCHMAN pricing. It is financially viable at most of the heart centers that we have contracted with. So we stay very close to that, and it's",119,"Sure. So on the NCD, it was a nice win for us, and we believe we really have the right sweet spot in terms of the WATCHMAN pricing. It is financially viable at most of the heart centers that we have contracted with. So we stay very close to that, and it's really part of our category leadership strategy. So we want to price it at the appropriate level, given the investment that we've made in the platform as well as future clinical trials that we're supporting as we advance this new therapy. But we do believe it's financially viable and a healthy product with appropriate margins for the vast majority of our hospitals that are using this today."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay, that's helpful color. And on Dan -- for Dan on some of the work that you're doing to drive manufacturing efficiencies and working capital efficiencies, net operating asset turnover here, obviously, a key driver for ROIC, and you do have an opportuni",124,"Okay, that's helpful color. And on Dan -- for Dan on some of the work that you're doing to drive manufacturing efficiencies and working capital efficiencies, net operating asset turnover here, obviously, a key driver for ROIC, and you do have an opportunity there. From what we can tell, it's obviously a focus. Wondering if you could sketch out how we should see that begin to play out because understanding your manufacturing rationalization or the efforts you have underway, it may not be apparent from the numbers, sort of on a turnover basis, the improvements that you're been making, but would love to get a sense of when that will start to become apparent and maybe start having additional impact on returns on capital."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. I think you'd -- I'd like to believe you'll see some of that impact this year. So we have a significant emphasis on reducing inventory, and I mentioned that in some of my prepared remarks and trying to prove that from our perspective, we can grow sa",175,"Sure. I think you'd -- I'd like to believe you'll see some of that impact this year. So we have a significant emphasis on reducing inventory, and I mentioned that in some of my prepared remarks and trying to prove that from our perspective, we can grow sales at the rate that we're doing but also optimize inventory. And we have a lot of work ongoing to try and do some things to rationalize that. And from a cash flow as well as the other metrics that you mentioned, reduce inventory overall by the end of the year as a company. So my goal would be that as we go through the year, you'd see that. It was pretty reasonable compared to Q4 of last year -- inventory this year -- and so we've kind of stemmed the tide of it now and I'd look to, for the last 3 quarters, to see that reduce, which will help all the turnover and asset metrics as well as the contribution of working capital to cash flow."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","All right. With that, we'd like to conclude the call. Thank you for joining us today. We appreciate your interest. And before you disconnect, Roxanne will give all the pertinent details for the replay. Thank you.",36,"All right. With that, we'd like to conclude the call. Thank you for joining us today. We appreciate your interest. And before you disconnect, Roxanne will give all the pertinent details for the replay. Thank you."
317627,329821425,964798,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","And ladies and gentlemen, this conference will be made available for replay after 10:30 a.m. today running through May 11, 2016, at midnight. You may access the AT&T executive playback service at any time by dialing (800) 475-6701 and entering the access",80,"And ladies and gentlemen, this conference will be made available for replay after 10:30 a.m. today running through May 11, 2016, at midnight. You may access the AT&T executive playback service at any time by dialing (800) 475-6701 and entering the access code of 390210. International participants may dial 1 (320) 365-3844. And again the code is 390210. That concludes our conference for today. Thank you for your participation and for using AT&T Executive TeleConference service. You may now disconnect."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2016 Boston Scientific Earnings Call. [Operator Instructions] And as a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Susie Lisa",46,"Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2016 Boston Scientific Earnings Call. [Operator Instructions] And as a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Susie Lisa. Please go ahead."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Roxanne. Good morning, everyone, and thanks for joining us. With me on today's call are Mike Mahoney, President and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.We issued a press release earli",366,"Thank you, Roxanne. Good morning, everyone, and thanks for joining us. With me on today's call are Mike Mahoney, President and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.
We issued a press release earlier this morning announcing our Q1 2016 results, which included reconciliations of the non-GAAP measures used in the release.
We have posted a copy of that release as well as reconciliations of the non-GAAP measures used in today's call to the Investor Relations section of our website under the heading, Financial Information.
The duration of this morning's call will be approximately 1 hour. Mike will provide strategic and revenue highlights of Q1 '16. Dan will review the financials for the quarter and then Q2 '16 and full year 2016 guidance, and then we'll take your questions. During today's Q&A session, Mike and Dan will be joined by our Chief Medical Officers, Dr. Keith Dawkins and Dr. Ken Stein. 
Before we begin, I'd like to remind everyone that on the call, organic revenue growth is defined as excluding the impact of sales from divested businesses, changes in foreign currency exchange rates and sales from the acquisition of the American Medical Systems male urology portfolio over the prior year period. Also of note, this call contains forward-looking statements within the meaning of Federal securities laws, which may be identified by words like anticipate, expect, believe, estimate and other similar words.
They include, among other things, statements about our growth and market share; new product approvals and launches; clinical trials; cost savings and growth opportunities; our cash flow and expected use; our financial performance, including sales, margins, earnings and other Q1 2016 results and Q2 and full year 2016 guidance; as well as our tax rates, R&D spend and other expenses.
Actual results may differ materially from those discussed in the forward-looking statements.
Factors that may cause such differences include those described in the Risk Factors section of our most recent 10-K and subsequent 10-Qs filed with the SEC.
These statements speak only as of today's date, and we disclaim any intention or obligation to update them.
At this point, I'll turn it over to Mike for his comments. Mike?"
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Susie, and good morning, everyone. We continue to perform against our strategic plan goals, and we're encouraged by the consistent strong execution of our global team. The success of our new product launches across many of our businesses is hel",1637,"Thank you, Susie, and good morning, everyone. We continue to perform against our strategic plan goals, and we're encouraged by the consistent strong execution of our global team. The success of our new product launches across many of our businesses is helping us accelerate expansion into faster-growth markets and deliver solutions that address unmet clinical needs. 
We continue to believe that Boston Scientific is uniquely positioned to deliver differentiated shareholder value through durable mid-single-digit organic revenue growth and double-digit adjusted EPS growth through our ongoing operating margin improvement initiatives. We're very excited about the excellent start to 2016 and our plans to build upon our global momentum in 2017 and beyond. 
We posted excellent results this quarter with total operational revenue growth of 13% and organic revenue growth of 8%, excluding the impact of AMS acquisition benefit. Four of our 7 businesses grew revenue double-digits organically, and we, in turn, leveraged that revenue growth to drive 24% adjusted operating income growth, resulting in an adjusted operating margin of 25.1% and a 260 basis point improvement year-over-year. 
We delivered adjusted EPS of $0.28, exceeding the high end of guidance and representing 31% growth, including the negative impact from foreign currency. Importantly, we're increasing our 2016 guidance for revenue, adjusted operating margin and adjusted EPS. We're increasing our full year organic revenue growth guidance from 4% to 7% previously to 6% to 8%. Full year operational revenue, which includes the benefit of AMS, has been increased from 7% to 10%, to 9% to 11%. We're increasing our adjusted operating margin guidance to 24% to 24.5%, and we're also increasing our adjusted EPS guidance up $0.03 over our prior range to $1.06 to $1.10, which now represents 14% to 18% growth. And importantly, this EPS guidance includes an expected $0.05 to $0.06 negative impact from foreign exchange. 
I'll now provide some highlight on Q1 results and the 2016 outlook. And in my remarks, all references to growth are on a constant currency organic year-over-year basis, excluding the benefit of AMS, unless otherwise specified. 
Our Q1 revenue growth of 8% was broad based across our businesses and regions, led again by exciting new product launches, continued global expansion and execution of our category leadership strategy. With the exception of a 3% decline in our Cardiac Rhythm Management sales, all of our other businesses delivered strong organic growth, led by Endo at plus 11%, Urology and Pelvic Health of plus 12%, Interventional Cardiology at 13% and Peripheral Intervention at 14%. 
We also saw strong growth globally with Asia delivering 14%; U.S., 7%; and Europe, up 6%. Emerging market sales grew 21%, including China, sales at 19%. The MedSurg businesses all accelerated from Q4 of last year and delivered adjusted operating margin of 32.6%, up 360 basis points year-over-year. 
Endoscopy revenue grew 11%, driven by our single-use SpyGlass digital DS visualization system, the AXIOS Stent for drainage of pancreatic fluid and the limited launch of our next-generation hemostasis clip, the Resolution 360. We're also extending our category leadership in Endoscopy by developing commercial capabilities in the emerging markets, adding a focus in pulmonary, which helped drive 15% growth in bronchial thermoplasty as they recently launched in both Japan and China. Urology and pelvic health organic growth accelerated 12% and was broadly based with double-digit growth in kidney stone, and pelvic floor and surg/gyn. Our legacy business grew 15% internationally, led by 36% growth in the emerging markets. The AMS remediation and integration are on track, and we're delivering against our synergy commitments and the global teams are now fully integrated. 
As expected, stand-alone AMS sales declined slightly in the quarter, and we expect inventory to be appropriate levels in the second quarter. At LithoVue, an innovative single digital ureteroscope that provides customers with visualization and navigation capabilities, will be featured in multiple presentations next weekend at the American Urology Association meeting in San Diego. 
Neuromodulation revenue growth accelerated 8% in the first quarter, and sales were driven by the market-leading Spectra platform, the most flexible spinal cord stimulation system in the market; the launch of Precision Novi for the primary cell non-rechargeable market; and the solid contribution from our Vercise, our emerging Deep Brain Stimulation platform. 
Our U.S. DBS trial is making great progress, and we expect to launch in the U.S. in late 2017 or early 2018. In Cardiovascular, our segment sales grew 14% in the quarter and delivered adjusted operating margin of 34.1%, up over 350 basis points, both sequentially and year-over-year. 
Peripheral sales grew 14% in strong results in atherectomy, thrombectomy and our Innova bare metal and Eluvia drug-eluting stent platforms. The legacy Peripheral business continued its recent impressive trend as we grow share in the atherectomy market and see very strong demand for our new Zelante Deep Vein Thrombosis platform. 
The Eluvia IDE trial called IMPERIAL is on track to complete enrollment by late 2016 or early '17, and we look forward to presenting 24-month data from our initial trial of MAJESTIC -- which had a 12-month patency rate of 96.1% -- later this year. We're also seeing continued progress for our Lutonix distribution agreement and encouraging EU sales of our Ranger Drug-Coated Balloon. We're excited to be the only company developing leading drug-eluting technologies globally on multiple platforms, providing physicians with a variety of tools for treating complex peripheral vascular disease. 
Interventional Cardiology turned another double-digit quarter, a 13% growth, led by complex coronary drug-eluting stents, PCI guidance and structural heart. SYNERGY had a very strong quarter, and we estimate that we add it to our market-leading share position in the U.S. and regain market leadership position in Japan. 
DES sales grew 14% in the quarter, and we believe SYNERGY is on track to represent approximately 50% of our U.S. DES revenue mix by the end of the year '16. 
PCI guidance again grew double digits on continued share gains on intravascular ultrasound, and we're encouraged by strong feedback on the ease-of-use of our Comet Fractional Flow Reserve platform. Our leading portfolio of solutions for complex high-risk PCI patients continues to drive global growth as well. 
The 13% IC revenue growth was also fueled by our strengthening structural heart business, which includes our Lotus transcatheter aortic valve and WATCHMAN Left Atrial Appendage Closure device. We believe we are uniquely positioned to drive long-term growth in these 2 fast-growing markets via our differentiated platforms. 
Our Lotus valve continues to gain share in Europe, and we are investing significantly to further develop our capabilities. Most recently, best-in-class paravalvular leakage rates were reported for Lotus at ACC last month with predischarge rates of 0.4% for moderate paravalvular regurgitation in the first 750 patients of the RESPOND Post-Market Study. 
We also continue to plan for the U.S. launch with the Lotus EDGE delivery system at the end of 2017, and we also completed enrollment in our REPRISE Japan trial, where we target a 2018 launch. 
Importantly the Lotus EDGE features a 14 French compatible sheath, more flexibility, simplified deployment and our new depth guard technology, which controls depth of the valve in the left ventricular outflow tract. Studies to demonstrate an improved permanent pacemaker rate with this optimized technique will begin enrollment in mid-2016. 
Also at structural heart, WATCHMAN sales were strong on procedure growth and new account openings, both helped by the finalized national coverage determination. We're developing additional WATCHMAN capabilities, primarily by adding resources in field clinical support, market development and training courses. Implant success rates and patient outcomes remain very high quality due to our controlled rollout and proven training programs. 
In the ACC earlier this month, Dr. David Holmes of the Mayo Clinic presented data from the first 1,600 patients implanted with a WATCHMAN commercially and revealed 96% procedural success at an average procedure time of 15 minutes. So overall, we are very pleased with our progress in our 2016 revenue guidance of $175 million to $200 million in Structural Heart revenue. 
Rhythm Management segment sales declined 2% in the quarter yet delivered adjusted operating margin of 16.8%, which is up 290 basis points sequentially as improving profitability remains a core focus. In CRM, as anticipated, sales declined 3% as we faced competitive launches in the U.S. and replacement cycle headwinds. We're optimistic for a second quarter and second half 2016 improvement in our CRM performance. 
Also, as projected, we received 2 key FDA approvals in March for our ACUITY X4 quad CRT lead, and earlier this week for our ACCOLADE Brady MRI platforms, including the INGEVITY MRI patient lead. Pacemaker sales grew 3% globally, aided by a recently launched X4 CRT-P quad device while worldwide ICD sales declined 4%. 
We continue to be very pleased with the performance of the EMBLEM S-ICD, which is enjoying strong growth in both Europe and the U.S. and is currently launching in Japan. In Electrophysiology, we're encouraged by double-digit growth in Europe, led by our arrhythmia installations and the recent launches of the IntellaMap OI and IntellaTip MiFi OI ablation catheters. In the U.S., we're now launching our Blazer Open-Irrigated Therapeutic Catheter for the treatment of Type 1 atrial flutter as we continue to invest in the franchise, launch a portfolio of navigation-enabled therapeutic catheters and build capabilities in capital equipment sales and service. 
We have a strong arrhythmia customer pipeline as many of our new platform enhancements scheduled for release in 2016. So to wrap up, our company had an excellent quarter. First quarter results reflect the strength of our portfolio, our ongoing investment in faster-growth markets and our globalization efforts. More importantly, we are well positioned to continue our strong performance in 2016 and beyond. I want to thank our employees for their continued winning spirit and their commitment to the company. 
Now let me turn the call over to Dan for a more detailed review of our financials."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Mike. In Q1, we generated organic revenue growth of 8% versus our 4% to 6% guidance range and adjusted EPS of $0.28, exceeding our guidance range of $0.23 to $0.25 and representing 31% year-over-year growth. Adjusted EPS of $0.28 includes a slig",1941,"Thanks, Mike. In Q1, we generated organic revenue growth of 8% versus our 4% to 6% guidance range and adjusted EPS of $0.28, exceeding our guidance range of $0.23 to $0.25 and representing 31% year-over-year growth. 
Adjusted EPS of $0.28 includes a slightly lower-than-expected tax rate for the quarter due to some discrete tax items. The strong performance in Q1 was driven primarily by revenue growth upside, gross margin expansion and a lower SG&A rate versus the prior year. 
And as Mike mentioned, given the outperformance in Q1, we are raising full year guidance for revenue growth, adjusted operating margin and adjusted EPS. Consolidated revenue of $1,964,000,000 represented operational revenue growth of 13%, which excludes the impact of a $58 million headwind from foreign exchange. Excluding an approximate 500 basis point contribution from the AMS male urology portfolio acquisition, organic revenue growth was 8% in the quarter. 
On an as-reported basis, revenue grew 11% year-over-year. Adjusted gross margin for the first quarter was 72.3%, increasing 100 basis points year-over-year. The increase resulted primarily from cost improvements driven by our value improvement programs and favorable mix, partially offset by price. And similar to Q4 of 2015, the impact of foreign exchange on gross margin was negligible in the quarter. 
We continue to expect full year 2016 adjusted gross margin to be in the range of 72% to 73%, which we forecast to include approximately 50 basis points of unfavorable FX. Our Q1 2016 adjusted operating margin of 25.1% represents a 260 basis point improvement over Q1 2015, which marks the 7th consecutive quarter in which we've expanded adjusted operating margin by 100 basis points or more. 
There was very modest reinvestment of the medical device tax benefit in Q1, which represents some timing favorability in the quarter, but we are committed to reinvesting substantially all of the full year benefit during the year. Thus, adjusted SG&A expenses were $698 million or 35.5% of sales in the quarter, down 150 basis points year-over-year with some of the benefit due to our targeted initiatives focused on reducing SG&A and a portion due to the more modest medical device tax benefit reinvestment I just mentioned. 
Our Q1 adjusted SG&A rate was the lowest in the last 12 quarters, and we continue to believe our full year rate will be between 35.5% and 36.5%, which, at the midpoint, would be a 140 basis point reduction compared to 2015. 
Adjusted research and development expenses were $209 million in the first quarter or 10.7% of sales, which is roughly flat year-over-year. This is another key area for us to reinvest the benefit of the medical device tax suspension. As a result, we expect our full year 2016 adjusted R&D rate to be between 11% and 12% of sales. 
Royalty expense was 1% of sales in both Q1 of this year and last year and consistent with our guidance. On an adjusted basis, operating income was $494 million in the quarter or 25.1% of sales, up 260 basis points year-over-year. 
Q1 adjusted operating income grew 24% year-over-year, with all 3 reportable segments expanding adjusted operating margin by at least 250 basis points over Q1 of last year. Of particular focus is Rhythm Management, which delivered an adjusted operating margin of 16.8%, which is up from Q4 2015's 13.9% and the full year 2015 rate of 15%. 
For the first half of 2016, we expect Rhythm Management adjusted operating margin to be slightly above 16%. In the second half of 2016, we expect Rhythm Management adjusted operating margin to increase roughly 200 basis points over the first half rate. This second half improvement is expected to result from realizing the full benefit of 2016 product costs, leveraging the improved top line performance expected of the global CRM and EP businesses and realizing the full benefits of our Plant Network Optimization program, which is transferring a portion of our EP manufacturing to lower-cost locations. We continue to believe Rhythm Management is on track to deliver an adjusted operating margin of 20% in 2017. 
GAAP operating income, which includes GAAP to adjusted items of $201 million, was $293 million in Q1 2016. The primary GAAP to adjusted items for the quarter included amortization expense of $136 million, restructuring and related charges of $13 million, acquisition-related SG&A expenses of $14 million and litigation-related charges of $10 million. Our total legal reserve was $1,895,000,000 as of March 31, 2016. 
Now I'll move on to other income and expense. Interest expense for the quarter was $59 million compared to $56 million in Q1 last year, and the increase was primarily due to the incremental debt raised in Q2 of last year to finance the AMS male urology portfolio acquisition. 
Our average interest rate was 4% in Q1 2016 compared to 5.1% in Q1 last year, and the lower interest expense rate in Q1 this year was primarily due to lower average cost of debt resulting from the senior notes refinancing, which we completed in Q2 last year. 
Other expense was $10 million, and this consisted primarily of foreign exchange losses and investment losses incurred during the quarter. 
Our tax rate for the quarter was 11.4% on a reported basis and 11.8% on an adjusted basis. Excluding discrete tax items in the quarter, our adjusted tax rate would have been 13.5%, and we continue to expect our full year 2016 adjusted tax rate to be approximately 14%. 
On a reported GAAP basis, Q1 2016 EPS was $0.15 and includes net charges and amortization expense totaling $176 million after tax. GAAP EPS of $0.15 compares to breakeven in Q1 of last year. 
Moving on to the balance sheet. DSO of 60 days increased 1 day compared to March of last year. Days inventory on hand of 162 days was down 4 days compared to March of last year and 1 day from year-end 2015. 
Capital expenditures were $59 million in the quarter compared to $46 million in Q1 2015. And as a reminder, we expect full year 2016 capital expenditures to be roughly $350 million. This is $100 million higher than the full year 2015, primarily due to the construction of our new manufacturing facility and distribution center in Malaysia. And beyond 2016, we expect capital expenditures to return to our more historical run rate of approximately $250 million annually. 
Adjusted free cash flow for the quarter was $250 million compared to $118 million in Q1 2015, and this strong start gives us confidence in our adjusted free cash flow target of $1.5 billion, which represents 10% growth and better visibility to our stretch goal of $1.6 billion, which would represent 17% growth, even in a year with an incremental $100 million in CapEx spend as I mentioned. 
We're also continuing to pursue inventory management initiatives designed to improve the working capital contribution to cash flow. In Q1, we used cash primarily to fund previously agreed legal settlements as well as business development activities. 
Consistent with our goal of returning to pre-AMS debt leverage by year-end 2016, we still expect to repay $250 million of bank term loans by the end of this year. As of March 31 this year, we had cash on hand of $338 million. 
Near term, our capital allocation priorities are to prepay debt, manage our contingencies and pursue tuck-in M&A. We ended the quarter with 1,370,000,000 fully diluted weighted average shares outstanding. Consistent with our prior guidance, we expect our share count to increase by roughly 5 million per quarter through the end of the year as we plan to keep the buybacks suspended for the balance of 2016. We would expect this to result in a fully diluted weighted average share count of approximately 1,380,000,000 for the full year 2016. 
I'd like to conclude with revenue and earnings per share guidance for Q2 and full year 2016. For the full year, we now expect consolidated revenue to be in the range of $8,075,000,000 to $8,225,000,000, which represents year-over-year growth of 6% to 8% on an organic basis; 9% to 11% on an operational basis, which includes the AMS revenue; and 8% to 10% on a reported basis. 
As a result of a stronger dollar, at current rates, we expect foreign exchange to be a headwind of approximately $100 million for the full year 2016. As we move through 2016, we are reinvesting the benefit of the medical device tax suspension into innovation to help treat patients and sustain top line growth over the long term. Focus areas will include R&D efforts, including clinical trial spend as well as market development, and in Q2, we've already begun to ramp this reinvestment, primarily in the areas of structural heart with both Lotus and WATCHMAN, and other durable long-term revenue growth platforms such as the EMBLEM S-ICD, our electrophysiology portfolio, deep brain stimulation and other fast-growing adjacent market. 
In addition, Q2 is our seasonally high SG&A spend quarter partially due to the highest trade show activity of the year. Thus, for Q2 2016, and consistent with prior years, we would expect a sequential decline in adjusted operating margin to a range of 23% to 24%, which, at the midpoint, represents 140 basis points of improvement year-over-year and puts first half 2016 adjusted operating margin at 200 basis points up versus the first half of last year. 
And for the full year 2016, we are raising our adjusted operating margin guidance from 23.5% to 24.5% to a range of 24% to 24.5% now, which also represents a 200 basis point year-over-year gain. This gain is from operational efficiencies and not the med device act, as we are reinvesting the benefits. 
Turning to adjusted EPS. We now expect full year adjusted EPS for 2016 to be in a range of $1.06 to $1.10, representing 14% to 18% adjusted earnings growth and an increase of $0.03 to each end of the range compared to our prior guidance. 
Now let me walk you through our updated assumptions for the FX impact on adjusted EPS. Our initial 2016 guidance assumed $0.02 of unfavorable FX on adjusted EPS in Q1 and $0.06 for the full year. 
In Q1, the combination of exchange rate movements and timing of hedging contracts resulted in an unfavorable impact of $0.01, and we now believe the full year 2016 unfavorable impact will be $0.05 to $0.06. 
In addition to the $0.01 in Q1, we would expect the remaining $0.04 to $0.05 of unfavorable FX for the full year to break down into $0.02 in Q2 and $0.02 to $0.03 in the second half of 2016. Excluding the unfavorable foreign exchange, our full year adjusted EPS guidance range represents growth of 19% to 24%. 
On a GAAP basis, we expect EPS to be in a range of $0.64 to $0.69. 
Now turning specifically to Q2 2016. We expect consolidated revenues to be in a range of $2,010,000,000 to $2,060,000,000. If current foreign exchange rates hold constant, the headwind from FX should be approximately $25 million or 135 basis points relative to Q2 of last year. 
We expect consolidated Q2 sales to grow year-over-year in a range of 6% to 8% organically and 11% to 13% operationally. For the second quarter, adjusted EPS is expected to be in a range of $0.25 to $0.27 per share, and GAAP EPS is expected to be in a range of $0.14 to $0.17 per share. 
Please check our Investor Relations website for Q1 2016 financial and operational highlights, which outlines Q1 results as well as Q2 and full year 2016 guidance, including P&L line item guidance. 
So with that, I'll turn it back to Susie, who will moderate the Q&A."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Dan. Roxanne, let's open it up to questions for the next 30 minutes or so. [Operator Instructions] Roxanne, please go ahead.",22,"Thanks, Dan. Roxanne, let's open it up to questions for the next 30 minutes or so. [Operator Instructions] Roxanne, please go ahead."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","[Operator Instructions] Our first question comes from the line of Bob Hopkins, Bank of America.",15,"[Operator Instructions] Our first question comes from the line of Bob Hopkins, Bank of America."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","So to start off, Mike, obviously, this was one of the best growth quarter you guys have had in a while and congratulations on the great start to the year. I was wondering if you could talk to us a little bit about just the broader macro environment and th",105,"So to start off, Mike, obviously, this was one of the best growth quarter you guys have had in a while and congratulations on the great start to the year. I was wondering if you could talk to us a little bit about just the broader macro environment and the health of the markets you're in and maybe just talk about the factors driving growth. And I would really appreciate if you could talk a little bit about uro and endo as well and some of the products that are driving growth in that division because, obviously, that's where you had some really nice outperformance."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. Thanks for the question. Overall, the market growth we see is consistent with what we mentioned in the past, kind of playing in 3% to 4% growth markets overall for Boston Scientific and similar to Investor Day presentation. We're investing into fast",347,"Sure. Thanks for the question. Overall, the market growth we see is consistent with what we mentioned in the past, kind of playing in 3% to 4% growth markets overall for Boston Scientific and similar to Investor Day presentation. We're investing into faster-growth markets that would basically accelerate the growth profile another 100, 200 basis points of the markets that we serve. So kind of similar growth rates in IC and cardiology and CRM, kind of in the low single-digit range and more in the 4% to 5% market growth rates for our MedSurg. But I guess, what we're most proud of is really across the board with the exception of CRM, we're growing -- and EP, we're growing significantly faster than our competition. And based on -- that's really driven by our product launches and really excellent global execution. Really pleased with the growth in Asia product; almost 15%, very strong growth in Japan, a very strong growth in Europe. So across our businesses, our regions, our teams are really delivering. In terms of your question on endo and urology, we are very thoughtful about the AMS acquisition, and we're seeing the benefits of the commercial synergies between those organizations, given the additional commercial footprint that we have as well as the broadness of the bag, and you're seeing that with really acceleration of our legacy Urology division, in part due to the synergies of our AMS business. We continue to invest in physician training for our Stone Institute, and we continue to benefit from the category leadership based on the premise of the AMS acquisition. In Endoscopy, it's a very innovative division, and we continue to lead innovation with our digital SpyGlass system, which is really a terrific platform for us that we can continue to build from, and that also helps drive pull-through of our core portfolio. So the R&D teams are executing, as well as the commercial teams, and we continue to be committed to our durable mid-single-digit revenue growth, our operating margin expansion and our double-digit EPS growth over the long term."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Great. And then a follow-up maybe for Dan. Dan, can you just help us? Was there any, in your view, selling day mismatch this quarter versus a year ago? And then on the operating margin performance in the quarter, it sounds like over the course of the rest",107,"Great. And then a follow-up maybe for Dan. Dan, can you just help us? Was there any, in your view, selling day mismatch this quarter versus a year ago? And then on the operating margin performance in the quarter, it sounds like over the course of the rest of the year, there's going to be some incremental spending because, obviously, you're guiding to a lower operating margin than you started out in Q1. So maybe just comment on the selling day year-over-year, and then also maybe quantify and describe some of the extra spending that you're going to be undertaking here in the remainder of the year."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, Bob. First quickly on the calendar. No, we don't believe there's an extra impact in Q1. There was obviously a Leap year day, but then when you factor in the timing of the Easter holiday, I believe it's a true 8% growth for the quarter organically. R",253,"Sure, Bob. First quickly on the calendar. No, we don't believe there's an extra impact in Q1. There was obviously a Leap year day, but then when you factor in the timing of the Easter holiday, I believe it's a true 8% growth for the quarter organically. Relative to operating margin, so I think the -- when you look at Q1 at the 25% and then you look at the 24.25%, which is the midpoint for the full year, one of the key changes there is that, as I mentioned in my prepared remarks, the reinvestment of the medical device tax benefit over the rest of the year. So a little delayed in Q1 getting off to that start but committed to reinvesting the entire amount for the rest of the year. So that's one. And I think the -- there's R&D timing as well in Q1 so our Q1 R&D was 10.7%. If you look at the guidance range, you'd see 11.5% at the midpoint. Part of that's the med device tax reinvestment and part of it's just the timing of overall R&D. So that's another 80 basis points there going from the 10.7% in Q1 to the overall average of 11.5% for the full year. So still -- I mean, as you look at the 24.25%, still significant growth versus last year, 190 basis points and feel good that we're striking a good balance between delivering differentiated adjusted operating margin and investing for a continually growing top line for the future."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","And our next question comes from the line of David Lewis with Morgan Stanley.",14,"And our next question comes from the line of David Lewis with Morgan Stanley."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Just a few quick questions. Mike, I guess, the issue, I think, for us this quarter is that we expected an inflection quarter sometime this year. Obviously, it's coming earlier. But I guess, as we think about the balance of the businesses, we actually thou",124,"Just a few quick questions. Mike, I guess, the issue, I think, for us this quarter is that we expected an inflection quarter sometime this year. Obviously, it's coming earlier. But I guess, as we think about the balance of the businesses, we actually thought there could be acceleration from whatever the growth rate was in the first quarter. And I wonder, can you point us to tailwinds/headwinds of the business throughout about of the year based on sort of this thought of acceleration throughout the year? And then specific attention perhaps within Cardiovascular. You talked about those businesses in terms of stents, WATCHMAN, Lotus. What's really driving that strength in Cardio? So acceleration and in particular Cardiovascular, then one quick one for Dan."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","That's a multi-point question. Thanks, Dave. Just overall, we are pleased with our performance for the quarter. We took the guidance up from 4% to 7% to 6% to 8% organically, not impacting AMS. And as I mentioned, the businesses and regions are performing",420,"That's a multi-point question. Thanks, Dave. Just overall, we are pleased with our performance for the quarter. We took the guidance up from 4% to 7% to 6% to 8% organically, not impacting AMS. And as I mentioned, the businesses and regions are performing at a nice level. As we look -- we obviously anticipate a solid second quarter, given our 6% to 8% guidance in second quarter -- we do face a couple of headwinds throughout the year. We do anniversary some key product launches in our Peripheral Vascular as well as our Endoscopy business. We do anticipate some Japan reimbursement cuts that we'll be working through. And we're very bullish on our WATCHMAN program, but we're also anniversary-ing the initial launch. So there are a few headwinds. But overall, we have an excellent product cadence. The business is performing well, and we feel comfortable with raising our guidance to 6% to 8%. On the cardiology side, we're seeing excellent -- our strategy play out. We continue to diversify our interventional cardiology portfolio. As we talked in the future, we really see in the future about 1/3 of our business coming from structural heart, about 1/3 from imaging and complex coronary and about 1/3 from drug-eluting stents. And across those kind of 3 slices of the pie, we're doing a nice job of delivering in the short term and investing for the long term. Our SYNERGY program is really going as planned. We're on track for SYNERGY to represent about 50% of our mix at an appropriate premium price, and physicians continue to see the benefit of the deliverability and the excellent 0 stent thrombosis at beyond the first 24 hours. So excellent clinical data there. Our complex coronary business continues to do well as does our imaging business. And in structural heart, as Dan mentioned, I'm actually over in Korea as we speak here, we just had a live case from Australia today and just the physician reaction to the deliverability and the low PVL rates of our Lotus Valve continues to be very high. And so we are really increasing our investment in that category, given the size of the market potential in the future and also given the differentiation that we believe that Lotus delivers and our commercial capability. So hopefully that gives you a bit of flavor. We're pleased with our raise on the guidance, and we'll manage our headwinds and continue to hopefully deliver revenue growth at the top tier of our sector."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Mike, that's great color. And Dan, I hate to bore you with a nit here, it was such a good quarter, but we're actually getting your constant currency growth rate this quarter as even higher than you reported. We have a $58 million FX headwind for a 3.3% he",72,"Mike, that's great color. And Dan, I hate to bore you with a nit here, it was such a good quarter, but we're actually getting your constant currency growth rate this quarter as even higher than you reported. We have a $58 million FX headwind for a 3.3% headwind versus 2%. Are we missing something here in the quarter or -- and we can take it off-line if it's -- if we're..."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","No, David, I think it's just a rounding of 3%. The way we see it is 3%. So it's just a little bit in the rounding of the numbers.",29,"No, David, I think it's just a rounding of 3%. The way we see it is 3%. So it's just a little bit in the rounding of the numbers."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","Our next question is from the line of Mike Weinstein, JPMorgan.",11,"Our next question is from the line of Mike Weinstein, JPMorgan."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","So when's the last time Boston Scientific grew 8% organic? Do you guys know the answer?",17,"So when's the last time Boston Scientific grew 8% organic? Do you guys know the answer?"
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","I bet you Dan knows.",5,"I bet you Dan knows."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","I'd say 10 years, Mike.",6,"I'd say 10 years, Mike."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","2Q 2005?",2,"2Q 2005?"
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","That's right.",3,"That's right."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","There you go. Do it again.",6,"There you go. Do it again."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","So what strikes me in particular is if I look at the U.S. performance and I back out CRM and I back out AMS, I'm getting to about 15% growth for the U.S. business in aggregate, which is obviously very, very strong. So I want to circle back first to Bob's",160,"So what strikes me in particular is if I look at the U.S. performance and I back out CRM and I back out AMS, I'm getting to about 15% growth for the U.S. business in aggregate, which is obviously very, very strong. So I want to circle back first to Bob's question just to make sure you don't think that there's anything kind of unusual going on in selling days, and I heard your answer there, but we are seeing this particular strength. And not just Boston Scientific, we've seen this in some other end markets over the course of the past week that have come in stronger. Anything that you think is going on that showed up this quarter in particular that is driving this real increase in volumes? And I'm speaking not just of your own performance, but do you have any theories on the broader market looking stronger this quarter than we've seen in a while?"
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, we don't see a big change in the market. From our peers that have reported, we were kind of seeing the kind of 1% to 4% growth rate with the exception of one, which was higher than ours. So we do feel like we're growing faster than most of our peers.",256,"Yes, we don't see a big change in the market. From our peers that have reported, we were kind of seeing the kind of 1% to 4% growth rate with the exception of one, which was higher than ours. So we do feel like we're growing faster than most of our peers. And I also think we're going through maybe a bit of a cycle of some good innovation and some mix benefit. That we clearly see a lot of enthusiasm, for example, for S-ICD despite our headwinds in the near term on MRI -- which we're pleased with the pacer approval -- we're getting nice mix benefit from S-ICD as well as global uptake of the S-ICD, particularly in Japan. And I think our strategy of category leadership, which we've really stressed for a number of years now, is starting to pay off; what made large systems in the U.S. willing and wanting to partner with Boston Scientific, given our current platform as well as the pipeline that we've committed to. So I think the markets are steady. We have a nice pipeline that's helping some of our mix benefit. And I think, importantly, we're really building up our capabilities outside the U.S. Our Asia business grew very well, and just this year, we've done a grand opening for our Malaysia plant. We have a new R&D center in India. We have new training centers. So our capabilities in Asia are significantly stronger than they used to be. So that's also helping strengthen our business."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Mike, if I look at the Interventional Cardiology business in the U.S., if I look at the peripheral vascular business in the U.S., I mean, both just had exceptional quarters. Interventional cardiology up 21%. Peripheral vascular up 13%. Can you -- would yo",71,"Mike, if I look at the Interventional Cardiology business in the U.S., if I look at the peripheral vascular business in the U.S., I mean, both just had exceptional quarters. Interventional cardiology up 21%. Peripheral vascular up 13%. Can you -- would you mind just peeling the onion a little bit and help us understand how those businesses are doing as well as they are? Because, obviously, that's well above expectations."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, I think it really speaks to category leadership. So we're -- 2 words that get used a lot in the industry, but I think we're delivering it. We have an excellent portfolio. Interventional cardiology, as I mentioned I'm in Korea here at this large confe",158,"Yes, I think it really speaks to category leadership. So we're -- 2 words that get used a lot in the industry, but I think we're delivering it. We have an excellent portfolio. Interventional cardiology, as I mentioned I'm in Korea here at this large conference, and we believe we have the best drug-eluting stent in the marketplace. We have an excellent imaging platform with IVUS, and we're launching FFR. We're the leaders in chronic total occlusion. We have the WATCHMAN product for interventional cardiologists who want to implant it and a very promising and differentiated TAVR valve. So I think our category leadership strategy is working in cardiology and similarly in peripheral vascular with our -- I won't go through all of them, but the Bayer acquisition really has exceeded the investment models that we've had in terms of synergies and growth. And our drug-eluting stent platforms with the stents and the balloon are doing quite well."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","And our next question is from Rick Wise, Stifel.",9,"And our next question is from Rick Wise, Stifel."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Let me turn to one area of weakness. Obviously, CRM, high power down 4%, Mike. Can you talk a little bit more about that? And specifically, you called out the replacement headwinds. You've been talking about replacement headwinds in CRM and high power for",110,"Let me turn to one area of weakness. Obviously, CRM, high power down 4%, Mike. Can you talk a little bit more about that? And specifically, you called out the replacement headwinds. You've been talking about replacement headwinds in CRM and high power for a while. My sense is from your comments in the past is that, that is going to shift more to neutral or even a tailwind at some point in the not-too-distant future. Can you give us any more concrete thoughts about what -- when that happens and the kind of drag it is now and how that could change as we look to '17 and beyond?"
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. Thanks for the question, Rick. Just regarding our CRM performance broadly, and I'll comment on the replacement headwind, it's really as we projected almost a year ago. We knew we were going to have some challenges in the U.S; our Asia business, our J",272,"Yes. Thanks for the question, Rick. Just regarding our CRM performance broadly, and I'll comment on the replacement headwind, it's really as we projected almost a year ago. We knew we were going to have some challenges in the U.S; our Asia business, our Japanese business and our European business in CRM are doing quite well and growing either at or above market. And the 2 launches will help us improve growth, we anticipate, in the second quarter and for the second half. So -- and also, the team continues to improve operating income margins despite a negative growth in the quarter, which is good to see. On the replacement headwinds, we don't have any additional breakdown of data that we're going to provide on this call, but I will say, and I think in the future, we'll consider providing some additional detail so we can quantify that. But similar to our last call, I do think we have brighter days ahead of us in CRM with a pacer MRI approval, with a quad approval. We've also initiated our MRI approval for our defib platform, which we see getting approval in mid-'17. So the portfolio is very strong. We'll have EMBLEM MRI likely approved in U.S. in third quarter. And so we do see the headwind of the replacement cycle improving at the end of 2016, which will help us in 2017. So with the product cadence and improved replacement cycle headwind, we see some brighter days for our CRM business. And in the future, we'll look at quantifying more precisely some of the benefit of that tailwind on the replacement cycle."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","And as a follow-up, maybe turning to WATCHMAN. Can you -- are you inclined to give us any kind of numbers for the quarter you're at -- you're on track for the next 100 accounts? Was there any stocking? Maybe any more granular detail about the progress you",56,"And as a follow-up, maybe turning to WATCHMAN. Can you -- are you inclined to give us any kind of numbers for the quarter you're at -- you're on track for the next 100 accounts? Was there any stocking? Maybe any more granular detail about the progress you're making and the impact of the NCD."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, WATCHMAN continues doing a nice job. Most importantly, we continue to believe in our $175 million to $200 million in structural heart revenue guidance. We're on track as planned to open up another 100 centers, and we again continually add very though",113,"Yes, WATCHMAN continues doing a nice job. Most importantly, we continue to believe in our $175 million to $200 million in structural heart revenue guidance. We're on track as planned to open up another 100 centers, and we again continually add very thoughtful training programs. The NCD is a very good outcome for us, and it really reassures and strengthens our view as to the potential size of the market. And we invest, as you mentioned, in clinical specialists. We're investing in physician training and really to build up the market the appropriate way. So we're kind of delivering as planned, and we're very pleased with the outcomes and enthusiasm of WATCHMAN globally."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","And Rick, I would probably just add one little bit of color on the replacement headwinds as well. It's kind of a Tale of Two Pieces within the franchise there. So as Mike said, as we head into the end of '16 and more likely '17, you'll see more of a tailw",89,"And Rick, I would probably just add one little bit of color on the replacement headwinds as well. It's kind of a Tale of Two Pieces within the franchise there. So as Mike said, as we head into the end of '16 and more likely '17, you'll see more of a tailwind on the CRTD side and then it's more of an ending '17 into '18 on the traditional transvenous ICD side. So it's a little bit of a bifurcation on that one, so a little bit extra color."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","And our next question comes from the line of Bruce Nudell, SunTrust.",12,"And our next question comes from the line of Bruce Nudell, SunTrust."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","This is actually Imron Zafar in for Bruce. I wanted to ask a couple of questions about the TAVR business. Can you just talk about where you think you are in Europe vis--vis market share and where you think you can go in the next, call it, couple of year",74,"This is actually Imron Zafar in for Bruce. I wanted to ask a couple of questions about the TAVR business. Can you just talk about where you think you are in Europe vis--vis market share and where you think you can go in the next, call it, couple of years in that geography? And then also if you could just give any commentary around this litigation with Edwards on transcatheter valves in the U.S."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. So on the Lotus program, as Dan outlined, we continue to invest a significant portion of our med device benefit; in our structural heart franchise. In terms of share, we don't break out our shares specifically in Europe. We are more limited than -- v",164,"Yes. So on the Lotus program, as Dan outlined, we continue to invest a significant portion of our med device benefit; in our structural heart franchise. In terms of share, we don't break out our shares specifically in Europe. We are more limited than -- versus some of our peers in terms of the number of countries we're selling into. So we're waiting to get reimbursements still for France. So that's a large market that will open up for us in the future. But we continue to grow above market in the markets that we're serving, particularly in Germany. And the physician feedback continues to be very strong on the low PVL rates, which we believe are best-in-class and really the control, and fully retrievable and reposition-able capabilities of the platform. So we continue to invest, and we're excited about the enhancements of our depth guard technology that I mentioned in the prepared comments. Keith, any additional comments you want to mention on Lotus?"
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. So we've got a pretty rich number of presentations: The EuroPCR next month on Lotus, late-breaking trial on 1,000 patients from the RESPOND study, bicuspid valve subgroup from the RESPOND study, subclavian approach from the RESPOND study, Lotus sympo",150,"Yes. So we've got a pretty rich number of presentations: The EuroPCR next month on Lotus, late-breaking trial on 1,000 patients from the RESPOND study, bicuspid valve subgroup from the RESPOND study, subclavian approach from the RESPOND study, Lotus symposium. And on the stent side, the EVOLVE [indiscernible] used 5 years data for the first time. And then obviously, as we said, at ACC, coincident with London Valves later this year. We're anticipating launching Lotus EDGE, which has a number of features including 14 French compatibility, more simple implantation procedure, more flexible device and the depth guard technology, which reduces the amount that the valve dips into the left ventricular outflow tract during deployment. So we have a lot going on with Lotus and then the additional sizes of 21 and 29 millimeter. And we've completed, as Mike said in his statement earlier, a REPRISE Japan study, which is important."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. And can you give just any color on the litigation with Edwards?",13,"Okay. And can you give just any color on the litigation with Edwards?"
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, yes, we're not going to comment on our pending legal matters.",12,"Yes, yes, we're not going to comment on our pending legal matters."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","Our next question is from the line of Vijay Kumar, Evercore.",11,"Our next question is from the line of Vijay Kumar, Evercore."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","So maybe the first question I had was maybe a housekeeping question on you mentioned sort of ICD declines and double-digit growth in stents. Was that in both geographies? When you say stents up double digits, was that double digits in both geographies, U.",67,"So maybe the first question I had was maybe a housekeeping question on you mentioned sort of ICD declines and double-digit growth in stents. Was that in both geographies? When you say stents up double digits, was that double digits in both geographies, U.S., OUS? And similarly, on ICDs, I'm just wondering whether declines was only in the U.S. or did you see declines in OUS?"
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Dan, do you want to comment on that one?",9,"Dan, do you want to comment on that one?"
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, Vijay, thanks for the question. We're not going to get too specific in terms of the growth rates by geography. Obviously, if you think of Japan, we had approval for SYNERGY early in the quarter. So we're off and running there. We're on offense there.",166,"Yes, Vijay, thanks for the question. We're not going to get too specific in terms of the growth rates by geography. Obviously, if you think of Japan, we had approval for SYNERGY early in the quarter. So we're off and running there. We're on offense there. We had SYNERGY in kind of the middle of the fourth quarter in the U.S. So strong growth there in stents. So -- and Europe has -- which has had SYNERGY for a long time is still doing very well. So no, I don't want to quote specific numbers for each of the regions there, and I think overall -- I think Mike's commentary around CRM was pretty detailed, that if you think of -- we're doing very well in Japan. We're doing well in Europe. And the CRM softness has been more of a U.S. product gap issue and we've hopefully solved a couple of those product gaps with the recent quad approval and with the MRI-safe Brady approval."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Understood. And I just had one follow-up, Dan. When you think about the longer-term operating model rate, I know you guys have laid out the 25% margin targets for '17. Can you just talk about the leverage and your confidence in bending that SG&A sort of l",77,"Understood. And I just had one follow-up, Dan. When you think about the longer-term operating model rate, I know you guys have laid out the 25% margin targets for '17. Can you just talk about the leverage and your confidence in bending that SG&A sort of line? Because it feels like, just looking at the trends, the 25% might be a -- there's upside to that 25% number for '17 and then any comments on beyond 2017?"
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. We've stated publicly before that by 2020, we believe we'd be at 27% to 28% operating margin -- just operating margin as a company and the 25.1% is a great start to the year. But as I mentioned, the average for the year should be between 24% and 24.",151,"Sure. We've stated publicly before that by 2020, we believe we'd be at 27% to 28% operating margin -- just operating margin as a company and the 25.1% is a great start to the year. But as I mentioned, the average for the year should be between 24% and 24.5%, and as always, we seek to strike that balance between delivering the adjusted operating margin and ensuring that durable consistent revenue growth for the long term. And if you look at our numbers this year, if you look at 6% to 8% organic revenue growth, 190 basis points of adjusted operating margin expansion at the midpoint of the range and adjusted EPS growth of 14% at the low and 18% at the high end, I think we're effectively achieving that objective. And as you look at '17 and beyond, we look to continue to deliver high performance, and that's the goal."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","Our next question is from the line of Josh Jennings, Cowen and Company.",13,"Our next question is from the line of Josh Jennings, Cowen and Company."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Wanted to hopefully start off with a question for Dan and just a follow-up on the operating margin discussion and some of the strength you saw in Q1 and the uptick in the guidance. Can you talk about AMS integration? And is AMS contributing already to ope",87,"Wanted to hopefully start off with a question for Dan and just a follow-up on the operating margin discussion and some of the strength you saw in Q1 and the uptick in the guidance. Can you talk about AMS integration? And is AMS contributing already to operating margin? And how do you see the AMS contribution going through the year? And also as it flows down into the bottom line and the accretion levels you guys had guided to historically, are you still on track there?"
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, I think the short answer to that, Josh, is that we are right on track. So we had talked about $0.03 accretion in the year from AMS. We're on track to achieve that. And then next year, we had talked about $0.07 and we should be on track for that. And",113,"Yes, I think the short answer to that, Josh, is that we are right on track. So we had talked about $0.03 accretion in the year from AMS. We're on track to achieve that. And then next year, we had talked about $0.07 and we should be on track for that. And the difference is really some of the integration costs that we have this year, with respect to the quality remediation and some of the things like IT and such that are pushing that down a bit this year. And next year, you should see kind of the full power of what AMS can bring to the margin story for the company."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. Great. That's helpful. And then, Mike, I was hoping to just follow up on the CRM business. Clearly, you have some nice approvals over the last month and particularly this week with the MRI-safe product gap on the low-voltage side, and you initiated",111,"Okay. Great. That's helpful. And then, Mike, I was hoping to just follow up on the CRM business. Clearly, you have some nice approvals over the last month and particularly this week with the MRI-safe product gap on the low-voltage side, and you initiated your MRI-safe trial for high voltage. I just wanted to get your level of confidence, your team's level of confidence in the time lines there. And maybe just help us think about the steps going forward in terms of the times of enrollment and the enrollment period and follow-up period just to help us think about the safety of that mid-'17 time line on the high-voltage side."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. We feel comfortable with it. I think we've been reasonably accurate on the forecast for some of these big product approvals with the quad and the MRI pacer. So we're looking at, call it, mid-'17, maybe to hedge that a bit, third quarter 2017 for app",52,"Sure. We feel comfortable with it. I think we've been reasonably accurate on the forecast for some of these big product approvals with the quad and the MRI pacer. So we're looking at, call it, mid-'17, maybe to hedge that a bit, third quarter 2017 for approval of our tachy MRI product."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","Our next question comes down the line of Matt Miksic, UBS.",11,"Our next question comes down the line of Matt Miksic, UBS."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","So a couple, if I could. One on WATCHMAN, just a follow-up on some of the questions that have already been asked, but what we hear, I guess for centers, obviously, the NCD in place and differentiated device, and I think everyone's excited to see how this",139,"So a couple, if I could. One on WATCHMAN, just a follow-up on some of the questions that have already been asked, but what we hear, I guess for centers, obviously, the NCD in place and differentiated device, and I think everyone's excited to see how this rolls out. But there is some question, I guess, about how profitable this is to some of these centers. For some, it does seem to be a little bit on the tight side, pricing net of reimbursement but, at the same time, it doesn't seem to be, from what we could tell, a significant impediment to interest or early adoption. So any thoughts on how you see that playing out over time or regionally playing out as it begins to pick up steam here? And then I have one follow-up for Dan."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. So on the NCD, it was a nice win for us, and we believe we really have the right sweet spot in terms of the WATCHMAN pricing. It is financially viable at most of the heart centers that we have contracted with. So we stay very close to that, and it's",119,"Sure. So on the NCD, it was a nice win for us, and we believe we really have the right sweet spot in terms of the WATCHMAN pricing. It is financially viable at most of the heart centers that we have contracted with. So we stay very close to that, and it's really part of our category leadership strategy. So we want to price it at the appropriate level, given the investment that we've made in the platform as well as future clinical trials that we're supporting as we advance this new therapy. But we do believe it's financially viable and a healthy product with appropriate margins for the vast majority of our hospitals that are using this today."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay, that's helpful color. And on Dan -- for Dan on some of the work that you're doing to drive manufacturing efficiencies and working capital efficiencies, net operating asset turnover here, obviously, a key driver for ROIC, and you do have an opportuni",124,"Okay, that's helpful color. And on Dan -- for Dan on some of the work that you're doing to drive manufacturing efficiencies and working capital efficiencies, net operating asset turnover here, obviously, a key driver for ROIC, and you do have an opportunity there. From what we can tell, it's obviously a focus. Wondering if you could sketch out how we should see that begin to play out because understanding your manufacturing rationalization or the efforts you have underway, it may not be apparent from the numbers, sort of on a turnover basis, the improvements that you're been making, but would love to get a sense of when that will start to become apparent and maybe start having additional impact on returns on capital."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. I think you'd -- I'd like to believe you'll see some of that impact this year. So we have a significant emphasis on reducing inventory, and I mentioned that in some of my prepared remarks and trying to prove that from our perspective, we can grow sa",175,"Sure. I think you'd -- I'd like to believe you'll see some of that impact this year. So we have a significant emphasis on reducing inventory, and I mentioned that in some of my prepared remarks and trying to prove that from our perspective, we can grow sales at the rate that we're doing but also optimize inventory. And we have a lot of work ongoing to try and do some things to rationalize that. And from a cash flow as well as the other metrics that you mentioned, reduce inventory overall by the end of the year as a company. So my goal would be that as we go through the year, you'd see that. It was pretty reasonable compared to Q4 of last year -- inventory this year -- and so we've kind of stemmed the tide of it now and I'd look to, for the last 3 quarters, to see that reduce, which will help all the turnover and asset metrics as well as the contribution of working capital to cash flow."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Executives","All right. With that, we'd like to conclude the call. Thank you for joining us today. We appreciate your interest. And before you disconnect, Roxanne will give all the pertinent details for the replay. Thank you.",36,"All right. With that, we'd like to conclude the call. Thank you for joining us today. We appreciate your interest. And before you disconnect, Roxanne will give all the pertinent details for the replay. Thank you."
317627,329821425,966462,"Boston Scientific Corporation, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Boston Scientific Corporation","Operator","And ladies and gentlemen, this conference will be made available for replay after 10:30 a.m. today running through May 11, 2016, at midnight. You may access the AT&T executive playback service at any time by dialing (800) 475-6701 and entering the access",80,"And ladies and gentlemen, this conference will be made available for replay after 10:30 a.m. today running through May 11, 2016, at midnight. You may access the AT&T executive playback service at any time by dialing (800) 475-6701 and entering the access code of 390210. International participants may dial 1 (320) 365-3844. And again the code is 390210. That concludes our conference for today. Thank you for your participation and for using AT&T Executive TeleConference service. You may now disconnect."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Second Quarter 2016 Boston Scientific Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.I would now like to turn the conference over to your",46,"Ladies and gentlemen, thank you for standing by. Welcome to the Second Quarter 2016 Boston Scientific Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
I would now like to turn the conference over to your host, Susie Lisa. Please go ahead."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you very much good morning, everyone, and thanks for joining us. With me on today's call are Mike Mahoney, Chairman and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.We issued a press release earlie",364,"Thank you very much good morning, everyone, and thanks for joining us. With me on today's call are Mike Mahoney, Chairman and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.
We issued a press release earlier this morning announcing our Q2 2016 results, which included reconciliations of the non-GAAP measures used in the release, and we have posted a copy of that release as well as reconciliations of the non-GAAP measures used in today's call to the Investor Relations section of our website under the heading Financial Information.  The duration of the morning's call will be approximately 1 hour. Mike will provide strategic and revenue highlights of Q2 of '16, Dan will review the financials for the quarter and then Q3 '16 and full year 2016 guidance, and then we'll take your questions.  During today's Q&A session, Mike and Dan will be joined by our Chief Medical Officers, Dr. Keith Dawkins and Dr. Ken Stein.
Before we begin, I'd like to remind everyone that on the call, organic revenue growth is defined as excluding the impact of changes in foreign currency exchange rates and sales from the acquisition of the American Medical System, AMS, male urology portfolio over the prior-year period. Also note this call contains forward-looking statements within the meaning of federal securities laws, which may be identified by words like anticipate, expect, believe, estimate and other similar words.  They include among other things statements about our growth and market share; new product approvals and launches; clinical trials; cost savings and growth opportunities; our cash flow and expected use; our financial performance, including sales, margins, earnings and other Q2 2016 results and Q3 and full year 2016 guidance; as well as our tax rates, R&D spend and other expenses.
Actual results may differ materially from those discussed in the forward-looking statements. Factors that may cause such differences include those described in the Risk Factors section of our most recent 10-K and subsequent 10-Qs filed with the SEC.  These statements speak only as of today's date, and we disclaim any intention or obligation to update them. 
At this point, I'll turn it over to Mike for his comments. Mike?"
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Susie, and good morning, everyone. We continue to beat our long-range strategic plan goals and execute very well as a global team. The success of our category leadership strategy is helping us gain share in our core markets, expanding the faste",2090,"Thank you, Susie, and good morning, everyone. We continue to beat our long-range strategic plan goals and execute very well as a global team. The success of our category leadership strategy is helping us gain share in our core markets, expanding the faster growth adjacencies and deliver solutions that address unmet clinical needs.  Our consistent results continue to demonstrate that Boston Scientific is uniquely positioned to deliver differentiated long-term shareholder value. With long term visibility to mid-single digit organic revenue growth, complemented by ongoing operating margin improvement initiatives, our goal is to consistently drive double-digit adjusted EPS growth.
We're very excited about our excellent second quarter performance, first half results and most importantly, our plans for the future.  In Q2, we drove total operational revenue growth of 16% and organic revenue growth of 10%, excluding the impact of the AMS Urology acquisition. We had strong results across all regions, and 5 of our sovereign business units grew revenue double digits organically. We leverage the revenue growth to drive adjusted operating income growth of 22%, resulting in an adjusted operating margin of 23.4% and 130 basis point improvement year-over-year.
We delivered adjusted EPS of $0.27, achieving the high end of guidance and representing 25% growth, including the negative $0.015 [ph] impact from or foreign currency. So given our strong performance we're increasing our 2016 guidance for revenue and adjusted EPS. We're are increasing our full year organic revenue growth guidance from 6% to 8% to 8% to 9% full year operational revenue growth guidance, which includes the benefit of AMS, is increased from 9% to 11% to 11% to 12%. We're maintaining our full year adjusted operating margin guidance of 24% to 24.5%, which is the midpoint is roughly 200 basis points of improvement over 2015. We're also increasing our adjusted EPS guidance by $0.01 over our prior range to $1.07 to $1.11, which represents 15% and [ph] 19% growth. Importantly, this adjusted EPS guidance includes an expected $0.05 negative impact from foreign exchange.
I'll now provide some highlight on Q2 results and our 2016 outlook. And Mars, all references to growth are in a constant currency organic year-over-year basis, and they exclude the benefit of AMS. Our second quarter revenue growth of 10% was broad based across businesses and regions, led again by exciting new product launches, continued global expansion and execution of our category leadership strategy. We drove double-digit growth in 5 businesses: endo, urology public-health, Neuromodulation, Interventional Cardiology and Peripheral Interventions. In addition, each region accelerated sequentially. The U.S. grew 8%; Europe, grew 9%; Asia PAC delivered 16% growth, with every major country in the Asia Pac region up double digits this quarter.  The emerging markets also continued to deliver sales grew [ph] 20%, including China revenue act of 21%. 
Our MedSurg businesses, endo, Urology public health and Neuromodulation continue to be a priority focus area for the company, and each of the businesses maintained or accelerated growth from first quarter. These 3 businesses represent 40% of our operating income in the second quarter and they delivered adjusted operating margin of 32.8%. This is up 20 basis points sequentially and 240 basis points year-over-year.  Our global Endoscopy team continues to perform at a high level with the revenue growing 11% in the second quarter. We continue to see strong growth in our core endo business, supported by our innovative portfolio and broad-based global expansion initiatives. Key endo growth drivers include the single-use SpyGlass, DS visualization system, the Axia stent for drainage of pancreatic fluid and our next-generation hemostasis clip, the Resolution 360. High single-digit growth in U.S. endo was complemented by double-digit growth in every region outside the U.S. As we continue to develop commercial and position-training abilities in emerging markets and add focus in pulmonary, which helped drive 25% growth in BT, bronchial thermoplasty, led by the U.S., Japan and China. 
In Urology and public health, our investments to become the clear market leader and category leader have been rewarded, as growth excluding AMS accelerated to 18%. The business is performing at a high-level across the various regions in segment, including kidney stone, BPH, ED and surg. Our global commercial footprint and focus on physician education has helped us to convert a meaningful portion of the market opportunity, created by a store's exit from the market at the end of March. 
AMS sales strength in the quarter and importantly, remediation and integration efforts remain on track. An exciting new growth platform in our urology business is the launch of a LithoVue platform. LithoVue is an innovative single-use digital scope for treatment of kidney stones that provide customers with enhanced visualization and navigation capabilities. LithoVue resonates with physicians and hospitals to the less OR downtime for sterile processing of reusable scopes. Performance navigation characteristics that allows physicians to tackle tougher procedures and the ability to schedule full-day procedures without the fear of cancellation due to reusable scopes being down.
In Neuromodulation, we continue to invest in the fast-growing microelectronics market, where we enjoy innovation and supply chain leverage between our CRM and neuromod business. Neuromodulation revenues and grew in the quarter to 12% -- grew 12%. Sales were driven by the U.S. market-leading Spectra platform, the launch of precision montage which offers full body MRI capability; and our PRECISE brain stimulation platform.  Our U.S. DBS trial continues to progress, and we expect to launch in the U.S. in first quarter 2018. Additionally, earlier this week, we announced the acquisition of Cosman Medical, a technology leader in the field of radiofrequency ablation systems for the treatment of chronic pain. This acquisition broadens our neuromodulation portfolio and is highly synergistic with our U.S. commercial team. We're excited to offer physicians treating patients with chronic pain, another non-opioid therapeutic option earlier in the treatment  continuum.
Now turning to Cardiovascular, which includes our peripheral and Interventional Cardiology businesses. Overall, this segment grew sales 13% in the quarter and delivered adjusted operating margin of 32.2%, up more than 170 basis points year-over-year.  Our peripheral business delivered exceptional results with strong global sales across all regions, fueled by an innovative portfolio. Sales grew 14% on strong results across all regions and segments, including stents, thrombectomy and our emerging drug-eluting portfolio. We also delivered strong growth in Interventional Oncology, with the integration of Interventional Radiology business of Solmolva remains on track. In our Venus segment, we continue to see very strong demand for our Zante, deep vein thrombosis system. With leading drug-eluting technologies globally on multiple platforms, noted to treat complex, peripheral vascular disease. The Eluvia peripheral drug stent ID trial called IMPERIAL is on track to complete enrollment by yearend  2016. 
In Interventional Cardiology, we are focused on getting share in our core businesses and while expanding in faster growth segments that leverage our capabilities. This strategy is working. In the second quarter interventional cardiology grew 12% led by structural heart, drug-eluting stent and PCI guidance. Synergy had an excellent quarter as we grew DES sales 9%. Synergy is now the market-leading premium DS platform and it's on track to represent 50% to 60% of our U.S. DES revenue mix by the end of 2016.  PCI guidance grew mid-teens and continued share gains in intravascular ultrasound, and we're encouraged by strong early feedback on the ease-of-use of our Comma and fractional flow reserve system. Our leading portfolio of solutions for complex high-risk PCI patients also contributed to global growth.
The 12% IT revenue growth was fueled by our strength in structural heart business, which includes our LOTUS transcatheter aortic valve and WATCHMAN Left Atrial Appendage Closure. We believe we are well-positioned to drive long-term growth in these 2 fast-growing markets via our differentiated platforms and expanded capabilities.  We also aim to deliver the high-end of our 2016 structural our guidance range of $175 million turning to $200 million.
Our LOTUS valve continues to gain share in Europe, and we're investing significantly in clinical studies, R&D in our global supply chain to develop our capabilities further. We remain on track to launch LOTUS EDGE at PCR London in September. The LOTUS EDGE delivery system features a 14 French expandable sheet called iSleeve and is designed for more flexibility and simplified deployment. It also offers an new Depth Guard technology, which limits the depth of the valve in the left ventricular outflow tract. LOTUS also offers best-in-class [indiscernible] leakage rates and we aim to enhance LOTUS with studies to demonstrate improve permanent pacemaker rates with LOTUS EDGE and Depth Guard.  So our goal is to provide initial LOTUS EDGE data at PCR london valves. We do expect a slight delay in our expanded LOTUS Valve matrix in Europe, with a 21-millimeter valve estimated CE Mark timing first quarter '17, and a 29-millimeter valve in Europe in mid-2017.  We continue to invest in plan for U.S. launch with the LOTUS EDGE platform in late 2017.
Also at structural heart, WATCHMAN sales were strong and procedure growth and new account openings. we're developing additional WATCHMAN capabilities in field clinical support, market development and physician training courses. Implant success rates and patient outcomes remain very high as evidenced by the 98.5% success rate and evolution registry detailed at HRS in May.
We continue to expand WATCHMAN in new markets and we're pleased with the recent reimbursement approval and launch in France.  Importantly, the unique clinical benefits of WATCHMAN are being rewarded, as evidenced by the French reimbursement at a meaningful premium to competitive LAAC devices.
We post a limited market release of our next generation WATCHMAN FLX device. We have decided to pursue design enhancements before we turn in next-gen platform to market. Importantly, we anticipate this delay will have no impact on our current WATCHMAN product and thus no change to our market outlook for LAAC.
Rhythm Management sales increased 5% in the quarter and delivered adjusted operating margin of 16.9%, up 200 basis points year-over-year as improving profitability remains a core focus.
In CRM, we improved our global performance in delivered 4% growth in second quarter. Our European and Asia PAC CRM businesses continue to grow faster than the market, offset by slower growth in U.S. CRM. Pacemaker sales grew 15% globally, with excellent U.S. performance, fueled by our ACCOLADE, MRI launch. And growth from our X4 CRT-P quad device. Worldwide ICD sales are flat as we delivered above-market growth internationally that was offset by weaker sales in the U.S.  In the U.S., we faced some near-term headwinds due to our tachy MRI product app and replacement cycle headwinds. However, we recently earned FDA approval of our ACUITY X4 quad CRT lead and the early results are promising. Importantly, EMBLEM S-ICD is a key differentiator and growth continues to accelerate globally.  We continue to expand global S-ICD utilization with more long-term data from the EFFORTLESS Registry, growing physician implant experience, geographic expansion and the recent second quarter '16 EU launch of EMBLEM MRI, which contributed to our solid international growth.
Due to change in protocol of our U.S. enabled MRI clinical trial, we are revising our goal for transvenous tachy MRI U.S. approval by yearend 2017, but continue to expect to gain MRI labeling for both new and previously implanted ICDs and CRT-Ds with a new timeline.  The continued cadence of data proving the superiority of EnduraLife batteries and the pending FDA approval of EMBLEM MRI S-ICD, which is expected in the third quarter, will help us offset the near-term headwinds from the U.S. MRI high-voltage segment.
In the second quarter, European CRM sales grew 5%, representing 9 straight quarters of above-market growth, giving us further confidence in our long-term CRM outlook.  Our EP business grew 6% in the second quarter and were encouraged by double-digit growth in Europe, led by new arrhythmia installs and the recent launches of and IntellaTip MiFi OI ablation catheters. The U.S. launch in late first quarter of Blazer OI catheter will be augmented in Q3 with the upcoming launch with a navigable version of this catheter. 
So to wrap up, our company delivered another excellent quarter. Our second quarter  performance reflects the strength of our global team, the depth and breadth of our portfolio, our globalization efforts in our ongoing investment in the faster growing markets. Importantly, we believe we are well-positioned to deliver continued strong results in the second half of '16 and beyond.  I really want to thank our employees globally for their winning spirit and their strong commitment to Boston Scientific.
Now let me turn the call over to Dan for more detailed review of our financial results."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Mike. In Q2, we generated organic revenue growth of 10% versus our 6% to 8% guidance range, and adjusted EPS of $0.27, representing 25% year-over-year growth in the high-end of our guidance range of $0.25 to $0.27.  The strong adjusted EPS growth",1917,"Thanks, Mike. In Q2, we generated organic revenue growth of 10% versus our 6% to 8% guidance range, and adjusted EPS of $0.27, representing 25% year-over-year growth in the high-end of our guidance range of $0.25 to $0.27.  The strong adjusted EPS growth performance in Q2 was driven primarily by revenue growth upside and a lower SG&A rate versus prior year.  And given the strong performance in the first half of 2016, we are again raising full year guidance of revenue growth and adjusted EPS.  Consolidated revenue of $2,126,000,000 represented operational revenue growth of 16%, exceeding the high end of guidance and excludes the impact of a $24 million headwind from foreign exchange, which was in line with guidance. Excluding an approximate 500 basis point contribution from the AMS male urology portfolio acquisition, organic revenue growth was 10% in the quarter and 15% on an as-reported basis.
Adjusted gross margin for the second quarter was 70.7%, decreasing 60 basis points year-over-year and unfortunately, 130 basis points below the midpoint of Q2 guidance due to a few factors that I will detail.  The year-over-year decrease is due to the unfavorable impact of foreign exchange, which was a 120 basis point headwind, as well as costs related to our new Malaysia manufacturing plant, the AMS integration, including the AMS quarterly mediation expense. Compared to guidance, the shortfall is due to inventory charges in advance of new product launches, inventory write-offs related to WATCHMAN FLX and more unfavorable FX.
We now expect Q3 and full year 2016 adjusted gross margin to be in the range of a 71.5% to 72.5%, which includes an expected 75 to 100 basis point of unfavorable foreign exchange. A key element in the second half increase is a lower expected inventory charges, and will also benefit fully from the lower 2016 standard cost of our products as we will have sold through all of the inventory valued at last year's higher standards.  Adjusted SG&A expenses were $763 million or 35.9% of sales in Q2, down 140 basis points year-over-year.  We continue to believe our full year rate will be between 35.5% and 36.5%, which at the midpoint would be a 140 basis point improvement compared to last year.
Adjusted research and development expenses were $222 million  in the second quarter or 10.4% of sales, which is down 50 basis points year-over-year. As a result of a slightly lower R&D rate in the first half, we expect our full year 2016 adjusted R&D rate to be between 10.5% and 11.5% of sales or 50 basis points lower than prior guidance.  Royalty expense was 0.9% of sales in Q2, roughly flat year-over-year. Our Q2 2016 adjusted operating margin of 23.4% was in line with our guidance and represents a 130 basis point improvement over Q2 last year, which marks the eighth consecutive quarter in which we will have expanded adjusted operating margin by 100 basis points or more.
As a reminder, we've signaled a sequential decrease in adjusted operating margin from Q1's rate as we experienced the usual increase in SG&A from Q1 to Q2 due to seasonal trade show activity and began to ramp reinvestment of the medical device excise tax expansion.  Our first half 2016 adjusted operating margin of 24.2% positions us well to achieve our full year adjusted operating margin guidance of 24% to 24.5%, and we remain on track to reach 25%-plus in 2017.
Q2 adjusted operating income grew 22% year-over-year, with all 3 reportable segments expanding adjusted operating margin by at least 170 basis points over Q2 2015. Specific to Rhythm Management, the team has delivered an adjusted operating margin of 16.9%, up 280 basis points year-over-year.  In the second half of 2016, we expect Rhythm Management adjusted operating margin to continue to improve and be 18% and 19%.  This second half gain is expected to result from realizing the full benefit of 2016 product costs, leveraging the improved top line performance expected of the global CRM and EP businesses, and we continue to believe that the management is on track to deliver an adjusted operating margin of 20% in 2017.
Turning to the balance sheet, we had some key developments in the quarter that helped reduce future uncertainties. Before I get into the details of the activity in the quarter, let me try to frame out the next 3 years of expected cash flow at a high level.  From 2017 through 2019, we believe we can generate cumulative adjusted free cash flow after CapEx approaching $6 billion. We expect to allocate roughly 2/3 of that $6 billion to a combination of M&A and share repurchases.  As you are aware, the 2 most significant liabilities on our balance sheet are our IRS Chesser pricing case and the mesh litigation. During the quarter, which are 2 important steps to manage these liabilities. First, we reached the stipulation of settled issues with the IRS for the 2001 to 2007 tax years. And importantly, this stipulation also provides a framework to settle the remaining years 2008 through 2015 as well.  While there's work to do, to conclude all the years, we are confident we will bring these to conclusion over the coming quarters.  With a payment in 12 to 24 months, this would eliminate one of the most significant liabilities on our balance sheet. With regards to mash, we increased our reserved by $608 million during the quarter. With the same goal of managing our liabilities, we reached conditional or final settlements on 12,000 claims and made significant progress towards reaching agreement on principle on another 7,000 claims  for a total of 19,000 claims. This represents approximately half of the roughly 40,000 known claims, and we expect to make even more progress during the remainder of 2016.  As you know, every quarter, we assess all 4 key components involving calculating the reserve and make any necessary adjustments for all probable and estimable charges, including the volume of known claims, the estimated cost to resolve each claim, an estimate of future claims and the cost to defend each claim.
Our total legal reserve of which mesh is included, was $2,375,000,000 as of June 30, 2016 and we believe it reflected our best estimate of what is probable and estimable. Of note as well, is that included in this reserve is the Maresca adjustment which we have paid in full sequential to quarter end. So as of today, the reserve would be closer to $2 billion.  As a reminder, this $2 billion includes a number of claims we have agreed in principle to settle but have not yet paid. Once those settlements are funded, the amount of the reserve will be adjusted accordingly.
Now I'll move on to interest expense. Interest expense for the quarter was $59 million, compared to $106 million in Q2 of last year. The decrease is primarily due to the pretax onetime charge of approximately $45 million associated with the senior note refinancing in Q2 of last year. Excluding this charge, Q2 2015 interest expense was $61 million [ph].  Our average interest expense rate was 4% in Q2 this year compared to 8% in Q2 last year. The low interest-rate expense in Q2 of '16 was primarily due to lower average cost of debt resulting from the senior notes refinancing and the inclusion of the pretax onetime charge in Q2 of last year that I mentioned.  Excluding this charge, Q2 2015 interest expense would have been 4.6%.
Our tax rate for the second quarter was 47.8% on a reported basis and 14.2% on an adjusted basis. As reported last week, we're pleased with the conditional settlement reached with the IRS council regarding our transfer pricing litigation and plan to use some of the current benefit to repatriate overseas cash, thus we continue to expect our full year 2016 adjusted tax rate to be approximately 14%.  We believe this IRS settlement in addition to recent progress we've made towards reaching agreements in principle to settle additional mesh claims, as I mentioned, are prudent actions to take in the management of our balance sheet.
Finally, Q2 2016 adjusted EPS of $0.27  includes approximately $0.015 [ph] of unfavorable FX and represents 25% year-over-year growth or 32% growth, excluding the impact of foreign exchange. On a reported GAAP basis, Q2 2016 EPS was a loss of $0.15 and includes net charges and amortization expense totaling $580 million after tax.
Adjusted free cash flow for the quarter was $464 million [ph] compared to $406 million in Q2 of last year. Given the strong adjusted free cash flow generation in the first half of this year, we are raising our full year adjusted free cash flow guidance from $1.5 billion to $1.6 billion, which was formally our stretch goal. Achieving adjusted free cash flow of $1.6 billion would represent 17% growth, and we continue to pursue inventory management initiatives designed to improve the working capital contribution to cash flow.
In Q2, we used cash primarily to repay $250 million of bank term loans, as well as fund the previously agreed legal settlements. As of June 30, 2016, we had cash on hand of $438 million.  Near term, our capital allocation priorities are to manage contingencies and pursue tuck-in M&A. 
We ended Q2 with 1,375,000,000 fully diluted weighted average shares outstanding. Consistent with our prior guidance, we expect our share count to increase by roughly 5 million per quarter through the end of 2016 as we plan to keep the buybacks suspended for the balance of this year. We expect this to result in a fully diluted weighted average share count of approximately 1,380,000,000 shares for full year 2016.
I'll now walk-through guidance for Q3 and full year 2016. For the full year, we now expect consolidated revenue to be in a range of $8,270,000,000 to $8,370,000,000, which represents year-over-year growth of 8% to 9% on an organic basis and 11% to 12% on both an operational and reported basis.  As a result of a stronger dollar, at current rates, we expect foreign exchange to be a headwind of approximately $70 million for the full year 2016. 
Turning to adjusted EPS, we now expect full year 2016 adjusted EPS to be in a range of $1.07 to $1.11, representing 15% to 19% adjusted earnings growth. Our previous guidance assumed the unfavorable FX on full year adjusted EPS would be between $0.05 and $0.06, given the fact that Q2 saw slightly less unfavorable impact on affected we know we believe the full year impact will be closer to $0.05.  Which is assumes $0.02 to $0.03 in the second half of this year.  On a GAAP basis, we expect EPS to be in a range of $0.30 to $0.35.
Now turning to Q3 2016, we expect consolidated revenues to be in a range of $2,035,000,000 to $2,085,000,000. This represents year-over-year growth in a range of 7% to 9% organically and 8% to 10% operationally.  We expect the foreign exchange headwind on Q3 revenue to be negligible. For the third year -- for the third quarter, adjusted EPS is expected to be in a range of $0.25 to $0.27 per share, and GAAP EPS is expected to be in a range of $0.13 to $0.15 per share.
Please check our Investor Relations website for Q2 2016 financial and operational highlights, which outlines Q2 results, as well as Q3 and full year 2016 guidance, including P&L line item guidance.  So with that, I'll turn it back over to Susie who will moderate the Q&A."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Dan. Grad, let's open up for questions for the next 30 minutes. [Operator Instructions] Greg, please go ahead.",19,"Thanks, Dan. Grad, let's open up for questions for the next 30 minutes. [Operator Instructions] Greg, please go ahead."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","[Operator Instructions] Your first question comes from the line of Mike Weinstein from JPMorgan.",14,"[Operator Instructions] Your first question comes from the line of Mike Weinstein from JPMorgan."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Let me just clarify this on a few items. So number one, the pacemaker performance being strong as it is on the back of the MRI launch question of elegant is that a clean number in stalking in that number that we should be aware of. Second, the move in the",77,"Let me just clarify this on a few items. So number one, the pacemaker performance being strong as it is on the back of the MRI launch question of elegant is that a clean number in stalking in that number that we should be aware of. Second, the move in the structural heart guidance to the high end of the range, is that WATCHMAN, was it LOTUS? Kind of share insights into that and then I'll follow-up."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, good morning, Mike. On the pacemaker, our team has been waiting for a long time for that product approval. We've had some slow quarters in our pacemaker business in the U.S. Outside the U.S., it's done quite well with our product for a while. So tha",265,"Sure, good morning, Mike. On the pacemaker, our team has been waiting for a long time for that product approval. We've had some slow quarters in our pacemaker business in the U.S. Outside the U.S., it's done quite well with our product for a while. So that's not a stalking number. We were ready for that launch for quite a while and the team -- our commercial teams did an excellent job executing it. So we think it's a very innovative product and long and coming. And the U.S. team essentially is OUS teams have done with that product for a while. And structural heart, we continue to be really excited about the future for structural heart. It continues to be our largest investment area as a company. We were comfortable with the high-end of our guidance that we provided at $175 million to $200 million. We continue to invest long-term in R&D capabilities, clinical capabilities and commercial capabilities to prepare ourselves for the launch in the U.S. And we're really excited about the upcoming data that will expect to see an london valves on our pacemaker rate with the addition of LOTUS EDGE and Depth Guard. So it's really an important category for us. As you know, we continue to -- we outlined at Investor Day back I think 2013 and '15, our focus to continue to grow in our core businesses and take share, which we're doing, and importantly, expand in the faster-growth markets. And that's exactly what you're seeing is a company in our structural heart investment is leading the pack there."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","So Mike, I apologize. The question was structural was within structural heart WATCHMAN was driving to the higher end of the range range there?",24,"So Mike, I apologize. The question was structural was within structural heart WATCHMAN was driving to the higher end of the range range there?"
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Most are we the high-end range there is we just continue to open up new accounts. We continue to improve our account utilization. And we continue to build up our commercial capabilities in the U.S.",36,"Most are we the high-end range there is we just continue to open up new accounts. We continue to improve our account utilization. And we continue to build up our commercial capabilities in the U.S."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay, the gross margin kind of issues in the quarter, I think you did a good job of walking through what those are. So if we look at the back half of the year, and if that's a improvement to gross margin, that's because one, your inventory issues from the",83,"Okay, the gross margin kind of issues in the quarter, I think you did a good job of walking through what those are. So if we look at the back half of the year, and if that's a improvement to gross margin, that's because one, your inventory issues from the AMS transaction basically you get to a better, safer cost than on those products, and then the FX headwind that you saw this quarter on the gross margin should dissipate. It that accurate?"
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","No, somewhat. Let me just make sure we're clear on that. So we're at $70.7 million in the quarter. The guidance range for Q3 and the full year is 71.5% to 72.5% so it implies the uptick that you mentioned in the second half. I think that to key drivers of",236,"No, somewhat. Let me just make sure we're clear on that. So we're at $70.7 million in the quarter. The guidance range for Q3 and the full year is 71.5% to 72.5% so it implies the uptick that you mentioned in the second half. I think that to key drivers of that are the inventory charges for the CRM products related to the better uptake of MRI-safe Brady and Quad in the U.S. as well as the WATCHMAN FLX. We don't believe that those repeat themselves. And then secondly, we will get the full benefit in the second half of the lower manufacturing costs that we had for 2016 standards because we'll now be selling all the inventory at the new standards, and we will have sold off all of the inventory at last year's standards. So those are the 2 main drivers that put us back in the 71.5% to 72.5% range. FX, we actually assume is probably somewhat in the same range as where it was in Q2. That's really the reason if you think back to the last quarter, our guidance for FX in gross margin would have implied about 70 to 75 basis points each quarter for Qs 2, 3 and 4. Now it's 120. So that's a 50 basis point difference. And that's the reason why the guidance for the full year came from 72% to 73% to 71.5% to 72.5%."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of David Lewis from Morgan Stanley.",13,"Your next question comes from the line of David Lewis from Morgan Stanley."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","In light of a very strong revenue quarter, guys, I hate to ask something as banal as cash flow, Dan, but you don't give us multiyear cash flow often and I notice that you're $6 billion free cash estimate in the next 2 [ph] years is 10% higher than what we",103,"In light of a very strong revenue quarter, guys, I hate to ask something as banal as cash flow, Dan, but you don't give us multiyear cash flow often and I notice that you're $6 billion free cash estimate in the next 2 [ph] years is 10% higher than what we were looking for. Can you sort of walk us through kind of why the will be some the components I imagine one component is CapEx and perhaps the other is margins, but our margin numbers are pretty high and you're still 10% above us. So what could be driving that significant upside?"
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","I think you answered your own question there, David, it's margins and CapEx. So one of the things we have this year as we detailed in our guidance, at the beginning of the year is the CapEx number at 3 50 that's $100 million higher than we need to effecti",197,"I think you answered your own question there, David, it's margins and CapEx. So one of the things we have this year as we detailed in our guidance, at the beginning of the year is the CapEx number at 3 50 that's $100 million higher than we need to effectively run each year. So we get that back hopefully each of the next 3 years and then expanding margins. So our goal next year is 25%-plus and as we've given guidance for long-term goals for 27% to 28% by 2020, the combination of those 2 factors and the CapEx I think gets you a long way there. And then the other piece is that we're going to continue to try from a working capital perspective to make that be our friend. We have a lot of inventory initiatives in place to really hopefully lead the industry in that regard, and be best-in-class, and when we do that, that'll turn something that's been a drag on cash flow into a positive and hopefully see the beginnings of that this year. You see that from us taking our guidance from 1.5 [ph]  to 1.6 [ph] of the inventory initiatives."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay, very helpful. Product questions, first is just it's a forgotten business for Boston MedSurg no longer for gun giving the organic growth and specifically Endoscopy has gone from mid-single growth last year to double-digit growth this year. I wonder i",115,"Okay, very helpful. Product questions, first is just it's a forgotten business for Boston MedSurg no longer for gun giving the organic growth and specifically Endoscopy has gone from mid-single growth last year to double-digit growth this year. I wonder if you just give us a sense of sort of where we are in the product cycles? Is it -- share gain for competitors, is it product cycles that is driving that? And then secondarily, on TES, on synergy, would be think you are in set of share versus mix and obviously you're growing dramatically ahead of market. So what are some of the factors that are driving that and I'll come back in queue."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks. David. We definitely never forgot about endo. It's really an incredibly high performing business and has been for a number of years. And a really just continuing to do -- continue to grow and expand. So our and the business enjoys a first of all,",434,"Thanks. David. We definitely never forgot about endo. It's really an incredibly high performing business and has been for a number of years. And a really just continuing to do -- continue to grow and expand. So our and the business enjoys a first of all, a strong market, a bit fewer competitors in our Endoscopy markets in some of our others. It is very strong growth profile in terms of the market growth in OUS expansion. and we're a very strong category leader. Across the globe, we continue to expand emerging markets. The portfolio is really driving a lot of the launch out of the success that you're seeing in 2016, led by our SpyGlass digital DS platform, which is driving solid double-digit growth and helps pull through the core portfolio. We also launched a product called the AXIOS Stent, which is doing very well, as well as a hemostasis clip. So the portfolio cadence for Endo is very strong. It's very well-led. It's very globally oriented, and they also do a great job of laying out the economic value proposition for hospitals beyond the portfolio. So they continue to perform very well and intentionally, some of my comments with Mike in his first question, we're intentionally focusing on investing greater in faster-growth markets, in faster growth businesses and they represent 40% of our operating income, the MedSurg sector does now for BSC, so more to come there. DS is doing excellent. We had a few critics early on in our launch saying we won't be as aggressive we've signaled all along that we're going to be driving an appropriate premium price for this product because we believe it is the best product available in the marketplace and the data is proving that out and maybe Keith can comment in a minute. So we believe it's in the premium product. We do operate a premium price for it. And so we've been smart in our rollout of it and I think physicians and customers are seeing the value of the ease-of-use and the clinical data synergy and we expect the U.S. penetration to be probably above 50% closer to 50% to 60% in the U.S. in 2016. And we continue to roll that out globally. So the team is doing a nice job there but again, it's part of the overall story in cardiology again, faster growth segments, our DS is doing well a lot of investments and complex coronary and imaging which are part of the portfolio and clearly our structural heart. So Kevin and his team is doing a nice job."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, David, I think the SYNERGY Stent operators around the world are appreciating the best in class performance  because honestly if you can't deliver the stent, it's really the end of the discussion. And that we have a lot of data and now, including the",124,"Yes, David, I think the SYNERGY Stent operators around the world are appreciating the best in class performance  because honestly if you can't deliver the stent, it's really the end of the discussion. And that we have a lot of data and now, including the EVOLVE II pivotal data, the EVOLVE 5-year data and the real world sky data from Europe confirming the safety. Everybody, both patients and physicians, are interested in stent thrombosis and stent thrombosis, as you know from the data, is very low. We have 20,000 patients in investigator sponsored trials with Synergy. And these trials are beginning to release their data, and you'll see more flows of data at the meetings during the rest of this year and next year."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of Larry Biegelsen from Wells Fargo.",13,"Your next question comes from the line of Larry Biegelsen from Wells Fargo."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","So Dan, you raise the organic growth from 6% 8% to 8% to 9% but you only raised EPS guidance by $0.01. And so can you talk about why you're not getting better leverage in the incremental revenue? You kept the operating margin guidance same and then I have",51,"So Dan, you raise the organic growth from 6% 8% to 8% to 9% but you only raised EPS guidance by $0.01. And so can you talk about why you're not getting better leverage in the incremental revenue? You kept the operating margin guidance same and then I have one follow-up."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, Larry. I think probably the best way to explain that is to do a quick summary of the increase in revenue. So the revenue is $170 million higher at the midpoint of guidance, and that breaks down into 3 things: $20 million comes from FX, $75 million c",162,"Sure, Larry. I think probably the best way to explain that is to do a quick summary of the increase in revenue. So the revenue is $170 million higher at the midpoint of guidance, and that breaks down into 3 things: $20 million comes from FX, $75 million comes from revenue that already came in Q2 and then $75 million comes in the second half. I think the main factor that's offsetting that is if you look at our R&D rate, our R&D rate in the first half was 10.5%. And looking at the second half, it's going to be 11.5% to get to the full year rate of 11% so that's 100 basis point increase in R&D, largely related to timing in the investments in structural heart that Mike have mentioned. So that for the most part offsets the additional flow through in the revenue that you get -- the additional $75 million of revenue you get in the second half."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Got it. And then...",4,"Got it. And then..."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","As you look at it, still very pleased to be at 15% to 19% full year EPS growth, which would be 4 years straight of double-digit adjusted EPS growth.",29,"As you look at it, still very pleased to be at 15% to 19% full year EPS growth, which would be 4 years straight of double-digit adjusted EPS growth."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Got it, sorry to interrupt there. And then for my follow up, at the 2015 analyst meeting, the organic revenue goal was 3% to 6% in 2016 and [ph] 2017, you're now guiding to 8% to 9% in 2016. How should we think about the sustainability of the 8% to 9% and",81,"Got it, sorry to interrupt there. And then for my follow up, at the 2015 analyst meeting, the organic revenue goal was 3% to 6% in 2016 and [ph] 2017, you're now guiding to 8% to 9% in 2016. How should we think about the sustainability of the 8% to 9% and your goals in 2017 and beyond? And I recognize you're not giving guidance here, but you're way outperforming what your expected to do at your analyst meeting last year."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, yes, the team is outperforming. It's part of the high-performance culture that we have as a company. We're very excited about the full year guidance at 8% to 9%. As you said, it compares to 3% to 6% we laid out, so it's a pretty strong beat the",126,"Thank you, yes, the team is outperforming. It's part of the high-performance culture that we have as a company. We're very excited about the full year guidance at 8% to 9%. As you said, it compares to 3% to 6% we laid out, so it's a pretty strong beat there and strong momentum across really each region and each business. So we're not going to provide any outlook in the 2017. Clearly, outperforming the market at these levels -- at this level is not likely sustainable each year. But that being said, we're confident we'll continue to outperform the market. We're investing in faster growth businesses, and we're very confident in our ability long-term to drive midsingle revenue growth, improve margins and our double-digit EPS growth."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of Bob Hopkins from Bank of America.",14,"Your next question comes from the line of Bob Hopkins from Bank of America."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","So obviously, you've got the best revenue growth year for Boston Scientific essentially since the financial crisis. Higher absolute the level of revenues and then I think any of the thoughts, so congratulations on the unbelievable progress. I guess my fir",152,"So obviously, you've got the best revenue growth year for Boston Scientific essentially since the financial crisis. Higher absolute the level of revenues and then I think any of the thoughts, so congratulations on the unbelievable progress. I guess my first question is really kind of philosophical in terms of the long time know that you got this out of a higher level of revenues and higher level of revenue growth you guys have given some long-term guidance on operating margin targets and goals. So now that you're kind of outperforming on revenues, what's the thought on those operating margin targets? Is the thought that you'll take an opportunity to spend more and continue to sort of keep those operating margin targets, or is it more likely that with this high level of growth that you could be towards the high end or higher of the long-term target that you've set previously?"
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, I don't think we'll be changing the trajectory in terms of the margin guidance we've given. As we always say, it's about striking a balance between delivering durable, consistent revenue growth and expanding operating margins. And if you look at t",107,"Thanks, I don't think we'll be changing the trajectory in terms of the margin guidance we've given. As we always say, it's about striking a balance between delivering durable, consistent revenue growth and expanding operating margins. And if you look at the numbers and see what we've done for the last 3 years relative to revenue growth and particularly on the margin expansion front, looking at 27% to 28% adjusted operating margin by 2020 and a consistent durable growing top line through that period, and the goal of double-digit adjusted EPS growth each of those years, I think we're going to stick with that as our target."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","I understand you're sticking with the targets, but I'm just trying to understand philosophically because you're outperforming so nicely here. Is the bias more towards opportunities to invest more, or let some of that true because levels are just so much h",47,"I understand you're sticking with the targets, but I'm just trying to understand philosophically because you're outperforming so nicely here. Is the bias more towards opportunities to invest more, or let some of that true because levels are just so much higher than we originally thought."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Again, it's striking a balance. We do have a lot of investment, as Mike mentioned, relative to structural heart. That's a lot of investment to get to the U.S. market and be successful there and I think we're -- it's always about striking a balance.",45,"Again, it's striking a balance. We do have a lot of investment, as Mike mentioned, relative to structural heart. That's a lot of investment to get to the U.S. market and be successful there and I think we're -- it's always about striking a balance."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, and I think also, we'll do an Investor Day 2017. We haven't nailed down yet, but we're making significant investments in platforms and markets that will have a big impact on the growth through the business in '18, '19 and '20. And so you look at our",118,"Yes, and I think also, we'll do an Investor Day 2017. We haven't nailed down yet, but we're making significant investments in platforms and markets that will have a big impact on the growth through the business in '18, '19 and '20. And so you look at our launch in the U.S. of TAVR, our launch in the U.S. in the future of Deep Brain Stimulation, launching [indiscernible] drug-eluting stent and a drug-coated balloon for peripheral vascular and we continue to expand into pulmonary and other areas across the company. So we definitely are investing for long-term growth and a lot of it is the clinical investments in R&D that'll impact the company, particularly in '18, '19, '20."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","And structural heart grew quickly, what was a driver of you guys providing guidance will it be at the high end of the range, is it that LOTUS and WATCHMAN or both?",32,"And structural heart grew quickly, what was a driver of you guys providing guidance will it be at the high end of the range, is it that LOTUS and WATCHMAN or both?"
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","It's both aircraft both are doing quite well.",9,"It's both aircraft both are doing quite well."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of Brooks West from Piper Jaffray.",13,"Your next question comes from the line of Brooks West from Piper Jaffray."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Just to put a cap on the gross margin discussion, so Dan, those all seem like transient issues with the inventory, and I'm not trying to push for guidance for next year, but as look at my model, we got about 73% gross margins for 2017. I don't see anythin",104,"Just to put a cap on the gross margin discussion, so Dan, those all seem like transient issues with the inventory, and I'm not trying to push for guidance for next year, but as look at my model, we got about 73% gross margins for 2017. I don't see anything I really to flow through into '17 from this. Is that the correct way to think about it? I mean, you're little bit lower for '16, but in terms of thinking about the forward model, that should resolve itself and we should kind of go back to where we thought we were going, correct?"
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, I mean, I wouldn't talk specifically about a rate for 2017. Obviously, the goal is to continually increase the gross margin rate and it will be part of what we believe is 25%-plus adjusted operating margin for the next year. So with that as the goal,",104,"Yes, I mean, I wouldn't talk specifically about a rate for 2017. Obviously, the goal is to continually increase the gross margin rate and it will be part of what we believe is 25%-plus adjusted operating margin for the next year. So with that as the goal, -- the FX in the back-office really the only thing that we believe is consistent from the Q2 performance of the other thing that I mentioned relative to inventory charges and the benefit from the standard hopefully to your point, is a transient thing. For the FX is the only one that continues into the second half."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay, perfect. And then maybe kind of piggybacking on Bob's question, but also thinking about some of the questions around MedSurg. You kind of condition does in terms of the long-term operating margin progression to think about Rhythm Management. And obv",121,"Okay, perfect. And then maybe kind of piggybacking on Bob's question, but also thinking about some of the questions around MedSurg. You kind of condition does in terms of the long-term operating margin progression to think about Rhythm Management. And obviously, you're making great progress there. But given the growth we're seeing in MedSurg and Interventional Cardiology, it seems like that equation maybe needs to change a little bit and if we allocate a little bit more of the strength in MedSurg to that equation, it seems like we push up to and through those targets maybe more quickly than if we were just relying on Rhythm Management. Is that also a fair kind of way to look at your business?"
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, I think the focus on Rhythm Management has really then just because of where they were, right? Starting off in the high single digits, it's gotten a lot of focus over the last 3 or 4 years. I think we've made doing team have major matters progress ge",183,"Yes, I think the focus on Rhythm Management has really then just because of where they were, right? Starting off in the high single digits, it's gotten a lot of focus over the last 3 or 4 years. I think we've made doing team have major matters progress getting it to the '16 [indiscernible] in Q2, the 18% to 19% will be in the second half of this year and then ultimately, the 20% next year and beyond that in 2018 and beyond. All the while, to your point, MedSurg and cardiovascular have continued to grow their margins as well. So I think it goes back to what Mike said to the answer to the last question, which is there's investments that we're making to ensure that durable growth '18, [ph] '19 [ph] '20 [ph] and beyond and if not just one business that has that investment we are investing in all of the businesses. So we spent a lot of time looking at each of the individual segments and the profitability there, and the math to what we've given for our goals."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Perfect, sneak in one product question on wondering if [indiscernible] decided whether to [indiscernible] U.S. or not?",17,"Perfect, sneak in one product question on wondering if [indiscernible] decided whether to [indiscernible] U.S. or not?"
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, will likely be providing additional in science on our clinical strategy with our balloon at the next quarterly call.",20,"Yes, will likely be providing additional in science on our clinical strategy with our balloon at the next quarterly call."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of Rick Wise from Stifel.",12,"Your next question comes from the line of Rick Wise from Stifel."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Maybe let me start off with LOTUS. Mike, you talked about gaining EU share in the quarter. Maybe give us a little more color on that are you ready to quantify that at all? You talked about penetration or share greater than 30% in your selected accounts. A",87,"Maybe let me start off with LOTUS. Mike, you talked about gaining EU share in the quarter. Maybe give us a little more color on that are you ready to quantify that at all? You talked about penetration or share greater than 30% in your selected accounts. And maybe just add some more color on the EDGE launch coming up in September. is this is share gain or that's going to require more time in those additional sizes that are coming in the first half of '17?"
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, sure. Again, the big investment for us in structural heart was WATCHMAN and TAVR. And we're playing it for the long-term here, particularly with our TAVR given the market growth profile and how large the market is. And our view that we have a very di",209,"Yes, sure. Again, the big investment for us in structural heart was WATCHMAN and TAVR. And we're playing it for the long-term here, particularly with our TAVR given the market growth profile and how large the market is. And our view that we have a very differentiated platform from the market contenders given the controlled release of our LOTUS Valve and the LOTUS [indiscernible] rates. so I think it's truly have a differentiated platform in a very large market. We're a bit hamstrung in the near term in Europe without having all 5 sizes. We have 3 of them today. So that hurts us a bit but we'll solve that with a 21-millimeter [ph] in first quarter '17 and eventually the largest size first half of 2017. So that will help. So in the meantime, we continue to do very well with the 3 valve sizes that we have. We won't provide any additional guidance in terms of number of accounts or penetration. But clearly, it's a share taking strategy. The market's already large, the market's growing, and we're quite confident that we are clearly the strong #3 player. But that's not going to be our aspiration over the years, particularly as we launch LOTUS EDGE and Depth Guard."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Yes, turning to a bigger picture question. Dan, obviously, is emphasizing the growth in free cash flow this year, the $6 billion number you have over the next few years. [indiscernible] saying, then, that I think correctly that with the settling or going",109,"Yes, turning to a bigger picture question. Dan, obviously, is emphasizing the growth in free cash flow this year, the $6 billion number you have over the next few years. [indiscernible] saying, then, that I think correctly that with the settling or going a long way towards settling the IRS [indiscernible] major uncertainty it's off the table. I mean, all that suggests to me that, that might give you more flexibility in thinking about M&A or portfolio additions. Just announced Cosman. How are you thinking about this Mike and Dan, should we be thinking that there is more possibility for M&A as a result? Any color would be appreciated."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Sure yes, financial perspective Mike can jump in on the strategic side. The goal I think you forget out very well. That's our goal is to eliminate the uncertainties that we have on the balance sheet at think we've taken a lot of good steps in the quarter",148,"Sure yes, financial perspective Mike can jump in on the strategic side. The goal I think you forget out very well. That's our goal is to eliminate the uncertainties that we have on the balance sheet at think we've taken a lot of good steps in the quarter to do that. And that's going to give us more financial flexibility in the future. And that's the goal. So we should hopefully free up more of the cash flow for the long-term. We gave you the numbers hopefully as kind of goals for the next 3 years, and the goal is to have as much of that available to fuel the business from an M&A and share repurchase perspective. So I don't know if anything specific but, yes, I mean, that's really the goal, is to eliminate the uncertainties and give us as much financial visibility a second half."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of the Matt Taylor from Barclays.",13,"Your next question comes from the line of the Matt Taylor from Barclays."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","The first question that wanted to clarify when you talk about MRI-safe timelines, could you just inform us what revising the goal for tachy MRI timeline and tell us what the change was there? And then as SCD is still on track, can you talk about how you t",63,"The first question that wanted to clarify when you talk about MRI-safe timelines, could you just inform us what revising the goal for tachy MRI timeline and tell us what the change was there? And then as SCD is still on track, can you talk about how you that's doing and how you expect MRI-safe approval to potentially improve sales for S-ICD?"
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Absolutely, I'll ask Dr. Stein to comment on this question.",10,"Absolutely, I'll ask Dr. Stein to comment on this question."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, on the MRI, not going to get into any of the details of the change in the protocol. But in the course of conduct of our ENABLE MRI trial, we have made a decision that we do need to revise the protocol with respect to patient screening and eligibility",83,"Yes, on the MRI, not going to get into any of the details of the change in the protocol. But in the course of conduct of our ENABLE MRI trial, we have made a decision that we do need to revise the protocol with respect to patient screening and eligibility, and that's just the process of getting that protocol vision was going to cause the push in the timeline. We still have a goal of getting that approved by the end of 2017."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay, and on S-ICD?",4,"Okay, and on S-ICD?"
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Sorry, could you clarify the question on for S-ICD?",9,"Sorry, could you clarify the question on for S-ICD?"
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","As I was just curious a may have missed the committee because comments were by and at a fast this to have the same timeline for S-ICD of my approval and just how is S-ICD performing today?",38,"As I was just curious a may have missed the committee because comments were by and at a fast this to have the same timeline for S-ICD of my approval and just how is S-ICD performing today?"
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, we saw the same time line anticipated approval Q3 of this year, and really, couldn't be more pleased with what we've seen in terms of uptake of EMBLEM MRI, where it's been launched in Europe and the existing EMBLEM device in the U.S. and globally. An",58,"Yes, we saw the same time line anticipated approval Q3 of this year, and really, couldn't be more pleased with what we've seen in terms of uptake of EMBLEM MRI, where it's been launched in Europe and the existing EMBLEM device in the U.S. and globally. And we expect MRI approval in the U.S. and the third quarter."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Q3 this year.",3,"Q3 this year."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes.",1,"Yes."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Great, talk about broader utilization, obviously your results were phenomenal this quarter. Are you seeing something going on in either the U.S. market or some of the emerging markets that you plan that's contributing to higher levels of utilization that",59,"Great, talk about broader utilization, obviously your results were phenomenal this quarter. Are you seeing something going on in either the U.S. market or some of the emerging markets that you plan that's contributing to higher levels of utilization that may not continue going forward, or do you think that you're really just outperforming your markets from good execution?"
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Well, thanks, Matt. It's Mike. I don't want to sound like a broken record here, but I want to reinforce consistent with our investor day presentations in '13 and '15, we continue to invest our portfolio into faster-growth markets. So kind of in the maybe",171,"Well, thanks, Matt. It's Mike. I don't want to sound like a broken record here, but I want to reinforce consistent with our investor day presentations in '13 and '15, we continue to invest our portfolio into faster-growth markets. So kind of in the maybe the 2011 timeframe, we called our market growth about -- market growth profile 3% in the markets we compete in. So as we shifted our portfolio over time in the faster-growth markets, we think the markets that we compete in now are kind of in the 4% to 5% growth range. If you look at the composite BSE. So we are pleased that we're outperforming the market. We'll strive to continue to do so, but we think we have fundamentally shifted the markets that we play in to about a 4% to 5% growth market versus maybe a 2% to 3% growth market 4, 5 years ago. The markets are stronger that we compete in, and the team is doing a really nice job of outperforming."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Okay, the question comes from the line of Glenn Novarro from RBC Capital Markets.",14,"Okay, the question comes from the line of Glenn Novarro from RBC Capital Markets."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Two questions, one, drug-eluting stents in the quarter, up high single digits, significantly outpacing the market. You have it launching Absorb. So my question is does this high single-digit sustainable given absorbed coming into the market, or should we",52,"Two questions, one, drug-eluting stents in the quarter, up high single digits, significantly outpacing the market. You have it launching Absorb. So my question is does this high single-digit sustainable given absorbed coming into the market, or should we anticipate a little moderation going forward? And then I had a quick follow-up."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","So yes, we're not giving DES guidance for the third quarter or fourth quarter. We're going to continue to run the play, which is we believe we have the best product in the market, and Keith can comment a bit more on the clinical data. And we have been com",167,"So yes, we're not giving DES guidance for the third quarter or fourth quarter. We're going to continue to run the play, which is we believe we have the best product in the market, and Keith can comment a bit more on the clinical data. And we have been competing with Absorb in Europe for quite a while. We would point at that probably less than in the 7% the DBS probably less than 7% of the global markets been in the market for quite a while. So we feel like we're in the position of strength in terms of our product portfolio, and we continue to look at DBS. It's an interesting technology, and we've got a number of bets and it's in fact in the future. We can look at a second gen or a third generation device, then we'll eventually bring that to market. But at this time, we believe that synergy is the premium device, and we'll continue to focus on driving that."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","And then with Keith on the line, I'd love to get his thoughts on kind of synergy versus absorbed and then my follow-up was on ELUVIA, which was just launched in Europe. And the data is very strong and once you come to the U.S., you'll be by far -- you wil",102,"And then with Keith on the line, I'd love to get his thoughts on kind of synergy versus absorbed and then my follow-up was on ELUVIA, which was just launched in Europe. And the data is very strong and once you come to the U.S., you'll be by far -- you will be the second DES on the market for peripherals, but by far the best data. So how is ELUVIA doing in Europe and it just seems like this is one product that has a significant opportunity that is flat under the radar screens. Just thoughts on ELUVIA as well. Thanks."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","So Glenn in terms of synergy and of the see, there's not a lot of head-to-head data between the 2. But  DBS has been available in Europe's CE Mark for 5.5 years and penetration, as Mike said, is mid-single-digits. And you and everybody else in the call is",158,"So Glenn in terms of synergy and of the see, there's not a lot of head-to-head data between the 2. But  DBS has been available in Europe's CE Mark for 5.5 years and penetration, as Mike said, is mid-single-digits. And you and everybody else in the call is well aware of the Absorb 2 and Absorb 3 data. The safety profile of a drug-eluting stent is paramount. Safety profile is more important than efficacy, and with the stent thrombosis rate of at least 2x, synergy, we feel that the first generation fully [indiscernible] scaffold safety profile is open to question. We do have an interest in the space, obviously, and we have to have that as you know, also, we have 3 shots on goal and our own internal flash program, which is [indiscernible] more deliverable stent, more compliant, less [indiscernible] position as an first use trials now, and we are still anticipating commercialization in Europe in 2018."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","And then your thoughts on ELUVIA, how it's performing in Europe? And your thoughts on how it'll perform in the United States once launched?",24,"And then your thoughts on ELUVIA, how it's performing in Europe? And your thoughts on how it'll perform in the United States once launched?"
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, so we're early with our OLUVIA platform. It's a large investment. We'll be announcing additional data sets on both our balloon and our stent at CIRSE, which is I think in Barcelona in September   third quarter this year. So we'll continue to lay out",151,"Sure, so we're early with our OLUVIA platform. It's a large investment. We'll be announcing additional data sets on both our balloon and our stent at CIRSE, which is I think in Barcelona in September   third quarter this year. So we'll continue to lay out our clinical data there. But I think just the -- again, the strength of having in Europe a drug-coated balloon and a differentiated drug-eluting stent for the peripheral vascular offers physicians more options. And so it uniquely positions us in the SFA and also helps us pull through our core portfolio. So I think these investments are paying off in Europe based on the growth, and we've got to wrap up our clinical trial of ELUVIA, which we anticipate the year end 2016. And so we look forward to that finishing, and then we'll provide additional comments on our balloon at our third quarter earnings call."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Great, with that, will it does conclude the call. Thanks for joining us today and we appreciate your interest in Boston Scientific. Before you disconnect, Greg, will give you all the pertinent details for the replay.",36,"Great, with that, will it does conclude the call. Thanks for joining us today and we appreciate your interest in Boston Scientific. Before you disconnect, Greg, will give you all the pertinent details for the replay."
317627,370563598,1015026,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Thank you. Ladies and gentlemen, this conference will be available for replay after 10:30 Eastern Time today through August 11. You may access the AT&T Teleconference Replay System by diluting 18004756701 and entering the access code 396158. International",64,"Thank you. Ladies and gentlemen, this conference will be available for replay after 10:30 Eastern Time today through August 11. You may access the AT&T Teleconference Replay System by diluting 18004756701 and entering the access code 396158. International participants dial (320) 365-3844. That does conclude your conference for today. Thank you for your participation and for using AT&T Executive Teleconference. You may now disconnect."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Second Quarter 2016 Boston Scientific Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.I would now like to turn the conference over to your",46,"Ladies and gentlemen, thank you for standing by. Welcome to the Second Quarter 2016 Boston Scientific Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
I would now like to turn the conference over to your host, Susie Lisa. Please go ahead."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Greg. Good morning, everyone, and thanks for joining us. With me on today's call are Mike Mahoney, Chairman and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.We issued a press release earlier t",363,"Thank you, Greg. Good morning, everyone, and thanks for joining us. With me on today's call are Mike Mahoney, Chairman and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.
We issued a press release earlier this morning announcing our Q2 2016 results, which included reconciliations of the non-GAAP measures used in the release. 
We have posted a copy of that release as well as reconciliations of the non-GAAP measures used in today's call to the Investor Relations section of our website under the heading Financial Information. 
The duration of the morning's call will be approximately 1 hour. Mike will provide strategic and revenue highlights of Q2 of '16. Dan will review the financials for the quarter and then Q3 '16 and full year 2016 guidance, and then we'll take your questions. During today's Q&A session, Mike and Dan will be joined by our Chief Medical Officers, Dr. Keith Dawkins and Dr. Ken Stein.
Before we begin, I'd like to remind everyone that on the call, organic revenue growth is defined as excluding the impact of changes in foreign currency exchange rates and sales from the acquisition of the American Medical System, AMS, male urology portfolio over the prior-year period. Also of note, this call contains forward-looking statements within the meaning of federal securities laws, which may be identified by words like anticipate, expect, believe, estimate and other similar words. 
They include, among other things, statements about our growth and market share; new product approvals and launches; clinical trials; cost savings and growth opportunities; our cash flow and expected use; our financial performance, including sales, margins, earnings and other Q2 2016 results and Q3 and full year 2016 guidance as well as our tax rates, R&D spend and other expenses.
Actual results may differ materially from those discussed in the forward-looking statements. 
Factors that may cause such differences include those described in the Risk Factors section of our most recent 10-K and subsequent 10-Qs filed with the SEC. 
These statements speak only as of today's date, and we disclaim any intention or obligation to update them. 
At this point, I'll turn it over to Mike for his comments. Mike?"
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Susie, and good morning, everyone. We continue to beat our long-range strategic plan goals and execute very well as a global team. The success of our category leadership strategy is helping us gain share in our core markets, expanding the faste",2114,"Thank you, Susie, and good morning, everyone. We continue to beat our long-range strategic plan goals and execute very well as a global team. The success of our category leadership strategy is helping us gain share in our core markets, expanding the faster growth adjacencies and deliver solutions that address unmet clinical needs. Our consistent results continue to demonstrate that Boston Scientific is uniquely positioned to deliver differentiated long-term shareholder value. With long term visibility to mid-single digit organic revenue growth, complemented by ongoing operating margin improvement initiatives, our goal is to consistently drive double-digit adjusted EPS growth.
We're very excited about our excellent second quarter performance, first half results, and most importantly, our plans for the future. In Q2, we drove total operational revenue growth of 16% and organic revenue growth of 10%, excluding the impact of the AMS Urology acquisition. We had strong results across all regions, and 5 of our 7 business units grew revenue double digits organically. We leveraged that revenue growth to drive adjusted operating income growth of 22%, resulting in an adjusted operating margin of 23.4% and 130 basis point improvement year-over-year.
We delivered adjusted EPS of $0.27, achieving the high end of guidance and representing 25% growth, including the negative $0.015 impact from foreign currency. So given our strong performance, we are increasing our 2016 guidance for revenue and adjusted EPS. We're are increasing our full year organic revenue growth guidance from 6% to 8% to 8% to 9%, full year operational revenue growth guidance, which includes the benefit of AMS, is increased from 9% to 11% to 11% to 12%. We're maintaining our full year adjusted operating margin guidance of 24% to 24.5%, which at the midpoint is roughly 200 basis points of improvement over 2015. We're also increasing our adjusted EPS guidance by $0.01 over our prior range to $1.07 to $1.11, which represents 15% and 19% growth. Importantly, this adjusted EPS guidance includes an expected $0.05 negative impact from foreign exchange.
I'll now provide some highlights on Q2 results and our '16 outlook. In my remarks, all references to growth are in a constant currency organic year-over-year basis, and they exclude the benefit of AMS. Our second quarter revenue growth of 10% was broad based across businesses and regions, led again by exciting new product launches, continued global expansion and execution of our category leadership strategy. We drove double-digit growth in 5 businesses: endo, urology public-health, Neuromodulation, Interventional Cardiology and Peripheral Interventions. In addition, each region accelerated sequentially. The U.S. grew 8%; Europe, grew 9%; Asia PAC delivered 16% growth, with every major country in the Asia Pac region up double digits this quarter. The emerging markets also continued to deliver. Sales grew 20%, including China revenue at 21%. 
Our MedSurg businesses, endo, Urology public health and Neuromodulation, continue to be a priority focus area for the company, and each of the businesses maintained or accelerated growth from first quarter. These 3 businesses represent 40% of our operating income in the second quarter and they delivered adjusted operating margin of 32.8%. This is up 20 basis points sequentially and 240 basis points year-over-year. Our global Endoscopy team continues to perform at a high level with the revenue growing 11% in the second quarter. We continue to see strong growth in our core endo business, supported by our innovative portfolio and broad-based global expansion initiatives. Key endo growth drivers include the single-use SpyGlass DS Visualization System, the AXIOS Stent for drainage of pancreatic fluid and our next-generation hemostasis clip, the Resolution 360. High single-digit growth in U.S. endo was complemented by double-digit growth in every region outside the U.S., as we continue to develop commercial and position-training abilities in emerging markets and add focus in pulmonary, which helped drive 25% growth in BT, bronchial thermoplasty, led by the U.S., Japan and China. 
In Urology and public health, our investments to become the clear market leader and category leader have been rewarded, as growth excluding AMS accelerated to 18%. The business is performing at a high-level across the various regions and segments, including kidney stone, BPH, ED and surg gyn. Our global commercial footprint and focus on physician education has helped us to convert a meaningful portion of the market opportunity created by a STORZ's exit from the market at the end of March. 
AMS sales strength in the quarter and importantly, remediation and integration efforts remain on track. An exciting new growth platform in our urology business is the launch of a LithoVue platform. LithoVue is an innovative single-use digital scope for treatment of kidney stones that provide customers with enhanced visualization and navigation capabilities. LithoVue resonates with physicians and hospitals due to less OR downtime for sterile processing of reusable scopes. Performance navigation characteristics that allow physicians to tackle tougher procedures and the ability to schedule full day of procedures without the fear of cancellation due to reusable scopes being down.
In Neuromodulation, we continue to invest in the fast-growing microelectronics market, where we enjoy innovation and supply chain leverage between our CRM and neuromod business. Neuromodulation revenues grew in the quarter to 12% -- grew 12%. Sales were driven by the U.S. market-leading Spectra platform; the launch of Precision montage, which offers full body MRI capability; and our Vercise Deep Brain Stimulation platform. Our U.S. DBS trial continues to progress, and we expect to launch in the U.S. in the first quarter of 2018. Additionally, earlier this week, we announced the acquisition of Cosman Medical, a technology leader in the field of radiofrequency ablation systems for the treatment of chronic pain. This acquisition broadens our neuromodulation portfolio and is highly synergistic with our U.S. commercial team. We're excited to offer physicians treating patients with chronic pain another non-opioid therapeutic option earlier in the treatment continuum.
Now turning to Cardiovascular, which includes our peripheral and Interventional Cardiology businesses. Overall, this segment grew sales 13% in the quarter and delivered adjusted operating margin of 32.2%, up more than 170 basis points year-over-year. Our peripheral business delivered exceptional results with strong global sales across all regions fueled by an innovative portfolio. Sales grew 14% on strong results across all regions and segments, including stents, thrombectomy and our emerging drug-eluting portfolio. We also delivered strong growth in Interventional Oncology, where the integration of Interventional Radiology business of CeloNova remains on track. In our Venous segment, we continue to see very strong demand for our Zelante deep vein thrombosis system. We are the only company that have been leading drug-eluting technology globally on multiple platforms in order to treat complex, peripheral vascular disease. The Eluvia peripheral drug-eluting stent ID trial called IMPERIAL is on track to complete enrollment by yearend 2016. 
In Interventional Cardiology, we are focused on gaining share in our core businesses while expanding in faster growth segments that leverage our capabilities. This strategy is working. In the second quarter, interventional cardiology grew 12% led by structural heart, drug-eluting stents and PCI guidance. SYNERGY had an excellent quarter, as we grew DES sales 9%. SYNERGY is now the market-leading premium DES platform and it's on track to represent 50% to 60% of our U.S. DES revenue mix by the end of 2016. PCI guidance grew mid-teens and continues its share gains in intravascular ultrasound, and we're encouraged by strong early feedback on the ease-of-use of our COMET fractional flow reserve system. Our leading portfolio of solutions for complex high-risk PCI patients also contributed to global growth.
The 12% IT revenue growth was fueled by our strength in the structural heart business, which includes our Lotus transcatheter aortic valve and WATCHMAN Left Atrial Appendage Closure. We believe we are well-positioned to drive long-term growth in these 2 fast-growing markets via our differentiated platforms and expanded capabilities. We also aim to deliver the high-end of our 2016 Structural OR guidance range of $175 million to $200 million.
Our Lotus Valve continues to gain share in Europe, and we are investing significantly in clinical studies, R&D and a global supply chain to develop our capabilities further. We remain on track to launch Lotus EDGE at PCR London Valves in September. The Lotus EDGE delivery system features a 14 French expandable sheet called iSleeve [ph] and is designed for more flexibility and simplified deployment. It also offers our new Depth Guard technology, which limits the depth of the valve in the left ventricular outflow tract. Lotus also offers best-in-class paravalvular leakage rates, and we aim to enhance Lotus with studies to demonstrate improved permanent pacemaker rates with Lotus EDGE and Depth Guard. So our goal is to provide initial Lotus EDGE data at PCR London Valves. We do expect a slight delay in our expanded Lotus Valve matrix in Europe, with a 21-millimeter valve estimated CE Mark timing first quarter '17, and a 29-millimeter valve in Europe in mid-2017. We continue to invest and plan for a U.S. launch with the Lotus EDGE platform in late 2017.
Also in structural heart, WATCHMAN sales were strong on procedure growth and new account openings. We are developing additional WATCHMAN capabilities in field clinical support, market development and physician training courses. Implant success rates and patient outcomes remain very high as evidenced by the 98.5% success rate in the evolution registry detailed at HRS in May.
We continue to expand WATCHMAN in the new markets and we're pleased with the recent reimbursement approval and launch in France. Importantly, the unique clinical benefits of WATCHMAN are being rewarded, as evidenced by the French reimbursement at a meaningful premium to competitive LAAC devices.
We post a limited market release of our next generation WATCHMAN FLX device. We've have decided to pursue design enhancements before we turn in the next-gen platform to market. Importantly, we anticipate this delay will have no impact on our current WATCHMAN product and thus, no change to our market outlook for LAAC.
Rhythm Management sales increased 5% in the quarter and delivered adjusted operating margin of 16.9%, up 200 basis points year-over-year, as improving profitability remains a core focus.
In CRM, we improved our global performance and delivered 4% growth in second quarter. Our European and Asia PAC CRM businesses continue to grow faster than the market, offset by slower growth in U.S. CRM. Pacemaker sales grew 15% globally, with excellent U.S. performance fueled by our ACCOLADE MRI launch, and growth from our X4 CRT-P quad device. Worldwide ICD sales were flat as we delivered above-market growth internationally that was offset by weaker sales in the U.S. In the U.S., we faced some near-term headwinds due to our tachy MRI product gap and replacement cycle headwinds. However, we recently we earned FDA approval of our ACUITY X4 quad CRT lead and the early results are promising. Importantly, EMBLEM S-ICD is a key differentiator, and growth continues to accelerate globally. We continue to expand global S-ICD utilization with more long-term data from the EFFORTLESS Registry, growing physician implant experience, geographic expansion and the recent second quarter of '16 EU launch at EMBLEM MRI, which contributed to our solid international growth.
Due to a change in protocol of our U.S. enabled MRI clinical trial, we are revising our goal for transvenous tachy MRI U.S. approval by year-end 2017, but continue to expect a gain in MRI labeling for both new and previously implanted ICDs and CRT-Ds with a new timeline. The continued cadence of data proving the superiority of EnduraLife batteries and the pending FDA approval of EMBLEM MRI S-ICD, which is expected in the third quarter, will help us offset the near-term headwinds from the U.S. MRI high-voltage segment.
In the second quarter, European CRM sales grew 5%, representing 9 straight quarters of above-market growth, giving us further confidence in our long-term CRM outlook. Our EP business grew 6% in the second quarter and we're encouraged by double-digit growth in Europe, led by new arrhythmia installs and the recent launches of Nitinol OI and IntellaTip MiFi OI ablation catheters. The U.S. launch in late first quarter of Blazer OI catheter will be augmented in Q3 with the upcoming launch of the nav-enabled version of this catheter. 
So to wrap up, our company delivered another excellent quarter. Our second quarter performance reflects the strength of our global team, the depth and breadth of our portfolio, our globalization efforts and our ongoing investment in the faster growing markets. Importantly, we believe we are well-positioned to deliver continued strong results in the second half of '16 and beyond. I really want to thank our employees globally for their winning spirit and their strong commitment to Boston Scientific.
Now let me turn the call over to Dan for a more detailed review of our financial results."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Mike. In Q2, we generated organic revenue growth of 10% versus our 6% to 8% guidance range, and adjusted EPS of $0.27, representing 25% year-over-year growth in the high-end of our guidance range of $0.25 to $0.27. The strong adjusted EPS growth p",1909,"Thanks, Mike. In Q2, we generated organic revenue growth of 10% versus our 6% to 8% guidance range, and adjusted EPS of $0.27, representing 25% year-over-year growth in the high-end of our guidance range of $0.25 to $0.27. The strong adjusted EPS growth performance in Q2 was driven primarily by revenue growth upside and a lower SG&A rate versus prior year. And given the strong performance in the first half of 2016, we are again raising full year guidance for revenue growth and adjusted EPS. Consolidated revenue of $2,126,000,000 represented operational revenue growth of 16%, exceeding the high end of guidance and excludes the impact of a $24 million headwind from foreign exchange, which was in line with guidance. Excluding an approximate 500 basis point contribution from the AMS male urology portfolio acquisition, organic revenue growth was 10% in the quarter and 15% on an as-reported basis.
Adjusted gross margin for the second quarter was 70.7%, decreasing 60 basis points year-over-year and unfortunately, 130 basis points below the midpoint of Q2 guidance due to a few factors that I will detail. The year-over-year decrease is due to the unfavorable impact of foreign exchange, which was a 120 basis point headwind, as well as costs related to our new Malaysia manufacturing plant, the AMS integration, including the AMS quality remediation expense. Compared to guidance, the shortfall is due to inventory charges in advance of new product launches, inventory write-offs related to WATCHMAN FLX and more unfavorable FX.
We now expect Q3 and full year 2016 adjusted gross margin to be in the range of a 71.5% to 72.5%, which includes an expected 75 to 100 basis point of unfavorable foreign exchange. A key element in the second half increase is lower expected inventory charges, and we will also benefit fully from the lower 2016 standard cost of our products as we will have sold through all of the inventory valued at last year's higher standards. Adjusted SG&A expenses were $763 million or 35.9% of sales in Q2, down 140 basis points year-over-year. We continue to believe our full year rate will be between 35.5% and 36.5%, which at the midpoint would be a 140 basis point improvement compared to last year.
Adjusted research and development expenses were $222 million in the second quarter or 10.4% of sales, which is down 50 basis points year-over-year. As a result of a slightly lower R&D rate in the first half, we expect our full year 2016 adjusted R&D rate to be between 10.5% and 11.5% of sales or 50 basis points lower than prior guidance. Royalty expense was 0.9% of sales in Q2, roughly flat year-over-year. Our Q2 2016 adjusted operating margin of 23.4% was in line with our guidance and represents a 130 basis point improvement over Q2 last year, which marks the eighth consecutive quarter in which we will have expanded adjusted operating margin by 100 basis points or more.
As a reminder, we've signaled a sequential decrease in adjusted operating margin from Q1's rate as we experienced the usual increase in SG&A from Q1 to Q2 due to seasonal trade show activity and began to ramp reinvestment of the medical device excise tax suspension. Our first half 2016 adjusted operating margin of 24.2% positions us well to achieve our full year adjusted operating margin guidance of 24% to 24.5%, and we remain on track to reach 25%-plus in 2017.
Q2 adjusted operating income grew 22% year-over-year, with all 3 reportable segments expanding adjusted operating margin by at least 170 basis points over Q2 2015. Specific to Rhythm Management, the team delivered an adjusted operating margin of 16.9%, up 280 basis points year-over-year. In the second half of 2016, we expect Rhythm Management adjusted operating margin to continue to improve and be 18% to 19%. This second half gain is expected to result from realizing the full benefit of 2016 product costs, leveraging the improved top line performance expected of the global CRM and EP businesses, and we continue to believe Rhythm management is on track to deliver an adjusted operating margin of 20% in 2017.
Turning to the balance sheet, we had some key developments in the quarter that helped reduce future uncertainties. Before I get into the details of the activity in the quarter, let me try to frame out the next 3 years of expected cash flow at a high level. From 2017 through 2019, we believe we can generate cumulative adjusted free cash flow after CapEx approaching $6 billion. We expect to allocate roughly 2/3 of that $6 billion to a combination of M&A and share repurchases. As you're aware, the 2 most significant liabilities on our balance sheet are our IRS transfer pricing case and the mesh litigation. During the quarter, we took 2 important steps to manage these liabilities. First, we reached a stipulation of settled issues with the IRS for the 2001 to 2007 tax years. And importantly, this stipulation also provides a framework to settle the remaining years 2008 through 2015 as well. While there's work to do to conclude all the years, we are confident we will bring these to conclusion over the coming quarters. With the payment in 12 to 24 months, this would eliminate one of the most significant liabilities on our balance sheet. With regards to mesh, we increased our reserve by $608 million during the quarter. With the same goal of managing our liabilities, we've reached conditional or final settlements on 12,000 claims and made significant progress towards reaching agreement in principle on another 7,000 claims for a total of 19,000 claims. This represents approximately half of the roughly 40,000 known claims, and we expect to make even more progress during the remainder of 2016. As you know, every quarter, we assess all 4 key components involving calculating the reserve and make any necessary adjustments for all probable and estimable charges, including the volume of known claims, the estimated cost to resolve each claim, an estimate of future claims and the cost to defend each claim.
Our total legal reserve, of which mesh is included, was $2,375,000,000 as of June 30, 2016 and we believe it reflected our best estimate of what is probable and estimable. Of note as well, is that included in this reserve is the Mirowski Judgment which we have paid in full, subsequent to quarter end. So as of today, the reserve would be closer to $2 billion. As a reminder, this $2 billion includes a number of claims we have agreed in principle to settle but have not yet paid. Once those settlements are funded, the amount of the reserve will be adjusted accordingly.
Now I'll move on to interest expense. Interest expense for the quarter was $59 million, compared to $106 million in Q2 of last year. The decrease is primarily due to the pretax onetime charge of approximately $45 million associated with a senior note refinancing in Q2 of last year. Excluding this charge, Q2 2015 interest expense was $61 million. Our average interest expense rate was 4% in Q2 this year compared to 8% in Q2 last year. The lower interest-rate expense in Q2 of '16 was primarily due to lower average cost of debt resulting from the senior notes refinancing and the inclusion of the pretax onetime charge in Q2 of last year that I mentioned. Excluding this charge, Q2 2015 interest expense would have been 4.6%.
Our tax rate for the second quarter was 47.8% on a reported basis and 14.2% on an adjusted basis. As reported last week, we're pleased with the conditional settlement reached with the IRS council regarding our transfer pricing litigation, and plan to use some of the current benefit to repatriate overseas cash. Thus we continue to expect our full year 2016 adjusted tax rate to be approximately 14%. We believe this IRS settlement, in addition to recent progress we've made towards reaching agreements in principle to settle additional mesh claims, as I mentioned, are prudent actions to take in the management of our balance sheet.
Finally, Q2 2016 adjusted EPS of $0.27 includes approximately $0.015 of unfavorable FX and represents 25% year-over-year growth or 32% growth excluding the impact of foreign exchange. On a reported GAAP basis, Q2 2016 EPS was a loss of $0.15 and includes net charges and amortization expense totaling $580 million after tax.
Adjusted free cash flow for the quarter was $464 million compared to $406 million in Q2 of last year. Given the strong adjusted free cash flow generation in the first half of this year, we are raising our full year adjusted free cash flow guidance from $1.5 billion to $1.6 billion, which was formally our stretch goal. Achieving adjusted free cash flow of $1.6 billion would represent 17% growth, and we continue to pursue inventory management initiatives designed to improve the working capital contribution to cash flow.
In Q2, we used cash primarily to repay $250 million of bank term loans, as well as fund the previously agreed legal settlements. As of June 30, 2016, we had cash on hand of $438 million. Near term, our capital allocation priorities are to manage contingencies and pursue tuck-in M&A. 
We ended Q2 with 1,375,000,000 fully diluted weighted average shares outstanding. Consistent with our prior guidance, we expect our share count to increase by roughly 5 million per quarter through the end of 2016, as we plan to keep the buybacks suspended for the balance of this year. We expect this to result in a fully diluted weighted average share count of approximately 1,380,000,000 shares for full year 2016.
I'll now walk-through guidance for Q3 and full year 2016. For the full year, we now expect consolidated revenue to be in a range of $8,270,000,000 to $8,370,000,000, which represents year-over-year growth of 8% to 9% on an organic basis and 11% to 12% on both on operational and reported basis. As a result of a stronger dollar, at current rates, we expect foreign exchange to be a headwind of approximately $70 million for the full year 2016. 
Turning to adjusted EPS, we now expect full year 2016 adjusted EPS to be in a range of $1.07 to $1.11, representing 15% to 19% adjusted earnings growth. Our previous guidance assumed the unfavorable FX on full year adjusted EPS would be between $0.05 and $0.06. Given the fact that Q2 saw a slightly less unfavorable impact than expected, we now believe the full year impact will be closer to $0.05 which assumes $0.02 to $0.03 in the second half of this year. On a GAAP basis, we expect EPS to be in a range of $0.30 to $0.35.
Now turning to Q3 2016, we expect consolidated revenues to be in a range of $2,035,000,000 to $2,085,000,000. This represents year-over-year growth in a range of 7% to 9% organically and 8% to 10% operationally. We expect the foreign exchange headwind on Q3 revenue to be negligible. For the third year -- for the third quarter, adjusted EPS is expected to be in a range of $0.25 to $0.27 per share, and GAAP EPS is expected to be in a range of $0.13 to $0.15 per share.
Please check our Investor Relations website for Q2 2016 financial and operational highlights, which outlines Q2 results, as well as Q3 and full year 2016 guidance, including P&L line item guidance. So with that, I'll turn it back over to Susie, who'll moderate the Q&A."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Dan. Greg, let's open it up to questions for the next 30 minutes. [Operator Instructions] Greg, please go ahead.",20,"Thanks, Dan. Greg, let's open it up to questions for the next 30 minutes. [Operator Instructions] Greg, please go ahead."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","[Operator Instructions] Your first question comes from the line of Mike Weinstein from JPMorgan.",14,"[Operator Instructions] Your first question comes from the line of Mike Weinstein from JPMorgan."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Let me just clarify this on a few items. So number one, the pacemaker performance being as strong as it is on the back of the MRI launch. One question that I've already got with people is, is that a clean number, is there any stocking in that number that",90,"Let me just clarify this on a few items. So number one, the pacemaker performance being as strong as it is on the back of the MRI launch. One question that I've already got with people is, is that a clean number, is there any stocking in that number that we should be aware of? Second, the movement in the structural heart guidance to the high end of the range, is that WATCHMAN, was it Lotus? If you could kind of share any insights into that, and then I'll follow-up."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, good morning, Mike. On the pacemaker, our team has been waiting for a long time for that product approval. We've had some slow quarters in our pacemaker business in the U.S. Outside the U.S., we've done quite well with our product for a while. So th",273,"Sure, good morning, Mike. On the pacemaker, our team has been waiting for a long time for that product approval. We've had some slow quarters in our pacemaker business in the U.S. Outside the U.S., we've done quite well with our product for a while. So that's not a stocking number. We were ready for that launch for quite a while and the team -- our commercial team's did an excellent job executing it. So we think it's a very innovative product and long in coming. And the U.S. team, essentially, has did what the OUS teams have done with that product for a while. And now, structural heart, we continue to be really excited about the future for structural heart. It continues to be our largest investment area as a company. We were comfortable with the high-end of our guidance that we provided at $175 million to $200 million. We continued to invest long-term in R&D capabilities, clinical capabilities and commercial capabilities to prepare ourselves for the launch in the U.S. And we're really excited about the upcoming data that we expect to see in London Valves on our pacemaker rate with the addition of Lotus EDGE and Depth Guard. So it's really an important category for us. As you know, we continue to -- we outlined at Investor Day, back in, I think 2013 and '15, our focus to continue to grow in our core businesses and take share, which we're doing, and importantly, expand in the faster-growth markets. And that's exactly what you're seeing as a company, and our structural heart investment really is kind of leading the pack there."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","So Mike, I would apologize. The question was structural heart -- within structural heart, WATCHMAN is what's driving to the high end of the range there?",26,"So Mike, I would apologize. The question was structural heart -- within structural heart, WATCHMAN is what's driving to the high end of the range there?"
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","What's driving the high-end range there is, we're just continue to open up new accounts. We continue to improve our account utilization. And we continue to build up our commercial capabilities in the U.S.",35,"What's driving the high-end range there is, we're just continue to open up new accounts. We continue to improve our account utilization. And we continue to build up our commercial capabilities in the U.S."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. The gross margin issues in the quarter, I think -- I feel you did a good job of -- Dan walking through what those are. So if we look at the back half of the year, and expect an improvement in gross margin, that's because, one, your inventory issues",86,"Okay. The gross margin issues in the quarter, I think -- I feel you did a good job of -- Dan walking through what those are. So if we look at the back half of the year, and expect an improvement in gross margin, that's because, one, your inventory issues from the AMS transaction, basically, you get to a better, safer cost than on those products, and then the FX headwind that you saw in this quarter on the gross margin should dissipate. Is that accurate?"
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","No, somewhat. Let me just make sure we're clear on that. So we're at 70.7% in the quarter. The guidance range for Q3 and the full year is 71.5% to 72.5%, so it implies the uptick that you mentioned in the second half. I think the 2 key drivers of that are",230,"No, somewhat. Let me just make sure we're clear on that. So we're at 70.7% in the quarter. The guidance range for Q3 and the full year is 71.5% to 72.5%, so it implies the uptick that you mentioned in the second half. I think the 2 key drivers of that are, the inventory charges for the CRM products related to the better uptake of MRI-safe brady and quad in the U.S. as well as the WATCHMAN FLX. We don't believe that those repeat themselves. And then secondly, we will get the full benefit in the second half of the lower manufacturing costs that for 2016 standards because we'll now be selling all the inventory at the new standards, and we'll have sold off all of the inventory at last year's standards. Those are the 2 main drivers that put us back in the 71.5% to 72.5% range. FX, we actually assume is probably somewhat in the same range as where it was in Q2. That's really the reason. If you think back to last quarter, our guidance for FX in gross margin would have implied about 70 to 75 basis points each quarter for Qs 2, 3 and 4. Now it's 120. So that's a 50 basis point difference. And that's the reason why the guidance for the full year came from 72% to 73% to 71.5% to 72.5%."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of David Lewis from Morgan Stanley.",13,"Your next question comes from the line of David Lewis from Morgan Stanley."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","In light of the very strong revenue quarter, guys, I hate to ask something as banal as cash flow, Dan, but you don't give us multiyear cash flow spins that often, and I noticed that your $6 billion free cash estimate in the next 3 years is 10% higher than",105,"In light of the very strong revenue quarter, guys, I hate to ask something as banal as cash flow, Dan, but you don't give us multiyear cash flow spins that often, and I noticed that your $6 billion free cash estimate in the next 3 years is 10% higher than what we were looking for. Can you sort of walk us through kind of why that'll be in some of the components? I imagine one component is CapEx and perhaps the other is margins, but our margin numbers are pretty high and you're still 10% above us. So what could be driving that significant upside?"
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","I think you answered your own question there, David. It's margins and CapEx. So the -- one of the things we have this year is, as we detailed in our guidance at the beginning of the year is, the CapEx number at $350 million, that's $100 million higher tha",207,"I think you answered your own question there, David. It's margins and CapEx. So the -- one of the things we have this year is, as we detailed in our guidance at the beginning of the year is, the CapEx number at $350 million, that's $100 million higher than we think we need to effectively run each year. So we get that back hopefully each of the next 3 years. And then, the expanding margins. So our goal next year is 25%-plus, and as we've given guidance for long-term goals for 27% to 28% by 2020, the combination of those 2 factors and the CapEx, I think, gets you a long way there. And then the other piece is that, we're going to continue to try from a working capital perspective to make that be our friend. We have a lot of inventory initiatives in place to really hopefully lead the industry in that regard, and be best-in-class, and when we do that, that'll turn something that's been a drag on cash flow into a positive, and hopefully see the beginnings of that this year. You see that from us taking our guidance from $1.5 billion to $1.6 billion a piece of that is the inventory initiatives."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay, very helpful. And then Mike, maybe a couple of product questions. I guess the first is just, it's just sort of a forgotten business for Boston MedSurg is sort of no longer forgotten given the organic growth and specifically, Endoscopy has gone from",131,"Okay, very helpful. And then Mike, maybe a couple of product questions. I guess the first is just, it's just sort of a forgotten business for Boston MedSurg is sort of no longer forgotten given the organic growth and specifically, Endoscopy has gone from mid-single growth last year to double-digit growth this year. I wonder if you can just give us a sense of sort of where we are in the product cycles? Is it share gain from competitors? Is it product cycles that is driving that? And then, secondarily, on DES, on synergy, where you think we are in sort of share versus mix? And obviously, you're growing dramatically ahead of market. So what are some of the factors that are driving that? And I'll now jump back in queue."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks. David. We definitely never forgot about endo. It's really an incredibly high performing business and it has been for a number of years. And it really had just continue to do -- continue to grow and expand. So our endo business enjoys, a, first of",446,"Thanks. David. We definitely never forgot about endo. It's really an incredibly high performing business and it has been for a number of years. And it really had just continue to do -- continue to grow and expand. So our endo business enjoys, a, first of all, a strong market, a bit fewer competitors in our Endoscopy markets than some of our others. It has very strong growth profile in terms of the market growth in OUS expansion, and we are a very strong category leader. Across the globe, when we continue to expand and taking emerging markets. The portfolio is really driving a lot of the launch out of the success that you're seeing in 2016, led by our SpyGlass digital DS platform, which is driving solid double-digit growth and helps pull through the core portfolio. We also launched a product called the AXIOS Stents, which is doing very well, as well as a hemostasis clip. So the portfolio cadence for endo is very strong, it's very well-led, it's very globally oriented, and they also do a great job of laying out the economic value proposition for hospitals beyond the portfolio. So they continue to perform very well and intentionally, in some of my comments with Mike in his first question, we are intentionally focusing on investing greater in faster-growth markets, in faster growth businesses and they represent 40% of our operating income, the MedSurg sector does now for BSC. So more to come there. DES is doing excellent. We had a few critics early on in our launch saying we won't be an aggressive NOAS. We signaled all along that we're going to be drive an appropriate premium price for this product because we believe it is the best product available in the marketplace and the data is proving that out, and maybe Keith can comment in a minute. So we believe it's the premium product. We do operate a premium price for it. And so we've been smart in our rollout of it, and I think physicians and customers are seeing the value of the ease-of-use and the clinical data synergy and we expect the U.S. penetration to be probably above 50%, closer to 50% to 60% in the U.S. in 2016. And we continue to roll that out globally. So the team is doing a nice job there. But again, it's part of the overall story in interventional cardiology. Again pointing to faster growth segments, our DES is doing well. A lot of investments in complex coronary and imaging, which are part of the portfolio, and then clearly our structural heart. So Kevin Ballinger and the team are doing a nice job."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Keith?",1,"Keith?"
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, David, I think the SYNERGY Stent operators around the world are appreciating the best-in-class acu performance because, obviously, if you can't deliver the stent, that's really the end of the discussion. And it -- we have a lot of data now, including",124,"Yes, David, I think the SYNERGY Stent operators around the world are appreciating the best-in-class acu performance because, obviously, if you can't deliver the stent, that's really the end of the discussion. And it -- we have a lot of data now, including the EVOLVE II pivotal data, the EVOLVE personally use 5-year data, and the Real-World Sky data from Europe confirming the safety. Everybody, both patients and physicians, are interested in stent thrombosis. And the stent thrombosis, as you know from the data, is very low. We have 20,000 patients in investigator-sponsored trials with Synergy. And these trials are beginning to release their data, and you'll see more flows of data at the meetings during the rest of this year and next year."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of Larry Biegelsen from Wells Fargo.",13,"Your next question comes from the line of Larry Biegelsen from Wells Fargo."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","So Dan, you raised the organic growth from 6% to 8% to 8% to 9%, but you only raised the EPS guidance by $0.01. And so can you talk about why you're not getting better leverage in the incremental revenue? You kept the operating margin guidance same. And t",53,"So Dan, you raised the organic growth from 6% to 8% to 8% to 9%, but you only raised the EPS guidance by $0.01. And so can you talk about why you're not getting better leverage in the incremental revenue? You kept the operating margin guidance same. And then, I had 1 follow-up."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, Larry. I think, probably the best way to explain that is to do a quick summary of the increase in revenue. So the revenue is $170 million higher at the midpoint of guidance and that breaks down into 3 things: $20 million comes from FX, $75 million c",163,"Sure, Larry. I think, probably the best way to explain that is to do a quick summary of the increase in revenue. So the revenue is $170 million higher at the midpoint of guidance and that breaks down into 3 things: $20 million comes from FX, $75 million comes from revenue that already came in Q2, and then $75 million comes in the second half. I think the main factor that's offsetting that is, if you look at our R&D rate, our R&D rate in the first half was 10.5%. And looking at the second half, it's going to be 11.5% to get to the full year rate of 11%. So that's 100 basis point increase in R&D, largely related to the timing in the investments in structural heart that Mike had mentioned. So that for, the most part, offsets the additional flow through in the revenue that you get -- the additional $75 million of revenue you get in the second half."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Got it. And then...",4,"Got it. And then..."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Just as a footnote. As you look at it, still very pleased to be at 15% to 19% full year EPS growth, which would be 4 years straight of double-digit adjusted EPS growth.",33,"Just as a footnote. As you look at it, still very pleased to be at 15% to 19% full year EPS growth, which would be 4 years straight of double-digit adjusted EPS growth."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Got it, sorry to interrupt there. And then, for my follow up. At the 2015 analyst meeting, the organic revenue goal was 3% to 6% in 2016 and 2017. You're now guiding to 8% to 9% in 2016. How should we think about the sustainability of the 8% to 9%, and yo",80,"Got it, sorry to interrupt there. And then, for my follow up. At the 2015 analyst meeting, the organic revenue goal was 3% to 6% in 2016 and 2017. You're now guiding to 8% to 9% in 2016. How should we think about the sustainability of the 8% to 9%, and your goals in 2017 and beyond? And I recognize you're not giving guidance here, but you're way outperforming what you expected to do at your analyst meeting last year."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, yes, the team is outperforming. It's part of the high-performance culture that we have as a company. We're very excited about the full year guidance at 8% to 9%. As you said, it compares to 3% to 6% we laid out, so it's a pretty strong beat the",125,"Thank you, yes, the team is outperforming. It's part of the high-performance culture that we have as a company. We're very excited about the full year guidance at 8% to 9%. As you said, it compares to 3% to 6% we laid out, so it's a pretty strong beat there. And strong momentum across, really, each region and each business. So we're not going to provide any outlook into 2017. Clearly, outperforming the market at these levels -- at this level is not likely sustainable each year. But that being said, we're confident we'll continue to outperform the market. We're investing in faster growth businesses, and we're very confident in our ability long-term to drive mid-single revenue growth, improve margins and drive double-digit EPS growth."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of Bob Hopkins from Bank of America.",14,"Your next question comes from the line of Bob Hopkins from Bank of America."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","So obviously, you've got the best revenue growth year for Boston Scientific, essentially since the financial crisis. Higher absolute level of revenues then, I think, any of the thought, so congratulations on the unbelievable progress. I guess my first que",149,"So obviously, you've got the best revenue growth year for Boston Scientific, essentially since the financial crisis. Higher absolute level of revenues then, I think, any of the thought, so congratulations on the unbelievable progress. I guess my first question is really kind of philosophical in terms of the long term. Now that you've got this sort of higher level of revenues and higher level of revenue growth, you guys have given some long-term guidance on operating margin targets and goals. So now that you're kind of outperforming on revenues, what's the thought on those operating margin targets? Is the thought that you'll take an opportunity to spend more and continue to sort of keep those operating margin targets, or is it more likely that with this higher level of growth, that you could be towards the high end or higher of the long-term target that you've set previously?"
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Bob. I don't think we'll be changing the trajectory in terms of the margin guidance we've given. As we always say, it's about striking a balance between delivering durable, consistent revenue growth and expanding operating margins. And if you look",109,"Thanks, Bob. I don't think we'll be changing the trajectory in terms of the margin guidance we've given. As we always say, it's about striking a balance between delivering durable, consistent revenue growth and expanding operating margins. And if you look at the numbers and see what we've done for the last 3 years relative to revenue growth and particularly on the margin expansion front, looking at 27% to 28% adjusted operating margin by 2020 and a consistent, durable growing top line through that period and the goal of double-digit adjusted EPS growth each of those years, I think we are going to stick with that as our targets."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","I understand you're sticking with the targets, but I'm just trying to understand philosophically, because you're outperforming so nicely here. Is the bias more towards opportunities to invest more, or let some of that through, because again, these levels",49,"I understand you're sticking with the targets, but I'm just trying to understand philosophically, because you're outperforming so nicely here. Is the bias more towards opportunities to invest more, or let some of that through, because again, these levels are just so much higher than we originally thought."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Again, it's striking a balance. We do have a lot of investment, as Mike mentioned, relative to structural heart. That's a lot of investment to get to the U.S. market and be successful there and I think we're -- it's always about striking that balance.",45,"Again, it's striking a balance. We do have a lot of investment, as Mike mentioned, relative to structural heart. That's a lot of investment to get to the U.S. market and be successful there and I think we're -- it's always about striking that balance."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, and I think also, we'll do an Investor Day in 2017. We haven't nailed down yet, but we're making significant investments in platforms and markets that will have a big impact on the growth through to the business in '18, '19 and '20. And so you look a",124,"Yes, and I think also, we'll do an Investor Day in 2017. We haven't nailed down yet, but we're making significant investments in platforms and markets that will have a big impact on the growth through to the business in '18, '19 and '20. And so you look at our launch in the U.S. of TAVR, our; launch in the U.S., in the future of Deep Brain Stimulation, launching all-in-one when we'll have a drug-eluting stent and a drug-coated balloon for peripheral vascular, and we continue to expand into pulmonary and other areas across the company. So we definitely are investing for long-term growth and a lot of it is big clinical investments in R&D that'll impact the company, particularly in '18, '19, '20."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","And then on structural heart just real quickly. What was the driver of you guys providing guidance there that it'll be at the high end of the range. Is that Lotus or WATCHMAN or both?",35,"And then on structural heart just real quickly. What was the driver of you guys providing guidance there that it'll be at the high end of the range. Is that Lotus or WATCHMAN or both?"
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","It's both. Both are doing quite well.",8,"It's both. Both are doing quite well."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of Brooks West from Piper Jaffray.",13,"Your next question comes from the line of Brooks West from Piper Jaffray."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Just to put a cap on the gross margin discussion. So Dan, those all seem like transient issues with the inventory, and I'm not trying to push for guidance for next year, but as I look at my model, we've got you at about 73% gross margins for 2017. I don't",109,"Just to put a cap on the gross margin discussion. So Dan, those all seem like transient issues with the inventory, and I'm not trying to push for guidance for next year, but as I look at my model, we've got you at about 73% gross margins for 2017. I don't see anything that I really to flow through into '17 from this. Is that the correct way to think about it? I mean, you're a little bit lower for '16, but in terms of thinking about the forward model, that should resolve itself and we should kind of go back to where we thought we are going, correct?"
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, I mean, I wouldn't talk specifically about a rate for 2017. Obviously, the goal is to continually increase the gross margin rate and it'll be part of what we believe is 25%-plus adjusted operating margin for next year. So with that as the goal, -- th",103,"Yes, I mean, I wouldn't talk specifically about a rate for 2017. Obviously, the goal is to continually increase the gross margin rate and it'll be part of what we believe is 25%-plus adjusted operating margin for next year. So with that as the goal, -- the FX in the back-half is really the only thing that we believe is consistent from the Q2 performance. The other things that I mentioned relative to inventory charges and the benefit from the standards, hopefully is, to your point, is a transient thing. So the FX is the only one that continues into the second half."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay, perfect. And then, maybe kind of piggybacking on Bob's question, but also thinking about some of the questions around MedSurg. You kind of conditioned us, in terms of the long-term operating margin progression, to think about Rhythm Management. And",121,"Okay, perfect. And then, maybe kind of piggybacking on Bob's question, but also thinking about some of the questions around MedSurg. You kind of conditioned us, in terms of the long-term operating margin progression, to think about Rhythm Management. And obviously, you're making great progress there. But given the growth we're seeing in MedSurg and Interventional Cardiology, it seems like that equation maybe needs to change a little bit and if we allocate a little bit more of the strength in MedSurg to that equation, it seems like we push up to and through those targets maybe more quickly than if we were just relying on Rhythm Management. Is that also a fair kind of way to look at your business?"
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, I think the focus on Rhythm Management has really been just because of where they were, right? Starting off in the high single digits, it's gotten a lot of focus over the last 3 or 4 years. I think we've made -- Jill and team have made tremendous pro",187,"Yes, I think the focus on Rhythm Management has really been just because of where they were, right? Starting off in the high single digits, it's gotten a lot of focus over the last 3 or 4 years. I think we've made -- Jill and team have made tremendous progress getting it to the 16.9% that it is in Q2, the 18% to 19% that it'll be in the second half of this year and then ultimately, the 20% next year and beyond that -- in 2018 and beyond. All the while, to your point, MedSurg and cardiovascular have continued to grow their margins as well. So I think it goes back to what Mike said to the answer to the last question which is, there's investments that we're making to ensure that durable growth '18, '19, '20 and beyond, and it's not just one business that has that investment. We're investing in all of the businesses. So we've spent a lot of time looking at each of the individual segments and the profitability there, and the math adds up to what we've given for our goals."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Perfect. If I could sneak in just one product question on -- I'm wondering if Marvis [ph] has decided whether to bring [indiscernible] into the U.S. or not?",28,"Perfect. If I could sneak in just one product question on -- I'm wondering if Marvis [ph] has decided whether to bring [indiscernible] into the U.S. or not?"
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, we'll likely be providing additional insights on our clinical strategy with our balloon at the next quarterly call.",19,"Yes, we'll likely be providing additional insights on our clinical strategy with our balloon at the next quarterly call."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of Rick Wise from Stifel.",12,"Your next question comes from the line of Rick Wise from Stifel."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Maybe let me start off with Lotus. Mike, you talked about gaining EU share in the quarter. Maybe give us a little more color on that. Are you ready to quantify that at all? You've talked about a penetration or share of greater than 30% in your selected ac",90,"Maybe let me start off with Lotus. Mike, you talked about gaining EU share in the quarter. Maybe give us a little more color on that. Are you ready to quantify that at all? You've talked about a penetration or share of greater than 30% in your selected accounts. And maybe just add some more color on the EDGE launch coming up in September. Is this is share gainer or no? That's going to require more time and those additional sizes that are coming in the first half of '17?"
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, sure. Again, this is a big investment for us in structural heart with the WATCHMAN and TAVR. And we're playing it for the long-term here, particularly with our TAVR, given the market growth profile and how large the market is. And our view that we ha",218,"Yes, sure. Again, this is a big investment for us in structural heart with the WATCHMAN and TAVR. And we're playing it for the long-term here, particularly with our TAVR, given the market growth profile and how large the market is. And our view that we have a very differentiated platform from the other market contenders given the controlled release of our Lotus Valve and the low paravalvular leakage rates. So we think we have -- truly have a differentiated platform in a very large market. We're a bit hamstrung in the near term in Europe without having all 5 sizes. We have 3 of them today. So that hurts us a bit, but we'll solve that with a 21-millimeter in 2000 -- first quarter '17 and eventually the largest size in probably first half of 2017. So that'll help. So in the meantime, we continue to do very well with the 3 valve sizes that we have. We won't provide any additional guidance in terms of number of accounts or penetration. But clearly, it is a share taking strategy. The market's already large, the market's growing, and we're quite confident that we're currently the strong #3 player. But that's not going to be our aspiration over the years, particularly as we launch Lotus EDGE and Depth Guard."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Yes, turning to a bigger picture question. Dan obviously, is emphasizing the growth in free cash flow this year, the $6 billion number you've threw over the next few years. You're also saying, Dan, that -- I think correctly, that with the settling or goin",114,"Yes, turning to a bigger picture question. Dan obviously, is emphasizing the growth in free cash flow this year, the $6 billion number you've threw over the next few years. You're also saying, Dan, that -- I think correctly, that with the settling or going a long way towards settling the IRS remiss, a major uncertainty is off the table. I mean, all that suggest to me that, that might give you more flexibility in thinking about M&A or portfolio additions. You just announced Cosman. How are you thinking about this, Mike and Dan? And should we be thinking that there is more possibility for M&A as a result? Any color would be appreciated."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Sure yes. I'll hit it from a financial perspective, and maybe Mike can jump in on the strategic side. The goal, I think, you framed it out very well. That's our goal is to eliminate the uncertainties that we have on the balance sheet, and I think we've ta",159,"Sure yes. I'll hit it from a financial perspective, and maybe Mike can jump in on the strategic side. The goal, I think, you framed it out very well. That's our goal is to eliminate the uncertainties that we have on the balance sheet, and I think we've taken a lot of good steps in the quarter to do that. And that's going to give us more financial flexibility in the future. And that's the goal. So we should hopefully free up more of that cash flow for the long-term. We gave you the numbers hopefully as kind of goals for the next 3 years, and the goal is to have as much of that available to fuel the business from an M&A and share repurchase perspective. So I don't know if anything specific -- but, yes, I mean, that's really the goal, is to eliminate the uncertainties and give us as much financial flexibility as we can have."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of Matt Taylor from Barclays.",12,"Your next question comes from the line of Matt Taylor from Barclays."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","I guess the first question that wanted to clarify on, when you talked about MRI-safe timelines, could you just inform us what revising the goal for tachy MRI timeline and tell what the change was there? And then, S-ICD is still on track. Could you talk ab",63,"I guess the first question that wanted to clarify on, when you talked about MRI-safe timelines, could you just inform us what revising the goal for tachy MRI timeline and tell what the change was there? And then, S-ICD is still on track. Could you talk about how you that's doing and how you expect MRI-safe approval to potentially improve sales for S-ICD?"
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Absolutely, I'll ask Dr. Stein to comment on this question.",10,"Absolutely, I'll ask Dr. Stein to comment on this question."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, on the MRI, not going to get into any of the details of the change in the protocol. But in the course of conduct of our ENABLE MRI trial, we have made a decision that we do need to revise the protocol with respect to patient screening and eligibility",86,"Yes, on the MRI, not going to get into any of the details of the change in the protocol. But in the course of conduct of our ENABLE MRI trial, we have made a decision that we do need to revise the protocol with respect to patient screening and eligibility, and that's just the process of getting that protocol or vision sphere was. What's going to cause the push in the timeline. We still have a goal of getting that approved by the end of 2017."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay, and on S-ICD?",4,"Okay, and on S-ICD?"
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","I am sorry, could you clarify the question on S-ICD?",10,"I am sorry, could you clarify the question on S-ICD?"
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Yes, I was just curious -- I may have missed the comment here because the comments were by kind of fast. But do you still having the same timeline for S-ICD MRI approval? And just how is S-ICD performing today?",40,"Yes, I was just curious -- I may have missed the comment here because the comments were by kind of fast. But do you still having the same timeline for S-ICD MRI approval? And just how is S-ICD performing today?"
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, we saw the same timeline anticipating approval in Q3 of this year, and really, couldn't be more pleased with what we've seen in terms of uptake of EMBLEM MRI, where it's been launched in Europe and the existing EMBLEM device in the U.S. and globally.",59,"Yes, we saw the same timeline anticipating approval in Q3 of this year, and really, couldn't be more pleased with what we've seen in terms of uptake of EMBLEM MRI, where it's been launched in Europe and the existing EMBLEM device in the U.S. and globally. So we expect EMBLEM MRI approval in the U.S. in the third quarter."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Q3 of this year.",4,"Q3 of this year."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes.",1,"Yes."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Great. And could you just talk about broader utilization? Obviously your results were phenomenal this quarter. Are you seeing something going on in either in the U.S. market or some of the emerging markets that you plan, that's contributing to higher leve",64,"Great. And could you just talk about broader utilization? Obviously your results were phenomenal this quarter. Are you seeing something going on in either in the U.S. market or some of the emerging markets that you plan, that's contributing to higher levels of utilization that may not continue going forward? Or do you think that you're really just outperforming your markets from good execution?"
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Well, thanks, Matt. It's Mike. I also don't want to be a broken record here, but I think, I want just to reinforce, consistent with our investor day presentations in '13 and '15, we continue to invest our portfolio into faster-growth markets. So kind of i",177,"Well, thanks, Matt. It's Mike. I also don't want to be a broken record here, but I think, I want just to reinforce, consistent with our investor day presentations in '13 and '15, we continue to invest our portfolio into faster-growth markets. So kind of in the -- maybe the 2011 timeframe, we called our market growths about -- market growth profile 3% in the markets we compete in. So as we've shifted our portfolio over time into the faster-growth markets, we think the markets that we compete in now are kind of in the 4% to 5% growth range. If you look at the compositive BSE. So we are pleased that we're outperforming the market. We'll strive to continue to do so, but we think we have fundamentally shifted the markets that we play in to about a 4% to 5% growth market versus maybe a 2% to 3% growth market 4 or 5 years ago. So the markets are stronger that we compete in, and the team is doing a really nice job of outperforming."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","That question comes from the line of Glenn Novarro from RBC Capital Markets.",13,"That question comes from the line of Glenn Novarro from RBC Capital Markets."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Two questions, one, drug-eluting stents in the quarter up high single digits, significantly outpacing the market. You have it launching Absorb. So my question is, is this high single-digit sustainable given ABSORB coming into the market, or should we anti",52,"Two questions, one, drug-eluting stents in the quarter up high single digits, significantly outpacing the market. You have it launching Absorb. So my question is, is this high single-digit sustainable given ABSORB coming into the market, or should we anticipate a little moderation going forward? And then I had a quick follow-up."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","So yes, we're not giving the DES guidance for the third quarter or fourth quarter. We're going to continue to run the play which is, we believe we have the best product in the market, and Keith can comment a bit more on the clinical data. And we've been c",171,"So yes, we're not giving the DES guidance for the third quarter or fourth quarter. We're going to continue to run the play which is, we believe we have the best product in the market, and Keith can comment a bit more on the clinical data. And we've been competing with ABSORB in Europe for quite a while. We would put at that probably less than the 7% the DBS. So it probably less than 7% of the global market has been in the market for quite a while. So we feel like we're in the position of strength in terms of our product portfolio, and you know we continue to look at DBS. It's an interesting technology, and we've got a number of bets and it's a fact in the future. We can look at a second gen or a third generation device, then we'll eventually bring that to market. But at this time, we believe that SYNERGY is the premium device, and we'll continue to focus on driving that."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","And then, with Keith on the line, I'd love to get his thoughts on kind of SYNERGY versus ABSORB. And then my follow-up was on Eluvia, which was just launched in Europe. And the data is very strong and once you come to the U.S., you'll be by far -- you wil",102,"And then, with Keith on the line, I'd love to get his thoughts on kind of SYNERGY versus ABSORB. And then my follow-up was on Eluvia, which was just launched in Europe. And the data is very strong and once you come to the U.S., you'll be by far -- you will be the second DES on the market for peripherals, but with, by far, the best data. So how is Eluvia doing in Europe? And it just seems like this is one product that has a significant opportunity that's flying under the radar screen. So just thoughts on Eluvia as well."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","So Glenn, in terms of SYNERGY and DBS, obviously, there's not a lot of head-to-head data between the two. But DBS has been available and Europe's had CE Mark for 5.5 years and the penetration, as Mike said, is mid-single digits. And you and everybody else",169,"So Glenn, in terms of SYNERGY and DBS, obviously, there's not a lot of head-to-head data between the two. But DBS has been available and Europe's had CE Mark for 5.5 years and the penetration, as Mike said, is mid-single digits. And you and everybody else on the call is well aware of the ABSORB II and ABSORB III data. The safety profile of a drug-eluting stent is paramount. Safety profile is more important than efficacy, and with a stent thrombosis rate that is at least 2x, SYNERGY, we feel that the first generation fully resemble a scaffold safety profile is open to question. We do have an interest in the space, obviously, and are leader in DES. We have to have that. And as you know, also, we have 3 shots on goal and our own internal FAST program, which is thinner strap, more deliverable stent and more compliant. Less [indiscernible] is in first human use trials now, and we are still anticipating commercialization in Europe in 2018."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","And then, your thoughts on Eluvia, how it's performing in Europe? And your thoughts on how it'll perform in the United States once launched?",24,"And then, your thoughts on Eluvia, how it's performing in Europe? And your thoughts on how it'll perform in the United States once launched?"
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, so we're early with our Eluvia platform. It's a large investment. We will be announcing additional data sets on both our balloon and our stent at CIRSE, which is I think in Barcelona in September, third quarter this year. So we'll continue to lay ou",154,"Sure, so we're early with our Eluvia platform. It's a large investment. We will be announcing additional data sets on both our balloon and our stent at CIRSE, which is I think in Barcelona in September, third quarter this year. So we'll continue to lay out our clinical data there. But I think just the -- again, the strength of having a -- in Europe a drug-coated balloon and a differentiated drug-eluting stent for the peripheral vascular offers physicians more options. And so it uniquely positions us in the SFA, and also helps us pull through our core portfolio. So I think these investments are paying off in Europe based on the growth, and we've got to wrap up our clinical trial of Eluvia, which we anticipate by year end 2016. And so we look forward to that finishing, and then we'll provide additional comments on our balloon at our third quarter earnings call."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Great. With that, we'd like to conclude the call. Thanks for joining us today, and we appreciate your interest in Boston Scientific. Before you disconnect, Greg will give you all the pertinent details for the replay.",36,"Great. With that, we'd like to conclude the call. Thanks for joining us today, and we appreciate your interest in Boston Scientific. Before you disconnect, Greg will give you all the pertinent details for the replay."
317627,370563598,1015457,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Thank you. And ladies and gentlemen, this conference will be available for replay after 10:30 Eastern Time today through August 11. You may access the AT&T Teleconference Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 3",86,"Thank you. And ladies and gentlemen, this conference will be available for replay after 10:30 Eastern Time today through August 11. You may access the AT&T Teleconference Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 396158. International participants dial (320) 365-3844. Those numbers, once again, are 1 (800) 475-6701 or (320) 365-3844 with the access code 396158. That does conclude your conference for today. Thank you for your participation and for using AT&T Executive Teleconference. You may now disconnect."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Second Quarter 2016 Boston Scientific Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.I would now like to turn the conference over to your",46,"Ladies and gentlemen, thank you for standing by. Welcome to the Second Quarter 2016 Boston Scientific Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
I would now like to turn the conference over to your host, Susie Lisa. Please go ahead."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Greg. Good morning, everyone, and thanks for joining us. With me on today's call are Mike Mahoney, Chairman and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.We issued a press release earlier t",363,"Thank you, Greg. Good morning, everyone, and thanks for joining us. With me on today's call are Mike Mahoney, Chairman and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.
We issued a press release earlier this morning announcing our Q2 2016 results, which included reconciliations of the non-GAAP measures used in the release. 
We have posted a copy of that release as well as reconciliations of the non-GAAP measures used in today's call to the Investor Relations section of our website under the heading Financial Information. 
The duration of the morning's call will be approximately 1 hour. Mike will provide strategic and revenue highlights of Q2 of '16. Dan will review the financials for the quarter and then Q3 '16 and full year 2016 guidance, and then we'll take your questions. During today's Q&A session, Mike and Dan will be joined by our Chief Medical Officers, Dr. Keith Dawkins and Dr. Ken Stein.
Before we begin, I'd like to remind everyone that on the call, organic revenue growth is defined as excluding the impact of changes in foreign currency exchange rates and sales from the acquisition of the American Medical System, AMS, male urology portfolio over the prior-year period. Also of note, this call contains forward-looking statements within the meaning of federal securities laws, which may be identified by words like anticipate, expect, believe, estimate and other similar words. 
They include, among other things, statements about our growth and market share; new product approvals and launches; clinical trials; cost savings and growth opportunities; our cash flow and expected use; our financial performance, including sales, margins, earnings and other Q2 2016 results and Q3 and full year 2016 guidance as well as our tax rates, R&D spend and other expenses.
Actual results may differ materially from those discussed in the forward-looking statements. 
Factors that may cause such differences include those described in the Risk Factors section of our most recent 10-K and subsequent 10-Qs filed with the SEC. 
These statements speak only as of today's date, and we disclaim any intention or obligation to update them. 
At this point, I'll turn it over to Mike for his comments. Mike?"
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Susie, and good morning, everyone. We continue to beat our long-range strategic plan goals and execute very well as a global team. The success of our category leadership strategy is helping us gain share in our core markets, expanding the faste",2113,"Thank you, Susie, and good morning, everyone. We continue to beat our long-range strategic plan goals and execute very well as a global team. The success of our category leadership strategy is helping us gain share in our core markets, expanding the faster growth adjacencies and deliver solutions that address unmet clinical needs. Our consistent results continue to demonstrate that Boston Scientific is uniquely positioned to deliver differentiated long-term shareholder value. With long term visibility to mid-single digit organic revenue growth, complemented by ongoing operating margin improvement initiatives, our goal is to consistently drive double-digit adjusted EPS growth.
We're very excited about our excellent second quarter performance, first half results, and most importantly, our plans for the future. In Q2, we drove total operational revenue growth of 16% and organic revenue growth of 10%, excluding the impact of the AMS Urology acquisition. We had strong results across all regions, and 5 of our 7 business units grew revenue double digits organically. We leveraged that revenue growth to drive adjusted operating income growth of 22%, resulting in an adjusted operating margin of 23.4% and 130 basis point improvement year-over-year.
We delivered adjusted EPS of $0.27, achieving the high end of guidance and representing 25% growth, including the negative $0.015 impact from foreign currency. So given our strong performance, we are increasing our 2016 guidance for revenue and adjusted EPS. We're are increasing our full year organic revenue growth guidance from 6% to 8% to 8% to 9%, full year operational revenue growth guidance, which includes the benefit of AMS, is increased from 9% to 11% to 11% to 12%. We're maintaining our full year adjusted operating margin guidance of 24% to 24.5%, which at the midpoint is roughly 200 basis points of improvement over 2015. We're also increasing our adjusted EPS guidance by $0.01 over our prior range to $1.07 to $1.11, which represents 15% and 19% growth. Importantly, this adjusted EPS guidance includes an expected $0.05 negative impact from foreign exchange.
I'll now provide some highlights on Q2 results and our '16 outlook. In my remarks, all references to growth are in a constant currency organic year-over-year basis, and they exclude the benefit of AMS. Our second quarter revenue growth of 10% was broad based across businesses and regions, led again by exciting new product launches, continued global expansion and execution of our category leadership strategy. We drove double-digit growth in 5 businesses: endo, urology public-health, Neuromodulation, Interventional Cardiology and Peripheral Interventions. In addition, each region accelerated sequentially. The U.S. grew 8%; Europe, grew 9%; Asia PAC delivered 16% growth, with every major country in the Asia Pac region up double digits this quarter. The emerging markets also continued to deliver. Sales grew 20%, including China revenue at 21%. 
Our MedSurg businesses, endo, Urology public health and Neuromodulation, continue to be a priority focus area for the company, and each of the businesses maintained or accelerated growth from first quarter. These 3 businesses represent 40% of our operating income in the second quarter and they delivered adjusted operating margin of 32.8%. This is up 20 basis points sequentially and 240 basis points year-over-year. Our global Endoscopy team continues to perform at a high level with the revenue growing 11% in the second quarter. We continue to see strong growth in our core endo business, supported by our innovative portfolio and broad-based global expansion initiatives. Key endo growth drivers include the single-use SpyGlass DS Visualization System, the AXIOS Stent for drainage of pancreatic fluid and our next-generation hemostasis clip, the Resolution 360. High single-digit growth in U.S. endo was complemented by double-digit growth in every region outside the U.S., as we continue to develop commercial and position-training abilities in emerging markets and add focus in pulmonary, which helped drive 25% growth in BT, bronchial thermoplasty, led by the U.S., Japan and China. 
In Urology and public health, our investments to become the clear market leader and category leader have been rewarded, as growth excluding AMS accelerated to 18%. The business is performing at a high-level across the various regions and segments, including kidney stone, BPH, ED and surg gyn. Our global commercial footprint and focus on physician education has helped us to convert a meaningful portion of the market opportunity created by a STORZ's exit from the market at the end of March. 
AMS sales strength in the quarter and importantly, remediation and integration efforts remain on track. An exciting new growth platform in our urology business is the launch of a LithoVue platform. LithoVue is an innovative single-use digital scope for treatment of kidney stones that provide customers with enhanced visualization and navigation capabilities. LithoVue resonates with physicians and hospitals due to less OR downtime for sterile processing of reusable scopes. Performance navigation characteristics that allow physicians to tackle tougher procedures and the ability to schedule full day of procedures without the fear of cancellation due to reusable scopes being down.
In Neuromodulation, we continue to invest in the fast-growing microelectronics market, where we enjoy innovation and supply chain leverage between our CRM and neuromod business. Neuromodulation revenues grew in the quarter to 12% -- grew 12%. Sales were driven by the U.S. market-leading Spectra platform; the launch of Precision montage, which offers full body MRI capability; and our Vercise Deep Brain Stimulation platform. Our U.S. DBS trial continues to progress, and we expect to launch in the U.S. in the first quarter of 2018. Additionally, earlier this week, we announced the acquisition of Cosman Medical, a technology leader in the field of radiofrequency ablation systems for the treatment of chronic pain. This acquisition broadens our neuromodulation portfolio and is highly synergistic with our U.S. commercial team. We're excited to offer physicians treating patients with chronic pain another non-opioid therapeutic option earlier in the treatment continuum.
Now turning to Cardiovascular, which includes our peripheral and Interventional Cardiology businesses. Overall, this segment grew sales 13% in the quarter and delivered adjusted operating margin of 32.2%, up more than 170 basis points year-over-year. Our peripheral business delivered exceptional results with strong global sales across all regions fueled by an innovative portfolio. Sales grew 14% on strong results across all regions and segments, including stents, thrombectomy and our emerging drug-eluting portfolio. We also delivered strong growth in Interventional Oncology, where the integration of Interventional Radiology business of CeloNova remains on track. In our Venous segment, we continue to see very strong demand for our Zelante deep vein thrombosis system. We are the only company that have been leading drug-eluting technology globally on multiple platforms in order to treat complex, peripheral vascular disease. The Eluvia peripheral drug-eluting stent ID trial called IMPERIAL is on track to complete enrollment by yearend 2016. 
In Interventional Cardiology, we are focused on gaining share in our core businesses while expanding in faster growth segments that leverage our capabilities. This strategy is working. In the second quarter, interventional cardiology grew 12% led by a structural heart, drug-eluting stents and PCI guidance. SYNERGY had an excellent quarter, as we grew DES sales 9%. SYNERGY is now the market-leading premium DES platform and it's on track to represent 50% to 60% of our U.S. DES revenue mix by the end of 2016. PCI guidance grew mid-teens and continues share gains in intravascular ultrasound, and we're encouraged by strong early feedback on the ease-of-use of our COMET fractional flow reserve system. Our leading portfolio of solutions for complex high-risk PCI of patients also contributed to global growth.
The 12% IT revenue growth was fueled by our strength in the structural heart business, which includes our Lotus transcatheter aortic valve and WATCHMAN Left Atrial Appendage Closure. We believe we are well-positioned to drive long-term growth in these 2 fast-growing markets via our differentiated platforms and expanded capabilities. We also aim to deliver at the high-end of our 2016 Structural OR guidance range of $175 million to $200 million.
Our Lotus Valve continues to gain share in Europe, and we are investing significantly in clinical studies, R&D and our global supply chain to develop our capabilities further. We remain on track to launch Lotus EDGE at PCR London Valves in September. The Lotus EDGE delivery system features a 14 French expandable sheet called iSleeve and is designed for more flexibility and simplified deployment. It also offers our new Depth Guard technology, which limits the depth of the valve in the left ventricular outflow tract. Lotus also offers best-in-class paravalvular leakage rates, and we aim to enhance Lotus with studies to demonstrate improved permanent pacemaker rates with Lotus EDGE and Depth Guard. So our goal is to provide initial Lotus EDGE data at PCR London Valves. We do expect a slight delay in our expanded Lotus Valve matrix in Europe, with a 21-millimeter valve estimated CE Mark timing first quarter '17, and the 29-millimeter valve in Europe in mid-2017. We continue to invest and plan for a U.S. launch with the Lotus EDGE platform in late 2017.
Also in structural heart, WATCHMAN sales were strong on procedure growth and new account openings. We are developing additional WATCHMAN capabilities in field clinical support, market development and physician training courses. Implant success rates and patient outcomes remain very high as evidenced by the 98.5% success rate in the evolution registry detailed at HRS in May.
We continue to expand WATCHMAN in the new markets and we're pleased with the recent reimbursement approval and launch in France. Importantly, the unique clinical benefits of WATCHMAN are being rewarded, as evidenced by the French reimbursement at a meaningful premium to competitive LAAC devices.
We post a limited market release of our next generation WATCHMAN FLX device. We've have decided to pursue design enhancements before we turn in the next-gen platform to market. Importantly, we anticipate this delay will have no impact on our current WATCHMAN product and thus, no change to our market outlook for LAAC.
Rhythm Management sales increased 5% in the quarter and delivered adjusted operating margin of 16.9%, up 200 basis points year-over-year, as improving profitability remains a core focus.
In CRM, we improved our global performance and delivered 4% growth in second quarter. Our European and Asia PAC CRM businesses continue to grow faster than the market, offset by slower growth in U.S. CRM. Pacemaker sales grew 15% globally, with excellent U.S. performance fueled by our ACCOLADE MRI launch, and growth from our X4 CRT-P quad device. Worldwide ICD sales were flat as we delivered above-market growth internationally that was offset by weaker sales in the U.S. In the U.S., we faced some near-term headwinds due to our tachy MRI product gap and replacement cycle headwinds. However, we recently we earned FDA approval of our ACUITY X4 quad CRT lead and the early results are promising. Importantly, EMBLEM S-ICD is a key differentiator, and growth continues to accelerate globally. We continue to expand global S-ICD utilization with more long-term data from the EFFORTLESS Registry, growing physician implant experience, geographic expansion and the recent second quarter of '16 EU launch at EMBLEM MRI, which contributed to our solid international growth.
Due to a change in protocol of our U.S. enabled MRI clinical trial, we are revising our goal for transvenous tachy MRI U.S. approval by year-end 2017, but continue to expect to gain MRI labeling for both new and previously implanted ICDs and CRT-Ds with a new timeline. The continued cadence of data proving the superiority of EnduraLife batteries and the pending FDA approval of EMBLEM MRI S-ICD, which is expected in third quarter, will help us offset the near-term headwinds from the U.S. MRI high-voltage segment.
In the second quarter, European CRM sales grew 5%, representing 9 straight quarters of above-market growth, giving us further confidence in our long-term CRM outlook. Our EP business grew 6% in second quarter and we're encouraged by double-digit growth in Europe, led by new arrhythmia installs and the recent launches of Nitinol OI and IntellaTip MiFi OI ablation catheters. The U.S. launch in late first quarter of the Blazer OI catheter will be augmented in Q3 with the upcoming launch of the nav-enabled version of this catheter. 
So to wrap up, our company delivered another excellent quarter. Our second quarter performance reflects the strength of our global team, the depth and breadth of our portfolio, our globalization efforts and our ongoing investments in the faster growth markets. Importantly, we believe we are well-positioned to deliver continued strong results in the second half of '16 and beyond. I really want to thank our employees globally for their winning spirit and their strong commitment to Boston Scientific.
Now let me turn the call over to Dan for a more detailed review of our financial results."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Mike. In Q2, we generated organic revenue growth of 10% versus our 6% to 8% guidance range, and adjusted EPS of $0.27, representing 25% year-over-year growth in the high-end of our guidance range of $0.25 to $0.27. The strong adjusted EPS growth p",1909,"Thanks, Mike. In Q2, we generated organic revenue growth of 10% versus our 6% to 8% guidance range, and adjusted EPS of $0.27, representing 25% year-over-year growth in the high-end of our guidance range of $0.25 to $0.27. The strong adjusted EPS growth performance in Q2 was driven primarily by revenue growth upside and a lower SG&A rate versus prior year. And given the strong performance in the first half of 2016, we are again raising full year guidance for revenue growth and adjusted EPS. Consolidated revenue of $2,126,000,000 represented operational revenue growth of 16%, exceeding the high end of guidance and excludes the impact of a $24 million headwind from foreign exchange, which was in line with guidance. Excluding an approximate 500 basis point contribution from the AMS male urology portfolio acquisition, organic revenue growth was 10% in the quarter and 15% on an as-reported basis.
Adjusted gross margin for the second quarter was 70.7%, decreasing 60 basis points year-over-year and unfortunately, 130 basis points below the midpoint of Q2 guidance due to a few factors that I will detail. The year-over-year decrease is due to the unfavorable impact of foreign exchange, which was a 120 basis point headwind, as well as costs related to our new Malaysia manufacturing plant, the AMS integration, including the AMS quality remediation expense. Compared to guidance, the shortfall is due to inventory charges in advance of new product launches, inventory write-offs related to WATCHMAN FLX and more unfavorable FX.
We now expect Q3 and full year 2016 adjusted gross margin to be in the range of a 71.5% to 72.5%, which includes an expected 75 to 100 basis point of unfavorable foreign exchange. A key element in the second half increase is lower expected inventory charges, and we will also benefit fully from the lower 2016 standard cost of our products as we will have sold through all of the inventory valued at last year's higher standards. Adjusted SG&A expenses were $763 million or 35.9% of sales in Q2, down 140 basis points year-over-year. We continue to believe our full year rate will be between 35.5% and 36.5%, which at the midpoint would be a 140 basis point improvement compared to last year.
Adjusted research and development expenses were $222 million in the second quarter or 10.4% of sales, which is down 50 basis points year-over-year. As a result of a slightly lower R&D rate in the first half, we expect our full year 2016 adjusted R&D rate to be between 10.5% and 11.5% of sales or 50 basis points lower than prior guidance. Royalty expense was 0.9% of sales in Q2, roughly flat year-over-year. Our Q2 2016 adjusted operating margin of 23.4% was in line with our guidance and represents a 130 basis point improvement over Q2 last year, which marks the eighth consecutive quarter in which we will have expanded adjusted operating margin by 100 basis points or more.
As a reminder, we've signaled a sequential decrease in adjusted operating margin from Q1's rate as we experienced the usual increase in SG&A from Q1 to Q2 due to seasonal trade show activity and began to ramp reinvestment of the medical device excise tax suspension. Our first half 2016 adjusted operating margin of 24.2% positions us well to achieve our full year adjusted operating margin guidance of 24% to 24.5%, and we remain on track to reach 25%-plus in 2017.
Q2 adjusted operating income grew 22% year-over-year, with all 3 reportable segments expanding adjusted operating margin by at least 170 basis points over Q2 2015. Specific to Rhythm Management, the team delivered an adjusted operating margin of 16.9%, up 280 basis points year-over-year. In the second half of 2016, we expect Rhythm Management adjusted operating margin to continue to improve and be 18% to 19%. This second half gain is expected to result from realizing the full benefit of 2016 product costs, leveraging the improved top line performance expected of the global CRM and EP businesses, and we continue to believe Rhythm management is on track to deliver an adjusted operating margin of 20% in 2017.
Turning to the balance sheet, we had some key developments in the quarter that helped reduce future uncertainties. Before I get into the details of the activity in the quarter, let me try to frame out the next 3 years of expected cash flow at a high level. From 2017 through 2019, we believe we can generate cumulative adjusted free cash flow after CapEx approaching $6 billion. We expect to allocate roughly 2/3 of that $6 billion to a combination of M&A and share repurchases. As you're aware, the 2 most significant liabilities on our balance sheet are our IRS transfer pricing case and the mesh litigation. During the quarter, we took 2 important steps to manage these liabilities. First, we reached a stipulation of settled issues with the IRS for the 2001 to 2007 tax years. And importantly, this stipulation also provides a framework to settle the remaining years 2008 through 2015 as well. While there's work to do to conclude all the years, we are confident we will bring these to conclusion over the coming quarters. With the payment in 12 to 24 months, this would eliminate one of the most significant liabilities on our balance sheet. With regards to mesh, we increased our reserve by $608 million during the quarter. With the same goal of managing our liabilities, we've reached conditional or final settlements on 12,000 claims and made significant progress towards reaching agreement in principle on another 7,000 claims for a total of 19,000 claims. This represents approximately half of the roughly 40,000 known claims, and we expect to make even more progress during the remainder of 2016. As you know, every quarter, we assess all 4 key components involving calculating the reserve and make any necessary adjustments for all probable and estimable charges, including the volume of known claims, the estimated cost to resolve each claim, an estimate of future claims and the cost to defend each claim.
Our total legal reserve, of which mesh is included, was $2,375,000,000 as of June 30, 2016 and we believe it reflected our best estimate of what is probable and estimable. Of note as well, is that included in this reserve is the Mirowski Judgment which we have paid in full, subsequent to quarter end. So as of today, the reserve would be closer to $2 billion. As a reminder, this $2 billion includes a number of claims we have agreed in principle to settle but have not yet paid. Once those settlements are funded, the amount of the reserve will be adjusted accordingly.
Now I'll move on to interest expense. Interest expense for the quarter was $59 million, compared to $106 million in Q2 of last year. The decrease is primarily due to the pretax onetime charge of approximately $45 million associated with a senior note refinancing in Q2 of last year. Excluding this charge, Q2 2015 interest expense was $61 million. Our average interest expense rate was 4% in Q2 this year compared to 8% in Q2 last year. The lower interest-rate expense in Q2 of '16 was primarily due to lower average cost of debt resulting from the senior notes refinancing and the inclusion of the pretax onetime charge in Q2 of last year that I mentioned. Excluding this charge, Q2 2015 interest expense would have been 4.6%.
Our tax rate for the second quarter was 47.8% on a reported basis and 14.2% on an adjusted basis. As reported last week, we're pleased with the conditional settlement reached with the IRS council regarding our transfer pricing litigation, and plan to use some of the current benefit to repatriate overseas cash. Thus we continue to expect our full year 2016 adjusted tax rate to be approximately 14%. We believe this IRS settlement, in addition to recent progress we've made towards reaching agreements in principle to settle additional mesh claims, as I mentioned, are prudent actions to take in the management of our balance sheet.
Finally, Q2 2016 adjusted EPS of $0.27 includes approximately $0.015 of unfavorable FX and represents 25% year-over-year growth or 32% growth excluding the impact of foreign exchange. On a reported GAAP basis, Q2 2016 EPS was a loss of $0.15 and includes net charges and amortization expense totaling $580 million after tax.
Adjusted free cash flow for the quarter was $464 million compared to $406 million in Q2 of last year. Given the strong adjusted free cash flow generation in the first half of this year, we are raising our full year adjusted free cash flow guidance from $1.5 billion to $1.6 billion, which was formally our stretch goal. Achieving adjusted free cash flow of $1.6 billion would represent 17% growth, and we continue to pursue inventory management initiatives designed to improve the working capital contribution to cash flow.
In Q2, we used cash primarily to repay $250 million of bank term loans, as well as fund the previously agreed legal settlements. As of June 30, 2016, we had cash on hand of $438 million. Near term, our capital allocation priorities are to manage contingencies and pursue tuck-in M&A. 
We ended Q2 with 1,375,000,000 fully diluted weighted average shares outstanding. Consistent with our prior guidance, we expect our share count to increase by roughly 5 million per quarter through the end of 2016, as we plan to keep the buybacks suspended for the balance of this year. We expect this to result in a fully diluted weighted average share count of approximately 1,380,000,000 shares for full year 2016.
I'll now walk-through guidance for Q3 and full year 2016. For the full year, we now expect consolidated revenue to be in a range of $8,270,000,000 to $8,370,000,000, which represents year-over-year growth of 8% to 9% on an organic basis and 11% to 12% on both an operational and reported basis. As a result of a stronger dollar, at current rates, we expect foreign exchange to be a headwind of approximately $70 million for the full year 2016. 
Turning to adjusted EPS, we now expect full year 2016 adjusted EPS to be in a range of $1.07 to $1.11, representing 15% to 19% adjusted earnings growth. Our previous guidance assumed the unfavorable FX on full year adjusted EPS would be between $0.05 and $0.06. Given the fact that Q2 saw a slightly less unfavorable impact than expected, we now believe the full year impact will be closer to $0.05 which assumes $0.02 to $0.03 in the second half of this year. On a GAAP basis, we expect EPS to be in a range of $0.30 to $0.35.
Now turning to Q3 2016, we expect consolidated revenues to be in a range of $2,035,000,000 to $2,085,000,000. This represents year-over-year growth in a range of 7% to 9% organically and 8% to 10% operationally. We expect the foreign exchange headwind on Q3 revenue to be negligible. For the third year -- for the third quarter, adjusted EPS is expected to be in a range of $0.25 to $0.27 per share, and GAAP EPS is expected to be in a range of $0.13 to $0.15 per share.
Please check our Investor Relations website for Q2 2016 financial and operational highlights, which outlines Q2 results, as well as Q3 and full year 2016 guidance, including P&L line item guidance. So with that, I'll turn it back over to Susie, who'll moderate the Q&A."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Dan. Greg, let's open it up to questions for the next 30 minutes. [Operator Instructions] Greg, please go ahead.",20,"Thanks, Dan. Greg, let's open it up to questions for the next 30 minutes. [Operator Instructions] Greg, please go ahead."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","[Operator Instructions] Your first question comes from the line of Mike Weinstein from JPMorgan.",14,"[Operator Instructions] Your first question comes from the line of Mike Weinstein from JPMorgan."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Let me just clarify this on a few items. So number one, the pacemaker performance being as strong as it is on the back of the MRI launch. One question that I've already got with people is, is that a clean number, is there any stocking in that number that",90,"Let me just clarify this on a few items. So number one, the pacemaker performance being as strong as it is on the back of the MRI launch. One question that I've already got with people is, is that a clean number, is there any stocking in that number that we should be aware of? Second, the move in the structural heart guidance to the high end of the range, is that WATCHMAN more than Lotus? If you could kind of share any insights into that, and then I'll follow-up."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, good morning, Mike. On the pacemaker, our team has been waiting for a long time for that product approval. We've had some slow quarters in our pacemaker business in the U.S. Outside the U.S., we've done quite well with our product for a while. So th",273,"Sure, good morning, Mike. On the pacemaker, our team has been waiting for a long time for that product approval. We've had some slow quarters in our pacemaker business in the U.S. Outside the U.S., we've done quite well with our product for a while. So that's not a stocking number. We were ready for that launch for quite a while and the team -- our commercial team's did an excellent job executing it. So we think it's a very innovative product and long in coming. And the U.S. team, essentially, has did what the OUS teams have done with that product for a while. And now, structural heart, we continue to be really excited about the future for structural heart. It continues to be our largest investment area as a company. We were comfortable with the high-end of our guidance that we provided at $175 million to $200 million. We continued to invest long-term in R&D capabilities, clinical capabilities and commercial capabilities to prepare ourselves for the launch in the U.S. And we're really excited about the upcoming data that we expect to see in London Valves on our pacemaker rate with the addition of Lotus EDGE and Depth Guard. So it's really an important category for us. As you know, we continue to -- we outlined at Investor Day, back in, I think 2013 and '15, our focus to continue to grow in our core businesses and take share, which we're doing, and importantly, expand in the faster-growth markets. And that's exactly what you're seeing as a company, and our structural heart investment really is kind of leading the pack there."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","So Mike, I would apologize. The question was structural heart -- within structural heart, WATCHMAN is what's driving to the high end of the range there?",26,"So Mike, I would apologize. The question was structural heart -- within structural heart, WATCHMAN is what's driving to the high end of the range there?"
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","What's driving the high-end range there is, we're just continue to open up new accounts. We continue to improve our account utilization. And we continue to build up our commercial capabilities in the U.S.",35,"What's driving the high-end range there is, we're just continue to open up new accounts. We continue to improve our account utilization. And we continue to build up our commercial capabilities in the U.S."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. The gross margin issues in the quarter, I think -- I feel you did a good job of -- Dan walking through what those are. So if we look at the back half of the year, and the expected improvement to gross margin, that's because, one, your inventory issu",85,"Okay. The gross margin issues in the quarter, I think -- I feel you did a good job of -- Dan walking through what those are. So if we look at the back half of the year, and the expected improvement to gross margin, that's because, one, your inventory issues from the AMS transaction, basically, you get to a better, safer cost on those products, and then the FX headwind that you saw in this quarter on the gross margin should dissipate. Is that accurate?"
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","No, somewhat. Let me just make sure we're clear on that. So we're at 70.7% in the quarter. The guidance range for Q3 and the full year is 71.5% to 72.5%, so it implies the uptick that you mentioned in the second half. I think the 2 key drivers of that are",232,"No, somewhat. Let me just make sure we're clear on that. So we're at 70.7% in the quarter. The guidance range for Q3 and the full year is 71.5% to 72.5%, so it implies the uptick that you mentioned in the second half. I think the 2 key drivers of that are, the inventory charges for the CRM products related to the better uptake of MRI-safe brady and quad in the U.S. as well as the WATCHMAN FLX. We don't believe that those repeat themselves. And then secondly, we will get the full benefit in the second half of the lower manufacturing costs that we have for 2016 standards because we'll now be selling all the inventory at the new standards, and we'll have sold off all of the inventory at last year's standards. Those are the 2 main drivers that put us back in the 71.5% to 72.5% range. FX, we actually assume is probably somewhat in the same range as where it was in Q2. That's really the reason. If you think back to last quarter, our guidance for FX in gross margin would have implied about 70 to 75 basis points each quarter for Qs 2, 3 and 4. Now it's 120. So that's a 50 basis point difference. And that's the reason why the guidance for the full year came from 72% to 73% to 71.5% to 72.5%."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of David Lewis from Morgan Stanley.",13,"Your next question comes from the line of David Lewis from Morgan Stanley."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","In light of the very strong revenue quarter, guys, I hate to ask something as banal as cash flow, Dan, but you don't give us multiyear cash flow spins that often, and I noticed that your $6 billion free cash estimate in the next 3 years is 10% higher than",106,"In light of the very strong revenue quarter, guys, I hate to ask something as banal as cash flow, Dan, but you don't give us multiyear cash flow spins that often, and I noticed that your $6 billion free cash estimate in the next 3 years is 10% higher than what we were looking for. Can you sort of walk us through kind of why that would be in some of the components? I imagine one component is CapEx and perhaps the other is margins, but our margin numbers are pretty high and you're still 10% above us. So what could be driving that significant upside?"
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","I think you answered your own question there, David. It's margins and CapEx. So the -- one of the things we have this year is, as we detailed in our guidance at the beginning of the year is, the CapEx number at $350 million, that's $100 million higher tha",207,"I think you answered your own question there, David. It's margins and CapEx. So the -- one of the things we have this year is, as we detailed in our guidance at the beginning of the year is, the CapEx number at $350 million, that's $100 million higher than we think we need to effectively run each year. So we get that back hopefully each of the next 3 years. And then, the expanding margins. So our goal next year is 25%-plus, and as we've given guidance for long-term goals for 27% to 28% by 2020, the combination of those 2 factors and the CapEx, I think, gets you a long way there. And then the other piece is that, we're going to continue to try from a working capital perspective to make that be our friend. We have a lot of inventory initiatives in place to really hopefully lead the industry in that regard, and be best-in-class, and when we do that, that'll turn something that's been a drag on cash flow into a positive, and hopefully see the beginnings of that this year. You see that from us taking our guidance from $1.5 billion to $1.6 billion a piece of that is the inventory initiatives."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay, very helpful. And then Mike, maybe a couple of product questions. I guess the first is just, it's just sort of a forgotten business for Boston MedSurg is sort of no longer forgotten given the organic growth and specifically, Endoscopy has gone from",132,"Okay, very helpful. And then Mike, maybe a couple of product questions. I guess the first is just, it's just sort of a forgotten business for Boston MedSurg is sort of no longer forgotten given the organic growth and specifically, Endoscopy has gone from mid-single growth last year to double-digit growth this year. I wonder if you can just give us a sense of sort of where we are in the product cycles? Is it share gain from competitors? Is it product cycles that is driving that? And then, secondarily, on DES, on synergy, where do you think we are in sort of share versus mix? And obviously, you're growing dramatically ahead of market. So what are some of the factors that are driving that? And I'll now jump back in queue."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks. David. We've definitely never forgot about endo. It's really an incredibly high performing business and it has been for a number of years. And they really have just continue to do -- continue to grow and expand. So our endo business enjoys, a, fir",444,"Thanks. David. We've definitely never forgot about endo. It's really an incredibly high performing business and it has been for a number of years. And they really have just continue to do -- continue to grow and expand. So our endo business enjoys, a, first of all, a strong market, a bit fewer competitors in our Endoscopy markets than some of our others. It has very strong growth profile in terms of the market growth in OUS expansion, and we are a very strong category leader. Across the globe, when we continue to expand into emerging markets. The portfolio is really driving a lot of the launch out of the success that you're seeing in 2016, led by our SpyGlass digital DS platform, which is driving solid double-digit growth and helps pull through the core portfolio. We also launched a product called the AXIOS Stents, which is doing very well, as well as a hemostasis clip. So the portfolio cadence for endo is very strong, it's very well-led, it's very globally oriented, and they also do a great job of laying out the economic value proposition for hospitals beyond the portfolio. So they continue to perform very well and intentionally, some of my comments with Mike in his first question, we're intentionally focusing on investing greater in faster-growth markets, in faster growth businesses and they represent 40% of our operating income, the MedSurg sector does now for BSC. So more to come there. DES is doing excellent. We had a few critics early on in our launch saying we weren't be an aggressive enough. We signaled all along that we're going to be -- drive an appropriate premium price for this product because we believe it is the best product available in the marketplace and the data is proving that out, and maybe Keith can comment in a minute. So we believe it's the premium product. We do offer a premium price for it. And so we've been smart in our rollout of it, and I think physicians and customers are seeing the value of the ease-of-use and the clinical data synergy and we expect the U.S. penetration to be probably above 50%, closer to 50% to 60% in the U.S. in 2016. And we continue to roll that out globally. So the team is doing a nice job there. But again, it's part of the overall story in interventional cardiology. Again pointing to faster growth segments, our DES is doing well. A lot of investments in complex coronary and imaging, which are part of the portfolio, and then clearly our structural heart. So Kevin Ballinger and the team are doing a nice job."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Keith?",1,"Keith?"
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, David, I think the SYNERGY Stent operators around the world are appreciating the best-in-class acu performance because, obviously, if you can't deliver the stent, that's really the end of the discussion. And it -- we have a lot of data now, including",124,"Yes, David, I think the SYNERGY Stent operators around the world are appreciating the best-in-class acu performance because, obviously, if you can't deliver the stent, that's really the end of the discussion. And it -- we have a lot of data now, including the EVOLVE II pivotal data, the EVOLVE personally use 5-year data, and the Real-World Sky data from Europe confirming the safety. Everybody, both patients and physicians, are interested in stent thrombosis. And the stent thrombosis, as you know from the data, is very low. We have 20,000 patients in investigator-sponsored trials with Synergy. And these trials are beginning to release their data, and you'll see more flows of data at the meetings during the rest of this year and next year."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of Larry Biegelsen from Wells Fargo.",13,"Your next question comes from the line of Larry Biegelsen from Wells Fargo."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","So Dan, you raised the organic growth from 6% to 8% to 8% to 9%, but you only raised the EPS guidance by $0.01. And so can you talk about why you're not getting better leverage in the incremental revenue? You kept the operating margin guidance the same. A",54,"So Dan, you raised the organic growth from 6% to 8% to 8% to 9%, but you only raised the EPS guidance by $0.01. And so can you talk about why you're not getting better leverage in the incremental revenue? You kept the operating margin guidance the same. And then, I had 1 follow-up."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, Larry. I think, probably the best way to explain that is to do a quick summary of the increase in revenue. So the revenue is $170 million higher at the midpoint of guidance and that breaks down into 3 things: $20 million comes from FX, $75 million c",163,"Sure, Larry. I think, probably the best way to explain that is to do a quick summary of the increase in revenue. So the revenue is $170 million higher at the midpoint of guidance and that breaks down into 3 things: $20 million comes from FX, $75 million comes from revenue that already came in Q2, and then $75 million comes in the second half. I think the main factor that's offsetting that is, if you look at our R&D rate, our R&D rate in the first half was 10.5%. And looking at the second half, it's going to be 11.5% to get to the full year rate of 11%. So that's 100 basis point increase in R&D, largely related to the timing in the investments in structural heart that Mike had mentioned. So that for, the most part, offsets the additional flow through in the revenue that you get -- the additional $75 million of revenue you get in the second half."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Got it. And then...",4,"Got it. And then..."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Just as a footnote. As you look at it, still very pleased to be at 15% to 19% full year EPS growth, which would be 4 years straight of double-digit adjusted EPS growth.",33,"Just as a footnote. As you look at it, still very pleased to be at 15% to 19% full year EPS growth, which would be 4 years straight of double-digit adjusted EPS growth."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Got it, sorry to interrupt there. And then, for my follow up. At the 2015 analyst meeting, the organic revenue goal was 3% to 6% in 2016 and 2017. You're now guiding to 8% to 9% in 2016. How should we think about the sustainability of the 8% to 9%, and yo",80,"Got it, sorry to interrupt there. And then, for my follow up. At the 2015 analyst meeting, the organic revenue goal was 3% to 6% in 2016 and 2017. You're now guiding to 8% to 9% in 2016. How should we think about the sustainability of the 8% to 9%, and your goals in 2017 and beyond? And I recognize you're not giving guidance here, but you're way outperforming what you expected to do at your analyst meeting last year."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, yes, the team is outperforming. It's part of the high-performance culture that we have as a company. We're very excited about the full year guidance at 8% to 9%. As you said, it compares to 3% to 6% we laid out, so it's a pretty strong beat the",125,"Thank you, yes, the team is outperforming. It's part of the high-performance culture that we have as a company. We're very excited about the full year guidance at 8% to 9%. As you said, it compares to 3% to 6% we laid out, so it's a pretty strong beat there. And strong momentum across, really, each region and each business. So we're not going to provide any outlook into 2017. Clearly, outperforming the market at these levels -- at this level is not likely sustainable each year. But that being said, we're confident we'll continue to outperform the market. We're investing in faster growth businesses, and we're very confident in our ability long-term to drive mid-single revenue growth, improve margins and drive double-digit EPS growth."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of Bob Hopkins from Bank of America.",14,"Your next question comes from the line of Bob Hopkins from Bank of America."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","So obviously, you've got the best revenue growth year for Boston Scientific, essentially since the financial crisis. Higher absolute level of revenues then, I think, any of the thought, so congratulations on the unbelievable progress. I guess my first que",149,"So obviously, you've got the best revenue growth year for Boston Scientific, essentially since the financial crisis. Higher absolute level of revenues then, I think, any of the thought, so congratulations on the unbelievable progress. I guess my first question is really kind of philosophical in terms of the long term. Now that you've got this sort of higher level of revenues and higher level of revenue growth, you guys have given some long-term guidance on operating margin targets and goals. So now that you're kind of outperforming on revenues, what's the thought on those operating margin targets? Is the thought that you'll take an opportunity to spend more and continue to sort of keep those operating margin targets, or is it more likely that with this higher level of growth, that you could be towards the high end or higher of the long-term targets that you've set previously?"
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Bob. I don't think we'll be changing the trajectory in terms of the margin guidance we've given. As we always say, it's about striking a balance between delivering durable, consistent revenue growth and expanding operating margins. And if you look",109,"Thanks, Bob. I don't think we'll be changing the trajectory in terms of the margin guidance we've given. As we always say, it's about striking a balance between delivering durable, consistent revenue growth and expanding operating margins. And if you look at the numbers and see what we've done for the last 3 years relative to revenue growth and particularly on the margin expansion front, looking at 27% to 28% adjusted operating margin by 2020 and a consistent, durable growing top line through that period and the goal of double-digit adjusted EPS growth each of those years, I think we are going to stick with that as our targets."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","I understand you're sticking with the targets, but I'm just trying to understand philosophically, because you're outperforming so nicely here. Is the bias more towards opportunities to invest more, or let some of that through, because again, these levels",49,"I understand you're sticking with the targets, but I'm just trying to understand philosophically, because you're outperforming so nicely here. Is the bias more towards opportunities to invest more, or let some of that through, because again, these levels are just so much higher than we originally thought."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Again, it's striking a balance. We do have a lot of investment, as Mike mentioned, relative to structural heart. That's a lot of investment to get to the U.S. market and be successful there and I think we're -- it's always about striking that balance.",45,"Again, it's striking a balance. We do have a lot of investment, as Mike mentioned, relative to structural heart. That's a lot of investment to get to the U.S. market and be successful there and I think we're -- it's always about striking that balance."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, and I think also, we'll do an Investor Day in 2017. That we haven't nailed down yet, but we're making significant investments in platforms and markets that will have a big impact on the growth through to the business in '18, '19 and '20. And so you l",125,"Yes, and I think also, we'll do an Investor Day in 2017. That we haven't nailed down yet, but we're making significant investments in platforms and markets that will have a big impact on the growth through to the business in '18, '19 and '20. And so you look at our launch in the U.S. of TAVR, our; launch in the U.S., in the future of Deep Brain Stimulation, launching all-in-one when we'll have a drug-eluting stent and a drug-coated balloon for peripheral vascular, and we continue to expand into pulmonary and other areas across the company. So we definitely are investing for long-term growth and a lot of it is big clinical investments in R&D that'll impact the company, particularly in '18, '19, '20."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","And then on structural heart just real quickly. What was the driver of you guys providing guidance there that it'll be at the high end of the range. Is that Lotus or WATCHMAN or both?",35,"And then on structural heart just real quickly. What was the driver of you guys providing guidance there that it'll be at the high end of the range. Is that Lotus or WATCHMAN or both?"
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","It's both. Both are doing quite well.",8,"It's both. Both are doing quite well."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of Brooks West from Piper Jaffray.",13,"Your next question comes from the line of Brooks West from Piper Jaffray."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Just to put a cap on the gross margin discussion. So Dan, those all seem like transient issues with the inventory, and I'm not trying to push for guidance for next year, but as I look at my model, we've got you at about 73% gross margins for 2017. I don't",109,"Just to put a cap on the gross margin discussion. So Dan, those all seem like transient issues with the inventory, and I'm not trying to push for guidance for next year, but as I look at my model, we've got you at about 73% gross margins for 2017. I don't see anything that I really to flow through into '17 from this. Is that the correct way to think about it? I mean, you're a little bit lower for '16, but in terms of thinking about the forward model, that should resolve itself and we should kind of go back to where we thought we are going, correct?"
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, I mean, I wouldn't talk specifically about a rate for 2017. Obviously, the goal is to continually increase the gross margin rate and it'll be part of what we believe is 25%-plus adjusted operating margin for next year. So with that as the goal, -- th",103,"Yes, I mean, I wouldn't talk specifically about a rate for 2017. Obviously, the goal is to continually increase the gross margin rate and it'll be part of what we believe is 25%-plus adjusted operating margin for next year. So with that as the goal, -- the FX in the back-half is really the only thing that we believe is consistent from the Q2 performance. The other things that I mentioned relative to inventory charges and the benefit from the standards, hopefully is, to your point, is a transient thing. So the FX is the only one that continues into the second half."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay, perfect. And then, maybe kind of piggybacking on Bob's question, but also thinking about some of the questions around MedSurg. You kind of conditioned us, in terms of the long-term operating margin progression, to think about Rhythm Management. And",121,"Okay, perfect. And then, maybe kind of piggybacking on Bob's question, but also thinking about some of the questions around MedSurg. You kind of conditioned us, in terms of the long-term operating margin progression, to think about Rhythm Management. And obviously, you're making great progress there. But given the growth we're seeing in MedSurg and Interventional Cardiology, it seems like that equation maybe needs to change a little bit and if we allocate a little bit more of the strength in MedSurg to that equation, it seems like we push up to and through those targets maybe more quickly than if we were just relying on Rhythm Management. Is that also a fair kind of way to look at your business?"
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, I think the focus on Rhythm Management has really been just because of where they were, right? Starting off in the high single digits, it's gotten a lot of focus over the last 3 or 4 years. I think we've made -- Joe and team have made tremendous prog",187,"Yes, I think the focus on Rhythm Management has really been just because of where they were, right? Starting off in the high single digits, it's gotten a lot of focus over the last 3 or 4 years. I think we've made -- Joe and team have made tremendous progress getting it to the 16.9% that it is in Q2, the 18% to 19% that it'll be in the second half of this year and then ultimately, the 20% next year and beyond that -- in 2018 and beyond. All the while, to your point, MedSurg and cardiovascular have continued to grow their margins as well. So I think it goes back to what Mike said to the answer to the last question which is, there's investments that we're making to ensure that durable growth '18, '19, '20 and beyond, and it's not just one business that has that investment. We're investing in all of the businesses. So we've spent a lot of time looking at each of the individual segments and the profitability there, and the math adds up to what we've given for our goals."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Perfect. If I could sneak in just one product question on -- I'm wondering if MaRVis has decided whether to bring drug-coatable balloon to the U.S. or not?",28,"Perfect. If I could sneak in just one product question on -- I'm wondering if MaRVis has decided whether to bring drug-coatable balloon to the U.S. or not?"
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, we'll likely be providing additional insights on our clinical strategy with our balloon at the next quarterly call.",19,"Yes, we'll likely be providing additional insights on our clinical strategy with our balloon at the next quarterly call."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of Rick Wise from Stifel.",12,"Your next question comes from the line of Rick Wise from Stifel."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Maybe let me start off with Lotus. Mike, you talked about gaining EU share in the quarter. Maybe give us a little more color on that. Are you ready to quantify that at all? You've talked about a penetration or share of greater than 30% in your selected ac",90,"Maybe let me start off with Lotus. Mike, you talked about gaining EU share in the quarter. Maybe give us a little more color on that. Are you ready to quantify that at all? You've talked about a penetration or share of greater than 30% in your selected accounts. And maybe just add some more color on the EDGE launch coming up in September. Is this is share gainer or no? That's going to require more time and those additional sizes that are coming in the first half of '17?"
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, sure. Again, this is a big investment for us in structural heart with the WATCHMAN and TAVR. And we're playing it for the long-term here, particularly with our TAVR, given the market growth profile and how large the market is. And our view that we ha",218,"Yes, sure. Again, this is a big investment for us in structural heart with the WATCHMAN and TAVR. And we're playing it for the long-term here, particularly with our TAVR, given the market growth profile and how large the market is. And our view that we have a very differentiated platform from the other market contenders given the controlled release of our Lotus Valve and the low paravalvular leakage rates. So we think we have -- truly have a differentiated platform in a very large market. We're a bit hamstrung in the near term in Europe without having all 5 sizes. We have 3 of them today. So that hurts us a bit, but we'll solve that with a 21-millimeter in 2000 -- first quarter '17 and eventually the largest size in probably first half of 2017. So that'll help. So in the meantime, we continue to do very well with the 3 valve sizes that we have. We won't provide any additional guidance in terms of number of accounts or penetration. But clearly, it is a share taking strategy. The market's already large, the market's growing, and we're quite confident that we're currently the strong #3 player. But that's not going to be our aspiration over the years, particularly as we launch Lotus EDGE and Depth Guard."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Yes, turning to a bigger picture question. Dan obviously, is emphasizing the growth in free cash flow this year, the $6 billion number you've threw over the next few years. You're also saying, Dan, that -- I think correctly, that with the settling or goin",114,"Yes, turning to a bigger picture question. Dan obviously, is emphasizing the growth in free cash flow this year, the $6 billion number you've threw over the next few years. You're also saying, Dan, that -- I think correctly, that with the settling or going a long way towards settling the IRS remiss, a major uncertainty is off the table. I mean, all that suggest to me that, that might give you more flexibility in thinking about M&A or portfolio additions. You just announced Cosman. How are you thinking about this, Mike and Dan? And should we be thinking that there is more possibility for M&A as a result? Any color would be appreciated."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Sure yes. I'll hit it from a financial perspective, and maybe Mike can jump in on the strategic side. The goal, I think, you framed it out very well. That's our goal is to eliminate the uncertainties that we have on the balance sheet, and I think we've ta",159,"Sure yes. I'll hit it from a financial perspective, and maybe Mike can jump in on the strategic side. The goal, I think, you framed it out very well. That's our goal is to eliminate the uncertainties that we have on the balance sheet, and I think we've taken a lot of good steps in the quarter to do that. And that's going to give us more financial flexibility in the future. And that's the goal. So we should hopefully free up more of that cash flow for the long-term. We gave you the numbers hopefully as kind of goals for the next 3 years, and the goal is to have as much of that available to fuel the business from an M&A and share repurchase perspective. So I don't know if anything specific -- but, yes, I mean, that's really the goal, is to eliminate the uncertainties and give us as much financial flexibility as we can have."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of Matt Taylor from Barclays.",12,"Your next question comes from the line of Matt Taylor from Barclays."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","I guess the first question that wanted to clarify on, when you talked about MRI-safe timelines, could you just inform us what revising the goal for tachy MRI timeline, entail what the change was there? And then, S-ICD is still on track. Could you talk abo",62,"I guess the first question that wanted to clarify on, when you talked about MRI-safe timelines, could you just inform us what revising the goal for tachy MRI timeline, entail what the change was there? And then, S-ICD is still on track. Could you talk about how you that's doing and how you expect MRI-safe approval to potentially improve sales for S-ICD?"
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Absolutely, I'll ask Dr. Stein to comment on this question.",10,"Absolutely, I'll ask Dr. Stein to comment on this question."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, on the MRI, not going to get into any of the details of the change in the protocol. But in the course of conduct of our ENABLE MRI trial, we have made a decision that we do need to revise the protocol with respect to patient screening and eligibility",85,"Yes, on the MRI, not going to get into any of the details of the change in the protocol. But in the course of conduct of our ENABLE MRI trial, we have made a decision that we do need to revise the protocol with respect to patient screening and eligibility, and that's just the process of getting that protocol or vision through. What's going to cause the push in the timeline. We still have a goal of getting that approved by the end of 2017."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay, and on S-ICD?",4,"Okay, and on S-ICD?"
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","I am sorry, could you clarify the question on S-ICD?",10,"I am sorry, could you clarify the question on S-ICD?"
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Yes, I was just curious -- I may have missed the comment here because the comments were by kind of fast. But do you still having the same timeline for S-ICD MRI approval? And just how is S-ICD performing today?",40,"Yes, I was just curious -- I may have missed the comment here because the comments were by kind of fast. But do you still having the same timeline for S-ICD MRI approval? And just how is S-ICD performing today?"
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, we saw the same timeline anticipating approval in Q3 of this year, and really, couldn't be more pleased with what we've seen in terms of uptake of EMBLEM MRI, where it's been launched in Europe and the existing EMBLEM device in the U.S. and globally.",46,"Yes, we saw the same timeline anticipating approval in Q3 of this year, and really, couldn't be more pleased with what we've seen in terms of uptake of EMBLEM MRI, where it's been launched in Europe and the existing EMBLEM device in the U.S. and globally."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","So we expect EMBLEM MRI approval in the U.S. in the third quarter.",14,"So we expect EMBLEM MRI approval in the U.S. in the third quarter."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Q3 of this year.",4,"Q3 of this year."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes.",1,"Yes."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Great. And could you just talk about broader utilization? Obviously your results were phenomenal this quarter. Are you seeing something going on in either in the U.S. market or some of the emerging markets that you plan, that's contributing to higher leve",64,"Great. And could you just talk about broader utilization? Obviously your results were phenomenal this quarter. Are you seeing something going on in either in the U.S. market or some of the emerging markets that you plan, that's contributing to higher levels of utilization that may not continue going forward? Or do you think that you're really just outperforming your markets from good execution?"
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Well, thanks, Matt. It's Mike. I also don't want to be a broken record here, but I think, I want just to reinforce, consistent with our investor day presentations in '13 and '15, we continue to invest our portfolio into faster-growth markets. So kind of i",177,"Well, thanks, Matt. It's Mike. I also don't want to be a broken record here, but I think, I want just to reinforce, consistent with our investor day presentations in '13 and '15, we continue to invest our portfolio into faster-growth markets. So kind of in the -- maybe the 2011 timeframe, we called our market growths about -- market growth profile 3% in the markets we compete in. So as we've shifted our portfolio over time into the faster-growth markets, we think the markets that we compete in now are kind of in the 4% to 5% growth range. If you look at the compositive BSE. So we are pleased that we're outperforming the market. We'll strive to continue to do so, but we think we have fundamentally shifted the markets that we play in to about a 4% to 5% growth market versus maybe a 2% to 3% growth market 4 or 5 years ago. So the markets are stronger that we compete in, and the team is doing a really nice job of outperforming."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","That question comes from the line of Glenn Novarro from RBC Capital Markets.",13,"That question comes from the line of Glenn Novarro from RBC Capital Markets."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Two questions, one, drug-eluting stents in the quarter up high single digits, significantly outpacing the market. You have it launching Absorb. So my question is, is this high single-digits sustainable given ABSORB coming into the market, or should we ant",52,"Two questions, one, drug-eluting stents in the quarter up high single digits, significantly outpacing the market. You have it launching Absorb. So my question is, is this high single-digits sustainable given ABSORB coming into the market, or should we anticipate a little moderation going forward? And then I had a quick follow-up."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","So yes, we're not giving the DES guidance for the third quarter or fourth quarter. We're going to continue to run the play which is, we believe we have the best product in the market, and Keith can comment a bit more on the clinical data. And we've been c",171,"So yes, we're not giving the DES guidance for the third quarter or fourth quarter. We're going to continue to run the play which is, we believe we have the best product in the market, and Keith can comment a bit more on the clinical data. And we've been competing with ABSORB in Europe for quite a while. We would put at that probably less than the 7% the DBS. So it probably less than 7% of the global market has been in the market for quite a while. So we feel like we're in a position of strength in terms of our product portfolio, and you know we continue to look at DBS. It's an interesting technology, and we've got a number of bets and it's a fact in the future. We can look at a second gen or a third generation device, then we'll eventually bring that to market. But at this time, we believe that SYNERGY is the premium device, and we'll continue to focus on driving that."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","And then, with Keith on the line, I'd love to get his thoughts on kind of SYNERGY versus ABSORB. And then my follow-up was on Eluvia, which was just launched in Europe. And the data is very strong and once you come to the U.S., you'll be by far -- you wil",102,"And then, with Keith on the line, I'd love to get his thoughts on kind of SYNERGY versus ABSORB. And then my follow-up was on Eluvia, which was just launched in Europe. And the data is very strong and once you come to the U.S., you'll be by far -- you will be the second DES on the market for peripherals, but with, by far, the best data. So how is Eluvia doing in Europe? And it just seems like this is one product that has a significant opportunity that's flying under the radar screen. So just thoughts on Eluvia as well."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","So Glenn, in terms of SYNERGY and DBS, obviously, there's not a lot of head-to-head data between the two. But DBS has been available and Europe's had CE Mark for 5.5 years and the penetration, as Mike said, is mid-single digits. And you and everybody else",169,"So Glenn, in terms of SYNERGY and DBS, obviously, there's not a lot of head-to-head data between the two. But DBS has been available and Europe's had CE Mark for 5.5 years and the penetration, as Mike said, is mid-single digits. And you and everybody else on the call is well aware of the ABSORB II and ABSORB III data. The safety profile of a drug-eluting stent is paramount. Safety profile is more important than efficacy, and with a stent thrombosis rate that is at least 2x, SYNERGY, we feel that the first generation fully resemble a scaffold safety profile is open to question. We do have an interest in the space, obviously, and are leader in DES. We have to have that. And as you know, also, we have 3 shots on goal and our own internal FAST program, which is thinner strap, more deliverable stent and more compliant. Less [indiscernible] is in first human use trials now, and we are still anticipating commercialization in Europe in 2018."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","And then, your thoughts on Eluvia, how it's performing in Europe? And your thoughts on how it'll perform in the United States once launched?",24,"And then, your thoughts on Eluvia, how it's performing in Europe? And your thoughts on how it'll perform in the United States once launched?"
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, so we're early with our Eluvia platform. It's a large investment. We will be announcing additional data sets on both our balloon and our stent at CIRSE, which is I think in Barcelona in September, third quarter this year. So we'll continue to lay ou",154,"Sure, so we're early with our Eluvia platform. It's a large investment. We will be announcing additional data sets on both our balloon and our stent at CIRSE, which is I think in Barcelona in September, third quarter this year. So we'll continue to lay out our clinical data there. But I think just the -- again, the strength of having a -- in Europe a drug-coated balloon and a differentiated drug-eluting stent for the peripheral vascular offers physicians more options. And so it uniquely positions us in the SFA, and also helps us pull through our core portfolio. So I think these investments are paying off in Europe based on the growth, and we've got to wrap up our clinical trial of Eluvia, which we anticipate by year end 2016. And so we look forward to that finishing, and then we'll provide additional comments on our balloon at our third quarter earnings call."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Great. With that, we'd like to conclude the call. Thanks for joining us today, and we appreciate your interest in Boston Scientific. Before you disconnect, Greg will give you all the pertinent details for the replay.",36,"Great. With that, we'd like to conclude the call. Thanks for joining us today, and we appreciate your interest in Boston Scientific. Before you disconnect, Greg will give you all the pertinent details for the replay."
317627,370563598,1015673,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Thank you. And ladies and gentlemen, this conference will be available for replay after 10:30 Eastern Time today through August 11. You may access the AT&T Teleconference Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 3",86,"Thank you. And ladies and gentlemen, this conference will be available for replay after 10:30 Eastern Time today through August 11. You may access the AT&T Teleconference Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 396158. International participants dial (320) 365-3844. Those numbers, once again, are 1 (800) 475-6701 or (320) 365-3844 with the access code 396158. That does conclude your conference for today. Thank you for your participation and for using AT&T Executive Teleconference. You may now disconnect."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Second Quarter 2016 Boston Scientific Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.I would now like to turn the conference over to your",46,"Ladies and gentlemen, thank you for standing by. Welcome to the Second Quarter 2016 Boston Scientific Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
I would now like to turn the conference over to your host, Susie Lisa. Please go ahead."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Greg. Good morning, everyone, and thanks for joining us. With me on today's call are Mike Mahoney, Chairman and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.We issued a press release earlier t",364,"Thank you, Greg. Good morning, everyone, and thanks for joining us. With me on today's call are Mike Mahoney, Chairman and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.
We issued a press release earlier this morning announcing our Q2 2016 results, which included reconciliations of the non-GAAP measures used in the release. 
We have posted a copy of that release as well as reconciliations of the non-GAAP measures used in today's call to the Investor Relations section of our website under the heading Financial Information. 
The duration of the morning's call will be approximately 1 hour. Mike will provide strategic and revenue highlights of Q2 of '16. Dan will review the financials for the quarter and then Q3 '16 and full year 2016 guidance, and then we'll take your questions. During today's Q&A session, Mike and Dan will be joined by our Chief Medical Officers, Dr. Keith Dawkins and Dr. Ken Stein.
Before we begin, I'd like to remind everyone that on the call, organic revenue growth is defined as excluding the impact of changes in foreign currency exchange rates and sales from the acquisition of the American Medical System, AMS, male urology portfolio over the prior year period. Also of note, this call contains forward-looking statements within the meaning of federal securities laws, which may be identified by words like anticipate, expect, believe, estimate and other similar words. 
They include, among other things, statements about our growth and market share; new product approvals and launches; clinical trials; cost savings and growth opportunities; our cash flow and expected use; our financial performance, including sales, margins, earnings and other Q2 2016 results and Q3 and full year 2016 guidance as well as our tax rates, R&D spend and other expenses.
Actual results may differ materially from those discussed in the forward-looking statements. 
Factors that may cause such differences include those described in the Risk Factors section of our most recent 10-K and subsequent 10-Qs filed with the SEC. 
These statements speak only as of today's date, and we disclaim any intention or obligation to update them. 
At this point, I'll turn it over to Mike for his comments. Mike?"
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Susie, and good morning, everyone. We continue to beat our long-range strategic plan goals and execute very well as a global team. The success of our category leadership strategy is helping us gain share in our core markets, expanding the faste",2113,"Thank you, Susie, and good morning, everyone. We continue to beat our long-range strategic plan goals and execute very well as a global team. The success of our category leadership strategy is helping us gain share in our core markets, expanding the faster growth adjacencies and deliver solutions that address unmet clinical needs. Our consistent results continue to demonstrate that Boston Scientific is uniquely positioned to deliver differentiated long-term shareholder value. With long term visibility to mid-single digit organic revenue growth, complemented by ongoing operating margin improvement initiatives, our goal is to consistently drive double-digit adjusted EPS growth.
We're very excited about our excellent second quarter performance, first half results, and most importantly, our plans for the future. In Q2, we drove total operational revenue growth of 16% and organic revenue growth of 10%, excluding the impact of the AMS Urology acquisition. We had strong results across all regions, and 5 of our 7 business units grew revenue double digits organically. We leveraged that revenue growth to drive adjusted operating income growth of 22%, resulting in an adjusted operating margin of 23.4% and 130 basis point improvement year-over-year.
We delivered adjusted EPS of $0.27, achieving the high end of guidance and representing 25% growth, including the negative $0.015 impact from foreign currency. So given our strong performance, we are increasing our 2016 guidance for revenue and adjusted EPS. We're are increasing our full year organic revenue growth guidance from 6% to 8% to 8% to 9%, full year operational revenue growth guidance, which includes the benefit of AMS, is increased from 9% to 11% to 11% to 12%. We're maintaining our full year adjusted operating margin guidance of 24% to 24.5%, which at the midpoint is roughly 200 basis points of improvement over 2015. We're also increasing our adjusted EPS guidance by $0.01 over our prior range to $1.07 to $1.11, which represents 15% and 19% growth. Importantly, this adjusted EPS guidance includes an expected $0.05 negative impact from foreign exchange.
I'll now provide some highlights on Q2 results and our '16 outlook. In my remarks, all references to growth are in a constant currency organic year-over-year basis, and they exclude the benefit of AMS. Our second quarter revenue growth of 10% was broad based across businesses and regions, led again by exciting new product launches, continued global expansion and execution of our category leadership strategy. We drove double-digit growth in 5 businesses: endo, urology public-health, Neuromodulation, Interventional Cardiology and Peripheral Interventions. In addition, each region accelerated sequentially. The U.S. grew 8%; Europe, grew 9%; Asia PAC delivered 16% growth, with every major country in the Asia Pac region up double digits this quarter. The emerging markets also continued to deliver. Sales grew 20%, including China revenue at 21%. 
Our MedSurg businesses, endo, Urology public health and Neuromodulation, continue to be a priority focus area for the company, and each of the businesses maintained or accelerated growth from first quarter. These 3 businesses represent 40% of our operating income in the second quarter and they delivered adjusted operating margin of 32.8%. This is up 20 basis points sequentially and 240 basis points year-over-year. Our global Endoscopy team continues to perform at a high level with the revenue growing 11% in the second quarter. We continue to see strong growth in our core endo business, supported by our innovative portfolio and broad-based global expansion initiatives. Key endo growth drivers include the single-use SpyGlass DS Visualization System, the AXIOS Stent for drainage of pancreatic fluid and our next-generation hemostasis clip, the Resolution 360. High single-digit growth in U.S. endo was complemented by double-digit growth in every region outside the U.S., as we continue to develop commercial and position-training abilities in emerging markets and add focus in pulmonary, which helped drive 25% growth in BT, bronchial thermoplasty, led by the U.S., Japan and China. 
In Urology and public health, our investments to become the clear market leader and category leader have been rewarded, as growth excluding AMS accelerated to 18%. The business is performing at a high-level across the various regions and segments, including kidney stone, BPH, ED and surg gyn. Our global commercial footprint and focus on physician education has helped us to convert a meaningful portion of the market opportunity created by a STORZ's exit from the market at the end of March. 
AMS sales strength in the quarter and importantly, remediation and integration efforts remain on track. An exciting new growth platform in our urology business is the launch of a LithoVue platform. LithoVue is an innovative single-use digital scope for treatment of kidney stones that provide customers with enhanced visualization and navigation capabilities. LithoVue resonates with physicians and hospitals due to less OR downtime for sterile processing of reusable scopes. Performance navigation characteristics that allow physicians to tackle tougher procedures and the ability to schedule full day of procedures without the fear of cancellation due to reusable scopes being down.
In Neuromodulation, we continue to invest in the fast-growing microelectronics market, where we enjoy innovation and supply chain leverage between our CRM and neuromod business. Neuromodulation revenues grew in the quarter to 12% -- grew 12%. Sales were driven by the U.S. market-leading Spectra platform; the launch of Precision montage, which offers full body MRI capability; and our Vercise Deep Brain Stimulation platform. Our U.S. DBS trial continues to progress, and we expect to launch in the U.S. in the first quarter of 2018. Additionally, earlier this week, we announced the acquisition of Cosman Medical, a technology leader in the field of radiofrequency ablation systems for the treatment of chronic pain. This acquisition broadens our neuromodulation portfolio and is highly synergistic with our U.S. commercial team. We're excited to offer physicians treating patients with chronic pain another non-opioid therapeutic option earlier in the treatment continuum.
Now turning to Cardiovascular, which includes our peripheral and Interventional Cardiology businesses. Overall, this segment grew sales 13% in the quarter and delivered adjusted operating margin of 32.2%, up more than 170 basis points year-over-year. Our peripheral business delivered exceptional results with strong global sales across all regions fueled by an innovative portfolio. Sales grew 14% on strong results across all regions and segments, including stents, thrombectomy and our emerging drug-eluting portfolio. We also delivered strong growth in Interventional Oncology, where the integration of Interventional Radiology business of CeloNova remains on track. In our Venous segment, we continue to see very strong demand for our Zelante deep vein thrombosis system. We are the only company that have been leading drug-eluting technology globally on multiple platforms in order to treat complex, peripheral vascular disease. The Eluvia peripheral drug-eluting stent ID trial called IMPERIAL is on track to complete enrollment by yearend 2016. 
In Interventional Cardiology, we are focused on gaining share in our core businesses while expanding in faster growth segments that leverage our capabilities. This strategy is working. In the second quarter, interventional cardiology grew 12% led by a structural heart, drug-eluting stents and PCI guidance. SYNERGY had an excellent quarter, as we grew DES sales 9%. SYNERGY is now the market-leading premium DES platform and it's on track to represent 50% to 60% of our U.S. DES revenue mix by the end of 2016. PCI guidance grew mid-teens and continues share gains in intravascular ultrasound, and we're encouraged by strong early feedback on the ease-of-use of our COMET fractional flow reserve system. Our leading portfolio of solutions for complex high-risk PCI of patients also contributed to global growth.
The 12% IT revenue growth was fueled by our strength in the structural heart business, which includes our Lotus transcatheter aortic valve and WATCHMAN Left Atrial Appendage Closure. We believe we are well-positioned to drive long-term growth in these 2 fast-growing markets via our differentiated platforms and expanded capabilities. We also aim to deliver at the high-end of our 2016 Structural OR guidance range of $175 million to $200 million.
Our Lotus Valve continues to gain share in Europe, and we are investing significantly in clinical studies, R&D and our global supply chain to develop our capabilities further. We remain on track to launch Lotus EDGE at PCR London Valves in September. The Lotus EDGE delivery system features a 14 French expandable sheet called iSleeve and is designed for more flexibility and simplified deployment. It also offers our new Depth Guard technology, which limits the depth of the valve in the left ventricular outflow tract. Lotus also offers best-in-class paravalvular leakage rates, and we aim to enhance Lotus with studies to demonstrate improved permanent pacemaker rates with Lotus EDGE and Depth Guard. So our goal is to provide initial Lotus EDGE data at PCR London Valves. We do expect a slight delay in our expanded Lotus Valve matrix in Europe, with a 21-millimeter valve estimated CE Mark timing first quarter '17, and the 29-millimeter valve in Europe in mid-2017. We continue to invest and plan for a U.S. launch with the Lotus EDGE platform in late 2017.
Also in structural heart, WATCHMAN sales were strong on procedure growth and new account openings. We are developing additional WATCHMAN capabilities in field clinical support, market development and physician training courses. Implant success rates and patient outcomes remain very high as evidenced by the 98.5% success rate in the evolution registry detailed at HRS in May.
We continue to expand WATCHMAN in the new markets and we're pleased with the recent reimbursement approval and launch in France. Importantly, the unique clinical benefits of WATCHMAN are being rewarded, as evidenced by the French reimbursement at a meaningful premium to competitive LAAC devices.
We post a limited market release of our next generation WATCHMAN FLX device. We've have decided to pursue design enhancements before we turn in the next-gen platform to market. Importantly, we anticipate this delay will have no impact on our current WATCHMAN product and thus, no change to our market outlook for LAAC.
Rhythm Management sales increased 5% in the quarter and delivered adjusted operating margin of 16.9%, up 200 basis points year-over-year, as improving profitability remains a core focus.
In CRM, we improved our global performance and delivered 4% growth in second quarter. Our European and Asia PAC CRM businesses continue to grow faster than the market, offset by slower growth in U.S. CRM. Pacemaker sales grew 15% globally, with excellent U.S. performance fueled by our ACCOLADE MRI launch, and growth from our X4 CRT-P quad device. Worldwide ICD sales were flat as we delivered above-market growth internationally that was offset by weaker sales in the U.S. In the U.S., we faced some near-term headwinds due to our tachy MRI product gap and replacement cycle headwinds. However, we recently we earned FDA approval of our ACUITY X4 quad CRT lead and the early results are promising. Importantly, EMBLEM S-ICD is a key differentiator, and growth continues to accelerate globally. We continue to expand global S-ICD utilization with more long-term data from the EFFORTLESS Registry, growing physician implant experience, geographic expansion and the recent second quarter of '16 EU launch at EMBLEM MRI, which contributed to our solid international growth.
Due to a change in protocol of our U.S. enabled MRI clinical trial, we are revising our goal for transvenous tachy MRI U.S. approval by year-end 2017, but continue to expect to gain MRI labeling for both new and previously implanted ICDs and CRT-Ds with a new timeline. The continued cadence of data proving the superiority of EnduraLife batteries and the pending FDA approval of EMBLEM MRI S-ICD, which is expected in third quarter, will help us offset the near-term headwinds from the U.S. MRI high-voltage segment.
In the second quarter, European CRM sales grew 5%, representing 9 straight quarters of above-market growth, giving us further confidence in our long-term CRM outlook. Our EP business grew 6% in second quarter and we're encouraged by double-digit growth in Europe, led by new arrhythmia installs and the recent launches of Nitinol OI and IntellaTip MiFi OI ablation catheters. The U.S. launch in late first quarter of the Blazer OI catheter will be augmented in Q3 with the upcoming launch of the nav-enabled version of this catheter. 
So to wrap up, our company delivered another excellent quarter. Our second quarter performance reflects the strength of our global team, the depth and breadth of our portfolio, our globalization efforts and our ongoing investments in the faster growth markets. Importantly, we believe we are well-positioned to deliver continued strong results in the second half of '16 and beyond. I really want to thank our employees globally for their winning spirit and their strong commitment to Boston Scientific.
Now let me turn the call over to Dan for a more detailed review of our financial results."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Mike. In Q2, we generated organic revenue growth of 10% versus our 6% to 8% guidance range, and adjusted EPS of $0.27, representing 25% year-over-year growth in the high-end of our guidance range of $0.25 to $0.27. The strong adjusted EPS growth p",1909,"Thanks, Mike. In Q2, we generated organic revenue growth of 10% versus our 6% to 8% guidance range, and adjusted EPS of $0.27, representing 25% year-over-year growth in the high-end of our guidance range of $0.25 to $0.27. The strong adjusted EPS growth performance in Q2 was driven primarily by revenue growth upside and a lower SG&A rate versus prior year. And given the strong performance in the first half of 2016, we are again raising full year guidance for revenue growth and adjusted EPS. Consolidated revenue of $2,126,000,000 represented operational revenue growth of 16%, exceeding the high end of guidance and excludes the impact of a $24 million headwind from foreign exchange, which was in line with guidance. Excluding an approximate 500 basis point contribution from the AMS male urology portfolio acquisition, organic revenue growth was 10% in the quarter and 15% on an as-reported basis.
Adjusted gross margin for the second quarter was 70.7%, decreasing 60 basis points year-over-year and unfortunately, 130 basis points below the midpoint of Q2 guidance due to a few factors that I will detail. The year-over-year decrease is due to the unfavorable impact of foreign exchange, which was a 120 basis point headwind, as well as costs related to our new Malaysia manufacturing plant, the AMS integration, including the AMS quality remediation expense. Compared to guidance, the shortfall is due to inventory charges in advance of new product launches, inventory write-offs related to WATCHMAN FLX and more unfavorable FX.
We now expect Q3 and full year 2016 adjusted gross margin to be in the range of a 71.5% to 72.5%, which includes an expected 75 to 100 basis point of unfavorable foreign exchange. A key element in the second half increase is lower expected inventory charges, and we will also benefit fully from the lower 2016 standard cost of our products as we will have sold through all of the inventory valued at last year's higher standards. Adjusted SG&A expenses were $763 million or 35.9% of sales in Q2, down 140 basis points year-over-year. We continue to believe our full year rate will be between 35.5% and 36.5%, which at the midpoint would be a 140 basis point improvement compared to last year.
Adjusted research and development expenses were $222 million in the second quarter or 10.4% of sales, which is down 50 basis points year-over-year. As a result of a slightly lower R&D rate in the first half, we expect our full year 2016 adjusted R&D rate to be between 10.5% and 11.5% of sales or 50 basis points lower than prior guidance. Royalty expense was 0.9% of sales in Q2, roughly flat year-over-year. Our Q2 2016 adjusted operating margin of 23.4% was in line with our guidance and represents a 130 basis point improvement over Q2 last year, which marks the eighth consecutive quarter in which we will have expanded adjusted operating margin by 100 basis points or more.
As a reminder, we've signaled a sequential decrease in adjusted operating margin from Q1's rate as we experienced the usual increase in SG&A from Q1 to Q2 due to seasonal trade show activity and began to ramp reinvestment of the medical device excise tax suspension. Our first half 2016 adjusted operating margin of 24.2% positions us well to achieve our full year adjusted operating margin guidance of 24% to 24.5%, and we remain on track to reach 25%-plus in 2017.
Q2 adjusted operating income grew 22% year-over-year, with all 3 reportable segments expanding adjusted operating margin by at least 170 basis points over Q2 2015. Specific to Rhythm Management, the team delivered an adjusted operating margin of 16.9%, up 280 basis points year-over-year. In the second half of 2016, we expect Rhythm Management adjusted operating margin to continue to improve and be 18% to 19%. This second half gain is expected to result from realizing the full benefit of 2016 product costs, leveraging the improved top line performance expected of the global CRM and EP businesses, and we continue to believe Rhythm management is on track to deliver an adjusted operating margin of 20% in 2017.
Turning to the balance sheet, we had some key developments in the quarter that helped reduce future uncertainties. Before I get into the details of the activity in the quarter, let me try to frame out the next 3 years of expected cash flow at a high level. From 2017 through 2019, we believe we can generate cumulative adjusted free cash flow after CapEx approaching $6 billion. We expect to allocate roughly 2/3 of that $6 billion to a combination of M&A and share repurchases. As you're aware, the 2 most significant liabilities on our balance sheet are our IRS transfer pricing case and the mesh litigation. During the quarter, we took 2 important steps to manage these liabilities. First, we reached a stipulation of settled issues with the IRS for the 2001 to 2007 tax years. And importantly, this stipulation also provides a framework to settle the remaining years 2008 through 2015 as well. While there's work to do to conclude all the years, we are confident we will bring these to conclusion over the coming quarters. With the payment in 12 to 24 months, this would eliminate one of the most significant liabilities on our balance sheet. With regards to mesh, we increased our reserve by $608 million during the quarter. With the same goal of managing our liabilities, we've reached conditional or final settlements on 12,000 claims and made significant progress towards reaching agreement in principle on another 7,000 claims for a total of 19,000 claims. This represents approximately half of the roughly 40,000 known claims, and we expect to make even more progress during the remainder of 2016. As you know, every quarter, we assess all 4 key components involving calculating the reserve and make any necessary adjustments for all probable and estimable charges, including the volume of known claims, the estimated cost to resolve each claim, an estimate of future claims and the cost to defend each claim.
Our total legal reserve, of which mesh is included, was $2,375,000,000 as of June 30, 2016 and we believe it reflected our best estimate of what is probable and estimable. Of note as well, is that included in this reserve is the Mirowski Judgment which we have paid in full, subsequent to quarter end. So as of today, the reserve would be closer to $2 billion. As a reminder, this $2 billion includes a number of claims we have agreed in principle to settle but have not yet paid. Once those settlements are funded, the amount of the reserve will be adjusted accordingly.
Now I'll move on to interest expense. Interest expense for the quarter was $59 million, compared to $106 million in Q2 of last year. The decrease is primarily due to the pretax onetime charge of approximately $45 million associated with a senior note refinancing in Q2 of last year. Excluding this charge, Q2 2015 interest expense was $61 million. Our average interest expense rate was 4% in Q2 this year compared to 8% in Q2 last year. The lower interest-rate expense in Q2 of '16 was primarily due to lower average cost of debt resulting from the senior notes refinancing and the inclusion of the pretax onetime charge in Q2 of last year that I mentioned. Excluding this charge, Q2 2015 interest expense would have been 4.6%.
Our tax rate for the second quarter was 47.8% on a reported basis and 14.2% on an adjusted basis. As reported last week, we're pleased with the conditional settlement reached with the IRS council regarding our transfer pricing litigation, and plan to use some of the current benefit to repatriate overseas cash. Thus we continue to expect our full year 2016 adjusted tax rate to be approximately 14%. We believe this IRS settlement, in addition to recent progress we've made towards reaching agreements in principle to settle additional mesh claims, as I mentioned, are prudent actions to take in the management of our balance sheet.
Finally, Q2 2016 adjusted EPS of $0.27 includes approximately $0.015 of unfavorable FX and represents 25% year-over-year growth or 32% growth excluding the impact of foreign exchange. On a reported GAAP basis, Q2 2016 EPS was a loss of $0.15 and includes net charges and amortization expense totaling $580 million after tax.
Adjusted free cash flow for the quarter was $464 million compared to $406 million in Q2 of last year. Given the strong adjusted free cash flow generation in the first half of this year, we are raising our full year adjusted free cash flow guidance from $1.5 billion to $1.6 billion, which was formally our stretch goal. Achieving adjusted free cash flow of $1.6 billion would represent 17% growth, and we continue to pursue inventory management initiatives designed to improve the working capital contribution to cash flow.
In Q2, we used cash primarily to repay $250 million of bank term loans as well as fund the previously agreed legal settlements. As of June 30, 2016, we had cash on hand of $438 million. Near term, our capital allocation priorities are to manage contingencies and pursue tuck-in M&A. 
We ended Q2 with 1,375,000,000 fully diluted weighted average shares outstanding. Consistent with our prior guidance, we expect our share count to increase by roughly 5 million per quarter through the end of 2016, as we plan to keep the buybacks suspended for the balance of this year. We expect this to result in a fully diluted weighted average share count of approximately 1,380,000,000 shares for full year 2016.
I'll now walk-through guidance for Q3 and full year 2016. For the full year, we now expect consolidated revenue to be in a range of $8,270,000,000 to $8,370,000,000, which represents year-over-year growth of 8% to 9% on an organic basis and 11% to 12% on both an operational and reported basis. As a result of a stronger dollar, at current rates, we expect foreign exchange to be a headwind of approximately $70 million for the full year 2016. 
Turning to adjusted EPS, we now expect full year 2016 adjusted EPS to be in a range of $1.07 to $1.11, representing 15% to 19% adjusted earnings growth. Our previous guidance assumed the unfavorable FX on full year adjusted EPS would be between $0.05 and $0.06. Given the fact that Q2 saw a slightly less unfavorable impact than expected, we now believe the full year impact will be closer to $0.05 which assumes $0.02 to $0.03 in the second half of this year. On a GAAP basis, we expect EPS to be in a range of $0.30 to $0.35.
Now turning to Q3 2016, we expect consolidated revenues to be in a range of $2,035,000,000 to $2,085,000,000. This represents year-over-year growth in a range of 7% to 9% organically and 8% to 10% operationally. We expect the foreign exchange headwind on Q3 revenue to be negligible. For the third year -- for the third quarter, adjusted EPS is expected to be in a range of $0.25 to $0.27 per share, and GAAP EPS is expected to be in a range of $0.13 to $0.15 per share.
Please check our Investor Relations website for Q2 2016 financial and operational highlights, which outlines Q2 results, as well as Q3 and full year 2016 guidance, including P&L line item guidance. So with that, I'll turn it back over to Susie, who'll moderate the Q&A."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Dan. Greg, let's open it up to questions for the next 30 minutes. [Operator Instructions] Greg, please go ahead.",20,"Thanks, Dan. Greg, let's open it up to questions for the next 30 minutes. [Operator Instructions] Greg, please go ahead."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","[Operator Instructions] Your first question comes from the line of Mike Weinstein from JPMorgan.",14,"[Operator Instructions] Your first question comes from the line of Mike Weinstein from JPMorgan."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Let me just clarify this on a few items. So number one, the pacemaker performance being as strong as it is on the back of the MRI launch. One question that I've already got with people is, is that a clean number, is there any stocking in that number that",90,"Let me just clarify this on a few items. So number one, the pacemaker performance being as strong as it is on the back of the MRI launch. One question that I've already got with people is, is that a clean number, is there any stocking in that number that we should be aware of? Second, the move in the structural heart guidance to the high end of the range, is that WATCHMAN more than Lotus? If you could kind of share any insights into that, and then I'll follow-up."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, good morning, Mike. On the pacemaker, our team has been waiting for a long time for that product approval. We've had some slow quarters in our pacemaker business in the U.S. Outside the U.S., we've done quite well with our product for a while. So th",273,"Sure, good morning, Mike. On the pacemaker, our team has been waiting for a long time for that product approval. We've had some slow quarters in our pacemaker business in the U.S. Outside the U.S., we've done quite well with our product for a while. So that's not a stocking number. We were ready for that launch for quite a while and the team -- our commercial team's did an excellent job executing it. So we think it's a very innovative product and long in coming. And the U.S. team, essentially, has did what the OUS teams have done with that product for a while. And now structural heart, we continue to be really excited about the future for structural heart. It continues to be our largest investment area as a company. We were comfortable with the high-end of our guidance that we provided at $175 million to $200 million. We continued to invest long-term in R&D capabilities, clinical capabilities and commercial capabilities to prepare ourselves for the launch in the U.S. And we're really excited about the upcoming data that we expect to see in London Valves on our pacemaker rate with the addition of Lotus EDGE and Depth Guard. So it's really an important category for us. As you know, we continue to -- we outlined at Investor Day, back in, I think 2013 and '15, our focus to continue to grow in our core businesses and take share, which we're doing, and importantly, expand in the faster-growth markets. And that's exactly what you're seeing as a company, and our structural heart investment really is kind of leading the pack there."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","So Mike, I would apologize. The question was structural heart -- within structural heart, WATCHMAN is what's driving to the high end of the range there?",26,"So Mike, I would apologize. The question was structural heart -- within structural heart, WATCHMAN is what's driving to the high end of the range there?"
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","What's driving the high-end range there is, we're just continue to open up new accounts. We continue to improve our account utilization. And we continue to build up our commercial capabilities in the U.S.",35,"What's driving the high-end range there is, we're just continue to open up new accounts. We continue to improve our account utilization. And we continue to build up our commercial capabilities in the U.S."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. The gross margin issues in the quarter, I think -- I feel you did a good job of -- Dan walking through what those are. So if we look at the back half of the year, and the expected improvement to gross margin, that's because, one, your inventory issu",85,"Okay. The gross margin issues in the quarter, I think -- I feel you did a good job of -- Dan walking through what those are. So if we look at the back half of the year, and the expected improvement to gross margin, that's because, one, your inventory issues from the AMS transaction, basically, you get to a better, safer cost on those products, and then the FX headwind that you saw in this quarter on the gross margin should dissipate. Is that accurate?"
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","No, somewhat. Let me just make sure we're clear on that. So we're at 70.7% in the quarter. The guidance range for Q3 and the full year is 71.5% to 72.5%, so it implies the uptick that you mentioned in the second half. I think the 2 key drivers of that are",232,"No, somewhat. Let me just make sure we're clear on that. So we're at 70.7% in the quarter. The guidance range for Q3 and the full year is 71.5% to 72.5%, so it implies the uptick that you mentioned in the second half. I think the 2 key drivers of that are, the inventory charges for the CRM products related to the better uptake of MRI-safe brady and quad in the U.S. as well as the WATCHMAN FLX. We don't believe that those repeat themselves. And then secondly, we will get the full benefit in the second half of the lower manufacturing costs that we have for 2016 standards because we'll now be selling all the inventory at the new standards, and we'll have sold off all of the inventory at last year's standards. Those are the 2 main drivers that put us back in the 71.5% to 72.5% range. FX, we actually assume is probably somewhat in the same range as where it was in Q2. That's really the reason. If you think back to last quarter, our guidance for FX in gross margin would have implied about 70 to 75 basis points each quarter for Qs 2, 3 and 4. Now it's 120. So that's a 50 basis point difference. And that's the reason why the guidance for the full year came from 72% to 73% to 71.5% to 72.5%."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of David Lewis from Morgan Stanley.",13,"Your next question comes from the line of David Lewis from Morgan Stanley."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","In light of the very strong revenue quarter, guys, I hate to ask something as banal as cash flow, Dan, but you don't give us multiyear cash flow spins that often, and I noticed that your $6 billion free cash estimate in the next 3 years is 10% higher than",106,"In light of the very strong revenue quarter, guys, I hate to ask something as banal as cash flow, Dan, but you don't give us multiyear cash flow spins that often, and I noticed that your $6 billion free cash estimate in the next 3 years is 10% higher than what we were looking for. Can you sort of walk us through kind of why that would be in some of the components? I imagine one component is CapEx and perhaps the other is margins, but our margin numbers are pretty high and you're still 10% above us. So what could be driving that significant upside?"
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","I think you answered your own question there, David. It's margins and CapEx. So the -- one of the things we have this year is, as we detailed in our guidance at the beginning of the year is, the CapEx number at $350 million, that's $100 million higher tha",207,"I think you answered your own question there, David. It's margins and CapEx. So the -- one of the things we have this year is, as we detailed in our guidance at the beginning of the year is, the CapEx number at $350 million, that's $100 million higher than we think we need to effectively run each year. So we get that back hopefully each of the next 3 years. And then, the expanding margins. So our goal next year is 25%-plus, and as we've given guidance for long-term goals for 27% to 28% by 2020, the combination of those 2 factors and the CapEx, I think, gets you a long way there. And then the other piece is that, we're going to continue to try from a working capital perspective to make that be our friend. We have a lot of inventory initiatives in place to really hopefully lead the industry in that regard, and be best-in-class, and when we do that, that'll turn something that's been a drag on cash flow into a positive, and hopefully see the beginnings of that this year. You see that from us taking our guidance from $1.5 billion to $1.6 billion a piece of that is the inventory initiatives."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay, very helpful. And then Mike, maybe a couple of product questions. I guess the first is just, it's just sort of a forgotten business for Boston MedSurg is sort of no longer forgotten given the organic growth and specifically, Endoscopy has gone from",132,"Okay, very helpful. And then Mike, maybe a couple of product questions. I guess the first is just, it's just sort of a forgotten business for Boston MedSurg is sort of no longer forgotten given the organic growth and specifically, Endoscopy has gone from mid-single growth last year to double-digit growth this year. I wonder if you can just give us a sense of sort of where we are in the product cycles. Is it share gain from competitors? Is it product cycles that is driving that? And then, secondarily, on DES, on synergy, where do you think we are in sort of share versus mix? And obviously, you're growing dramatically ahead of market. So what are some of the factors that are driving that? And I'll now jump back in queue."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks. David. We've definitely never forgot about endo. It's really an incredibly high performing business and it has been for a number of years. And they really have just continue to do -- continue to grow and expand. So our endo business enjoys, a, fir",444,"Thanks. David. We've definitely never forgot about endo. It's really an incredibly high performing business and it has been for a number of years. And they really have just continue to do -- continue to grow and expand. So our endo business enjoys, a, first of all, a strong market, a bit fewer competitors in our Endoscopy markets than some of our others. It has very strong growth profile in terms of the market growth in OUS expansion, and we are a very strong category leader. Across the globe, when we continue to expand into emerging markets. The portfolio is really driving a lot of the launch out of the success that you're seeing in 2016, led by our SpyGlass digital DS platform, which is driving solid double-digit growth and helps pull through the core portfolio. We also launched a product called the AXIOS Stents, which is doing very well as well as a hemostasis clip. So the portfolio cadence for endo is very strong, it's very well-led, it's very globally oriented, and they also do a great job of laying out the economic value proposition for hospitals beyond the portfolio. So they continue to perform very well and intentionally, some of my comments with Mike in his first question, we're intentionally focusing on investing greater in faster-growth markets, in faster growth businesses and they represent 40% of our operating income, the MedSurg sector does now for BSC. So more to come there. DES is doing excellent. We had a few critics early on in our launch saying we weren't be an aggressive enough. We signaled all along that we're going to be -- drive an appropriate premium price for this product because we believe it is the best product available in the marketplace and the data is proving that out, and maybe Keith can comment in a minute. So we believe it's the premium product. We do offer a premium price for it. And so we've been smart in our rollout of it, and I think physicians and customers are seeing the value of the ease-of-use and the clinical data synergy and we expect the U.S. penetration to be probably above 50%, closer to 50% to 60% in the U.S. in 2016. And we continue to roll that out globally. So the team is doing a nice job there. But again, it's part of the overall story in interventional cardiology. Again pointing to faster growth segments, our DES is doing well. A lot of investments in complex coronary and imaging, which are part of the portfolio, and then clearly our structural heart. So Kevin Ballinger and the team are doing a nice job."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Keith?",1,"Keith?"
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, David, I think the SYNERGY Stent operators around the world are appreciating the best-in-class acu performance because, obviously, if you can't deliver the stent, that's really the end of the discussion. And it -- we have a lot of data now, including",124,"Yes, David, I think the SYNERGY Stent operators around the world are appreciating the best-in-class acu performance because, obviously, if you can't deliver the stent, that's really the end of the discussion. And it -- we have a lot of data now, including the EVOLVE II pivotal data, the EVOLVE personally use 5-year data, and the Real-World Sky data from Europe confirming the safety. Everybody, both patients and physicians, are interested in stent thrombosis. And the stent thrombosis, as you know from the data, is very low. We have 20,000 patients in investigator-sponsored trials with Synergy. And these trials are beginning to release their data, and you'll see more flows of data at the meetings during the rest of this year and next year."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of Larry Biegelsen from Wells Fargo.",13,"Your next question comes from the line of Larry Biegelsen from Wells Fargo."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","So Dan, you raised the organic growth from 6% to 8% to 8% to 9%, but you only raised the EPS guidance by $0.01. And so can you talk about why you're not getting better leverage in the incremental revenue? You kept the operating margin guidance the same. A",54,"So Dan, you raised the organic growth from 6% to 8% to 8% to 9%, but you only raised the EPS guidance by $0.01. And so can you talk about why you're not getting better leverage in the incremental revenue? You kept the operating margin guidance the same. And then, I had 1 follow-up."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, Larry. I think, probably the best way to explain that is to do a quick summary of the increase in revenue. So the revenue is $170 million higher at the midpoint of guidance and that breaks down into 3 things: $20 million comes from FX, $75 million c",163,"Sure, Larry. I think, probably the best way to explain that is to do a quick summary of the increase in revenue. So the revenue is $170 million higher at the midpoint of guidance and that breaks down into 3 things: $20 million comes from FX, $75 million comes from revenue that already came in Q2, and then $75 million comes in the second half. I think the main factor that's offsetting that is, if you look at our R&D rate, our R&D rate in the first half was 10.5%. And looking at the second half, it's going to be 11.5% to get to the full year rate of 11%. So that's 100 basis point increase in R&D, largely related to the timing in the investments in structural heart that Mike had mentioned. So that for, the most part, offsets the additional flow through in the revenue that you get -- the additional $75 million of revenue you get in the second half."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Got it. And then...",4,"Got it. And then..."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Just as a footnote. As you look at it, still very pleased to be at 15% to 19% full year EPS growth, which would be 4 years straight of double-digit adjusted EPS growth.",33,"Just as a footnote. As you look at it, still very pleased to be at 15% to 19% full year EPS growth, which would be 4 years straight of double-digit adjusted EPS growth."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Got it, sorry to interrupt there. And then, for my follow up. At the 2015 analyst meeting, the organic revenue goal was 3% to 6% in 2016 and 2017. You're now guiding to 8% to 9% in 2016. How should we think about the sustainability of the 8% to 9%, and yo",80,"Got it, sorry to interrupt there. And then, for my follow up. At the 2015 analyst meeting, the organic revenue goal was 3% to 6% in 2016 and 2017. You're now guiding to 8% to 9% in 2016. How should we think about the sustainability of the 8% to 9%, and your goals in 2017 and beyond? And I recognize you're not giving guidance here, but you're way outperforming what you expected to do at your analyst meeting last year."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, yes, the team is outperforming. It's part of the high-performance culture that we have as a company. We're very excited about the full year guidance at 8% to 9%. As you said, it compares to 3% to 6% we laid out, so it's a pretty strong beat the",125,"Thank you, yes, the team is outperforming. It's part of the high-performance culture that we have as a company. We're very excited about the full year guidance at 8% to 9%. As you said, it compares to 3% to 6% we laid out, so it's a pretty strong beat there. And strong momentum across, really, each region and each business. So we're not going to provide any outlook into 2017. Clearly, outperforming the market at these levels -- at this level is not likely sustainable each year. But that being said, we're confident we'll continue to outperform the market. We're investing in faster growth businesses, and we're very confident in our ability long-term to drive mid-single revenue growth, improve margins and drive double-digit EPS growth."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of Bob Hopkins from Bank of America.",14,"Your next question comes from the line of Bob Hopkins from Bank of America."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","So obviously, you've got the best revenue growth year for Boston Scientific, essentially since the financial crisis. Higher absolute level of revenues then, I think, any of the thought, so congratulations on the unbelievable progress. I guess my first que",149,"So obviously, you've got the best revenue growth year for Boston Scientific, essentially since the financial crisis. Higher absolute level of revenues then, I think, any of the thought, so congratulations on the unbelievable progress. I guess my first question is really kind of philosophical in terms of the long term. Now that you've got this sort of higher level of revenues and higher level of revenue growth, you guys have given some long-term guidance on operating margin targets and goals. So now that you're kind of outperforming on revenues, what's the thought on those operating margin targets? Is the thought that you'll take an opportunity to spend more and continue to sort of keep those operating margin targets, or is it more likely that with this higher level of growth, that you could be towards the high end or higher of the long-term targets that you've set previously?"
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Bob. I don't think we'll be changing the trajectory in terms of the margin guidance we've given. As we always say, it's about striking a balance between delivering durable, consistent revenue growth and expanding operating margins. And if you look",109,"Thanks, Bob. I don't think we'll be changing the trajectory in terms of the margin guidance we've given. As we always say, it's about striking a balance between delivering durable, consistent revenue growth and expanding operating margins. And if you look at the numbers and see what we've done for the last 3 years relative to revenue growth and particularly on the margin expansion front, looking at 27% to 28% adjusted operating margin by 2020 and a consistent, durable growing top line through that period and the goal of double-digit adjusted EPS growth each of those years, I think we are going to stick with that as our targets."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","I understand you're sticking with the targets, but I'm just trying to understand philosophically, because you're outperforming so nicely here. Is the bias more towards opportunities to invest more, or let some of that through, because again, these levels",49,"I understand you're sticking with the targets, but I'm just trying to understand philosophically, because you're outperforming so nicely here. Is the bias more towards opportunities to invest more, or let some of that through, because again, these levels are just so much higher than we originally thought."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Again, it's striking a balance. We do have a lot of investment, as Mike mentioned, relative to structural heart. That's a lot of investment to get to the U.S. market and be successful there and I think we're -- it's always about striking that balance.",45,"Again, it's striking a balance. We do have a lot of investment, as Mike mentioned, relative to structural heart. That's a lot of investment to get to the U.S. market and be successful there and I think we're -- it's always about striking that balance."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, and I think also, we'll do an Investor Day in 2017. That we haven't nailed down yet, but we're making significant investments in platforms and markets that will have a big impact on the growth through to the business in '18, '19 and '20. And so you l",125,"Yes, and I think also, we'll do an Investor Day in 2017. That we haven't nailed down yet, but we're making significant investments in platforms and markets that will have a big impact on the growth through to the business in '18, '19 and '20. And so you look at our launch in the U.S. of TAVR, our; launch in the U.S., in the future of Deep Brain Stimulation, launching all-in-one when we'll have a drug-eluting stent and a drug-coated balloon for peripheral vascular, and we continue to expand into pulmonary and other areas across the company. So we definitely are investing for long-term growth and a lot of it is big clinical investments in R&D that'll impact the company, particularly in '18, '19, '20."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","And then on structural heart just real quickly. What was the driver of you guys providing guidance there that it'll be at the high end of the range. Is that Lotus or WATCHMAN or both?",35,"And then on structural heart just real quickly. What was the driver of you guys providing guidance there that it'll be at the high end of the range. Is that Lotus or WATCHMAN or both?"
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","It's both. Both are doing quite well.",8,"It's both. Both are doing quite well."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of Brooks West from Piper Jaffray.",13,"Your next question comes from the line of Brooks West from Piper Jaffray."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Just to put a cap on the gross margin discussion. So Dan, those all seem like transient issues with the inventory, and I'm not trying to push for guidance for next year, but as I look at my model, we've got you at about 73% gross margins for 2017. I don't",109,"Just to put a cap on the gross margin discussion. So Dan, those all seem like transient issues with the inventory, and I'm not trying to push for guidance for next year, but as I look at my model, we've got you at about 73% gross margins for 2017. I don't see anything that I really to flow through into '17 from this. Is that the correct way to think about it? I mean, you're a little bit lower for '16, but in terms of thinking about the forward model, that should resolve itself and we should kind of go back to where we thought we are going, correct?"
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, I mean, I wouldn't talk specifically about a rate for 2017. Obviously, the goal is to continually increase the gross margin rate and it'll be part of what we believe is 25%-plus adjusted operating margin for next year. So with that as the goal, -- th",103,"Yes, I mean, I wouldn't talk specifically about a rate for 2017. Obviously, the goal is to continually increase the gross margin rate and it'll be part of what we believe is 25%-plus adjusted operating margin for next year. So with that as the goal, -- the FX in the back-half is really the only thing that we believe is consistent from the Q2 performance. The other things that I mentioned relative to inventory charges and the benefit from the standards, hopefully is, to your point, is a transient thing. So the FX is the only one that continues into the second half."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay, perfect. And then, maybe kind of piggybacking on Bob's question, but also thinking about some of the questions around MedSurg. You kind of conditioned us, in terms of the long-term operating margin progression, to think about Rhythm Management. And",121,"Okay, perfect. And then, maybe kind of piggybacking on Bob's question, but also thinking about some of the questions around MedSurg. You kind of conditioned us, in terms of the long-term operating margin progression, to think about Rhythm Management. And obviously, you're making great progress there. But given the growth we're seeing in MedSurg and Interventional Cardiology, it seems like that equation maybe needs to change a little bit and if we allocate a little bit more of the strength in MedSurg to that equation, it seems like we push up to and through those targets maybe more quickly than if we were just relying on Rhythm Management. Is that also a fair kind of way to look at your business?"
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, I think the focus on Rhythm Management has really been just because of where they were, right? Starting off in the high single digits, it's gotten a lot of focus over the last 3 or 4 years. I think we've made -- Joe and team have made tremendous prog",187,"Yes, I think the focus on Rhythm Management has really been just because of where they were, right? Starting off in the high single digits, it's gotten a lot of focus over the last 3 or 4 years. I think we've made -- Joe and team have made tremendous progress getting it to the 16.9% that it is in Q2, the 18% to 19% that it'll be in the second half of this year and then ultimately, the 20% next year and beyond that -- in 2018 and beyond. All the while, to your point, MedSurg and cardiovascular have continued to grow their margins as well. So I think it goes back to what Mike said to the answer to the last question which is, there's investments that we're making to ensure that durable growth '18, '19, '20 and beyond, and it's not just one business that has that investment. We're investing in all of the businesses. So we've spent a lot of time looking at each of the individual segments and the profitability there, and the math adds up to what we've given for our goals."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Perfect. If I could sneak in just one product question on -- I'm wondering if MaRVis has decided whether to bring drug-coatable balloon to the U.S. or not?",28,"Perfect. If I could sneak in just one product question on -- I'm wondering if MaRVis has decided whether to bring drug-coatable balloon to the U.S. or not?"
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, we'll likely be providing additional insights on our clinical strategy with our balloon at the next quarterly call.",19,"Yes, we'll likely be providing additional insights on our clinical strategy with our balloon at the next quarterly call."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of Rick Wise from Stifel.",12,"Your next question comes from the line of Rick Wise from Stifel."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Maybe let me start off with Lotus. Mike, you talked about gaining EU share in the quarter. Maybe give us a little more color on that. Are you ready to quantify that at all? You've talked about a penetration or share of greater than 30% in your selected ac",90,"Maybe let me start off with Lotus. Mike, you talked about gaining EU share in the quarter. Maybe give us a little more color on that. Are you ready to quantify that at all? You've talked about a penetration or share of greater than 30% in your selected accounts. And maybe just add some more color on the EDGE launch coming up in September. Is this is share gainer or no? That's going to require more time and those additional sizes that are coming in the first half of '17?"
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, sure. Again, this is a big investment for us in structural heart with the WATCHMAN and TAVR. And we're playing it for the long-term here, particularly with our TAVR, given the market growth profile and how large the market is. And our view that we ha",218,"Yes, sure. Again, this is a big investment for us in structural heart with the WATCHMAN and TAVR. And we're playing it for the long-term here, particularly with our TAVR, given the market growth profile and how large the market is. And our view that we have a very differentiated platform from the other market contenders given the controlled release of our Lotus Valve and the low paravalvular leakage rates. So we think we have -- truly have a differentiated platform in a very large market. We're a bit hamstrung in the near term in Europe without having all 5 sizes. We have 3 of them today. So that hurts us a bit, but we'll solve that with a 21-millimeter in 2000 -- first quarter '17 and eventually the largest size in probably first half of 2017. So that'll help. So in the meantime, we continue to do very well with the 3 valve sizes that we have. We won't provide any additional guidance in terms of number of accounts or penetration. But clearly, it is a share taking strategy. The market's already large, the market's growing, and we're quite confident that we're currently the strong #3 player. But that's not going to be our aspiration over the years, particularly as we launch Lotus EDGE and Depth Guard."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Yes, turning to a bigger picture question. Dan obviously, is emphasizing the growth in free cash flow this year, the $6 billion number you've threw over the next few years. You're also saying, Dan, that -- I think correctly, that with the settling or goin",114,"Yes, turning to a bigger picture question. Dan obviously, is emphasizing the growth in free cash flow this year, the $6 billion number you've threw over the next few years. You're also saying, Dan, that -- I think correctly, that with the settling or going a long way towards settling the IRS remiss, a major uncertainty is off the table. I mean, all that suggest to me that, that might give you more flexibility in thinking about M&A or portfolio additions. You just announced Cosman. How are you thinking about this, Mike and Dan? And should we be thinking that there is more possibility for M&A as a result? Any color would be appreciated."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Sure yes. I'll hit it from a financial perspective, and maybe Mike can jump in on the strategic side. The goal, I think, you framed it out very well. That's our goal is to eliminate the uncertainties that we have on the balance sheet, and I think we've ta",159,"Sure yes. I'll hit it from a financial perspective, and maybe Mike can jump in on the strategic side. The goal, I think, you framed it out very well. That's our goal is to eliminate the uncertainties that we have on the balance sheet, and I think we've taken a lot of good steps in the quarter to do that. And that's going to give us more financial flexibility in the future. And that's the goal. So we should hopefully free up more of that cash flow for the long-term. We gave you the numbers hopefully as kind of goals for the next 3 years, and the goal is to have as much of that available to fuel the business from an M&A and share repurchase perspective. So I don't know if anything specific -- but, yes, I mean, that's really the goal, is to eliminate the uncertainties and give us as much financial flexibility as we can have."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Your next question comes from the line of Matt Taylor from Barclays.",12,"Your next question comes from the line of Matt Taylor from Barclays."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","I guess the first question that wanted to clarify on, when you talked about MRI-safe timelines, could you just inform us what revising the goal for tachy MRI timeline, entail what the change was there? And then, S-ICD is still on track. Could you talk abo",62,"I guess the first question that wanted to clarify on, when you talked about MRI-safe timelines, could you just inform us what revising the goal for tachy MRI timeline, entail what the change was there? And then, S-ICD is still on track. Could you talk about how you that's doing and how you expect MRI-safe approval to potentially improve sales for S-ICD?"
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Absolutely, I'll ask Dr. Stein to comment on this question.",10,"Absolutely, I'll ask Dr. Stein to comment on this question."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, on the MRI, not going to get into any of the details of the change in the protocol. But in the course of conduct of our ENABLE MRI trial, we have made a decision that we do need to revise the protocol with respect to patient screening and eligibility",85,"Yes, on the MRI, not going to get into any of the details of the change in the protocol. But in the course of conduct of our ENABLE MRI trial, we have made a decision that we do need to revise the protocol with respect to patient screening and eligibility, and that's just the process of getting that protocol or vision through. What's going to cause the push in the timeline. We still have a goal of getting that approved by the end of 2017."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay, and on S-ICD?",4,"Okay, and on S-ICD?"
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","I am sorry, could you clarify the question on S-ICD?",10,"I am sorry, could you clarify the question on S-ICD?"
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Yes, I was just curious -- I may have missed the comment here because the comments were by kind of fast. But do you still having the same timeline for S-ICD MRI approval? And just how is S-ICD performing today?",40,"Yes, I was just curious -- I may have missed the comment here because the comments were by kind of fast. But do you still having the same timeline for S-ICD MRI approval? And just how is S-ICD performing today?"
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, we saw the same timeline anticipating approval in Q3 of this year, and really, couldn't be more pleased with what we've seen in terms of uptake of EMBLEM MRI, where it's been launched in Europe and the existing EMBLEM device in the U.S. and globally.",46,"Yes, we saw the same timeline anticipating approval in Q3 of this year, and really, couldn't be more pleased with what we've seen in terms of uptake of EMBLEM MRI, where it's been launched in Europe and the existing EMBLEM device in the U.S. and globally."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","So we expect EMBLEM MRI approval in the U.S. in the third quarter.",14,"So we expect EMBLEM MRI approval in the U.S. in the third quarter."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Q3 of this year.",4,"Q3 of this year."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Yes.",1,"Yes."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Great. And could you just talk about broader utilization? Obviously your results were phenomenal this quarter. Are you seeing something going on in either in the U.S. market or some of the emerging markets that you plan, that's contributing to higher leve",64,"Great. And could you just talk about broader utilization? Obviously your results were phenomenal this quarter. Are you seeing something going on in either in the U.S. market or some of the emerging markets that you plan, that's contributing to higher levels of utilization that may not continue going forward? Or do you think that you're really just outperforming your markets from good execution?"
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Well, thanks, Matt. It's Mike. I also don't want to be a broken record here, but I think, I want just to reinforce, consistent with our investor day presentations in '13 and '15, we continue to invest our portfolio into faster-growth markets. So kind of i",177,"Well, thanks, Matt. It's Mike. I also don't want to be a broken record here, but I think, I want just to reinforce, consistent with our investor day presentations in '13 and '15, we continue to invest our portfolio into faster-growth markets. So kind of in the -- maybe the 2011 timeframe, we called our market growths about -- market growth profile 3% in the markets we compete in. So as we've shifted our portfolio over time into the faster-growth markets, we think the markets that we compete in now are kind of in the 4% to 5% growth range. If you look at the compositive BSE. So we are pleased that we're outperforming the market. We'll strive to continue to do so, but we think we have fundamentally shifted the markets that we play in to about a 4% to 5% growth market versus maybe a 2% to 3% growth market 4 or 5 years ago. So the markets are stronger that we compete in, and the team is doing a really nice job of outperforming."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","That question comes from the line of Glenn Novarro from RBC Capital Markets.",13,"That question comes from the line of Glenn Novarro from RBC Capital Markets."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","Two questions, one, drug-eluting stents in the quarter up high single digits, significantly outpacing the market. You have it launching Absorb. So my question is, is this high single-digits sustainable given ABSORB coming into the market, or should we ant",52,"Two questions, one, drug-eluting stents in the quarter up high single digits, significantly outpacing the market. You have it launching Absorb. So my question is, is this high single-digits sustainable given ABSORB coming into the market, or should we anticipate a little moderation going forward? And then I had a quick follow-up."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","So yes, we're not giving the DES guidance for the third quarter or fourth quarter. We're going to continue to run the play which is, we believe we have the best product in the market, and Keith can comment a bit more on the clinical data. And we've been c",171,"So yes, we're not giving the DES guidance for the third quarter or fourth quarter. We're going to continue to run the play which is, we believe we have the best product in the market, and Keith can comment a bit more on the clinical data. And we've been competing with ABSORB in Europe for quite a while. We would put at that probably less than the 7% the DBS. So it probably less than 7% of the global market has been in the market for quite a while. So we feel like we're in a position of strength in terms of our product portfolio, and you know we continue to look at DBS. It's an interesting technology, and we've got a number of bets and it's a fact in the future. We can look at a second gen or a third generation device, then we'll eventually bring that to market. But at this time, we believe that SYNERGY is the premium device, and we'll continue to focus on driving that."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","And then, with Keith on the line, I'd love to get his thoughts on kind of SYNERGY versus ABSORB. And then my follow-up was on Eluvia, which was just launched in Europe. And the data is very strong and once you come to the U.S., you'll be by far -- you wil",102,"And then, with Keith on the line, I'd love to get his thoughts on kind of SYNERGY versus ABSORB. And then my follow-up was on Eluvia, which was just launched in Europe. And the data is very strong and once you come to the U.S., you'll be by far -- you will be the second DES on the market for peripherals, but with, by far, the best data. So how is Eluvia doing in Europe? And it just seems like this is one product that has a significant opportunity that's flying under the radar screen. So just thoughts on Eluvia as well."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","So Glenn, in terms of SYNERGY and DBS, obviously, there's not a lot of head-to-head data between the two. But DBS has been available and Europe's had CE Mark for 5.5 years and the penetration, as Mike said, is mid-single digits. And you and everybody else",169,"So Glenn, in terms of SYNERGY and DBS, obviously, there's not a lot of head-to-head data between the two. But DBS has been available and Europe's had CE Mark for 5.5 years and the penetration, as Mike said, is mid-single digits. And you and everybody else on the call is well aware of the ABSORB II and ABSORB III data. The safety profile of a drug-eluting stent is paramount. Safety profile is more important than efficacy, and with a stent thrombosis rate that is at least 2x, SYNERGY, we feel that the first generation fully resemble a scaffold safety profile is open to question. We do have an interest in the space, obviously, and are leader in DES. We have to have that. And as you know, also, we have 3 shots on goal and our own internal FAST program, which is thinner strap, more deliverable stent and more compliant. Less [indiscernible] is in first human use trials now, and we are still anticipating commercialization in Europe in 2018."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Analysts","And then, your thoughts on Eluvia, how it's performing in Europe? And your thoughts on how it'll perform in the United States once launched?",24,"And then, your thoughts on Eluvia, how it's performing in Europe? And your thoughts on how it'll perform in the United States once launched?"
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, so we're early with our Eluvia platform. It's a large investment. We will be announcing additional data sets on both our balloon and our stent at CIRSE, which is I think in Barcelona in September, third quarter this year. So we'll continue to lay ou",154,"Sure, so we're early with our Eluvia platform. It's a large investment. We will be announcing additional data sets on both our balloon and our stent at CIRSE, which is I think in Barcelona in September, third quarter this year. So we'll continue to lay out our clinical data there. But I think just the -- again, the strength of having a -- in Europe a drug-coated balloon and a differentiated drug-eluting stent for the peripheral vascular offers physicians more options. And so it uniquely positions us in the SFA, and also helps us pull through our core portfolio. So I think these investments are paying off in Europe based on the growth, and we've got to wrap up our clinical trial of Eluvia, which we anticipate by year end 2016. And so we look forward to that finishing, and then we'll provide additional comments on our balloon at our third quarter earnings call."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Executives","Great. With that, we'd like to conclude the call. Thanks for joining us today, and we appreciate your interest in Boston Scientific. Before you disconnect, Greg will give you all the pertinent details for the replay.",36,"Great. With that, we'd like to conclude the call. Thanks for joining us today, and we appreciate your interest in Boston Scientific. Before you disconnect, Greg will give you all the pertinent details for the replay."
317627,370563598,1016516,"Boston Scientific Corporation, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Boston Scientific Corporation","Operator","Thank you. And ladies and gentlemen, this conference will be available for replay after 10:30 Eastern Time today through August 11. You may access the AT&T Teleconference Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 3",70,"Thank you. And ladies and gentlemen, this conference will be available for replay after 10:30 Eastern Time today through August 11. You may access the AT&T Teleconference Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 396158. International participants dial (320) 365-3844. That does conclude your conference for today. Thank you for your participation and for using AT&T Executive Teleconference. You may now disconnect."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Boston Scientific Q3 2016 Earnings Call. [Operator Instructions] As a reminder, today's conference is being recorded. I would now like to turn the conference over to Susie Lisa. Please go ahe",42,"Ladies and gentlemen, thank you for standing by. Welcome to the Boston Scientific Q3 2016 Earnings Call. [Operator Instructions] As a reminder, today's conference is being recorded. I would now like to turn the conference over to Susie Lisa. Please go ahead."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Shannon. Good morning, everyone, and thanks for joining us. For those of you having issues with the webcast, we apologize for the technical issues. We're working with Nasdaq, and ask you to consult our Investor Relations of our website to see t",391,"Thank you, Shannon. Good morning, everyone, and thanks for joining us. For those of you having issues with the webcast, we apologize for the technical issues. We're working with Nasdaq, and ask you to consult our Investor Relations of our website to see the dial in number. 
With me on today's call are Mike Mahoney, Chairman and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.
We issued a press release earlier this morning announcing our Q3 2016 results, which included reconciliations of the non-GAAP measures used in the release. We have posted a copy of that release as well as reconciliations of the non-GAAP measures used in today's call to the Investor Relations section of our website under the heading, Financial Information.
The duration of this morning's call will be up to 1 hour. Mike will provide strategic and revenue highlights of Q3 '16. Dan will review the financials for the quarter and then Q4 '16 and full year guidance, and then we'll take your questions. During today's Q&A session, Mike and Dan will be joined by our Chief Medical Officers, Dr. Keith Dawkins and Dr. Ken Stein. 
Before we begin, I'd like to remind everyone that on the call, organic revenue growth is defined as excluding the impact of changes in foreign currency exchange rates and sales from the acquisition of the American Medical Systems, AMS, Male Urology portfolio over the prior year period. Also of note, this call contains forward-looking statements within the meaning of federal securities laws, which may be identified by words like anticipate, expect, believe, estimates and other similar words. They include, among other things, statements about our growth and market share; new product approvals and launches; clinical trials; cost savings and growth opportunities; our cash flow and expected use; our financial performance, including sales, margins, earnings and other Q4 2016 guidance; as well as our tax rates, R&D spend and other expenses. Actual results may differ materially from those discussed in the forward-looking statements. Factors that may cause such differences include those described in the Risk Factors section of our most recent 10-K and subsequent 10-Qs filed with the SEC.These statements speak only as of today's date, and we disclaim any intention or obligation to update them.
At this point, I'll turn it over to Mike for his comments. Mike?"
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Susie. Good morning, everyone. Our third quarter 2016 results are excellent and reinforces success of our category leadership strategy and the strong execution of our global teams. We continue to grow faster than the market in most or all of ou",1821,"Thank you, Susie. Good morning, everyone. Our third quarter 2016 results are excellent and reinforces success of our category leadership strategy and the strong execution of our global teams. We continue to grow faster than the market in most or all of our business units while consistently improving operating income margin. As a result, we continue to deliver strong double-digit adjusted EPS growth. 
Importantly, we are investing in new adjacencies, capabilities and end markets that position Boston Scientific for very exciting future. In third quarter '16 we drove operational growth of 10% and organic revenue growth of 9%, normalized for currency and excluding the impact of 1 month of sales of the AMS acquisition, which anniversary-ed on August 3. Of note, we delivered this 9% organic growth against our toughest comparison of the year. And we leveraged that growth with 120 basis point equipment year-over-year in adjusted operating margin of 24.3%, which beat the high end of our guidance range by 30 basis points. 9% organic revenue growth in the quarter was leveraged to 12% EPS growth or $0.27 per share, which was at the high end of guidance range. For the full year '16, we're maintaining our strong guidance and point the low end of our ranges, and Dan will provide the details in a few minutes.
I'll now provide some highlights on Q3 results and our Q4 '16 outlook. In my remarks, all references of growth are at constant currency organic year-over-year basis, and they exclude the 1 month benefit of AMS unless otherwise specified. Organic revenue growth of 9% was broad-based across our businesses and regions with particular strength from new global product launches, emerging market expansion and share gains led by innovation and our category leadership strategy. On a regional basis EMEA led the pack with 12% growth, followed by the U.S. at 9% and Europe at 5%. Emerging markets sales grew 19%, led by an acceleration in growth in China at 26% and Latin America turning strong quarter with 21% growth. 
Across our businesses for the third straight quarter, both our cardiovascular and MedSurg segments grew sales organically double digits, 12% for cardiovascular and 10% for MedSurg. and Rhythm Management strong and consistent performance with second quarter sales up 3%. MedSurg continue to deliver growth and strong profitability. MedSurg remains a high priority segment for the company, with 2 recent tuck-in acquisition to enhance category leadership in neuromodulation in our and Endoscopy with the recently announced tender offer for EndoChoice. 9% global growth in Endoscopy was led by double-digit gains in both our Biliary and hemostasis franchises, with Spyglass digital DS and the AXIOS stent leading the charge in Biliary, and our newly launched Resolution 360 clip is driving growth in hemostasis. We continue to see upside from new product launches and strong emerging market growth in endo. 
We're also excited about the acquisition of EndoChoice, which we expect to close by year-end. EndoChoice is focused on the development of innovative products and services for gastroenterology health care providers, with a portfolio that's particularly well suited for the ambulatory surgery center. It also brings a portfolio of value-added services to the ASC market, including infection control and pathology services. This acquisition will further enhance the position of Boston Scientific as the global leader in the field of GI endoscopy. As previously announced, we expect to pursue strategic options for EndoChoice's  FUSE colonoscope business. We plan to provide an update at or around the time of closing of this transaction.
Turning to Urology and Pelvic Health. Uro and Pelvic Health grew double digits for the third consecutive quarter, up 13% in Q3. We're a strong category leader in the Urology segment, and we delivered broad-based growth across the combined Boston Scientific and AMS portfolio. International sales remained very strong with EMEA, Latin America and emerging markets all growing at double-digit rates. AMS sales grew 5% in the quarter, which is a nice acceleration from trend prior to acquisition. And importantly, our remediation and integration efforts are both on track.
Our Lithovue single-use ureteroscope continues to launch and is enjoying strong uptake in a variety of accounts. And finally, our growth was assisted by tailwinds from our market share capture post Astora's exit from the pelvic health market. 
Neuromod grew double digits, plus 12%, against a strong comp and robust Precision Spectra sales now with full-body MRI compatibility in our Vercise Deep Brain Stimulation platform in Europe. We continue to expect U.S. market entry for Vercise by late 2017 and believe this is an exciting new market opportunity for us.
Cosman Medical, an acquisition announced in July, broadens our Neuromodulation portfolio with RF ablation systems that enable us to offer patients with chronic pain another treatment option in non-opioid therapeutics. We will provide an update on our ACCELERATE clinical trial on our fourth quarter 2016 call. 
In Cardiovascular, segment sales grew 12% and reported an adjusted operating margin of 32.8%, up 160 basis points year-over-year. Peripheral Interventions revenue grew 11% and was led by strong balanced global growth in developed and emerging markets. This is PI's fourth straight quarter of double-digit above-market growth, fueled by our leadership -- category leadership strategy and the depth of our portfolio rather than any single product. 
We drove strong growth in the atherectomy and thrombectomy businesses, and new product launches are also going very well, including the AngioJet ZelanteDVT catheter; the Innova vascular stent; and our drug-eluting technologies, Eluvia DES and Ranger DCB. Finally, we're also pleased with the contribution and integration progress of the Spherical Embolics platform acquired from CeloNova. 
We continue to invest in the peripheral market, particularly in drug-eluting strategies, venous diseases and interventional oncology. Two important clinical trials were presented in the third quarter at the major European peripheral congresses, CIRSE. Our drug-eluting stent, Eluvia, in the MAJESTIC clinical trial demonstrated an unprecedented 92.5% freedom from total lesion revascularization at 2 years. And enrollment continues in our global IDE trial, IMPERIAL. This 92.5% freedom from TLR is of particular note given the patient population studied. 65% of patients had severely calcified lesions and 46% had chronic total occlusions. 
In addition, we reported results for our Ranger Drug-Coated Balloon from 105-patient randomized clinical trial studying the superficial femoral artery. With 94.4% freedom from total lesion revascularization at 6 months, average lesion length was 68 millimeters. We also posted strong results from our Ranger all-comers registry with 91.9% freedom from TLR at 6 months and an average lesion length of 135 millimeters. 
We plan to bring our Ranger DCB to the U.S., and we'll reveal details of our IDE trial shortly. We're excited to be the only company investing in a complete portfolio of drug-eluting therapies.
Turning to Interventional Cardiology. This business segment grew 13% in Q3, led by strong sales in structural heart, drug-eluting stents and PCI guidance or imaging. SYNERGY continues to penetrate the market as we grew worldwide DES sales 14%, and we remain on track to represent 50% to 60% of our global DES revenue mix by the end of fourth quarter. PCI guidance grew mid-teens as well, with strong IVUS catheter and service sales augmented by the ongoing global launch of our COMET FFR system. 
In structural heart, which includes our Lotus transcatheter aortic valve and WATCHMAN Left Atrial Appendage Closure Device, we're driving growth via our unique innovative platform technologies, and they're resonating with physicians and are supported by the strength of our commercial teams. Both franchises are performing very well, and we continue to expect to deliver structural heart revenue at the high end of our $175 million to $200 million guidance for 2016.
We also recently began the early launch of our Lotus EDGE valve in Europe, and thus, the results from our feasibility study of Lotus EDGE will be presented this Sunday at a lunchtime symposium at TCT. Also at TCT next week, we look forward to a number of Lotus presentations, including 4-year outcomes on REPRISE I, 3-year outcomes for REPRISE II and our Lotus EDGE feasibility study with a 7-day discharge data. We expect to present results of REPRISE III, our U.S. pivotal trial and the first to provide head-to-head data, at EuroPCR in May. 
The WATCHMAN platform also delivered an exciting quarter, with strong growth from opening new centers as well as driving growth in existing centers. We're very encouraged to see a strong initial launch in France, where we received higher reimbursement to peers based on the strength of our data. And we expect to enroll our first patient in ASP II [ph] , which is a study examining the use of WATCHMAN in warfarin-ineligible patients before the end of the year.
Turning now to Rhythm Management. Segment sales grew 3%, with another impressive gain in the adjusted operating margins of 20.1%, which is 320 basis points quarter-over-quarter and a 230 basis points growth year-over-year. Growth in CRM at 3% was above market and led by worldwide patient growth of 22%, with meaningful share capture from our premium-based brady MRI device. High-voltage sales declined 4% globally due to replacement cycle headwinds and competitive pressures in the U.S. and MRI-compatible tachy devices. We continue to be pleased with the growth and momentum of EMBLEM S-ICD, which has been fueled by a recent FDA approval for both MRI and MRI-backwards compatibility and increased physician acceptance of this differentiated therapy. 
In Europe, our CRM business grew above market for the 10th consecutive quarter, and in Japan, our above-market growth was driven by a strong launch of EMBLEM S-ICD, transvenous tachy MRI and 3.0T brady MRI. We also achieved important CRM clinical milestones in the quarter, including the first patients enrolled in the APPRAISE ATP trial to help clinicians understand which ICD patients could benefit from antitachycardia pacing and which may be harmed. 
Also, our MultiSENSE trial is accepted as a late breaker for the upcoming AHA scientific sessions in New Orleans. MultiSENSE is an international multicenter, non-randomized study, which is designed to develop and to evaluate prospectively a multi-sensor-based algorithm for the early detection of worsening heart failure. 
In Electrophysiology, 5% growth was led by strength in international markets. In Europe, we are pleased with the early feedback of our IntellaMap OI catheter, which was launched in the second quarter. We expect to launch this catheter in the U.S. in fourth quarter, which, combined with IntellaNav XP and MiFi XP catheters, will unlock the use of Rhythmia to a higher mix of procedures. We remain bullish that continued penetration of our next-generation mapping and navigation system, Rhythmia HDX and the commercialization of our complete portfolio of nav-enabled therapeutic catheters will strengthen our global EP business and improve growth in 2017. 
So to wrap up, I would like to thank our employees for their incredible winning spirit, terrific execution and commitment to the company. So with that, I'll turn it over to Dan for more details on the P&L and guidance."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Mike. In Q3, we generated organic revenue growth of 9% versus our 7% to 9% guidance range and adjusted earnings per share of $0.27, representing 12% year-over-year growth and hitting the high end of our guidance range of $0.25 to $0.27. The double",1256,"Thanks, Mike. In Q3, we generated organic revenue growth of 9% versus our 7% to 9% guidance range and adjusted earnings per share of $0.27, representing 12% year-over-year growth and hitting the high end of our guidance range of $0.25 to $0.27. The double-digit adjusted EPS growth in Q3 was driven primarily by strong revenue growth and solid gross margin, which was at the high end of our guidance range. 
Consolidated revenue of $2,105,000,000 represented operational revenue growth of 10%, at the high end of guidance and reflects an immaterial impact from foreign exchange, which was in line with guidance.
Excluding an approximate 100 basis point contribution from the AMS Male Urology portfolio acquisition for the month of July, organic revenue growth was 9% in the quarter and 11% on an as-reported basis. As a reminder, we completed the acquisition of the AMS Male Urology portfolio on August 3 last year, so August and September AMS sales were included in our organic sales growth calculation. 
Adjusted gross margin for the third quarter was 72.5%, at the high end of our guidance range and consistent with prior year despite a year-over-year negative 120 basis point impact from foreign exchange. In Q3, as expected, we had lower inventory charges than in Q2, and we're now realizing the full benefit of the lower 2016 standard cost of our products due to ongoing value improvement programs. We continue to expect full year 2016 adjusted gross margin to be approximately 72%, which includes an expected 75 to 100 basis point negative impact from unfavorable foreign exchange. 
Adjusted SG&A expenses were $763 million or 36.2% of sales in Q3, down 70 basis points year-over-year as we realize the benefit of our targeted initiatives focused on reducing SG&A, offset partially by the reinvestment of the medical device excise tax benefit. We continue to believe our full year rate will be approximately 36%, which would be a 140 basis point improvement compared to 2015.
Adjusted research and development expenses were $232 million in the third quarter or 11% of sales, which is down 70 basis points year-over-year. We continue to expect our full year 2016 adjusted R&D rate to be approximately 11% of sales. Royalty expense was 0.9% of sales in Q3, roughly flat year-over-year.
Q3 2016 adjusted operating income grew 17% year-over-year and adjusted operating margin of 24.3% was above our guidance range of 23% to 24% and represented a 120 basis point improvement over Q3 last year, the ninth consecutive quarter in which we have expanded adjusted operating margin by 100 basis points or more over the prior year comparable period.
The Rhythm Management team delivered an adjusted operating margin of 20.1%, up 230 basis points year-over-year. The increase year-over-year is a result of realizing the full benefit of 2016 product costs and leveraging the improved top line performance of the global business. For the first 9 months of 2016, Rhythm Management adjusted operating margin is 17.9%, and we continue to believe that, that segment is on track to deliver an adjusted full year operating margin of 20% in 2017.
With total company adjusted operating margin for the first 9 months of 2016 at 24.3%, this positions us well to achieve our full year adjusted operating margin guidance of 24% to 24.5%, and we remain on track to reach our goal of 25%-plus in 2017 we will provide more guidance on 2017 adjusted operating margin with our Q4 earnings call in February.
Now I'll move on to interest and other expense. Interest expense for the quarter was $58 million, roughly flat to Q3 of 2015. Our average interest expense rate was 3.9% in Q3 this year compared to the same 3.9% in Q3 of last year. Other expenses was $33 million in the quarter and includes approximately $20 million of impairment charges related to certain of our strategic investments. Other expenses for the quarter primarily included foreign exchange losses related to our hedging program. 
Our tax rate for the third quarter was 11.2% on a reported basis and 12.4% on an adjusted basis. We are making progress towards finalizing our conditional stipulation of settled issues with the Internal Revenue Service and expect to make a series of payments related to the settlement, most of which we expect to remit during the second half of 2017 and into the first half of 2018.
Finally, Q3 2016 adjusted earnings per share of $0.27 includes approximately $0.01 of unfavorable FX and represents 12% year-over-year growth or 17% growth excluding the impact of foreign exchange. Earnings per share upside from the strong revenue and margin performance was partially offset by the $0.01 of impairment charges we recorded. On a reported GAAP basis, which includes net charges and amortization expense totaling $140 million after tax, Q3 2016 EPS was $0.17. 
Adjusted free cash flow for the quarter was $440 million compared to $394 million in Q3 last year, and we continue to pursue inventory management initiatives designed to improve the working capital contribution to cash flow. Given the strong adjusted free cash flow generation year-to-date this year, we believe we can achieve our full year adjusted free cash flow guidance of $1.6 billion. In Q3, we used cash primarily to fund previously agreed legal settlements as well as business development activities. As of September 30, 2016, we had cash on hand of $237 million, and near term, our capital allocation priorities continue to be managing contingencies and pursuing tuck-in M&A. 
We ended the third quarter with 1,380,000,000 fully diluted weighted average shares outstanding. Consistent with our prior guidance, we expect our share count to increase by less than 5 million through the end of 2016. As consistent with our commitment at the time of the AMS Men's Health acquisition last year, we plan to keep the buybacks suspended for the balance of 2016. We expect this to result in a fully weighted average share count of approximately 1,380,000,000 shares for full year 2016. 
I'll now walk through the guidance for the fourth quarter and the full year 2016. For the full year, we now expect consolidated revenue to be in a range of $8,335,000,000 to $8,385,000,000, which represents year-over-year growth of 9% on an organic basis, 12% on an operational basis and 11% to 12% on a reported basis. We continue to expect foreign exchange to be a headwind of approximately $70 million for the full year.
Turning to adjusted earnings per share. We now expect full year 2016 adjusted EPS to be in a range of $1.09 to $1.11, representing 17% to 19% adjusted earnings growth, which continues to assume the full year negative impact of FX will be $0.05. On a GAAP basis, we expect earnings per share to be in a range of $0.32 to $0.34. 
Now turning specifically to the fourth quarter. We expect consolidated revenue to be in a range of $2,140,000,000 to $2,190,000,000. This represents year-over-year growth in a range of 7% to 9% operationally. We expect foreign exchange impact on Q4 revenue to be a slight tailwind. For the fourth quarter, adjusted earnings per share is expected to be in a range of $0.27 to $0.29 per share, and GAAP earnings per share is expected to be in a range of $0.15 to $0.17 per share. Please check our Investor Relations website for Q3 2016 financial and operational highlights, which outlines Q3 results as well as Q4 and full year 2016 guidance, including P&L line item guidance.
And with that, I'll turn it back to Susie, who'll moderate the Q&A."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Dan. Shannon, let's open it up to questions for the next 30 minutes or so. [Operator Instructions] Shannon, please go ahead.",22,"Thanks, Dan. Shannon, let's open it up to questions for the next 30 minutes or so. [Operator Instructions] Shannon, please go ahead."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","[Operator Instructions] Our first question comes from the line of David Lewis with Morgan Stanley.",15,"[Operator Instructions] Our first question comes from the line of David Lewis with Morgan Stanley."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","A couple of financial questions this morning. So just first off, Dan, I know it's a bit early, but I think '17 numbers, consensus is sort of in the upper part of mid-single digits and around sort of 13% earnings. I wonder if you could offer sort of any re",91,"A couple of financial questions this morning. So just first off, Dan, I know it's a bit early, but I think '17 numbers, consensus is sort of in the upper part of mid-single digits and around sort of 13% earnings. I wonder if you could offer sort of any refinement just given the strength you've seen here on '16. And if you can't kind of refine this early, any headwinds or tailwinds we should be thinking about on the top and bottom line heading into '17? Then I had a follow-up."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. David, I don't think we're going to provide any specific guidance for '17. We'll do that, as you would expect, on our call in early February. We have been very public about saying that we believe next year is a mid-single-digit year in terms of reven",60,"Yes. David, I don't think we're going to provide any specific guidance for '17. We'll do that, as you would expect, on our call in early February. We have been very public about saying that we believe next year is a mid-single-digit year in terms of revenue growth, but I wouldn't provide really any more than that at this point."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. And maybe just 2 quick ones, one clinical and one margin question. So for Dan, you eclipsed 20% margins here in CRM this quarter. I guess the question now is -- that's happening a lot earlier than many would have expected 2 years ago, so where can C",130,"Okay. And maybe just 2 quick ones, one clinical and one margin question. So for Dan, you eclipsed 20% margins here in CRM this quarter. I guess the question now is -- that's happening a lot earlier than many would have expected 2 years ago, so where can CRM margins go now? And then for fourth quarter margins to deliver the earnings, you need to do better year-on-year with margins in the fourth quarter than you did in the second and third quarters. So where can CRM go and the confidence in the fourth quarter margin? And then maybe for the clinical team, when do you think we're going to get the first read on what the true pacing rates are for Lotus EDGE? And I'll jump back in queue."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, David. I'll take the Rhythm Management operating margin and turn it over to Keith and Mike for the clinical questions. So obviously, very pleased to be at that 20% here in Q3 for Rhythm Management operating margin. It's 320 basis points sequentially",217,"Sure, David. I'll take the Rhythm Management operating margin and turn it over to Keith and Mike for the clinical questions. So obviously, very pleased to be at that 20% here in Q3 for Rhythm Management operating margin. It's 320 basis points sequentially and 230 points year-over-year. As you would expect in any given quarter, you'll see some variation in that. Would actually expect that to go back down in Q4, a little more spending in Q4 on SG&A initiatives and such. The full year should be about 18%, which is what we've said consistently that we'd be this year. And I think that puts us right in line to get to that 20% next year in Rhythm Management, which, as part of us getting to 25%-plus as a company, I think gives us the confidence in both those numbers. So I don't think we're going to talk more specifically about the 20%, where we'd go from there. Certainly, it goes north of that. We're not going to stop at 20% in 2017. Just as a company, we're not going to stop at 25%. So there's more room in that Rhythm Management segment to increase well beyond 20% as the company goes to, what we've said publicly, our goal of 27% to 28% operating margin by 2020."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. So just on Lotus EDGE, David, just a couple of high-level comments, and Keith could maybe highlight TCT, which we have an important investor meeting on Monday, quite a bit more detail there. But overall, we're really pleased. We continue to deliver o",199,"Yes. So just on Lotus EDGE, David, just a couple of high-level comments, and Keith could maybe highlight TCT, which we have an important investor meeting on Monday, quite a bit more detail there. But overall, we're really pleased. We continue to deliver our overall structural heart commitment in terms of our guidance. We guided to the high end of $175 million to $200 million range for WATCHMAN and TAVR. Really pleased about the CE Mark for Lotus EDGE that we received in one of the valves. We're very early in that phase. But over the long term, particularly I should point to the end of 2017 and the future, '18 and '19, we believe we're very well positioned with our Lotus platform in terms of our launch in these large global markets and eventually Japan, well positioned to gain share. We believe we have the very unique capabilities in terms of our operator control and physician control of the device, excellent PVL rates and our focus on improving the pacemaker rate. So our aim will be to take significant share in these larger markets, and we're building momentum there. So Keith, do you want to touch on TCT?"
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, sure. David, this Sunday, the 30th, the Lotus lunchtime symposium of TCT will be the first presentation of the first human use, early feasibility data of EDGE, only 21 patients but will certainly give us a guide. And we can discuss those data in more",99,"Yes, sure. David, this Sunday, the 30th, the Lotus lunchtime symposium of TCT will be the first presentation of the first human use, early feasibility data of EDGE, only 21 patients but will certainly give us a guide. And we can discuss those data in more detail at the investor meeting on Monday morning at TCT. Also, at TCT we'll have the 4-year outcomes for REPRISE I and 3-year outcomes for REPRISE II, and you'll get more EDGE data at ACC and -- further EDGE data and, of course, our pivotal trial data, REPRISE III, primary endpoint at EuroPCR."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Bob Hopkins with Bank of America.",14,"The next question comes from the line of Bob Hopkins with Bank of America."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","And I apologize for the background noise. I'm in an airport. So first of all, just on behalf of the med tech investment community, I'd like to thank you for a great third quarter. Certainly, some that have gone before you were starting to make investors n",169,"And I apologize for the background noise. I'm in an airport. So first of all, just on behalf of the med tech investment community, I'd like to thank you for a great third quarter. Certainly, some that have gone before you were starting to make investors nervous. So congrats on a great quarter. I wanted to ask a modeling question to Dan and then a product question for Mike. So first, just on the modeling side. It's a little thing, but it stuck out to us, which was that your other income line was an expense of $33 million and that hit EPS by probably up to $0.02. And I know you mentioned something in the prepared comments, but I would just love to get a little bit of a better sense for what caused that uptick and just where that line item goes from here. Does it go back down to normalized level that we've seen in the past? I just would love some comments on other income."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, Bob. So as you say, in the prepared commentary, we talked about a $20 million impairment in the quarter. We have an investment portfolio now that's over $300 million. So as you'd expect, you may see impairments from time to time. It's not a regular",97,"Sure, Bob. So as you say, in the prepared commentary, we talked about a $20 million impairment in the quarter. We have an investment portfolio now that's over $300 million. So as you'd expect, you may see impairments from time to time. It's not a regular occurrence. So that is the difference basically between the year-over-year comparison of that line, is that impairment. And it was worth about $0.01 overall. So without that, we would have been $0.01 higher. But that should not be a regular occurrence, from time to time but certainly not a regular occurrence."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. So that line item goes back down to normalized levels. And then on the product side, I just wanted to get 2 quick updates. One, is the time line for MRI-safe ICDs in the U.S. still the same as your previous guidance, which I think was the end of '17",110,"Okay. So that line item goes back down to normalized levels. And then on the product side, I just wanted to get 2 quick updates. One, is the time line for MRI-safe ICDs in the U.S. still the same as your previous guidance, which I think was the end of '17? And then on WATCHMAN, I'm trying to gauge the impact of the start of the post-approval study, what kind of impact that might have had on the NCD and the availability of reimbursement. So now that we've got that up and running, does that have a strong incremental impact on the ability of folks to get WATCHMAN properly reimbursed?"
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. Yes, on the MRI-safe, no changes to our time line there. We anticipate like the fourth quarter 2017. And importantly, in that category, we're down in the U.S. and down globally, but our European business continues to do well as our Asian business do",268,"Sure. Yes, on the MRI-safe, no changes to our time line there. We anticipate like the fourth quarter 2017. And importantly, in that category, we're down in the U.S. and down globally, but our European business continues to do well as our Asian business does with a full line of MRI-safe products. And the S-ICD continues to do very well. So despite not having it for what will be a decent part of '17, the pacer business continues to do very well. We're doing very well outside the United States, and S-ICD is continuing to support us and differentiate that platform. So we're very bullish on the future of our CRM business and the portfolio. And despite that, the team continues to drive operating income margin improvements. So really nice job there. With WATCHMAN, I mean, we're continuing to build momentum there. As you mentioned, the reimbursement headwinds really are beginning to neutralize based on the advances that we've made there. We continue to open up new centers, and we're really tracking. And we're not giving you much visibility to that, and in the future, we'll determine how to do that. But we're continuing to focus on our utilization rate and driving more physician awareness, more patient awareness and, in parallel, doing a really nice job on physician training, so oftentimes, training multiple physicians at the same site to increase utilization. And in parallel, we're opening up a new center. So again, on the structural heart side, we're at the high end of our range, $175 million to $200 million, and the WATCHMAN contribution is significant within there."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Mike Weinstein with JPMorgan.",12,"The next question comes from the line of Mike Weinstein with JPMorgan."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","3Q, by and large, looks a lot like 2Q. So I actually have a couple of finance questions for Dan. First question is with the mesh liabilities and IRS tax payments, can you fund that from OUS cash? Or are you are going to have to do any borrowing for that?",51,"3Q, by and large, looks a lot like 2Q. So I actually have a couple of finance questions for Dan. First question is with the mesh liabilities and IRS tax payments, can you fund that from OUS cash? Or are you are going to have to do any borrowing for that?"
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","The plan is not to have to do any borrowing on that. We should have full access to our cash through 2017 and don't anticipate any borrowings necessary.",28,"The plan is not to have to do any borrowing on that. We should have full access to our cash through 2017 and don't anticipate any borrowings necessary."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. Second quick one, Dan. Do you know at this point, based on current rates, what you think FX would mean to the bottom line in 2017? And it's simply we don't have a good visibility on your FX hedges and where they are and how they roll off. Do you hav",59,"Okay. Second quick one, Dan. Do you know at this point, based on current rates, what you think FX would mean to the bottom line in 2017? And it's simply we don't have a good visibility on your FX hedges and where they are and how they roll off. Do you have any insight to that at this point?"
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. I think it probably makes sense to hold that until the February earnings call and give all the guidance package altogether as opposed to kind of doing something one-off here. But have faith we'll give you full information on what we see as of Februar",46,"Yes. I think it probably makes sense to hold that until the February earnings call and give all the guidance package altogether as opposed to kind of doing something one-off here. But have faith we'll give you full information on what we see as of February."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Josh Jennings with Cowen and Company.",14,"The next question comes from the line of Josh Jennings with Cowen and Company."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","I just wanted 2 quick questions on CRM and post pacemaker approval. You clearly had 2 quarters of significant success getting back share. Any incremental color you can provide on how you've been successful? Anything in the market dynamics? And then also i",70,"I just wanted 2 quick questions on CRM and post pacemaker approval. You clearly had 2 quarters of significant success getting back share. Any incremental color you can provide on how you've been successful? Anything in the market dynamics? And then also if I was just curious about -- should we be thinking of your pacemaker recovery as a precedent for ICU recovery as you have MCI safe high-voltage approval?"
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks for the question, Josh. We're pleased we signaled at the end of the 2Q call that we thought overall CRM will be in line with 2Q, which we're pretty close to that. And we think fourth quarter will likely be in line with third quarter results. So pre",149,"Thanks for the question, Josh. We're pleased we signaled at the end of the 2Q call that we thought overall CRM will be in line with 2Q, which we're pretty close to that. And we think fourth quarter will likely be in line with third quarter results. So pretty consistent performance across our CRM business. And you highlighted particular strength in pacemaker, really strong since the launch of the new products. So I think it's just a combination of an excellent lead and ability to deliver that lead. Excellent battery longevity in our pacer line, very strong commercial team, and it's consistent -- actually, stronger performance in the U.S. that we saw globally upon launching this product. So the commercial team has done very well, and our physicians are very comfortable. I don't know, Ken, if you have any additional comments on our MRI pacer from a physician's standpoint?"
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, thanks, Mike. Josh, I think what's really helping drive the growth is the differentiated features we have in our brady platform on top of MRI, including automated remote daily monitoring of these devices, including the performance of our newly releas",157,"Yes, thanks, Mike. Josh, I think what's really helping drive the growth is the differentiated features we have in our brady platform on top of MRI, including automated remote daily monitoring of these devices, including the performance of our newly released longevity lead. We got really fantastic feedback from clinicians since commercial release of that lead, validating excellent results we saw on the clinical trial. And I think in terms of what does that portend for tachy, I think we take a lot of pride in looking at how the portfolio is delivering in Europe, where we do have full approval of our tachy MRI products, including backwards compatibility to our previously release products and have MRI approval both for traditional transvenous devices as well as for our S-ICD. And we believe that the same performance that we're seeing in Europe, where we have a full portfolio approved portends what we're going to see in the U.S."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Great. And just a follow up, one of your big competitors has had a recall of their high-voltage platform. They've had to design around, but how are you thinking about this as a potential opportunity for Boston going forward in front of MRI safe approval o",49,"Great. And just a follow up, one of your big competitors has had a recall of their high-voltage platform. They've had to design around, but how are you thinking about this as a potential opportunity for Boston going forward in front of MRI safe approval on the high-voltage side?"
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Well, I think what we've done is we very consistently promoted, and we promoted with proved unique benefits of our EnduraLife battery technology as being best-in-class. And that's really been proven out from 9 independent studies of contemporary device lo",146,"Well, I think what we've done is we very consistently promoted, and we promoted with proved unique benefits of our EnduraLife battery technology as being best-in-class. And that's really been proven out from 9 independent studies of contemporary device longevity. So even prior to some of the challenges that I think you'd have seen, we've been very clear to the marketplace that we have very unique battery technology and also excellent remote monitoring. So I think those 2 features stand the test of time and really been the anchor of our strategy for a number of years now. And we believe over time typically as health care modifies and more outcome-based that have that type of capability is enjoyed by certainly by patients and also by physicians. So we think those unique strengths combined with our commercial team put us in a good position to compete."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Rick Wise with Stifel.",12,"The next question comes from the line of Rick Wise with Stifel."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Just start with another LOTUS question. Mike, with LOTUS Edge approved and clearly some clarity on maybe better outcomes achieved with lower depth implant, when do you more broadly rollout in the technology and this procedural approach to a broader audien",86,"Just start with another LOTUS question. Mike, with LOTUS Edge approved and clearly some clarity on maybe better outcomes achieved with lower depth implant, when do you more broadly rollout in the technology and this procedural approach to a broader audience? And maybe just tie that in as well to Dr. Meredith's appointment. As much as I'll miss Dr. Dawkins dulcet tones and eloquent commentary, why the change now in bringing him in-house? What can you achieve with Dr. Meredith in-house versus out in the world?"
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Well, first, I'd like to thank Keith. He's done a remarkable job at Boston Scientific. He's been here for 9 years. He brings a patient focus first to our executive committee and has really helped along with Kevin and our broader team lead the turnaround a",215,"Well, first, I'd like to thank Keith. He's done a remarkable job at Boston Scientific. He's been here for 9 years. He brings a patient focus first to our executive committee and has really helped along with Kevin and our broader team lead the turnaround at sustained growth of our Interventional Cardiology business and Structural Heart. So Keith done a terrific job transitioning very smooth end the year. Dr. Meredith is joining. He is very well known in the structural heart community. Structural heart is a big investment and a key focus area for the company. So it will all be a seamless transition, and Ian will begin early in the year. So you'll see him at various conferences and so forth. But Keith did a great job transitioning. And again, just to repeat some of the comments earlier. We're very bullish on the future of our LOTUS platform for the reasons we've articulated with the PBL rates, controlled release of this device, and enhancements that depth guard and in Lotus EDGE promise to deliver. And we're being very appropriate in terms of the rollout of that. And at TCT, we'll provide some additional information on pacemaker rates and some clinical studies as well as some additional commentary from Tom Flemming, Keith and Kevin Bellinger."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Just a follow-up, Mike, on AMS. Obviously, you have obviously had a good quarter on multiple fronts. Can you talk about AMS? Where are you in achieving these sales synergies that you hoped for? Are you starting to see it? And is that side of the story whe",67,"Just a follow-up, Mike, on AMS. Obviously, you have obviously had a good quarter on multiple fronts. Can you talk about AMS? Where are you in achieving these sales synergies that you hoped for? Are you starting to see it? And is that side of the story where we expected it would be? Are you ahead or behind? Just any perspective there would be very welcome."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, I would say overall, we're likely slightly ahead on the cost energy side. Done a very nice job with that. We're certainly ahead overall in terms of the strategic value of the acquisition, given the overall strength of our urology business. And as a s",148,"Yes, I would say overall, we're likely slightly ahead on the cost energy side. Done a very nice job with that. We're certainly ahead overall in terms of the strategic value of the acquisition, given the overall strength of our urology business. And as a stand-alone business, the AMS business grew 5% in the quarter, which is slightly ahead of their kind of historical performance. So we think in our hands, the standalone business is performing better and will perform better. And more importantly, the complementary nature of the 2 businesses with stone BPH, ED is very comprehensive package for our commercial teams to take 2 customers and not only is it very broad base but it also has unique clinical differentiation. So the combination of the 2 makes our legacy portfolio stronger. And so overall, we're clearly at or ahead of our internal models on the acquisition."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Vijay Kumar with Evercore ISI.",13,"The next question comes from the line of Vijay Kumar with Evercore ISI."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","So I had 2 quick ones. Maybe I'll start with the Structural Heart side. On Lotus, can you maybe talk about comparative dynamics in Europe. Are you still gaining share? And I know that you guys are not yet there in France, so maybe any perspective on that",51,"So I had 2 quick ones. Maybe I'll start with the Structural Heart side. On Lotus, can you maybe talk about comparative dynamics in Europe. Are you still gaining share? And I know that you guys are not yet there in France, so maybe any perspective on that would be helpful."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, yes, we probably would not give as much detail as you'd like. Overall, we're at the high end of our guidance projected for our structural heart. Obviously, the Lotus is a key component of that. We're still -- I think it's safe to say we're growing f",204,"Sure, yes, we probably would not give as much detail as you'd like. Overall, we're at the high end of our guidance projected for our structural heart. Obviously, the Lotus is a key component of that. We're still -- I think it's safe to say we're growing faster than the market in Europe. And what's important to note is that we don't have all of our ammunition yet with Lotus. We don't yet have our largest valve and our smallest valve. And so we're doing quite well in the market with 3 valves and we're excited by getting the additional 2 valve sizes for the full matrix. And I think what's really different is kind of the same drumbeat. It's a different devise, it's a next-generation platform that doctors really enjoy the control that they have with it. And so I wouldn't say it's easy, but it's easier to differentiate this valve from some of the other balloon expandable devices that they have options to use in Europe. So we're very bullish on the future of it. In terms of France, we expect to have reimbursement by year-end '17. So hopefully, we'll see some upside from France reimbursement ideally in the fourth quarter '17."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Great. And then maybe one quick one on [indiscernible]. I think this has been a phenomenal segment for you guys, and -- if I look at those really, really strong growth rate you put up, can you help us understand what's the underlying growth rate versus wh",80,"Great. And then maybe one quick one on [indiscernible]. I think this has been a phenomenal segment for you guys, and -- if I look at those really, really strong growth rate you put up, can you help us understand what's the underlying growth rate versus what's been the contribution from your products? Because it's kind of hard for us to model and any sense sort of new product cadence that you have lined up for '17 would be helpful."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","So our MedSurg business, particularly endo and uro doesn't have call it singular blockbuster devices platforms like Synergy or WATCHMAN or Lotus. So Endoscopy is a very broad-based portfolio, as is urology. We have some kind of star platforms in Endoscopy",196,"So our MedSurg business, particularly endo and uro doesn't have call it singular blockbuster devices platforms like Synergy or WATCHMAN or Lotus. So Endoscopy is a very broad-based portfolio, as is urology. We have some kind of star platforms in Endoscopy with our axial stent and our Spyglass digital, but it's really a very broad-based portfolio that we continue to layer on new innovations to broaden out the adjacency that we compete in, similar to the recent acquisitions that we've done with EndoChoice and. So we really [indiscernible] one big product, but overall you're seeing us increase the R&D spending those businesses over the past few years. We've been more active in M&A in the Endoscopy, uro and neuromod area. And importantly, they were under scaled outside the U.S. And we put a lot of investment outside the U.S. over the past few years and that continues to pay off; and that's not a onetime pay off. It will continue to pay off as well as emerging markets. So it's really not a one product story, it's very diversified strength in those businesses. Keith, was there something else on the Lotus or we covered that sufficiently?"
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","I think we covered it sufficiently. France reimbursement is important because France is the second largest European market with a high penetration of Taber. So we're looking forward to the products to France. Obviously, there are French investigators in o",51,"I think we covered it sufficiently. France reimbursement is important because France is the second largest European market with a high penetration of Taber. So we're looking forward to the products to France. Obviously, there are French investigators in our trials, and they've been impressed with the [indiscernible] performance of those."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question is from the line of Larry Biegelsen of Wells Fargo.",13,"The next question is from the line of Larry Biegelsen of Wells Fargo."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Keith, good luck in your new endeavors. I'll miss Working with you. Two product-related questions. First on Neuromodulation and the Accelerate trial, you mentioned that you would give an update on the Q4 call in February. NAND this year is January. So doe",59,"Keith, good luck in your new endeavors. I'll miss Working with you. Two product-related questions. First on Neuromodulation and the Accelerate trial, you mentioned that you would give an update on the Q4 call in February. NAND this year is January. So does that mean we're not going to see the Accelerate data at NAND? Had one other question."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Larry. Yes, the plan is to provide an update on Accelerate trial on our fourth quarter 2016 earnings call, which is shortly after NAND I believe. So our plan is to provide some additional color at that call, fourth quarter '16.",42,"Thanks, Larry. Yes, the plan is to provide an update on Accelerate trial on our fourth quarter 2016 earnings call, which is shortly after NAND I believe. So our plan is to provide some additional color at that call, fourth quarter '16."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","So, Mike, just to be clear, no data at NAND?",10,"So, Mike, just to be clear, no data at NAND?"
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, our plan is to provide additional insight in the fourth quarter 2016 earnings call.",15,"Yes, our plan is to provide additional insight in the fourth quarter 2016 earnings call."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay, on drug-eluting stent growth obviously very strong this quarter. I think it accelerated to 14% from 9% last quarter. Was that balanced across geographies? And then, Keith, I think new competition will probably become more prominent at TCT given the",65,"Okay, on drug-eluting stent growth obviously very strong this quarter. I think it accelerated to 14% from 9% last quarter. Was that balanced across geographies? And then, Keith, I think new competition will probably become more prominent at TCT given the Tronic data coming and the methanol data coming as late breakers there. So any kind of previews from you on the competitive dynamics there?"
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Larry. I think the difference between some of the competitors synergies is that we have a very large data set with synergy. And we now have approximately 20,000 patients in multiple clinical trials in a lot of high-risk substance. And as you know",198,"Thanks, Larry. I think the difference between some of the competitors synergies is that we have a very large data set with synergy. And we now have approximately 20,000 patients in multiple clinical trials in a lot of high-risk substance. And as you know from the 2-year data from the pivotal Evoke II trial best-in-class [indiscernible] 2 years. In fact, no definite thrombosis, not a single thrombosis after the first 24 hours. So we do think safety is an important metric, and we don't think we have any competition in that area. I think what will be interesting in TCT is some of the longer-term follow-up of fully resolvable stents particularly the 3-year data from Absorb II because if fully resolvable stents get better, the longer they're in terms of your modeling and so on, that will be an important finding. Clearly, the 2-year data in that regard, [indiscernible]. So we also like the key performance of Synergy. The ease-of-use for interventional cardiologists worldwide is well appreciated. So we're very confident in Synergy. We had a very nice Japanese launch, and we think the appreciation of physicians is matched by the growth that you've seen in this quarter."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question is from the line of Matt Miksic with UBS.",12,"The next question is from the line of Matt Miksic with UBS."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","So I wanted to talk a little bit about the EndoChoice acquisition and the types of strategic investments that you're looking at or thinking about. One of the things that struck us about that was kind of to fill out that portfolio, better serve the ASTs. Y",113,"So I wanted to talk a little bit about the EndoChoice acquisition and the types of strategic investments that you're looking at or thinking about. One of the things that struck us about that was kind of to fill out that portfolio, better serve the ASTs. You mentioned in the prepared remarks something like sort of the broad line complete provider of solutions in that specialty. And just wanted to understand how you're thinking about acquisitions like that, the importance of certain brands if you will and where you see opportunities also to kind of go deep on the sort of WATCHMAN type integration type acquisitions? And then I have one follow-up."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. So we have a pretty active development group and we're very disciplined with the type of deal we look at. Obviously we need to focus on our strategic fit and also strong return. Dan also mentioned we had a slight impairment with one of our venture i",277,"Sure. So we have a pretty active development group and we're very disciplined with the type of deal we look at. Obviously we need to focus on our strategic fit and also strong return. Dan also mentioned we had a slight impairment with one of our venture investments, but we have a pretty significant venture investment portfolio that we think will strong values to the company. I think looking at '18 and '19 which is very exciting. I think just in terms of this deal is very consistent, the Endo deal with our strategy which is one is to continue to strengthen and diversify the company in the faster-growth market. So the MedSurg segment is a significant contributor. Endo business is a leader, but we're a little bit lighter in terms of our portfolio in the ambulatory surgery center. We also had that offered a pathology solution for this business. So it gives us the capability for surgery center market, which is a nice extension and expands us into some adjacencies in pathologies, builds in a few products in our core business. So it will be a nice tuck-in acquisition, nice cost synergies and probably on a lower risk scale in terms of integration. But we've also complemented those deals with some nice strong investments obviously the WATCHMAN acquisition. And also I think hopefully our M&A track record is pretty solid. We're ahead of deal model with AMS. We've done a very good job with the Bayer acquisition. So we continue to look with our acquisition which support our strategy, diversifying the faster-growth markets and category leadership, and we're active in scanning the market in those areas."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","And then the follow-up for Dr. Stein. Josh asked the question earlier about one of your competitors having a recall. And you have the perspective on this much more than most of us, but it doesn't seem like this is going to become any kind of market sort o",85,"And then the follow-up for Dr. Stein. Josh asked the question earlier about one of your competitors having a recall. And you have the perspective on this much more than most of us, but it doesn't seem like this is going to become any kind of market sort of clinician concern, patient concern in the long history of CRM. But if you could maybe help prospective what you've seen so far, heard so far, if you have any concerns that this becomes segment issue?"
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks for the question, Matt. I'm not going to comment about patient management for those patients who are affected by competitors adviser. Certainly, we take an individual patient safety issue very seriously. Overall, we do not believe this is going to",53,"Thanks for the question, Matt. I'm not going to comment about patient management for those patients who are affected by competitors adviser. Certainly, we take an individual patient safety issue very seriously. Overall, we do not believe this is going to have any impact on market growth either in the U.S. or globally."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Christ Pasquale with Guggenheim.",12,"The next question comes from the line of Christ Pasquale with Guggenheim."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Mike, can you talk a little bit more about the EndoChoice acquisition the decision to explore options for fuse. That product hasn't lived up to expectations yet, but it would seem that plugging it into a larger sales organization could be the missing piec",75,"Mike, can you talk a little bit more about the EndoChoice acquisition the decision to explore options for fuse. That product hasn't lived up to expectations yet, but it would seem that plugging it into a larger sales organization could be the missing piece of the puzzle. And you guys have had some successes historically imaging side of the business with Spyglass. So why not keep that is if you can realize the potential yourselves?"
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","We'll probably won't provide a lot of color on that. We sort of like the assets of EndoChoice, and we're pursuing options. So we haven't declared fully that we're going to sell that business or retain that business. So more information to come likely at o",57,"We'll probably won't provide a lot of color on that. We sort of like the assets of EndoChoice, and we're pursuing options. So we haven't declared fully that we're going to sell that business or retain that business. So more information to come likely at our next earnings call in terms of the status update there."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. And then you mentioned the ongoing replacement cycle headwind in ICDs which has been an issue you've dealt with for a long time. What's your latest estimate for when that should turn positive for you?",36,"Okay. And then you mentioned the ongoing replacement cycle headwind in ICDs which has been an issue you've dealt with for a long time. What's your latest estimate for when that should turn positive for you?"
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","So we anticipate especially like in the second half of 2017, the flattening out and ideally slight improvement on the CRT side on the replacement cycle. And then in '18 on the ICD side. So some benefit in '17 and more benefit in '18 based on the modeling",248,"So we anticipate especially like in the second half of 2017, the flattening out and ideally slight improvement on the CRT side on the replacement cycle. And then in '18 on the ICD side. So some benefit in '17 and more benefit in '18 based on the modeling that we've done. And that was also come in the heels of full '18 launch of our MRI full year benefit of MRI capabilities. So I just want to maybe close the call -- and Dan talked about kind of the mid-single-digit guidance for next year, we'll provide all that detail in the second quarter.
I think what you're most excited about is the future of the company, and we talked quite a bit about the platforms that we'll be entering in markets approaching $8 billion to $9 billion in 2020. We'll detail this out in the Investor Day, but an exciting future as we move into a very large market in TAVR, expanded indications in the future with WATCHMAN, our drug-eluting technologies, the real commitment that we have to neurostimulation, expanding the Deep Brain Stimulation potential in other areas. And really into area of Endoscopy where our teams are looking at breakthrough capabilities take more general surgery approaches to less invasive procedures. So there's a lot of new therapies that the business will be entering will show at our Investor Day that we'll really give the exciting future the company beyond our '17 guidance that we'll provide in February."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","With that, we'd like to conclude the call. Thanks for joining us today, and we appreciate your interest in Boston Scientific. Before you disconnect, Shannon will give you all the pertinent details for the replay.",35,"With that, we'd like to conclude the call. Thanks for joining us today, and we appreciate your interest in Boston Scientific. Before you disconnect, Shannon will give you all the pertinent details for the replay."
317627,403595084,1061269,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","Thank you. Ladies and gentlemen, this conference will be available for playback beginning today at 10:30 Eastern Time running through Wednesday, November 9, at midnight Eastern time. You may access the AT&T playback service by dialing 1 (800) 475-6701 and",79,"Thank you. Ladies and gentlemen, this conference will be available for playback beginning today at 10:30 Eastern Time running through Wednesday, November 9, at midnight Eastern time. You may access the AT&T playback service by dialing 1 (800) 475-6701 and entering the access code of 403036. International participants please dial 1 (320) 365-3844 with the access code of 403036. That does conclude our conference for today. Thank you for your participation and for using AT&T. You may now disconnect."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Boston Scientific Q3 2016 Earnings Call. [Operator Instructions] As a reminder, today's conference is being recorded. I would now like to turn the conference over to Susie Lisa. Please go a",42,"Ladies and gentlemen, thank you for standing by. Welcome to the Boston Scientific Q3 2016 Earnings Call. [Operator Instructions] As a reminder, today's conference is being recorded. 
I would now like to turn the conference over to Susie Lisa. Please go ahead."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Shannon. Good morning, everyone, and thanks for joining us. For those of you having issues with the webcast, we apologize for the technical issues, we're working with NASDAQ, and ask you to consult our Investor Relations section of our website",392,"Thank you, Shannon. Good morning, everyone, and thanks for joining us. For those of you having issues with the webcast, we apologize for the technical issues, we're working with NASDAQ, and ask you to consult our Investor Relations section of our website to see the dial-in number. 
With me on today's call are Mike Mahoney, Chairman and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.
We issued a press release earlier this morning announcing our Q3 2016 results, which included reconciliations of the non-GAAP measures used in the release. We have posted a copy of that release as well as reconciliations of the non-GAAP measures used in today's call to the Investor Relations section of our website under the heading Financial Information.
The duration of this morning's call will be up to 1 hour. Mike will provide strategic and revenue highlights of Q3 '16. Dan will review the financials for the quarter and then Q4 '16 and full year guidance, and then we'll take your questions. During today's Q&A session, Mike and Dan will be joined by our Chief Medical Officers, Dr. Keith Dawkins and Dr. Ken Stein. 
Before we begin, I'd like to remind everyone that on the call, organic revenue growth is defined as excluding the impact of changes in foreign currency exchange rates and sales from the acquisition of the American Medical Systems, AMS, Male Urology portfolio over the prior year period. Also of note, this call contains forward-looking statements within the meaning of federal securities laws, which may be identified by words like anticipate, expect, believe, estimate and other similar words. They include, among other things, statements about our growth and market share; new product approvals and launches; clinical trials; cost savings and growth opportunities; our cash flow and expected use; our financial performance, including sales, margins, earnings and other Q4 2016 guidance as well as our tax rates, R&D spend and other expenses. Actual results may differ materially from those discussed in the forward-looking statements. 
Factors that may cause such differences include those described in the Risk Factors section of our most recent 10-K and subsequent 10-Qs filed with the SEC. These statements speak only as of today's date, and we disclaim any intention or obligation to update them.
At this point, I'll turn it over to Mike for his comments. Mike?"
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Susie. Good morning, everyone. Our third quarter 2016 results are excellent and reinforce the success of our category leadership strategy and the strong execution of our global teams. We continue to grow faster than the market in almost all of",1834,"Thank you, Susie. Good morning, everyone. Our third quarter 2016 results are excellent and reinforce the success of our category leadership strategy and the strong execution of our global teams. We continue to grow faster than the market in almost all of our business units while consistently improving operating income margin. As a result, we continue to deliver strong double-digit adjusted EPS growth. 
Importantly, we are investing in new adjacencies, capabilities and end markets that position Boston Scientific for a very exciting future. In third quarter '16, we drove operational growth of 10% and organic revenue growth of 9%, normalized for currency and excluding the impact of 1 month of sales of the AMS acquisition, which anniversary-ed on August 3. Of note, we delivered this 9% organic growth against our toughest comparison of the year, and we leveraged that growth with 120 basis point improvement year-over-year in adjusted operating margin of 24.3%, which beat the high end of our guidance range by 30 basis points. Thus, 9% organic revenue growth in the quarter was leveraged to 12% EPS growth or $0.27 per share, which was at the high end of our guidance range. For the full year '16, we're maintaining our strong guidance and pulling up the low end of our previous ranges, and Dan will provide the details in a few minutes.
I'll now provide some highlights on Q3 results and our Q4 '16 outlook. In my remarks, all references of growth are on a constant-currency organic year-over-year basis, and they exclude the 1-month benefit of AMS unless otherwise specified. 
Organic revenue growth of 9% was broad-based across our businesses and regions, with particular strength from new global product launches, emerging market expansion and share gains led by innovation and our category leadership strategy. On a regional basis EMEA led the pack with 12% growth, followed by the U.S. at 9% and Europe at 5%. Emerging markets sales grew 19%, led by an acceleration in growth in China at 26% and Latin America turning a strong quarter with 21% growth. 
Across our businesses, for the third straight quarter, both our Cardiovascular and MedSurg segments grew sales organically double digits, 12% for cardiovascular and 10% for MedSurg. And Rhythm Management turned in a strong and consistent performance with second (sic) [ third ] quarter sales up 3%. MedSurg continues to deliver excellent growth and strong profitability. MedSurg remains a high-priority segment for the company, with 2 recent tuck-in acquisitions to enhance category leadership in Neuromodulation with Cosman Medical in RF ablation and Endoscopy with the recently announced tender offer for EndoChoice. 
9% global growth in Endoscopy was led by double-digit gains in both our Biliary and hemostasis franchises, with Spyglass digital DS and the AXIOS stent leading the charge in Biliary, and our newly launched Resolution 360 clip is driving growth in hemostasis. We continue to see upside from new product launches and strong emerging market growth in endo. 
We're also excited about the acquisition of EndoChoice, which we expect to close by year-end. EndoChoice is focused on the development of innovative products and services for gastroenterology health care providers, with a portfolio that's particularly well suited for the ambulatory surgery center. It also brings a portfolio of value-added services to the ASC market, including infection control and pathology services. This acquisition will further enhance the position of Boston Scientific as the global leader in the field of GI endoscopy. As previously announced, we expect to pursue strategic options for EndoChoice's  FUSE colonoscope business. We plan to provide an update at or around the time of closing of this transaction.
Turning to Urology and Pelvic Health. Uro and Pelvic Health grew double digits for the third consecutive quarter, up 13% in Q3. We're a strong category leader in the Urology segment, and we delivered broad-based growth across the combined Boston Scientific and AMS portfolio. International sales remained very strong with EMEA, Latin America and emerging markets all growing at double-digit rates. AMS sales grew 5% in the quarter, which is a nice acceleration from trend prior to acquisition. And importantly, our remediation and integration efforts are both on track.
Our Lithovue single-use ureteroscope continues to launch and is enjoying strong uptake in a variety of accounts. And finally, our growth was assisted by tailwinds from our market share capture post Astora's exit from the pelvic health market. 
Neuromod grew double digits, plus 12%, against a strong comp and robust Precision Spectra sales now with full-body MRI compatibility in our Vercise Deep Brain Stimulation platform in Europe. We continue to expect U.S. market entry for Vercise by late 2017 and believe this is an exciting new market opportunity for us.
Cosman Medical, an acquisition announced in July, broadens our Neuromodulation portfolio with RF ablation systems that enable us to offer patients with chronic pain another treatment option in non-opioid therapeutics. We will provide an update on our ACCELERATE clinical trial on our fourth quarter 2016 call. 
In Cardiovascular, segment sales grew 12% and reported an adjusted operating margin of 32.8%, up 160 basis points year-over-year. Peripheral Interventions revenue grew 11% and was led by strong balanced global growth in developed and emerging markets. This is PI's fourth straight quarter of double-digit above-market growth, fueled by our leadership -- category leadership strategy and the depth of our portfolio rather than any single product. 
We drove strong growth in the atherectomy and thrombectomy businesses, and new product launches are also going very well, including the AngioJet ZelanteDVT catheter; the Innova vascular stent; and our drug-eluting technologies, Eluvia DES and Ranger DCB. Finally, we're also pleased with the contribution and integration progress of the Spherical Embolics platform acquired from CeloNova. 
We continue to invest in the peripheral market, particularly in drug-eluting strategies, venous diseases and interventional oncology. Two important clinical trials were presented in the third quarter at the major European peripheral congresses, CIRSE. Our drug-eluting stent, Eluvia, in the MAJESTIC clinical trial demonstrated an unprecedented 92.5% freedom from total lesion revascularization at 2 years. And enrollment continues in our global IDE trial, IMPERIAL. This 92.5% freedom from TLR is of particular note given the patient population studied. 65% of patients had severely calcified lesions and 46% had chronic total occlusions. 
In addition, we reported results for our Ranger Drug-Coated Balloon from 105-patient randomized clinical trial studying the superficial femoral artery. With 94.4% freedom from total lesion revascularization at 6 months, average lesion length was 68 millimeters. We also posted strong results from our Ranger all-comers registry with 91.9% freedom from TLR at 6 months and an average lesion length of 135 millimeters. 
We plan to bring our Ranger DCB to the U.S., and we'll reveal details of our IDE trial shortly. We're excited to be the only company investing in a complete portfolio of drug-eluting therapies.
Turning to Interventional Cardiology. This business segment grew 13% in Q3, led by strong sales in structural heart, drug-eluting stents and PCI guidance or imaging. SYNERGY continues to penetrate the market as we grew worldwide DES sales 14%, and we remain on track to represent 50% to 60% of our global DES revenue mix by the end of fourth quarter. PCI guidance grew mid-teens as well, with strong IVUS catheter and service sales augmented by the ongoing global launch of our COMET FFR system. 
In structural heart, which includes our Lotus transcatheter aortic valve and WATCHMAN Left Atrial Appendage Closure Device, we're driving growth via our unique innovative platform technologies, and they're resonating with physicians and are supported by the strength of our commercial teams. Both franchises are performing very well, and we continue to expect to deliver structural heart revenue at the high end of our $175 million to $200 million guidance for 2016.
We also recently began the early launch of our Lotus EDGE valve in Europe, and thus, the results from our feasibility study of Lotus EDGE will be presented this Sunday at a lunchtime symposium at TCT. Also at TCT next week, we look forward to a number of Lotus presentations, including 4-year outcomes on REPRISE I, 3-year outcomes for REPRISE II and our Lotus EDGE feasibility study with a 7-day discharge data. We expect to present results of REPRISE III, our U.S. pivotal trial and the first to provide head-to-head data, at EuroPCR in May. 
The WATCHMAN platform also delivered an exciting quarter, with strong growth from opening new centers as well as driving growth in existing centers. We're very encouraged to see a strong initial launch in France, where we received higher reimbursement to peers based on the strength of our data. And we expect to enroll our first patient in ASP-II, which is a study examining the use of WATCHMAN in warfarin-ineligible patients before the end of the year.
Turning now to Rhythm Management. Segment sales grew 3%, with another impressive gain in the adjusted operating margins of 20.1%, which is 320 basis points quarter-over-quarter and a 230 basis points growth year-over-year. Growth in CRM at 3% was above market and led by worldwide patient growth of 22%, with meaningful share capture from our premium-based brady MRI device. High-voltage sales declined 4% globally due to replacement cycle headwinds and competitive pressures in the U.S. and MRI-compatible tachy devices. We continue to be pleased with the growth and momentum of EMBLEM S-ICD, which has been fueled by a recent FDA approval for both MRI and MRI-backwards compatibility and increased physician acceptance of this differentiated therapy. 
In Europe, our CRM business grew above market for the 10th consecutive quarter, and in Japan, our above-market growth was driven by a strong launch of EMBLEM S-ICD, transvenous tachy MRI and 3.0T brady MRI. We also achieved important CRM clinical milestones in the quarter, including the first patients enrolled in the APPRAISE ATP trial to help clinicians understand which ICD patients could benefit from antitachycardia pacing and which may be harmed. 
Also, our MultiSENSE trial is accepted as a late breaker for the upcoming AHA scientific sessions in New Orleans. MultiSENSE is an international multicenter, non-randomized study, which is designed to develop and to evaluate prospectively a multi-sensor-based algorithm for the early detection of worsening heart failure. 
In Electrophysiology, 5% growth was led by strength in international markets. In Europe, we are pleased with the early feedback of our IntellaMap OI catheter, which was launched in the second quarter. We expect to launch this catheter in the U.S. in fourth quarter, which, combined with IntellaNav XP and MiFi XP catheters, will unlock the use of Rhythmia to a higher mix of procedures. We remain bullish that continued penetration of our next-generation mapping and navigation system, Rhythmia HDX and the commercialization of our complete portfolio of nav-enabled therapeutic catheters will strengthen our global EP business and improve growth in 2017. 
So to wrap up, I would like to thank our employees for their incredible winning spirit, terrific execution and commitment to the company. So with that, I'll turn it over to Dan for more details on the P&L and guidance."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Mike. In Q3, we generated organic revenue growth of 9% versus our 7% to 9% guidance range and adjusted earnings per share of $0.27, representing 12% year-over-year growth and hitting the high end of our guidance range of $0.25 to $0.27. The double",1256,"Thanks, Mike. In Q3, we generated organic revenue growth of 9% versus our 7% to 9% guidance range and adjusted earnings per share of $0.27, representing 12% year-over-year growth and hitting the high end of our guidance range of $0.25 to $0.27. The double-digit adjusted EPS growth in Q3 was driven primarily by strong revenue growth and solid gross margin, which was at the high end of our guidance range. 
Consolidated revenue of $2,105,000,000 represented operational revenue growth of 10%, at the high end of guidance and reflects an immaterial impact from foreign exchange, which was in line with guidance.
Excluding an approximate 100 basis point contribution from the AMS Male Urology portfolio acquisition for the month of July, organic revenue growth was 9% in the quarter and 11% on an as-reported basis. As a reminder, we completed the acquisition of the AMS Male Urology portfolio on August 3 last year, so August and September AMS sales were included in our organic sales growth calculation. 
Adjusted gross margin for the third quarter was 72.5%, at the high end of our guidance range and consistent with prior year despite a year-over-year negative 120 basis point impact from foreign exchange. In Q3, as expected, we had lower inventory charges than in Q2, and we're now realizing the full benefit of the lower 2016 standard cost of our products due to ongoing value improvement programs. We continue to expect full year 2016 adjusted gross margin to be approximately 72%, which includes an expected 75 to 100 basis point negative impact from unfavorable foreign exchange. 
Adjusted SG&A expenses were $763 million or 36.2% of sales in Q3, down 70 basis points year-over-year as we realize the benefit of our targeted initiatives focused on reducing SG&A, offset partially by the reinvestment of the medical device excise tax benefit. We continue to believe our full year rate will be approximately 36%, which would be a 140 basis point improvement compared to 2015.
Adjusted research and development expenses were $232 million in the third quarter or 11% of sales, which is down 70 basis points year-over-year. We continue to expect our full year 2016 adjusted R&D rate to be approximately 11% of sales. Royalty expense was 0.9% of sales in Q3, roughly flat year-over-year.
Q3 2016 adjusted operating income grew 17% year-over-year and adjusted operating margin of 24.3% was above our guidance range of 23% to 24% and represented a 120 basis point improvement over Q3 last year, the ninth consecutive quarter in which we have expanded adjusted operating margin by 100 basis points or more over the prior year comparable period.
The Rhythm Management team delivered an adjusted operating margin of 20.1%, up 230 basis points year-over-year. The increase year-over-year is a result of realizing the full benefit of 2016 product costs and leveraging the improved top line performance of the global business. For the first 9 months of 2016, Rhythm Management adjusted operating margin is 17.9%, and we continue to believe that, that segment is on track to deliver an adjusted full year operating margin of 20% in 2017.
With total company adjusted operating margin for the first 9 months of 2016 at 24.3%, this positions us well to achieve our full year adjusted operating margin guidance of 24% to 24.5%, and we remain on track to reach our goal of 25%-plus in 2017 we will provide more guidance on 2017 adjusted operating margin with our Q4 earnings call in February.
Now I'll move on to interest and other expense. Interest expense for the quarter was $58 million, roughly flat to Q3 of 2015. Our average interest expense rate was 3.9% in Q3 this year compared to the same 3.9% in Q3 of last year. Other expenses was $33 million in the quarter and includes approximately $20 million of impairment charges related to certain of our strategic investments. Other expenses for the quarter primarily included foreign exchange losses related to our hedging program. 
Our tax rate for the third quarter was 11.2% on a reported basis and 12.4% on an adjusted basis. We are making progress towards finalizing our conditional stipulation of settled issues with the Internal Revenue Service and expect to make a series of payments related to the settlement, most of which we expect to remit during the second half of 2017 and into the first half of 2018.
Finally, Q3 2016 adjusted earnings per share of $0.27 includes approximately $0.01 of unfavorable FX and represents 12% year-over-year growth or 17% growth excluding the impact of foreign exchange. Earnings per share upside from the strong revenue and margin performance was partially offset by the $0.01 of impairment charges we recorded. On a reported GAAP basis, which includes net charges and amortization expense totaling $140 million after tax, Q3 2016 EPS was $0.17. 
Adjusted free cash flow for the quarter was $440 million compared to $394 million in Q3 last year, and we continue to pursue inventory management initiatives designed to improve the working capital contribution to cash flow. Given the strong adjusted free cash flow generation year-to-date this year, we believe we can achieve our full year adjusted free cash flow guidance of $1.6 billion. In Q3, we used cash primarily to fund previously agreed legal settlements as well as business development activities. As of September 30, 2016, we had cash on hand of $237 million, and near term, our capital allocation priorities continue to be managing contingencies and pursuing tuck-in M&A. 
We ended the third quarter with 1,380,000,000 fully diluted weighted average shares outstanding. Consistent with our prior guidance, we expect our share count to increase by less than 5 million through the end of 2016. As consistent with our commitment at the time of the AMS Men's Health acquisition last year, we plan to keep the buybacks suspended for the balance of 2016. We expect this to result in a fully weighted average share count of approximately 1,380,000,000 shares for full year 2016. 
I'll now walk through the guidance for the fourth quarter and the full year 2016. For the full year, we now expect consolidated revenue to be in a range of $8,335,000,000 to $8,385,000,000, which represents year-over-year growth of 9% on an organic basis, 12% on an operational basis and 11% to 12% on a reported basis. We continue to expect foreign exchange to be a headwind of approximately $70 million for the full year.
Turning to adjusted earnings per share. We now expect full year 2016 adjusted EPS to be in a range of $1.09 to $1.11, representing 17% to 19% adjusted earnings growth, which continues to assume the full year negative impact of FX will be $0.05. On a GAAP basis, we expect earnings per share to be in a range of $0.32 to $0.34. 
Now turning specifically to the fourth quarter. We expect consolidated revenue to be in a range of $2,140,000,000 to $2,190,000,000. This represents year-over-year growth in a range of 7% to 9% operationally. We expect foreign exchange impact on Q4 revenue to be a slight tailwind. For the fourth quarter, adjusted earnings per share is expected to be in a range of $0.27 to $0.29 per share, and GAAP earnings per share is expected to be in a range of $0.15 to $0.17 per share. Please check our Investor Relations website for Q3 2016 financial and operational highlights, which outlines Q3 results as well as Q4 and full year 2016 guidance, including P&L line item guidance.
And with that, I'll turn it back to Susie, who'll moderate the Q&A."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Dan. Shannon, let's open it up to questions for the next 30 minutes or so. [Operator Instructions] Shannon, please go ahead.",22,"Thanks, Dan. Shannon, let's open it up to questions for the next 30 minutes or so. [Operator Instructions] Shannon, please go ahead."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","[Operator Instructions] Our first question comes from the line of David Lewis with Morgan Stanley.",15,"[Operator Instructions] Our first question comes from the line of David Lewis with Morgan Stanley."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","A couple of financial questions this morning. So just first off, Dan, I know it's a bit early, but I think '17 numbers, consensus is sort of in the upper part of mid-single digits and around sort of 13% earnings. I wonder if you could offer sort of any re",91,"A couple of financial questions this morning. So just first off, Dan, I know it's a bit early, but I think '17 numbers, consensus is sort of in the upper part of mid-single digits and around sort of 13% earnings. I wonder if you could offer sort of any refinement just given the strength you've seen here on '16. And if you can't kind of refine this early, any headwinds or tailwinds we should be thinking about on the top and bottom line heading into '17? Then I had a follow-up."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. David, I don't think we're going to provide any specific guidance for '17. We'll do that, as you would expect, on our call in early February. We have been very public about saying that we believe next year is a mid-single-digit year in terms of reven",60,"Yes. David, I don't think we're going to provide any specific guidance for '17. We'll do that, as you would expect, on our call in early February. We have been very public about saying that we believe next year is a mid-single-digit year in terms of revenue growth, but I wouldn't provide really any more than that at this point."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. And maybe just 2 quick ones, one clinical and one margin question. So for Dan, you eclipsed 20% margins here in CRM this quarter. I guess the question now is -- that's happening a lot earlier than many would have expected 2 years ago, so where can C",130,"Okay. And maybe just 2 quick ones, one clinical and one margin question. So for Dan, you eclipsed 20% margins here in CRM this quarter. I guess the question now is -- that's happening a lot earlier than many would have expected 2 years ago, so where can CRM margins go now? And then for fourth quarter margins to deliver the earnings, you need to do better year-on-year with margins in the fourth quarter than you did in the second and third quarters. So where can CRM go and the confidence in the fourth quarter margin? And then maybe for the clinical team, when do you think we're going to get the first read on what the true pacing rates are for Lotus EDGE? And I'll jump back in queue."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, David. I'll take the Rhythm Management operating margin and turn it over to Keith and Mike for the clinical questions. So obviously, very pleased to be at that 20% here in Q3 for Rhythm Management operating margin. It's 320 basis points sequentially",217,"Sure, David. I'll take the Rhythm Management operating margin and turn it over to Keith and Mike for the clinical questions. So obviously, very pleased to be at that 20% here in Q3 for Rhythm Management operating margin. It's 320 basis points sequentially and 230 points year-over-year. As you would expect in any given quarter, you'll see some variation in that. Would actually expect that to go back down in Q4, a little more spending in Q4 on SG&A initiatives and such. The full year should be about 18%, which is what we've said consistently that we'd be this year. And I think that puts us right in line to get to that 20% next year in Rhythm Management, which, as part of us getting to 25%-plus as a company, I think gives us the confidence in both those numbers. So I don't think we're going to talk more specifically about the 20%, where we'd go from there. Certainly, it goes north of that. We're not going to stop at 20% in 2017. Just as a company, we're not going to stop at 25%. So there's more room in that Rhythm Management segment to increase well beyond 20% as the company goes to, what we've said publicly, our goal of 27% to 28% operating margin by 2020."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. So just on Lotus EDGE, David, just a couple of high-level comments, and Keith could maybe highlight TCT, which we have an important investor meeting on Monday, quite a bit more detail there. But overall, we're really pleased. We continue to deliver o",199,"Yes. So just on Lotus EDGE, David, just a couple of high-level comments, and Keith could maybe highlight TCT, which we have an important investor meeting on Monday, quite a bit more detail there. But overall, we're really pleased. We continue to deliver our overall structural heart commitment in terms of our guidance. We guided to the high end of $175 million to $200 million range for WATCHMAN and TAVR. Really pleased about the CE Mark for Lotus EDGE that we received in one of the valves. We're very early in that phase. But over the long term, particularly I should point to the end of 2017 and the future, '18 and '19, we believe we're very well positioned with our Lotus platform in terms of our launch in these large global markets and eventually Japan, well positioned to gain share. We believe we have the very unique capabilities in terms of our operator control and physician control of the device, excellent PVL rates and our focus on improving the pacemaker rate. So our aim will be to take significant share in these larger markets, and we're building momentum there. So Keith, do you want to touch on TCT?"
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, sure. David, this Sunday, the 30th, the Lotus lunchtime symposium of TCT will be the first presentation of the first human use, early feasibility data of EDGE, only 21 patients but will certainly give us a guide. And we can discuss those data in more",99,"Yes, sure. David, this Sunday, the 30th, the Lotus lunchtime symposium of TCT will be the first presentation of the first human use, early feasibility data of EDGE, only 21 patients but will certainly give us a guide. And we can discuss those data in more detail at the investor meeting on Monday morning at TCT. Also, at TCT we'll have the 4-year outcomes for REPRISE I and 3-year outcomes for REPRISE II, and you'll get more EDGE data at ACC and -- further EDGE data and, of course, our pivotal trial data, REPRISE III, primary endpoint at EuroPCR."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Bob Hopkins with Bank of America.",14,"The next question comes from the line of Bob Hopkins with Bank of America."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","And I apologize for the background noise. I'm in an airport. So first of all, just on behalf of the med tech investment community, I'd like to thank you for a great third quarter. Certainly, some that have gone before you were starting to make investors n",169,"And I apologize for the background noise. I'm in an airport. So first of all, just on behalf of the med tech investment community, I'd like to thank you for a great third quarter. Certainly, some that have gone before you were starting to make investors nervous. So congrats on a great quarter. I wanted to ask a modeling question to Dan and then a product question for Mike. So first, just on the modeling side. It's a little thing, but it stuck out to us, which was that your other income line was an expense of $33 million and that hit EPS by probably up to $0.02. And I know you mentioned something in the prepared comments, but I would just love to get a little bit of a better sense for what caused that uptick and just where that line item goes from here. Does it go back down to normalized level that we've seen in the past? I just would love some comments on other income."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, Bob. So as you say, in the prepared commentary, we talked about a $20 million impairment in the quarter. We have an investment portfolio now that's over $300 million. So as you'd expect, you may see impairments from time to time. It's not a regular",97,"Sure, Bob. So as you say, in the prepared commentary, we talked about a $20 million impairment in the quarter. We have an investment portfolio now that's over $300 million. So as you'd expect, you may see impairments from time to time. It's not a regular occurrence. So that is the difference basically between the year-over-year comparison of that line, is that impairment. And it was worth about $0.01 overall. So without that, we would have been $0.01 higher. But that should not be a regular occurrence, from time to time but certainly not a regular occurrence."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. So that line item goes back down to normalized levels. And then on the product side, I just wanted to get 2 quick updates. One, is the time line for MRI-safe ICDs in the U.S. still the same as your previous guidance, which I think was the end of '17",110,"Okay. So that line item goes back down to normalized levels. And then on the product side, I just wanted to get 2 quick updates. One, is the time line for MRI-safe ICDs in the U.S. still the same as your previous guidance, which I think was the end of '17? And then on WATCHMAN, I'm trying to gauge the impact of the start of the post-approval study, what kind of impact that might have had on the NCD and the availability of reimbursement. So now that we've got that up and running, does that have a strong incremental impact on the ability of folks to get WATCHMAN properly reimbursed?"
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. Yes, on the MRI-safe, no changes to our time line there. We anticipate like the fourth quarter 2017. And importantly, in that category, we're down in the U.S. and down globally, but our European business continues to do well as our Asian business do",268,"Sure. Yes, on the MRI-safe, no changes to our time line there. We anticipate like the fourth quarter 2017. And importantly, in that category, we're down in the U.S. and down globally, but our European business continues to do well as our Asian business does with a full line of MRI-safe products. And the S-ICD continues to do very well. So despite not having it for what will be a decent part of '17, the pacer business continues to do very well. We're doing very well outside the United States, and S-ICD is continuing to support us and differentiate that platform. So we're very bullish on the future of our CRM business and the portfolio. And despite that, the team continues to drive operating income margin improvements. So really nice job there. With WATCHMAN, I mean, we're continuing to build momentum there. As you mentioned, the reimbursement headwinds really are beginning to neutralize based on the advances that we've made there. We continue to open up new centers, and we're really tracking. And we're not giving you much visibility to that, and in the future, we'll determine how to do that. But we're continuing to focus on our utilization rate and driving more physician awareness, more patient awareness and, in parallel, doing a really nice job on physician training, so oftentimes, training multiple physicians at the same site to increase utilization. And in parallel, we're opening up a new center. So again, on the structural heart side, we're at the high end of our range, $175 million to $200 million, and the WATCHMAN contribution is significant within there."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Mike Weinstein with JPMorgan.",12,"The next question comes from the line of Mike Weinstein with JPMorgan."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","3Q, by and large, looks a lot like 2Q. So I actually have a couple of finance questions for Dan. First question is with the mesh liabilities and IRS tax payments, can you fund that from OUS cash? Or are you are going to have to do any borrowing for that?",51,"3Q, by and large, looks a lot like 2Q. So I actually have a couple of finance questions for Dan. First question is with the mesh liabilities and IRS tax payments, can you fund that from OUS cash? Or are you are going to have to do any borrowing for that?"
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","The plan is not to have to do any borrowing on that. We should have full access to our cash through 2017 and don't anticipate any borrowings necessary.",28,"The plan is not to have to do any borrowing on that. We should have full access to our cash through 2017 and don't anticipate any borrowings necessary."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. Second quick one, Dan. Do you know at this point, based on current rates, what you think FX would mean to the bottom line in 2017? And it's simply we don't have a good visibility on your FX hedges and where they are and how they roll off. Do you hav",59,"Okay. Second quick one, Dan. Do you know at this point, based on current rates, what you think FX would mean to the bottom line in 2017? And it's simply we don't have a good visibility on your FX hedges and where they are and how they roll off. Do you have any insight to that at this point?"
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. I think it probably makes sense to hold that until the February earnings call and give all the guidance package altogether as opposed to kind of doing something one-off here. But have faith we'll give you full information on what we see as of Februar",46,"Yes. I think it probably makes sense to hold that until the February earnings call and give all the guidance package altogether as opposed to kind of doing something one-off here. But have faith we'll give you full information on what we see as of February."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Josh Jennings with Cowen and Company.",14,"The next question comes from the line of Josh Jennings with Cowen and Company."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","I just wanted 2 quick questions on CRM post the MRI-safe pacemaker approval. You clearly had 2 quarters of significant success getting back share. Any incremental color you can provide on how you've been so successful? Anything in the market dynamics? And",76,"I just wanted 2 quick questions on CRM post the MRI-safe pacemaker approval. You clearly had 2 quarters of significant success getting back share. Any incremental color you can provide on how you've been so successful? Anything in the market dynamics? And then any -- also, I was just curious about why we should -- should we be thinking of your pacemaker recovery as a precedent for ICU recovery once you have MCI-safe high-voltage approval?"
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks for the question, Josh. We're pleased -- we signaled at the end of the 2Q call that we thought overall CRM would be in line with 2Q, which we're pretty close to that. And we think fourth quarter will likely be in line with third quarter results. So",149,"Thanks for the question, Josh. We're pleased -- we signaled at the end of the 2Q call that we thought overall CRM would be in line with 2Q, which we're pretty close to that. And we think fourth quarter will likely be in line with third quarter results. So pretty consistent performance across our CRM business. And you highlighted the particular strength in pacemaker, really strong since the launch of our new products. I think it's this combination of an excellent lead and the ability to deliver that lead, excellent battery longevity in our pacer line, very strong commercial team. And it's consistent -- actually, stronger performance in the U.S. that we saw globally upon launching this product. So the commercial team has done very well, and physicians are very comfortable. I don't know, Ken, if you have any additional comments on our MRI pacer from a physician's standpoint?"
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. Thanks, Mike. Josh, I think what's really helping drive the growth is the differentiated features we have in our brady platform on top of MRI, including automated remote daily monitoring of these devices, including the performance of our newly releas",157,"Yes. Thanks, Mike. Josh, I think what's really helping drive the growth is the differentiated features we have in our brady platform on top of MRI, including automated remote daily monitoring of these devices, including the performance of our newly released INGEVITY lead. We got really fantastic feedback from clinicians since commercial release of that lead, validating excellent results we saw on the clinical trial. And I think in terms of what that does portend for tachy, I think we take a lot of pride in looking at how the portfolio is delivering in Europe, where we do have full approval of our tachy MRI products, including backwards compatibility to our previously released products and have MRI approval both for traditional transvenous devices as well as for our S-ICD. And we believe that the same performance that we're seeing in Europe, where we have a full portfolio approved, portends what we're going to see in the U.S."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Great. And just a follow-up. One of your big competitors has had a recall of their high-voltage platform. They've had to design around. But how are you thinking about this as a potential opportunity for Boston going forward in front of MRI-safe approval o",47,"Great. And just a follow-up. One of your big competitors has had a recall of their high-voltage platform. They've had to design around. But how are you thinking about this as a potential opportunity for Boston going forward in front of MRI-safe approval on the high-voltage side?"
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Well, I think what we've done is we very consistently promoted and we promoted with proof the unique benefits of our EnduraLife battery technology as being best in class, and that's really been proven out from 9 independent studies of contemporary device",149,"Well, I think what we've done is we very consistently promoted and we promoted with proof the unique benefits of our EnduraLife battery technology as being best in class, and that's really been proven out from 9 independent studies of contemporary device longevity. So even prior to some of the challenges that St. Jude has seen, we've been very clear to the marketplace that we have very unique battery technology and also excellent remote monitoring. So I think those 2 features stand the test of time and really been the anchor of our strategy for a number of years now. And we believe, over time, typically as health care modifies and more outcome-based, that having that type of capability is enjoyed by -- certainly by patients and also by physicians. So we think those unique strengths, combined with our commercial team, put us in a good position to compete."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Rick Wise with Stifel.",12,"The next question comes from the line of Rick Wise with Stifel."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Just to start with another Lotus question. Mike, with Lotus EDGE approved and, clearly, some clarity on maybe better outcomes achieved with a lower-depth implant, when do you more broadly roll out the technology and this procedural approach to a broader a",87,"Just to start with another Lotus question. Mike, with Lotus EDGE approved and, clearly, some clarity on maybe better outcomes achieved with a lower-depth implant, when do you more broadly roll out the technology and this procedural approach to a broader audience? And maybe just tie that in as well to Dr. Meredith's appointment. As much as I'll miss Dr. Dawkins' dulcet tones and eloquent commentary, why the change now and bringing him in-house? What can you achieve with Dr. Meredith in-house versus out in the world?"
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Well, first, I'd like to thank Keith. He's done a remarkable job at Boston Scientific. He's been here for 9 years. He brings the patient focus first to our executive committee and has really helped, along with Kevin and our broader team, lead the turnarou",227,"Well, first, I'd like to thank Keith. He's done a remarkable job at Boston Scientific. He's been here for 9 years. He brings the patient focus first to our executive committee and has really helped, along with Kevin and our broader team, lead the turnaround and sustained growth of our Interventional Cardiology business and move into structural heart. So Keith has done a terrific job. Transition is very smooth in the end of the year. Dr. Meredith is joining. Ian is very well known in the structural heart community. Structural heart is a big investment and a key focus area for the company. And so there'll be a seamless transition, and Ian will begin early in the year. So you'll see him at various investor conferences and so forth. But Keith did a great job of transitioning. And again, I think, just to repeat some of the comments earlier. We're very bullish on the future of our Lotus platform for the reasons we've articulated with the PVL rates, the controlled release of this device and the enhancements that depth guard and Lotus EDGE promise to deliver. And we're being very appropriate in terms of the rollout of that. And at TCT, we'll provide some additional information on pacemaker rates and some early clinical studies as well as some additional commentary from Tom Fleming, Keith and Kevin Ballinger."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Just to follow up, Mike, on AMS. Obviously, urology had a good quarter on multiple fronts. Can you talk about AMS? Where are you in the -- in achieving the sales synergies that you hoped for? Are you starting to see it? And is that side of the story where",68,"Just to follow up, Mike, on AMS. Obviously, urology had a good quarter on multiple fronts. Can you talk about AMS? Where are you in the -- in achieving the sales synergies that you hoped for? Are you starting to see it? And is that side of the story where you expected it would be? Are you ahead or behind? Just any perspective there would be very welcome."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. I would say, overall, we're likely slightly ahead on the cost synergy side, done a very nice job with that. We're certainly ahead overall in terms of the strategic value of the acquisition given the overall strength of our urology business. And as a",149,"Yes. I would say, overall, we're likely slightly ahead on the cost synergy side, done a very nice job with that. We're certainly ahead overall in terms of the strategic value of the acquisition given the overall strength of our urology business. And as a stand-alone business, the AMS business grew 5% in the quarter, which is slightly ahead of their kind of historical performance. So we think in our hands, the stand-alone business is performing better and will perform better. And more importantly, the complementary nature of the 2 businesses with Stone, BPH, ED is very comprehensive package for our commercial teams to take to customers. And not only is it very broad-based, but it also has unique clinical differentiation. So the combination of the 2 makes our legacy portfolio stronger. And so overall, we're clearly at or ahead of our internal deal models on the overall acquisition."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Vijay Kumar with Evercore ISI.",13,"The next question comes from the line of Vijay Kumar with Evercore ISI."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","So I had 2 quick ones. Maybe I'll start with the -- on the structural heart side. On Lotus, can you maybe talk about comparative dynamics in Europe? Are you still gaining share? And I know that you guys are not yet there in France, so maybe any perspectiv",54,"So I had 2 quick ones. Maybe I'll start with the -- on the structural heart side. On Lotus, can you maybe talk about comparative dynamics in Europe? Are you still gaining share? And I know that you guys are not yet there in France, so maybe any perspective on that would be helpful."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, yes. We're probably not going to give as much detail as you'd like. Again, overall, we're at the high end of our guidance projected for our structural heart. Obviously, Lotus is a key component of that. We're still -- I think it's safe to say we're",209,"Sure, yes. We're probably not going to give as much detail as you'd like. Again, overall, we're at the high end of our guidance projected for our structural heart. Obviously, Lotus is a key component of that. We're still -- I think it's safe to say we're growing faster than the market in Europe. And what's important to note is we don't have all the -- all of our ammunition yet with Lotus. We don't yet have our largest valve and our smallest valve. And so we're doing quite well in the market with 3 valves, and we'll be excited about getting the additional 2 valve sizes for the full matrix. And I think what's really different is of the same drumbeat. It's a different device. It's a next-generation platform that doctors really enjoy the control that they have with it. And so it's -- I wouldn't say it's easy, but it's easier to differentiate this valve than some of the other balloon expandable devices that they have options to use in Europe. So we're very bullish on the future of it. In terms of France, we expect to have reimbursement by year-end '17. So hopefully, we'll see some upside from France reimbursement ideally in the fourth quarter '17."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Great. And then maybe one quick one on MedSurg. Again, I think this has been a phenomenal segment for you guys. And if I look at those really, really strong growth rate you put up, can you help us understand what's the underlying growth rate versus what's",82,"Great. And then maybe one quick one on MedSurg. Again, I think this has been a phenomenal segment for you guys. And if I look at those really, really strong growth rate you put up, can you help us understand what's the underlying growth rate versus what's been the contribution from new products, right? Because it's kind of hard for us to model. And any sort of new product cadence that you have lined up for '17, I think, would be helpful."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. So our MedSurg business, particularly endo and uro doesn't have the, call it, singular blockbuster devices or platforms like SYNERGY or WATCHMAN or Lotus. So Endoscopy is a very broad-based portfolio, as is urology. We have some kind of star platform",199,"Yes. So our MedSurg business, particularly endo and uro doesn't have the, call it, singular blockbuster devices or platforms like SYNERGY or WATCHMAN or Lotus. So Endoscopy is a very broad-based portfolio, as is urology. We have some kind of star platforms in Endoscopy with our AXIOS stent and our Spyglass digital, but it's really a very broad-based portfolio that we continue to layer on new innovations to broaden out the adjacencies that we compete in, similar to the recent acquisitions that we've done with EndoChoice and CeloNova. So really, not one big product, but, overall, you're seeing us increase the R&D spend in those businesses over the past few years. We've been more active in M&A in the Endoscopy, uro and neuromod area. And importantly, they were under-scaled outside the U.S. And we put a lot of investment outside the U.S. over the past few years, and that continues to pay off, and that's not a onetime payoff, it will continue to pay off, as well as emerging markets. So it's really not a one-product story, and it's very diversified strength in those businesses. Keith, was there something else on Lotus, TCT? Or did we cover that sufficiently?"
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","I think we covered it sufficiently. France reimbursement is important because France is the second-largest European market with a high penetration of TAVR. And so we're looking forward to bringing the products to France. Obviously, there are French invest",52,"I think we covered it sufficiently. France reimbursement is important because France is the second-largest European market with a high penetration of TAVR. And so we're looking forward to bringing the products to France. Obviously, there are French investigators in our trials, and they've been impressed with the acute performance of those."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question is from the line of Larry Biegelsen with Wells Fargo.",13,"The next question is from the line of Larry Biegelsen with Wells Fargo."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","And Keith, good luck in your new endeavors. I'll miss working with you. Two product-related questions. First on Neuromodulation and the ACCELERATE trial, you mentioned that you would give an update on the Q4 call in February. NANS this year is January. So",62,"And Keith, good luck in your new endeavors. I'll miss working with you. Two product-related questions. First on Neuromodulation and the ACCELERATE trial, you mentioned that you would give an update on the Q4 call in February. NANS this year is January. So does that mean we're not going to see the ACCELERATE data at NANS? And I had one other question."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Larry. Yes, our plan is to provide an update on the ACCELERATE trial at our fourth quarter 2016 earnings call, which is shortly after NANS, I believe. So our plan is to provide some additional color at that call, fourth quarter '16.",43,"Thanks, Larry. Yes, our plan is to provide an update on the ACCELERATE trial at our fourth quarter 2016 earnings call, which is shortly after NANS, I believe. So our plan is to provide some additional color at that call, fourth quarter '16."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","So Mike, just to be clear, no data at NANS? Is that what you're saying?",15,"So Mike, just to be clear, no data at NANS? Is that what you're saying?"
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. Our plan is to provide additional insight in the fourth quarter 2016 earnings call.",15,"Yes. Our plan is to provide additional insight in the fourth quarter 2016 earnings call."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay, clear. And then on drug-eluting stent growth, obviously very strong this quarter. I think it accelerated to 14% from 9% last quarter. Was that balanced across geographies? And then, Keith, I think new competition will probably become more prominent",68,"Okay, clear. And then on drug-eluting stent growth, obviously very strong this quarter. I think it accelerated to 14% from 9% last quarter. Was that balanced across geographies? And then, Keith, I think new competition will probably become more prominent at TCT given the BIOTRONIK  data coming and the Medinol data coming as late breakers there. So any kind of previews from you on the competitive dynamics there?"
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Larry. I think the difference between some of the competitors and SYNERGY is that we have a very large dataset with SYNERGY, and we now have approximately 20,000 patients in multiple clinical trials in a lot of high-risk subsets of patients. And a",210,"Thanks, Larry. I think the difference between some of the competitors and SYNERGY is that we have a very large dataset with SYNERGY, and we now have approximately 20,000 patients in multiple clinical trials in a lot of high-risk subsets of patients. And as you know from the 2-year data from the pivotal EVOLVE II trial, best-in-class stent thrombosis rates at 2 years. In fact, no definite stent thrombosis, not a single definite stent thrombosis after the first 24 hours. So we do think safety is an important metric, and we don't think we have any competition in that area. I think what will be interesting at TCT is some of the longer-term follow-up of fully resorbable stents, particularly the 3-year data from ABSORB II because if fully resorbable stents get better, the longer they're in, in terms of remodeling and so on, that will be an important finding. Clearly, the 2-year data in that regard were disappointing. So we also like the acute performance of SYNERGY. The ease of use for interventional cardiologists worldwide is well appreciated. So we're very confident in SYNERGY. We had a very nice Japanese launch, and we think the appreciation of physicians is matched by the growth that you've seen in this quarter's figures."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question is from the line of Matt Miksic with UBS.",12,"The next question is from the line of Matt Miksic with UBS."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","So I wanted to talk a little bit about the EndoChoice acquisition and the types of strategic investments and adds that you're looking at or thinking about. One of the things that struck us about that was this is necessary to kind of -- to fill out that po",124,"So I wanted to talk a little bit about the EndoChoice acquisition and the types of strategic investments and adds that you're looking at or thinking about. One of the things that struck us about that was this is necessary to kind of -- to fill out that portfolio, better serve the ASCs. I think you mentioned in your prepared remarks something like sort of they're broad line, complete provider of solutions in that specialty. And just wanted to understand how you're thinking about acquisitions like that, the importance of sort of breadth, if you will, and where -- if you see opportunities also to kind of go deep on the sort of WATCHMAN-type innovation type acquisitions. And then I have one follow-up."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. So we have a pretty active business development group, and we're very disciplined in the types of deals we look at. Obviously, we need to focus on our strategic fit and also strong return. Dan also mentioned we had a slight impairment with one of ou",292,"Sure. So we have a pretty active business development group, and we're very disciplined in the types of deals we look at. Obviously, we need to focus on our strategic fit and also strong return. Dan also mentioned we had a slight impairment with one of our venture investments, but we have a pretty significant venture investment portfolio that we think will bring strong value to the company, I think, as we look out at '18 and '19, which is very exciting. I think just in terms of this deal, it's very consistent, the Endo deal, with our strategy, which is one is to continue to strengthen and diversify the company in the faster-growth markets. So the MedSurg segment is a significant contributor. Endo business is a leader, but we're a little bit lighter in terms of our portfolio in the ambulatory surgery center. We also hadn't offered a pathology solution for this business. So it gives us the capability for -- in the surgery center market, which is a nice extension and expands us into some adjacencies in pathology and fills in a few products in our core business. So it will be a nice tuck-in acquisition, nice cost synergies and probably on a lower-risk scale in terms of integration. But we've also complemented those deals with some nice strong investments. Obviously, you mentioned the WATCHMAN acquisition. And also, I think our -- hopefully, our M&A track record is pretty solid. We're ahead of our deal model with AMS. We've done a very good job, the PI team, with our Bayer acquisition. So we'll continue to look at acquisitions which support the strategy, diversifying into faster-growth markets and category leadership, and we're very active in scanning the market in those areas."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","And then the follow-up for Dr. Stein. I know Josh asked the question earlier about one of your competitors having a recall. And you certainly have the perspective on this, much more than most of us. But it doesn't seem like this is going to become any kin",102,"And then the follow-up for Dr. Stein. I know Josh asked the question earlier about one of your competitors having a recall. And you certainly have the perspective on this, much more than most of us. But it doesn't seem like this is going to become any kind of market -- sort of clinician concern, patient concern event, as we've seen in the long history of CRM. But if you could maybe help put in perspective what you've seen so far, heard so far or any -- if you have any concerns that this becomes sort of like a segment issue."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. Thanks for the question, Matt. I'm not going to comment about patient management for those patients who are affected by a competitor's advisory. I mean, certainly, we take any individual patient's safety issue, patient concerns very seriously. Overal",59,"Yes. Thanks for the question, Matt. I'm not going to comment about patient management for those patients who are affected by a competitor's advisory. I mean, certainly, we take any individual patient's safety issue, patient concerns very seriously. Overall, we do not believe this is going to have any impact on market growth, either in the U.S. or globally."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Chris Pasquale with Guggenheim.",12,"The next question comes from the line of Chris Pasquale with Guggenheim."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Mike, can you talk a little bit more about the EndoChoice acquisition, the decision, in particular, to explore options for FUSE? That product hasn't lived up to expectations yet, but it would seem like plugging it into a larger sales organization could be",80,"Mike, can you talk a little bit more about the EndoChoice acquisition, the decision, in particular, to explore options for FUSE? That product hasn't lived up to expectations yet, but it would seem like plugging it into a larger sales organization could be the missing piece of the puzzle. And you guys have had some succes historically on the imaging side of the business with Spyglass. So why not keep that and see if you can realize that potential yourselves?"
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. We probably won't provide a lot of color on that. We sort of like the assets of EndoChoice, and we're pursuing options. So we haven't declared fully that we're going to sell that business or retain that business. So more information to come likely at",57,"Yes. We probably won't provide a lot of color on that. We sort of like the assets of EndoChoice, and we're pursuing options. So we haven't declared fully that we're going to sell that business or retain that business. So more information to come likely at our next earning call in terms of the status update there."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. And then you mentioned the ongoing replacement cycle headwind in ICDs, which has been an issue you've dealt with for a long time. What's your latest estimate for when that should turn positive for you?",36,"Okay. And then you mentioned the ongoing replacement cycle headwind in ICDs, which has been an issue you've dealt with for a long time. What's your latest estimate for when that should turn positive for you?"
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","So we anticipate, especially like the second half of 2017, the flattening out and ideally a slight improvement on the CRT-D side, on the replacement cycle; and then in '18, on the ICD side. So some benefit in '17 and more benefit in '18 based on the model",254,"So we anticipate, especially like the second half of 2017, the flattening out and ideally a slight improvement on the CRT-D side, on the replacement cycle; and then in '18, on the ICD side. So some benefit in '17 and more benefit in '18 based on the modeling that we've done. And that also will come on the heels of a full '18 launch of our MRI -- full year benefit of our MRI capabilities. So I just want to maybe close the call -- and Dan talked about kind of mid-single-digit guidance for next year. We'll provide all that detail in the second quarter.
I think what we're most excited about is the future of the company, and we talked quite a bit about the platforms that we'll be entering in markets approaching $8 billion to $9 billion in 2020. And we'll detail this out at the Investor Day. But it's exciting future as we move into a very large market in TAVR, expanded indications in the future with WATCHMAN, our drug-eluting technologies, the real commitment that we have to neurostimulation, expanding the Deep Brain Stimulation potentially to other areas and really in the field of Endoscopy where our team is looking at breakthrough capabilities to take more general surgery approaches to less invasive procedures. So there's a lot of new therapies that the business will be entering that will show at our Investor Day that really give an exciting future to the company beyond our '17 guidance that we'll provide in February."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Great. With that, we'd like to conclude the call. Thanks for joining us today, and we appreciate your interest in Boston Scientific. Before you disconnect, Shannon will give you all the pertinent details for the replay.",36,"Great. With that, we'd like to conclude the call. Thanks for joining us today, and we appreciate your interest in Boston Scientific. Before you disconnect, Shannon will give you all the pertinent details for the replay."
317627,403595084,1061434,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, this conference will be available for playback beginning today at 10:30 A.M. Eastern time running through Wednesday, November 9, at midnight Eastern time. You may access the AT&T playback service by dialing 1 (800) 475-6701 and enter",78,"Ladies and gentlemen, this conference will be available for playback beginning today at 10:30 A.M. Eastern time running through Wednesday, November 9, at midnight Eastern time. You may access the AT&T playback service by dialing 1 (800) 475-6701 and entering the access code of 403036. International participants, please dial 1 (320) 365-3844 with the access code of 403036. 
That does conclude our conference for today. Thank you for your participation and for using AT&T. You may now disconnect."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Boston Scientific Q3 2016 Earnings Call. [Operator Instructions] As a reminder, today's conference is being recorded. I would now like to turn the conference over to Susie Lisa. Please go a",42,"Ladies and gentlemen, thank you for standing by. Welcome to the Boston Scientific Q3 2016 Earnings Call. [Operator Instructions] As a reminder, today's conference is being recorded. 
I would now like to turn the conference over to Susie Lisa. Please go ahead."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Shannon. Good morning, everyone, and thanks for joining us. For those of you having issues with the webcast, we apologize for the technical issues, we're working with NASDAQ, and ask you to consult our Investor Relations section of our website",392,"Thank you, Shannon. Good morning, everyone, and thanks for joining us. For those of you having issues with the webcast, we apologize for the technical issues, we're working with NASDAQ, and ask you to consult our Investor Relations section of our website to see the dial-in number. 
With me on today's call are Mike Mahoney, Chairman and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.
We issued a press release earlier this morning announcing our Q3 2016 results, which included reconciliations of the non-GAAP measures used in the release. We have posted a copy of that release as well as reconciliations of the non-GAAP measures used in today's call to the Investor Relations section of our website under the heading Financial Information.
The duration of this morning's call will be up to 1 hour. Mike will provide strategic and revenue highlights of Q3 '16. Dan will review the financials for the quarter and then Q4 '16 and full year guidance, and then we'll take your questions. During today's Q&A session, Mike and Dan will be joined by our Chief Medical Officers, Dr. Keith Dawkins and Dr. Ken Stein. 
Before we begin, I'd like to remind everyone that on the call, organic revenue growth is defined as excluding the impact of changes in foreign currency exchange rates and sales from the acquisition of the American Medical Systems, AMS, Male Urology portfolio over the prior year period. Also of note, this call contains forward-looking statements within the meaning of federal securities laws, which may be identified by words like anticipate, expect, believe, estimate and other similar words. They include, among other things, statements about our growth and market share; new product approvals and launches; clinical trials; cost savings and growth opportunities; our cash flow and expected use; our financial performance, including sales, margins, earnings and other Q4 2016 guidance as well as our tax rates, R&D spend and other expenses. Actual results may differ materially from those discussed in the forward-looking statements. 
Factors that may cause such differences include those described in the Risk Factors section of our most recent 10-K and subsequent 10-Qs filed with the SEC. These statements speak only as of today's date, and we disclaim any intention or obligation to update them.
At this point, I'll turn it over to Mike for his comments. Mike?"
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Susie. Good morning, everyone. Our third quarter 2016 results are excellent and reinforce the success of our category leadership strategy and the strong execution of our global teams. We continue to grow faster than the market in almost all of",1833,"Thank you, Susie. Good morning, everyone. Our third quarter 2016 results are excellent and reinforce the success of our category leadership strategy and the strong execution of our global teams. We continue to grow faster than the market in almost all of our business units while consistently improving operating income margin. As a result, we continue to deliver strong double-digit adjusted EPS growth. 
Importantly, we are investing in new adjacencies, capabilities and markets that position Boston Scientific for a very exciting future. In third quarter '16, we drove operational growth of 10% and organic revenue growth of 9%, normalized for currency and excluding the impact of 1 month of sales of the AMS acquisition, which anniversary-ed on August 3. Of note, we delivered this 9% organic growth against our toughest comparison of the year, and we leveraged that growth with 120 basis point improvement year-over-year in adjusted operating margin of 24.3%, which beat the high end of our guidance range by 30 basis points. Thus, 9% organic revenue growth in the quarter was leveraged to 12% EPS growth or $0.27 per share, which was at the high end of our guidance range. For the full year '16, we're maintaining our strong guidance and pulling up the low end of our previous ranges, and Dan will provide the details in a few minutes.
I'll now provide some highlights on Q3 results and our Q4 '16 outlook. In my remarks, all references of growth are on a constant-currency organic year-over-year basis, and they exclude the 1-month benefit of AMS unless otherwise specified. 
Organic revenue growth of 9% was broad-based across our businesses and regions, with particular strength from new global product launches, emerging market expansion and share gains led by innovation and our category leadership strategy. On a regional basis EMEA led the pack with 12% growth, followed by the U.S. at 9% and Europe at 5%. Emerging markets sales grew 19%, led by an acceleration in growth in China at 26% and Latin America turning a strong quarter with 21% growth. 
Across our businesses, for the third straight quarter, both our Cardiovascular and MedSurg segments grew sales organically double digits, 12% for cardiovascular and 10% for MedSurg. And Rhythm Management turned in a strong and consistent performance with second (sic) [ third ] quarter sales up 3%. MedSurg continues to deliver excellent growth and strong profitability. MedSurg remains a high-priority segment for the company, with 2 recent tuck-in acquisitions to enhance category leadership in Neuromodulation with Cosman Medical in RF ablation and Endoscopy with the recently announced tender offer for EndoChoice. 
9% global growth in Endoscopy was led by double-digit gains in both our Biliary and hemostasis franchises, with SpyGlass digital DS and the AXIOS stent leading the charge in Biliary, and our newly launched Resolution 360 clip is driving growth in hemostasis. We continue to see upside from new product launches and strong emerging market growth in endo. 
We're also excited about the acquisition of EndoChoice, which we expect to close by year-end. EndoChoice is focused on the development of innovative products and services for gastroenterology health care providers, with a portfolio that's particularly well suited for the ambulatory surgery center. It also brings a portfolio of value-added services to the ASC market, including infection control and pathology services. This acquisition will further enhance the position of Boston Scientific as the global leader in the field of GI endoscopy. As previously announced, we expect to pursue strategic options for EndoChoice's  FUSE colonoscope business. We plan to provide an update at or around the time of closing of this transaction.
Turning to Urology and Pelvic Health. Uro and Pelvic Health grew double digits for the third consecutive quarter, up 13% in Q3. We're a strong category leader in the Urology segment, and we delivered broad-based growth across the combined Boston Scientific and AMS portfolio. International sales remained very strong with EMEA, Latin America and emerging markets all growing at double-digit rates. AMS sales grew 5% in the quarter, which is a nice acceleration from trend prior to acquisition. And importantly, our remediation and integration efforts are both on track.
Our Lithovue single-use ureteroscope continues to launch and is enjoying strong uptake in a variety of accounts. And finally, our growth was assisted by tailwinds from our market share capture post Astora's exit from the pelvic health market. 
Neuromod grew double digits, plus 12%, against a strong comp and robust Precision Spectra sales now with full-body MRI compatibility in our Vercise Deep Brain Stimulation platform in Europe. We continue to expect U.S. market entry for Vercise by late 2017 and believe this is an exciting new market opportunity for us.
Cosman Medical, an acquisition announced in July, broadens our Neuromodulation portfolio with RF ablation systems that enable us to offer patients with chronic pain another treatment option in non-opioid therapeutics. We will provide an update on our ACCELERATE clinical trial on our fourth quarter 2016 call. 
In Cardiovascular, segment sales grew 12% and reported an adjusted operating margin of 32.8%, up 160 basis points year-over-year. Peripheral Interventions revenue grew 11% and was led by strong balanced global growth in developed and emerging markets. This is PI's fourth straight quarter of double-digit above-market growth, fueled by our leadership -- category leadership strategy and the depth of our portfolio rather than any single product. 
We drove strong growth in the atherectomy and thrombectomy businesses, and new product launches are also going very well, including the AngioJet ZelanteDVT catheter; the Innova vascular stent; and our drug-eluting technologies, Eluvia DES and Ranger DCB. Finally, we're also pleased with the contribution and integration progress of the Spherical Embolics platform acquired from CeloNova. 
We continue to invest in the peripheral market, particularly in drug-eluting strategies, venous diseases and interventional oncology. Two important clinical trials were presented in the third quarter at the major European peripheral congresses, CIRSE. Our drug-eluting stent, Eluvia, in the MAJESTIC clinical trial demonstrated an unprecedented 92.5% freedom from total lesion revascularization at 2 years. And enrollment continues in our global IDE trial, IMPERIAL. This 92.5% freedom from TLR is of particular note given the patient population studied. 65% of patients had severely calcified lesions and 46% had chronic total occlusions. 
In addition, we reported results for our Ranger Drug-Coated Balloon from 105-patient randomized clinical trial studying the superficial femoral artery. With 94.4% freedom from total lesion revascularization at 6 months, average lesion length was 68 millimeters. We also posted strong results from our Ranger all-comers registry with 91.9% freedom from TLR at 6 months and an average lesion length of 135 millimeters. 
We plan to bring our Ranger DCB to the U.S., and we'll reveal details of our IDE trial shortly. We're excited to be the only company investing in a complete portfolio of drug-eluting therapies.
Turning to Interventional Cardiology. This business segment grew 13% in Q3, led by strong sales in structural heart, drug-eluting stents and PCI guidance or imaging. SYNERGY continues to penetrate the market as we grew worldwide DES sales 14%, and we remain on track to represent 50% to 60% of our global DES revenue mix by the end of fourth quarter. PCI guidance grew mid-teens as well, with strong IVUS catheter and service sales augmented by the ongoing global launch of our COMET FFR system. 
In structural heart, which includes our Lotus transcatheter aortic valve and WATCHMAN Left Atrial Appendage Closure Device, we're driving growth via our unique innovative platform technologies, and they're resonating with physicians and are supported by the strength of our commercial teams. Both franchises are performing very well, and we continue to expect to deliver structural heart revenue at the high end of our $175 million to $200 million guidance for 2016.
We also recently began the early launch of our Lotus EDGE valve in Europe, and thus, the results from our feasibility study of Lotus EDGE will be presented this Sunday at a lunchtime symposium at TCT. Also at TCT next week, we look forward to a number of Lotus presentations, including 4-year outcomes on REPRISE I, 3-year outcomes for REPRISE II and our Lotus EDGE feasibility study with a 7-day discharge data. We expect to present results of REPRISE III, our U.S. pivotal trial and the first to provide head-to-head data, at EuroPCR in May. 
The WATCHMAN platform also delivered an exciting quarter, with strong growth from opening new centers as well as driving growth in existing centers. We're very encouraged to see a strong initial launch in France, where we received higher reimbursement to peers based on the strength of our data. And we expect to enroll our first patient in ASP-II, which is a study examining the use of WATCHMAN in warfarin-ineligible patients before the end of the year.
Turning now to Rhythm Management. Segment sales grew 3%, with another impressive gain in the adjusted operating margins of 20.1%, which is 320 basis points quarter-over-quarter and a 230 basis points growth year-over-year. Growth in CRM at 3% was above market and led by worldwide patient growth of 22%, with meaningful share capture from our premium-based brady MRI device. High-voltage sales declined 4% globally due to replacement cycle headwinds and competitive pressures in the U.S. and MRI-compatible tachy devices. We continue to be pleased with the growth and momentum of EMBLEM S-ICD, which has been fueled by a recent FDA approval for both MRI and MRI-backwards compatibility and increased physician acceptance of this differentiated therapy. 
In Europe, our CRM business grew above market for the 10th consecutive quarter, and in Japan, our above-market growth was driven by a strong launch of EMBLEM S-ICD, transvenous tachy MRI and 3.0T brady MRI. We also achieved important CRM clinical milestones in the quarter, including the first patients enrolled in the APPRAISE ATP trial to help clinicians understand which ICD patients could benefit from antitachycardia pacing and which may be harmed. 
Also, our MultiSENSE trial is accepted as a late breaker for the upcoming AHA scientific sessions in New Orleans. MultiSENSE is an international multicenter, non-randomized study, which is designed to develop and to evaluate prospectively a multi-sensor-based algorithm for the early detection of worsening heart failure. 
In Electrophysiology, 5% growth was led by strength in international markets. In Europe, we are pleased with the early feedback of our IntellaMap OI catheter, which was launched in the second quarter. We expect to launch this catheter in the U.S. in fourth quarter, which, combined with IntellaNav XP and MiFi XP catheters, will unlock the use of Rhythmia to a higher mix of procedures. We remain bullish that continued penetration of our next-generation mapping and navigation system, Rhythmia HDX and the commercialization of our complete portfolio of nav-enabled therapeutic catheters will strengthen our global EP business and improve growth in 2017. 
So to wrap up, I would like to thank our employees for their incredible winning spirit, terrific execution and commitment to the company. So with that, I'll turn it over to Dan for more details on the P&L and guidance."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Mike. In Q3, we generated organic revenue growth of 9% versus our 7% to 9% guidance range and adjusted earnings per share of $0.27, representing 12% year-over-year growth and hitting the high end of our guidance range of $0.25 to $0.27. The double",1256,"Thanks, Mike. In Q3, we generated organic revenue growth of 9% versus our 7% to 9% guidance range and adjusted earnings per share of $0.27, representing 12% year-over-year growth and hitting the high end of our guidance range of $0.25 to $0.27. The double-digit adjusted EPS growth in Q3 was driven primarily by strong revenue growth and solid gross margin, which was at the high end of our guidance range. 
Consolidated revenue of $2,105,000,000 represented operational revenue growth of 10%, at the high end of guidance and reflects an immaterial impact from foreign exchange, which was in line with guidance.
Excluding an approximate 100 basis point contribution from the AMS Male Urology portfolio acquisition for the month of July, organic revenue growth was 9% in the quarter and 11% on an as-reported basis. As a reminder, we completed the acquisition of the AMS Male Urology portfolio on August 3 last year, so August and September AMS sales were included in our organic sales growth calculation. 
Adjusted gross margin for the third quarter was 72.5%, at the high end of our guidance range and consistent with prior year despite a year-over-year negative 120 basis point impact from foreign exchange. In Q3, as expected, we had lower inventory charges than in Q2, and we're now realizing the full benefit of the lower 2016 standard cost of our products due to ongoing value improvement programs. We continue to expect full year 2016 adjusted gross margin to be approximately 72%, which includes an expected 75 to 100 basis point negative impact from unfavorable foreign exchange. 
Adjusted SG&A expenses were $763 million or 36.2% of sales in Q3, down 70 basis points year-over-year as we realize the benefit of our targeted initiatives focused on reducing SG&A, offset partially by the reinvestment of the medical device excise tax benefit. We continue to believe our full year rate will be approximately 36%, which would be a 140 basis point improvement compared to 2015.
Adjusted research and development expenses were $232 million in the third quarter or 11% of sales, which is down 70 basis points year-over-year. We continue to expect our full year 2016 adjusted R&D rate to be approximately 11% of sales. Royalty expense was 0.9% of sales in Q3, roughly flat year-over-year.
Q3 2016 adjusted operating income grew 17% year-over-year and adjusted operating margin of 24.3% was above our guidance range of 23% to 24% and represented a 120 basis point improvement over Q3 last year, the ninth consecutive quarter in which we have expanded adjusted operating margin by 100 basis points or more over the prior year comparable period.
The Rhythm Management team delivered an adjusted operating margin of 20.1%, up 230 basis points year-over-year. The increase year-over-year is a result of realizing the full benefit of 2016 product costs and leveraging the improved top line performance of the global business. For the first 9 months of 2016, Rhythm Management adjusted operating margin is 17.9%, and we continue to believe that, that segment is on track to deliver an adjusted full year operating margin of 20% in 2017.
With total company adjusted operating margin for the first 9 months of 2016 at 24.3%, this positions us well to achieve our full year adjusted operating margin guidance of 24% to 24.5%, and we remain on track to reach our goal of 25%-plus in 2017 we will provide more guidance on 2017 adjusted operating margin with our Q4 earnings call in February.
Now I'll move on to interest and other expense. Interest expense for the quarter was $58 million, roughly flat to Q3 of 2015. Our average interest expense rate was 3.9% in Q3 this year compared to the same 3.9% in Q3 of last year. Other expenses was $33 million in the quarter and includes approximately $20 million of impairment charges related to certain of our strategic investments. Other expenses for the quarter primarily included foreign exchange losses related to our hedging program. 
Our tax rate for the third quarter was 11.2% on a reported basis and 12.4% on an adjusted basis. We are making progress towards finalizing our conditional stipulation of settled issues with the Internal Revenue Service and expect to make a series of payments related to the settlement, most of which we expect to remit during the second half of 2017 and into the first half of 2018.
Finally, Q3 2016 adjusted earnings per share of $0.27 includes approximately $0.01 of unfavorable FX and represents 12% year-over-year growth or 17% growth excluding the impact of foreign exchange. Earnings per share upside from the strong revenue and margin performance was partially offset by the $0.01 of impairment charges we recorded. On a reported GAAP basis, which includes net charges and amortization expense totaling $140 million after tax, Q3 2016 EPS was $0.17. 
Adjusted free cash flow for the quarter was $440 million compared to $394 million in Q3 last year, and we continue to pursue inventory management initiatives designed to improve the working capital contribution to cash flow. Given the strong adjusted free cash flow generation year-to-date this year, we believe we can achieve our full year adjusted free cash flow guidance of $1.6 billion. In Q3, we used cash primarily to fund previously agreed legal settlements as well as business development activities. As of September 30, 2016, we had cash on hand of $237 million, and near term, our capital allocation priorities continue to be managing contingencies and pursuing tuck-in M&A. 
We ended the third quarter with 1,380,000,000 fully diluted weighted average shares outstanding. Consistent with our prior guidance, we expect our share count to increase by less than 5 million through the end of 2016. As consistent with our commitment at the time of the AMS Men's Health acquisition last year, we plan to keep the buybacks suspended for the balance of 2016. We expect this to result in a fully weighted average share count of approximately 1,380,000,000 shares for full year 2016. 
I'll now walk through the guidance for the fourth quarter and the full year 2016. For the full year, we now expect consolidated revenue to be in a range of $8,335,000,000 to $8,385,000,000, which represents year-over-year growth of 9% on an organic basis, 12% on an operational basis and 11% to 12% on a reported basis. We continue to expect foreign exchange to be a headwind of approximately $70 million for the full year.
Turning to adjusted earnings per share. We now expect full year 2016 adjusted EPS to be in a range of $1.09 to $1.11, representing 17% to 19% adjusted earnings growth, which continues to assume the full year negative impact of FX will be $0.05. On a GAAP basis, we expect earnings per share to be in a range of $0.32 to $0.34. 
Now turning specifically to the fourth quarter. We expect consolidated revenue to be in a range of $2,140,000,000 to $2,190,000,000. This represents year-over-year growth in a range of 7% to 9% operationally. We expect foreign exchange impact on Q4 revenue to be a slight tailwind. For the fourth quarter, adjusted earnings per share is expected to be in a range of $0.27 to $0.29 per share, and GAAP earnings per share is expected to be in a range of $0.15 to $0.17 per share. Please check our Investor Relations website for Q3 2016 financial and operational highlights, which outlines Q3 results as well as Q4 and full year 2016 guidance, including P&L line item guidance.
And with that, I'll turn it back to Susie, who'll moderate the Q&A."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Dan. Shannon, let's open it up to questions for the next 30 minutes or so. [Operator Instructions] Shannon, please go ahead.",22,"Thanks, Dan. Shannon, let's open it up to questions for the next 30 minutes or so. [Operator Instructions] Shannon, please go ahead."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","[Operator Instructions] Our first question comes from the line of David Lewis with Morgan Stanley.",15,"[Operator Instructions] Our first question comes from the line of David Lewis with Morgan Stanley."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","A couple of financial questions this morning. So just first off, Dan, I know it's a bit early, but I think '17 numbers, consensus is sort of in the upper part of mid-single digits and around sort of 13% earnings. I wonder if you could offer sort of any re",91,"A couple of financial questions this morning. So just first off, Dan, I know it's a bit early, but I think '17 numbers, consensus is sort of in the upper part of mid-single digits and around sort of 13% earnings. I wonder if you could offer sort of any refinement just given the strength you've seen here on '16. And if you can't kind of refine this early, any headwinds or tailwinds we should be thinking about on the top and bottom line heading into '17? Then I had a follow-up."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. David, I don't think we're going to provide any specific guidance for '17. We'll do that, as you would expect, on our call in early February. We have been very public about saying that we believe next year is a mid-single-digit year in terms of reven",60,"Yes. David, I don't think we're going to provide any specific guidance for '17. We'll do that, as you would expect, on our call in early February. We have been very public about saying that we believe next year is a mid-single-digit year in terms of revenue growth, but I wouldn't provide really any more than that at this point."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. And maybe just 2 quick ones, one clinical and one margin question. So for Dan, you eclipsed 20% margins here in CRM this quarter. I guess the question now is -- that's happening a lot earlier than many would have expected 2 years ago, so where can C",130,"Okay. And maybe just 2 quick ones, one clinical and one margin question. So for Dan, you eclipsed 20% margins here in CRM this quarter. I guess the question now is -- that's happening a lot earlier than many would have expected 2 years ago, so where can CRM margins go now? And then for fourth quarter margins to deliver the earnings, you need to do better year-on-year with margins in the fourth quarter than you did in the second and third quarters. So where can CRM go and the confidence in the fourth quarter margin? And then maybe for the clinical team, when do you think we're going to get the first read on what the true pacing rates are for Lotus EDGE? And I'll jump back in queue."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, David. I'll take the Rhythm Management operating margin and turn it over to Keith and Mike for the clinical questions. So obviously, very pleased to be at that 20% here in Q3 for Rhythm Management operating margin. It's 320 basis points sequentially",218,"Sure, David. I'll take the Rhythm Management operating margin and turn it over to Keith and Mike for the clinical questions. So obviously, very pleased to be at that 20% here in Q3 for Rhythm Management operating margin. It's 320 basis points sequentially and 230 points year-over-year. As you would expect in any given quarter, you'll see some variation in that. Would actually expect that to go back down in Q4, a little more spending in Q4 on SG&A initiatives and such. The full year should be about 18%, which is what we've said consistently that we'd be this year. And I think that puts us right in line to get to that 20% next year in Rhythm Management, which, as part of us getting to 25%-plus as a company, I think gives us the confidence in both those numbers. So I don't think we're going to talk more specifically about the 20%, where it would go from there. Certainly, it goes north of that. We're not going to stop at 20% in 2017. Just as a company, we're not going to stop at 25%. So there's more room in that Rhythm Management segment to increase well beyond 20% as the company goes to, what we've said publicly, our goal of 27% to 28% operating margin by 2020."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. So just on Lotus EDGE, David, just a couple of high-level comments, and Keith could maybe highlight TCT, which we have an important investor meeting on Monday, quite a bit more detail there. But overall, we're really pleased. We continue to deliver o",199,"Yes. So just on Lotus EDGE, David, just a couple of high-level comments, and Keith could maybe highlight TCT, which we have an important investor meeting on Monday, quite a bit more detail there. But overall, we're really pleased. We continue to deliver our overall structural heart commitment in terms of our guidance. We guided to the high end of $175 million to $200 million range for WATCHMAN and TAVR. Really pleased about the CE Mark for Lotus EDGE that we received in one of the valves. We're very early in that phase. But over the long term, particularly I should point to the end of 2017 and the future, '18 and '19, we believe we're very well positioned with our Lotus platform in terms of our launch in these large global markets and eventually Japan, well positioned to gain share. We believe we have the very unique capabilities in terms of our operator control and physician control of the device, excellent PVL rates and our focus on improving the pacemaker rate. So our aim will be to take significant share in these larger markets, and we're building momentum there. So Keith, do you want to touch on TCT?"
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, sure. David, this Sunday, the 30th, the Lotus lunchtime symposium of TCT will be the first presentation of the first human use, early feasibility data of EDGE, only 21 patients but will certainly give us a guide. And we can discuss those data in more",99,"Yes, sure. David, this Sunday, the 30th, the Lotus lunchtime symposium of TCT will be the first presentation of the first human use, early feasibility data of EDGE, only 21 patients but will certainly give us a guide. And we can discuss those data in more detail at the investor meeting on Monday morning at TCT. Also, at TCT we'll have the 4-year outcomes for REPRISE I and 3-year outcomes for REPRISE II, and you'll get more EDGE data at ACC and -- further EDGE data and, of course, our pivotal trial data, REPRISE III, primary endpoint at EuroPCR."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Bob Hopkins with Bank of America.",14,"The next question comes from the line of Bob Hopkins with Bank of America."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","And I apologize for the background noise. I'm in an airport. So first of all, just on behalf of the med tech investment community, I'd like to thank you for a great third quarter. Certainly, some that have gone before you were starting to make investors n",169,"And I apologize for the background noise. I'm in an airport. So first of all, just on behalf of the med tech investment community, I'd like to thank you for a great third quarter. Certainly, some that have gone before you were starting to make investors nervous. So congrats on a great quarter. I wanted to ask a modeling question to Dan and then a product question for Mike. So first, just on the modeling side. It's a little thing, but it stuck out to us, which was that your other income line was an expense of $33 million and that hit EPS by probably up to $0.02. And I know you mentioned something in the prepared comments, but I would just love to get a little bit of a better sense for what caused that uptick and just where that line item goes from here. Does it go back down to normalized level that we've seen in the past? I just would love some comments on other income."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, Bob. So as you say, in the prepared commentary, we talked about a $20 million impairment in the quarter. We have an investment portfolio now that's over $300 million. So as you'd expect, you may see impairments from time to time. It's not a regular",97,"Sure, Bob. So as you say, in the prepared commentary, we talked about a $20 million impairment in the quarter. We have an investment portfolio now that's over $300 million. So as you'd expect, you may see impairments from time to time. It's not a regular occurrence. So that is the difference basically between the year-over-year comparison of that line, is that impairment. And it was worth about $0.01 overall. So without that, we would have been $0.01 higher. But that should not be a regular occurrence, from time to time but certainly not a regular occurrence."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. So that line item goes back down to normalized levels. And then on the product side, I just wanted to get 2 quick updates. One, is the time line for MRI-safe ICDs in the U.S. still the same as your previous guidance, which I think was the end of '17",110,"Okay. So that line item goes back down to normalized levels. And then on the product side, I just wanted to get 2 quick updates. One, is the time line for MRI-safe ICDs in the U.S. still the same as your previous guidance, which I think was the end of '17? And then on WATCHMAN, I'm trying to gauge the impact of the start of the post-approval study, what kind of impact that might have had on the NCD and the availability of reimbursement. So now that we've got that up and running, does that have a strong incremental impact on the ability of folks to get WATCHMAN properly reimbursed?"
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. Yes, on the MRI-safe, no changes to our time line there. We anticipate like the fourth quarter 2017. And importantly, in that category, we're down in the U.S. and down globally, but our European business continues to do well as our Asian business do",268,"Sure. Yes, on the MRI-safe, no changes to our time line there. We anticipate like the fourth quarter 2017. And importantly, in that category, we're down in the U.S. and down globally, but our European business continues to do well as our Asian business does with a full line of MRI-safe products. And the S-ICD continues to do very well. So despite not having it for what will be a decent part of '17, the pacer business continues to do very well. We're doing very well outside the United States, and S-ICD is continuing to support us and differentiate that platform. So we're very bullish on the future of our CRM business and the portfolio. And despite that, the team continues to drive operating income margin improvements. So really nice job there. With WATCHMAN, I mean, we're continuing to build momentum there. As you mentioned, the reimbursement headwinds really are beginning to neutralize based on the advances that we've made there. We continue to open up new centers, and we're really tracking. And we're not giving you much visibility to that, and in the future, we'll determine how to do that. But we're continuing to focus on our utilization rate and driving more physician awareness, more patient awareness and, in parallel, doing a really nice job on physician training, so oftentimes, training multiple physicians at the same site to increase utilization. And in parallel, we're opening up a new center. So again, on the structural heart side, we're at the high end of our range, $175 million to $200 million, and the WATCHMAN contribution is significant within there."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Mike Weinstein with JPMorgan.",12,"The next question comes from the line of Mike Weinstein with JPMorgan."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","3Q, by and large, looks a lot like 2Q. So I actually have a couple of finance questions for Dan. First question is with the mesh liabilities and IRS tax payments, can you fund that from OUS cash? Or are you are going to have to do any borrowing for that?",51,"3Q, by and large, looks a lot like 2Q. So I actually have a couple of finance questions for Dan. First question is with the mesh liabilities and IRS tax payments, can you fund that from OUS cash? Or are you are going to have to do any borrowing for that?"
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","The plan is not to have to do any borrowing on that. We should have full access to our cash through 2017 and don't anticipate any borrowings necessary.",28,"The plan is not to have to do any borrowing on that. We should have full access to our cash through 2017 and don't anticipate any borrowings necessary."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. Second quick one, Dan. Do you know at this point, based on current rates, what you think FX would mean to the bottom line in 2017? And it's simply we don't have a good visibility on your FX hedges and where they are and how they roll off. Do you hav",59,"Okay. Second quick one, Dan. Do you know at this point, based on current rates, what you think FX would mean to the bottom line in 2017? And it's simply we don't have a good visibility on your FX hedges and where they are and how they roll off. Do you have any insight to that at this point?"
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. I think it probably makes sense to hold that until the February earnings call and give all the guidance package altogether as opposed to kind of doing something one-off here. But have faith we'll give you full information on what we see as of Februar",46,"Yes. I think it probably makes sense to hold that until the February earnings call and give all the guidance package altogether as opposed to kind of doing something one-off here. But have faith we'll give you full information on what we see as of February."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Josh Jennings with Cowen and Company.",14,"The next question comes from the line of Josh Jennings with Cowen and Company."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","I just wanted 2 quick questions on CRM post the MRI-safe pacemaker approval. You clearly had 2 quarters of significant success getting back share. Any incremental color you can provide on how you've been so successful? Anything in the market dynamics? And",76,"I just wanted 2 quick questions on CRM post the MRI-safe pacemaker approval. You clearly had 2 quarters of significant success getting back share. Any incremental color you can provide on how you've been so successful? Anything in the market dynamics? And then any -- also, I was just curious about why we should -- should we be thinking of your pacemaker recovery as a precedent for ICU recovery once you have MRI-safe high-voltage approval?"
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks for the question, Josh. We're pleased -- we signaled at the end of the 2Q call that we thought overall CRM would be in line with 2Q, which we're pretty close to that. And we think fourth quarter will likely be in line with third quarter results. So",149,"Thanks for the question, Josh. We're pleased -- we signaled at the end of the 2Q call that we thought overall CRM would be in line with 2Q, which we're pretty close to that. And we think fourth quarter will likely be in line with third quarter results. So pretty consistent performance across our CRM business. And you highlighted the particular strength in pacemaker, really strong since the launch of our new products. I think it's this combination of an excellent lead and the ability to deliver that lead, excellent battery longevity in our pacer line, very strong commercial team. And it's consistent -- actually, stronger performance in the U.S. that we saw globally upon launching this product. So the commercial team has done very well, and physicians are very comfortable. I don't know, Ken, if you have any additional comments on our MRI pacer from a physician's standpoint?"
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. Thanks, Mike. Josh, I think what's really helping drive the growth is the differentiated features we have in our brady platform on top of MRI, including automated remote daily monitoring of these devices, including the performance of our newly releas",157,"Yes. Thanks, Mike. Josh, I think what's really helping drive the growth is the differentiated features we have in our brady platform on top of MRI, including automated remote daily monitoring of these devices, including the performance of our newly released INGEVITY lead. We got really fantastic feedback from clinicians since commercial release of that lead, validating excellent results we saw on the clinical trial. And I think in terms of what that does portend for tachy, I think we take a lot of pride in looking at how the portfolio is delivering in Europe, where we do have full approval of our tachy MRI products, including backwards compatibility to our previously released products and have MRI approval both for traditional transvenous devices as well as for our S-ICD. And we believe that the same performance that we're seeing in Europe, where we have a full portfolio approved, portends what we're going to see in the U.S."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Great. And just a follow-up. One of your big competitors has had a recall of their high-voltage platform. They've had to design around. But how are you thinking about this as a potential opportunity for Boston going forward in front of MRI-safe approval o",47,"Great. And just a follow-up. One of your big competitors has had a recall of their high-voltage platform. They've had to design around. But how are you thinking about this as a potential opportunity for Boston going forward in front of MRI-safe approval on the high-voltage side?"
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Well, I think what we've done is we very consistently promoted and we promoted with proof the unique benefits of our EnduraLife battery technology as being best in class, and that's really been proven out from 9 independent studies of contemporary device",149,"Well, I think what we've done is we very consistently promoted and we promoted with proof the unique benefits of our EnduraLife battery technology as being best in class, and that's really been proven out from 9 independent studies of contemporary device longevity. So even prior to some of the challenges that St. Jude has seen, we've been very clear to the marketplace that we have very unique battery technology and also excellent remote monitoring. So I think those 2 features stand the test of time and really been the anchor of our strategy for a number of years now. And we believe, over time, typically as health care modifies and more outcome-based, that having that type of capability is enjoyed by -- certainly by patients and also by physicians. So we think those unique strengths, combined with our commercial team, put us in a good position to compete."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Rick Wise with Stifel.",12,"The next question comes from the line of Rick Wise with Stifel."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Just to start with another Lotus question. Mike, with Lotus EDGE approved and, clearly, some clarity on maybe better outcomes achieved with a lower-depth implant, when do you more broadly roll out the technology and this procedural approach to a broader a",87,"Just to start with another Lotus question. Mike, with Lotus EDGE approved and, clearly, some clarity on maybe better outcomes achieved with a lower-depth implant, when do you more broadly roll out the technology and this procedural approach to a broader audience? And maybe just tie that in as well to Dr. Meredith's appointment. As much as I'll miss Dr. Dawkins' dulcet tones and eloquent commentary, why the change now and bringing him in-house? What can you achieve with Dr. Meredith in-house versus out in the world?"
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Well, first, I'd like to thank Keith. He's done a remarkable job at Boston Scientific. He's been here for 9 years. He brings the patient focus first to our executive committee and has really helped, along with Kevin and our broader team, lead the turnarou",227,"Well, first, I'd like to thank Keith. He's done a remarkable job at Boston Scientific. He's been here for 9 years. He brings the patient focus first to our executive committee and has really helped, along with Kevin and our broader team, lead the turnaround and sustained growth of our Interventional Cardiology business and move into structural heart. So Keith has done a terrific job. Transition is very smooth in the end of the year. Dr. Meredith is joining. Ian is very well known in the structural heart community. Structural heart is a big investment and a key focus area for the company. And so there'll be a seamless transition, and Ian will begin early in the year. So you'll see him at various investor conferences and so forth. But Keith did a great job of transitioning. And again, I think, just to repeat some of the comments earlier. We're very bullish on the future of our Lotus platform for the reasons we've articulated with the PVL rates, the controlled release of this device and the enhancements that depth guard and Lotus EDGE promise to deliver. And we're being very appropriate in terms of the rollout of that. And at TCT, we'll provide some additional information on pacemaker rates and some early clinical studies as well as some additional commentary from Tom Fleming, Keith and Kevin Ballinger."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Just to follow up, Mike, on AMS. Obviously, urology had a good quarter on multiple fronts. Can you talk about AMS? Where are you in the -- in achieving the sales synergies that you hoped for? Are you starting to see it? And is that side of the story where",68,"Just to follow up, Mike, on AMS. Obviously, urology had a good quarter on multiple fronts. Can you talk about AMS? Where are you in the -- in achieving the sales synergies that you hoped for? Are you starting to see it? And is that side of the story where you expected it would be? Are you ahead or behind? Just any perspective there would be very welcome."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. I would say, overall, we're likely slightly ahead on the cost synergy side, done a very nice job with that. We're certainly ahead overall in terms of the strategic value of the acquisition given the overall strength of our urology business. And as a",149,"Yes. I would say, overall, we're likely slightly ahead on the cost synergy side, done a very nice job with that. We're certainly ahead overall in terms of the strategic value of the acquisition given the overall strength of our urology business. And as a stand-alone business, the AMS business grew 5% in the quarter, which is slightly ahead of their kind of historical performance. So we think in our hands, the stand-alone business is performing better and will perform better. And more importantly, the complementary nature of the 2 businesses with Stone, BPH, ED is very comprehensive package for our commercial teams to take to customers. And not only is it very broad-based, but it also has unique clinical differentiation. So the combination of the 2 makes our legacy portfolio stronger. And so overall, we're clearly at or ahead of our internal deal models on the overall acquisition."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Vijay Kumar with Evercore ISI.",13,"The next question comes from the line of Vijay Kumar with Evercore ISI."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","So I had 2 quick ones. Maybe I'll start with the -- on the structural heart side. On Lotus, can you maybe talk about comparative dynamics in Europe? Are you still gaining share? And I know that you guys are not yet there in France, so maybe any perspectiv",54,"So I had 2 quick ones. Maybe I'll start with the -- on the structural heart side. On Lotus, can you maybe talk about comparative dynamics in Europe? Are you still gaining share? And I know that you guys are not yet there in France, so maybe any perspective on that would be helpful."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, yes. We're probably not going to give as much detail as you'd like. Again, overall, we're at the high end of our guidance projected for our structural heart. Obviously, Lotus is a key component of that. We're still -- I think it's safe to say we're",209,"Sure, yes. We're probably not going to give as much detail as you'd like. Again, overall, we're at the high end of our guidance projected for our structural heart. Obviously, Lotus is a key component of that. We're still -- I think it's safe to say we're growing faster than the market in Europe. And what's important to note is we don't have all the -- all of our ammunition yet with Lotus. We don't yet have our largest valve and our smallest valve. And so we're doing quite well in the market with 3 valves, and we'll be excited about getting the additional 2 valve sizes for the full matrix. And I think what's really different is of the same drumbeat. It's a different device. It's a next-generation platform that doctors really enjoy the control that they have with it. And so it's -- I wouldn't say it's easy, but it's easier to differentiate this valve than some of the other balloon expandable devices that they have options to use in Europe. So we're very bullish on the future of it. In terms of France, we expect to have reimbursement by year-end '17. So hopefully, we'll see some upside from France reimbursement ideally in the fourth quarter '17."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Great. And then maybe one quick one on MedSurg. Again, I think this has been a phenomenal segment for you guys. And if I look at those really, really strong growth rate you put up, can you help us understand what's the underlying growth rate versus what's",82,"Great. And then maybe one quick one on MedSurg. Again, I think this has been a phenomenal segment for you guys. And if I look at those really, really strong growth rate you put up, can you help us understand what's the underlying growth rate versus what's been the contribution from new products, right? Because it's kind of hard for us to model. And any sort of new product cadence that you have lined up for '17, I think, would be helpful."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. So our MedSurg business, particularly endo and uro doesn't have the, call it, singular blockbuster devices or platforms like SYNERGY or WATCHMAN or Lotus. So Endoscopy is a very broad-based portfolio, as is urology. We have some kind of star platform",199,"Yes. So our MedSurg business, particularly endo and uro doesn't have the, call it, singular blockbuster devices or platforms like SYNERGY or WATCHMAN or Lotus. So Endoscopy is a very broad-based portfolio, as is urology. We have some kind of star platforms in Endoscopy with our AXIOS stent and our SpyGlass digital, but it's really a very broad-based portfolio that we continue to layer on new innovations to broaden out the adjacencies that we compete in, similar to the recent acquisitions that we've done with EndoChoice and CeloNova. So really, not one big product, but, overall, you're seeing us increase the R&D spend in those businesses over the past few years. We've been more active in M&A in the Endoscopy, uro and neuromod area. And importantly, they were under-scaled outside the U.S. And we put a lot of investment outside the U.S. over the past few years, and that continues to pay off, and that's not a onetime payoff, it will continue to pay off, as well as emerging markets. So it's really not a one-product story, and it's very diversified strength in those businesses. Keith, was there something else on Lotus, TCT? Or did we cover that sufficiently?"
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","I think we covered it sufficiently. France reimbursement is important because France is the second-largest European market with a high penetration of TAVR. And so we're looking forward to bringing the products to France. Obviously, there are French invest",52,"I think we covered it sufficiently. France reimbursement is important because France is the second-largest European market with a high penetration of TAVR. And so we're looking forward to bringing the products to France. Obviously, there are French investigators in our trials, and they've been impressed with the acute performance of those."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question is from the line of Larry Biegelsen with Wells Fargo.",13,"The next question is from the line of Larry Biegelsen with Wells Fargo."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","And Keith, good luck in your new endeavors. I'll miss working with you. Two product-related questions. First on Neuromodulation and the ACCELERATE trial, you mentioned that you would give an update on the Q4 call in February. NANS this year is January. So",62,"And Keith, good luck in your new endeavors. I'll miss working with you. Two product-related questions. First on Neuromodulation and the ACCELERATE trial, you mentioned that you would give an update on the Q4 call in February. NANS this year is January. So does that mean we're not going to see the ACCELERATE data at NANS? And I had one other question."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Larry. Yes, our plan is to provide an update on the ACCELERATE trial at our fourth quarter 2016 earnings call, which is shortly after NANS, I believe. So our plan is to provide some additional color at that call, fourth quarter '16.",43,"Thanks, Larry. Yes, our plan is to provide an update on the ACCELERATE trial at our fourth quarter 2016 earnings call, which is shortly after NANS, I believe. So our plan is to provide some additional color at that call, fourth quarter '16."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","So Mike, just to be clear, no data at NANS? Is that what you're saying?",15,"So Mike, just to be clear, no data at NANS? Is that what you're saying?"
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. Our plan is to provide additional insight in the fourth quarter 2016 earnings call.",15,"Yes. Our plan is to provide additional insight in the fourth quarter 2016 earnings call."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay, clear. And then on drug-eluting stent growth, obviously very strong this quarter. I think it accelerated to 14% from 9% last quarter. Was that balanced across geographies? And then, Keith, I think new competition will probably become more prominent",68,"Okay, clear. And then on drug-eluting stent growth, obviously very strong this quarter. I think it accelerated to 14% from 9% last quarter. Was that balanced across geographies? And then, Keith, I think new competition will probably become more prominent at TCT given the BIOTRONIK data coming and the Medinol data coming as late breakers there. So any kind of previews from you on the competitive dynamics there?"
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Larry. I think the difference between some of the competitors and SYNERGY is that we have a very large dataset with SYNERGY, and we now have approximately 20,000 patients in multiple clinical trials in a lot of high-risk subsets of patients. And a",210,"Thanks, Larry. I think the difference between some of the competitors and SYNERGY is that we have a very large dataset with SYNERGY, and we now have approximately 20,000 patients in multiple clinical trials in a lot of high-risk subsets of patients. And as you know from the 2-year data from the pivotal EVOLVE II trial, best-in-class stent thrombosis rates at 2 years. In fact, no definite stent thrombosis, not a single definite stent thrombosis after the first 24 hours. So we do think safety is an important metric, and we don't think we have any competition in that area. I think what will be interesting at TCT is some of the longer-term follow-up of fully resorbable stents, particularly the 3-year data from ABSORB II because if fully resorbable stents get better, the longer they're in, in terms of remodeling and so on, that will be an important finding. Clearly, the 2-year data in that regard were disappointing. So we also like the acute performance of SYNERGY. The ease of use for interventional cardiologists worldwide is well appreciated. So we're very confident in SYNERGY. We had a very nice Japanese launch, and we think the appreciation of physicians is matched by the growth that you've seen in this quarter's figures."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question is from the line of Matt Miksic with UBS.",12,"The next question is from the line of Matt Miksic with UBS."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","So I wanted to talk a little bit about the EndoChoice acquisition and the types of strategic investments and adds that you're looking at or thinking about. One of the things that struck us about that was this desire to kind of -- to fill out that portfoli",123,"So I wanted to talk a little bit about the EndoChoice acquisition and the types of strategic investments and adds that you're looking at or thinking about. One of the things that struck us about that was this desire to kind of -- to fill out that portfolio, better serve the ASCs. I think you mentioned in your prepared remarks something like sort of they're broad line, complete provider of solutions in that specialty. And just wanted to understand how you're thinking about acquisitions like that, the importance of sort of breadth, if you will, and where -- if you see opportunities also to kind of go deep on the sort of WATCHMAN-type innovation type acquisitions. And then I have one follow-up."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. So we have a pretty active business development group, and we're very disciplined in the types of deals we look at. Obviously, we need to focus on our strategic fit and also strong return. Dan also mentioned we had a slight impairment with one of ou",292,"Sure. So we have a pretty active business development group, and we're very disciplined in the types of deals we look at. Obviously, we need to focus on our strategic fit and also strong return. Dan also mentioned we had a slight impairment with one of our venture investments, but we have a pretty significant venture investment portfolio that we think will bring strong value to the company, I think, as we look out at '18 and '19, which is very exciting. I think just in terms of this deal, it's very consistent, the Endo deal, with our strategy, which is one is to continue to strengthen and diversify the company in the faster-growth markets. So the MedSurg segment is a significant contributor. Endo business is a leader, but we're a little bit lighter in terms of our portfolio in the ambulatory surgery center. We also hadn't offered a pathology solution for this business. So it gives us the capability for -- in the surgery center market, which is a nice extension and expands us into some adjacencies in pathology and fills in a few products in our core business. So it will be a nice tuck-in acquisition, nice cost synergies and probably on a lower-risk scale in terms of integration. But we've also complemented those deals with some nice strong investments. Obviously, you mentioned the WATCHMAN acquisition. And also, I think our -- hopefully, our M&A track record is pretty solid. We're ahead of our deal model with AMS. We've done a very good job, the PI team, with our Bayer acquisition. So we'll continue to look at acquisitions which support the strategy, diversifying into faster-growth markets and category leadership, and we're very active in scanning the market in those areas."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","And then the follow-up for Dr. Stein. I know Josh asked the question earlier about one of your competitors having a recall. And you certainly have the perspective on this, much more than most of us. But it doesn't seem like this is going to become any kin",102,"And then the follow-up for Dr. Stein. I know Josh asked the question earlier about one of your competitors having a recall. And you certainly have the perspective on this, much more than most of us. But it doesn't seem like this is going to become any kind of market -- sort of clinician concern, patient concern event, as we've seen in the long history of CRM. But if you could maybe help put in perspective what you've seen so far, heard so far or any -- if you have any concerns that this becomes sort of like a segment issue."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. Thanks for the question, Matt. I'm not going to comment about patient management for those patients who are affected by a competitor's advisory. I mean, certainly, we take any individual patient's safety issue, patient concerns very seriously. Overal",59,"Yes. Thanks for the question, Matt. I'm not going to comment about patient management for those patients who are affected by a competitor's advisory. I mean, certainly, we take any individual patient's safety issue, patient concerns very seriously. Overall, we do not believe this is going to have any impact on market growth, either in the U.S. or globally."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Chris Pasquale with Guggenheim.",12,"The next question comes from the line of Chris Pasquale with Guggenheim."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Mike, can you talk a little bit more about the EndoChoice acquisition, the decision, in particular, to explore options for FUSE? That product hasn't lived up to expectations yet, but it would seem like plugging it into a larger sales organization could be",80,"Mike, can you talk a little bit more about the EndoChoice acquisition, the decision, in particular, to explore options for FUSE? That product hasn't lived up to expectations yet, but it would seem like plugging it into a larger sales organization could be the missing piece of the puzzle. And you guys have had some succes historically on the imaging side of the business with Spyglass. So why not keep that and see if you can realize that potential yourselves?"
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. We probably won't provide a lot of color on that. We sort of like the assets of EndoChoice, and we're pursuing options. So we haven't declared fully that we're going to sell that business or retain that business. So more information to come likely at",57,"Yes. We probably won't provide a lot of color on that. We sort of like the assets of EndoChoice, and we're pursuing options. So we haven't declared fully that we're going to sell that business or retain that business. So more information to come likely at our next earning call in terms of the status update there."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. And then you mentioned the ongoing replacement cycle headwind in ICDs, which has been an issue you've dealt with for a long time. What's your latest estimate for when that should turn positive for you?",36,"Okay. And then you mentioned the ongoing replacement cycle headwind in ICDs, which has been an issue you've dealt with for a long time. What's your latest estimate for when that should turn positive for you?"
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","So we anticipate, especially like the second half of 2017, the flattening out and ideally a slight improvement on the CRT-D side, on the replacement cycle; and then in '18, on the ICD side. So some benefit in '17 and more benefit in '18 based on the model",254,"So we anticipate, especially like the second half of 2017, the flattening out and ideally a slight improvement on the CRT-D side, on the replacement cycle; and then in '18, on the ICD side. So some benefit in '17 and more benefit in '18 based on the modeling that we've done. And that also will come on the heels of a full '18 launch of our MRI -- full year benefit of our MRI capabilities. So I just want to maybe close the call -- and Dan talked about kind of mid-single-digit guidance for next year. We'll provide all that detail in the second quarter.
I think what we're most excited about is the future of the company, and we talked quite a bit about the platforms that we'll be entering in markets approaching $8 billion to $9 billion in 2020. And we'll detail this out at the Investor Day. But it's exciting future as we move into a very large market in TAVR, expanded indications in the future with WATCHMAN, our drug-eluting technologies, the real commitment that we have to neurostimulation, expanding the Deep Brain Stimulation potentially to other areas and really in the field of Endoscopy where our team is looking at breakthrough capabilities to take more general surgery approaches to less invasive procedures. So there's a lot of new therapies that the business will be entering that will show at our Investor Day that really give an exciting future to the company beyond our '17 guidance that we'll provide in February."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Great. With that, we'd like to conclude the call. Thanks for joining us today, and we appreciate your interest in Boston Scientific. Before you disconnect, Shannon will give you all the pertinent details for the replay.",36,"Great. With that, we'd like to conclude the call. Thanks for joining us today, and we appreciate your interest in Boston Scientific. Before you disconnect, Shannon will give you all the pertinent details for the replay."
317627,403595084,1061719,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, this conference will be available for playback beginning today at 10:30 A.M. Eastern time running through Wednesday, November 9, at midnight Eastern time. You may access the AT&T playback service by dialing 1 (800) 475-6701 and enter",78,"Ladies and gentlemen, this conference will be available for playback beginning today at 10:30 A.M. Eastern time running through Wednesday, November 9, at midnight Eastern time. You may access the AT&T playback service by dialing 1 (800) 475-6701 and entering the access code of 403036. International participants, please dial 1 (320) 365-3844 with the access code of 403036. 
That does conclude our conference for today. Thank you for your participation and for using AT&T. You may now disconnect."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Boston Scientific Q3 2016 Earnings Call. [Operator Instructions] As a reminder, today's conference is being recorded. I would now like to turn the conference over to Susie Lisa. Please go a",42,"Ladies and gentlemen, thank you for standing by. Welcome to the Boston Scientific Q3 2016 Earnings Call. [Operator Instructions] As a reminder, today's conference is being recorded. 
I would now like to turn the conference over to Susie Lisa. Please go ahead."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Shannon. Good morning, everyone, and thanks for joining us. For those of you having issues with the webcast, we apologize for the technical issues, we're working with NASDAQ, and ask you to consult our Investor Relations section of our website",392,"Thank you, Shannon. Good morning, everyone, and thanks for joining us. For those of you having issues with the webcast, we apologize for the technical issues, we're working with NASDAQ, and ask you to consult our Investor Relations section of our website to see the dial-in number. With me on today's call are Mike Mahoney, Chairman and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.
We issued a press release earlier this morning announcing our Q3 2016 results, which included reconciliations of the non-GAAP measures used in the release. We have posted a copy of that release as well as reconciliations of the non-GAAP measures used in today's call to the Investor Relations section of our website under the heading Financial Information.
The duration of this morning's call will be up to 1 hour. Mike will provide strategic and revenue highlights of Q3 '16. Dan will review the financials for the quarter and then Q4 '16 and full year guidance, and then we'll take your questions. During today's Q&A session, Mike and Dan will be joined by our Chief Medical Officers, Dr. Keith Dawkins and Dr. Ken Stein. 
Before we begin, I'd like to remind everyone that on the call, organic revenue growth is defined as excluding the impact of changes in foreign currency exchange rates and sales from the acquisition of the American Medical Systems, AMS, Male Urology portfolio over the prior year period. Also of note, this call contains forward-looking statements within the meaning of federal securities laws, which may be identified by words like anticipate, expect, believe, estimate and other similar words. They include, among other things, statements about our growth and market share; new product approvals and launches; clinical trials; cost savings and growth opportunities; our cash flow and expected use; our financial performance, including sales, margins, earnings and other Q4 2016 guidance as well as our tax rates, R&D spend and other expenses. Actual results may differ materially from those discussed in the forward-looking statements. 
Factors that may cause such differences include those described in the Risk Factors section of our most recent 10-K and subsequent 10-Qs filed with the SEC. These statements speak only as of today's date, and we disclaim any intention or obligation to update them.
At this point, I'll turn it over to Mike for his comments. Mike?"
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thank you, Susie. Good morning, everyone. Our third quarter 2016 results are excellent and reinforce the success of our category leadership strategy and the strong execution of our global teams. We continue to grow faster than the market in almost all of",1833,"Thank you, Susie. Good morning, everyone. Our third quarter 2016 results are excellent and reinforce the success of our category leadership strategy and the strong execution of our global teams. We continue to grow faster than the market in almost all of our business units while consistently improving operating income margin. As a result, we continue to deliver strong double-digit adjusted EPS growth. 
Importantly, we are investing in new adjacencies, capabilities and markets that position Boston Scientific for a very exciting future. In third quarter '16, we drove operational growth of 10% and organic revenue growth of 9%, normalized for currency and excluding the impact of 1 month of sales of the AMS acquisition, which anniversary-ed on August 3. Of note, we delivered this 9% organic growth against our toughest comparison of the year, and we leveraged that growth with 120 basis point improvement year-over-year in adjusted operating margin of 24.3%, which beat the high end of our guidance range by 30 basis points. Thus, 9% organic revenue growth in the quarter was leveraged to 12% EPS growth or $0.27 per share, which was at the high end of our guidance range. For the full year '16, we're maintaining our strong guidance and pulling up the low end of our previous ranges, and Dan will provide the details in a few minutes.
I'll now provide some highlights on Q3 results and our Q4 '16 outlook. In my remarks, all references of growth are on a constant-currency organic year-over-year basis, and they exclude the 1-month benefit of AMS unless otherwise specified. 
Organic revenue growth of 9% was broad-based across our businesses and regions, with particular strength from new global product launches, emerging market expansion and share gains led by innovation and our category leadership strategy. On a regional basis EMEA led the pack with 12% growth, followed by the U.S. at 9% and Europe at 5%. Emerging markets sales grew 19%, led by an acceleration in growth in China at 26% and Latin America turning a strong quarter with 21% growth. 
Across our businesses, for the third straight quarter, both our Cardiovascular and MedSurg segments grew sales organically double digits, 12% for cardiovascular and 10% for MedSurg. And Rhythm Management turned in a strong and consistent performance with second (sic) [ third ] quarter sales up 3%. MedSurg continues to deliver excellent growth and strong profitability. MedSurg remains a high-priority segment for the company, with 2 recent tuck-in acquisitions to enhance category leadership in Neuromodulation with Cosman Medical in RF ablation and Endoscopy with the recently announced tender offer for EndoChoice. 
9% global growth in Endoscopy was led by double-digit gains in both our Biliary and hemostasis franchises, with SpyGlass digital DS and the AXIOS stent leading the charge in Biliary, and our newly launched Resolution 360 clip is driving growth in hemostasis. We continue to see upside from new product launches and strong emerging market growth in endo. 
We're also excited about the acquisition of EndoChoice, which we expect to close by year-end. EndoChoice is focused on the development of innovative products and services for gastroenterology health care providers, with a portfolio that's particularly well suited for the ambulatory surgery center. It also brings a portfolio of value-added services to the ASC market, including infection control and pathology services. This acquisition will further enhance the position of Boston Scientific as the global leader in the field of GI endoscopy. As previously announced, we expect to pursue strategic options for EndoChoice's FUSE colonoscope business. We plan to provide an update at or around the time of closing of this transaction.
Turning to Urology and Pelvic Health. Uro and Pelvic Health grew double digits for the third consecutive quarter, up 13% in Q3. We're a strong category leader in the Urology segment, and we delivered broad-based growth across the combined Boston Scientific and AMS portfolio. International sales remained very strong with EMEA, Latin America and emerging markets all growing at double-digit rates. AMS sales grew 5% in the quarter, which is a nice acceleration from trend prior to acquisition. And importantly, our remediation and integration efforts are both on track.
Our Lithovue single-use ureteroscope continues to launch and is enjoying strong uptake in a variety of accounts. And finally, our growth was assisted by tailwinds from our market share capture post Astora's exit from the pelvic health market. 
Neuromod grew double digits, plus 12%, against a strong comp and robust Precision Spectra sales now with full-body MRI compatibility in our Vercise Deep Brain Stimulation platform in Europe. We continue to expect U.S. market entry for Vercise by late 2017 and believe this is an exciting new market opportunity for us.
Cosman Medical, an acquisition announced in July, broadens our Neuromodulation portfolio with RF ablation systems that enable us to offer patients with chronic pain another treatment option in non-opioid therapeutics. We will provide an update on our ACCELERATE clinical trial on our fourth quarter 2016 call. 
In Cardiovascular, segment sales grew 12% and reported an adjusted operating margin of 32.8%, up 160 basis points year-over-year. Peripheral Interventions revenue grew 11% and was led by strong balanced global growth in developed and emerging markets. This is PI's fourth straight quarter of double-digit above-market growth, fueled by our leadership -- category leadership strategy and the depth of our portfolio rather than any single product. 
We drove strong growth in the atherectomy and thrombectomy businesses, and new product launches are also going very well, including the AngioJet ZelanteDVT catheter; the Innova vascular stent; and our drug-eluting technologies, Eluvia DES and Ranger DCB. Finally, we're also pleased with the contribution and integration progress of the Spherical Embolics platform acquired from CeloNova. 
We continue to invest in the peripheral market, particularly in drug-eluting strategies, venous diseases and interventional oncology. Two important clinical trials were presented in the third quarter at the major European peripheral congresses, CIRSE. Our drug-eluting stent, Eluvia, in the MAJESTIC clinical trial demonstrated an unprecedented 92.5% freedom from total lesion revascularization at 2 years. And enrollment continues in our global IDE trial, IMPERIAL. This 92.5% freedom from TLR is of particular note given the patient population studied. 65% of patients had severely calcified lesions and 46% had chronic total occlusions. 
In addition, we reported results for our Ranger Drug-Coated Balloon from 105-patient randomized clinical trial studying the superficial femoral artery. With 94.4% freedom from total lesion revascularization at 6 months, average lesion length was 68 millimeters. We also posted strong results from our Ranger all-comers registry with 91.9% freedom from TLR at 6 months and an average lesion length of 135 millimeters. 
We plan to bring our Ranger DCB to the U.S., and we'll reveal details of our IDE trial shortly. We're excited to be the only company investing in a complete portfolio of drug-eluting therapies.
Turning to Interventional Cardiology. This business segment grew 13% in Q3, led by strong sales in structural heart, drug-eluting stents and PCI guidance or imaging. SYNERGY continues to penetrate the market as we grew worldwide DES sales 14%, and we remain on track to represent 50% to 60% of our global DES revenue mix by the end of fourth quarter. PCI guidance grew mid-teens as well, with strong IVUS catheter and service sales augmented by the ongoing global launch of our COMET FFR system. 
In structural heart, which includes our Lotus transcatheter aortic valve and WATCHMAN Left Atrial Appendage Closure Device, we're driving growth via our unique innovative platform technologies, and they're resonating with physicians and are supported by the strength of our commercial teams. Both franchises are performing very well, and we continue to expect to deliver structural heart revenue at the high end of our $175 million to $200 million guidance for 2016.
We also recently began the early launch of our Lotus EDGE valve in Europe, and thus, the results from our feasibility study of Lotus EDGE will be presented this Sunday at a lunchtime symposium at TCT. Also at TCT next week, we look forward to a number of Lotus presentations, including 4-year outcomes on REPRISE I, 3-year outcomes for REPRISE II and our Lotus EDGE feasibility study with a 7-day discharge data. We expect to present results of REPRISE III, our U.S. pivotal trial and the first to provide head-to-head data, at EuroPCR in May. 
The WATCHMAN platform also delivered an exciting quarter, with strong growth from opening new centers as well as driving growth in existing centers. We're very encouraged to see a strong initial launch in France, where we received higher reimbursement to peers based on the strength of our data. And we expect to enroll our first patient in ASP-II, which is a study examining the use of WATCHMAN in warfarin-ineligible patients before the end of the year.
Turning now to Rhythm Management. Segment sales grew 3%, with another impressive gain in the adjusted operating margins of 20.1%, which is 320 basis points quarter-over-quarter and a 230 basis points growth year-over-year. Growth in CRM at 3% was above market and led by worldwide patient growth of 22%, with meaningful share capture from our premium-based brady MRI device. High-voltage sales declined 4% globally due to replacement cycle headwinds and competitive pressures in the U.S. and MRI-compatible tachy devices. We continue to be pleased with the growth and momentum of EMBLEM S-ICD, which has been fueled by a recent FDA approval for both MRI and MRI-backwards compatibility and increased physician acceptance of this differentiated therapy. 
In Europe, our CRM business grew above market for the 10th consecutive quarter, and in Japan, our above-market growth was driven by a strong launch of EMBLEM S-ICD, transvenous tachy MRI and 3.0T brady MRI. We also achieved important CRM clinical milestones in the quarter, including the first patients enrolled in the APPRAISE ATP trial to help clinicians understand which ICD patients could benefit from antitachycardia pacing and which may be harmed. 
Also, our MultiSENSE trial is accepted as a late breaker for the upcoming AHA scientific sessions in New Orleans. MultiSENSE is an international multicenter, non-randomized study, which is designed to develop and to evaluate prospectively a multi-sensor-based algorithm for the early detection of worsening heart failure. 
In Electrophysiology, 5% growth was led by strength in international markets. In Europe, we are pleased with the early feedback of our IntellaMap OI catheter, which was launched in the second quarter. We expect to launch this catheter in the U.S. in fourth quarter, which, combined with IntellaNav XP and MiFi XP catheters, will unlock the use of Rhythmia to a higher mix of procedures. We remain bullish that continued penetration of our next-generation mapping and navigation system, Rhythmia HDX and the commercialization of our complete portfolio of nav-enabled therapeutic catheters will strengthen our global EP business and improve growth in 2017. 
So to wrap up, I would like to thank our employees for their incredible winning spirit, terrific execution and commitment to the company. So with that, I'll turn it over to Dan for more details on the P&L and guidance."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Mike. In Q3, we generated organic revenue growth of 9% versus our 7% to 9% guidance range and adjusted earnings per share of $0.27, representing 12% year-over-year growth and hitting the high end of our guidance range of $0.25 to $0.27. The double",1256,"Thanks, Mike. In Q3, we generated organic revenue growth of 9% versus our 7% to 9% guidance range and adjusted earnings per share of $0.27, representing 12% year-over-year growth and hitting the high end of our guidance range of $0.25 to $0.27. The double-digit adjusted EPS growth in Q3 was driven primarily by strong revenue growth and solid gross margin, which was at the high end of our guidance range. 
Consolidated revenue of $2,105,000,000 represented operational revenue growth of 10%, at the high end of guidance and reflects an immaterial impact from foreign exchange, which was in line with guidance.
Excluding an approximate 100 basis point contribution from the AMS Male Urology portfolio acquisition for the month of July, organic revenue growth was 9% in the quarter and 11% on an as-reported basis. As a reminder, we completed the acquisition of the AMS Male Urology portfolio on August 3 last year, so August and September AMS sales were included in our organic sales growth calculation. 
Adjusted gross margin for the third quarter was 72.5%, at the high end of our guidance range and consistent with prior year despite a year-over-year negative 120 basis point impact from foreign exchange. In Q3, as expected, we had lower inventory charges than in Q2, and we're now realizing the full benefit of the lower 2016 standard cost of our products due to ongoing value improvement programs. We continue to expect full year 2016 adjusted gross margin to be approximately 72%, which includes an expected 75 to 100 basis point negative impact from unfavorable foreign exchange. 
Adjusted SG&A expenses were $763 million or 36.2% of sales in Q3, down 70 basis points year-over-year as we realize the benefit of our targeted initiatives focused on reducing SG&A, offset partially by the reinvestment of the medical device excise tax benefit. We continue to believe our full year rate will be approximately 36%, which would be a 140 basis point improvement compared to 2015.
Adjusted research and development expenses were $232 million in the third quarter or 11% of sales, which is down 70 basis points year-over-year. We continue to expect our full year 2016 adjusted R&D rate to be approximately 11% of sales. Royalty expense was 0.9% of sales in Q3, roughly flat year-over-year.
Q3 2016 adjusted operating income grew 17% year-over-year and adjusted operating margin of 24.3% was above our guidance range of 23% to 24% and represented a 120 basis point improvement over Q3 last year, the ninth consecutive quarter in which we have expanded adjusted operating margin by 100 basis points or more over the prior year comparable period.
The Rhythm Management team delivered an adjusted operating margin of 20.1%, up 230 basis points year-over-year. The increase year-over-year is a result of realizing the full benefit of 2016 product costs and leveraging the improved top line performance of the global business. For the first 9 months of 2016, Rhythm Management adjusted operating margin is 17.9%, and we continue to believe that, that segment is on track to deliver an adjusted full year operating margin of 20% in 2017.
With total company adjusted operating margin for the first 9 months of 2016 at 24.3%, this positions us well to achieve our full year adjusted operating margin guidance of 24% to 24.5%, and we remain on track to reach our goal of 25%-plus in 2017 we will provide more guidance on 2017 adjusted operating margin with our Q4 earnings call in February.
Now I'll move on to interest and other expense. Interest expense for the quarter was $58 million, roughly flat to Q3 of 2015. Our average interest expense rate was 3.9% in Q3 this year compared to the same 3.9% in Q3 of last year. Other expenses was $33 million in the quarter and includes approximately $20 million of impairment charges related to certain of our strategic investments. Other expenses for the quarter primarily included foreign exchange losses related to our hedging program. 
Our tax rate for the third quarter was 11.2% on a reported basis and 12.4% on an adjusted basis. We are making progress towards finalizing our conditional stipulation of settled issues with the Internal Revenue Service and expect to make a series of payments related to the settlement, most of which we expect to remit during the second half of 2017 and into the first half of 2018.
Finally, Q3 2016 adjusted earnings per share of $0.27 includes approximately $0.01 of unfavorable FX and represents 12% year-over-year growth or 17% growth excluding the impact of foreign exchange. Earnings per share upside from the strong revenue and margin performance was partially offset by the $0.01 of impairment charges we recorded. On a reported GAAP basis, which includes net charges and amortization expense totaling $140 million after tax, Q3 2016 EPS was $0.17. 
Adjusted free cash flow for the quarter was $440 million compared to $394 million in Q3 last year, and we continue to pursue inventory management initiatives designed to improve the working capital contribution to cash flow. Given the strong adjusted free cash flow generation year-to-date this year, we believe we can achieve our full year adjusted free cash flow guidance of $1.6 billion. In Q3, we used cash primarily to fund previously agreed legal settlements as well as business development activities. As of September 30, 2016, we had cash on hand of $237 million, and near term, our capital allocation priorities continue to be managing contingencies and pursuing tuck-in M&A. 
We ended the third quarter with 1,380,000,000 fully diluted weighted average shares outstanding. Consistent with our prior guidance, we expect our share count to increase by less than 5 million through the end of 2016. As consistent with our commitment at the time of the AMS Men's Health acquisition last year, we plan to keep the buybacks suspended for the balance of 2016. We expect this to result in a fully weighted average share count of approximately 1,380,000,000 shares for full year 2016. 
I'll now walk through the guidance for the fourth quarter and the full year 2016. For the full year, we now expect consolidated revenue to be in a range of $8,335,000,000 to $8,385,000,000, which represents year-over-year growth of 9% on an organic basis, 12% on an operational basis and 11% to 12% on a reported basis. We continue to expect foreign exchange to be a headwind of approximately $70 million for the full year.
Turning to adjusted earnings per share. We now expect full year 2016 adjusted EPS to be in a range of $1.09 to $1.11, representing 17% to 19% adjusted earnings growth, which continues to assume the full year negative impact of FX will be $0.05. On a GAAP basis, we expect earnings per share to be in a range of $0.32 to $0.34. 
Now turning specifically to the fourth quarter. We expect consolidated revenue to be in a range of $2,140,000,000 to $2,190,000,000. This represents year-over-year growth in a range of 7% to 9% operationally. We expect foreign exchange impact on Q4 revenue to be a slight tailwind. For the fourth quarter, adjusted earnings per share is expected to be in a range of $0.27 to $0.29 per share, and GAAP earnings per share is expected to be in a range of $0.15 to $0.17 per share. Please check our Investor Relations website for Q3 2016 financial and operational highlights, which outlines Q3 results as well as Q4 and full year 2016 guidance, including P&L line item guidance.
And with that, I'll turn it back to Susie, who'll moderate the Q&A."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Dan. Shannon, let's open it up to questions for the next 30 minutes or so. [Operator Instructions] Shannon, please go ahead.",22,"Thanks, Dan. Shannon, let's open it up to questions for the next 30 minutes or so. [Operator Instructions] Shannon, please go ahead."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","[Operator Instructions] Our first question comes from the line of David Lewis with Morgan Stanley.",15,"[Operator Instructions] Our first question comes from the line of David Lewis with Morgan Stanley."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","A couple of financial questions this morning. So just first off, Dan, I know it's a bit early, but I think '17 numbers, consensus is sort of in the upper part of mid-single digits and around sort of 13% earnings. I wonder if you could offer sort of any re",91,"A couple of financial questions this morning. So just first off, Dan, I know it's a bit early, but I think '17 numbers, consensus is sort of in the upper part of mid-single digits and around sort of 13% earnings. I wonder if you could offer sort of any refinement just given the strength you've seen here on '16. And if you can't kind of refine this early, any headwinds or tailwinds we should be thinking about on the top and bottom line heading into '17? Then I had a follow-up."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. David, I don't think we're going to provide any specific guidance for '17. We'll do that, as you would expect, on our call in early February. We have been very public about saying that we believe next year is a mid-single-digit year in terms of reven",60,"Yes. David, I don't think we're going to provide any specific guidance for '17. We'll do that, as you would expect, on our call in early February. We have been very public about saying that we believe next year is a mid-single-digit year in terms of revenue growth, but I wouldn't provide really any more than that at this point."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. And maybe just 2 quick ones, one clinical and one margin question. So for Dan, you eclipsed 20% margins here in CRM this quarter. I guess the question now is -- that's happening a lot earlier than many would have expected 2 years ago, so where can C",130,"Okay. And maybe just 2 quick ones, one clinical and one margin question. So for Dan, you eclipsed 20% margins here in CRM this quarter. I guess the question now is -- that's happening a lot earlier than many would have expected 2 years ago, so where can CRM margins go now? And then for fourth quarter margins to deliver the earnings, you need to do better year-on-year with margins in the fourth quarter than you did in the second and third quarters. So where can CRM go and the confidence in the fourth quarter margin? And then maybe for the clinical team, when do you think we're going to get the first read on what the true pacing rates are for Lotus EDGE? And I'll jump back in queue."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, David. I'll take the Rhythm Management operating margin and turn it over to Keith and Mike for the clinical questions. So obviously, very pleased to be at that 20% here in Q3 for Rhythm Management operating margin. It's 320 basis points sequentially",218,"Sure, David. I'll take the Rhythm Management operating margin and turn it over to Keith and Mike for the clinical questions. So obviously, very pleased to be at that 20% here in Q3 for Rhythm Management operating margin. It's 320 basis points sequentially and 230 points year-over-year. As you would expect in any given quarter, you'll see some variation in that. Would actually expect that to go back down in Q4, a little more spending in Q4 on SG&A initiatives and such. The full year should be about 18%, which is what we've said consistently that we'd be this year. And I think that puts us right in line to get to that 20% next year in Rhythm Management, which, as part of us getting to 25%-plus as a company, I think gives us the confidence in both those numbers. So I don't think we're going to talk more specifically about the 20%, where it would go from there. Certainly, it goes north of that. We're not going to stop at 20% in 2017. Just as a company, we're not going to stop at 25%. So there's more room in that Rhythm Management segment to increase well beyond 20% as the company goes to, what we've said publicly, our goal of 27% to 28% operating margin by 2020."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. So just on Lotus EDGE, David, just a couple of high-level comments, and Keith could maybe highlight TCT, which we have an important investor meeting on Monday, quite a bit more detail there. But overall, we're really pleased. We continue to deliver o",199,"Yes. So just on Lotus EDGE, David, just a couple of high-level comments, and Keith could maybe highlight TCT, which we have an important investor meeting on Monday, quite a bit more detail there. But overall, we're really pleased. We continue to deliver our overall structural heart commitment in terms of our guidance. We guided to the high end of $175 million to $200 million range for WATCHMAN and TAVR. Really pleased about the CE Mark for Lotus EDGE that we received in one of the valves. We're very early in that phase. But over the long term, particularly I should point to the end of 2017 and the future, '18 and '19, we believe we're very well positioned with our Lotus platform in terms of our launch in these large global markets and eventually Japan, well positioned to gain share. We believe we have the very unique capabilities in terms of our operator control and physician control of the device, excellent PVL rates and our focus on improving the pacemaker rate. So our aim will be to take significant share in these larger markets, and we're building momentum there. So Keith, do you want to touch on TCT?"
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes, sure. David, this Sunday, the 30th, the Lotus lunchtime symposium of TCT will be the first presentation of the first human use, early feasibility data of EDGE, only 21 patients but will certainly give us a guide. And we can discuss those data in more",99,"Yes, sure. David, this Sunday, the 30th, the Lotus lunchtime symposium of TCT will be the first presentation of the first human use, early feasibility data of EDGE, only 21 patients but will certainly give us a guide. And we can discuss those data in more detail at the investor meeting on Monday morning at TCT. Also, at TCT we'll have the 4-year outcomes for REPRISE I and 3-year outcomes for REPRISE II, and you'll get more EDGE data at ACC and -- further EDGE data and, of course, our pivotal trial data, REPRISE III, primary endpoint at EuroPCR."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Bob Hopkins with Bank of America.",14,"The next question comes from the line of Bob Hopkins with Bank of America."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","And I apologize for the background noise. I'm in an airport. So first of all, just on behalf of the med tech investment community, I'd like to thank you for a great third quarter. Certainly, some that have gone before you were starting to make investors n",169,"And I apologize for the background noise. I'm in an airport. So first of all, just on behalf of the med tech investment community, I'd like to thank you for a great third quarter. Certainly, some that have gone before you were starting to make investors nervous. So congrats on a great quarter. I wanted to ask a modeling question to Dan and then a product question for Mike. So first, just on the modeling side. It's a little thing, but it stuck out to us, which was that your other income line was an expense of $33 million and that hit EPS by probably up to $0.02. And I know you mentioned something in the prepared comments, but I would just love to get a little bit of a better sense for what caused that uptick and just where that line item goes from here. Does it go back down to normalized level that we've seen in the past? I just would love some comments on other income."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, Bob. So as you say, in the prepared commentary, we talked about a $20 million impairment in the quarter. We have an investment portfolio now that's over $300 million. So as you'd expect, you may see impairments from time to time. It's not a regular",97,"Sure, Bob. So as you say, in the prepared commentary, we talked about a $20 million impairment in the quarter. We have an investment portfolio now that's over $300 million. So as you'd expect, you may see impairments from time to time. It's not a regular occurrence. So that is the difference basically between the year-over-year comparison of that line, is that impairment. And it was worth about $0.01 overall. So without that, we would have been $0.01 higher. But that should not be a regular occurrence, from time to time but certainly not a regular occurrence."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. So that line item goes back down to normalized levels. And then on the product side, I just wanted to get 2 quick updates. One, is the time line for MRI-safe ICDs in the U.S. still the same as your previous guidance, which I think was the end of '17",110,"Okay. So that line item goes back down to normalized levels. And then on the product side, I just wanted to get 2 quick updates. One, is the time line for MRI-safe ICDs in the U.S. still the same as your previous guidance, which I think was the end of '17? And then on WATCHMAN, I'm trying to gauge the impact of the start of the post-approval study, what kind of impact that might have had on the NCD and the availability of reimbursement. So now that we've got that up and running, does that have a strong incremental impact on the ability of folks to get WATCHMAN properly reimbursed?"
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. Yes, on the MRI-safe, no changes to our time line there. We anticipate like the fourth quarter 2017. And importantly, in that category, we're down in the U.S. and down globally, but our European business continues to do well as our Asian business do",268,"Sure. Yes, on the MRI-safe, no changes to our time line there. We anticipate like the fourth quarter 2017. And importantly, in that category, we're down in the U.S. and down globally, but our European business continues to do well as our Asian business does with a full line of MRI-safe products. And the S-ICD continues to do very well. So despite not having it for what will be a decent part of '17, the pacer business continues to do very well. We're doing very well outside the United States, and S-ICD is continuing to support us and differentiate that platform. So we're very bullish on the future of our CRM business and the portfolio. And despite that, the team continues to drive operating income margin improvements. So really nice job there. With WATCHMAN, I mean, we're continuing to build momentum there. As you mentioned, the reimbursement headwinds really are beginning to neutralize based on the advances that we've made there. We continue to open up new centers, and we're really tracking. And we're not giving you much visibility to that, and in the future, we'll determine how to do that. But we're continuing to focus on our utilization rate and driving more physician awareness, more patient awareness and, in parallel, doing a really nice job on physician training, so oftentimes, training multiple physicians at the same site to increase utilization. And in parallel, we're opening up a new center. So again, on the structural heart side, we're at the high end of our range, $175 million to $200 million, and the WATCHMAN contribution is significant within there."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Mike Weinstein with JPMorgan.",12,"The next question comes from the line of Mike Weinstein with JPMorgan."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","3Q, by and large, looks a lot like 2Q. So I actually have a couple of finance questions for Dan. First question is with the mesh liabilities and IRS tax payments, can you fund that from OUS cash? Or are you are going to have to do any borrowing for that?",51,"3Q, by and large, looks a lot like 2Q. So I actually have a couple of finance questions for Dan. First question is with the mesh liabilities and IRS tax payments, can you fund that from OUS cash? Or are you are going to have to do any borrowing for that?"
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","The plan is not to have to do any borrowing on that. We should have full access to our cash through 2017 and don't anticipate any borrowings necessary.",28,"The plan is not to have to do any borrowing on that. We should have full access to our cash through 2017 and don't anticipate any borrowings necessary."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. Second quick one, Dan. Do you know at this point, based on current rates, what you think FX would mean to the bottom line in 2017? And it's simply we don't have a good visibility on your FX hedges and where they are and how they roll off. Do you hav",59,"Okay. Second quick one, Dan. Do you know at this point, based on current rates, what you think FX would mean to the bottom line in 2017? And it's simply we don't have a good visibility on your FX hedges and where they are and how they roll off. Do you have any insight to that at this point?"
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. I think it probably makes sense to hold that until the February earnings call and give all the guidance package altogether as opposed to kind of doing something one-off here. But have faith we'll give you full information on what we see as of Februar",46,"Yes. I think it probably makes sense to hold that until the February earnings call and give all the guidance package altogether as opposed to kind of doing something one-off here. But have faith we'll give you full information on what we see as of February."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Josh Jennings with Cowen and Company.",14,"The next question comes from the line of Josh Jennings with Cowen and Company."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","I just wanted 2 quick questions on CRM post the MRI-safe pacemaker approval. You clearly had 2 quarters of significant success getting back share. Any incremental color you can provide on how you've been so successful? Anything in the market dynamics? And",76,"I just wanted 2 quick questions on CRM post the MRI-safe pacemaker approval. You clearly had 2 quarters of significant success getting back share. Any incremental color you can provide on how you've been so successful? Anything in the market dynamics? And then any -- also, I was just curious about why we should -- should we be thinking of your pacemaker recovery as a precedent for ICU recovery once you have MRI-safe high-voltage approval?"
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks for the question, Josh. We're pleased -- we signaled at the end of the 2Q call that we thought overall CRM would be in line with 2Q, which we're pretty close to that. And we think fourth quarter will likely be in line with third quarter results. So",149,"Thanks for the question, Josh. We're pleased -- we signaled at the end of the 2Q call that we thought overall CRM would be in line with 2Q, which we're pretty close to that. And we think fourth quarter will likely be in line with third quarter results. So pretty consistent performance across our CRM business. And you highlighted the particular strength in pacemaker, really strong since the launch of our new products. I think it's this combination of an excellent lead and the ability to deliver that lead, excellent battery longevity in our pacer line, very strong commercial team. And it's consistent -- actually, stronger performance in the U.S. that we saw globally upon launching this product. So the commercial team has done very well, and physicians are very comfortable. I don't know, Ken, if you have any additional comments on our MRI pacer from a physician's standpoint?"
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. Thanks, Mike. Josh, I think what's really helping drive the growth is the differentiated features we have in our brady platform on top of MRI, including automated remote daily monitoring of these devices, including the performance of our newly releas",157,"Yes. Thanks, Mike. Josh, I think what's really helping drive the growth is the differentiated features we have in our brady platform on top of MRI, including automated remote daily monitoring of these devices, including the performance of our newly released INGEVITY lead. We got really fantastic feedback from clinicians since commercial release of that lead, validating excellent results we saw on the clinical trial. And I think in terms of what that does portend for tachy, I think we take a lot of pride in looking at how the portfolio is delivering in Europe, where we do have full approval of our tachy MRI products, including backwards compatibility to our previously released products and have MRI approval both for traditional transvenous devices as well as for our S-ICD. And we believe that the same performance that we're seeing in Europe, where we have a full portfolio approved, portends what we're going to see in the U.S."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Great. And just a follow-up. One of your big competitors has had a recall of their high-voltage platform. They've had to design around. But how are you thinking about this as a potential opportunity for Boston going forward in front of MRI-safe approval o",47,"Great. And just a follow-up. One of your big competitors has had a recall of their high-voltage platform. They've had to design around. But how are you thinking about this as a potential opportunity for Boston going forward in front of MRI-safe approval on the high-voltage side?"
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Well, I think what we've done is we very consistently promoted and we promoted with proof the unique benefits of our EnduraLife battery technology as being best in class, and that's really been proven out from 9 independent studies of contemporary device",149,"Well, I think what we've done is we very consistently promoted and we promoted with proof the unique benefits of our EnduraLife battery technology as being best in class, and that's really been proven out from 9 independent studies of contemporary device longevity. So even prior to some of the challenges that St. Jude has seen, we've been very clear to the marketplace that we have very unique battery technology and also excellent remote monitoring. So I think those 2 features stand the test of time and really been the anchor of our strategy for a number of years now. And we believe, over time, typically as health care modifies and more outcome-based, that having that type of capability is enjoyed by -- certainly by patients and also by physicians. So we think those unique strengths, combined with our commercial team, put us in a good position to compete."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Rick Wise with Stifel.",12,"The next question comes from the line of Rick Wise with Stifel."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Just to start with another Lotus question. Mike, with Lotus EDGE approved and, clearly, some clarity on maybe better outcomes achieved with a lower-depth implant, when do you more broadly roll out the technology and this procedural approach to a broader a",87,"Just to start with another Lotus question. Mike, with Lotus EDGE approved and, clearly, some clarity on maybe better outcomes achieved with a lower-depth implant, when do you more broadly roll out the technology and this procedural approach to a broader audience? And maybe just tie that in as well to Dr. Meredith's appointment. As much as I'll miss Dr. Dawkins' dulcet tones and eloquent commentary, why the change now and bringing him in-house? What can you achieve with Dr. Meredith in-house versus out in the world?"
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Well, first, I'd like to thank Keith. He's done a remarkable job at Boston Scientific. He's been here for 9 years. He brings the patient focus first to our executive committee and has really helped, along with Kevin and our broader team, lead the turnarou",227,"Well, first, I'd like to thank Keith. He's done a remarkable job at Boston Scientific. He's been here for 9 years. He brings the patient focus first to our executive committee and has really helped, along with Kevin and our broader team, lead the turnaround and sustained growth of our Interventional Cardiology business and move into structural heart. So Keith has done a terrific job. Transition is very smooth in the end of the year. Dr. Meredith is joining. Ian is very well known in the structural heart community. Structural heart is a big investment and a key focus area for the company. And so there'll be a seamless transition, and Ian will begin early in the year. So you'll see him at various investor conferences and so forth. But Keith did a great job of transitioning. And again, I think, just to repeat some of the comments earlier. We're very bullish on the future of our Lotus platform for the reasons we've articulated with the PVL rates, the controlled release of this device and the enhancements that depth guard and Lotus EDGE promise to deliver. And we're being very appropriate in terms of the rollout of that. And at TCT, we'll provide some additional information on pacemaker rates and some early clinical studies as well as some additional commentary from Tom Fleming, Keith and Kevin Ballinger."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Just to follow up, Mike, on AMS. Obviously, urology had a good quarter on multiple fronts. Can you talk about AMS? Where are you in the -- in achieving the sales synergies that you hoped for? Are you starting to see it? And is that side of the story where",68,"Just to follow up, Mike, on AMS. Obviously, urology had a good quarter on multiple fronts. Can you talk about AMS? Where are you in the -- in achieving the sales synergies that you hoped for? Are you starting to see it? And is that side of the story where you expected it would be? Are you ahead or behind? Just any perspective there would be very welcome."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. I would say, overall, we're likely slightly ahead on the cost synergy side, done a very nice job with that. We're certainly ahead overall in terms of the strategic value of the acquisition given the overall strength of our urology business. And as a",149,"Yes. I would say, overall, we're likely slightly ahead on the cost synergy side, done a very nice job with that. We're certainly ahead overall in terms of the strategic value of the acquisition given the overall strength of our urology business. And as a stand-alone business, the AMS business grew 5% in the quarter, which is slightly ahead of their kind of historical performance. So we think in our hands, the stand-alone business is performing better and will perform better. And more importantly, the complementary nature of the 2 businesses with Stone, BPH, ED is very comprehensive package for our commercial teams to take to customers. And not only is it very broad-based, but it also has unique clinical differentiation. So the combination of the 2 makes our legacy portfolio stronger. And so overall, we're clearly at or ahead of our internal deal models on the overall acquisition."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Vijay Kumar with Evercore ISI.",13,"The next question comes from the line of Vijay Kumar with Evercore ISI."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","So I had 2 quick ones. Maybe I'll start with the -- on the structural heart side. On Lotus, can you maybe talk about comparative dynamics in Europe? Are you still gaining share? And I know that you guys are not yet there in France, so maybe any perspectiv",54,"So I had 2 quick ones. Maybe I'll start with the -- on the structural heart side. On Lotus, can you maybe talk about comparative dynamics in Europe? Are you still gaining share? And I know that you guys are not yet there in France, so maybe any perspective on that would be helpful."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Sure, yes. We're probably not going to give as much detail as you'd like. Again, overall, we're at the high end of our guidance projected for our structural heart. Obviously, Lotus is a key component of that. We're still -- I think it's safe to say we're",209,"Sure, yes. We're probably not going to give as much detail as you'd like. Again, overall, we're at the high end of our guidance projected for our structural heart. Obviously, Lotus is a key component of that. We're still -- I think it's safe to say we're growing faster than the market in Europe. And what's important to note is we don't have all the -- all of our ammunition yet with Lotus. We don't yet have our largest valve and our smallest valve. And so we're doing quite well in the market with 3 valves, and we'll be excited about getting the additional 2 valve sizes for the full matrix. And I think what's really different is of the same drumbeat. It's a different device. It's a next-generation platform that doctors really enjoy the control that they have with it. And so it's -- I wouldn't say it's easy, but it's easier to differentiate this valve than some of the other balloon expandable devices that they have options to use in Europe. So we're very bullish on the future of it. In terms of France, we expect to have reimbursement by year-end '17. So hopefully, we'll see some upside from France reimbursement ideally in the fourth quarter '17."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Great. And then maybe one quick one on MedSurg. Again, I think this has been a phenomenal segment for you guys. And if I look at those really, really strong growth rate you put up, can you help us understand what's the underlying growth rate versus what's",82,"Great. And then maybe one quick one on MedSurg. Again, I think this has been a phenomenal segment for you guys. And if I look at those really, really strong growth rate you put up, can you help us understand what's the underlying growth rate versus what's been the contribution from new products, right? Because it's kind of hard for us to model. And any sort of new product cadence that you have lined up for '17, I think, would be helpful."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. So our MedSurg business, particularly endo and uro doesn't have the, call it, singular blockbuster devices or platforms like SYNERGY or WATCHMAN or Lotus. So Endoscopy is a very broad-based portfolio, as is urology. We have some kind of star platform",199,"Yes. So our MedSurg business, particularly endo and uro doesn't have the, call it, singular blockbuster devices or platforms like SYNERGY or WATCHMAN or Lotus. So Endoscopy is a very broad-based portfolio, as is urology. We have some kind of star platforms in Endoscopy with our AXIOS stent and our SpyGlass digital, but it's really a very broad-based portfolio that we continue to layer on new innovations to broaden out the adjacencies that we compete in, similar to the recent acquisitions that we've done with EndoChoice and CeloNova. So really, not one big product, but, overall, you're seeing us increase the R&D spend in those businesses over the past few years. We've been more active in M&A in the Endoscopy, uro and neuromod area. And importantly, they were under-scaled outside the U.S. And we put a lot of investment outside the U.S. over the past few years, and that continues to pay off, and that's not a onetime payoff, it will continue to pay off as well as emerging markets. So it's really not a one-product story, and it's very diversified strength in those businesses. Keith, was there something else on Lotus, TCT? Or did we cover that sufficiently?"
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","I think we covered it sufficiently. France reimbursement is important because France is the second-largest European market with a high penetration of TAVR. And so we're looking forward to bringing the products to France. Obviously, there are French invest",52,"I think we covered it sufficiently. France reimbursement is important because France is the second-largest European market with a high penetration of TAVR. And so we're looking forward to bringing the products to France. Obviously, there are French investigators in our trials, and they've been impressed with the acute performance of those."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question is from the line of Larry Biegelsen with Wells Fargo.",13,"The next question is from the line of Larry Biegelsen with Wells Fargo."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","And Keith, good luck in your new endeavors. I'll miss working with you. Two product-related questions. First on Neuromodulation and the ACCELERATE trial, you mentioned that you would give an update on the Q4 call in February. NANS this year is January. So",62,"And Keith, good luck in your new endeavors. I'll miss working with you. Two product-related questions. First on Neuromodulation and the ACCELERATE trial, you mentioned that you would give an update on the Q4 call in February. NANS this year is January. So does that mean we're not going to see the ACCELERATE data at NANS? And I had one other question."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Larry. Yes, our plan is to provide an update on the ACCELERATE trial at our fourth quarter 2016 earnings call, which is shortly after NANS, I believe. So our plan is to provide some additional color at that call, fourth quarter '16.",43,"Thanks, Larry. Yes, our plan is to provide an update on the ACCELERATE trial at our fourth quarter 2016 earnings call, which is shortly after NANS, I believe. So our plan is to provide some additional color at that call, fourth quarter '16."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","So Mike, just to be clear, no data at NANS? Is that what you're saying?",15,"So Mike, just to be clear, no data at NANS? Is that what you're saying?"
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. Our plan is to provide additional insight in the fourth quarter 2016 earnings call.",15,"Yes. Our plan is to provide additional insight in the fourth quarter 2016 earnings call."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay, clear. And then on drug-eluting stent growth, obviously very strong this quarter. I think it accelerated to 14% from 9% last quarter. Was that balanced across geographies? And then, Keith, I think new competition will probably become more prominent",68,"Okay, clear. And then on drug-eluting stent growth, obviously very strong this quarter. I think it accelerated to 14% from 9% last quarter. Was that balanced across geographies? And then, Keith, I think new competition will probably become more prominent at TCT given the BIOTRONIK data coming and the Medinol data coming as late breakers there. So any kind of previews from you on the competitive dynamics there?"
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Thanks, Larry. I think the difference between some of the competitors and SYNERGY is that we have a very large dataset with SYNERGY, and we now have approximately 20,000 patients in multiple clinical trials in a lot of high-risk subsets of patients. And a",210,"Thanks, Larry. I think the difference between some of the competitors and SYNERGY is that we have a very large dataset with SYNERGY, and we now have approximately 20,000 patients in multiple clinical trials in a lot of high-risk subsets of patients. And as you know from the 2-year data from the pivotal EVOLVE II trial, best-in-class stent thrombosis rates at 2 years. In fact, no definite stent thrombosis, not a single definite stent thrombosis after the first 24 hours. So we do think safety is an important metric, and we don't think we have any competition in that area. I think what will be interesting at TCT is some of the longer-term follow-up of fully resorbable stents, particularly the 3-year data from ABSORB II because if fully resorbable stents get better, the longer they're in, in terms of remodeling and so on, that will be an important finding. Clearly, the 2-year data in that regard were disappointing. So we also like the acute performance of SYNERGY. The ease of use for interventional cardiologists worldwide is well appreciated. So we're very confident in SYNERGY. We had a very nice Japanese launch, and we think the appreciation of physicians is matched by the growth that you've seen in this quarter's figures."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question is from the line of Matt Miksic with UBS.",12,"The next question is from the line of Matt Miksic with UBS."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","So I wanted to talk a little bit about the EndoChoice acquisition and the types of strategic investments and adds that you're looking at or thinking about. One of the things that struck us about that was this desire to kind of -- to fill out that portfoli",123,"So I wanted to talk a little bit about the EndoChoice acquisition and the types of strategic investments and adds that you're looking at or thinking about. One of the things that struck us about that was this desire to kind of -- to fill out that portfolio, better serve the ASCs. I think you mentioned in your prepared remarks something like sort of they're broad line, complete provider of solutions in that specialty. And just wanted to understand how you're thinking about acquisitions like that, the importance of sort of breadth, if you will, and where -- if you see opportunities also to kind of go deep on the sort of WATCHMAN-type innovation type acquisitions. And then I have one follow-up."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Sure. So we have a pretty active business development group, and we're very disciplined in the types of deals we look at. Obviously, we need to focus on our strategic fit and also strong return. Dan also mentioned we had a slight impairment with one of ou",292,"Sure. So we have a pretty active business development group, and we're very disciplined in the types of deals we look at. Obviously, we need to focus on our strategic fit and also strong return. Dan also mentioned we had a slight impairment with one of our venture investments, but we have a pretty significant venture investment portfolio that we think will bring strong value to the company, I think, as we look out at '18 and '19, which is very exciting. I think just in terms of this deal, it's very consistent, the Endo deal, with our strategy, which is one is to continue to strengthen and diversify the company in the faster-growth markets. So the MedSurg segment is a significant contributor. Endo business is a leader, but we're a little bit lighter in terms of our portfolio in the ambulatory surgery center. We also hadn't offered a pathology solution for this business. So it gives us the capability for -- in the surgery center market, which is a nice extension and expands us into some adjacencies in pathology and fills in a few products in our core business. So it will be a nice tuck-in acquisition, nice cost synergies and probably on a lower-risk scale in terms of integration. But we've also complemented those deals with some nice strong investments. Obviously, you mentioned the WATCHMAN acquisition. And also, I think our -- hopefully, our M&A track record is pretty solid. We're ahead of our deal model with AMS. We've done a very good job, the PI team, with our Bayer acquisition. So we'll continue to look at acquisitions which support the strategy, diversifying into faster-growth markets and category leadership, and we're very active in scanning the market in those areas."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","And then the follow-up for Dr. Stein. I know Josh asked the question earlier about one of your competitors having a recall. And you certainly have the perspective on this, much more than most of us. But it doesn't seem like this is going to become any kin",102,"And then the follow-up for Dr. Stein. I know Josh asked the question earlier about one of your competitors having a recall. And you certainly have the perspective on this, much more than most of us. But it doesn't seem like this is going to become any kind of market -- sort of clinician concern, patient concern event, as we've seen in the long history of CRM. But if you could maybe help put in perspective what you've seen so far, heard so far or any -- if you have any concerns that this becomes sort of like a segment issue."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. Thanks for the question, Matt. I'm not going to comment about patient management for those patients who are affected by a competitor's advisory. I mean, certainly, we take any individual patient's safety issue, patient concerns very seriously. Overal",59,"Yes. Thanks for the question, Matt. I'm not going to comment about patient management for those patients who are affected by a competitor's advisory. I mean, certainly, we take any individual patient's safety issue, patient concerns very seriously. Overall, we do not believe this is going to have any impact on market growth, either in the U.S. or globally."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","The next question comes from the line of Chris Pasquale with Guggenheim.",12,"The next question comes from the line of Chris Pasquale with Guggenheim."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Mike, can you talk a little bit more about the EndoChoice acquisition, the decision, in particular, to explore options for FUSE? That product hasn't lived up to expectations yet, but it would seem like plugging it into a larger sales organization could be",80,"Mike, can you talk a little bit more about the EndoChoice acquisition, the decision, in particular, to explore options for FUSE? That product hasn't lived up to expectations yet, but it would seem like plugging it into a larger sales organization could be the missing piece of the puzzle. And you guys have had some success historically on the imaging side of the business with Spyglass. So why not keep that and see if you can realize that potential yourselves?"
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Yes. We probably won't provide a lot of color on that. We sort of like the assets of EndoChoice, and we're pursuing options. So we haven't declared fully that we're going to sell that business or retain that business. So more information to come likely at",57,"Yes. We probably won't provide a lot of color on that. We sort of like the assets of EndoChoice, and we're pursuing options. So we haven't declared fully that we're going to sell that business or retain that business. So more information to come likely at our next earning call in terms of the status update there."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Analysts","Okay. And then you mentioned the ongoing replacement cycle headwind in ICDs, which has been an issue you've dealt with for a long time. What's your latest estimate for when that should turn positive for you?",36,"Okay. And then you mentioned the ongoing replacement cycle headwind in ICDs, which has been an issue you've dealt with for a long time. What's your latest estimate for when that should turn positive for you?"
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","So we anticipate, especially like the second half of 2017, the flattening out and ideally a slight improvement on the CRT-D side, on the replacement cycle; and then in '18, on the ICD side. So some benefit in '17 and more benefit in '18 based on the model",254,"So we anticipate, especially like the second half of 2017, the flattening out and ideally a slight improvement on the CRT-D side, on the replacement cycle; and then in '18, on the ICD side. So some benefit in '17 and more benefit in '18 based on the modeling that we've done. And that also will come on the heels of a full '18 launch of our MRI -- full year benefit of our MRI capabilities. So I just want to maybe close the call -- and Dan talked about kind of mid-single-digit guidance for next year. We'll provide all that detail in the second quarter.
I think what we're most excited about is the future of the company, and we talked quite a bit about the platforms that we'll be entering in markets approaching $8 billion to $9 billion in 2020. And we'll detail this out at the Investor Day. But it's exciting future as we move into a very large market in TAVR, expanded indications in the future with WATCHMAN, our drug-eluting technologies, the real commitment that we have to neurostimulation, expanding the Deep Brain Stimulation potentially to other areas and really in the field of Endoscopy where our team is looking at breakthrough capabilities to take more general surgery approaches to less invasive procedures. So there's a lot of new therapies that the business will be entering that will show at our Investor Day that really give an exciting future to the company beyond our '17 guidance that we'll provide in February."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Executives","Great. With that, we'd like to conclude the call. Thanks for joining us today, and we appreciate your interest in Boston Scientific. Before you disconnect, Shannon will give you all the pertinent details for the replay.",36,"Great. With that, we'd like to conclude the call. Thanks for joining us today, and we appreciate your interest in Boston Scientific. Before you disconnect, Shannon will give you all the pertinent details for the replay."
317627,403595084,1062349,"Boston Scientific Corporation, Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Boston Scientific Corporation","Operator","Ladies and gentlemen, this conference will be available for playback beginning today at 10:30 a.m. Eastern Time running through Wednesday, November 9, at midnight Eastern time. You may access the AT&T playback service by dialing 1 (800) 475-6701 and enter",78,"Ladies and gentlemen, this conference will be available for playback beginning today at 10:30 a.m. Eastern Time running through Wednesday, November 9, at midnight Eastern time. You may access the AT&T playback service by dialing 1 (800) 475-6701 and entering the access code of 403036. International participants, please dial 1 (320) 365-3844 with the access code of 403036. 
That does conclude our conference for today. Thank you for your participation and for using AT&T. You may now disconnect."
